Nuclear Medicine Technology: Procedures and Quick Reference

LWBK942-FM.qxd 6/25/11 8:45 AM Page x 10766-00_FM-rev.qxd 12/3/07 3:58 PM Page i Nuclear Medicine Technology: ...

Author: Pete Shackett

4334 downloads 5665 Views 5MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!

Report copyright / DMCA form

DOWNLOAD PDF

LWBK942-FM.qxd

6/25/11

8:45 AM

Page x

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page i

Nuclear Medicine Technology: Procedures and Quick Reference Second Edition

Pete Shackett, BA, ARRT[N], CNMT

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page ii

Acquisitions Editor: Peter Sabatini Managing Editor: Andrea M. Klingler Marketing Manager: Allison Noplock Production Editor: Sally Anne Glover Designer: Risa J. Clow Compositor: Circle Graphics, Inc. Second Edition Copyright © 2009, 2000 Pete Shackett. 351 West Camden Street Baltimore, MD 21201

530 Walnut Street Philadelphia, PA 19106

Printed in the United States of America. All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at [email protected], or via website at lww.com (products and services). 9

8

7

6

5

4

3

2

1

Library of Congress Cataloging-in-Publication Data Shackett, Pete. Nuclear medicine technology : procedures and quick reference / Pete Shackett.—2nd ed. p. ; cm. Includes bibliographical references and index. ISBN-13: 978-0-7817-7450-5 ISBN-10: 0-7817-7450-0 1. Radioisotope scanning—Handbooks, manuals, etc. I. Title. [DNLM: 1. Radionuclide Imaging—methods—Handbooks. 2. Radiopharmaceuticals— Handbooks. WN 39 S524n 2009] RC78.7.R4S48 2009 616.07'575—dc22 2007036323

DISCLAIMER Care has been taken to confirm the accuracy of the information present and to describe generally accepted practices. However, the author, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner; the clinical treatments described and recommended may not be considered absolute and universal recommendations. The author, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with the current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug. Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice. To purchase additional copies of this book, call our customer service department at (800) 638-3030 or fax orders to (301) 223-2320. International customers should call (301) 223-2300. Visit Lippincott Williams & Wilkins on the Internet: http://www.lww.com. Lippincott Williams & Wilkins customer service representatives are available from 8:30 am to 6:00 pm, EST.

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page iii

ABOUT THE AUTHOR Pete Shackett was born and raised in Newport, New Hampshire. In 1970, Pete received a Bachelor of Arts degree in Biology from Plymouth State College of the University of New Hampshire in Plymouth, New Hampshire. While studying under Dr. Mary Bilheimer, he received a science essay award for a treatise entitled “The Sanitary Significance of Fecal Coliforms in the Environment.” From 1970 to 1996, Pete pursued a career in music, publishing an album of all original music in 1988 entitled “Grouper Republic.” In 1994, he resumed study at Hillsborough Community College, majoring in Nuclear Medicine under the direction and guidance of Dr. Max Lombardi. During his tenure as a student, he wrote a disquisition entitled “99mTc-tetrofosmin: The Efficacy and Significance of a New Myocardial Perfusion Radiopharmaceutical.” The paper and presentation won an award at the Florida Nuclear Medicine Technologist conference in 1996 and was accepted for publication in the Journal of Nuclear Medicine Technology. Pete graduated with high honors in 1996, earning the Award for Academic Excellence in Nuclear Medicine from Hillsborough Community College. Lippincott Williams & Wilkins received a copy of the original manuscript for Nuclear Medicine Technology: Procedures and Quick Reference in 1998. The first edition of the book was published in 2000. Since then, Pete has continued to assimilate information, ideas, and experience in the field of nuclear medicine. Pete Shackett presently resides, plays music, and practices nuclear medicine out of the Tampa Bay area in Florida.

iii

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page iv

Dedication A true definition of devotion is when they weather the storm yet again. That said, I would like to dedicate the second edition to my lovely wife, Carolyn, and again to our canine gatekeeper and lifemate, Brandy. They bring the genuine meaning of happiness home. In loving memory of my parents, Bertha and Wilfard Shackett I would also like to extend a debt of gratitude and appreciation to my immediate family: Robert Shackett, Virginia Garrity, William Shackett, David Shackett, posthumously to Winifred (Dolly) Duhaime, to Carolyn’s brother, Donald Howe, and posthumously to her parents, Pauline and Viley Howe.

iv

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page v

ACKNOWLEDGMENTS A special expression of gratitude and deepest respect to Dr. Max H. Lombardi, Director of Nuclear Medicine Technology (Retired), Hillsborough Community College, Tampa, Florida, for the opportunity of knowledge, encouragement, inspiration, and assistance. I would also like to thank Mr. Bud Rogers, CNMT, past Chief Technologist, Bayfront Medical Center, St. Petersburg, Florida, now owner and operator of the Advanced Nuclear Imaging mobile unit. Also, thank you to the many technologists, students, nurses, and physicians who contributed opinions and information during the development of the original manual and this second edition. I would also like to honor and thank posthumously Dr. Mary G. Bilheimer for her understanding and contributions to my education at the then-named Plymouth State College of the University of New Hampshire (now Plymouth State University). Thanks to the following for donating their language translation expertise: Patrick DelMastro (Italian); Ania Lipska (Polish); Max Lombardi (Spanish, Portuguese, Italian); Joe Vuu (Mandarin Chinese); Victoria Russell, USF (Spanish); Shengrong Cai, USF (Mandarin Chinese); and Irshat Madyarov, USF (Russian). Special thanks also go to the incredibly helpful radiologists of Pasadena Radiologist Associates, PA, St. Petersburg, Florida, for their many years of information (thinking out loud for me) and support (Drs. Greg Arterburn, Kit Clarke, Ronnie Pollack, and, despite his reluctance to discuss nuclear medicine, Brian Cornnell). Thanks also to Carol Bonanno and Andrew Friden, Cytogen Prostascint; George Gonzales, West Coast Imaging of Clearwater, Florida, for PET information; Victoria Russell, USF Language Department, Tampa, Florida, for assistance and enlisting assistance at the University for language updates; Denise Merlino of the SNM for assistance with coding; Barbara J. Ossias, Reimbursement Revenue Solutions, LLC; Dale Walkey Partners Imaging Center of Sarasota, Sarasota, Florida, for PET information; Skip Watkins of Shared PET Imaging of Florida; the program directors that contributed ideas and opinions during the development of the second edition, including Nancy Clifton, Larry Gibson, Lorenzo Harrison, Max Lombardi, and Jasmin Trunzo. And thanks to the many students of Nuclear Medicine Technology that contributed ideas to the first and second editions of this book. Considerations and thanks are given to the many physicians, technologists, and nursing staff too numerous to mention at the various institutions for their continuing assistance, instruction, suggestions, observations, and insight. None were forgotten and all very much appreciated. Sincere appreciation is extended to those who made it obvious that they had little or no interest or enthusiasm for this project. Because of or despite their criticism, they challenged me to be stronger, more focused and determined, and to find better sources and solutions. Everyone, it seems, can serve a useful purpose.

v

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page vi

DISCLAIMER This manual is intended to be the clinician’s book. It is an amalgamation of protocols from many institutions, technologists’ experiences, physicians’ input, and written resources. It is to serve only as a guide in the performance of the procedures listed. Specific department protocols should always be followed as written when available. The manual is not intended to be the consummate and quintessential encyclopedia of nuclear medicine. The scope of the manual covers the basic data needed for most routine imaging and includes a reference section of peripheral material utilized on a daily basis by many personnel (not only nuclear medicine) within the hospital and clinic settings. Tables, charts, and data are incorporated that are usually difficult to find quickly or in any one source. These may be of use to departments, students, physicians’ reading rooms, various diagnostic technicians, and nursing stations. A list of references is included that were used in the collation of this material in hopes that the readers will pursue them for more specific information. If there is ever a question, without question, discuss it with your radiologist or nuclear physician.

vi

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page vii

TABLE OF CONTENTS About the Author . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii Dedication

................................................................................................

iv

Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

v

Disclaimer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

vi

SECTION ONE SCANS 1. Adrenocortical Scan

.............................................................................

2. Adrenal Medulla: Pheochromocytoma Scan (mIBG)

...................................

2 7

3. Angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4. Bone Density (Densitometry)

.................................................................

17

5. Bone Marrow Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 6. Bone Scan (Skeletal Imaging)

.................................................................

7. Brain Scan/Death (Brain Flow)

...............................................................

28 36

8. Brain SPECT (Single Photon Emission Computed Tomography) . . . . . . . . . . . . . . . . . . . . 41 9. Breath Test for H. pylori: PYtest® C-14 Urea Breath Test (UBT) . . . . . . . . . . . . . . . . . . . . . . 47 10. Cardiac: Gated First-Pass Study (First-Transit Radionuclide Angiocardiography)

........................................

51

............................................

56

.................................................

62

..........................................................

66

...............................................................

71

...................................................................................

79

11. Cardiac: MUGA and MUGA-X (Stress MUGA) 12. Cardiac: Myocardial Infarction (MI) Scan 13. Cardiac: Resting Study (Perfusion) 14. Cardiac: Stress Test (Perfusion) 15. Cisternography

16. Cystography (Voiding Cystourethrogram): Direct and Indirect . . . . . . . . . . . . . . . . . . . . . 84 17. Dacryoscintigraphy (Lacrimal Study)

......................................................

18. DVT (Deep Venous Thrombosis): Venography 19. Esophageal Transit Time 20. Gallium Scan

...........................................

89 94

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104

21. Gastric Emptying (Solid and Liquid) 22. Gastroesophageal Reflux 23. Gastrointestinal Bleed

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120

24. HIDA (Hepatobiliary or Gallbladder) Scan 25. LeVeen or Denver Shunt Patency

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134

vii

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page viii

Table of Contents

26. Liver SPECT (Hepatic Hemangioma) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138 27. Liver/Spleen Scan

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142

28. Lung Perfusion and Quantitation

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148

29. Lung Transmission (and Transmission Imaging) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156 30. Lung Ventilation: Gas and Aerosol

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160

31. Lymphoscintigraphy (Lymphangiogram) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166 32. Meckel’s Diverticulum

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173

33. NeutroSpec®: Radioimmunoscintigraphy (RIS) for Infection . . . . . . . . . . . . . . . . . . . . . . . . 178 34. OctreoScan®

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182

35. Parathyroid Scan

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188

36. Positron Emission Tomography (PET): An Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196 37. PET: Brain Imaging 18F-FDG

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205

38. PET: Cardiac Perfusion and Viability

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212

39. PET: Whole Body (Tumor) Imaging 18F-FDG and PET/CT

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222

40. ProstaScint® Scan (Radioimmunoscintigraphy [RIS]) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 41. Red Blood Cell Studies: Plasma Volume, Red Blood Cell Volume, Red Blood Cell Survival, and Splenic Sequestration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238 42. Renal: Cortical Imaging (99mTc-DMSA)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244

43. Renal: Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR 44. Salivary Gland Imaging 45. Schilling Test

.....

249

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263

46. Scintimammography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268 47. SPECT (Single Photon Emission Computed Tomography) Imaging and Hybrid Imaging Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274 48. Testicular Scan

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283

49. Therapy: BEXXAR® (Radioimmunotherapy: RIT for B-cell non-Hodgkin’s Lymphoma) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287 50. Therapy: Bone Pain (Palliation)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 293

51. Therapy: Intra-articular (Joint); Synovectomy

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 299

52. Therapy: Intracavitary (Serosal) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 304 53. Therapy: Polycythemia Vera

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309

54. Therapy: Zevalin® (Radioimmunotherapy for B-cell non-Hodgkin’s Lymphoma) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313 viii

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page ix

Table of Contents

55. Thyroid: Ablation

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318

56. Thyroid: Ectopic Tissue Scan (Substernal) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325 57. Thyroid: Hyperthyroid Therapy (<30 mCi)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330

58. Thyroid: Scan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335 59. Thyroid: Uptake

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341

60. Thyroid: Whole Body 131I Cancer Study and rTSH Augmentation

. . . . . . . . . . . . . . . . . . 349

61. White Blood Cell Scan (111In-oxime and 99mTc-HMPAO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 354

SECTION TWO QUICK REFERENCE A. Conversion Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362 Lbs/Kgs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363 In/Cm

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364

Target Heart Rates (Cardiac Studies) mCi/MBq

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 365

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366

B. Radiopharmaceuticals

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 367

Standard Adult Dose Ranges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368 Medical Radionuclides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370 Common Math Equations for Nuclear Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 373 Kit Preparations (An Overview)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374

Pediatric Dosing in Nuclear Medicine

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379

Radioactive Isotopes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386 C. Decay Tables of Common Radionuclides 137

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410

Cs

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 411

57

Co

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 412

18

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413

67

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 414

F

Ga

111

In

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415

123 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

416

131 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

417

I I

99

Mo

99m

Tc

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 419

201

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420

133

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421

Tl Xe

ix

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page x

Table of Contents

D. Standard Drug Interventions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Calculations, Preparations, and Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423 Infusion Rate Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428 Side Effects Of Common Drugs

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433

Drugs And Studies Affecting 123I and 131I Uptake

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435

Drug Lists: Anticoagulants and ACE Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437 E. Laboratory Tests Normal Ranges

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440

Enzymes and Hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 446 F. Language Barrier Buster™ / Interpretech™ Chinese

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 452

French . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 454 German Italian

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 457

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459

Portuguese . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 462 Russian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 464 Spanish

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 467

Japanese

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 470

Polish . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471 G. Regulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 474 Misadministration

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 475

Radiation Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 476 State Inspections (self-assessment)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483

Example: Patient End-of-Day Report . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 489 Example: RP Rec-Disp Daily Report

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490

H. Patient Release Methods and Information for Thyroid Therapies Methods of Patient Release Inpatient Information

I.

. . . . . . . . . . . . . . . . . . . 491

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 492

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495

Outpatient Information

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495

Patient History Sheets

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 496

Adrenal Scans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 497 Bexxar®/Zevalin® Bone Scans

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499

Brain Scan (SPECT) Cardiac/MUGA x

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page xi

Table of Contents

Gallium/Indium/Ceretec® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 502 Gastric Emptying Scan (liquid/solid) GI Bleeding Scan/Meckel’s

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 503

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 504

HIDA (gallbladder study) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505 Lung Scan (Aerosol) Lung Scan (Gas)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507

Liver/Spleen Scan

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508

Miscellaneous Worksheet

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509

NeutroSpec® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510 Octreoscan® PET Scans

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512

ProstaScint® Scan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513 Renal/Renogram/Captopril Scan

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 514

Scintimammography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 515 Thyroid Uptake and Scan J.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 516

Abbreviations Commonly Used in Nuclear Medicine

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518

K. Coding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 529 Exams (CPT)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 530

Radiopharmaceuticals (HCPCS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 L. Anatomical Images . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535 Brain (and Brain CSF) Cardiac System

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 536

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 540

Endocrine System and Thyroid

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542

Gastrointestinal System (Esophagus, GI Tract, Stomach) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 543 Hepatobiliary System

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 545

Lungs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 547 Lymphatic System

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548

Miscellaneous Systems (Catecholamine Sites, Lacrimal, Salivaries, Testicular)

. . . . . . . . 549

Renal System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 552 Skeletal System

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 553

Vascular System (Arteries, Veins)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 557

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 559 Acknowledgment of Trademarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 563 Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567

xi

10766-00_FM-rev.qxd

12/3/07

3:58 PM

Page xii

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 1

section

1

Scans

1

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 2

chapter

1

Adrenocortical Scan RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV Type: β−, γ, fission product

Radiopharmaceutical •

131

I-6-β-Iodomethyl-19-norcholesterol (NP-59). Available from the University of Michigan Nuclear Pharmacy under an Investigational New Drug (IND) application.

Localization • Compartmental, blood flow, into the adrenal cortex, bound to and transported by plasma low-density lipoproteins. • Taken up by low-density lipoprotein receptors on adrenocortical cells. • Cholesterol is the main precursor in the production of adrenocortical steroid; NP-59 is a cholesterol analog.

Quality Control • Done at factory, NP-59 > 90%. • Assay dosage in dose calibrator for activity.

Adult Dose Range • 2 mCi (74 MBq). • Some recommend 1.0 mCi (37 MBq) per 1.73 m2 body surface area.

Method of Administration • Intravenous slow injection over 2–3 minutes. • Observe patient for 30 minutes after injection for reaction to injection. • Injection may be required to be performed by physician as per institution protocol.

INDICATIONS • Detection and localization of adrenal glands. • Evaluation of documented primary hyperaldosteronism. • Detection and localization of abnormal adrenal function in adrenocorticotropic hormone (ACTH)-independent Cushing’s syndrome. 2

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 3

Chapter 1 — Adrenocortical Scan

• • • • •

Detection and localization of adrenal incidentalomas. Evaluation of adrenal lesions visualized on other imaging techniques. Evaluation of virilization and/or amenorrhea secondary to suspected adrenal hyperandrogenism. Differentiation of bilateral hyperplasia from adenoma in hyperaldosteronism. Evaluation for biopsy or surgical intervention.

CONTRAINDICATIONS • Allergy to iodine may be a consideration, although doses are small. • Patient taking interfering medications.

PATIENT PREPARATION Before Day of Injection • Physician instructs the patient to take SSKI (saturated solution potassium iodide) or Lugol’s solution to block free iodine uptake in thyroid. This is administered 1 drop, t.i.d., beginning the day before radiotracer administration and continuing for 10 days after injection. If there is an allergy to iodine, perchlorate may be used. • Physician instructs the patient to take bisacodyl (e.g., Dulcolax®) 10 mg orally (PO), b.i.d. × 3 days before imaging, to reduce bowel activity. Patient may be required to take laxatives and/or enemas on afternoons before imaging days; check with radiologist. • Physician instructs patients with atopic history (genetic disposition to hypersensitivity or allergy to medications such as iodine or steroids) to be treated with oral antihistamine (e.g., Benadryl® 50 mg) 1 hour before injection of radiotracer.

Day of Injection • Identify the patient. Verify the doctor’s order. Explain the procedure. • Obtain signed consent from the patient and a prescription for the iodine. • Ensure that the patient is not taking the following drugs: steroids, antihypertensives, reserpine, tricyclic antidepressants, sympathomimetics (adrenergic, stimulates release of epinephrine), diuretics as per physician’s order.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Statics • 131I: 50,000 to 100,000 counts or up to 20 min/image

Collimator • Medium or high energy, parallel hole

PROCEDURE

Single Photon Emission Computed Tomography (SPECT) • 360°, 64 stops at 20 sec/stop

(TIME: ~45 MIN/SESSION)

Single Isotope: NP-59 • Begin imaging 5 days (120 hours) after injection, followed by images on day 6 and 7 if required. • Place patient in supine position, with camera posterior and kidneys centered (∼12th rib). • Collect statics to at least 100,000 counts or 5–20 minutes. 3

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 4

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Obtain lateral and posterior views with markers along spine on one of the imaging days to allow for determination of depth of each adrenal gland (5 µCi 131I capsule or store injection syringe for markers until imaging is done). • Record percent uptake using regions of interest (ROIs) for counts and correcting for depth differences. (Some processing systems have this software.) • Determine whether SPECT images need to be taken. Check with radiologist.

Dual Isotope: NP-59 and 99mTc-DTPA • Begin imaging 48 hours after injection and repeat at 2- to 3-day intervals until results are satisfactory. • Place patient in supine position, with camera posterior and renal area centered. • Collect 131I images up to 20 minutes (1200 seconds). • Change energy window; without moving patient, inject 5 mCi 99mTc-DTPA (diethylenetriaminepentaacetic acid) and collect 500,000–1,000,000 counts for subtraction image (computer protocol). • Proceed with anterior views of chest and abdomen if adrenals are not visualized.

Procedure for Adrenocortical Scan with Suppression • This scan differentiates bilateral hyperplasia from adenoma in hyperaldosteronism and hyperandrogenism. Unilateral visualization indicates adenoma. Bilateral visualization is indicative of hyperplasia. Dexamethasone suppresses pituitary ACTH secretion, thus embellishing NP-59 uptake into the ACTH-independent zona glomerulosa, while inhibiting NP-59 uptake into the ACTH-dependent zona fasciculata-reticularis. • Patient preparation is the same. Administer 2–4 mg dexamethasone b.i.d. beginning 2–7 days before injection of nuclide and continuing until completion of the study. • Scan using same procedures; however, begin imaging 24–48 hours after injection.

Procedure for Adrenocortical Scan with ACTH Augmentation • Patient preparation is the same. Administer 50 IU of ACTH IV daily beginning 2 days before radiotracer injection. • Scan using single isotope or dual isotope procedures.

NORMAL RESULTS • Visualization of both adrenal glands with the right slightly superior to the left. • On posterior image, most normal patients present with the right adrenal gland showing greater intensity than the left because of the difference in depth and because the left adrenal gland is partially shielded by the kidney. • Liver and gallbladder present brightly. If there is interference, laterals or SPECT can help localize. A fatty meal or cholecystokinin can also diminish the activity in the gallbladder. • Colon may also visualize. Cathartics can be used to reduce colon activity. • Dexamethasone will suppress about 50% of adrenal uptake of NP-59 that is ACTH dependent. These studies will show only faint visualization or bilateral nonvisualization by day 5. Imaging may be discontinued after the 24- or 48-hour studies.

ABNORMAL RESULTS • In the nonsuppression study, faint visualization or nonvisualization (usually bilateral) indicates adrenal carcinoma. • Asymmetric, bilateral, intense uptake suggests autonomous, ACTH-independent cortical nodular hyperplasia. • Cushing’s syndrome produces bilateral adrenal hyperplasia causing bilateral visual uptake of NP-59. 4

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 5

Chapter 1 — Adrenocortical Scan

• Unilateral, intense uptake in the presence of known Cushing’s syndrome is highly suggestive of adrenal cortical adenoma. • No uptake bilaterally in the presence of known Cushing’s syndrome is suggestive of carcinoma. • In primary aldosteronism, bilateral early visualization indicates bilateral adrenocortical hyperplasia, unilateral early visualization indicates aldosterone-secreting adenoma (Conn’s tumor), and bilateral late visualization or nonvisualization is usually nondiagnostic. • Incidentally discovered (nonhyperfunctioning) adrenal mass lesion, with increased uptake on the same side, indicates benign nonhyperfunctioning adenoma; reduced uptake indicates a malignant lesion or infarction. • In the suppression study, failure to suppress uptake with dexamethasone indicates adenoma if unilateral, hyperplasia if bilateral. • In androgen excess (hyperandrogenism), also done with suppression, bilateral early visualization indicates bilateral adrenocortical hyperplasia and unilateral early visualization indicates adrenal adenoma. This syndrome occurs secondary to polycystic ovarian disease and is also produced by primary adrenal cortical (zona reticularis) hyperplasia but rarely by adrenal tumors.

ARTIFACTS • Attenuating articles in clothing. • Images not taken for enough counts. • Focal areas of interest usually linger over time and grow in intensity. False-positive results can be limited by delayed images and lateral views. • Bilateral uptake in patients with unilateral disease—spironolactone and other diuretics. • Early bilateral uptake in patients with no disease or unilateral disease—oral contraceptives. May occur even with dexamethasone suppression.

NOTE • The adrenal cortex makes up about 90% of the adrenal gland. It contains three zones: (1) The zona glomerulosa, which is outermost, produces aldosterone, the principal mineralocorticoid hormone. (2) The zona fasciculata produces cortisol, the principal glucocorticoid hormone. (3) The zona reticularis produces androgenic steroids, principally androstenedione. • The adrenal medulla secretes the catecholamines epinephrine and norepinephrine. • Secretion from the adrenal cortex is controlled by ACTH from the anterior pituitary. The exception is aldosterone from the zona glomerulosa, which is controlled by angiotensin II, blood volume, and electrolyte concentrations. Cholesterol is stored in the cortex as the metabolic precursor for the synthesis of adrenocorticosteroids, e.g., aldosterone. NP-59 uses the similarity to cholesterol for uptake into the cortex. Increased ACTH increases the uptake, occurring gradually over a period of days.

PATIENT HISTORY (or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of hypertension or hypotension?

Y

N

Do you have a history or family history of cancer?

Y

N

Have you had any recent weight gain?

Y

N

Have you experienced hirsutism (abnormal hair growth)?

Y

N (continued) 5

10766-01_ST1-CH01_redo.qxd

12/3/07

3:39 PM

Page 6

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you had any chemotherapy or radiation therapy?

Y

N

Have you had any recent examinations such as CT, ultrasonography (US), MRI?

Y

N

Y

N

Y

N

Y

N

If so, when and what facility? What medications are you currently taking? Have you had any recent blood or laboratory work done (of interest will be cholesterol levels, ACTH, aldosterone, catecholamines and metabolites, plasma renin activity, blood sugar)? Female patients: Are you pregnant or nursing? When was your last menstrual period? Have you experienced amenorrhea (suppression of menstruation)? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

6

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 7

chapter

2

Adrenal Medulla: Pheochromocytoma Scan (mIBG) RADIOPHARMACY Radionuclide •

123

I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator • or: 131I t1/2: 8.1 days Energies: 364 keV Type: β−, γ, fission product

Radiopharmaceutical •

chromaffin cells of the adrenergic tissue and stored in adrenergic granules.

123

I- or 131I-mIBG (-meta-iodobenzylguanidine). Available from the University of Michigan Nuclear Pharmacy under an Investigational New Drug (IND) application.

Localization

Quality Control •

123

I- and 131I-mIBG > 90%

Adult Dose Range •

131

I: 500 µCi (18.5 MBq), 1 mCi (37 MBq) for suspected metastatic pheochromocytoma • 123I: 3–10 mCi (111–370 MBq)

Method of Administration • Intravenous injected slowly over 5 minutes if possible.

• Blood flow, guanethidine analog absorbed much the same as norepinephrine into the

INDICATIONS • Detection and localization of benign and malignant intra-adrenal and extra-adrenal pheochromocytomas (usually benign chromaffin cell tumors of the sympathoadrenal system that produce and 7

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 8

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• • •

•

• • • • • •

secrete catecholamines, e.g., norepinephrine and epinephrine, producing hypertension and orthostatic [standing] hypotension). These occur within the adrenal medulla and are frequently associated with hereditary multiple endocrine neoplasia (MEN) types 2A and 2B, neurofibromatosis, von Hippel-Lindau disease, Carney’s triad, and familial pheochromocytoma. Localization of site(s) of hormonal overproduction. Detection and localization of neuroectodermal (nerve tissue) tumors. Detection and localization of neuroblastomas (malignant hemorrhagic tumors of cells resembling neuroblasts of the sympathetic system, especially the adrenal medulla, and usually occurring in childhood). Detection and localization of other neuroendocrine tumors that share the property of amine precursor uptake in decarboxylation (APUD), such as: • Carcinoid (argentaffin cells of the intestinal tract, bile ducts, pancreas, bronchus, or ovary that secrete serotonin) tumors • Medullary thyroid tumors • Paragangliomas (tumors of the adrenal medulla, chromaffin cells, and the paraganglia) • Merkel cell skin tumors • Chemodectomas (tumors of the chemoreceptor system) • Small cell lung carcinoma • Schwannoma Evaluation of myocardial norepinephrine receptors. Distinguishing neuroendocrine tumors from nonneuroendocrine tumors. Detection and localization of metastatic deposits from previously diagnosed pheochromocytoma. Staging of the disease. Evaluation of chemotherapy and to exclude sub-clinical relapse in bone marrow or bone pain. Evaluation of surgery.

CONTRAINDICATIONS • Allergy to iodine may be a consideration, although doses are small. • Patient taking interfering medications.

PATIENT PREPARATION Before Day of Injection • Physician instructs the patient to take SSKI (saturated solution potassium iodide) or Lugol’s solution to block free iodine uptake in thyroid. This is administered 1 drop, t.i.d., beginning the day before radiotracer administration and continuing for 6 days after injection. If there is an allergy to iodine, perchlorate may be used. • Physician instructs the patient to take bisacodyl (e.g., Dulcolax®) 10 mg PO, b.i.d. × 3 days before imaging, to reduce bowel activity. Patient may be required to take laxatives and/or enemas on afternoons before imaging days; check with radiologist. • Physician instructs patients with atopic history (genetic disposition to hypersensitivity or allergy to medications such as iodine or steroids) to be treated with oral antihistamine (e.g., Benadryl® 50 mg) 1 hour before injection of radiotracer.

Days of Injection • Identify the patient. Verify doctor’s order. Explain the procedure. • Obtain signed consent from patient and a prescription for the iodine. • Ensure that the patient is not taking the following drugs: steroids, antihypertensives, reserpine, tricyclic antidepressants, sympathomimetics (adrenergic, stimulates release of epinephrine), diuretics as per physician’s order. Ideally, no medications for 2–3 weeks before the examination (see Drugs to Withhold). 8

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 9

Chapter 2 — Adrenal Medulla: Pheochromocytoma Scan (mlBG)

EQUIPMENT Camera

Computer Set-up

• Large field of view

Statics • 131I: 100,000 counts or up to 20 min/image • 123I: 500,000 counts or time

Collimator •

131

I: Medium energy, general purpose, or medium energy, high resolution • 123I: Low energy, all purpose, or low energy, high resolution

PROCEDURE

Whole Body • 5–10 cm/min, image at least head to pelvis Single Photon Emission Computed Tomography (SPECT) • 360°, 64 stops at 20 sec/stop

(TIME: ~30–60 MIN/SESSION)

• Ensure patient is off medications and has taken thyroid blocker the night before. • Instruct patient to empty bladder. • Place patient in supine position. 131

I-mIBG: Images at 24, 48, and possibly 72 Hours

• Acquire anterior/posterior images of head/neck, thorax, abdomen, and pelvis. • Set whole body sweep slow (10 cm/min or less). • Acquire static images of areas of interest if preferred or protocol. Statics should run at least 100,000 counts or 5–20 minutes. • Acquire lateral views of abnormal uptake to aid in localization. • Acquire marker images if protocol (on axillae, lower ribs, and iliac crests). Use 5 µCi 131I capsule or perhaps store injection syringe for markers until imaging is done. • Acquire SPECT images if protocol or requested. 123

I-mIBG: Images at 24, 40 Hours and possibly 72 hours

• • • • •

Same imaging procedures as above. Acquire statics of at least 500 k counts or 15 minutes each. Statics should at least include chest, posterior mid-thorax, kidneys centered, and lumbar. Whole body sweep at 10 cm/minute or less, anterior/posterior, head to pelvis. SPECT images at 45 to 60 seconds/stop.

NORMAL RESULTS • • • • • •

Uptake occurs in the pituitary, salivary glands, thyroid, liver, and spleen. The gallbladder will be visualized in patients with renal failure. The kidneys and bladder will visualize because of the renal excretion. The heart is visualized in patients with normal catecholamine levels. Diffuse lung activity, nasal, neck muscle, and bowel activity may present in some patients. The normal adrenal medulla seldom visualizes (30% to 40% on delayed images) and is of low intensity. • The heart and adrenal medulla are visualized more clearly with 123I-mIBG. • There should be no skeletal uptake. • Areas of normal uptake diminish in intensity over time. 9

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 10

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ABNORMAL RESULTS • Focal areas of increased activity that increase more over time occur. • Sporadic, unilateral tumors show focal intense uptake. • Metastatic disease is visualized in the axial skeleton, heart, lung, mediastinum, lymph nodes, and liver. • Neuroblastomas may arise in any location of sympathetic nervous system tissue, but most often are visualized as an abdominal mass, metastasizing early to bone and bone marrow. • Images at 72 hours will provide maximal contrast between foci of activity and background. • Localizes in pheochromocytoma, neuroblastoma, and also carcinoid, medullary thyroid carcinoma and paraganglioma.

ARTIFACTS • • • •

Attenuating articles in clothing. Images not taken for enough counts. Aggressive chemotherapy may hinder the visualization of some metastasis. False-positive results may be caused by recent surgical sites, x-ray therapy to the lungs, and bleomycin-induced pulmonary changes. • False-negatives can be due to lesions too close to large primary or metastatic mass, or tissue with high normal uptake. No or low tumor uptake related to tumor heterogeneity, ischemic necrosis in tumor mass, lack of granules, loss of tumor capacity to absorb tracer, or pharmaceutical inhibition. • Focal areas of interest usually linger over time and grow in intensity. Limit false-positive results by delayed images (with obliques and laterals). • Because of the nature of the disease and because they are off medications, patients may be agitated and not lie still.

DRUGS TO WITHHOLD (IDEALLY, NO MEDICATIONS 2–3 WEEKS BEFORE THE EXAMINATION)

For Three Weeks (affect reuptake mechanism presenting with absence of uptake by salivary glands and heart, and may inhibit uptake in pheochromocytoma) • Tricyclic antidepressants: e.g., reserpine • Sympathomimetics: e.g., dobutamine, dopamine, norepinephrine

For Two Weeks (affect depletion of storage vesicle) • • • • • • • • • • • • • •

Amphetamines ACE inhibitors (captopril, enalapril) ARBs (irbesartan, valsartan) Bretylium tosylate Calcium channel blockers (nifedipine, nicardipine, amlodipine) Cocaine Digoxin Fenoterol Guanethidine Haloperidol Imipramine Insulin Phenothiazine Pseudoephedrine (nasal decongestants) 10

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 11

Chapter 2 — Adrenal Medulla: Pheochromocytoma Scan (mlBG)

• • • • • •

Phenylpropanolamine (diet-control drugs) Phenylephrine (nasal decongestants) Salbutamol Terbutaline Thiothixene Xylometazoline

Alpha- and beta-adrenergic blocking drugs will not affect study with the exception of labetalol (affects both reuptake and storage depletion).

NOTE • mIBG is similar to the catecholamine norepinephrine. Epinephrine and norepinephrine are hormones that regulate smooth muscle tone, heart rate and force of contraction, and physiologic responses associated with stress. Pheochromocytomas produce excess amounts of these hormones resulting in hypertension and other symptoms associated with overabundance of catecholamines. • Renal and skeletal imaging with 99mTc agents can be used in conjunction with this test to aid in localization. Their injections can be timed for optimal scan times at the 24- or 48-hour images with two sets of images taken by changing the energy windows to suit the radiotracer.

PATIENT HISTORY (or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of hypertension or hypotension?

Y

N

Do you have palpitations?

Y

N

Have you felt anxiety or apprehension?

Y

N

Have you experienced excessive diaphoresis (sweating)?

Y

N

Do you have headaches?

Y

N

Have you experienced a flushed face?

Y

N

Do you experience nausea or vomiting?

Y

N

Have you experienced tingling of extremities?

Y

N

Are you taking oral contraceptives?

Y

N

Have you had any recent surgery?

Y

N

If so, what type and for how long?

If so, where and when? (continued)

11

10766-02_CH02_redo.qxd

12/3/07

3:40 PM

Page 12

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you had any chemotherapy or radiation therapy?

Y

N

Are there any recent or planned PET, CT, ultrasonography (US), MRI, or nuclear medicine (NM) scans?

Y

N

Have you had any recent laboratory reports (with attention to adrenocorticotropic hormone, aldosterone, catecholamines and metabolites, Na, K)?

Y

N

Female: Are you pregnant or nursing?

Y

N

What medications are you taking?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

12

10766-03_CH03_redo.qxd

12/3/07

3:45 PM

Page 13

chapter

3

Angiography RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • Na99mTcO4− (pertechnetate). 99mTc-DTPA (diethylenetriaminepentaacetic acid). Tagged red blood cells by pyrophosphate or stannous chloride to 99mTcO4− by in vivo, in vitro, or kit, e.g., UltraTag®.

Quality Control TcO4−: Moly-Al breakthrough, chromatography. • 99mTc-DTPA: chromatography: > 90%, use within 1 hour. •

99m

Adult Dose Range • 8–25 mCi (296–925 MBq)

Method of Administration • Intravenous injection, good bolus for flow.

Localization • Compartmental to blood supply.

INDICATIONS • Evaluation of blood flow through major vessels as with arteriograms and venograms (more venous than arterial because contrast radiography is now largely used for arterial flow). • Evaluation of regional perfusion in organs and extremities. • Evaluation of penetrating wounds to thorax, abdomen, or extremities. • Detection and localization of known or suspected hematoma or bleeding from large vessel. • Detection and localization of vessel obstruction (e.g., deep venous thrombosis). • Detection and evaluation of vessel abnormalities. • Detection and evaluation of vascularized tumors. • Evaluation of vessel location and/or anatomic position. • Evaluation of vessels because of abnormal results on related studies. 13

10766-03_CH03_redo.qxd

12/3/07

3:45 PM

Page 14

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS • None

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • For 99mTcO4−: administer 200–400 mg perchlorate PO 30 minutes before imaging to block thyroid uptake if that area is within the region of interest (ROI). Lemon can be used to stimulate and reduce uptake in salivary glands.

EQUIPMENT Camera • Large field of view.

Collimator • Low energy, all purpose, or low energy, high resolution.

Computer Set-up Flow • 1–5 sec/image for 30–60 seconds. • Time for flow is according to size of vessels of interest. Choose shorter times for structures with large vessels and quick blood flows,

PROCEDURE

longer times for structures with smaller vessels and less blood flow. Suggested times: • 1 sec/image for heart • 2 sec/image for brain • 3 sec/image for kidneys • 5 sec/image for extremities • Length of flow: 30–60 seconds. Statics • 300,000–750,000 counts or set for time, e.g., 180 seconds. • Acquire anterior or posterior images (according to ROI). • Acquire added views (laterals, etc.) if needed for visualization.

(TIME: ~20 MINUTES)

• Position patient on table if torso is to be imaged, such that the entire area of interest (suspected side and normal side) is completely in camera view. • Position extremities (left and right) in field of view if one or both are the areas of interest. • Position camera as close as possible to area or organ of interest. • Consider a foot injection if the arterial or venous flow to arms is the area of interest. • Inject patient and start camera at appropriate time to catch flow. • Optional quantitative analysis can be done with computer software. • Acquire flow at 1 image/sec. • Draw ROIs on desired structures. • Generate time-activity curves with computer software. • Calculate quantitative analysis of transit time, blood volume, and flow by this method. • Optional blood tagging: • In vitro method: Extract ∼2–2.5 mL of blood into heparinized syringe from patient and tag with UltraTag® • In vivo method: Inject cold pyrophosphate, then 20 minutes later, inject radiotracer under camera for flow • Modified in vivo method: Inject cold pyrophosphate and wait 20 minutes; then extract ∼2–2.5 mL of blood into a heparinized, shielded syringe containing ∼30 mCi 99mTc-O4 and mix for 5–10 minutes 14

10766-03_CH03_redo.qxd

12/3/07

3:45 PM

Page 15

Chapter 3 — Angiography

• Inject patient (or reinject blood) under camera to image flow to ROI. • Obtain static images of ROI at 5- to 10-minute intervals as per physician’s request.

NORMAL RESULTS • Depending on the position of the camera and the injection site, veins appear first, leading to the right heart, then out to the lungs, back to the left heart, then out the aorta to the body. • Large vessels appear prominently and subsequently show branching. With extremities, approximate bilateral symmetry should be present. • Organs present shortly after aorta, then vascularization of general body tissue.

ABNORMAL RESULTS • Punctures to a vessel will present with diffuse radiotracer collecting outside the vessel in that area. • Obstruction presents as vessel to point of obstruction and no vessel appearing distal to the obstruction. • Obstruction to organs presents as partial or complete lack of perfusion. • Vascularized tumors and cysts will present as localized areas of increased uptake. • Nonvascularized tumors and cysts will present as localized areas of decreased or no uptake.

ARTIFACTS • Attenuating articles obscuring ROI. • Patient movement blurs image. • Causes of a poor tag: • Drug interactions e.g., heparin, methyldopa, hydralazine, quinidine, digoxin, prazosin, propranolol, doxorubicin, iodinated contrast agents • Cold pyrophosphate not injected soon enough after mixing • Antibodies: transfusions, transplantation • Short incubation time • Too much or too little stannous ion

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and for how long? Do you have any pain and if so, where and for how long? Do you have a history of aneurysm, blood clots, peripheral vascular disease, or any vessel abnormalities? If so, explain. (continued)

15

10766-03_CH03_redo.qxd

12/3/07

3:45 PM

Page 16

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you been diagnosed with any major organ disorders?

Y

N

Do you have any discolored skin?

Y

N

Do you have any tingling in the extremities?

Y

N

Do you have any blood in your stool or urine?

Y

N

Do you have any unusual lumps or swelling?

Y

N

Have you had any recent or planned related studies?

Y

N

Do you have the results of any recent laboratory tests?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, which one(s) and for how long?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Alazraki NP, Mishkin FS, eds. Fundamentals of Nuclear Medicine, 2nd ed. New York: Society of Nuclear Medicine, 1988. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

16

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 17

chapter

4

Bone Density (Densitometry) RADIOPHARMACY Radionuclide

Localization

• Single radionuclide: 125I t1/2: 60.1 days Energies: 23–31 keV Type: EC, x, γ, accelerator • or: 241Am (americium) t1/2: 432.7 years Energies: 60 keV Type: α, γ, spontaneous fission product. • Dual radionuclide: 153Gd (gadolinium) t1/2: 241.6 days Energies: 44, 100 keV (γ); 35, 70 keV (x-ray) Type: x, γ, neutron irradiation of 152Gd

• N/A

Quality Control • Image phantom every day of use.

Adult Dose Range • N/A

Method of Administration Radiopharmaceutical

• Exposure to, not administration by injection.

• N/A

INDICATIONS • Detection of osteoporosis. • Monitoring and evaluation of treatment programs for osteoporosis (e.g., estrogen, progesterone, testosterone replacement, calcitonin therapy, exercise, or pharmacologic interventions with vitamins). • Evaluation of osteopenia (diminished bone tissue). • Evaluation of effect of menopause and premature spontaneous menopause on bone density (for hormone therapy management). • Evaluation for premenopausal oophorectomy. • Evaluation of effect of steroid therapy on bone density. 17

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 18

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Evaluation of effect of Cushing’s syndrome on bone density (and other endocrinopathies, e.g., prolactinoma, hyperparathyroidism, hyperthyroidism, and male hypogonadism). • Detection and evaluation of pathologic fractures. • Evaluation of effect of chronic renal disease on bone density. • Evaluation of effect of gastrointestinal syndromes on bone density. • Evaluation of effect of postgastrectomy and other malabsorption diseases on bone density. • Evaluation of effect of long-term immobilization on bone density. • Evaluation of bone density due to abnormal results on related studies.

CONTRAINDICATIONS • Dense vertebrae from degenerative disease, fracture, injury, or metastatic cancer should be excluded as area of interest. • Nuclear medicine scan within 7 days of bone density scan.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Remove metal objects from person and/or pockets.

EQUIPMENT Camera

Computer Set-up

• Rectilinear-style scanner • Bone densitometer—single or dual energy x-ray absorptiometry

• Factory settings

Collimator • Collimated x-ray pencil beam

PROCEDURE

(TIME: ~30–60 MINUTES)

• SPA (single photon absorptiometry) is suggested in pediatric through adolescent patients because long bones are most metabolically active. It is useful in determining bone development in many childhood and pediatric diseases. There is also SEXA (single energy x-ray absorptiometry), which is more expensive but does not require replacement of the gamma source. • Position patient’s region of interest (ROI) under the scanner. The denser the bone, the more absorption of photons. • Image patient’s nondominant arm unless there is a known fracture to that extremity. • Because of the low energy of 125I, it is used mainly on wrist or distal forearm studies. (The junction of the middle and distal third of the radius is the preferred site.) Most scanners have preprogrammed scan lengths and processing. • Compare results with database table for that patient (usually contained in a software processing program). • DPA (dual photon absorptiometry of gamma rays, 20- to 40-minute scan) or DEXA (dual energy x-ray absorptiometry, 2- to 5-minute scan) for other patients emphasizes lumbar spine and proximal femur at the hip. • Position patient supine on imaging table; elevate legs at knees to flatten pelvis and lumbar spine against scanning table. • Obtain scan of L1–L5, rectilinear fashion, with dual energy photon beam beneath table. Gamma or x-rays pass through patient and are picked up by detector on C-arm above the table. 18

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 19

Chapter 4 — Bone Density (Densitometry)

• Obtain scan of proximal femur (hip area). • Obtain scan of distal radius and/or wrist. • Compare values to those of a database established for patient’s characteristics (e.g., age, sex, race, and weight).

NORMAL RESULTS • Values obtained from scan or scans fall within normal limits listed in established database table. • Results are compared with age-matched controls (Z score) or to a young normal population (T score) that represents the peak bone mass. This is expressed as percentages or standard deviations from the normal range. • T score of greater (less negative) than −1.0 (<1 standard deviation below young normal controls) is normal.

ABNORMAL RESULTS Values between −1.0 and −2.5 are evidence of osteopenia. Values of less (more negative) than −2.5 are osteoporosis. Values ≥ 10% lower than published mean for patient’s age are considered mildly osteoporotic. Clinically significant osteopenia. Patients with vertebral values between 0.8 and 0.99 g/cm2 have about a 20% predictability of spontaneous fracture. • Patients with vertebral values between 0.62 and 0.8 g/cm2 are more likely to have a spontaneous fracture. • Patients with vertebral values < 0.62 g/cm2 will be found to have already had at least one spontaneous fracture 100% of the time.

• • • • •

ARTIFACTS • Overlying metal objects will cause falsely elevated results. • A dense vertebra from severe degenerative disease or fracture, injury, or metastatic cancer should not be used for analysis. • Degenerative disease with severe facet sclerosis may result in artificially high values. • A heavily calcified overlying aorta may result in artificially high values. • Recent gastrointestinal barium studies may interfere because of attenuation of the photons by barium. • For patients approaching 300 pounds, because of the weak strength of the photons, extra care may be needed to reduce soft-tissue attenuation. • For patients over 300 pounds in weight, the average table weight limit, it may not be possible to do lower back/hip measurements. The alternative is to do distal forearm/wrist measurements.

NOTE • Usual analysis includes averaging anterior-posterior image values taken from the L2–L4 vertebrae. Studies include bone density (of trabecular and cortical bone), bone mineral content, percent fat, and lean body mass. The lifetime risk to women for hip fracture is 15%, compared with men, 5%. Vertebral fractures usually occur earlier and carry with them pain, decreased physical activity, and change in physical appearance, e.g., reduced height and “dowager’s hump” or senile dorsal kyphosis. With the treatment available, the earlier the diagnosis of osteopenia or osteoporosis, the more likely the better outcome. • SPA and SEXA work extremely well for pediatric patients in determining bone density and mineral content of the radius by comparing values with published normal tables. 19

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 20

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• DEXA delivers improved precision (<1%) because of increased photon flux of x-rays (35 and 70 keV), greater stability, and constancy of the photon source and hence at present is considered the superior system for measuring bone density. Scan time is ∼4 minutes for lumbar spine with whole-body bone mineral content studies in 10–20 minutes (multiple detectors). These systems can also perform ROI studies on any bone in the body, opening application possibilities to a wide variety of orthopedic and metabolic studies not easily accommodated by other modalities. • DPA may soon surpass 1% precision as well because of refinements in equipment. Both deliver clinically useful data and both deliver low radiation exposure (1–2 mrem to the skin surface). If 153Gd is used as the gamma source (44 and 100 keV), although the useful life might be up to 18 months, it is recommended that it be changed once a year. • CT can also be used for single or dual photon technique. The scanner can be programmed or modified to accommodate either. The radiation exposure, however, is 250–1000 mrem per study. Some of the positions required are awkward to achieve. • Drugs for osteoporosis: • Estrogen therapy and Hormone therapy (e.g., Prempro®) • Raloxifene (Evista®) • Teriparatide (parathyroid hormone, Forteo®) • Alendronate (Fosamax®) • Risedronate (Actonel®) • Calcitonin (Miacalcin®, Calcimar®, or Fortical®) • Pamidronate (Aredia®) • Ibandronate (Boniva®) • Corticosteroids • Etidronate (Didronel®) • Sodium fluoride (Fluoritab®, Karidium®, Pharmaflur®)

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of bone disease?

Y

N

Is there a family history of osteoporosis or dowager’s hump?

Y

N

Do you have any breaks or fractures?

Y

N

Have you had any recent surgery requiring metal or screws in back, hip, legs, or arms?

Y

N

Have you had any recent trauma to arms, hips, or legs?

Y

N

If so, where and when?

Y

N

Are you on steroid therapy?

Y

N

Are you taking calcium supplements?

Y

N

If so, what type and for how long? What is your age, height, and weight?

(continued)

20

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 21

Chapter 4 — Bone Density (Densitometry)

Are you taking Didronel or alendronic sodium (Fosamax®) or any drug for osteoporosis?

Y

N

Do you have any prostheses?

Y

N

Have you had any recent barium studies?

Y

N

Have you had any of the following diseases: rheumatoid arthritis, lupus, hyperthyroidism, hypothyroidism, kidney disease, diabetes, Cushing’s syndrome, Crohn’s disease, colitis, gastrectomy?

Y

N

Are you physically inactive?

Y

N

Have you had any recent related studies or scans?

Y

N

Y

N

Have you experienced a pregnancy?

Y

N

Have you experienced menopause?

Y

N

Have you had your ovaries removed?

Y

N

Have you had a hysterectomy?

Y

N

Are you on any female hormone replacement therapy?

Y

N

If so, for how long?

Female patients: Are you pregnant or nursing? When was your last menstrual cycle?

If so, at what age?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Brener T, ed. Nursing 2007 Drug Handbook, 27th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Chohan N, ed. Nursing 99 Drug Handbook. Springhouse, PA: Springhouse, 1999. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 21

10766-04_CH04_redo.qxd

12/3/07

3:47 PM

Page 22

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notes

22

10766-05_CH05_redo.qxd

12/3/07

3:48 PM

Page 23

chapter

5

Bone Marrow Study RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-SC (sulfur colloid). Filtered can be used.

bone marrow study demonstrates the distribution of the functioning intravascular mononuclear phagocyte component of bone marrow.

Quality Control • Chromatography >90%, particle size 0.1 to 1.0 um. • Use within 6 hours.

Localization • Phagocytosis by reticular cells of liver, spleen, bone marrow, and lungs. Complete clearance by reticuloendothelial system (RES) by liver (80–90%), spleen (5–10%), and bone marrow (8%). Localization is flow dependent and requires functional integrity of RES cells in bone marrow sinusoids. The

Adult Dose Range • 12–15 mCi (444–555 MBq).

Method of Administration • Intravenous straight stick • Or: Intravenous catheter and flush.

INDICATIONS • • • • • •

Evaluation of functional capacity of bone marrow (especially in cases of anemia). Evaluation of bone marrow space enlargement (e.g., polycythemia). Assessment of bone marrow for metastasis. Evaluation of bone marrow abnormalities (e.g., infarct, ischemia, asymmetric distribution). Evaluation of bone marrow sites for biopsy. Evaluation for liver disease, chronic anemia, leukemia or other blood disorders, thrombocytopenia (too few platelets), thrombocytosis (too many platelets), tumors, abscesses, cysts, and trauma. • Evaluation of prosthetic joint for infection. 23

10766-05_CH05_redo.qxd

12/3/07

3:48 PM

Page 24

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Evaluation of abnormal blood-work results or abnormal findings on related diagnostic scans. • Confirmation of effect of cytokine.

CONTRAINDICATIONS • None.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Patient to void before imaging.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• Statics: • 100,000 to 200,000 counts. • Whole body: • 10 to 12 cm per minute.

Collimator • Low energy, all purpose or low energy, high resolution

PROCEDURE • Time: 60 minutes • Inject patient, wait at least 15 minutes to 1 hour before imaging. This allows time for particles to concentrate in the reticuloendothelial system. • Position patient supine after emptying bladder. • Statics: Obtain the following posterior images: • Lumbar and pelvis area (do NOT include liver/spleen) • Head and thoracic spine. • Left and right hips to include femur. • Left shoulder to include humerus (do NOT include liver/spleen) • Right shoulder to include humerus (do NOT include liver/spleen) • Long bones if ectopic bone marrow production suspected. • Anterior: head to thigh. • Whole body: • Anterior head to toe. • Posterior at least head to knees. • Statics of arms if necessary. • May want to shield liver/spleen.

NORMAL RESULTS • Active physiologic bone marrow in sternum, vertebral column, shoulders, humerus, pelvis and femoral heads. • Majority of radiotracer will visualize in the axial skeleton. • Uptake in the appendicular skeleton should not extend beyond proximal one third. • Relative radiotracer uptake is roughly 82% liver, 10% spleen, 8% bone marrow. 24

10766-05_CH05_redo.qxd

12/3/07

3:48 PM

Page 25

Chapter 5 — Bone Marrow Study

ABNORMAL RESULTS • Enlarged bone marrow space will present with bone marrow activity throughout the rest of the bony skeleton (peripheral extension, distal extremities). • Increased visualization outside normal regions may indicate extramedullary hematopoiesis, e.g., chronic hemolytic anemias (thalassemia, sickle cell anemia, hereditary spherocytosis), myelophthisic anemias, myeloproliferative disorders (postpolycythemic myeloid metaplasia). • Focal defects, e.g., bone marrow infarcts, heterogeneous appearance (sickle cell anemia). • Increased liver and spleen size. • Polycythemia presents with easily visible normal bone marrow and proliferation of bone marrow pattern is noted. • Primary or metastatic tumors in bone marrow may present if at least 2 cm in size or greater depending on infiltration. • Abscess may present if at least 2 cm in size. • Atrophy in bone marrow is gross and ectopic areas of bone marrow are visualized, e.g., long bones and small bones of hands and feet. • Leukemia and lymphoma will present with deficient bone marrow visualization with perhaps ectopic bone marrow visualization and focal defects. • Femoral head avascular necrosis presents with a complete absence of visualization of bone marrow activity (graded 0 to 4: 0 or minus value most significant, 1 to 4+ is adequate flow). • Prosthesis evaluation: bone scan hot, bone marrow scan with no abnormality or photopenic defect.

NOTE • Bone marrow imaging can be performed after a positive 111In-WBC scan for osteomyelitis. • Image after the 24 hour 111In-WBC scan. • Image only the areas that were positive. • Use a 10% window with a low energy collimator if possible. • Acquire 300 second images. • A liver/spleen study can also be performed while patient is injected for a bone marrow study. • A higher dose is needed for bone marrow imaging than for liver/spleen scan to visualize the bone marrow. • 111In-chloride has been used to image bone marrow: • t1/2: 2.8 d • Energies: 173, 247 keV • Type: EC, γ, accelerator • Indium binds to transferrin similar to iron. • Behaves similarly to sulfur colloid. • Clinically useful in aplastic anemia, myelofibrosis, and a variety of other hematologic disorders not to include hypoplastic marrow diseases (e.g., RBC aplasia). • Inject 1 to 2 mCi, 24 to 48 hour images, whole body, medium energy collimator. • Normal activity would be similar to colloid and renal uptake but very little liver/spleen uptake.

ARTIFACTS • Liver/spleen uptake will make visualization of lower rib cage, lower thoracic and perhaps upper lumbar vertebrae difficult to analyze. • Patients with suppressed RES will affect the diagnostic value of the test. • Lung uptake may indicate colloid clumping within radiopharmaceutical due to aluminum contamination of antacids or androgen therapy. • Surgery using anesthetic within 1 month can cause colloid shift from liver to spleen and contribute to decreased hepatic uptake of radiocolloid. 25

10766-05_CH05_redo.qxd

12/3/07

3:48 PM

Page 26

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Radiation therapy to bony areas does not decrease the visualization in those areas. • Chemotherapy may cause irregular distribution, hepatomegaly, and/or greater than normal shift to spleen and bone marrow. • Normal bilateral femoral head uptake in children and teens but 50% of adults demonstrate no uptake. Positive only when asymmetry is present.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have any known blood disorders?

Y

N

Do you have a history of liver or spleen disease?

Y

N

Do you have a history of malaria or tropical diseases?

Y

N

Do you have anemia of any kind?

Y

N

Have you had any recent trauma?

Y

N

Are you diabetic?

Y

N

Have you been feeling lethargic?

Y

N

Do you have high or low blood pressure?

Y

N

Have you had any previous related MRI, CT, PET scans, or x-rays?

Y

N

Have you had any surgery on the bones?

Y

N

Do you have any recent blood-work results?

Y

N

Females: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. 26

10766-05_CH05_redo.qxd

12/3/07

3:48 PM

Page 27

Chapter 5 — Bone Marrow Study

Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

27

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 28

chapter

6

Bone Scan (Skeletal Imaging) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • MDP (methylene diphosphonate) or HDP (hydroxymethylene diphosphonate)

Localization • Chemisorption; chemically bonds on surface of hydroxyapatite crystals. These hydrolyze and bind normally to bone as tin oxide and/or TcO2, and present as prominent focal areas during the process of osteoblastic activity of bone repair.

Quality Control • No O2 in kit. Chromatography, 90–95% tagging. Use within 4 hours.

Adult Dose Range • 20–30 mCi (740–1110 MBq), pediatrics by weight.

Method of Administration • Intravenous: Straight stick, butterfly or existing IV catheter with saline flush. Flow requires fast bolus injection.

INDICATIONS • Detection of primary and staging metastatic disease. (Types known to frequently metastasize to bone are breast, lung, prostate, and kidney.) • Evaluation of neoplasm or known lesion(s). • Differentiation of monostotic (single bone) from polyostotic primary bone tumors. • Differentiation between osteomyelitis (inflammation of bone and bone marrow) and cellulitis (inflammation of cellular or connective tissues). A three-phase flow study is indicated. Three-phase 28

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 29

Chapter 6 — Bone Scan (Skeletal Imaging)

• • • • •

• • • •

• • •

studies examine vascular, immediate blood pool, then osseous (osteoblastic) activity distinguishing cellulitis (activity in flow and immediate phases) from osteomyelitis (activity in third or all three phases). A fourth phase includes a 24-hour delay. Evaluation of prosthesis concerning suspected loosening, infections, avascular necrosis, and/or pain. In some institutions, this also indicates a three-phase bone scan. Evaluation of reflex sympathetic dystrophy. In some institutions, this also indicates a three-phase bone scan. Detection of occult (obscure, difficult to find) fractures and known or suspected fractures. Some institutions flow fractures. Evaluation of bone pain and/or trauma. Detection and evaluation of metabolic bone diseases such as Paget’s disease (bone inflammation and resorption replaced by soft bone), osteoporosis, and osteomalacia (vitamin D deficiency) and other osteopathies. Detection and evaluation of arthritis and degenerative disk and/or joint (osteoarthrosis) disease. Evaluation of bone graft viability, bone viability when blood supply is in question (infarct). Evaluation for bone surgery (e.g., vertebroplasty, total knee or hip replacements). Evaluation of abnormal laboratory results (e.g., elevated prostate specific antigen [PSA], elevated alkaline phosphatase in osteogenic sarcoma and metastatic prostate cancer, elevated Ca2+ in breast, lung, and kidney cancer bone). Evaluation of abnormal findings on other diagnostic images, e.g., x-ray images, PET, MRI, CT. Evaluation of response to chemotherapy, radiation therapy, antibiotic therapy, and other treatment. Localization of sites for biopsy.

CONTRAINDICATIONS • Patient who has recently ingested contrast medium (particularly barium) for a different study (x-ray) or has one scheduled between injection and imaging. CT and MRI agents do not seem to attenuate these studies. • Patient who has recently (24–48 hours) had a technetium-based nuclear medicine scan performed. • Some institutions require approval from case management for inpatients before a scan can be performed.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. For flow of three phase bone study; remove any attenuating material from region of interest (ROI). Instruct patient to drink lots of fluids (hydrate well) and urinate often before imaging. Instruct patient to return in 2–4 hours (usually 3 hours) after injection for delayed statics, whole body imaging or SPECT.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Flow • Dynamic, 2–4 seconds for 60 seconds with immediate blood pool image ∼500,000 counts

Collimator • Low energy, high resolution, or low energy, all purpose

Static Imaging • Extremities 200,000–300,000 counts; torso 500,000–800,000 counts 29

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 30

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Whole Body Sweep • Check length of patient, usually 10–14 cm/min, and patient orientation

Single Photon Emission Computed Tomography (SPECT) • Circular or noncircular, 360°. 64 stops, 20–25 sec/stop; ROI centered

PROCEDURE

(TIME: IMMEDIATE FLOWS, ~10 MINUTES; SCANS, ACQUIRED 2–4 HOURS [USUALLY 3 HOURS] AFTER INJECTION; IMAGES TAKE 20–60 MINUTES) • Instruct patient to empty bladder, empty pockets, remove jewelry and necklaces, check pants and shirts for buttons, external prosthesis, braces, etc., anything that can cause artifacts and attenuation. • Remove cardiac monitors from field of view (FOV). • Note location of pacemaker, pumps, colostomy bags, etc. • For whole body scan, position patient supine (although prone, sitting, or standing is not uncommon), arms at side, with knee pillow and foot band (if protocol). • For SPECT, position ROI in center FOV. Some require SPECT for all pars interarticularis spinal stress fractures or defects. Pars interarticularis is the region between the superior and inferior articulating facets of the vertebra, an area where fracture frequently occurs with spondylolysis.

Images • Three-phase: Obtain flow and immediate blood pool. Position ROI in camera view. • Inject radiotracer; start pictures after slight delay to capture the flow into ROI (watch for first sign of “blush” in persistence scope. It takes a little longer for feet or elderly patients). • Obtain immediate blood pool image after flow (∼200,000–500,000 counts). • For extremities, obtain at least immediate blood pool image of ROI; also may take images including nearest joint and laterals/medials. • For reflex sympathetic dystrophy (RSD), obtain flow to wrists, then bilateral statics for hands to shoulders. If hands or wrists need to be flowed, consider a foot vein injection. • Obtain statics: 2–4 hours after injection, 24-hour delays (fourth phase) uncommon but can be requested. • Limited: ROI same as immediate blood pool. • Axial: Acquire anterior/posterior, laterals, obliques. • Extremities: Anterior/posterior, proximal and distal joints, legs—add laterals and medials. If knees are ROI, take laterals and medial with knees at 90° angle. • With flow: Obtain images the same as acquired with flow. Be sure to include ROI, images to closest proximal joint, and laterals/medials (especially with lower extremities). • For reflex sympathetic dystrophy, obtain images up to shoulder. • For carpal tunnel syndrome and all hand and wrist flows, obtain images up to elbow. Include shoulders if pain radiates there. • Other common static images: Right and left posterior obliques, right and left anterior obliques, tail on detector (TOD), tail in air (TIA), laterals/medials, frog leg, plantar, palmar, vertex, etc. • Whole body statics: 2–4 hours after injection. Overlapping images. • Anterior: Pelvis, femur, knees, tibia/fibula, feet, abdomen, thorax, right shoulder, left shoulder, head. • Posterior: Pelvis, abdomen, thorax arms down/arms up to move scapula, head. No extremities unless there is an area of interest that needs defining. • Whole body sweep, single and dual head cameras: 2–4 hours after injection. Low energy, high resolution collimator(s). Matrix set for 256 × 1025 × 16 or greater, time set for 20–30 minutes (10–20 cm/min), 24-hour delays if ordered. • If anything is visualized that cannot be easily identified or the position assessed, add static oblique and lateral views, particularly with an outpatient. 30

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 31

Chapter 6 — Bone Scan (Skeletal Imaging)

• SPECT: Position patient ROI in camera view. 360° rotation (dual head; 180° per head) at 60–64 steps/ head, 20–40 sec/stop. Process as per protocol: transverse, coronal, and sagittal slices.

NORMAL RESULTS • • • • • •

Symmetric, uniform uptake with increased activity in joints, junctions, and scapulas. Nasopharynx and soft tissue uptake. Kidneys show lightly, bladder shows brightly. Liver uptake can be a normal variant if there is slow release or liver disease. Epiphysial plates and cranial sutures show brightly in growing children. The top and front of the cranium will sometimes present with increased activity especially in women. This occurrence is called hyperostosis frontalis internus and is not associated with a pathological condition. • THR (cemented) should be negative within 6 months. THR (non-cemented) can remain with increased uptake for up to 24 months. • Older patients may have a globally poor quality scan. • It usually takes 3–5 days for new fractures to present positive but may present as early as 24 hours because of bone healing process.

ABNORMAL RESULTS • Asymmetric, focal areas of increased or decreased activity. • “Super Scan” with bone uptake showing brightly, no kidney, bladder, appendicular skeleton, distal extremities, facial bones, subtle asymmetries of the rib, skull vault, and proximal long bones, and no soft-tissue uptake apparent on film at normal intensities; caused by intense and widespread metastatic involvement. Tumors causing this type of osseous metastasis are prostate, breast, lung, renal, bladder, or lymphoma. • Nontumor (metabolic disease) causes are hyperparathyroidism, hyperthyroidism, osteomalacia, Paget’s disease of the bone (elevated alkaline phosphatase levels), or fibrous dysplasia. • Metabolic diseases involve the calvarium (cranium) axial skeleton, mandible, costochondral junctions, sternum, and long bones, whereas metastases tend to spare them. • Paget’s disease may present with “Halloween mask” skull and uptake in sacrum, pelvis, and long bones. • Cold lesions: Diminished activity or none is indicative of osteonecrosis, osteoporosis, osteomalacia, multiple myeloma (normal or lowered), radiation or steroid therapy, end-stage cancer patients with diminished metabolism, renal cell carcinoma, thyroid cancer, anaplastic tumors, neuroblastoma. • Osteomyelitis: Increased uptake in flow, blood pool, and delays. • Cellulitis: Increased uptake in flow and blood pool with mild or no uptake in delays. • Prosthesis loosening and/or infection: Increased activity around prosthesis on bone surfaces and inside bone surfaces, e.g., proximal femur. 99mTc-Ceretec WBC or 111In-WBC or 67Ga scans may help differentiate infection from loosening (and Neutrospec® if it is on the market for infection). • Primary malignant tumors (osteogenic and chondrosarcomas): Increased vascular flow, blood pool, and delays focally. • Benign primary tumors (osteoid osteoma): Increased blood pool and delays, focally intense. May have double-intensity sign of hot area surrounded by less but increased intensity. Other types of benign lesions may show increased uptake. • Arthritis presents as increased activity in and around joints in flow, blood pool, and delays. • Reflex sympathetic dystrophy (RSD) presents very early; increased flow and increased uptake around the joint (periarticular). Within first year; increased perfusion, normal blood pool and increased delayed images, later; decreased flow and blood pool and decreased delayed images. Some, especially children and lower extremity involvement will present with reduced or normal flow, increased blood pool and any appearance on delayed bone uptake. 31

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 32

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• A pars defect that is a bone fracture (there are many types of pars defects) will present in the posterior view of the vertebrae, usually lumbar. It may appear as slightly increased activity in the planar or whole-body sweep. SPECT images often assist in pinpointing the existence and location of the defect(s). They can present as single (right or left side of the vertebrae) or double involving both sides of the vertebrae or involving more than one vertebra. These are often the result of falling and/or twisting motions of the torso as with athletic activities. • Cartilage of the rib cage may present if there is an inflammatory process in progress. This could be due to blunt trauma or aggravation to the chest, e.g., recent CPR, an accident involving hitting the chest. It could also (especially if bilateral) be due to a pathologic condition, e.g., costochondritis (Tietze’s syndrome) which is an inflammation of the cartilage. • “Donut” sign or lesion usually in cranium looks like a hot halo in skull. If not a bullet hole, then referred to as idiopathic bone dysplasia. It could be caused by eosinophilic granuloma, metastasis, sickle cell infarct, Paget’s disease, avascular necrosis, among others. • Heart uptake in a bone scan: Amyloidosis (soft-tissue deposition of amyloid protein has affinity to bone agents) on a background of tuberculosis, prostate cancer, and coronary artery disease. Also by chemo-related cardiomyopathy. • Bright areas on liver or other organs could be calcified metastasis to that organ. • Diffusely increased soft-tissue uptake in the body presents with poor kidney function. • No uptake in focal areas: Radiation, bone infarct, avascular necrosis, metal prosthesis, tumor has replaced bone, poor venous return, edema in extremity. • No uptake or very little globally: Bad radiochemical tag, wrong radiopharmaceutical, extreme metabolic lesion involvement (diffuse lytic metastatic disease), hyperparathyroidism, age and/or disease process inhibiting uptake.

DRUG INTERACTIONS • Bone visualization decreased (and sometimes increased blood pool and increased renal retention): Iron-containing compounds, phosphorus containing mixtures, therapy dose of diphosphonate, also osteoporosis or CHF. • Bone uptake increased (mimics osteomyelitis): Chemoperfusion, calcium gluconate, iron dextran, heparin, meperidine. • Breast tissue uptake: Estrogens • Calvarium uptake diffuse: Cytotoxic chemotherapy, “sickle sign.” • Liver visualization: Aluminum containing antacids, metastatic liver disease, hepatic necrosis, hypercalcemia, amyloidosis. • Muscle uptake: E-amino caproic acid

ARTIFACTS • Belt buckles, medallions, buttons, glasses, zippers, prostheses, dental work, metal articles implanted with surgery, guns, knives, and other articles (money, keys, wallets, asthma sprays, cell phones, etc.) in pockets cause cold spots. • Bladder may need lead shield or catheterization. • Pubic lesions may be obscured by bladder activity. • Catheters or urine seepage, IV infiltration, and contaminated clothing or linen cause hot spots. • Patient movement or rotation may distort view. • Radiotracer tag may break down or be delivered to the department with a bad tag resulting in “free Tc” that localizes in the thyroid, stomach, gastrointestinal tract or other systems but not the bones. Image the results for proof using 2- to 5-minute statics that include the stomach and thyroid. • Imaging begun too soon or with patient not hydrating adequately before imaging may show excessive activity in soft tissue. • Degenerative joint disease, surgery, and old trauma may give false-positives. 32

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 33

Chapter 6 — Bone Scan (Skeletal Imaging)

• Scan ordered too early for fractures. Although a nuclear scan can detect a hairline fracture before a radiograph, it usually takes 3 to 5 days for new fractures to present as positive. If looking for pseudoarthrosis or stress fracture, take 3-hour postinjection images. • Take laterals, obliques, and/or any other helpful positions if there is any question about a visualization (better too many than too few, or needing the patient to return at radiologist’s request).

NOTE: • It takes 15% loss of calcium mineral to be detected by nuclear medicine procedure; 30–50% loss of calcium mineral to be detected by x-ray. • Positive bone scan for fractures need: Adult; 24 hours, elderly; 72 hours. Bone uptake returns to normal within 1 year for ribs to 3 years for elderly and long bones. • 3-phase bone scan can detect osteomyelitis much earlier (23–72 hours after onset) than plain radiographs (7–14 days). • Some like to use 3-phase for stress fractures versus shin splints. Stress fractures will be positive in all three phases (solitary, focal, fusiform, longitudinal increase in uptake), shin splints only in the delays (linear and longitudinally posteriorly tibial). Stress fractures will present positive only on delays up to 2 to 4 weeks post-injury. • Alkaline phosphorus levels elevated in patients with osteogenic sarcoma. • Ca2+ levels elevated in patients with breast, lung, and kidney cancer bone metastasis. • Acid phosphatase levels elevated in patients with metastatic prostate cancer. • Metastasis to the bone is uncommon if PSAs are <20 and there is no bone pain. • Gleason Scores: As well as using PSA levels as an indicator. Gleason Grading for prostate cancer is a method employed by pathology labs, using tissue from biopsy, to determine the histologic grade (degree of aggressiveness) of a tumor. • Gleason Grades are numbered 1–5, with grade 1 most well-differentiated cancer (slow-growing), and grade 5 most poorly differentiated (fast-growing). They assign a number to the primary grade (the most common pattern) and another number to the secondary grade (the next most common pattern). • Grade 1: Least common, especially in needle biopsies. Circumscribed mass of evenly placed uniform glands. Closely resembles normal prostate glands. • Grade 2: Similar to grade 1 but do not form a circumscribe mass. • Grade 3: Most common. Considerable variation in size, shape, and spacing of glands. • Grade 4: Fusion of glands forming anastomosing network punctuated by glandular lumens. Glands no longer recognized as individual units. • Grade 5: Cancer cells are solid sheets and clusters, may infiltrate prostate as individual cells. Necrosis may be present. No attempt at gland formation by cancer. • By adding the two grades (e.g., 3 + 2 = 5), a Gleason Score is obtained. The scale of combined grades is from 2 to 10.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have history or family history of cancer?

Y

N

Y

N

If so, what type and when was it diagnosed? Have you had any chemotherapy or radiation therapy?

(continued)

33

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 34

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have any bone pain?

Y

N

Have you had any recent falls, fractures, breaks, or trauma?

Y

N

Do you have any old sports injuries?

Y

N

Have you had any recent surgery?

Y

N

Do you have any pumps, a pacemaker, or prostheses?

Y

N

Do you have a history of any bone or kidney disease?

Y

N

Have you had any recent dental work?

Y

N

Have you had recent abnormal blood tests or lab work (e.g., tumor markers, PSAs, Gleason scores)?

Y

N

Have you had any previous scans or x-rays or have any scheduled diagnostic tests (e.g., x-ray barium studies, CT with contrast)?

Y

N

If so, where? Since when?

If so, what type, when, and where? Reflex sympathetic dystrophy (RSD) patients: How long have you had or suspected RSD? Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington: American Pharmacists Association, 2004. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Smeltzer SC, Bare BG. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 8th ed. Philadelphia: Lippincott, 1996. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 34

10766-06_CH06_redo.qxd

12/3/07

3:49 PM

Page 35

Chapter 6 — Bone Scan (Skeletal Imaging)

Notes

35

10766-07_CH07_redo.qxd

12/3/07

3:51 PM

Page 36

chapter

7

Brain Scan/Death (Brain Flow) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • Non–blood–brain barrier (BBB)-penetrating: Na 99mTcO−4 (pertechnetate), 99mTc-GH (Glucoheptonate), 99mTc-DTPA (diethylenetriaminepentaacetic acid) • BBB-penetrating: 99mTc-HMPAO (d,l-hexamethylpropyleneamine oxime or Ceretec™) and others (see list at end)

Localization • Compartmental to blood supply

Quality Control • Moly-Al breakthrough, chromatography. > 90% tag.

Adult Dose Range • 15–30 mCi (555–1110 MBq)

Method of Administration • Bolus IV

INDICATIONS • Determination of brain death. This is the most common usage of brain flow because other types of studies and modalities are as good or better for other indications. • Evaluation of blood flow. • Evaluation and localization of primary and metastatic tumors, abscesses, subdural hematomas, and lesions. • Detection of vascular malformations, inflammatory or infectious diseases, cerebrovascular accidents (CVAs), and transient ischemic attacks (TIAs). • Differentiation between contusions from simple concussions or brain tumors from vascular accidents. 36

10766-07_CH07_redo.qxd

12/3/07

3:51 PM

Page 37

Chapter 7 — Brain Scan/Death (Brain Flow)

• Evaluation of suspected arteriovenous malformations (AVMs). • Evaluation of surgical procedure, radiation therapy, or chemotherapy. • Evaluation of intracerebral inflammatory or degenerative diseases, e.g., acquired immunodeficiency syndrome (AIDS), multiple sclerosis, collagen diseases. • Evaluation of unexplained neurologic symptoms. • Evaluation of blood flow because of abnormal results on related studies.

CONTRAINDICATIONS • Patient too agitated or uncooperative to remain still for acquisition. • In brain death, metal components of halo, breathing apparatus, or patient physical positioning may impede the protocol for the exam.

PATIENT PREPARATION • Brain death: None. • Other: Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to remain motionless during imaging.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Flow • 2–10 sec/frame, 60 seconds

Collimator Flow and Blood Pool • Low energy, all purpose, or low energy, high sensitivity Delays • Low energy, all purpose, or low energy, high resolution

Dynamic Blood Pool Images • 60 sec/frame for 30 minutes. Blood Pool Statics and Delays • 200,000–800,000 counts

PROCEDURE

(TIME: INITIAL FLOW AND BLOOD POOL ~30 MINUTES; DELAYS ~45 MINUTES) Flow: Can be anterior (usually for adults) or posterior (usually for children) (or dual head camera, get both, position head straight up). • Position patient supine, camera anterior, as close as possible, entire cranium in field of view (FOV), head flexed back facing straight up (head is held or strapped in place). Or: • Position patient supine, camera posterior, as close as possible, entire cranium in FOV, chin tucked down to expose posterior fossa and for better evaluation of transverse sinus, head straight up (head is held or strapped in place). • Place a tourniquet or ace bandage around head to limit amount of scalp circulation. • Inject good bolus, start camera immediately. Better too early than too late. The flow is extremely important to the diagnosis. • Obtain at least one blood-pool image in same position at end of flow. 37

10766-07_CH07_redo.qxd

12/3/07

3:51 PM

Page 38

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Optional views include anterior, posterior, right and left laterals, and vertex (right side markers sometimes help in orientation, and if possible, use lead apron around patient’s shoulders to shield body counts on vertex view) views at this time, 200,000–800,000 counts/image.

Delays • Patient is returned after 1–2 hours (usually 2 hours) for delayed images. • Anterior, posterior, right and left laterals, and vertex views are repeated (right side markers sometimes help in orientation). Radiologists may want them repeated again at 4 or more hours. • With 99mTc-HMPAO, images acquired at 15 minutes after injection. Single photon emission computed tomography (SPECT) acquisition may also be performed if required.

NORMAL RESULTS • Flow: Three phases • Arterial phase: Subclavian, carotid, cerebral arteries visualize symmetrically • Capillary phase: Symmetric diffuse activity in both cerebral hemispheres • Venous phase: Sagittal sinus and jugulars visualized • Blood pool: Soft tissue and venous sinus activity • Delays: (Depending on view) • Superior rim, sagittal sinus, transverse sinus (small or absent left sinus not unusual), occipital sinus, facial vascularity, and salivary glands increased activity • Cerebral cortex normally devoid of activity

ABNORMAL RESULTS • Brain death criteria: • Flow: No intracranial blood flow (arterial, capillary, or venous) from base of skull up. No perfusion with BBB-penetrators. • Blood pool: No visualization of sagittal sinus on immediate postinjection images. • Delays: No visualization of dural sinus. Occasionally, sagittal or transverse sinus seen faintly over time because of scalp circulation or drainage through basilar system. In pediatric patients, sutures may visualize because of diminished background. • “Hot nose” effect: Blood flow is blocked in the internal carotid arteries, shunted to the external carotid arteries, increasing blood flow in the nasal/sinus area presenting on the anterior flow as a “hot nose.” • Other: (Look for areas of increased uptake, “doughnut” sign, lack of uptake, or diminished flow) • Flow: Focal area(s) of increased or decreased uptake other than normal vascularity and/or abnormal appearance to vascularity. Asymmetric flow. “Flip-flop” sign, one side visualizing then the other. Unmatched activity in any phase. • Blood pool: Focal area(s) of increased or decreased uptake persist and/or abnormal appearance to vascularity. • Delays: Focal area(s) of increased or decreased uptake persist. Perhaps visualization of new areas not present on initial dynamic study.

ARTIFACTS • The flow is all-important. “Don’t blow the flow!” If necessary, set for 120 seconds and start as soon as or just before the injection is in. • Increased blood pool activity–aluminum containing antacids, sulfonamides, pyrophosphates, other radiopharmaceuticals present in system. • Increased uptake in superior sagittal sinus and transverse sinuses—the above list. 38

10766-07_CH07_redo.qxd

12/3/07

3:51 PM

Page 39

Chapter 7 — Brain Scan/Death (Brain Flow)

• Patient movement. • Metal plates and respirator or life-support equipment attenuation.

NOTE • This procedure is nonspecific. It delineates areas of increased vascular permeability secondary to a variety of disease processes. Early strokes, abscesses, tumors of the pituitary, and grade I and II astrocytomas often visualize poorly. The latter two problems account for more than half of the false-negative results.

Non–BBB Penetrating Radiopharmaceuticals TcO−4 (pertechnetate) 99mTc-DTPA (diethylenetriaminepentaacetic acid) 99mTc-GH (glucoheptonate) 99mTc-RBCs (tagged red blood cells) 99mTc-MDP (methylene diphosphonate) 99mTc-HDP (hydroxymethylene diphosphonate) 67Ga-citrate 201Tl-chloride 99m

Delays 2–4 hours 0.5–1 hour 1–4 hours 0.5–1 hour 2–4 hours 2–4 hours 24–72 hours None

BBB Penetrators 133

Xe-gas 123I-Iodoamphetamine 99mTc-HMPAO (d,l-hexamethylpropyleneamine oxime or Ceretec®) 99mTc-ECD (ethyl cysteinate dimer, bicisate, or Neurolite®)

Delays None 0.5–1 hour 0.25–3 hours 2–3 hours

PATIENT HISTORY

The patient should answer the following questions. Ask relative, care taker, or medical team that brought the patient if the patient’s alertness and/or responsiveness is in question. For brain death Any known head/neck trauma?

Y

N

Any known plates? (Check chart)

Y

N

Do you have a history or family history of cancer?

Y

N

Do you have a history of recent or old trauma?

Y

N

Do you have any head pain?

Y

N

Brain flow

(continued)

39

10766-07_CH07_redo.qxd

12/3/07

3:51 PM

Page 40

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Are you suffering from headaches, speech problems, equilibrium or vision problems, unusual motor functions, unusual body function, mood changes, or seizures?

Y

N

Have you had any recent surgery?

Y

N

Do you have a shunt or metal plates?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, which and since when?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

40

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 41

chapter

8

Brain SPECT (Single Photon Emission Computed Tomography) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical 99mTc-HMPAO (d,l-hexamethylpropyleneamine oxime or Ceretec®) • 99mTc-ECD (ethyl cysteinate dimer, bicisate, or Neurolite®)

•

Localization • Compartmental, blood flow, lipophilic agent that penetrates through the blood-brainbarrier (BBB) merging with lipid molecules that makeup capillary membranes and brain tissue. • Trapped within the neurons where it remains constant for 8 hours. • Maximum activity (peak brain activity) at 1 minute, plateau at 2 minutes (88% peak).

Quality Control • Chromatography, > 95% radiochemical purity • Stable only for about 30 minutes and must be used within 4 hours after preparation. Breaks down into a less lipophilic compound of D, L-HMPAO, which does not accumulate in the brain. ECD does not appear to have that time limitation.

Adult Dose Range • 20–30 mCi (740–1110 MBq) • Pediatrics: 0.285 mCi/kg (5 mCi minimum)

Method of Administration • Usually through catheter or butterfly, IV slow injection with 10 mL flush in a dimly lit room. • HMPAO should have methylene blue stabilizer and injected using an accompanying filter.

41

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 42

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Evaluation of cerebrovascular accidents (CVAs), e.g., infarction, hemorrhage, transient ischemic attacks (TIAs). • Evaluation of neuropsychiatric disorders, e.g., Alzheimer’s, memory loss, behavioral changes, schizophrenia, manic depression, and dementias. • Evaluation of head trauma (acute or chronic). • Evaluation and localization of cerebral ischemia and brain perfusion. • Evaluation of brain death. • Evaluation of convulsive disorders (grand mal and petit mal). • Assessment of cognitive functions. • Detection and localization of recurring brain tumors, especially using dual-isotope method with 99mTc-HMPAO and 201Tl-thallous chloride for tumor viability study. • Assessment of brain tissue viability using 123I-Imp (N-isopropyl-P-[123I] iodoamphetamine) imaging 3–4 hours after injection for redistribution and possible viability. • Evaluation of brain because of abnormal results on related studies.

CONTRAINDICATIONS • Patient too agitated or uncooperative to hold head still. • Patient who has not adhered to the preparations for the exam or taking interfering medications.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • No caffeine, alcohol, or nicotine for a minimum of 24 hours prior to day of test. • Bring medication if necessary for cooperation during imaging, which may require another driver for after the scan. • Instruct patient to bring previous related scans and reports. • Place patient in a quiet environment before injection and examination if protocol. • Instruct patient to remain motionless during imaging (approximately 1 hour).

EQUIPMENT Camera

Computer Set-up

• Rotating large field of view camera, single- or multi-head

• Single photon emission computed tomography (SPECT) acquisition, e.g., 360° rotation, 64 projections per rotation, 20 to 40 sec/stop (200,000 counts), 128 × 128 or 64 × 64 matrix, magnified 1.3–1.5.

Collimator • Low energy, high resolution

PROCEDURE • • • • •

(TIME: ~45 MINUTES)

Start butterfly IV or catheter and wait 10 minutes. Inject patient with radiotracer via butterfly and flush. Patient is not to speak, read, or move prior to, during, and up to 5 minutes post-injection. Patient is to sit or lay in darkened room for 15 to 90 minutes. Allow patient to void prior to imaging. 42

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 43

Chapter 8 — Brain SPECT (Single Photon Emission Computed Tomography)

• Obtain images beginning 15 minutes to 3 hours after injection (90 minutes post-injection is optimal). • Position patient supine on table, head in toward camera(s). • Place head in head-holder or place an ace bandage around patient’s head and table to hold in place. • Position head into camera view so that cerebrum and cerebellum are in view. • Remind patient of absolutely no movement during acquisition. • Camera(s) mapped around head and SPECT acquisition taken as per protocol. Acquisition should begin anterior or lateral, 360°. • Use subdued lighting and noise if possible to limit extraneous brain activity.

NORMAL RESULTS • Symmetric uptake, especially of gray matter of brain. • Gray matter uptake is greater than white matter uptake. • Slight perfusion of scalp veins may be present.

ABNORMAL RESULTS • Asymmetric areas of uptake in any part of the gray matter. • Alzheimer’s presents with bilateral perfusion defects in temporoparietal regions, usually follows a pattern of decreased activity in the parietal, then temporal, then frontal lobes, but not always. • Multi-infarct dementia presents with asymmetric areas of increased or decreased activity. • Parkinson’s disease presents with increased perfusion in basal ganglia. • Huntington’s disease presents with decreased striatal (referring to the corpus striatum or the caudate and lentiform nuclei) metabolism.

BRAIN SPECT WITH DIAMOX®

(ACETAZOLAMIDE)

• This drug is a diuretic, anticonvulsant, glaucoma pressure reducer, ventilation stimulant, and a potent cerebral vasodilator.

Indications • Evaluation of cerebrovascular ischemia and regional cerebral blood flow (rCBF). • Evaluation of possible neurovascular shunt surgery.

Contraindications • Sulfonamide allergy

Procedure • • • • • • • •

Two-part test, first with chemical, second (baseline) without chemical 1 or 2 days later. Start IV on patient. Inject patient with 1 g Diamox® slowly over 2 minutes (or oral caplet). Monitor for reaction for 25 minutes (visually, take blood pressure). Inject radiotracer slowly, flush with 10 mL saline. Wait 20 minutes. Image using SPECT procedure as above. Repeat procedure without chemical after 24–48 hours. 43

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 44

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Possible Reactions to Drug Intervention (usually short acting, ~15 minutes) • Numbness in extremities or around mouth. • Feeling flushed or lightheaded, or having blurred vision.

ARTIFACTS • • • •

Movement blurs or disallows acquisition. TIAs can fill back in between attacks. May clip bottom of cerebellum. Because the patient population that generally needs this scan may be confused, uncooperative, incoherent, or encumbered with involuntary movement, patience is needed with these patients. Get a history from whoever accompanies the patient.

PROCESSING • SPECT, some use ramp and Butterworth filters (order .5) or Gaussian (alpha 3.0). Include transverse, coronal, and sagittal slices for presentation.

MEDICATIONS HELD ON PHYSICIAN’S ORDERS FOR BRAIN SPECT (BENZODIAZEPINES) • • • • • • • • • • • •

Alprazolam (Xanax®) Chlordiazepoxide HCl (Librium®) Clonazepam (Klonopin®) Diazepam (Valium®) Flurazepam (Dalmane®) Halazepam (Paxipam®) Lorazepam (Ativan®) Oxazepam (Serax®) Prazepam (Centrex®) Quazepam (Doral®) Temazepam (Restoril®) Triazolam (Halcyon®)

MEDICATIONS ALTERING HMPAO DISTRIBUTION (VASODILATORS, VASOCONSTRICTORS, ACE INHIBITORS AND OTHERS, UCLA) • • • • • • • • • •

Adenosine Anesthetics Angiotensin Captopril Halothane Methoxamine Nitroglycerin Nitroprusside Papaverine Trimethaphan 44

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 45

Chapter 8 — Brain SPECT (Single Photon Emission Computed Tomography)

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Ask relative or care taker if patient’s alertness is in question. Is there a history or family history of cancer?

Y

N

Y

N

Is there a history of any brain disorders?

Y

N

Have there been any recent behavioral changes?

Y

N

Has there been any recent head trauma or headaches?

Y

N

Has there been any recent infection?

Y

N

Have there been any recent seizures or balance problems?

Y

N

Have there been any surgeries?

Y

N

Does the patient have a shunt or metal plate?

Y

N

Are there any recent PET, CT or MRI scans?

Y

N

Y

N

If so, what type and when was it diagnosed? Has there been any recent memory loss? If so, is it long or short memory?

If so, what type and at what institution? What is the patient taking for medications? Female: Are you pregnant or nursing? Other department-specific questions

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 45

10766-08_CH08_redo.qxd

12/3/07

3:52 PM

Page 46

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notes

46

10766-09_CH09_redo.qxd

12/3/07

3:54 PM

Page 47

chapter

9

Breath Test for H. pylori: PYtest® C-14 Urea Breath Test (UBT) RADIOPHARMACY Radionuclide •

14

C t1/2: 5,730 years Energies: 156 keV(max), 49 keV(mean) Type: β−, fission byproduct

Radiopharmaceutical • Urea (NH14 2 CONH2)

Urea that is not hydrolyzed by H. pylori is excreted in urine, Tb = ∼12 hours, with the last 10% Tb = ∼40 days.

Quality Control • Capsule is precalibrated at factory.

Adult Dose Range

Localization

• 1 µCi (0.037MBq)

• Gastric urease from Helicobacter pylori splits urea molecule to form CO2 and NH3 at the interface between gastric epithelium and lumen. The 14CO2 is absorbed into the blood and exhaled in the breath, Tb = ∼15 minutes.

Method of Administration • PO by capsule taken from cup. Patient or technologist should have no other contact with capsule.

INDICATIONS • Detection of gastric urease as an aid in the diagnosis of H. pylori infection in the human stomach and/or duodenum. • Evaluation for H. pylori due to abnormal results on related studies.

47

10766-09_CH09_redo.qxd

12/3/07

3:54 PM

Page 48

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS The following may give false-negative results. • • • • •

Antibiotics within the last 30 days. Bismuth: Pepto-Bismol® within the last 30 days. Sucralfate within the last 14 days. Nonfasting: Patient should be NPO for 6 hours before test. Proton pump inhibitors within the last 14 days.

PATIENT PREPARATION • • • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Instruct patient to be NPO for 6 hours minimum before test. Physician to instruct patient to be off antibiotics and bismuth (e.g., Pepto-Bismol®) for 1 month. Physician to instruct patient to be off proton pump inhibitors and sucralfate for 2 weeks. Physician to instruct patient to be off omeprazole (e.g., Prilosec®) for 7 days. Instruct patient to bring list of pending related exams and results from past related exams. Instruct patient to brush teeth carefully in days before the test.

EQUIPMENT Camera

Computer Set-up

• Liquid scintillation counter (LSC). Single-sample (Tri-Med) or multi-sample versions available.

• 300-second counting statistics are needed for sample and background.

Collimator • N/A

PROCEDURE: SUPPLIED BY KIT. HAVE STOPWATCH AVAILABLE (TIME: ~20 MINUTES) • • • • • • •

• •

•

Order kit from radiopharmacy or directly from Tri-Med. Label balloon provided; check all materials. Place capsule into cup provided, fill second cup provided with 20 mL of water. Administer capsule to patient. Ensure no other contact with capsule. Administer 20 mL of water to patient. Time for 3 minutes. At 3 minutes, administer 20 mL more water to patient. Time for 10–15 minutes. Place straw into neck of balloon provided. Instruct patient to take deep breath and hold for 5–10 seconds, then blow into balloon (the balloon should be filled completely to comply with manufacturer’s protocol). If the patient fails to fill the balloon with the first breath, pinch off the straw, instruct patient to hold breath for 10 more seconds, then blow second (or more) breath into balloon until it is full. In the event of a leak, locate leak and tape it, or use any 2-L Mylar balloon as backup. Tie neck of balloon into tight knot. Prepare sample per manufacturer’s protocol. Send balloon back to radiopharmacy or send directly to Tri-Med by means provided. Results are faxed within 24 hours of time when Tri-Med receives the package or counted in-house with proper equipment. For counting in-house: Sample is counted in LSC for 5 minutes (300 seconds). Tri-Med supplies a detailed description of measurements, background, and efficiency ratings to use for analysis. 48

10766-09_CH09_redo.qxd

12/3/07

3:54 PM

Page 49

Chapter 9 — Breath Test for H. pylori: PYtest® C-14 Urea Breath Test (UBT)

• If the count is between 50 and 300 disintegrations per minute (DPM), wait for 30 minutes, up to several hours, or the next day, then count again because chemical activity called chemiluminescence can temporarily produce false counts on the order of 100 DPM. Samples outside this range need not be recounted.

NORMAL RESULTS • < 50 DPM, background subtracted, is negative.

ABNORMAL RESULTS • 50–199 DPM, background subtracted, is indeterminate. • ≥ 200 DPM, background subtracted, is positive for urease and H. pylori. The numbers could range into the thousands.

ARTIFACTS • Negative results do not completely rule out the presence of H. pylori. Other diagnostic tests should be performed. • False-positive results could occur in patients with achlorhydria (absence of free hydrochloric acid in stomach), antacid use, H2-receptor antagonist use, and uremia. These will allow the gastric pH to rise, allowing colonization of urease-producing flora. • False-positive results could occur in patients having urease associated with Helicobacter organisms other than H. pylori (e.g., H. heilmannii). • False-negative results could occur if the patient is not off of antibiotics, bismuth, sucralfate, or omeprazole (7 days), has rapid gastric emptying, e.g., dumping syndrome or surgery, or is nonfasting (6 hours). • Test may not work well with the physiology of the elderly or in patients who have no systemic antibody response to H. pylori. • Proton pump inhibitors • Esomeprazole magnesium (Nexium®) • Lansoprazole (Prevacid®) • Omeprazole (Prilosec®) • Pantoprazole sodium (Protonix®) • Rabeprazole sodium (AcipHex®) • H2 blockers (e.g., cimetidine [Tagamet®], ranitidine [Zantac®], nizatidine [Axid®], famotidine [Pepcid®]) and antacids (e.g., Maalox®, Rolaids®, Tums®, Mylanta®, Gelusil®) are not contraindicated.

NOTE • Urease enzyme is not normally present in mammalian cells. If found to be present, it is evidence of the presence of bacteria.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

If so, what type and for how long? (continued)

49

10766-09_CH09_redo.qxd

12/3/07

3:54 PM

Page 50

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have a history of any type of gastric disease?

Y

N

Do you have gastric or abdominal pain?

Y

N

Do you have a history of ulcers?

Y

N

Do you have a history of gastritis?

Y

N

Have you had any gastric surgery?

Y

N

Do you have a history of pernicious anemia?

Y

N

Do you have a history of adrenal insufficiencies?

Y

N

Are you a diabetic?

Y

N

Are you taking any medications?

Y

N

Are you taking any bismuth products like Pepto-Bismol®?

Y

N

Are you on antibiotic therapy?

Y

N

Are there any prior or pending related tests (endoscopy, biopsy, blood samples, CLOtest® [urease test], NM-gastric emptying, and Schilling)?

Y

N

If so, exactly where and for how long? When does it occur, after meals, what type of meals? When did you last have a meal?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Brener T, ed. Nursing 2007 Drug Handbook, 27th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Manufacturer’s pamphlet, insert, and user’s guide. Lenexa, KS: Tri-Med Specialties, Inc. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

50

10766-10_CH10_redo.qxd

12/3/07

3:56 PM

Page 51

chapter

10

Cardiac: Gated First-Pass Study (First-Transit Radionuclide Angiocardiography) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-pertechnatate, 99mTc-sestamibi (hexakis[2-methoxyisobutylisonitril]), 99mTc-tetrofosmin (1,2-bis[bis(2-ethoxyethyl)phosphino]ethane)

Adult Dose Range • 8–30 mCi (296–1110 MBq).

Method of Administration • IV catheter, butterfly, or straight stick. Small volume, < 1 mL; 6-inch or greater extension tubing attached to IV catheter and threeway stopcock for radiotracer and 10–20 mL or greater of saline flush. Use large-bore (18–22 gauge) IV catheter, fast bolus injection. Example of preparation listed below.

Localization • Compartmental to blood flow

Quality Control •

99m

Tc-sestamibi, 99mTc-tetrofosmin, chromatography > 90%

51

10766-10_CH10_redo.qxd

12/3/07

3:56 PM

Page 52

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Determination of ejection fraction of right and/or left ventricle. • Evaluation of overall function of heart for congenital heart disease or defects. • Evaluation of right ventricular dysfunction, e.g., infarct, atrial or ventricular septal defect, cardiomyopathy, chronic lung disease, primary pulmonary hypertension, pulmonic stenosis, and lung transplantation. • Detection of aortic or mitral valve insufficiency. • Evaluation of baseline study for surgery candidates. • Evaluation of follow-up study for post-therapy or post-surgical patients. • Evaluation of right and/or left ventricular wall motion. • Detection of prolapse or shunts (e.g., quantification of left-to-right intracardiac shunts). • Evaluation of chamber-to-chamber transit times. • Evaluation of pulmonary transit times.

CONTRAINDICATIONS • None.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Instruct patient to be NPO for 4–12 hours (no sugar, caffeine, or dairy products). Place five- or three-lead ECG setup on patient. Position patient supine on table; if possible have right antecubital basilic vein accessible for injection site. Some prefer jugular vein.

EQUIPMENT Camera

Computer Set-up

• Large field of view gamma camera or multicrystal

• Most have a preprogrammed study. List mode, 16 frames/cycle or frame mode, 20–35 frames/sec, 64 × 64 matrix or can use 32 × 32 matrix for a 20-cm field of view (FOV). Study is usually about 20–120 seconds or 800–1200 frames.

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

(TIME: 15 MINUTES, USUALLY IN CONJUNCTION WITH ANOTHER TEST) • Position patient supine on bed. • Connect three-lead ECG for gated first-pass study. • Position camera anterior (although 30° RAO or LAO can be used depending on intent) with right arm (or IV arm) and heart in camera view. • Start IV or butterfly, preferably in basilic vein of right arm (left will do if need be; some use right external jugular vein). • Start camera and inject quickly to catch bolus. • When program is done, IV or butterfly is removed if not required for second study to follow, e.g., patient may be scheduled for a 1-day perfusion protocol. 52

10766-10_CH10_redo.qxd

12/3/07

3:56 PM

Page 53

Chapter 10 — Cardiac: Gated First-Pass Study (First-Transit Radionuclide Angiocardiography)

• Options: Position patient and camera for single photon emission computed tomography (SPECT) perfusion study, ask to return at specified time for resting SPECT, image for a multi-gated acquisition (MUGA) study if patient was administered 99mTc-stannous pyrophosphate-labeled red blood cells, ask to return for myocardial infarction scan if pyrophosphate was used, or appropriate timing if any other test was planned after the use of whatever radiopharmaceutical for the first pass, or dismiss if patient is finished with procedure.

NORMAL RESULTS • Left ventricular ejection fraction: 50–80%. • Right ventricular ejection fraction: 40–60%. • Bolus travels through right atrium and ventricle to lungs and back through left atrium and ventricles with no obvious obstruction or alteration in path. • No deviations in full contraction of heart; all walls working and pushing in a coordinated manner.

ABNORMAL RESULTS • Cine showing one or more walls with abnormal movement (dyskinesis-paradoxic passive expansion, rather than contraction, of a myocardial segment during systole, e.g., a left ventricular aneurysm is characterized by localized dyskinesis), decreased wall motion (hypokinesis), or no movement (akinesis). • Low ejection fraction, i.e., 35–45%, or less. Severe impairment is present below 30%. • Regional wall abnormalities indicate coronary artery disease.

EXAMPLE OF A SET-UP

(OTHERS ARE NOT SO ELABORATE)

• Fill a 35-mL syringe with saline. • Attach a three-way stopcock to syringe, attach 20-inch extension tubing to three-way stopcock, prime tubing with saline from the 35-mL syringe. • Using a 3-mL syringe, pull plunger back to draw in 0.5 mL air. Attach 3-mL syringe to stopcock. With stopcock turned off toward the 35-mL syringe, add the 0.5 mL air into the tubing. Close off the stopcock. • Using the dose syringe (provided by the radiopharmacy), carefully pull back plunger and draw in 0.5 mL air. Carefully invert syringe upside down and ensure all the air moves upward toward the plunger. • Carefully remove needle on dose syringe, add dose with 0.5 mL air to extension through three-way stopcock (turned off toward 35-mL syringe), close off three-way stopcock. The 20-inch extension tubing should have an 18-gauge needle on the end. • Place lead cylinder over dose in extension tube or keep covered with lead. • To a 3-mL syringe, add 0.5 mL of heparin; fill with saline. • Add 5-inch extension tube (must have pinch-off plastic) with “T” attachment to 3-mL syringe; prime. These two setups are brought out to the patient, who is attached to the ECG and under the camera. • On a portable table beside the patient, start the IV catheter. • Attach “T” with 5-inch tubing and syringe; draw to test patency, tape well, and test again. • Pinch off the 5-inch tubing. This is important; otherwise it blows technetium everywhere when bolus is pushed! • Insert 18-ga needle on 20-inch extension into “T”; tape to make sure it is secure, and open three-way stopcock for 35-mL syringe push. • Optional, cover site with towel in the event of a blowout. • Start camera; when it begins to acquire, push hard, fast, and steady for good bolus. Should only run for a minute or two. • Remove apparatus and proceed. 53

10766-10_CH10_redo.qxd

12/3/07

3:56 PM

Page 54

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ARTIFACTS • Because initial push must be fairly hard for good bolus, IV might blow when injecting. Make sure everything is secure and covered with a towel in the event of a mishap. • Arrhythmia may hamper acquisition. Run ECG to verify status of rhythm. • May not get good bolus. Bolus should be tight and together; a mean transit time of 1–3 seconds is considered adequate for the study.

NOTE • If multiple determinations are to be performed, and because of their rapid clearance by the liver and kidneys, 99mTc-sulfur colloid and 99mTc-DTPA (diethylene triamine penta-acetic acid) can be used as the imaging agent. Any technetium-labeled agent can be used for this test if immediately repeated studies are not ordered. Many are done using sestamibi or tetrofosmin at the injection time for the resting images. They also can be done at the beginning of a gated equilibrium study (MUGA) to allow accurate determinations of both left and right ventricular ejection fractions. • Done separately, in conjunction with gated or nongated resting study at injection, or at injection with some types of stress studies.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

Y

N

When did you quit?

Y

N

Do you have a pacemaker?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy?

Y

N

Do you have high blood pressure or diabetes?

Y

N

Are you allergic to any medications?

Y

N

If so, when, and are you having chest pain now? Have you been short of breath or had trouble breathing, or do you have asthma? Do you or did you smoke? How much?

What medications are you presently taking?

54

10766-10_CH10_redo.qxd

12/3/07

3:56 PM

Page 55

Chapter 10 — Cardiac: Gated First-Pass Study (First-Transit Radionuclide Angiocardiography)

Have you had any prior ECG tests or related tests (e.g., echocardiography, stress tests, etc.)?

Y

N

Do you have the results of recent lab work (e.g., CPK, LDH, Cholesterol, Troponin, Myoglobin, C-reactive protein)?

Y

N

Females: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

55

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 56

chapter

11

Cardiac: MUGA and MUGA-X (Stress MUGA) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • Tagged red blood cells (RBC) by pyrophosphate (pyp) in combination with 99mTcO4− (pertechnetate) or stannous chloride kit, e.g., UltraTag® RBC in combination with 99mTcO4− .

Localization • Compartmental, tagged to, and circulating with blood

Quality Control •

TcO4− , chromatography. Tagging, 90% in vivo; 95% in vitro. 99m

56

Adult Dose Range • 20–30 mCi (740–1110 MBq)

Method of Administration • Two intravenous straight injections into opposite arms (pyp, then after 20–30 minutes, 99mTcO4− ). Some use existing IV catheter with mixed “good tag” results. Get as close to the insertion site as possible to reduce the amount of tubing to go through (especially with the pyp) and flush with 10 cc or more saline. • Two intravenous straight accesses, blood draw (∼30 mL into syringe containing − heparin, pyp, and 99mTcO4 ), then reinject tagged RBCs after ∼30 minutes. • IV setup (IV catheter or butterfly, large bore). Use modified in vivo or UltraTag® preparation.

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 57

Chapter 11 — Cardiac: MUGA and MUGA-X (Stress MUGA)

INDICATIONS MUGA • • • • • • • • • •

Evaluation of left and sometimes right (for congestive heart failure [CHF]) wall motion. Calculation of ejection fraction, ventricular volume, cardiac output, and diastolic function. Assessment of CHF as to ischemic or nonischemic causes. Detection and evaluation of presence, location, and extent of coronary artery disease (CAD). Evaluation of patient’s heart condition before and/or after surgery, chemotherapy, or radiation therapy. Evaluation of cause of dyspnea: Cardiac or pulmonary. Evaluation of physical indicators: Myocardial infarction, chest pain, shortness of breath, or history of heart disease. Evaluation of laboratory indicators: Elevated levels of creatine phosphokinase, lactate dehydrogenase, and the newer tests for troponin and myoglobin (specific indicators for heart damage). Evaluation of the effects of valvular abnormalities. Evaluation of heart because of abnormal results on related studies.

MUGA-X (all of the above, with emphasis on the following) • • • •

Diagnosis and prognostication of coronary artery disease (CAD). Detection and evaluation of valvular dysfunction. Evaluation of cardiomyopathy. Evaluation of precardiac and postcardiac transplantation.

CONTRAINDICATIONS • • • •

Patient experiencing chest pain. Patient in an unstable medical condition. Patient with known severe arrhythmia. Patient known to be allergic to pyrophosphate or phosphates.

PATIENT PREPARATION • • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Instruct patient to be NPO 4–8 hours before the study. Physician is to discontinue patient’s cardiac medications and caffeine ∼4 hours before exam. Start IV setup (unless using the in vivo method). Prepare patient with three- or five-lead ECG. Remove articles from chest area that may attenuate images, e.g., bras, buttons, medallions, or breast prostheses.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• Typically, 16 frames/sec (ejection fraction), 32 frames/sec (diastolic parameters), 20–50 ms/frame (40 ms/frame for resting, 30 ms/frame for exercise), matrix 64 × 64, reject ± 20%, 600 to 800 sec/view, or 3 million counts.

Collimator • 30° slant hole, low energy, high resolution or low energy, all purpose

57

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 58

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PROCEDURE

(TIME: ~1 HOUR)

Blood Preparation (tagging the RBCs) Procedure one (in vivo) • • • •

Make up cold pyp kit; 2–3 mL normal saline into pyp vial. Mix. Let sit for 5 minutes. Inject 1–3 mL pyp. Wait ∼20 minutes. Inject 20–30 mCi 99mTcO4− into opposite arm. Follow acquisition steps below.

Procedure two (modified in vivo) • Make up cold pyp kit; 2–3 mL normal saline into pyp vial. Mix. Let sit for 5 minutes. • Inject patient with pyp, straight stick whenever possible; 1.5 mL for small patient or patient not on blood thinners; 3 mL for large patients or those on blood thinners. • Wait 20 minutes; meanwhile start butterfly IV, hook up three- or five-lead ECG and run a test strip for baseline (and to make sure there is a good heart rhythm for gate). • At 20 minutes, carefully draw 3–5 mL of blood into a 5- to 10-mL syringe containing 1 mL heparin and ∼25 mCi (925 MBq) of 99mTcO4− . • Mix for 5–10 minutes, then reinject. • Follow acquisition steps below. Procedure three (in vitro commercial kits, e.g., UltraTag® RBC) • Start catheter, large bore. (Straight stick with large-bore needle is an option.) • Draw 1.5–3 mL blood slowly into 5- to 10-mL syringe containing 0.3–0.5 mL of heparin (or ADC). Inject into reaction vial. Swirl for 5 minutes. • Add contents of syringe I, swirl; then add contents of syringe II, swirl; then add ∼30 mCi of 99mTcO4− . • Wait 20 minutes, swirling occasionally; reinject slowly through catheter (or straight stick). • Follow acquisition steps below.

MUGA Imaging • Position patient supine on bed. • Hook up three- or five-lead ECG. Check R–R wave, adjust acquisition parameters accordingly. Run a 15-second test ECG sheet if protocol. • Position camera anteriorly, typically, ANT, LAO (∼35–60° looking for best septal wall separation for ejection fraction (EF) calculation and processing, slight caudal tilt, 5–10%, to camera can help), LLAT, and sometimes RLAT or RAO (looking for “shoe” picture), displaying anterior and inferior wall motion and apex. • Before starting the EF image (usually the LAO), start at about 40°. In the monitor, there should be a nice separation between ventricles nearly straight up and down. The camera may be rotated back and forth as some are better at closer to 30° and some better at close to 50°. • Collect 300–600 beats/image or go by preset time (∼5–10 min/image). • Process for EF. Use auto, then manual. If skeptical about results, have another technologist try the EF or try different color schemes.

MUGA-X Imaging • Prepare patient as above. Position patient in exercise device, e.g., a bicycle ergometer. • Position patient supine, feet in pedals, connect ECG leads, and position camera for test as per protocol. • If resting images are first, obtain ANT, best LAT, then best LAO for septal separation as above or as per protocol. 58

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 59

Chapter 11 — Cardiac: MUGA and MUGA-X (Stress MUGA)

• Physician is to determine stress settings, e.g., 25 W or 50 W, etc. Ensure patient’s feet are secure in pedals. Ensure camera has best septal separation. • Start camera, start stress, collect for up to 3 million counts if possible. • Obtain blood pressures and record ECGs at each level if protocol (some institutions have nurses and specialized technicians available for these functions). • The test endpoint is usually decided by achieving a predetermined workload, percentage of the maximum predicted heart rate, anginal symptoms, significant ST depression, other ECG abnormalities, fatigue, or pain.

PROCESSING • Draw regions of interest manually and/or automatically on computer. • Calculate EF = (ED–ES) / ED × 100 where ED is end-diastolic volume and ES is end-systolic volume. • Calculate SV (stroke volume) = ED–ES. • Calculate CO (cardiac output in mL) = SV × HR (heart rate).

NORMAL RESULTS • Should get a good tag with blood. Circulation in major vessels and heart should present clearly. • Septal image should show easily definable separation between right and left ventricles. • Cine should show fair amount of motion in all (septal, anterior, lateral, inferior, and apex) walls (no defects). • EF = 50–70% or better left ventricle, 40–60% right ventricle.

ABNORMAL RESULTS • Cine showing one or more walls with abnormal movement (dyskinesis-paradoxic passive expansion, rather than contraction, of a myocardial segment during systole, e.g., a left ventricular aneurysm is characterized by localized dyskinesis), decreased wall motion (hypokinesis), or no movement (akinesis). • Low EF, i.e., 35–45%, or less. Severe impairment is present below 30%. • Regional wall abnormalities indicate CAD.

ARTIFACTS • Arrhythmias may make the study impossible to gate. It has been suggested that 100 mg Lidocaine IV (or 1 mg/kg) will quiet PVCs. • Cold pyp may oxidize if not used soon after mixing. • If reseals or IV lines are used, heparin or other pharmaceuticals may interact. Flush extremely well. • Doxorubicin may reduce the real abnormality of an EF. • β-blockers, Ca2+ channel blockers, and nitrates may cause the appearance of normal results in the presence of CAD leading to missed or underestimated diagnosis. • Do not use chest ports as they will show in pictures and distort count information. • If patient is obese, heart may be oriented more laterally; if thin, more anteriorly. • Test should be performed before any contrast material type examination. • Check clothing for articles in pockets, big buttons on shirts, ECG electrodes in way, medallions, or pacemakers (at least there should be a good R–R). 59

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 60

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Get good separation of right and left ventricles and good regions of interest for EF. It is not unusual to do automatic and manual EFs to compare results, or to have other technologists try their luck for comparison if time allows. • Patient may be taking chemicals or drugs that interfere. All may cause a poor tag. • Causes of a poor tag: • Drug interactions, e.g., heparin, methyldopa, hydralazine, quinidine, digoxin, prazosin, propranolol, doxorubicin, iodinated contrast agents. • Cold pyrophosphate not injected soon enough after mixing • Antibodies: transfusions, transplantation • Short incubation time • Too much or too little stannous ion

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

Have you been short of breath, had trouble breathing, or do you have asthma?

Y

N

Do you or did you smoke? How much? When did you quit?

Y

N

Do you have a pacemaker?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy?

Y

N

Do you have high blood pressure or diabetes?

Y

N

Are you allergic to any medications?

Y

N

Have you had any prior ECG tests or related tests (e.g., echocardiography, stress tests, radiographs, etc.)?

Y

N

Do you have the results of recent lab work (e.g., CPK, LDH, Cholesterol Troponin, Myoglobin, C-reactive protein)?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, when, and are you having chest pain now?

What medications are you presently taking?

Other department-specific questions.

60

10766-11_CH11_redo.qxd

12/3/07

4:02 PM

Page 61

Chapter 11 — Cardiac: MUGA and MUGA-X (Stress MUGA)

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Cardiac Scintigraphy. Revised 2004, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson, MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes (Multi-Gated Acquisition/Equilibrium Gated Ventriculography/Gated Blood Pool Study/Ventricular Wall Motion Study)

61

10766-12_CH12_redo.qxd

12/3/07

4:05 PM

Page 62

chapter

12

Cardiac: Myocardial Infarction (MI) Scan RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

blood flow decreases to 30–40% of normal. Maximum pyrophosphate deposition occurs usually 48–72 hours after infarction.

99m

Tc-stannous pyrophosphate (“hot pyp”)

Localization • Flows with blood stream, pyrophosphate deposition accumulates with calcium in the mitochondria and within the cytoplasm of necrotic myocardial tissue. Maximum concentration occurs when myocardial

Quality Control •

99m

−

TcO4 ; chromatography. Tagging, 90% in vivo; 95% in vitro.

Adult Dose Range • 15–30 mCi (555–1110 MBq)

Method of Administration • Intravenous, fast bolus if flow is required.

INDICATIONS • Evaluation of myocardial infarction (MI) several days after acute event. • Evaluation of patients having chest pain at least 48 hours before. The imaging window considered by some is from 24 to 72 hours. • Evaluation of equivocal ECG or elevated laboratory results indicating an event. 62

10766-12_CH12_redo.qxd

12/3/07

4:05 PM

Page 63

Chapter 12 — Cardiac: Myocardial Infarction (MI) Scan

• • • •

Evaluation of bundle branch block ECGs that are difficult to interpret. Evaluation of right ventricular infarction. Evaluation of infarctions after coronary artery surgery. Evaluation of heart due to abnormal results on related studies.

CONTRAINDICATIONS • Patient presently has severe angina. • Too soon after the event. • Too late after the event.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • No preparation for injection. • Instruct the patient to hydrate well and empty bladder often after the injection.

EQUIPMENT Camera

Flow

• Large field of view

• List mode for first-pass or 1 sec/frame for 30 seconds

Collimator • Low energy, all purpose, or low energy, high resolution

Computer Set-up

Single Photon Emission Computed Tomography (SPECT) • 360°, 64 steps at 25 sec/step

Statics • 500,000–1,000,000 counts, 20% window, 99mTc

PROCEDURE

(TIME: ~30 MIN/SESSION)

• Position patient supine on table. • Obtain flow if protocol; inject good bolus under anterior camera for a first-pass type study (list mode, ANT or shallow LAO for right and left ventricular ejection fractions), followed by some or all of the static images for immediate blood pool. • Obtain only the immediate blood pool images if protocol. Check with radiologist. • Obtain the following static images at 2–3 hours after the injection: ANT, LAO 45°, LLAT, and RAO 30°, adjusting views to separate and/or discern any cardiac visualization from sternum and rib cage. Check with radiologist if unsure as to other images. • Obtain SPECT images, usually performed at 3 hours with thorax in region of interest, if protocol. • Obtain extra-delayed images at 6 hours or longer if requested.

NORMAL RESULTS • 99mTc-pyp is a skeletal imaging agent. • Sternum and ribs should show evenly along with vertebrae and other bones in field of view. • There should be no cardiac muscle visible in any of the thorax views. 63

10766-12_CH12_redo.qxd

12/3/07

4:05 PM

Page 64

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ABNORMAL RESULTS • Part or all of the myocardium will present to varying degrees within the rib cage and sternum. • Image interpretation (level of activity in the region of the heart) may be reported as follows: • 0 = no increase above background, no cardiac uptake. • 1+ = faint, diffuse definite increase but less than rib cage levels. • 2+ = definite activity increase equal to rib levels but less than sternum. • 3+ = activity level equal to that of sternum levels. • 4+ = activity level greater than that of sternum levels. • A positive study will usually return to normal within a week to a month after the acute event. Repeating the scan in 7–10 days may help the assessment of sustained abnormal uptake. Persistent abnormal uptakes indicate a poor prognosis. • 2+ indicates subendocardial infarction and/or unstable angina. Patients with unstable angina have focal areas of myocardial necrosis even though there are no corroborating laboratory results for myocardial damage. • 3+ and 4+ indicate acute transmural myocardial damage. • Drug interactions: • Diffuse myocardial uptake—doxorubicin • Diffuse myocardial uptake also—angina, ventricular aneurysm, congestive cardiomyopathy, chest irradiation, calcified intracardial valves, pericarditis, cardio-version.

ARTIFACTS • • • •

Attenuating objects on necklaces, shirt pockets, etc. Unexpected bone metastasis in thorax region may obscure cardiac visualization. Background from inadequate hydration may hinder visualization. Pyrophosphate has been shown to localize in regions of old myocardial infarcts several months after the acute episode, yielding a possible false-positive result. • Recent thoracic injury or surgery involving skeletal muscle would have to be localized by various oblique views.

NOTE • Trials were performed with a cardiac drug called cariporide, which may prevent damage to cardiac tissue during and immediately after an MI. Normally, calcium is needed in muscle cell contraction by interacting with myosin and actin, causing them to attach and move against each other, and thus causing the contraction. The calcium then displaces, the cell relaxes, and the process is repeated. During an attack, blood flow is restricted, the affected cells become too acidic, sodium is pumped in to replace the acid, and calcium is then exchanged for the sodium. • The excess calcium causes a sustained contraction until the cell dies. By blocking the initial acid/ sodium exchange, Cariporide interferes with these reactions, leaving the cell acidic but still alive.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

If so, when, and are you having chest pain now?

64

10766-12_CH12_redo.qxd

12/3/07

4:05 PM

Page 65

Chapter 12 — Cardiac: Myocardial Infarction (MI) Scan

Have you been short of breath, had trouble breathing, or do you have asthma?

Y

N

Do you or did you smoke? How much?

Y

N

Do you have a pacemaker?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy?

Y

N

Do you have high blood pressure or diabetes?

Y

N

Are you allergic to any medications?

Y

N

Have you had any prior ECG tests or related tests (e.g., echocardiography, stress tests, etc.)?

Y

N

Do you have the results of recent lab work (e.g., CPK, LDH, Cholesterol Troponin, Myoglobin, C-reactive protein)?

Y

N

Female: Are you pregnant or nursing?

Y

N

When did you quit?

What medications are you presently taking?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Bernier DR, Christian PE, Langan JK, eds. Nuclear Medicine: Technology and Techniques, 3rd ed. St. Louis: Mosby, 1994. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

65

10766-13_CH13_redo.qxd

12/3/07

4:07 PM

Page 66

chapter

13

Cardiac: Resting Test (Perfusion) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator; or • 201TI t1/2: 73 hours Energies: 68–80 keV k x-ray, 135, 167 keV Type: EC, γ, accelerator

Quality Control •

•

99m

Tc-sestamibi, 99mTc-tetrofosmin; 8–30 mCi (296–1110 MBq), 201Tl-thallous chloride; 2–5 mCi (74–185 MBq).

99m

Tc-sestamibi (hexakis[2-methoxyisobutylisonitril]), 99mTc-tetrofosmin (1,2-bis [bis(2-ethoxyethyl)phosphino]ethane), 201Tl-thallous chloride

Localization •

Tc-sestamibi, 99mTc-tetrofosmin, chromatography > 90%; 201Tl-thallous chloride, chromatography > 95%, use within 7 days.

Adult Dose Range •

Radiopharmaceutical

99m

99m

Tc-sestamibi; passive transport into myocardial mitochondria in proportion to blood flow. 99mTc-tetrofosmin; same, binds to myocytes. 201Tl-thallous chloride; similar to potassium, distributes with Na/K pump within 20 minutes of injection, then seeps out of myocardium and redistributes (Tb = 10 days ± 2.5 days).

66

Method of Administration • Tetrofosmin, sestamibi, or thallium: intravenous, butterfly, IV catheter. • Thallium redistribution (3–4 hours after injection): no injection for redistribution needed unless it is a rest-only study. Some stress-redistribution protocols call for a second injection (∼1 mCi IV) 15 minutes before imaging. Separate day: IV

10766-13_CH13_redo.qxd

12/3/07

4:07 PM

Page 67

Chapter 13 — Cardiac: Resting Test (Perfusion)

INDICATIONS • Detection and evaluation of coronary artery disease. For both sestamibi and thallium, uptake in the myocardium is proportional to flow. At rest there are no increased flow requirements. Diminished or restricted flow will be detected in areas served by diseased vessels. Results are usually compared with the cardiac stress test. • Evaluation for coronary bypass surgery or angioplasty. • Detection and evaluation for viable or hibernating myocardial tissue (particularly with thallium). • Evaluation of physical indicators: Myocardial infarction, chest pain, shortness of breath, history or family history of heart disease. • Evaluation of laboratory indicators: Elevated levels of creatine phosphokinase, lactate dehydrogenase, and the newer tests for troponin and myoglobin (specific indicators for heart damage). • Evaluation of the heart because of abnormal results on related studies.

CONTRAINDICATIONS • Patient should not be taking chemical stressors, e.g., caffeine, dipyridamole, nitroglycerin drips and patches, etc. Most prefer to discontinue heart medications until after test. • Patient should be NPO for 4–12 hours. • Severe arrhythmia if a gated resting study is ordered.

PATIENT PREPARATION • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Instruct patient to be NPO for 4–12 hours (no sugar, caffeine, or dairy products). Patient should be well rested and avoid strenuous exercise the day of test before exam. Remove 10 ECG leads and electrodes if necessary or use three-lead ECG if it is a gated test. Position patient sitting upright for 15 minutes before injection to reduce pulmonary and splanchnic (intestinal/visceral) blood flow.

EQUIPMENT Camera

Static • Timed for 300 seconds

• Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Single Photon Emission Computed Tomography (SPECT) • 180°, 32 or 64 projections at 20 to 40 sec/frame, 8 frames/cycle if gated, matrix at 64 × 64, runs ∼25 minutes.

Computer Set-up •

99m

Tc window at 140 keV, 201Tl windows at (minimum) Hg k x-rays (68–80 keV) and 167 keV at 20%

PROCEDURE

(MANY PROTOCOLS; TIME: ~15–30 MINUTES)

• Thallium: Rest only; patient waits 5–20 minutes after injection before imaging. • Sestamibi: Patient waits 45–60 minutes after injection before imaging. Give patient a glass of cold water before imaging to clear thyroid, liver, and bowel. 67

10766-13_CH13_redo.qxd

12/3/07

4:07 PM

Page 68

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Tetrofosmin: Patient waits 5–30 minutes after injection before imaging (give water). • Position patient supine with heart in center field of view and left arm up over head if possible. If arm is down at side because of problems with shoulder joint or recent surgery, both the rest and stress images should be taken the same way. • Images may include a static anterior picture first (300 seconds). • Start SPECT images at appropriate time with camera right anterior oblique to left posterior oblique (except for patients with dextrocardia). • Processing: Computer analysis of left ventricle showing the vertical long axis, horizontal long axis, and short axis. Usually done at the same time as stress images; the results of the two are compared. Can be processed separately.

NORMAL RESULTS • Heterogeneous uptake of the left ventricular myocardium. • Heterogeneous uptake of the right ventricle myocardium if that processing was requested.

ABNORMAL RESULTS • Area(s) of little or no uptake exhibiting a cold spot. If the lack of uptake matches the stress results in the same area, it may be infarcted myocardium or severe ischemic tissue. • Left ventricular walls of interest and their supply arteries: • Apical: Left anterior descending, distal end, and/or right coronary artery, posterior descending • Septal: Left anterior descending • Anterior: Left anterior descending • Lateral: Left circumflex • Inferior: Right coronary artery

ARTIFACTS • Patient may not be NPO for 4 plus hours. • Articles in pockets, medallions, necklaces, heart monitors, pacemakers, or metal buttons may cause artifacts. • If patient has left arm down to side, it may cause unwanted attenuation. • With sestamibi, possibly shield gall bladder because of uptake.

PROTOCOLS

(THERE ARE SEVERAL STRESS-REST PROTOCOLS BEING FOLLOWED AT PRESENT) • Thallium (only): The stress is done first, imaged as soon as possible (some perform an anterior view first for heart: lung ratio), then imaged again 3–4 hours later (sometimes with a small reinjection of ∼1 mCi). The rest study is completed using its ability to redistribute. Some perform a 24-hour delay rest study with a 1 mCi reinjection (wait 5–20 minutes to image), looking for hibernating tissue. • Thallium-Thallium: Both tests are done with thallium but on different days. • Thallium-Sestamibi (dual energy-dual isotope): The thallium rest study (3 mCi) is done first (inject, wait ∼20 minutes, image), followed fairly quickly (within the hour) by the stress test using sestamibi. Some add 24-hour resting thallium for viability. • Sestamibi-Sestamibi: Both tests are done with sestamibi but on different days. The stress test can be done first. If no defects are observed, some choose not to do the rest study. • Sestamibi-Sestamibi: Both tests are done on the same day. Either rest or stress can be done first; however, most prefer to do resting pictures first, and then stress. The first study is done with a low dose, ∼8 mCi, and the second (an hour or more later) with a high dose, ∼25–30 mCi. Gated images are usually taken with whichever study used the higher dose. 68

10766-13_CH13_redo.qxd

12/3/07

4:07 PM

Page 69

Chapter 13 — Cardiac: Resting Test (Perfusion)

NOTE • Many departments are now substituting tetrofosmin (Myoview®) for sestamibi (Cardiolite®). Some facilities may be performing cardiac SPECT using these radiotracers on emergency room patients with chest pain if their initial ECG is suspicious. PDR®: Cardiovascular Preparations (has full list of drugs). Beta Blockers Blocadren® Brevibloc® Cartrol® Corgard® Inderal® Inderide® Kerlone® Levatol® Lopressor® Normozide® Sectral® Tenoretic Tablets® Tenormin® Timolide Tablets® Visken®

Calcium-Channel Blockers Adalat® Calan® Cardene® Cardizem® DynaCirc® Isoptin® Nimotop® Plendil® Procardia® Vascor®

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

Have you been short of breath, had trouble breathing, or do you have asthma?

Y

N

Do you or did you smoke? How much?

Y

N

Do you have a pacemaker?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy?

Y

N

Do you have high blood pressure or diabetes?

Y

N

If so, when, and are you having chest pain now?

When did you quit?

(continued)

69

10766-13_CH13_redo.qxd

12/3/07

4:07 PM

Page 70

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Are you allergic to any medications?

Y

N

Have you had any prior ECG tests or related tests (e.g., echocardiography, stress tests, etc.)?

Y

N

Do you have the results of recent lab work (e.g., CPK, LDH, Cholesterol Troponin, Myoglobin, C-reactive protein)?

Y

N

Female: Are you pregnant or nursing?

Y

N

What medications are you presently taking?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

70

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 71

chapter

14

Cardiac: Stress Test (Perfusion, Usually with Cardiac Rest Test) RADIOPHARMACY Radionuclide •

of injection, then seeps out of myocardium and redistributes. (Tb = 10 days ± 2.5 days)

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator; or • 201Tl t1/2: 73 hours Energies: 68–80 keV k x-ray, 135, 167 keV Type: EC, γ, accelerator

Quality Control •

99m

Tc-sestamibi, 99mTc-tetrofosmin, chromatography > 90%; 201Tl-thallous chloride, chromatography > 95%, use within 7 days (Tb = 56 hours)

Radiopharmaceutical •

99m

Tc-sestamibi (hexakis[2-methoxyisobutylisonitril]), 99mTc-tetrofosmin (1,2-bis[bis(2-ethoxyethyl)phosphino]ethane), 201Tl-thallous chloride

Localization •

99m

Tc-sestamibi; passive transport into myocardial mitochondria in proportion to blood flow. 99mTc-tetrofosmin; same, binds to myocytes. 201Tl-thallous chloride; similar to potassium, distributes with Na/K pump within 20 minutes

Adult Dose Range •

99m

Tc-sestamibi, 99mTc-tetrofosmin; 20–30 mCi (740–1110 MBq), 201Tl-thallous chloride; 3–5 mCi (111–185 MBq)

Method of Administration • Intravenous catheter or butterfly setup, which can include a three-way stopcock, 10-mL syringe filled with normal saline, and an injection port.

71

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 72

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Detection and evaluation of coronary artery disease. For sestamibi, tetrofosmin, and thallium, uptake in the myocardium is proportional to blood flow. With stress, there are increased flow requirements. Diminished or restricted flow will occur and be detected in areas served by diseased vessels. Results are usually compared with the cardiac rest test (although some order no rest test if stress is normal). • Evaluation of suspected or known coronary artery stenosis. • Evaluation of possible candidates for coronary bypass surgery or angioplasty. • Evaluation of physical indicators: Acute myocardial infarction, chest pain, shortness of breath, history or family history of heart disease. • Determination of prognosis after a myocardial infarction. • Evaluation of the viability of dysfunctional myocardium. • Assessment of risk of myocardial events. • Evaluation of ventricular function (using gated imaging). • Evaluation of laboratory indicators: elevated levels of creatine phosphokinase, lactate dehydrogenase, and the newer tests for troponin and myoglobin (specific indicators for heart damage). • Evaluation of heart due to abnormal results on related studies.

CONTRAINDICATIONS • Patient experiencing chest pain, or have documented acute myocardial infarction within 2–4 days of test. • Patient should discontinue chemical stressors, e.g., caffeine, Persantine® theophylline, Viagra® (hypotension or worse if given nitroglycerin during test) 24 to 48 hours. • Patient on heart medications. Some cardiologists prefer to hold all heart medications until after test (check with cardiologist). • Patient with extremely high blood pressure, arrhythmias, congestive heart failure, pulmonary hypertension, acute myocarditis, acute pericarditis, severe mitral or aortic stenosis, obstructive cardiomyopathy, systemic illness, or neurologic or physical conditions that may hamper the stress test. • Patient who is not comfortably weaned from nitroglycerin drip or is medically unstable. • Patient may have allergies to chemicals and/or be unable to walk. • Patients with lung conditions may get asthmatic reaction to Persantine® or adenosine. Dobutamine is suggested in those cases. • Heart conditions not conducive to Persantine® or adenosine: • Second or third AV block except with pacemaker • Sinus node disease: sick sinus or bradycardia • Bronchoconstriction/spasms • Hypersensitivity to adenosine

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to be NPO for 4–12 hours. Clear liquids and crackers only for sestamibi and tetrofosmin, nothing at all for thallium. Orange juice allowed for diabetics; may need to monitor blood sugar and adjust. • Instruct patient to ingest no caffeine, dairy products, or sugar. No Viagra® within 48 hours. • Patient should be well rested and avoid strenuous exercise the day of test before exam. • Some doctors prefer to hold heart medications until after test, e.g., verapamil, Cardizem®, beta blockers (check with cardiologist). • Obtain a signed consent form. • Remove cardiac monitor from in-patient. • Female: Remove bra. • Shave and wipe chest with alcohol (as necessary). 72

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 73

Chapter 14 — Cardiac: Stress Test (Perfusion, Usually with Cardiac Rest Test)

• Prepare patient with a 10- or 12-lead ECG setup, run standing and lying or sitting test sheets. • Start IV setup, flush IV, ensure patency. • Triage patient for treadmill, Persantine® (dipyridamole), adenosine, or dobutamine. (If stress is dobutamine, have available atropine to boost heart rate and propranolol to lower heart rate. If Persantine® or adenosine, have aminophylline available to counter the effect.) • Obtain a baseline blood pressure and record (some take both sitting and standing blood pressures).

EQUIPMENT Camera • Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Static • Timed for 300 seconds Single Photon Emission Computed Tomography (SPECT) • 180°, 32 or 64 projections at 20–40 sec/frame, 8 frames/cycle if gated, matrix at 64 × 64, runs ∼25 minutes.

Computer Set-up •

99m

Tc window at 140 keV, 201Tl windows at (minimum) Hg k x-rays (68–80 keV) and 167 keV at 20%

PROCEDURE

(TIME: EXERCISE, ~10 MINUTES; IMAGE, ~15–30 MINUTES)

Stress (many protocols) • Patient prepared with 10- or 12-lead ECG. Run baseline ECG, with patient standing on the treadmill. • Position patient on treadmill or supine for pharmacologic stress. • Perform stress test by exercise or pharmacology in the presence of a physician. Heart rate should be between 85% and 100% of maximum (220 minus age of patient). • Treadmill: Monitor heart rate, blood pressure, ECG changes, and patient (closely). Inject and flush on physician’s order (when target heart rate is obtained or about 1 minute before patient gives out). Maintain exercise for 60–90 seconds after injection. Have crash cart handy. Some require a stretcher in proximity. • Dobutamine: (Tb = 2 min) Connect patient to pump. Begin first of five levels of drip on physician’s order. Infusion changes are made by protocol. Inject and flush on physician’s order. Used if there are known allergies, asthma, or pulmonary disease. Antidote: Inderal® or Lopressor®. • Persantine®: Push or pump over 4 minutes on physician’s order. Wait 3–4 minutes more, then inject and flush (ask physician). Antidote: Aminophylline (1–2 mg/kg). • Adenosine: Connect patient to pump. Infuse drug for 6 minutes. Inject at 3 or 4 minutes (ask physician). Continue infusion and patient monitoring until done. Antidote: aminophylline (1–2 mg/kg). Wgt. in kg × .28 (= amount adenosine to withdraw) × 3 (= total mg adenosine administered). Queue to 30 mL and administer over 6 minutes with Baxter pump. • Some protocols ask that, if possible, the patient is walked on the treadmill for a few minutes after the infusion to aid the perfusion process. • 4-minute protocol: Infusion over 4 minutes with injection at 2 minutes. If the patient can walk on treadmill, infusion and treadmill start at same time. • Treadmill is set to low incline, low speed. If patient cannot walk, some have patient move legs as best they can in supine position. Weight in kg × .187 (= amount adenosine to withdraw) × 3 (= total mg adenosine administered). • Queue to 20 mLs and administer over 4 minutes. 73

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 74

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Treadmill • Sestamibi: Help patient get down from treadmill, remove IV setup (unless resting study is pending or it is an inpatient who may need the IV site) after proper monitoring time (∼6–10 minutes), give patient glass of cold water, wait 35–45 minutes to image (some are imaging much sooner). • Tetrofosmin: Same, but can image 5 minutes to 4 hours after injection. • Thallium: Same, but image as soon as possible; some wait 15 minutes to eliminate heart creep. Redistribution images taken in 3–4 hours if a 1-day protocol. 24-hour imaging may be requested for viability study of myocardium. • Chemical: Persantine®, adenosine, and dobutamine • Sestamibi: Monitor, disconnect, give water, wait 45–90 minutes to image. • Tetrofosmin: Same, wait 5 minutes to 4 hours. • Thallium: Image as soon as possible. Redistribution images taken in 3–4 hours if a 1-day protocol, some with a reinjection of 1 mCi • Adenosine note: Some image after 11 minutes for sestamibi or thallium. Most however, for sestamibi; wait 45–60 minutes to image, tetrofosmin; about 20–30 minutes, thallium; image as soon as possible. Some wait 15 minutes to avoid “heart creep.”

Imaging • Remove ECG electrodes if necessary unless it is a gated study (for gated study, connect three-lead ECG, check for good R-R interval). • Position patient supine with heart in center field of view and left arm up over head (if possible). If patient has shoulder problems or will have surgery that necessitates leaving the arm down, do both resting and stress images the same way. • Images may include a static anterior picture first (300 seconds) for heart:lung ratio, e.g., for thallium studies. • Start SPECT images at appropriate time (RAO to LPO). Some cameras allow mapping, noncircular orbits, or circular with setting the radius. • Processing: Images are processed to show myocardium of left ventricle in vertical long axis, horizontal long axis, and short axis views. Some also require bull’s eye, polar and cequal images. Some software allows ejection fraction information. Most software allows ejection fraction information. The films obtained vary greatly from hospital to hospital and cardiologist to cardiologist.

NORMAL RESULTS • • • •

Heterogeneous uptake throughout the myocardium of the left ventricle. Normal left ventricular end-diastolic volume is ∼70 mL, end-systolic volume is ∼25 mL. Normal heart: Lung ratio is 70:30. Some consider 50:50 within normal limits. Gated studies: Left ventricular ejection fraction: 50–80%, right ventricular ejection fraction: 40–60%. No deviations in full contraction of heart, all walls contracting in a coordinated manner. Global wall-thickening and wall-motion

ABNORMAL RESULTS • Defect (area of little to no uptake in localized area[s]) in stress but not in rest, the myocardium is ischemic and reversible. • Defect in both stress and rest tests in the same area, it is most likely infarcted and considered a fixed defect. • Trans-ischemic dilatation; left ventricular dilation with stress. • Enlarged right ventricle; possible pulmonary hypertension. • Bone uptake on images; possible multiple myeloma. 74

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 75

Chapter 14 — Cardiac: Stress Test (Perfusion, Usually with Cardiac Rest Test)

• Focal area of uptake in chest/breast area using sestamibi or tetrofosmin; possible breast cancer lesion. • Left ventricle walls of interest and supply arteries: • Apical: Left anterior descending, distal end, and/or right coronary artery, posterior descending • Septal: Left anterior descending • Anterior: Left anterior descending • Lateral: Left circumflex • Inferior: Right coronary artery • Transverse (transaxial) is horizontal long axis (slices, superior to inferior; image, left is septal wall, top is apex, right is lateral wall). • Sagittal is vertical long axis (slices, right side of heart to left; image, top is anterior wall, right is apex, bottom is inferior wall). • Coronal is short axis (slices, apex to base; image, top is anterior wall, right is lateral wall, bottom is inferior wall, left is septal wall). • Heart:lung ratios greater than 30% in the lungs are considered abnormal. Some say anything greater than 50% in the lungs. Abnormal heart:lung ratios indicate heart disease, e.g., congestive heart failure. • Gated studies: Cine showing one or more walls with abnormal movement (dyskinesis-paradoxic passive expansion, rather than contraction, of a myocardial segment during systole, e.g., an LV aneurysm, is characterized by localized dyskinesis), decreased wall motion (hypokinesis), or no movement (akinesis). Low EF, i.e., 35–45% or less. Severe impairment is present below 30%. Wall-thickening impaired or non-existent in one or more walls of myocardium.

ARTIFACTS • Attenuation artifacts: Men—most common is left hemidiaphragm affecting inferior wall; Women—most common is left breast affecting anterior wall. • Bowel activity close to heart during imaging may mask inferior wall defects. • Pericardial effusion may cause a “dark” ring around the heart during acquisition in the monitor and may be visible in the processing. • Patient may not be NPO for 12 hours. • Patient may not reach 85% maximum heart rate. • Articles in pockets, medallions, necklaces, metal buttons, or ECG electrodes may cause artifacts. • If patient has left arm down to side, it may cause unwanted attenuation. • Patient may be on Theo-Dur®, theophylline, Elixophyllin®, Quibron®, Slo-Phyllin®, or areolate, disallowing Persantine® stress, or may be allergic to pharmacology. • With sestamibi, possibly shield gall bladder because of uptake. • Test should be discontinued if patient experiences angina, severe shortness of breath, fall in blood pressure, ischemic ECG changes, arrhythmias, exhaustion, or reaches the 85% maximum heart rate. • Risks involve adverse drug-related events and a mortality rate of 1 in 2000 (0.05%). • With sestamibi and tetrofosmin, always look for focal uptake in thorax for possible tumor uptake. • Drug interactions: • 201Tl: Decreased number and size of perfusion defects—beta blockers, nitrates. • Defect visualization—vasopressin. • Patients with CAD, decrease myocardial localization, increased liver uptake—propranolol, cardiac glycerides, phenytoin, doxorubicin. • False-positives • Coronary anomaly • Coronary spasm (variant angina) • Noncoronary disease (mitral valve prosthesis, cardiomyopathies, aortostenosis, myocardial bridge, idiopathic hypertrophic subaortic stenosis, conduction defects, left bundle-branch block, long-distance runners, young females, ischemia of noncoronary origin) • Artifacts (chest wall artifacts, breast tissue or pectoral muscles, breast prosthesis, electrocardiogram leads, braces, articles in clothing, heart monitors, pendants, obesity) • Patient motion (deep respiration) 75

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 76

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Misinterpretation (over- or under-appreciation of apical defects, variant activity at cardiac base, proximal septal area, and posterolateral walls, papillary muscle attachments, small ventricular cavity) • False-negatives • Early or delayed redistribution • Submaximal exercise • Noncritical stenosis (< 50%) • Small ischemic area • Isolated right coronary lesion • Coronary collaterals • Multivessel disease (balanced) • Overestimation of stenosis on angiogram • Interfering medication

PROTOCOLS One-Day • Thallium (only): The stress is performed first (∼3 mCi), imaged immediately (within 10 minutes, although some wait 10–15 minutes to allow for “heart creep” after stress), then 3–4 hours later the rest is completed using its ability to redistribute often with a 1 mCi booster shot. Some do a 24-hour delay rest study with a 1 mCi reinjection (wait 5–20 minutes to image), looking for viable or hibernating stunned tissue. Also performed with sublingual nitroglycerin dose. • Thallium–Sestamibi (dual energy-dual isotope): The thallium rest study (3 mCi) is done first (inject, wait ∼20 minutes, image), followed fairly quickly (within the hour) by the stress test using sestamibi or tetrofosmin (∼25 mCi). A 24-hour delay rest study with a 1 mCi thallium reinjection (wait 5–20 minutes to image) looking for viable-hibernating-stunned tissue can also be performed with this study. • Sestamibi–Sestamibi: Both tests are done on the same day. Either rest or stress can be done first; however, most prefer to do resting pictures first (e.g., in the morning), then set up for the stress (treadmill or chemical). The first study is done with a low dose, ∼8 mCi, followed by the second (an hour or more later) with a high dose, ∼25–30 mCi. Gated pictures are usually taken with whichever study used the higher dose. • Tetrofosmin–Tetrofosmin: Same as sestamibi.

Two-Day • Thallium–Thallium: Both tests are done with thallium but on different days. • Thallium–Sestamibi: Thallium rest on first day with a redistribution and even a 24-hour delay looking for hibernating tissue; sestamibi or tetrofosmin stress on second day. • Sestamibi–Sestamibi: Both tests are done with sestamibi but on different days. Some do the stress test first. If no defects are observed, there is no need for the rest study. Others do both tests, regardless. • Tetrofosmin–Tetrofosmin: Same as sestamibi.

NOTE • Myoview® (99mTc-tetrofosmin) is similar in some characteristics to Cardiolite® (sestamibi). • Preliminary research indicated that they both localize in the mitochondria of the myocytes of the myocardium and elicit the same-quality pictures; however, 99mTc-tetrofosmin has a faster clearance rate from the liver and gallbladder (within 5 minutes on stress and 15 minutes on rest) than sestamibi, making the agent a consideration for busy nuclear cardiac departments. The clearance has been disputed, and different departments have had a variety of results. 76

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 77

Chapter 14 — Cardiac: Stress Test (Perfusion, Usually with Cardiac Rest Test)

PDR®: Cardiovascular Preparations (has full list of drugs). Beta-Blockers: Blocadren® Brevibloc® Cartrol® Corgard® Inderal® Inderide® Kerlone® Levatol® Lopressor® Normozide® Sectral® Tenoretic Tablets® Tenormin® Timolide Tablets® Visken®

Calcium-Channel Blockers: Adalat® Calan® Cardene® Cardizem® DynaCirc® Isoptin® Nimotop® Plendil® Procardia® Vascor®

PATIENT HISTORY (or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

Have you been short of breath, had trouble breathing, or do you have asthma?

Y

N

Do you or did you smoke? How much?

Y

N

Do you have a pacemaker?

Y

N

Do you have a nitro patch or are you taking nitroglycerin?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy?

Y

N

Do you have high blood pressure or diabetes?

Y

N

Are you allergic to any medications?

Y

N

If so, when, and are you having chest pain now?

When did you quit?

What medications are you presently taking? (continued)

77

10766-14_CH14_redo.qxd

12/3/07

4:08 PM

Page 78

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you had any prior ECG tests or related tests (e.g., echocardiography, stress tests, etc.)?

Y

N

Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Cardiac Scintigraphy. Revised 2004, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler, Fred A. Jr., and Milton J. Guiberteau. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Myocardial Perfusion Imaging. Version 3.0, June 15, 2002. SNM.org. Webmd.com. Internet site. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

78

10766-15_CH15_redo.qxd

12/3/07

4:09 PM

Page 79

chapter

15

Cisternography RADIOPHARMACY Radionuclide •

111

In t1/2: 2.8 days Energies: 173, 247 keV Type: EC, γ, accelerator • 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

111

In-DTPA (diethylenetriaminepentaacetic acid) • 99mTc-DTPA (diethylenetriaminepentaacetic acid)

Localization • Compartmental, cerebrospinal fluid

Quality Control • Test for radiochemical purity, chromatography for DTPA tag

Adult Dose Range • •

111

In: 0.5–1.5 mCi (18.5–55.5 MBq) Tc: 0.4–12 mCi (14.8–444 MBq) depending on scan

99m

Method of Administration • Spinal needle, intrathecal injection (lumbar puncture: slowly into the subarachnoid space of lumbar spine, usually performed by radiologist). • Patient must lay flat for at least 2 hours postinjection.

INDICATIONS • Evaluation of cerebrospinal fluid (CSF) flow in the spinal column and brain. • Detection of CSF leak (rhinorrhea or otorrhea). • Evaluation for normal-pressure hydrocephalus. Patients should have clinical evidence of dementia, dyspraxia (disturbance in programming, control, and execution of conscious movement), and incontinence. • Differentiation of normal-pressure hydrocephalus from hydrocephalus secondary to age-related atrophy. • Evaluation and detection of obstructive hydrocephalus. 79

10766-15_CH15_redo.qxd

12/3/07

4:09 PM

Page 80

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Evaluation and detection of ventriculoperitoneal (VP) or ventriculoatrial (VA) shunt obstruction or patency. • Evaluation of dispersal of intrathecally injected chemotherapy (Ommaya shunt). • Evaluation of spinal fluid due to abnormal results on related studies.

CONTRAINDICATIONS • None

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain a signed consent from patient. Prepare patient for spinal injection by physician. Instruct patient to remain horizontal for 2 hours after injection to minimize headache from CSF leakage.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Statics • 50,000–200,000 counts each

Collimator • •

111

In: medium energy, parallel hole Tc: low energy, all purpose, or low energy, high resolution

99m

PROCEDURE

(TIME: ~30 MINUTES EACH SET OF IMAGES)

• Patient is injected by a physician with patient in left or right lateral decubitus or Sims’ position. • Position patient supine with camera anterior (generally). To image the injection site if extravasation is suspected, place patient in a lateral decubitus, Sims’, or prone position. Obtain an image at injection site at 5–30 minutes after injection. • Obtain diagnostic images for study within 1–2 hours after injection. • Obtain images of anterior head, and lateral and vertex views. Other views can include posterior images of the spinal column and skull. Optional: Turn patient prone for lumbar spine images. • Obtain repeat delayed images at 4, 24, 48, and 72 hours according to protocol. • Obtain image of injection site if there is little or no activity in cranium at 2 hours after injection. This is to confirm injection extravasation, at which time, if confirmed, the study may be terminated. • Obtain delayed anterior abdominal images (particularly at 48 and 72 hours after injection) to detect and/or confirm progress of CSF for shunt patency. Some use 1–10 mCi (37–370 MBq) 99mTc-DTPA and image 5 minutes to 1 or 2 hours. • CSF leaks (otorrhea and rhinorrhea) • Pledgets (cotton, 1.5 × 1.5 cm) bilaterally inserted by otolaryngologist (ENT) either before injection or within 1 hour after. Some use 10 mCi (370 MBq) 99mTc-DTPA. Suggested placements are at both cribriform plates, at each sphenoethmoid recess under the middle turbinate, and one in the buccal mucosa (underside of tongue) for a control (counted to use for background). • Image injection site shortly after injection to confirm success. Place patient with head flexed forward and downward or in position known to exacerbate leakage. Image skull (anterior and laterals) at 2, 4, and 6 hours. 80

10766-15_CH15_redo.qxd

12/3/07

4:09 PM

Page 81

Chapter 15 — Cisternography

• Remove pledgets after 6 hours; place in separate, labeled, pre-weighed tubes; separately weigh (subtract tube weight); and count in a well counter. Count all tubes the same amount of time, up to 10 minutes each. • Draw enough blood at this time so that after centrifuging, there is .5 mL of serum. Count the serum (with the buccal mucosa pledget, this is also used for background). Count for same amount of time as others. • If a leak is suspected, 24-hour images can be performed with or without new pledget placement and counting. • Posterior images should be added if a leak presents in other images.

NORMAL RESULTS • Activity appears in basal cisterns by 3 hours after injection, then enters interhemispheric and sylvian fissures, forming Neptune’s triumvirate or “Viking helmet.” • Flow over cerebral convexities to the sagittal sinus and activity in the basal cisterns should begin to clear by 24 hours. • No reflux into ventricles is seen, although transient reflux at 12–24 hours is not considered significant. • Shunt patency: Using 99mTc-DTPA, with manual pressure on distal limb, after injection into port, there should be prompt visualization of activity in ventricle. When manual pressure is released from distal limb, there should be prompt passage of radiotracer through distal limb. For a VP shunt, it should be seen spilling into the peritoneal cavity within minutes to an hour. For a VA shunt, the radiotracer reaches the systemic circulation and visualizes in the kidneys. With 111In-DTPA, radiotracer will show an area of increased activity particularly on the side of the shunt and more identifiable in 48 and 72 hour delays as there is an increase in target to background ratio and more time for movement to that area. • Leakage (otorrhea or rhinorrhea): Ratio of pledget to plasma is 1 (buccal mucosa pledget and/or serum counts). There should be no appreciable activity in the blood at 4 hours.

ABNORMAL RESULTS • Persistence of activity in lateral ventricles is abnormal. • Ascent over the cerebral convexities is markedly delayed. • Hydrocephalus (enlargement of the ventricles): Increase in CSF volume caused by overproduction, decreased absorption, blockage of flow, or cerebral atrophy. • Nonobstructive: Cerebral atrophy. • Obstructive: Caused by obstruction of outflow from • Noncommunicating hydrocephalus caused by blockage of CSF motion. • Communicating obstructive hydrocephalus caused by extraventricular blockage, e.g., cisterns or villi. • Normal-pressure hydrocephalus (look for dementia, gait disorder, urinary incontinence); ventricle reflux that persists on 24-, 48-, and perhaps 72-hour images; delayed or lack of flow to convexities. • Shunt patency: Activity not reaching the vascular system or peritoneal cavity. • Porencephalic cysts (meninges dilated), rhinorrhea (leaking out of meninges through nose), otorrhea (leaking out of ears). • For leakage (otorrhea or rhinorrhea), it is considered significant leakage and positive if the ratio of pledget to plasma activity is greater than 1.5 to 1 and the leak should have corroborating images. The pledgets should help localize the leak. Some institutions say that it must be 10 times background to be considered positive. Check with the nuclear physician or radiologist if a protocol is in place. • Drug interaction: Delayed parasagittal migration with reflux into ventricles in normal patients, acetazolamide.

ARTIFACTS • Injection into spinal fluid is difficult and often missed. • Patient motion to a minimum. 81

10766-15_CH15_redo.qxd

12/3/07

4:09 PM

Page 82

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Necklaces, metal plates in head, or metal glasses may give artifacts. • Correct collimator, peaks, and windows must be used.

NOTE • CSF leak can be performed with 1–12 mCi (37–444 MBq) with 99mTc-DTPA. Intrathecal injection followed by 15–20 mL of fresh non-bacteriostatic sterile saline to accelerate time of study by quickly moving activity into region of suspected leak. Pledgets placed in area of suspected leak, removed, weighed, and counted at 5 hours after injection. The most common cause is trauma and located in the skull base between the region of the sphenoid sinus and temporal bone. • Shunt patency can be performed with 0.4–0.8 mCi (14.8–29.6 MBq) 99mTc-DTPA in 0.3–0.5 mL. Needle is inserted into shunt reservoir by physician. With needle in place, position patient for best view. Start camera, inject tracer. Take 2-minute immediate view, 2-minute orthogonal (oblique to first image) view, 2-minute thorax view, and 2-minute abdominal view. Repeat series at 20 minutes and 2–6 hours. • CSF is for the most part formed by the choroid plexuses of the lateral, third, and fourth ventricles. That which is produced in the lateral ventricles flows through the interventricular foramina, into the third ventricle, through the cerebral aqueduct into the fourth ventricle and into the subarachnoid space around the brain and spinal cord. Most flow in the subarachnoid space is cephalad around the cerebral convexities toward the superior sagittal sinus. Absorption back into the venous system is through the arachnoid villi.

PATIENT HISTORY

The patient or caretaker should answer the following questions.

Do you have a history of hydrocephalus?

Y

N

Have you had any seizures?

Y

N

Do you have urinary incontinence?

Y

N

Do you have balance problems?

Y

N

Do you have memory problems?

Y

N

Do you feel any head pressure or pain?

Y

N

Do you have a shunt or have you had any other neurologic procedures?

Y

N

Do you have any ear or nasal discharge?

Y

N

Have you had any other related tests?

Y

N

Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and since when? Female: Are you pregnant or nursing? Other department-specific questions.

82

10766-15_CH15_redo.qxd

12/3/07

4:09 PM

Page 83

Chapter 15 — Cisternography

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

83

10766-16_CH16_redo.qxd

12/3/07

4:11 PM

Page 84

chapter

16

Cystography (Voiding Cystourethrogram): Direct and Indirect RADIOPHARMACY Radionuclide

Quality Control

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator, or • 131I t1/2: 8.1 days Energies: 364 keV Type: β−, γ, fission product

Tc: chromatography; 99mTc-SC, > 90%; particle size, < 1 µm; Use within 6 hours. DTPA, > 90%, use within 1 hour. • 131I: chemical purity test for 131I iodide (< 1.5%) and 131I orthoiodobenzoic acid; radionuclide purity for anything other than 131I, spectrometer test for tracer tag.

Radiopharmaceutical

Adult Dose Range

•

99m

− 4

•

99m

• Na 99mTcO (pertechnetate), 99mTc-SC (sulfur colloid), 99mTc-DTPA (diethylenetriaminepentaacetic acid), 99mTc-MAG3® (mercaptoacetyltriglycine), 131I-OIH (orthoiodohippurate)

• Direct: 99mTc, .5–1 mCi (18.5–37 MBq) • Indirect: 99mTc, 3–10 mCi (111–370 MBq); 131I, 150–300 µCi (5.55–11.1 MBq) • Children’s dosage should be adjusted using weight or body surface area using as low as practical for appropriate image quality.

Localization

Method of Administration

• Direct (retrograde): compartmental, flows with saline and urine • Indirect (antegrade): compartmental, blood (bound to protein and some red blood cells)

• Direct (retrograde): injection into Foley catheter by injection port or needle puncture of tube. • Indirect (antegrade): Intravenous injection, butterfly, or IV catheter.

84

10766-16_CH16_redo.qxd

12/3/07

4:11 PM

Page 85

Chapter 16 — Cystography (Voiding Cystourethrogram): Direct and Indirect

INDICATIONS • • • • •

Evaluation and detection of vesicoureteral reflux. Quantification of postvoid bladder residual. Evaluation of management and continuing assessment of patients with reflux. Evaluation for surgical intervention or other to prevent subsequent impairment of renal function. Evaluation of genitourinary system due to abnormal results on related studies.

CONTRAINDICATIONS • Indirect method not recommended in patients with known significant renal dysfunction.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Patients are usually pediatric and require special attention to relieve apprehension. Most institutions require a signed consent to do the procedure. • Instruct patient to void completely just before exam. • Catheterize (sterile urethral catheterization) patient for direct cystography (see note). • Patient will be instructed to hydrate and void after exam as well to reduce exposure to bladder.

EQUIPMENT Camera

• Statics: 120-second images, bladder at full capacity and postvoid.

• Large field of view

Collimator • Low energy, all purpose, or low energy, high sensitivity

Indirect • Flow and static images during void and postvoid.

Computer Set-up Direct • Flow: 1 or 2 sec/frame for 30 seconds to 1 minute during filling and voiding segments: 128 × 128 matrix.

PROCEDURE

(TIME: ~45 MINUTES)

Direct (retrograde) −

• Usually with 99mTcO4, 99mTc-SC, or 99mTc-DTPA. • Cover camera and table area with disposable pads (“chucks”) to absorb leakage and/or contamination. • Hang 50–1500 mL (depending on size of patient) normal saline (tubing clamped) for gravity-feed infusion (no higher than 100 cm above table). • For pediatric patients (normal ∼250 mL): expected bladder capacity (oz) = age (in years) + 2 × 30 (30 mL = 1 oz). • Note amount at start and finish. • Position catheterized patient supine with camera posterior (or patient sitting with back and pelvis against camera), the dome of the bladder in lower field of view (FOV), kidneys in upper. This can 85

10766-16_CH16_redo.qxd

12/3/07

4:11 PM

Page 86

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• • • • •

• • • • • •

be done before imaging if radiotracer is injected into catheter before filling starts, or “eyeball” position if radiotracer is to be injected after patency is established and while filling. For infants and children, the radiotracer is injected into the catheter followed by the appropriate amount of saline. For adults, the radiotracer may be added to an appropriately shielded 500 mL bag of normal saline and infused slowly. Start camera for flow; fill bladder completely with radiotracer/saline mixture (this is usually verified by patient’s urgency to micturate, leakage around the catheter, or cessation of flow into bladder). Monitor p-scope closely for signs of reflux. If reflux (activity just above bladder) is visualized, record amount of saline infused at time (see Note). When bladder is full, stop flow images and take 120-second immediate static of posterior and left and right posterior oblique images. Record the amount of saline used to fill bladder and the count rate (cpm) during posterior view. Instruct patient to resist the urge to micturate. Some remove catheter at this point, others do not. Position patient sitting, camera behind, or lateral decubitus, camera behind. Start second flow study, instruct patient to void into empty urinal or bedpan. Some take only a static while patient voids. Take a 120-second immediate postvoid posterior static. Record count rate (cpm). Measure and determine volume (in mL) voided by patient. To determine residual volume (bladder retention in mL) Postvoid cpm × vol. of voided urine ( mL ) = Bladder retention ( Residual Volume ) ( Prevoid cpm − Postvoid cpm )

• Or: Postvoid bladder ROI count × Postvoid volume ( mL ) = Residual Volume ( Bladder retention ) Prevoid bladder ROI count − Postvoid bladder ROI count • If the infused volume into the bladder is known: Postvoid bladder ROI count × Maximum bladder volume ( mL ) = Residual Volume Full bladder ROI count • Review images for signs of reflux. • For patients that cannot cooperate and micturate spontaneously, record mL’s infused and begin the voiding flow images immediately. • For those patients that cannot micturate on command and are not catheterized, they will need to be catheterized using a tubing clamp, then open clamp and begin voiding images. Record amount voided. • For reflux while filling bladder, quantify by recording the amount infused at time of reflux occurrence, use ROI’s over both kidneys and ureters and bladder. • The degree of reflux is also estimated using a visual grading system of 1 to 3 (mild, moderate, or marked), or a 1 to 5 system similar to that used for contrast cystography.

Indirect (antegrade) • Usually with 99mTc-DTPA, 131I-OIH, or 99mTc-MAG3®. • Patient is injected and must not void for 2 hours. • At 2 hours after injection, when the radiotracer has cleared the kidneys and filled the bladder, the patient is positioned sitting with back and pelvis toward camera, bladder and kidneys in FOV, and told to void. 86

10766-16_CH16_redo.qxd

12/3/07

4:11 PM

Page 87

Chapter 16 — Cystography (Voiding Cystourethrogram): Direct and Indirect

• Obtain dynamic images as patient voids. • Obtain statics (120 seconds) when completely voided. • Carefully monitor p-scope when patient is voiding for signs of reflux.

NORMAL RESULTS • No visualization of reflux of solution and tracer past bladder during filling and/or voiding. (Normal valve action at ureterovesical junction depends on oblique entry of ureter into bladder, adequate length of intramural ureter, contraction of ureterotrigonal muscles, and active ureteral peristalsis.) • All or nearly all solution is voided from bladder.

ABNORMAL RESULTS • Significant activity in upper urinary tracts during filling, at full capacity, and/or while voiding. This will visualize as a spot or elongated activity in one or both of the ureters just above the bladder. • Reflux is associated with causing urinary tract infections (UTIs), particularly in pediatric patients. Reflux usually resolves itself. Reflux is potentially damaging to the kidneys. • Reflux nephropathy usually develops in infancy or early childhood; low-grade reflux more likely to resolve than high-grade reflux. • Bacterial infection of the kidney(s) may present with fever, leukocytosis, and bacteremia. Bacterial nephritis may present with only fever and leukocytosis. This test could help distinguish between lower and the more serious upper tract urinary infections.

ARTIFACTS • Recent contrast radiographic studies may interfere with results. • Contamination of area by infusion leakage, etc. • Indirect method: Reflux may be missed during filling phase, which is not imaged. Kidneys may retain radiotracer. Patient may not be able to hold contents of bladder for 2 hours until imaging or void on command.

NOTE Suggested Catheterization • • • • • •

Boys under 1 year old, number 5–8 infant feeding tube. 1–3 years old, number 8 Foley catheter. 3 years and older boys, number 8 Foley catheter or greater. Girls under 1 year old, number 8 Foley catheter. 1–3 years old, number 10 Foley catheter. 3 years and older girls, number 12 Foley catheter.

Bladder volume at reflux helps predict which patients may experience spontaneous resolution of the problem. Children who have progressively larger volumes at reflux on follow-up studies tend to resolve the reflux naturally with no surgery. Contamination to camera surfaces and bedding is highly probable. Protect equipment with proper padding and make plans for storage and disposal of radioactive urine waste and materials. Infusion usually ends when the patient voids spontaneously, the estimated bladder volume is reached or the flow from the bag stops due to back pressure. 87

10766-16_CH16_redo.qxd

12/3/07

4:11 PM

Page 88

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history of or family history of renal obstruction or disease?

Y

N

Do you have a history of or family history of cancer?

Y

N

Do you have a history of ureter, bladder, or urethra infections or obstructions?

Y

N

Do you have any pain or problems with micturition?

Y

N

Adult female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography. Revised 2005, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

88

10766-17_CH17_redo.qxd

12/3/07

4:12 PM

Page 89

chapter

17

Dacryoscintigraphy (Lacrimal Study) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 KeV Type: IT, γ, generator

Radiopharmaceutical −

Quality Control • Moly breakthrough, Al breakthrough, chromatography.

Adult Dose Range • 50–200 uCi (1.85–7.4 MBq).

• Na 99mTcO4 (Pertechnetate)

Localization • Passive transport, following path of tears in nasolacrimal system from eye to nose.

Method of Administration • Application of drops using eye-dropper or pipette to one or both eyes.

INDICATIONS • • • • • • •

Assessment of lacrimal duct patency. Localization of functional nasolacrimal duct obstruction. Assessment of epiphora (pathological watering of eyes). Assessment of surgical candidates. Assessment of inflammations, e.g., conjunctivitis, chronic or acute dacryocystitis. Assessment of paranasal sinus infections. Assessment of post-trauma, post-surgery, tumors, and systemic diseases causing nasolacrimal duct obstructions.

89

10766-17_CH17_redo.qxd

12/3/07

4:12 PM

Page 90

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS • None

PATIENT PREPARATION • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Patient to supply a list of all medications being taken. Patient to supply reports of previous related exams if applicable. No other special preparation. Patient instructed not to blink on application. A trial run using normal saline may help “train” response.

EQUIPMENT Camera

Computer Set-up

• Large Field Of View or specialized small field of view.

Flow • 1–5 seconds/frame for 5 minutes.

Collimator

Dynamic • 1 minute/frame for up to 60 minutes.

• Low Energy, All Purpose or Low Energy, High Resolution, pinhole if available with 1-mm or 2-mm insert.

PROCEDURE

Statics • Acquire 1 minute or 25 k count images every 5 to 10 minutes for up to 60 minutes. • Magnification may be useful.

(TIME: 30 TO 60 MINUTES)

Preparation for Procedure • Eye dropper or pipette, cotton or cloth to ensure no spillage, camera near acquisition position, patient head tilted back slightly.

Preparation of Radiopharmaceutical −

• Dilute 10 mCi (37 MBq) 99mTcO4 to .5 mL using normal saline. 1 drop equals approximately 20 uCi (0.76 MBq). 3 to 5 drops should be sufficient. Less dilution would result in fewer drops necessary. Use the same in both eyes.

Patient Positioning • Position patient in a sitting or semi-reclined position facing camera or: • Position patient supine with head slightly elevated and camera anterior. • Apply 1 to 10 drops per eye to lower eyelid ensuring no seepage down face, position camera quickly close to the face (1.5 to 6.0 cm from camera) and start camera for flow, dynamic study, or immediate static as soon as possible.

Flow • Flow for 5 to 10 minutes. Then dynamic to at least 30 or statics. • Dynamic for 30 to 60 minutes.

Statics • Obtain immediate image and, depending on length of desired study, one image every 5 minutes up to 30 minutes, then every 10 minutes up to 60 minutes post application. 90

10766-17_CH17_redo.qxd

12/3/07

4:12 PM

Page 91

Chapter 17 — Dacryoscintigraphy (Lacrimal Study)

Marker • A marker image or marker frame (depending on the type of study) should be taken toward the end of the study by placing a small 99mTc marker spot on the end of the nose as a landmark. • NOTE: The head needs to be tilted back but not supine so that the radiotracer accumulates along the bottom eyelid and has the opportunity to drain into the lacrimal system. It is very important that there is no spillage down the anterior of the face.

NORMAL RESULTS • Radiotracer flowing from conjunctival sac to nose bilaterally without undue delay (within 10 to 15 minutes).

ABNORMAL RESULTS • Lack of radiotracer flow 15 minutes after dose administration from conjunctival sac to nose on either side. • Some classify various results: • Type 1: Delayed excretion distal to the nasolacrimal duct. • Type 2: Delayed excretion proximal to the nasolacrimal duct. • Type 3: Delayed excretion at pre-lacrimal sac. • Obstructed or closed ducts. • Inflammation of lacrimal sac. • Dysfunctional pump system, e.g., palpebral laxity or facial palsy. • Aberrant punctum lacrimal location. • Congenital lacrimal gland agenesis.

ARTIFACTS • Radiotracer spillage externally from either eye may contribute to a false-positive or hamper interpretation. • Deviated septum may contribute to a false-positive.

NOTE • Given normal conditions, the lacrimal glands release tears to maintain a thin protective liquid film over the cornea of the eye through the blinking process. The extra tear fluid collects in the conjunctival sac and is drained through the lacrimal puncta located on each eye in the upper and lower eyelid in the region of the medial canthus. The fluid drains through the upper and lower canaliculi into the nasolacrimal sac and down the nasolacrimal duct through the valve of Hasner, and into the nasal cavity or nose. Normal human lacrimal volume is about 7 uL. Up to 30 uL can be added without overflow provided the patient does not blink. The normal transit time from the conjunctiva to the nasolacrimal sac is < 1.5 minutes. • A concern that the patients may have is the radiation exposure to the eye. The exposure to the normally draining eye will be approximately 0.014 to 0.021 rad (cGy) per 100 to 150 uCi (3.7 to 5.55 MBq). Total obstruction can yield 0.4 to 0.6 rad (cGy). The threshold for initiating cataract formation is 200 rad (2 Gy) making this procedure well within acceptably safe limits. Flushing with normal saline at the end of the exam will reduce the exposure still more. • There is also a Jones dye test. This requires the insertion of a tube into the nasolacrimal duct to insert the dye and is more invasive, demands patient cooperation, and tends to distort the location and cause of the duct obstruction. Dacryoscintigraphy is less invasive, more easily tolerated, and yields more detailed results in cases of partial obstruction. There are also 91

10766-17_CH17_redo.qxd

12/3/07

4:12 PM

Page 92

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

radiographic contrast studies, one called dacryocystography, where a drop of topical anaesthetic is placed into the palpebral aperture of both eyes. The procedure involves intubating both lower puncta, introduction of an iodized oil-based contrast medium and imaged with a series of macroradiographs. It is considered extremely useful at demonstrating the anatomy of the lacrimal systems. • Treatments include for cases of partial lacrimal duct obstruction, silicone tube insertions, dacryocystorhinostomy, and conjunctivodacryocystorhinostomy, punctoplasty in cases of punctum stenosis, and blepharoplasty in cases of eyelid laxity or ectropion.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Do you have a history or family history of tearing problems?

Y

N

Do you have non-draining tearing?

Y

N

Does it affect both eyes?

Y

N

Do you have or have you had any eye or nose infection?

Y

N

Have you had any recent related exams or contrast radiographic exams?

Y

N

Are you being considered for a surgical procedure?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long? Do you have any pain or scratchiness in eyes? If so, where and for how long?

If so, for how long?

Other department specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Chung YA, et al. The clinical value of dacryoscintigraphy in the selection of the surgical approach for patients with functional lacrimal duct obstruction. Ann Nucl Med 19(6):479–483, 2005. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Wearne MJ, et al. Comparison of dacryocystography and lacrimal scintigraphy in the diagnosis of functional nasolacrimal duct obstruction. Br J Ophthalmol 83:1032–1035, 1999. 92

10766-17_CH17_redo.qxd

12/3/07

4:12 PM

Page 93

Chapter 17 — Dacryoscintigraphy (Lacrimal Study)

Notes

93

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 94

chapter

18 DVT:

(Deep Venous Thrombosis) Venography RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-MAA (macroaggregated albumin). Tagged red blood cells by pyrophosphate − or stannous chloride to 99mTcO4 (pertechnetate) by in vivo, in vitro, or kit, e.g., UltraTag®.

Localization • Compartmental to blood supply

Quality Control • •

99m

Tc-MAA: chromatography; 90–95% tagging − TcO4: chromatography; tagging; 90% in vivo, 95% in vitro 99m

Adult Dose Range • •

99m

Tc-MAA: total of 6 mCi (222 MBq) − TcO4: 20–30 mCi (740–1110 MBq)

99m

Method of Administration •

99m

Tc-MAA: Intravenous using butterfly needles in a dorsal vein of each foot; 3 mCi (111 MBq) in each of two syringes brought up to 3 mL with normal saline. − • 99mTcO4: IV injections, or drawing, tagging, and reinjection of tagged red blood cells.

INDICATIONS • Evaluation of deep venous thrombosis (DVT), especially with patients who do not tolerate radiographic contrast material. 94

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 95

Chapter 18 — DVT: (Deep Venous Thrombosis) Venography

• Evaluation of acute-onset symptoms in patients who have had no prior DVT (acute versus chronic or old). • Detection of acute thrombophlebitis (with tagged red blood cell technique).

CONTRAINDICATIONS • Should not be performed on patients with pulmonary hypertension.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to bring all results of previous related examinations. • Ensure leg(s) are horizontal if DVTs are already known or highly suspected.

EQUIPMENT Camera

Statics • 30 seconds per image. Delays: 1,000,000 counts

• Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Whole Body • Variable cm/min, toe to abdomen. Delayed head to toe optional.

Computer Set-up Flow • 60 frames at 1 sec/frame

PROCEDURE

(TIME: ~30 MINUTES)

• Position patient supine on table. • IV setup: for procedures A and B. • Insert 23- to 25-gauge butterfly needles, one in each foot, into a dorsal vein. • Attach three-way stopcocks to tubing. • Attach 10-mL syringes of saline flush to each stopcock. • Attach two doses to stopcocks.

Procedure A: Statics • • • • • • • • • •

Position camera anterior (and posterior, dual head) over knees and tibia/fibula. Inject 1 mL (containing 1 mCi) from each syringe. Obtain a 30-second image. Reposition camera to thighs. Inject another 1 mL from each syringe. Obtain a 30-second image. Reposition camera to pelvis/lower abdomen. Inject last 1 mL from each syringe. Obtain a 30-second image. Remove butterfly catheters, and, if patient is not already believed to have DVTs, allow patient to walk around for several minutes. • Reposition patient and camera. • Obtain delays in same sequence for same amount of time as initial images. 95

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 96

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Procedure B: Whole Body • Set camera to run at 64 cm/min and to cover from feet to mid-abdomen (about 130 cm). • Apply tourniquets at both ankles and just below both knees (this forces radiotracer to seek deep venous routes up the legs). • Start camera. Inject all of both doses and flush both (there is always a short delay after the camera is started before it actually begins imaging). • When the camera reaches the knees, reduce the speed of the camera to 48 cm/min. • Reduce the speed again, to 16 cm/min, when it reaches the pelvis/abdomen. • Remove tourniquets when imaging is complete. • Obtain a 1,000,000-count anterior image of the lungs while patient exercises lower extremities. • Repeat the whole-body scan of legs at 120 cm/min. • Optional lung perfusion study can be performed after venography. If both a ventilation and perfusion is indicated, ventilation should be performed before venography.

Procedure C: Tagged Red Blood Cell Study, No Dorsal Vein Injections • Patient must sign consent form to take and return blood. It must also be signed by technologist and witness. • Introduce a large-bore venous catheter. • In vitro method: Extract ∼2–2.5 mL of blood into heparinized syringe from patient and follow instructions to tag with UltraTag®. Inject under camera for flow. • In vivo method: Inject cold pyrophosphate, then 20 minutes later, inject radiotracer under camera for flow. • Modified in vivo method: Inject cold pyrophosphate and wait 20 minutes. Extract ∼2–2.5 mL of − blood into a heparinized shielded syringe containing ∼30 mCi of 99mTcO4. Mix for 5–10 minutes. Reinject under camera for flow. • Position patient under camera with camera set up for flow. Field of view should be lower extremity including area having pain, inflammation, or redness. − • Depending on method of tagging, at proper time, inject 99mTcO4 or tagged blood, wait 8 seconds, then start camera for flow. • Obtain static images of 1,000,000 counts each of anterior/posterior femoral, popliteals, calves, and feet immediately after flow. • Optional: Obtain whole-body anterior/posterior pelvis to feet at 15–20 cm/min.

NORMAL RESULTS Flow • Veins appear with a cellular flush that dissipates with time.

Statics and Whole Body • Deep veins and collateral circulation should present clearly, smoothly, well defined, and with bilaterally even uptake.

ABNORMAL RESULTS Flow • Higher uptake in tissue and collateral circulation in area(s) of swelling or inflammation. • Late and asymmetric arrival of activity on one side of the deep venous system. This is useful only if postphlebitic syndrome and deep or superficial varicose veins have been excluded. Soft-tissue induration, inflammation, and edema can also result in uneven arrival of radiotracer. 96

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 97

Chapter 18 — DVT: (Deep Venous Thrombosis) Venography

Statics and Whole Body • Absence of blood flow (e.g., nonvisualization of a major vein) beyond a point in affected leg (segmental or total). May or may not be associated with the presence of whorled or medusa-like collaterals. Occlusions at the iliac levels are associated with rich collateral formations; popliteal levels are associated with a paucity or absence of collaterals. • Larger uptake than usual in a localized area of vein as opposed to nonaffected leg in that area (a hot spot). Some consider the hot spot a reliable sign of acute DVT if they are segmental rather than focal, there is a smudgy backdrop, and they present with a network of collaterals. • More collateral uptake in affected leg in edematous areas. • Thrombi are not directly visualized. Decreased flow in the venous system or the obstruction to the deep venous system is apparent and comparable to radiographic venography. • Venography cannot distinguish between acute (newly formed) and chronic DVT.

OTHER METHODS • MRI—can image all important venous channels, even proximal upper limb veins. Cost and availability is restrictive. • CT—detection in complicated cases involving abdomen or pelvis should be considered; can be used in limbs, generally superior to conventional contrast venography for proximal disease. • Ultrasonography (US)—duplex, triplex, or color Doppler ultrasonography is now the gold standard for initial screening. Real-time imaging with color Doppler produces a color map of flow within the vessels. Compressibility of a deep vein is one of the most sensitive and specific criteria for Doppler detection of DVT, although the method detected only a low percentage of actual DVTs in patients showing pulmonary emboli by angiography. For patients with prior DVTs or postphlebitic syndrome, other tests are needed to improve the diagnostic accuracy. • Plethysmography—measures the capacity of the venous system to fill and empty. Best used in symptomatic patients with no prior history of DVT. Not reliable in patients with prior DVT, cord injuries, strokes, arterial vascular insufficiency, impaired venous return from right heart failure, or external compression of veins, and varies greatly with patient population types. • 125I-fibrinogen—poor results above mid-thigh because of bladder uptake and larger adjacent blood vessels. Fibrinogen is a part of clot formation. Radiolabeled fibrinogen incorporates into a freshly formed clot and is detected with hand-held scintillation detector. Injections of 100 µCi in approximately 1 mg fibrinogen are used, and counts of the lower extremities are taken with a hand-held scintillation detector twice a day for 7 days. • 111In-platelets—sensitive and specific for active DVT. It requires 18- to 24-hour delayed imaging for diagnostic results, particularly with those patients having venous stasis or low-grade thrombosis. Many false-negative results with patients receiving heparin or warfarin therapy. False-positive results are also seen from venous trauma, venipuncture, or persistent asymmetric increased blood pool activity in popliteal or inguinal regions. 99m • Tc-hexamethylpropyleneamine oxime-platelets—perhaps a useful alternative to the expense and time consumption of indium-oxine. • 99mTc-T2G1 antifibrin—2- to 4-minute images of immediate up to 6 hours is an advantage localizing at sites of active thrombus formation in patients receiving anticoagulants. Dissociation and lysis of labeled antibody from the clot, poor binding to chronic thrombi, and cost limit use. • D-dimer—serum laboratory test for DVT (hypercoagulability) or DIC (Disseminated Intravascular Coagulation, numerous minute blood clots from surgery, septic shock, poisonous snake bites, liver disease, and postpartum). Clotting can also occur in oxygen-carrying arteries causing infarcts to organ systems. The combination of possibilities is referred to as venous thromboembolism (VTE). A positive D-dimer indicates an abnormally high level of fibrin degradation products in the blood stream. Although it cannot pinpoint the site(s), it indicates that there is an acute condition or disease that is causing abnormal clot formation and breakdown. Anticoagulant therapy already in progress can cause a false-negative test result. The Simplify D-dimer assay is a D-dimer specific 97

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 98

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

murine monoclonal antibody DD3B6/22. The conjugate binds specifically to D-dimer-containing molecules found with the degradation products from cross-linked fibrin products (XL-FDP’s), making it an indicator for VTE.

ARTIFACTS • MAA can trap behind a venous valve presenting a false-positive result. • The ipsilateral saphenous vein, a main collateral, can easily be mistaken for an occluded main vein. • DVT may appear to be the diagnosis in extraluminal causes, e.g., non-Hodgkin’s lymphoma.

NOTE • The lower extremities hold the majority of the blood volume. The large deep venous system includes the iliacs, femorals, popliteals, and saphenous veins along with the smaller deep venous system of the calf. • Even in the absence of clinical suggestion of pulmonary emboli (PE), 35–51% of patients with clots detected above the knee have evidence of pulmonary emboli. All lower limb thrombi do not pose the same threat. Most clots arise in the soleal sinuses of the calf or near a venous valve, and 20–45% propagate to the iliofemoral veins, which greatly enhances the possibility of pulmonary emboli. Pulmonary embolism is not the only medical concern. There is high correlation between distal vein (popliteal and below the knee) DVT and postphlebitic syndrome, skin pigmentation, and leg ulcers.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of deep venous thrombosis?

Y

N

Do you have phlebitis or other leg problems?

Y

N

Have you had any recent operations?

Y

N

Y

N

Do you have any chest pain?

Y

N

Have you been coughing up any blood?

Y

N

Have you been short of breath?

Y

N

Are you taking blood thinners?

Y

N

If so, what type and for how long?

If so, what type and when? Do you have any leg pain or swelling? If so, where and for how long?

98

10766-18_CH18_redo.qxd

12/3/07

4:13 PM

Page 99

Chapter 18 — DVT: (Deep Venous Thrombosis) Venography

Have you recently remained lying or seated for a long time, as in a hospital stay or long trip?

Y

N

Are there any planned or recent related examinations?

Y

N

Y

N

If so, what and when, and do you have the results with you? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Labtestonline.org. D-dimer, the test. www.labtestonline.org. 2006. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

99

10766-19_CH19_redo.qxd

12/3/07

4:16 PM

Page 100

chapter

19

Esophageal Transit Time RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-SC (sulfur colloid)

Localization • Compartmental; esophagus to stomach

Quality Control • Chromatography, > 90%; particle size, < 1 µm

Adult Dose Range • 150–300 µCi (5.55–11.1 MBq)

Method of Administration • PO in 15 mL of water, one bolus swallow. • Alternative: PO using 1.35 mCi (50 MBq) of 99mTc-SC in 50 mL of apple sauce.

INDICATIONS • Evaluation of esophageal sphincter dysfunction. • Evaluation of dysphagia and decreased esophageal motility attributed to achalasia (delay in peristalsis and marked esophageal retention), strictures, obstruction, retention, scleroderma, diffuse esophageal spasm (multiple uncoordinated peaks), or hiatal hernia. • Evaluation of patients who cannot tolerate manometry or with equivocal or negative manometry results having reasonable suggestion of disease. • Evaluation of clinical management by monitoring for serial changes or response to therapy. • Evaluation of esophageal dysmotility in systemic sclerosis and Raynaud’s phenomenon (episodic digital ischemia manifested by development of digital blanching, cyanosis, and rubor of the fingers or toes after cold exposure and subsequent rewarming). It is classified as primary (occurring in an otherwise healthy subject) or secondary (associated with a disease process, e.g., connective tissue disease such as systemic sclerosis; fibroblast proliferation, and collagen deposition frequently with esophageal involvement). • Evaluation of swallow functioning due to abnormal results on related studies. 100

10766-19_CH19_redo.qxd

12/3/07

4:16 PM

Page 101

Chapter 19 — Esophageal Transit Time

CONTRAINDICATIONS • None

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Ensure patient has fasted for 8 hours or overnight. • Instruct patient as to cooperation with swallowing.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Flow • .25 sec/15 sec for 1 minute

Collimator

Or 1–2 sec/frame for 1 minute

• Low energy, all purpose, or low energy, high sensitivity

PROCEDURE

Dynamic • 15 sec/frame for 9 minutes

(TIME: ~30 MINUTES)

• • • • • • •

Patient supine, camera anterior over thorax, mouth to proximal stomach. Upright views may better assess therapy results in achalasia and scleroderma. Patient draws dose into mouth with straw and holds. On command, patient swallows once in a single bolus; camera is started. Patient dry-swallows once every 15 seconds for 5 to 10 minutes. Because of variability in swallowing, some repeat study as many as five times. The esophageal transit time is the time interval between peak activity in the proximal third of the esophagus and the peak activity in the distal third of the esophagus. • For processing • Regions of interest (ROIs) are drawn around bolus dose, then entire esophagus, to calculate remaining activity at various times. • ROIs can be drawn around upper, middle, and lower regions of esophagus to evaluate regional esophageal dysfunction. % remaining esophageal activity =

A−B × 100 A

where A is total activity of bolus dose, and B is activity of bolus during any one image.

NORMAL RESULTS • Low count rates or none detectable 5–10 seconds after first swallow. • Transit rates > 90% after one to eight swallows. • < 4% of the maximal activity in esophagus by 10 minutes.

ABNORMAL RESULTS • Transit rates 5–40% after eight swallows. • In patients with achalasia or scleroderma, transit may be reduced to 20–40%. 101

10766-19_CH19_redo.qxd

12/3/07

4:16 PM

Page 102

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Diffuse esophageal spasm has significantly reduced transit rate for first half of study, then normal after 20 swallows.

ARTIFACTS • Inability to swallow or aspiration of dose. • Regurgitation with or without aspiration. • Attenuating articles or clothing.

NOTE Some definitions: • Transit time: The time from the entry of 50% of radioactivity into the upper esophagus until the clearance of 50% of the bolus from the whole esophagus. • Emptying time: The time from the entry of 50% of radioactivity into the upper esophagus until the clearance of 100% of the bolus from the whole esophagus. • Integral value: The total counts beneath the curve normalized to the maximum value. • Radionuclide stagnation: An esophageal emptying time >300 seconds. The study is useful as a quantitative measure, however, because of the limited anatomic resolution, this study should not be considered a replacement for the barium esophagram.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of esophageal motility dysfunction?

Y

N

Have you had any therapy?

Y

N

Do you have trouble swallowing?

Y

N

Do you have any pain when swallowing?

Y

N

Do you feel that you must swallow many times to get food down?

Y

N

Do you have any abdominal pain?

Y

N

Do you have a history of Raynaud’s phenomenon?

Y

N

Do you have a history of systemic sclerosis?

Y

N

Do you have a history of reflux esophagitis?

Y

N

If so, what type and for how long?

102

10766-19_CH19_redo.qxd

12/3/07

4:16 PM

Page 103

Chapter 19 — Esophageal Transit Time

Is there a recent or planned esophageal manometry study?

Y

N

Have you had a recent barium x-ray study?

Y

N

Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

103

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 104

chapter

20

Gallium Scan RADIOPHARMACY Radionuclide •

67

Ga t1/2: 78 hours Energies: 93, 185, 300, 394 keV Type: EC, γ, accelerator

Radiopharmaceutical • Gallium citrate (isotonic citrate solution)

Localization • Gallium-67 (an iron analogue) avidly binds to iron-binding proteins. Competes for iron sites in transferrin and is absorbed by lysosomes and endoplasmic reticulum of white blood cells (WBCs). Also has an affinity for lactoferrin (released by leucocytes at sites of inflammation), ferritin (an intracellular protein), and siderophores (low molecular

weight compounds that are produced by bacteria). Distributes through plasma and body tissue with a Tb of 25 days.

Quality Control • Chromatography, < 95%; use within 2 weeks

Adult Dose Range • 3–6 mCi (111–222 MBq) for inflammation; 8–10 mCi (296–370 MBq) for tumors

Method of Administration • Intravenous straight stick, Hep-Lock, or reseal catheter (with saline flush), or because of the amount, a butterfly and three-way stopcock with flush.

INDICATIONS • • • • • • •

Evaluation of fever of unknown origin. Evaluation of chronic inflammations (abscesses). Evaluation of pulmonary disorders. Evaluation of lymphocytic or granulomatous inflammation (sarcoidosis, tuberculosis). Detection of myocardial or pericardial inflammation. Detection and localization of osteomyelitis and/or disk space infection. Detection and follow-up of retroperitoneal fibrosis.

104

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 105

Chapter 20 — Gallium Scan

• Evaluation of patients with acquired immunodeficiency syndrome (AIDS). • Detection and localization of tumors and/or neoplasms of Hodgkin’s disease, non-Hodgkin’s disease, lung cancer (bronchogenic carcinomas), malignant melanoma, hepatocellular carcinoma (hepatomas), sarcoma, testicular tumors, multiple myeloma, head and neck tumors, and neuroblastomas. • Detection and localization of possible infection or tumors due to abnormal results on related studies.

CONTRAINDICATIONS • Patients having other nuclear medicine studies during the time period needed for the gallium scan. • Patients cannot have contrast (x-ray, CT, MRI with gadolinium) studies during the time period needed for the gallium scan.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Study should be done prior to chemotherapy or after three weeks past last course. Administer injection to patient. Instruct patient to return for images at designated hours from injection (e.g., 6, 24, 48, 72, 96, 120 hours) in accordance with purpose of diagnosis. • Instruct patient to return home or send back to hospital room to await images.

EQUIPMENT Camera • Large field of vision

Collimator • Medium to high energy, parallel hole

Computer Set-up

Whole Body • 10 cm/min Single Photon Emission Computed Tomography (SPECT) • Circular or noncircular, 360°, 64 stops, 20–25 sec/stop; region-of-interest (ROI) centered.

Statics • Peak for gallium, windows at 25%, 1,000,000 counts/image

PROCEDURE

(TIME: ~20–60 MINUTES)

• Suggested returns: Infections; 6 hour (inflammation, abdominal abscess, AIDs patients with fever), 24 hour, occasionally 48 hour. Tumor; 48 hour, occasionally 72 hour and beyond. • Instruct patient to void on return to department. • Place patient in supine position; check for attenuating material. • Obtain statics: Anterior and posterior of head, thorax, abdomen, pelvis, and mid-femur; also anterior of extremities, obliques of ROI, axillas for history of lymphoma. • Collect 600,000 to 1,000,000 counts according to protocol. • Whole-body sweep: head to at least mid-femur. • SPECT: center ROI(s). 105

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 106

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

NORMAL RESULTS • Excretion pattern: 20–25% administered dose via kidneys in first 12–24 hours. After which, the major route is intestinal mucosa. This accounts for approximately one third of the injected dose. The remaining two thirds is retained for a prolonged period. • Soft-tissue activity at 6 and 24 hours, renal activity at 24 hours. • Some bowel activity that will move over time. • Lactoferrin content visualizes lacrimal glands, salivary glands (particularly after radiation therapy), external genitalia, breasts, nasopharynx, bone marrow, spleen, and liver (most prominent). • Some early activity in osseous structures of the skull, thorax, sternum, diffuse lung activity, thymus, surgical wounds, and epiphyseal plates, thymus, and spleen in children. • At 48 hours and beyond, renal and lung activity light; lacrimals and salivaries dimly; some nasal activity present; liver, transverse colon, thoracic spine, sternum, scapula tips, skeleton, and genitalia still present.

ABNORMAL RESULTS • • • • • • • •

• • • • •

Inflammations show up as hot spots within 6 hours. 6-hour scan is also good for abdominal abscess. Any bowel activity in the 4- to 6-hour scan is significant in patients with AIDS who have a fever. Persistent focal or diffuse non-moving bowel activity in delayed imaging. Large hematomas present as cold spots. Benign sarcoidosis present as intense uptake in organs. Lung activity that persists. Can show AIDS-related pulmonary infections (e.g., Pneumocystis carinii pneumonia), especially when compared with a recent chest x-ray. A normal gallium scan and focal mass or infiltrate on chest x-ray suggests Kaposi’s sarcoma. Bilateral intense diffuse uptake of gallium is the appearance of Pneumocystis carinii pneumonia (PCP). This may be positive before the chest x-ray becomes abnormal. Bacterial pneumonias present with a solitary focal area without lymph node activity. Multi-focal uptake is usually more aggressive infections, such as actinomycosis or nocardia. Neoplasia (tumors) associated with Hodgkin’s disease, hepatomas from alcoholic cirrhosis, and malignant melanomas of bone, brain, and lung as focal or diffuse increased activity. Hepatomas present as greater intensity in the suspected region than elsewhere in the liver. Greatly diminished intensity in suspected region implies hepatoma extremely unlikely. Persistent renal activity at 48 hours may indicate hypertension pyelonephritis or interstitial nephritis. Continued renal activity at 72 hours may indicate inflammation, infection, acute tubular necrosis, acute pyelonephritis, interstitial nephritis, amyloidosis, or impaired renal function. Increased parotid or lacrimal uptake could be sarcoid activity, the result of radiation, or Sjögren’s syndrome (thought to be an immunologic disorder presenting in postmenopausal women with rheumatoid arthritis, xerostomia, and keratoconjunctivitis sicca).

Drug Interactions • Bowel localization—antibiotics • Breast, male and female localization—metoclopramide, reserpine, phenothiazines, oral contraceptives, diethylstilbestrol. • Kidney transplant rejection—no accumulation due to a high dose of heparin. • Mediastinum and pulmonary hilar structure localization—phenytoin in patients with clinical evidence of lymphadenopathy or pseudolymphoma. • Pulmonary uptake, diffuse and local—amiodarone, bleomycin, busulfan, nitrofurantoin, Cytoxan, methotrexate, procarbazine, vincristine, bacillus Calmette-Guérin, chemo-multiple cycles, contrast media, addictive drug abuse. • Skeletal increased uptake (also increases renal elimination, decreases hepatic uptake, decreases tumor and abscess uptake)—methotrexate, cisplatinum, gallium nitrate, mechlorethamine, vincristine sulfate, iron, chemotherapy treatment. 106

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 107

Chapter 20 — Gallium Scan

• Soft tissue accumulation—calcium gluconate, intra-muscular injections. • Thymus accumulation—chemotherapy or antibiotics.

Causes of diffuse, persistent lung uptake: • • • • • • • •

Idiopathic pulmonary fibrosis Diffuse pneumonitis Pulmonary sarcoid Lymphangitic metastases Pneumocystis carinii pneumonia Miliary tuberculosis Bleomycin toxicity Radiation pneumonitis (early exudative phase)

Causes of persistent kidney activity: • • • • • • • • • • • • •

Obstruction Renal parenchymal pathology Neoplasm Pyelonephritis Vasculitis Acute tubular necrosis Infiltrative disease Leukemia Lymphoma Plasma transferring saturation Parenteral iron injections Blood transfusions Perirenal inflammatory disease

ARTIFACTS • • • • • • • •

MRI gadolinium administration within 24 hours of gallium injection may decrease localization. Recent blood transfusions will saturate iron-binding transferrin sites. Patient motion due to length of scans. Articles in pockets, medallions, necklaces, metal buttons on shirts and blouses, belt buckles, and prostheses may cause attenuation. Patient not voiding before scan. Bladder activity could mask ROI. Wrong collimator will burn out film. Care must be taken for analog cameras to have proper anatomy in view as pictures are hard to visualize on standard p-scopes. False-positives possible from bowel (also false-negatives), spleen, spine or bladder activity, bone repair activity around orthopedic hardware or prostheses.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

If so, what type and when? (continued)

107

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 108

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have any pain?

Y

N

Have you had any infections?

Y

N

Have you had any surgery?

Y

N

Have you had any recent trauma?

Y

N

Are you a diabetic?

Y

N

Do you have any bowel disease?

Y

N

Do you have a fever?

Y

N

Have you had any previous or planned related scans, x-rays, x-ray procedures, CT, MRI, PET, nuclear medicine studies, biopsies, or antibiotic therapy?

Y

N

Have you had any chemotherapy or radiation therapy?

Y

N

Y

N

If so, where and for how long?

What medications are you on or have recently been on? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in Inflammation. Version 3.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in the Evaluation of Malignant Disease. Version 3.0, June 23, 2001. SNM.org. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 108

10766-20_CH20_redo.qxd

12/3/07

4:19 PM

Page 109

Chapter 20 — Gallium Scan

Notes

109

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 110

chapter

21

Gastric Emptying (Solid and Liquid) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator • 111In t1/2: 2.8 d Energies: 173, 247 keV Type: EC, γ, accelerator

Radiopharmaceutical • Solid: 99mTc-SC (sulfur colloid), 99mTc-albumin colloid • Liquid: 99mTc-DTPA (diethylenetriaminepentaacetic acid), 111In-DTPA (diethylene triamine pentaacetic acid)

Localization • Compartmental; moved along with food through gastrointestinal tract

110

Quality Control • Chromatography: SC, >90%; particle size, <1 µm; >92% tagging. Use either within 6 hours. DTPA, >90%; use within 1 hour.

Adult Dose Range • •

99m

Tc: 100 µCi to 1 mCi (3.7–37 MBq) In: 125 uCi (4.6 MBq)

111

Method of Administration • Solid: Radiotracer usually mixed with 1 or 2 whole eggs or egg whites (or oatmeal, beef stew, liver, some use a whole sandwich) with or without toast (type of meal and amounts vary). • Liquid: Radiotracer mixed into 120 cc water or other (orange juice, milk) for liquid and ingested orally. 111In-DTPA in 300 mL of water for simultaneous study. Pediatrics: “milk scan” (mix in milk or formula).

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 111

Chapter 21 — Gastric Emptying (Solid and Liquid)

INDICATIONS • • • • • • • •

Determination of delayed gastric emptying with quantitation of gastric emptying rate. Evaluation of mechanical obstruction. Evaluation of anatomic obstruction (pyloric, postsurgical, postradiotherapy). Evaluation for altered function, e.g., gastroparesis (diabetic and idiopathic), scleroderma, amyloidosis, or anorexia nervosa. Evaluation of suspected tumors or surgery. Evaluation of nausea, vomiting, early satiety, upper abdominal discomfort, bloating, gastroesophageal reflux and/or chronic aspiration. Evaluation of weight loss. Evaluation of gastric therapy, e.g., Reglan®.

CONTRAINDICATIONS • Allergy to eggs; use oatmeal, baby food, sweet potatoes, chicken or beef livers, or beef stew. • Hypoglycemic patient.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Ensure that diabetics receive orange juice 2 hours before test if necessary. Ensure patient to be NPO 4–12 hours before examination. Physician to discontinue sedatives 12 hours before examination.

EQUIPMENT Camera

Computer Set-up

• Large or small field of view

Statics • Preset for 60–120 seconds or 50,000 counts

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

Dynamic • Preset for 60 sec/image, 60–90 minutes

(TIME: ~1.5 HOURS LIQUID, UP TO 3 HOURS SOLID)

Baseline Solid Study • • • •

Prepare one or two eggs and mix in radiotracer. Stir and scramble. Or prepare choice of gastronomic vehicle with radiotracer. Administer to patient PO followed by 30–120 mL of water. Encourage patient to eat quickly (within 10 minutes).

Patient Supine • Place patient in supine position. Acquisition should be started as quickly as possible after ingestion of food. • Position camera anterior or LAO. 111

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 112

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Instruct patient to remain motionless during imaging. • Obtain static images every 5 minutes up to 30 minutes, then every 15 minutes thereafter, allowing patient to ambulate between images. If camera and/or patient moves between images, reposition patient for subsequent imaging by using a small marker at a specific point on the patient and circling the spot on the p-scope for ease of processing. Realign marker and circle, then remove marker for subsequent images. • Dynamic supine images: preset for 60–90 minutes. Patient remains motionless under camera. • Supine is good for checking esophageal reflux. Patient Standing • Position patient standing or sitting upright, one image facing camera. Optional: one image with back to camera. • Use patient realignment technique described above. • Obtain immediate image(s), then every 10 minutes. • Standing, sitting, then standing uses normal movement and gravity to aid realism in study.

Baseline Liquid Study • Add 500 µCi of 99mTc-DTPA to 120 mL of water or orange juice. • Administer to patient PO. Encourage patient to drink quickly. • Images same as solid study, although only imaged for 1.5 hours.

Dual Solid and Liquid Study Peak camera for both 99mTc and 111In (247 keV), 20% windows, LEHR or LEAP collimator. Patient fasting for at least 8 hours. Solid portion is 500 uCi 99mTc-sulfur colloid in eggs or meal usually given. Liquid portion is 125 uCi 111In-DTPA in 300 mLs of water. Patient is instructed to eat eggs within 5 minutes, and then wash down with liquid portion of meal. Begin imaging immediately using protocol of choice. If computer has correct software, both can be imaged at the same time. • Imaging should run 60 to 120 minutes.

• • • • • •

Additional Testing • If emptying is slow or nonexistent, Reglan® (metoclopramide) may be administered (standard adult dose, 5–10 mg IV slowly for 2 minutes) to cause stomach contractions; check with radiologist. Reglan® is supplied in a 10-mg vial. Mix with 2 cc saline. If 5 mg is wanted, draw 1 cc and add 1 cc saline to equal 2 cc. Reglan® IV should show movement within 3 minutes after injection; oral Reglan® may take up to 60 minutes for a response. • Continue with protocol for 60 minutes. • If there is still abnormally slow movement, administer erythromycin. Reconstitute vial with 10 cc sterile water, draw amount that equals 250 mg of erythromycin (should be 5 cc liquid), mix into a 50 mL bag of normal saline, hook up to patient and drip (14–20 drips per minute) for 20 minutes.

NORMAL RESULTS • Liquid (e.g., radiolabeled water or orange juice): t1/2 (50%) at 10–65 minutes or 80% in 1 hour with an adult mean of 40 minutes. • Solid (type and size of meals and population varies): t1/2 (50%) movement out of stomach within a lower limit of 32 minutes to an upper limit of 120 minutes with an adult mean of 90 minutes. Others suggest 63% by 1 hour. • Terminate study before 60 minutes if gastric emptying becomes ≥95%. • T1/2 (50%) for infants given breast milk: 25–48 minutes, or formula or bovine milk: 60–90 minutes. 112

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 113

Chapter 21 — Gastric Emptying (Solid and Liquid)

ABNORMAL RESULTS • Very little or no movement from stomach after 60 minutes. Causes of delayed gastric emptying are mechanical obstruction or altered function (e.g., diabetic gastroparesis, diabetes mellitus, surgery, drugs, gastric outlet obstruction, scleroderma, chronic idiopathic intestinal pseudoobstruction [CIIP], idiopathic gastroparesis, amyloidosis, anorexia nervosa). • Rapid emptying may occur in cases of “dumping syndrome.”

PROCESSING • For either study, calculate percent emptying by following methods: • Computer program. • Generate regions of interest (ROIs) around stomach. • Manual: Use counts taken in ROI, correct counts by following decay factors: Start Time (xo) 10 min 20 min 30 min 40 min 50 min 60 min

1.00 0.981 0.962 0.944 0.926 0.909 0.891

• Divide gastric counts by decay factor to obtain corrected counts. • This is performed on each frame, plotted on a semilogarithmic graph, and compared with a normal curve. Obtain the t1/2 emptying time from graph. • If it is noticed that the duodenum loops up behind the stomach, this will add false counts to the ROI, leading to an erroneous t1/2. If the test needs to be repeated, sometimes a cephalic tilt to the camera will separate the loop of bowel enough to get an accurate count of the stomach.

ARTIFACTS • Burn eggs; nonuniform mixing of radiotracer and eggs. • Too little or too much food or water. • Inconsistent amounts of food will yield inconsistent data. Each patient should receive the same type and amount. • Patient allergies or intolerance to eggs or food. • Patient unable to eat or may vomit or aspirate food and dose. • Belt buckles or buttons. • Camera or patient position changes, which affects the number of counts. Patient must be placed exactly in same position for each picture. To help, for supine/anterior pictures, place camera as close as possible, reposition patient for subsequent imaging by using a small marker at a specific point on the patient and circling the spot on the p-scope, realign marker and circle, then remove marker before imaging, especially if going for counts. Or draw outline of initial activity in stomach on p-scope to reposition patient for next picture. The same can be performed for standing pictures. Draw outline on p-scope; realign in p-scope for next picture.

NOTE • Drugs that delay emptying are atropine, propantheline, levodopa, albuterol, isoproterenol, morphine, Librax, and TPN therapy. • Drugs that promote motility are Reglan® (not to be confused with diabetic insulin medication referred to as “regular”), domperidone, cisapride, and erythromycin. These cause the stomach to be more sensitive to nervous stimulation and increase motility of solid foods in the stomach. • Female hormones for menstruating women affect gastrointestinal motility to varying degrees. 113

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 114

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Causes of Gastric Motility Disorders • Mechanical • Peptic ulceration • Duodenal ulcer • Pyloric channel ulcer • Postsurgical • Pyloroplasty • Hemigastrectomy • Hypertrophic pyloric stenosis • Cancer of the stomach • Postradiotherapy • Trauma • Nonmechanical • Metabolic • Diabetes • Uremia • Hypothyroidism or hyperthyroidism • Gastrinoma • Neurologic • Vagotomy • Neuropathy • Gastroparesis • Systemic diseases • Scleroderma • Amyloidosis • Smooth muscle disorders • Anorexia nervosa • Drug-induced • Anticholinergics • Opiates

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history of or family history of cancer?

Y

N

Are you diabetic?

Y

N

Do you have abdominal pain?

Y

N

Do you feel bloated or have acid burning after eating?

Y

N

Do you have nausea and vomiting?

Y

N

Do you have a history of ulcers?

Y

N

If so, what type and when?

If so, where and since when?

114

10766-21_CH21.qxd

12/3/07

4:20 PM

Page 115

Chapter 21 — Gastric Emptying (Solid and Liquid)

Do you have a hiatal hernia?

Y

N

Have you had any gastric surgery?

Y

N

Are you on any medications, especially drugs such as Reglan® or domperidone?

Y

N

Have you had any previous related tests?

Y

N

Female: Are you pregnant or nursing?

Y

N

When was your last menstrual period? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gastric Emptying and Motility. Version 2.0, June 6, 2004. SNM.org. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

115

10766-22_CH22.qxd

12/3/07

4:22 PM

Page 116

chapter

22

Gastroesophageal Reflux RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-SC (sulfur colloid)

Localization • Compartmental, esophagus to gastrointestinal tract

Quality Control

Adult Dose Range • 300 µCi to 2 mCi (11.1–74 MBq); 1 mCi or more if acidified orange juice is used.

Method of Administration • Oral (PO) in water, orange juice, milk, wet oatmeal, or saline, total of 300 mL. • PO with acidified orange juice (150 mL orange juice and 150 mL of 0.1 normal HCl) to delay gastric emptying time and predispose the patient to reflux. • Ingested through a nasogastric tube if patient has a history of esophageal motility dysfunction or for children.

• Chromatography, >90%; particle size, <1 µm

INDICATIONS • • • •

Detection and quantitation of gastroesophageal reflux. Evaluation of patients with diaphragmatic hernia. Evaluation of patients with heartburn, regurgitation, or bilious vomiting. Evaluation of children with asthma, chronic lung disease, or aspiration pneumonia.

CONTRAINDICATIONS • None 116

10766-22_CH22.qxd

12/3/07

4:22 PM

Page 117

Chapter 22 — Gastroesophageal Reflux

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Ensure patient has fasted for 6 hours or overnight.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Statics • 30 sec/image; some go for 300,000–500,000 counts

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

(TIME: ~30 MINUTES)

• At 30 seconds after ingestion, patient is in sitting position, camera anterior, and a 30- to 60-second image is acquired to ensure passage to stomach. If there is residual activity in the esophagus, an additional 30 mL’s of water may be given to flush esophagus. • At 15 minutes after ingestion, position patient sitting or standing in front of camera, anterior projection. • Acquire 30-second image. • From this baseline image before abdominal binding, a region of interest (ROI) of the esophagus will be drawn to use as esophageal background subtraction. • From this image, the ROI around the stomach is also drawn to obtain total counts of dose ingested for quantitation of reflux. • If there are significant counts remaining in the esophagus, administer more fluid and image again. If the counts remain, consider rescheduling the test at a later date using a nasogastric tube. • Place patient in supine position on table. • Place an abdominal binder around lower abdomen below the rib cage. Do not apply a binder to infants and/or children. • Attach a sphygmomanometer anterior, under the binder (or use manual pressure). This can also be accomplished by using a plastic block used for IV pyelograms, for example, placed beneath the binder and a blood pressure cuff folded underneath the plastic block. • Acquire 30-second images with pressures in the abdominal binder at 0, 20, 40, 60, 80, and 100 mm Hg. • Processing: to obtain percent gastroesophageal reflux • Draw ROIs around lower esophagus, stomach, and lower left lung (for background). • Calculate reflux at each pressure with the following equation using counts from each ROI. %Gastroesophageal reflux =

A− B × 100 C

where A is esophageal counts (minus the prebinder esophageal ROI counts), B is background counts (lung ROI), and C is gastric counts from prebinder gastric ROI image. • To be extremely accurate, correct the prebinder counts (esophageal and gastric counts) for each image by a decay factor. • For pulmonary aspiration in infants, administer 5 uCi/mL (0.19 MBq) in milk or formula for a total of 500 uCi (18.5 MBq). Camera is placed over lungs and imaged at 4, 6, and 12 hours as needed. This is sometimes referred to as the “milk scan.” No abdominal binder is used and the patient is imaged from the left anterior oblique position as opposed to supine. The patient imaged immediately and then at 2- and 4-hour delays if pulmonary aspiration is suspected. 117

10766-22_CH22.qxd

12/3/07

4:22 PM

Page 118

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

NORMAL RESULTS • ≤3% refluxed radiotracer at any pressure level. • Dose should present brightly in stomach with very little or no residual activity in esophagus. • The activity should remain in the stomach (and perhaps begin to move out toward the duodenum as in a gastric empty study) with no reflux at any pressure level. • For pulmonary aspiration, there should be no activity in the lungs or pathways to the lungs.

ABNORMAL RESULTS • ≥4–5% refluxed radiotracer. • Activity will appear to be refluxing up the esophagus toward the mouth. • For pulmonary aspiration, activity in the lungs. Detection of aspiration during esophageal reflux exams is 0 to 25%.

ARTIFACTS • • • • •

Inability to swallow or aspiration of dose. Esophageal retention. Regurgitation with or without aspiration. Attenuating articles or clothing. Patient with known esophageal varices (potentially life-threatening condition involving dilation of distal esophageal blood vessels usually associated with chronic obstruction of venous drainage from esophageal veins into the hepatic portal system caused by cirrhosis of the liver and alcoholism); perhaps not enough for a contraindication, but consideration may be given to this condition.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of esophageal motility dysfunction?

Y

N

Do you feel burning or have pain in upper abdomen or lower chest after eating?

Y

N

Do you have any liver diseases?

Y

N

Do you have any stomach diseases or problems?

Y

N

After a meal, does it taste like gastric juices when you belch (as in a mini-vomit)?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

Other department-specific questions.

118

10766-22_CH22.qxd

12/3/07

4:22 PM

Page 119

Chapter 22 — Gastroesophageal Reflux

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

119

10766-23_CH23.qxd

12/3/07

4:23 PM

Page 120

chapter

23

Gastrointestinal Bleed RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Quality Control TcO−4: chromatography; tagging, 90% in vivo, 95% in vitro • 99mTc-SC: chromatography, >90% •

99m

Radiopharmaceutical

Adult Dose Range

• Tagged red blood cells by pyrophosphate or stannous chloride to 99mTcO−4 (pertechnetate) by in vivo, in vitro, or kit, e.g., UltraTag®. For active bleeding, 99mTc-SC (sulfur colloid).

• •

Localization

• Intravenous injections, or drawing, tagging, and reinjection of tagged red blood cells

TcO−4: 20–30 mCi (740–1110 MBq) Tc-SC: 10–20 mCi (370–740 MBq)

99m 99m

Method of Administration

• Compartmental, tagged to and circulating with blood

INDICATIONS • Detection and localization of bleeding sites in patients with active or intermittent gastrointestinal bleeding. This usually presents as low red blood cell counts in labs and/or blood in stool (hematochezia) or melena (dark stool). Dark red blood may be small bowel or old bleed, bright red blood may be large bowel or anal. It could be caused by aspirin, ulcers, perforation, cancers, inflammation, diverticula, hemorrhoids, or angiodysplasia. • Detection and localization of secondary blood loss as in blood pooling in peritoneal cavity or ruptured arterial or venous supplies. • 99mTc-SC: Detection and localization of actively bleeding sites, for patients with portal hypertension (caused by obstruction of blood flow through the liver), and hypertension to abdominal collateral vessels. 120

10766-23_CH23.qxd

12/3/07

4:23 PM

Page 121

Chapter 23 — Gastrointestinal Bleed

CONTRAINDICATIONS • Patients with contrast studies under way. • Medically unstable patient (e.g., uncontrolled hypotension).

PATIENT PREPARATION • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain a signed consent for blood work. Instruct patient to empty bowel and bladder before beginning procedure. If possible, have patient or attending nurse look for active signs of bleeding. Check patient’s current vital signs (blood pressure and heart rate) and assess for orthostatic hypotension. • Obtain lab work and information concerning recent blood transfusions.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Flow • 2–5 sec/frame, 60–180 seconds

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

Dynamics • 60 sec/frame for 60 minutes Statics • 500,000–2 million counts

(TIME: ~1 HOUR; DELAYS, ~15 MINUTES)

• Patient must sign consent form to take and return blood if those methods are employed. It must also be signed by technologist and witness. • In vitro method: extract ∼2–2.5 mL of blood into heparinized syringe from patient and tagged with UltraTag®. • In vivo method: Inject cold pyrophosphate, then 20 minutes later, inject radiotracer under camera for flow. • Modified in vivo method: Inject cold pyrophosphate and wait 20 minutes. Extract ∼2–2.5 mL of blood into a heparinized shielded syringe containing ∼30 mCi of 99mTcO4−. Mix for 5–10 minutes. • Place patient in supine position, camera anterior and if possible from bottom of heart to lower bowel in view. If patient is tall, upper and lower pictures may be taken. • Inject under camera for initial flow if protocol. • Acquire flow if active bleeding is suggested. 99mTc-SC is best used to present the active bleeding site. Sulfur colloid is taken up and removed quickly by the reticuloendothelial system (RES), so careful positioning, injection, and computer start are important. • Acquire statics anteriorly. Include immediately and at 5, 10, 15, 30, 45, and 60 minutes with RAOs and LAOs indicated if positive. • Image a suspected area after the dynamic is done for clarification if necessary. If the area is high, move the camera up to clarify, if there is possible bleeding in the lower pelvic area, take a static of that area postvoid anterior and/or lateral. • Or acquire dynamic study for 60 minutes after flow study. Delayed images as necessary. Patients with melena (black, tarry feces because of intestinal chemical interaction with free blood) are candidates for prolonged studies with delays. 121

10766-23_CH23.qxd

12/3/07

4:23 PM

Page 122

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Show study. Laterals and posteriors may be indicated with presentation of a positive scan. Fourand 24-hour delays may also be indicated. • If a patient has a bowel movement after tagging, some hardy souls bag the bedpan and image it for activity, which would be signs of active bleeding. • If bleeding is found on a delay, another delay should be taken to establish the direction of flow (antegrade or retrograde) of the blood from the initial site. • If the method of filming or sending images does not allow for cine images to be sent, it is helpful to ask the radiologist to view the images in cine mode in the department if possible.

NORMAL RESULTS • Heart, vascular space of liver and spleen, and great vessels prominent. • Soft tissue uptake is light and homogeneous. • Bladder, bowel, and penile activity not unlikely.

ABNORMAL RESULTS • Flow: focal area of increased activity. Blood pooling in abdominal cavity may also be present. • Dynamic study: focal area that may or may not move with time. These studies can be most helpful when viewed in a cine mode to verify movement of focal area. • Statics: focal area peristalses with time. Blood pool may persist in abdominal cavity and may or may not move. • If little or no movement, it may be vascular activity or pool in abdominal cavity. Typical focal areas of active bleeding include ascending, transverse, descending, and sigmoid colon, right colonic (hepatic) flexure, left colonic (splenic) flexure, and small bowel. • Uptake with no change over time may be inflammatory bowel disease or bad tag excreted into bowel. • Bleeding in small bowel can usually be delineated from bleeding in the large bowel by its rapid movement. • Intensity of bleeding rates can be assessed when compared to the activity in the liver. A low bleeding rate will appear with less intensity than the liver, a high bleeding rate appears early and at equal or greater intensity than that of the liver. • Uptake not conforming to bowel may be aneurysm.

ARTIFACTS • Bad radiotracer tag could lead to poor results. Do a thyroid image to confirm a bad tag. Free 99mTc will go to thyroid, salivary glands, kidneys, and gastric mucosa. • Causes of a poor tag: • Drug interactions e.g., heparin, methyldopa, hydralazine, quinidine, digoxin, prazosin, propranolol, doxorubicin, iodinated contrast agents • Cold pyrophosphate not injected soon enough after mixing • Antibodies: transfusions, transplantation • Thalassemia, chemotherapy • Short incubation time • Too much or too little stannous ion • Belt buckles, articles in clothing, necklaces, and so forth, may attenuate image. • A full bladder may mask a bleeding area. • Mesenteric varices, uterine or penile blood pool, hepatic hemangioma, accessory spleen, and/or renal pelvis of transplanted kidney may be interpreted as a false-positive. • Intermittence of bleeding compounds the problem of detection. • 99mTc-SC (10–20 mCi or 370–740 MBq) may be indicated if there is known active bleeding. The drawback is the relatively quick removal by the RES when intermittence is indicated. Do a flow 122

10766-23_CH23.qxd

12/3/07

4:23 PM

Page 123

Chapter 23 — Gastrointestinal Bleed

at 1 sec/frame for 60 seconds to catch the bleed site. If positive, take full series of immediates (obliques, laterals, posterior) to localize, followed by timed images. • R. King Smith, MD (one of the, if not the originator of this exam) explained to the author that at the time he was developing this study, Mallinckrodt had just developed tagging red blood cells for MUGA scans. The timing and availability was fortuitous and he applied this technique to his research in St. Petersburg, FL. • Note: Gastrointestinal bleeding is either upper (proximal to the ligament of Treitz) or lower (distal to the ligament of Treitz). The ligament of Treitz (the suspensory ligament of the duodenum) is the tissue that connects the duodenum of the small intestines to the diaphragm. This landmark divides the upper and lower GI tract and is important as to location for malrotation of the gut affecting young children with recurrent vomiting. Causes for upper GI bleeding include but are not limited to esophageal varices, gastric and duodenal ulcers, gastritis, esophagitis, Mallory-Weiss tear, or neoplasm. Causes of lower GI bleeding include angiodysplasia, diverticula, neoplasms, inflammation, and in pediatric patients, Meckel’s diverticulum. The test can detect bleeding rates as low as 0.1 to 0.35 mL per minute.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of bleeding?

Y

N

Are you bleeding now?

Y

N

Y

N

Are you taking aspirin or blood thinners?

Y

N

Do you have any pain?

Y

N

Do you have a history of diverticulitis, Crohn’s disease, or other disease?

Y

N

Have you had a colostomy or other surgery?

Y

N

Have you had any related studies, e.g., endoscopy, CT, upper gastrointestinal, barium enema, colonoscopy?

Y

N

Have you had any recent blood transfusions?

Y

N

Have you had recent lab work done?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

If so, for how long and what is the color of the stool? Do you have active or hx of internal or external hemorrhoids (non-bleeding or actively bleeding)?

Other department-specific questions.

123

10766-23_CH23.qxd

12/3/07

4:23 PM

Page 124

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Hladik WB, et al. eds. Essentials of Nuclear Medicine Science: Iatrogenic Alterations in the Biodistribution of Radiotracers as a Result of Drug Therapy: Reported Instances. Pamphlet. Du Pont, circa 1985. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gastrointestinal Bleeding and Meckel’s Diverticulum Scintigraphy. Version 1.0, February 7, 1999. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wikipedia. Suspensory muscle of the duodenum. http://en.wikipedia.org/wiki/Ligament_of_Treitz. 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

124

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 125

chapter

24

HIDA (Hepatobiliary or Gallbladder Scan) with Ejection Fraction RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • IDA (iminodiacetic acid). 2,6-diisopropylacetanilido-iminodiacetic acid, disofenin (DISIDA, Hepatolite®), and 2,4,6-trimethyl, 5-bromoacetanilido-iminodiacetic acid, mebrofenin (BRIDA, Choletec®)

Localization • Polygonal cell uptake and excretion, follows bile path • IDA agents are removed from the blood stream by hepatocytes using active transport via the anionic site on the hepatocyte membrane and are excreted into the bile unconjugated.

• Agents compete with serum bilirubin for transport binding sites explaining why agent uptake falls as bilirubin rises.

Quality Control • Chromatography for 99mTc > 90%; 6-hour shelf life

Adult Dose Range • 3–15 mCi (111–555 MBq), higher doses for patients with elevated bilirubin levels (>30 mg/dL causes less hepatic uptake, more background activity, and greater renal excretion). Mebrofenin, because of its greater hepatic specificity than others, is indicated for use in these cases, 10 mCi (370 MBq) or more. • For children: 0.05–0.07 mCi (1.85–2.59 MBq) per kg or 5.0 mCi (185 MBq) × body surface area/1.73 sq meters (minimum dose = 0.3 mCi [1.11 MBq]). 125

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 126

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Method of Administration • Intravenous (IV) injection, direct or with butterfly catheter if using cholecystokinin (CCK) for pre-emptying or gallbladder ejection fraction.

• IV injection under camera if flow is requested or immediate image at injection is taken. Some radiologists want to see how long the heart shadow remains after the injection and immediate view to ascertain clearance time.

INDICATIONS • Evaluation of abdominal (especially right upper quadrant) pain. • Evaluation of cholecystitis; acute (calculous or acalculous), inflammation of gallbladder (GB), cystic, or common bile ducts. • Evaluation of cholelithiasis; obstruction. Acute is caused by cystic duct obstruction, usually by stone; chronic is recurring gallstones and many other types of obstruction, e.g., stenosis, tumor, lack of ability to react to cholecystokinin (CCK), or sphincter failure. • Evaluation of biliary colic (spasms in bile ducts usually associated with gallstones). • Evaluation for biliary dyskinesia (cystic duct syndrome [CDS] e.g., obstruction or kinking, sphincter of Oddi spasm [SOS], sphincter of Oddi disease [SOD], and congenital anomalies e.g., biliary atresia). • Evaluation of gallbladder function (e.g., stasis allowing “sludge” to accumulate). • Evaluation of post-gallbladder surgery for suspected leakage. • Detection of perforation of gallbladder; may occur in chronic cholecystitis, immunocompromised patients, and atherosclerotic disease. • Detection of enterogastric reflux. • Evaluation of choledochal cyst and Caroli disease (congenital cystic dilatation of the intrahepatic biliary radicles of the liver). • Evaluation of biliary enteric bypass (e.g., Kasai procedure, hepatoportoenterostomy for biliary atresia that creates an open duct for bile drainage). • Evaluation of hepatic transplant. • Evaluation of neonatal hyperbilirubinemia (biliary atresia versus neonatal hepatitis syndrome). • Evaluation of liver anatomy and function, and biliary tract disorders. • Evaluation of hepatobiliary function due to abnormal results on related studies.

CONTRAINDICATIONS • Recent food intake (affects liver uptake and gallbladder function). Most agree on none within 4 hours prior to exam but having a meal within 24 hours of exam. • No CCK if recently diagnosed as positive for gallstones. Some administer fatty meal or Pulmocare® instead as it is not so forceful in contracting the gallbladder. • NO morphine sulfate (MS) if the patient is allergic to morphine (there are alternative drugs) or has elevated amylase (hyperamylasemia) or other pancreatic enzymes indicating pancreatitis, or respiratory compromise, or opiate addiction, or if the physician does not want to obscure clinical symptoms with morphine. • Known common bile duct (CBD) obstruction regarding use of interventions. • Known intestinal obstruction regarding use of interventions.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. • Ensure patient NPO 2–14 hours before exam (usually 4–6 hours, 2 hours for infants). Clear liquids may be used only if necessary. • Ensure patient has had no opiates for 4 to 8 hours prior to exam. Make a notation if this is not the case. Injection and imaging may be postponed 4 hours if patient has been injected with this type of medication. 126

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 127

Chapter 24 — HIDA (Hepatobiliary or Gallbladder Scan) with Ejection Fraction

• Explain the procedure; usually runs ∼1 hour but baseline studies can go as long as 4 hours with up to 24-hour delays required in some instances. • Some physicians require that a form of CCK such as Kinevac® is given 15 minutes prior to the injection of the radiotracer to ensure that the gallbladder is clear. Administer .01–.14 µg/kg to facilitate gallbladder visualization. A suggestion would be to use the minimal amount for stimulation if it is a “blanket policy” from an office unless there is a direct physician’s order to the contrary.

EQUIPMENT Camera • Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Flow Studies • 2 sec/frame for 60 seconds, then immediate blood pool image Dynamic Studies • 60 sec/frame for 60–90 minutes

Computer Set-up Static Images • Peak for 99mTc, preset time 90–180 seconds, or for 500,000–1 million counts; correct orientation.

PROCEDURE

(TIME: ~1 HOUR, POSSIBLY LONGER, DELAYS ~15 MINUTES) • Position patient supine, camera anterior (or left anterior oblique), liver in upper left quadrant of field of view (FOV). Position liver in middle FOV if taking immediate heart shadow image, and then move camera to position liver in upper left quadrant of view for remaining images. ROIs can be drawn around heart and heart/liver to ascertain radiotracer clearance from blood pool. • Static imaging: Immediate, then every 5 minutes up to 30 minutes. Every 10 to 15 minutes from 30 minutes on. Some take the time in seconds from the 5- or 10-minute view for the rest of the views in the study, giving a better visualization of the radiotracer washout from the liver. • Dynamic imaging: If patient can hold still for 60 minutes. Stop dynamic at 30 to 45 minutes if gallbladder and bowel present. Acquire to 90 minutes if not. Acquire a right lateral (RLAT) static if gallbladder presents. • Other useful images may be taken from obliques, laterals, posterior, or using pinhole collimators and magnified views for children. • Neonatal hepatitis/biliary atresia: place on phenobarbital regimen (see below), image every 10 minutes for 1 hour. Delays up to 24 hours. With chosen procedure in progress: • Gallbladder and bowel visualization: image RLAT. Some require RAO and LAO. The study is complete. • For dynamic imaging, ingestion of water (100 mL) may assist in distinguishing duodenal loop tracer from true gallbladder visualization. • No visualization of gallbladder and/or bowel with no intervention: This is a baseline HIDA, image every 5 to 15 minutes up to 60 minutes, then images to protocol or ask radiologist, e.g., patient returns for 2- to 6-hour delays. • No visualization with nonpharmacologic intervention: • No visualization of gallbladder and/or bowel by 30–45 minutes and patient is supine, turn patient to right decubitus position for 5 to 10 minutes. Return patient to supine position and image. 127

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 128

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• No visualization of gallbladder and/or bowel by 30–45 minutes and patient is ambulatory, let patient walk around for a few minutes. Reposition and image. • Gallbladder but no bowel; turn patient to left decubitus position for 5 to 10 minutes. Return patient to supine position and image. • Gallbladder but no bowel; if a dynamic study is underway and patient is alert, try discussing the patient’s favorite food, or encourage him or her to think about the favorite meal or treat. This can stimulate the gallbladder to contract. • Delayed images: 3–24 hours after initial injection. This may require a reinjection of a small amount of radiotracer. Check with radiologist. • For leakage (e.g., post-gallbladder surgery): If there is suspected pooling visualized in abdomen, place patient on left side for 10 minutes to allow area to move with gravity. If it moves into the abdomen, it is leakage. If the area did not move, it is more than likely bowel. • No visualization with pharmacologic interventions (see Note). • Gallbladder but no bowel: CCK (suggested over a 3-minute injection minimum) or fatty meal (e.g., Pulmocare®, potato chips, creamy coffee, etc.). • Bowel but no gallbladder: MS. Check for contraindications, and then obtain order from radiologist. • Images: Preinjection CCK or pre-morphine injection image, then postinjection images by protocol, usually every 5 minutes for 30 minutes. Check again with radiologist for continuance or delays before releasing patient. • If patient has not eaten for a substantial amount of time (e.g., 24 hours or more), the gallbladder may be in “shock” or stasis and filled with “sludge.” In this case, the study may appear as bowel with no gallbladder but may need a fatty meal or CCK to contract the gallbladder and empty the sludge before it can refill and present. Some physicians routinely require CCK administered 10–15 minutes before injection of radiotracer. HIDA with ejection fraction: • Start a butterfly or IV catheter. • Use the same procedure as above for a HIDA scan and assuming gallbladder visualization. If morphine must be used to visualize gallbladder, CCK should not be given for ejection fraction evaluation for at least 4 hours if at all. • After injection, a suggestion is to “heparin-ize” the IV to ensure patency until needed for the CCK. • When the gallbladder visualizes (there must be a prominent gallbladder to work with), wait until it becomes large enough in the monitor to get a good ejection fraction from the computer. This could be as soon as 20 to 30 minutes or it may take much longer. It may not visualize at all. • When the gallbladder is visually full, begin the slow injection of CCK and note the time. This should be done over several minutes or in a slow “drip.” Also document any reaction from the patient while giving the CCK. • Most protocols ask for 30 minutes of imaging post CCK injection for maximum and minimum counts to ascertain the ejection fraction (see equation below). These can be ascertained manually from the images or by computer program. Manual: Note largest count in ROI just prior to CCK administration, note lowest count after administration. Note the time of actual start of CCK administration and the time of lowest count after administration. Some require a 20 minute percent regardless of actual lowest count.

NORMAL RESULTS • Visualization of liver 5–15 seconds after injection, hepatic and common bile duct and gallbladder 5–20 minutes up to 60 minutes. • Cardiac blood pool should no longer be seen after 5 to 10 minutes. • Intestinal activity should be visualized and move within 10–60 minutes. • A flow study will show the liver immediately but dimly from activity entering through the hepatic artery, then brightly with portal vein flow. • The liver diminishes in activity as the gallbladder visualizes in its “bed” and grows brighter and bowel activity visualizes and moves with time. Bile ducts, the biliary tree, appear in the liver as lines leading to the bowel. 128

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 129

Chapter 24 — HIDA (Hepatobiliary or Gallbladder Scan) with Ejection Fraction

• In about 19% normal population, small bowel does not present until after 1 hour. • For post-gallbladder surgery, there should be no activity pooling around the liver or in the abdomen. • The gallbladder can visualize nearly anywhere in or under the liver and in most any orientation. If it appears in a questionable location, it is helpful to compare the exam to a prior ultrasound or CT to verify the gallbladder’s location.

ABNORMAL RESULTS • Nonvisualization of gallbladder within 1 hour with visualization of common bile duct and bowel (indicating possible acute cholecystitis; contracted gallbladder; gallbladder filled with stones, bile, and/or sludge; poor hepatic function; or acalculous cystic duct obstruction). • Nonvisualization of gallbladder within 1 hour with visualization of bowel but having a “rim-sign” (faint outline of gallbladder) in gallbladder fossa indicating phlegmonous/gangrenous acute cholecystitis. • Nonvisualization of bowel within 1 hour with good hepatic uptake, visualization of gallbladder and common bile duct (indicating possible sphincter of Oddi dysfunction or obstruction). • Nonvisualization of gallbladder or bowel within 1 hour with good hepatic uptake but no draining (indicating complete or near-complete obstruction of hepatic ducts or hepatocyte dysfunction). • For post-gallbladder surgery, pooling of activity either in area of extracted gallbladder or in abdominal cavity adjacent to area. This should visualize quickly, but images should be taken for about 60 minutes. • Prompt hepatic uptake with persistent non-visualization of biliary tract and small bowel postgallbladder surgery (indicating total common bile obstruction). • Partial or nonvisualization of liver: Due to severe hepatocellular disease, space-occupying vascular or non-vascular lesion, hepatoma (malignant tumor of liver originating from mature liver cells), or surgery. • Non-visualization of gallbladder 30 minutes after MS is administered (indicating cystic duct obstruction and/or acute cholecystitis). • Visualization of gallbladder after MS is administered indicates chronic cholecystitis. • Acute cholecystitis: cystic duct calculus, inspissated bile in cystic duct (acalculous cholecystitis), trauma, burn, diabetes. • Reflux into stomach. Enterogastric reflux from duodenum to stomach and may be related to bile gastritis and abdominal discomfort or pain. • Cardiac blood pool visualization lasting longer than 5 to 10 minutes indicates hepatic dysfunction. • Rim sign: pericholecystic hepatic activity sign—acute cholecystitis. Activity around gallbladder fossa especially above on right inferior hepatic edge. • Cystic duct sign: acute cholecystitis. Enlarged area of activity proximal to the obstruction in the cystic duct. This may preclude use of morphine. • Liver scan sign: Acute complete obstruction of the common bile duct. Lack of visualization of the biliary tree. • Re-appearing liver sign: Post-cholecystectomy leak seeping into perihepatic space. It can also fill gallbladder fossa forming a biloma, accumulate in pelvis, and right paracolic gutter. • Biliary atresia versus neonatal hepatitis: no radiotracer excretion into bowel within 24 hours indicates biliary atresia. If there is excretion of tracer into the bowel within 24 hours, biliary atresia can be excluded and the patient treated for neonatal hepatitis. • Drug interactions: • Delayed biliary to bowel transit time–narcotics, phenobarbital (mimics CBD obstruction or disease). • Poor extraction and elimination of tracer from liver—high dose of nicotinic acid. • No or delayed visualization of gallbladder—TPN (mimics cholecystitis). • Nonvisualization of gallbladder—hepatic artery infusion of chemotherapy. • Low ejection fraction—morphine, atropine, calcium channel blockers, octreotide, progesterone, indomethacin, theophylline, benzodiazepines, histamine-2 receptor antagonists. 129

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 130

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Gallbladder EF • Normal: ∼ 35%. Some literature indicates > 50% for males, > 20% for females. • Abnormal: < 35% indicates impaired gallbladder contraction and/or evacuation suggestive of chronic cholecystitis, cystic duct syndrome, sphincter of Oddi spasm, or gallbladder dyskinesia. • Ejection fractions from 35% to 50% are considered borderline. Greater than 50% is unequivocally normal. The mean is 75% to 20%. The normal empty rate is 6% per minute. • If CCK is unavailable, a fatty meal may be substituted; however, the mean is lowered to 50% to 20% and the emptying rate is 2% per minute. • Computer: Using image just prior to CCK injection and post-CCK images, draw ROIs, make note of counts, and then process if automatic. Find the image with the lowest counts to get the ejection fraction. • Manually: It is similar to MUGA: EF =

ED − ES pre-CCK cts − lowest post-CCK cts × 100 or: × 100 ED pre-CCK cts

where ED is end-diastolic volume, ES is end-systolic volume, pre-CCK cts is counts before CCK, and post-CCK cts is counts after CCK injection.

ARTIFACTS • Previous undisclosed cholecystectomy. • Breast attenuation (may need to tape or strap breast up out of the way or have patient help hold breast up), buttons or articles in shirt pockets. • A meal too soon before study will deleteriously affect results (e.g., false-positive nonvisualization of gallbladder because of intermittent contractions). • Not eating for 24 or more hours may cause stasis in contractions or sludge formation in the gallbladder. • Other false-positives: TPN, alcoholism, pancreatitis, cholangiocarcinoma of cystic duct, severe intercurrent illness. • False-negatives: acalculous cholecystitis, duodenal diverticulum simulating gallbladder, accessory cystic duct, biliary duplication cyst. • In jaundiced patients, there may be increased renal excretion of the radiotracer causing the right extrarenal pelvis to be confused with gallbladder uptake. • Elevated serum bilirubin levels may not allow uptake by hepatocytes causing radiotracer to excrete too quickly (use larger dose). • If patient is already taking Demerol®, the action may occlude the images by obstructing normal radiotracer flow into the bowel. • Morphine sulfate: false-positive; chronic cholecystitis caused by fluid or stones in gallbladder preventing adequate filling. • Morphine sulfate: false-negative; gallbladder perforation (lower GB luminal pressure dislodges stone, tracer refluxed into contained perforation) and acute gangrenous cholecystitis (cystic duct walls thickened and inflamed but not enough to occlude lumen).

NOTE • Patients can be asymptomatic or present with any number of the following: RUQ pain radiating to scapula tip, bloating, N/V, heartburn, fatty food intolerance, and flatulence. Severe cases (those with advanced hepatic disease) present with jaundiced (yellowed) eyes and skin. • Reasons for RUQ pain: Gallbladder; cholecystitis, biliary colic. Hepatic; abscess, hepatitis, hepatoma, peptic ulcer disease. Pancreatitis. Renal; colic or pyelonephritis. Appendicitis. Cardiac; pericarditis, CHF, infarction. Lung; pleuritis, pneumonia, empyema (pus in the body cavity usually as a result of infection in lungs). Herpes zoster. 130

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 131

Chapter 24 — HIDA (Hepatobiliary or Gallbladder Scan) with Ejection Fraction

• Ultrasound shows wall thickening, collection of fluid around gallbladder and/or stones, and “Murphy” sign (pain to touch). • Anecdotal: The 6 F’s of gallbladder problems: fat, forty, female, flatulence, fair skin, frothy stool. • Some of the factors affecting patient and gallbladder studies are common bile duct obstruction, intestinal obstruction, and pregnancy. • It may be helpful to note on the history sheet for the reading physician in cases in which CCK is given, if the patient experienced the same discomfort as previously described in the history or if it was different, or if he or she had no discomfort or pain at all with the administration of the drug. Many feel bloating or bowel discomfort, as in feeling that they must “go to the bathroom.” Many feel nausea and some vomit. Be prepared.

Pharmacologic Interventions • CCK (or fatty meal) is used to contract gallbladder so that visualization of bowel may occur. For CCK, .02 µg × patient weight in kilograms, IV (1 µg/mL) slow push for 3 minutes. With GB visualization and no common bile duct and/or gut, CCK squeezes activity out into system. (This could be painful to the patient depending on the degree of obstruction.) It is also used to calculate gallbladder ejection fraction (EF). Note: If patient is NPO for many hours, GB is inactive (in shock) and may be full of bile or sludge and not visualizing. CCK empties GB to refill for visualization. Contraindicated if patient has recent positive ultrasound examination for gallstones. CCK relaxes the sphincter of Oddi. Nitroglycerin can be used for the same effect. Check with physician for dose. A fatty meal or preparation such as Pulmocare® may also produce the desired result. • MS is used to spasm (contract) the sphincter of Oddi forcing radiopharmaceutical (RP) back into gallbladder if cystic duct is patent (distinguishes between acute [no visualization] and chronic [eventual visualization] cholecystitis). Nonvisualization of gallbladder 30–150 minutes after morphine injection (cholecystitis). For MS, .04 mg × patient weight in kilograms, IV (diluted to 5–10 mL) slow push for 3 minutes. Some just administer 2.0 mg regardless of weight. Reverse the effects with naloxone hydrochloride. Contraindicated for patients allergic to morphine or history of pancreatitis (check for elevated amylase levels). • Other: Some literature indicates that if there is a known allergy to MS, other controlled drugs are available to constrict the sphincter of Oddi. This would have to be discussed with the radiologist as the literature was not specifically in a HIDA scan. • Fentanyl citrate: Administered as 50 µg slowly for 3 minutes. Onset at 1 minute, peak at 5 minutes with a short pharmacologic half-life. • Hydromorphone hydrochloride (Dilaudid®): Onset at 15 minutes, peak up to 30 minutes. Requires 1 mg or less for the desired result. Slow injection for 3 minutes. • Pentazocine hydrochloride: Onset at 2–3 minutes, peaks at 15 minutes, 30 mg/mL IV. • Meperidine hydrochloride (Demerol®): Onset at 1 minute, peak at 7 minutes, 1 mg/kg, 10 mg/mL IV, or 50 mg slow push for 2–3 minutes. This approach and amounts given (the above are adult doses) would have to be discussed with the nuclear physician or radiologist. Demerol® was successfully substituted at Palms of Pasadena Hospital in St. Petersburg, FL. An adult male patient with a history of violence when given MS presented with bowel visualization but no gallbladder after 60 minutes. After consultation with the radiologist, he was given 50 mg of Demerol® IV slow push for 3 minutes. The results were gallbladder visualization shortly after injection and no violent episodes. • Phenobarbital: For neonatal hyperbilirubinemia, oral b.i.d. for a total dosage of 5 mg/kg/day for 3–5 days before the study may stimulate the flow of bile.

Biliary Dyskinesia • Cystic duct syndrome (CDS) (chronic acalculous gallbladder disease or chronic acalculous cholecystitis): Kinking, fibrosis, and thickening of the wall causing narrowing of the lumen of the cystic duct. Slow release of hepatic bile even with CCK. • Sphincter of Oddi spasm (SOS) (sphincter of Oddi dysfunction, papillary stenosis, and bile duct dyskinesia): Sphincter of Oddi remains tightened or in spasm. Liver function laboratory tests and 131

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 132

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ultrasonography examination appear normal. Gallbladder or common bile duct may serve as compensatory reservoir. In these cases, CCK only serves to increase constriction.

Cholecystokinin • Release is stimulated by food from cells in mucosa of duodenum and upper jejunum only. Kinevac® (sincalide) is a synthetic of the functional 8-amino acid chain. • Actions of CCK include the following: • Contraction and emptying of the gallbladder. • Relaxation of the sphincter of Oddi. • Increase in pancreatic enzyme secretion. • Increase in secretion of insulin, glucagon, and somatostatin by islet cells. • Inhibition of gastric emptying by contraction of the pyloric sphincter. • Increase in hepatic bile secretion. • Increase in intestinal peristalsis. • Increase in intestinal blood flow. • Suppression of appetite. • Decrease in systolic blood pressure. • CCK acts by attaching to CCK receptors in smooth muscle of gallbladder and sphincter of Oddi. • The liver produces 600 to 1000 mL of bile a day. 50% passes through the gallbladder at 12.5 to 20 mL per hour. The gallbladder holds 40 to 70 mL of bile. Fatty meals stimulate the production of CCK from gastric mucosa, causing the gallbladder to contract. Food stimulates peristalsis in small bowel. Bile salts emulsify the fat within the ingested food. Lipase from the pancreas breaks down the fat molecules. Cholesterol is found in bile and in many cases, leads to the formation of stones. Stones are made of cholesterol in 85% of the presenting cases, 20% are calcium formations. Fifty percent of the affected population are nonsymptomatic; 20% of the affected population present profoundly, and 30% of that population are acute cases. • The sphincter of Oddi refers to three sphincters: The choledochal sphincter surrounding the intraduodenal part of the distal CBD, the pancreatic sphincter at the distal end of the pancreatic duct (of Wirsung), and the ampullary sphincter surrounding the common channel. This common channel or duct surrounded by the ampullary sphincter opens into the duodenum at the ampulla of Vater.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. When was your last solid meal? Do you have a history or family history of cancer?

Y

N

Do you have a history of gallbladder or liver disease (e.g., gallstones, hepatitis)?

Y

N

Have you had recent abdominal pain?

Y

N

Do you experience nausea or vomiting?

Y

N

Are you running a fever?

Y

N

If so, what type and for how long?

If so, where, when (e.g., after eating), and for how long?

132

10766-24_CH24.qxd

12/3/07

4:24 PM

Page 133

Chapter 24 — HIDA (Hepatobiliary or Gallbladder Scan) with Ejection Fraction

Have you had abnormal blood test results?

Y

N

Have you had any recent surgery (e.g., cholecystectomy, abdominal)?

Y

N

Have you had any recent CT, MRI, ultrasonography (US), or nuclear medicine (NM) scans of abdomen?

Y

N

Y

N

Assess for jaundice or signs of alcohol abuse (discern discreetly). For inpatients, note laboratory results for serum glutamate pyruvate transaminase (SGPT), serum glutamic-oxaloacetic transaminase (SGOT), GGTP, alkaline phosphatase, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), white blood cells (WBC), amylase, total bilirubin, creatinine/blood urea nitrogen (BUN). Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Adult and Pediatric Hepatobiliary Scintigraphy. Amended 2006, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

133

10766-25_CH25.qxd

12/3/07

4:25 PM

Page 134

chapter

25

LeVeen or Denver Shunt Patency RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-MAA (macroaggregated albumin) or HAM (human albumin microspheres) • 99mTc-SC (sulfur colloid)

Localization • Compartmental, peritoneal cavity to blood circulation

Quality Control •

Chromatography (MAA and SC), 90% to 95% tagging.

Adult Dose Range • •

99m

Tc-MAA; 1.5–5 mCi (55.5–187 MBq) Tc-SC; 3 mCi (111 MBq)

99m

Method of Administration • Intraperitoneal injection with local anesthetic by physician. • Typically, lower left quadrant. Can be guided by ultrasonography (US) to location of ascites. • Usually administered in 7–10 mL of normal saline solution.

99m

Tc-MAA: particle size, 10–90 µm; 75,000–700,000 particles/injection.

INDICATIONS • Evaluation of LeVeen shunt (peritoneovenous) patency (shunts ascitic fluid from the peritoneal cavity to the venous circulation using a low-pressure valve activated by breathing exercises, inserted into the abdominal wall with collection tube inserted through the jugular vein into the superior vena cava). 134

10766-25_CH25.qxd

12/3/07

4:25 PM

Page 135

Chapter 25 — LeVeen or Denver Shunt Patency

• Evaluation of Denver shunt (peritoneovenous) patency (shunts ascitic fluid from the peritoneal cavity to the venous circulation using a mechanical pumping device inserted into the abdominal wall with collection tube inserted through the jugular vein into the superior vena cava). • Evaluation of increasing ascites secondary to the use of implanted shunt, e.g., increased sodium consumption, inadequate diuretic agents, or worsening liver (hepatic cirrhosis) or heart failure.

CONTRAINDICATIONS • Patient with pulmonary hypertension may be a consideration with 99mTc-MAA.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Prepare patient for intraperitoneal injection. • Supplies for procedure: • 20-ga needle • 25-ga needle • (2) 3 cc syringes • 1% lidocaine • 3-way stopcock • sterile gloves • sterilization solution/swabs • (3) 4 × 4 sterile gauzes • Arrange for paracentesis by physician.

EQUIPMENT Camera • Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Statics • 180–300 sec/image or 500,000 counts Dynamic • Dynamic: 10 minutes/frame for six frames. Whole Body Sweep • Check length of patient, patient orientation, 8–10 cm/min

Computer Set-up •

Tc peak, 15% window, 128 × 128 matrix.

99m

Flow • Denver shunt; 3 sec/frame for 60 seconds. Injection directly into pump.

PROCEDURE (TIME: ~1 HOUR) • Place patient on table in supine position. Ensure that there are no objects on patient or in clothing to cause attenuation. • Patient instructed to inhale through kinked straw. • Flow: Position camera anterior over abdomen/thorax to visualize as much of the pump and tubing as possible. Start camera on injection. 135

10766-25_CH25.qxd

12/3/07

4:25 PM

Page 136

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Injection (usually into lower left quadrant of abdomen) performed by physician. • LeVeen: Perform ballottement (abdominal palpation) to distribute radiotracer or roll the patient from side to side. • Denver: Instruct patient to pump system vigorously after injection as in normal operation. • Obtain images • One image or frame should have xiphoid process and right side markers. • Immediate anterior abdominal image after injection. • Anterior abdomen and thorax at 15, 30, 45, and 60 minutes after injection. • Dynamic: Anterior of chest and upper abdomen. • Option: Whole-body sweep from head to pelvis. • Obtain 2- to 4-hour delays if no lung (or liver) visualization within 60 minutes.

NORMAL RESULTS • Lungs and/or shunt tubing present within 60 minutes. Usually this is a rapid visualization (within 10–30 minutes of injection). • If 99mTc-SC is used, liver is the target organ within 60 minutes. This method is not presently used as much because of the difficulty of separating the liver from the ascites.

ABNORMAL RESULTS • 99mTc-MAA: No activity in the lungs after 4-hour delays, indicating obstruction. • 99mTc-SC: No activity in the liver after 4-hour delays, indicating obstruction. • Activity stops at abdominal pump; very little or no activity in tubing (indicating valve failure or obstruction in tubing).

ARTIFACTS • Risk of infection with injection. Patient should be monitored. • Jewelry, medallions, buttons, items in shirt pockets, or belt buckles can cause artifacts. Also note any surgically implanted devices. • 99mTc-MAA: Test should be performed with reduced amounts of radiotracer (and hence reduced number of injected particles) on patients with known compromised pulmonary function (known disease, shunting, arteriole malformation, and liver disease) or one lung, and considerations should be made whether to perform the test on patients with pulmonary hypertension. • If little or no visualization of lungs with visualization of superior vena cava and right heart, check patient history for compromising diseases, operations, and cancers. • If no visualization of radiotracer in abdomen, check needle and radiotracer tag.

NOTE • The excess fluid in the peritoneal cavity is drained by the one-way pressure operated valve into a tube that empties into the superior vena cava. A pressure differential is created during inspiration of > 5 cm of water when the diaphragm descends. The thoracic pressure drops below that of the intraperitoneal pressure allowing the ascites to drain to the superior vena cava via the shunt. Shunts often malfunction because of accumulating fibrous tissue in the peritoneal limb of the shunt.

136

10766-25_CH25.qxd

12/3/07

4:25 PM

Page 137

Chapter 25 — LeVeen or Denver Shunt Patency

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have abdominal pain?

Y

N

Do you have abdominal distention?

Y

N

Y

N

Y

N

If so, what type and for how long?

If so, more so than before or after surgery? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. UCLA Nuclear Medicine Clinic. Protocols-LeVeen Shunt. Laxmi.nuc.ucla.edu:8000/nm-mediabook/ main_protocols, 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

137

10766-26_CH26.qxd

12/3/07

4:26 PM

Page 138

chapter

26

Liver SPECT (Hepatic Hemangioma) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • Tagged red blood cells by pyrophosphate (pyp) or stannous chloride to 99mTc O4− by in vivo, in vitro, or kit, e.g., UltraTag®.

Localization

Quality Control •

Tc O4− : chromatography; tagging, 90% in vivo, 95% in vitro

99m

Adult Dose Range •

Tc O4− : 20–30 mCi (740–1110 MBq)

99m

Method of Administration • Intravenous injections, or drawing, tagging, and reinjection of tagged red blood cells using IV catheter or butterfly

• Compartmental, tagged to and circulating with blood

INDICATIONS • Detection and localization of hepatic hemangiomas. • Detection and localization of vascularized primary and metastatic tumors. • Detection and localization of cysts, space-occupying lesions, necrosis, and/or abnormal focal areas (marked increased or decreased activity) considered for biopsy. • Evaluation of the vascularity of liver because of abnormal results on related studies.

138

10766-26_CH26.qxd

12/3/07

4:26 PM

Page 139

Chapter 26 — Liver SPECT (Hepatic Hemangioma)

CONTRAINDICATIONS • Patients with contrast studies underway. • Patient receiving blood products.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Obtain a signed consent form for blood return if required.

EQUIPMENT Camera • Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Computer Set-up

Statics • 500,000–2 million counts Single photon emission computed tomography (SPECT): • 1.4–1.5 magnification, noncircular or elliptical orbit, 64 × 64 or 128 × 128 matrix, 360°, 64 stops, 20–30 sec/stop, Butterworth filter with 0.3 cutoff or Hanning with 0.8 cutoff, slice thickness 6–12 mm.

Flow • 1–5 sec/frame, 60–120 seconds

PROCEDURE

(TIME: ~40 MINUTES FOR FLOW AND STATICS; ~30–45 MINUTES FOR SPECT) • Obtain a signed consent form from patient to take and return blood. It must also be signed by technologist and witness. • In vitro method: ∼2–2.5 mL of blood is extracted into heparinized syringe from patient and tagged with UltraTag® • Or in vivo method: Inject cold pyp, wait 20 minutes, then inject radiotracer under camera for flow if required. • Place patient in supine position, camera anterior for flow if required, liver and spleen centered in field of view (FOV), or preload setup for SPECT orbit. Camera posterior if that is what is determined for best view from other imaging techniques (e.g., lesion posterior in liver). • Flow: Obtain images of early blood supply from hepatic artery to primary and metastatic tumors and hemangiomas. A flow may help determine a nonvascularized lesion which will remain cold over time from hemangiomas that are vascularized and fill in over time to become hot. • Statics: Obtain immediate anterior with marker, anterior, right anterior oblique, right lateral, posterior, and more as to protocol. • SPECT: Obtain images 1–2 hours (recommended) after injection. Set proper patient orientation, set camera with ROI over liver and spleen area. • Process transverse, sagittal, and coronal slices. Use .11–.12 attenuation correction.

NORMAL RESULTS • Heart, great vessels, spleen, and kidneys prominent. • Heterogeneous light uptake of liver within seconds of injection from hepatic artery. 139

10766-26_CH26.qxd

12/3/07

4:26 PM

Page 140

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Heterogeneous brighter uptake from portal system. • SPECT: Heterogeneous uptake of liver parenchyma. Hepatic vessels prominent in various slices. Organs and great vessels prominent.

ABNORMAL RESULTS • Initially (typically), hemangiomas are hypovascular, filling with time. They become hypervascular with delays. A differential diagnosis is a solitary hepatoma that is typically hypervascular. Although some hemangiomas do not present with early hypovascularity, typically they present with increased intensity over time. • Flow: Focal area(s) of increased or decreased activity. Hemangiomas, because they are benign tumors of dilated blood vessels, show markedly increased activity that increases with time. • Statics: Focal area(s) persist in relative positions from different views. • SPECT: Focal areas of an overabundance of vascularity (e.g., hemangiomas) present as hot spots; focal areas of less than normal or lacking vascularity present as cold spots. Although flow and statics can establish the existence of a suspected hemangioma, SPECT images can aid in the presentation of added unsuspected sites that were hidden in other diagnostic techniques. • Cold spots can be caused by cysts, tumors (benign, primary, or metastatic), encapsulations, necrotic lesions from trauma, surgery, or therapy, or poorly vascularized hemangioma.

ARTIFACTS • Bad radiotracer tag could lead to poor results. Do a thyroid image to confirm a bad tag as 99mTc will go to thyroid, salivary glands, and gastric mucosa. • Causes of a poor tag: • Drug interactions e.g., heparin, methyldopa, hydralazine, quinidine, digoxin, prazosin, propranolol, doxorubicin, iodinated contrast agents • Cold pyrophosphate not injected soon enough after mixing • Antibodies: transfusions, transplantation • Short incubation time • Too much or too little stannous ion • Belt buckles, articles in clothing, necklaces, and so forth may attenuate image. • Different slice orientations of SPECT images may allow liver vessels to present as possible hot or cold spots. SPECT increases sensitivity for lesions that are deep or < 5 cm in diameter • Detection depends on lesion size: <1 cm, 25%, 1–2 cm, 65%, >2 cm, 100%. Helical CT with contrast, US, and MRI are used more commonly.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of liver disease?

Y

N

Have you had any recent abdominal pain?

Y

N

If so, what type and for how long?

If so, where and for how long?

140

10766-26_CH26.qxd

12/3/07

4:26 PM

Page 141

Chapter 26 — Liver SPECT (Hepatic Hemangioma)

Have you had any recent trauma?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent related studies (US, MRI, CT, NM)?

Y

N

Have you had any recent laboratory tests performed?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, where?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Hladik WB, et al. eds. Essentials of Nuclear Medicine Science: Iatrogenic Alterations in the Biodistribution of Radiotracers as a Result of Drug Therapy: Reported Instances. Pamphlet. Du Pont, circa 1985. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

141

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 142

chapter

27

Liver/Spleen Scan RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

cells. Particle size .3–1.0 µm. Clearance from blood stream t1/2 = 2–3 minutes.

Quality Control • Chromatography, >90%; particle size, .1–1.0 µm; use within 6 hours

99m

Tc-SC (sulfur colloid)

Adult Dose Range Localization • Phagocytosis by reticular cells of liver, spleen, bone marrow, and lungs. Complete clearance by reticuloendothelial system (RES) by liver (80–90%), spleen (5–10%), and bone marrow. Localization is flow dependent and requires functional integrity of RES

• 2–7 mCi (74–259 MBq)

Method of Administration • Intravenous (IV) injection or IV catheter and flush. Invert syringe before administering the dose to mix particles.

INDICATIONS • Assessment of anatomy, size, and relative position of liver and spleen. • Assessment of hepatomegaly, splenomegaly, splenic infarcts, accessory spleen or splenosis, or situs inversus. • Assessment of benign mesenchymal (Kupffer cells) focal lesions (hemangioma, hamartoma) and hepatocellular focal nodular hyperplasia. • Assessment of chronic liver or spleen disease including primary liver tumors and metastasis, jaundice, cirrhosis, hepatocellular disease, hepatitis, hepatic abscess, reticuloendothelial system function, or elevated blood work results. • Detection and assessment of hepatic or splenic trauma. 142

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 143

Chapter 27 — Liver/Spleen Scan

• Evaluation for liver disease, chronic anemia, leukemia or other blood disorders, thrombocytopenia, white blood cell (WBC) sequestration, tumors, abscesses, cysts, hemangiomas, hematomas, and trauma. • Evaluation of hepatic infections, e.g., amoebic abscess, hydatid cyst, pyogenic abscess. • Evaluation of relative splenic function by liver:spleen ratio. • Evaluation for liver biopsy. • Detection and assessment of congenital asplenia or polysplenia in children. • Assessment of previous splenectomy. • Detection and evaluation of splenic mass. • Assessment of hepatic artery catheter patency and delivery. • Evaluation of liver and/or spleen because of abnormal findings on related diagnostic scans.

CONTRAINDICATIONS • Study should be performed before any iodinated or barium containing contrast agents. Particularly barium in the colon may result in artifactual defects with the liver and spleen.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • If available, write concentrations of alanine amino transferase (ALT, a.k.a SGPT), aspartate amino transferase (AST, a.k.a SGOT), lactate dehydrogenase (LDH), and total bilirubin on history sheet.

EQUIPMENT Camera • Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Statics • 500,000–1 million counts Single Photon Emission Computed Tomography (SPECT) • 360° rotation, 128 × 128 matrix, 64 to 120 stops at 30 sec/stop

Computer Set-up Flow • 1–3 sec/frame for 1 minute followed by immediate static blood pool (60 seconds or 500,000 counts)

PROCEDURE (TIME: ~30–60 MINUTES) • Place patient in supine position, camera anterior over lower thorax-abdomen. • Flow: Position using point source on xiphoid process at top of camera field of view (FOV). • Inject, wait a couple of seconds, then start camera. • Take immediate blood pool image when flow is complete. • Statics: Without flow, inject and wait 15 minutes. (Patients with liver dysfunction or portal hypertension may require 20–30 minutes before imaging.) Position liver and spleen in middle to upper left and right quadrants of FOV. • Obtain images: Anterior with marker(s) over last costal margin for liver (and spleen if splenomegaly indicated), anterior, RAO, RLAT, (RPO if protocol), posterior, LLAT, and LAO. • Optional: Posterior with marker on spleen, anterior inspiration, and expiration (10 seconds each) to show viability of organs, and standing to reduce motion and improve resolution. 143

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 144

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• SPECT: Center region of interest (ROI) in FOV. Set parameters and start camera. Contoured or noncircular. • Processing may include centering liver and spleen, getting ROIs, and doing some combination of computer-generated regional ratios of spleen:liver, vertebrae:liver, and vertebrae:spleen uptakes (vertebrae ROI taken from center just below organs). Try Hanning filter, 0.8 cutoff, uniformity correction, 1–2 pixel thickness.

Hepatic Artery Study • 1–3 mCi (37–111 MBq) 99mTc-MAA. • Inject slowly through hepatic artery catheter or infusion pump (<1 mL/minute). • Images: Immediate, anterior, posterior, and right lateral of liver. 500,000–1 million counts. Image lungs to identify intrahepatic arteriovenous fistulas.

Splenic Study and Imaging • 1–3 mCi (37–111 MBq) 99mTc-heat-damaged red blood cells. This is accomplished by heating tagged RBCs for 20 minutes in a warm water bath at 49 to 50°C (120.2–122°F). • Imaging: 30–120 minutes after injection. Anterior, posterior, and posterior oblique views, 300,000–750,000 counts. Image abdomen if ectopic splenic tissue is suspected. Image chest in cases of diaphragmatic rupture due to trauma. SPECT imaging may be requested.

NORMAL RESULTS • Flow: Because liver is fed 75% by portal system, there should be ∼6-second delay from aorta presenting to liver presenting. Liver will show dimly at first from aortic (hepatic artery) flush, then brightly from the portal venous system of the superior mesentery vein (small intestine) and splenic vein (including the stomach, large intestine, and pancreatic veins). • Statics: Liver and spleen should have equal heterogeneous distribution with little or no bone marrow uptake. A large patient with soft-tissue attenuation may present with hepatomegaly and slightly decreased uptake. Liver uptake is homogeneous, dominant right and smaller left lobe, variants are normal, e.g., Riedel’s lobe (long, thin right lobe), indentations from porta hepatis, rib margins, xiphoid, gallbladder, right kidney, suprahepatic veins, heart, and affected diaphragmatic configurations. Normal liver right lobe size is about 18 cm (anterior view) highest point to inferior tip. Splenic uptake is homogeneous and equal to or less than the liver. Normal splenic size is 10 cm not to exceed 13 cm (posterior view). • Relative radiotracer uptake is 85% liver, 10% spleen, and 5% bone marrow. • Hepatic artery study: Hepatic uptake. A small amount of lung uptake may be visible with a properly placed catheter due to arteriovenous fistulas in the liver. • Splenic imaging: Uptake of tagged heat-damaged red blood cells in spleen.

ABNORMAL RESULTS • Flow • Fast uptake: Tumors or hepatitis. • Increased uptake: Hepatomas, hemangiomas. • Slow uptake: Congestive heart failure, severe cirrhosis. • Statics • Hepatomegaly: Fatty infiltration, chronic passive congestion, hepatitis, metastasis, diabetes, hemochromatosis, amyloidosis, lymphoma, leukemia, sarcoidosis, lipid storage disorders. • Splenomegaly: Leukemia, myelofibrosis, malaria, visceral leishmaniasis (e.g., Kala-azar, black fever, tropical). • Splenic dominance: Compromised liver function. • Splenic absence: Functional asplenia (sickle cell). • Bone marrow shifting (shunting): Hepatitis, cirrhosis, anemia, leukemia, infection, tumor, diabetes, chronic heart failure. 144

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 145

Chapter 27 — Liver/Spleen Scan

• Colloid shifting presents in marrow, spleen, lungs, and kidneys. These may be caused by severe liver dysfunction (especially cirrhosis), recent chemotherapy or malignant melanoma, and/or portal hypertension. • Hot spots: Tumors, superior vena cava obstruction (lung cancer, quadrate lobe, arm injection), Budd-Chiari syndrome (hepatic vein thrombosis, caudate lobe), and focal nodular hyperplasia, hepatic cell adenomas (women on birth control). • Cold spots: Metastatic tumors (primary), hepatomas, adenomas, abscess, cyst, infarction, hematoma, trauma, and hemangioma, pseudotumor caused by cirrhosis. • Patchy areas: Lacerations, liver diseases e.g., advanced (alcoholic or postnecrotic) cirrhosis. • Pulmonary uptake: Hepatic cirrhosis, chronic obstructive pulmonary disease with superimposed infection, bacterial endotoxin, estrogen therapy, neoplasms, disseminated intravascular coagulopathy, mucopolysaccharidosis type II (Hunter’s syndrome), Histiocytosis X, faulty colloid preparation (excess aluminum), high serum aluminum level (antacids), children (normal minimal uptake), transplant recipients, pulmonary trauma. • Accumulation in renal transplant indicates rejection of that organ. • Hepatic artery study: Extrahepatic uptake, e.g., stomach, spleen, pancreas, lung. This indicates improper positioning of catheter. High concentrations in the lung may preclude the use of certain types of therapy. • Splenic imaging: Little or no uptake of heat-damaged cells in spleen.

ARTIFACTS • Tape marker to clothes or camera to prevent movement and distortion of holes in marker. • For females, breasts may cause attenuation. Patient can hold them up out of FOV or they can be taped. Also, obese skin folds may cause attenuation; standing in front of camera will help eliminate these. • Lung uptake caused by aluminum contamination of antacids or virilizing androgen therapy, iron preparations, magnesium preparations, niacin, or large colloid size and may indicate colloid clumping within radiopharmaceutical. • Increased bone marrow shifting may be the result of nitrosoureas (alkylating agent in treatment of neoplasms), or colloid particles that are too small. • Increased spleen uptake caused by nitrosoureas, recent halothane or methylcellulose. • Decreased spleen uptake may result from chemotherapy, epinephrine, and antimalarials. • Deep lesions may be missed. • Deep respirations may blur images. • Reversible rectangular area (usually liver) of decreased activity from radiation therapy. • Surgery using anesthetic within 1 month can cause colloid shift from liver to spleen and contribute to decreased hepatic uptake of radiocolloid. • Chemotherapy may cause irregular distribution, hepatomegaly, and/or shift to spleen and bone marrow. • Splenic imaging: Amount of damaged RBCs will affect outcome of images.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and for how long? Do you have a history of liver or spleen disease?

(continued)

145

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 146

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have a history of malaria or tropical diseases?

Y

N

Do you have any abdominal pain?

Y

N

Have you had any recent trauma?

Y

N

Are you diabetic?

Y

N

Have you been feeling lethargic?

Y

N

Do you have high blood pressure?

Y

N

Have you had any previous related scans, x-rays, or recent barium studies?

Y

N

Have you had any surgery on the liver or spleen?

Y

N

Do you have any recent blood-work results?

Y

N

Do you have a hepatic artery catheter?

Y

N

Have you had any recent radiation or chemotherapy?

Y

N

Female: Are you pregnant or nursing?

Y

N

Are you taking birth control pills?

Y

N

Assess patient for jaundice and possible alcohol abuse (discern discreetly).

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Hepatic and Splenic Imaging 3.0. Version 3.0, July 20, 2003. Stedman TL. Stedman’s Medical Dictionary, 27th ed. Baltimore: Lippincott Williams & Wilkins, 2006. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 146

10766-27_CH27.qxd

12/3/07

4:27 PM

Page 147

Chapter 27 — Liver/Spleen Scan

Notes

147

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 148

chapter

28

Lung Perfusion (Usually Performed with Lung Ventilation) and Quantitation RADIOPHARMACY Radionuclide •

99m

Tc T1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • MAA (macroaggregated albumin) or HAM (human albumin microspheres)

Localization • Blood flow to pulmonary capillary or arteriolar embolism

Quality Control • Particle size, 10–90 µm, 75,000–700,000 particles/injection; chromatography, 90–95% tagging

148

Adult Dose Range • 2–6 mCi (74–222 MBq); Tb = ∼4–6 hours

Method of Administration • Optimally, before injection, the patient should cough and take several deep breaths. • Patient supine. Intravenous (IV) injection, or if existing IV catheter, slowly, flush heavily with saline only (MAA and heparin do not mix, flush well). • No reblush of blood in the hub of the needle (it may clot and cause a hot spot or falsepositive). Lift injected arm momentarily to assist in circulation of radiotracer. • Avoid injecting through any indwelling catheter that contains a filter, e.g., Swan-Ganz or chemotherapy line.

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 149

Chapter 28 — Lung Perfusion (Usually Performed with Lung Ventilation) and Quantitation

INDICATIONS • Evaluation for pulmonary embolism (PE), the main cause being deep vein thromboses (DVTs), clots from recent surgery, or trauma. If perfusion defects match with same areas as ventilation defects, chronic obstructive pulmonary disease (COPD) is the diagnosis. If defects mismatch, PE is the diagnosis. A reverse mismatch is most commonly due to atelectasis (collapsed lung). • Evaluation of pulmonary perfusion. • Evaluation of chest pain. • Evaluation of shortness of breath. • Evaluation of low blood oxygen saturation. • Evaluation and management of carcinoma of the bronchus. • Evaluation of perfusion affected by emphysema, chronic bronchitis, asthma, inflammatory disease, and cardiac disease. • Detection of right to left cardiac shunt. Primarily for pediatrics patients; dose must be adjusted down for both adults and pediatric patients. • Evaluation of lungs for pre- and post-lung surgery. • Evaluation of lung transplantation.

CONTRAINDICATIONS • Should not be performed on patients with pulmonary hypertension. Dose must be adjusted down if study is to be done. If pulmonary hypertension is suspected or known, some will get a chest x-ray and/or a venous pressure measurement before the perfusion study is done. • Studies on patients with known active pneumonia or other known debilitating lung disease will yield a nondeterminable result for PE. • Right to left shunts (unless it is the reason for the scan). Particles are shunted into the systemic circulation. • Hypersensitivity to human serum albumin.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain a recent (within 24 hours) chest x-ray or suggest that one is ordered. A more recent chest x-ray (within 1 hour) should be obtained if the patient is symptomatic. To assist in distribution to lungs, patient should be asked to cough and take in several deep breaths before injection.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Perfusion Flow • Dynamic, 1–3 sec/frame, 60–120 seconds

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

Statics • 500,000–1 million counts or as per protocol

(TIME: ~15–30 MINUTES)

• Flow: • Place patient in supine position with camera posterior. • Start computer just before injection. 149

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 150

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Static: • Administer injection to patient in supine position. • Acquire series of static images in supine or upright (sitting) position for 500,000–1 million counts each. • Images (typically): anterior, RAO, RLAT, RPO, posterior, LPO, LLAT, and LAO, or as per protocol. A lung transmission (nuclear x-ray) picture may also be taken but should precede ventilation or perfusion study. • Right-to-left shunt: • Acquire anterior, posterior, and right and left laterals of head to verify shunt. • Acquire whole-body sweep if quantitation is desired.

NORMAL RESULTS • Homogeneous uptake except for normal attenuation by skeletal structures, breasts, and heart. • Upright position allows for better lung base visualization. • Supine position may show slight gradient from posterior to anterior reflecting greater perfusion to dependent portions of lung. • Apical activity usually less than bases. • Subsegmental defects affect 7% of the normal population.

ABNORMAL RESULTS • Segmental or wedge-shaped areas of decreased activity, sometimes involving much of the lung, shows high probability of PE especially with mismatch (filled-in areas) on ventilation scan. • Stripe sign of activity may indicate COPD. This presents as a zone of preserved peripheral perfusion looking like a stripe down an outer edge. PE is pleural based hence presence of this sign makes PE unlikely. • Matching defects with ventilation scan can indicate COPD, bullae (deep seated vesicles), emphysema, lung dysfunction, or tumors. • Emphysema presents as increased size of lungs. • Bronchogenic carcinoma can present as complete absence of activity in affected lung or as “edge sign.” • Pleural effusion is indicated by decreased or lack of activity at the base of affected lung(s) and/or the “fissure sign” or “highlighting” (decreased interlobar activity). May be caused by pulmonary edema. • Reverse mismatch, missing areas in vent, filled in on perfusion, shows possible pneumonia or some form of atelectasis (collapsed or clogged lung). • Bacterial pneumonia presents as slightly decreased perfusion and markedly decreased ventilation. • Pulmonary arterial hypertension presents as diffusely heterogeneous perfusion with many small perfusion abnormalities. • Radiation causes vasculitis and obliteration of small blood vessels. • One lung presenting on ventilation but not on perfusion may be congenital absence of the pulmonary artery, massive central pulmonary embolus, mediastinal fibrosis, or hilar neoplasm. • One lung not presenting or presenting very poorly on ventilation scan and presenting lightly on perfusion scan indicates collapsed lung, complete or partial bronchial obstruction, e.g., tumor, mucus, or surgery to lung on that side, e.g., complete or partial removal. • Right-to-left cardiac shunt: Activity in the cerebral hemispheres. Quantitation can be performed by drawing regions of interest (ROIs) on whole-body sweep (around lungs, then around whole body). % shunt =

total body counts − lung counts × 100 total body counts

• Activity outside lung area, thyroid or kidneys can be from right to left shunt, free 99mTc, or previous nuclear medicine scan. Image of head or kidneys will delineate 99mTc from right to left shunt (free 99mTc will go to thyroid and stomach mucosa, shunt to head and kidneys). 150

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 151

Chapter 28 — Lung Perfusion (Usually Performed with Lung Ventilation) and Quantitation

• Defects on perfusion: May cause ventilation/perfusion mismatch: • Pulmonary embolism (thrombotic, septic, marrow, or air), acute or old • Pleural effusion • Tumor (hilar or mediastinal) • Pulmonary artery atresia or hypoplasia • Fibrosing mediastinitis • Fat emboli • Radiation therapy • Vasculitis May cause ventilation/perfusion matching defects: • Bulla or cyst • Localized hypoxia due to asthma, bronchitis, emphysema, COPD • Surgery (e.g., pneumonectomy) • Metastasis (hematogenous or lymphangitic) • Mucus plug • Hilar adenopathy (lymphoma, sarcoidosis) • Pneumonia • Pulmonary edema • Atelectasis • Fibrosis (postinflammatory, postradiation, pleural thickening) Decreased perfusion to one lung: • Pulmonary agenesis or stenosis • Swyer-James syndrome • Embolus • Pneumothorax • Massive effusion • Mediastinal fibrosis • Tumor • Aortic dissection Modified PIOPED (Prospective Investigation of Pulmonary Embolism Diagnosis) • Normal: No perfusion defects, ventilation and chest x-ray normal or abnormal (scoliosis, pneumonectomy). Perfusion image outlines the shape of the lungs. • Very low probability (0–10%): Nonsegmental perfusion defects (cardiomegaly, enlarged aorta, enlarged hila, elevated diaphragm, linear atelectasis, costophrenic angle effusion), no other perfusion defects, perfusion defect with larger chest x-ray abnormality, perfusion defects matched with ventilation defects given that there is a negative chest x-ray and some normal perfusion in lungs, up to three small segmental perfusion defects, a single matched defect of the mid- or upper lung zone in one segment, stripe sign, pleural effusion of a third or greater in pleural cavity and no other perfusion defect in lungs. • Low probability (10–19%): One moderate or large matched defect, greater than three small perfusion defects with negative chest x-ray, one lung not perfusing, single lobar mismatch, moderate pleural effusion (more than costophrenic angle but less than one third of pleural cavity) and no other perfusion defects in lungs, heterogeneous perfusion. • Intermediate probability (20–79%): One moderate to less than two large mismatched perfusion defects or equivalent in moderate or large and moderate defects. (Note: A large segmental defect or >75% of a segment equals one segmental equivalent, a moderate defect or 25–75% of a segment, equals 0.5 segmental equivalents, and a small defect or <25% of a segment is not counted), one matched ventilation/perfusion defect with a negative chest x-ray but may be classified as low probability, any that are difficult to place in low or high probability. • High probability (80% or better): Two or more large mismatched segmental perfusion defects or equivalent in moderate or large and moderate defects with negative chest x-ray. Two large mismatched segmental perfusion defects or equivalent are borderline for high probability, but the recommendation is for more than this degree of mismatching to be truly a high probability. Other criteria are available, e.g., McNeil and Biello, and some that have more steps or classifications. 151

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 152

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

QUANTITATION • Lung perfusion quantitation is used to evaluate high-risk patients preoperatively for surgical candidacy. The normal right:left ratio is 55:45. • Obtain results from pulmonary function test if available. • Quantitation obtained with the computer software. • Usually uses the posterior lung perfusion view for analysis although when study is requested, a full perfusion study (all views) is usually performed. In some cases an entire ventilation and perfusion study is performed especially if the ventilation study is to be used in the quantitation. • Most software is set up to draw ROIs in a specific order around areas of the lung, e.g., upper left lung, lower left lung, upper right lung, lower right lung. • The computer then calculates percent uptake of the four lobes of the lungs. It can be done using ROIs, recording the counts, and doing the math. • Perfusion laterals can be used by drawing an ROI around the entire lung. • Record the total counts. Draw three regions of the lateral, e.g., right upper lobe, right anterior lobe, right posterior lobe. Do the math to get each percent. • The four lobe method can also be done using the posterior ventilation dynamic using the frame that has the fullest view with the most counts. • Other calculations (one method) • Add the counts of both lungs together for total counts. • Divide each lung counts by the total counts and multiply by 100 to give percent function of each lung. • From the pulmonary function test, record the actual results (e.g., 1.46 L). Convert to milliliters (e.g., 1.46 L = 1460 mL). • Multiply the 1460 mL by the percent of each lung for predicted postsurgical expiratory volume. • If this method is used for the decision, the patient is approved for surgery if the volume is >800 mL in the good lung. • If asked for a “split-crystal” quantitation or V/Q, it is old school for having both lungs in view at the same time for counts. This began many years back with renal scans, getting both kidneys in view for comparison.

ARTIFACTS • Indeterminant lung scan if >75% of a lung zone has obstructive lung disease. • Turn syringe before injection to mix MAA in dose. Do not pull blush back and reinject as hot spots may occur because of radioactive clots injected into system. Patient should be injected while in supine position to avoid gravity-fill of lower lobes. • Jewelry, medallions, buttons, or items in shirt pockets can cause artifacts. • Test on patients with known compromised pulmonary function (known disease, shunting, arteriole malformation, liver disease) or one lung should be performed with reduced amounts of radiotracer (and hence reduced number of injected particles) and not performed on patients with pulmonary hypertension. • If little or no visualization of lungs occurs, check patient history for compromising diseases, operations, or cancers, and check syringe for radiotracer retention in hub or needle (carefully redrawing about 0.5 mL of saline and reinjecting can yield results). • Nonstandard patient positioning for perfusion/ventilation studies may affect distribution of radiotracers and/or cause mismatches in the imaging. Position should be noted. • Central line injections can result in poor mixing of particles particularly if injected through a pulmonary artery line. • At least 75,000 particles per injected adult dose. Too few injected will yield “quantum mottled” views. Optimally 200,000 to 700,000 particles are needed for imaging. • Particles in MAA cause micro emboli in 100,000 capillaries of the 350 million arterioles and 280 billion small capillaries of lungs. Because of the 10- to 90-micron size of the particles, the total particle numbers injected have upper limits so as not to compromise patient. In general, <0.1% of the capillaries are blocked from a typical injection. Please refer to Kit Preparation in the Reference Section. 152

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 153

Chapter 28 — Lung Perfusion (Usually Performed with Lung Ventilation) and Quantitation

When making kits, check the insert for manufacturer’s suggestions. Some make sure that the mCis (MBqs) are within normal kit ranges and that not more than 1 mL total quantity of radiotracer is drawn from the kit. This is particularly important with patients who already have a compromising pulmonary condition. • Patients receiving lung scans can be critically compromised without showing it. If at all possible, never take your eyes off the patient or leave him or her unattended in a room. • Serious PE involvement may present with no symptoms of chest pain, shortness of breath, hemoptysis, history of recent long trips, or history of DVT. Tachycardia is a classic symptom of PE and, together with low O2 saturation and distention of the vessels in the neck, could mean cardiac tamponade (ruled out with an echocardiograph) or PE (ruled out with a lung scan). Tachycardia may arise because the brain perceives the diminished supply of oxygen, causing an increase in beats per minute to compensate. There may be other mechanisms. • Because of the possible insidious nature of pulmonary emboli, if at all possible, remain extremely attentive and mindful of the patient as things can “go bad” very quickly.

NOTE • Usually performed in conjunction with the lung ventilation or aerosol scan and recent (taken within 24 hours) chest x-ray. Some other agents and modalities for lung scans: • 186Re, 117mSn, 99mTc-Antibodies or peptides (go directly to PE and DVT). • D-Dimer assay lab test for venous thromboembolism (VTE) (the collective name for deep vein thrombosis [DVT] and pulmonary emboli [PE]). The Simplify D-dimer assay is a D-dimer specific murine monoclonal antibody DD3B6/22. The conjugate binds specifically to D-dimer–containing molecules found with the degradation products from cross-linked fibrin products (XL-FDPs), making it an indicator for VTE. • Venous compression ultrasonography for DVT leading to possible PE. • Spiral CT of chest with contrast. Contraindicated in patients with allergies to iodine and/or elevated creatinine (normal: .7–1.4 mg/dl) and/or BUN (normal 10–20 mg/dl). Any renal failure patient is not a good candidate for CT or patients with veins that will fail with a bolus injection. Please note: Some institutions are combining the terms PE (pulmonary emboli) and DVT (deep vein thrombosis) and using the term VTE (venous thromboembolism).

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

Y

N

Y

N

If so, what type and for how long? Do you have any difficulty or pain with breathing? If so, where? Do you have shortness of breath (dyspnea)? If so, for how long? Are you coughing up blood (hemoptysis)?

(continued)

153

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 154

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have a history of any lung diseases, e.g., pulmonary emboli, pulmonary hypertension, asthma, emphysema, chronic bronchitis, COPD?

Y

N

Do you now or have you ever smoked?

Y

N

Are you running a fever?

Y

N

Do you have fainting spells (syncope)?

Y

N

Are you taking any oral contraceptives?

Y

N

Do you have a history of heart problems (tachycardia, atrial fibrillation, clots, left-to-right shunt, congestive heart failure)?

Y

N

Do you have a history of deep vein thrombosis (DVTs) or phlebitis?

Y

N

Have you had any recent long-distance travel?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent related scans e.g., CT, compression US, x-rays, or lab tests?

Y

N

Are you on heparin, Coumadin, warfarin, aspirin, or other blood-thinning drugs?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, how much and for how long?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Lung Scintigraphy, Version 3.0, February 7, 2004. SNM.org. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 154

10766-28_CH28.qxd

12/3/07

4:29 PM

Page 155

Chapter 28 — Lung Perfusion (Usually Performed with Lung Ventilation) and Quantitation

Notes

155

10766-29_CH29.qxd

12/3/07

4:30 PM

Page 156

chapter

29

Lung Transmission (and Transmission Imaging) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical

Quality Control • Moly breakthrough, Al breakthrough, chromatography

Adult Dose Range

• Na 99mTcO4− (pertechnetate)

• 50 mCi (1850 MBq)

Localization

Method of Administration

• N/A

• Exposed to, not administered

INDICATIONS • Detection of gross anatomy and relative position of lungs. • Detection and localization of major lesions, constrictions, or gross physical deformities. • Evaluation of thorax in conjunction with lung ventilation and lung perfusion tests. Test is used as a type of nuclear medicine x-ray.

CONTRAINDICATIONS • None 156

10766-29_CH29.qxd

12/3/07

4:30 PM

Page 157

Chapter 29 — Lung Transmission (and Transmission Imaging)

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• One static picture, 3 million counts

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE (TIME: ~15 MINUTES) • • • •

Place patient in supine position on scanning bed, camera anterior, thorax. Roll container, e.g., large drum, holding 99mTcO4− directly under patient. Position container and patient such that lungs are centered in camera field of view. Take one static image for 3 million counts.

NORMAL RESULTS • Both lungs will present fully, uniform, and symmetric.

ABNORMAL RESULTS • Lung does not present. • Lung(s) appears deformed, portions missing or containing light or dark areas depending on defect.

ARTIFACTS • Jewelry, medallions, buttons, pacemakers, and prostheses may attenuate the picture.

OTHER TYPES OF TRANSMISSION SCANS • Outlining patient: Using 57Co “cookie sheet,” place opposite side of patient to camera. Image acquired has outline of patient that can be useful for relative positioning of region of interest (ROI). • Lung ventilation positioning: Using the syringe containing 133Xe, as patient lies supine with camera posterior, wave syringe over anterior thorax and check p-scope to make sure lungs are fully in camera view. This allows proper positioning before 133Xe gas is administered and dynamic pictures are started. This method, if used, should be done quickly to reduce exposure, or tape into dosage lead-container (pig) using opening toward patient. It also works well in the seated position with camera behind patient. • Transmission scans generally refer to protocols in SPECT, PET, CT, and MRI imaging at present. They are used as attenuation correction and alignment for whichever modality is imaging and also as an aid in combined imaging. SPECT studies can incorporate a line source containing 20 mCi (740 MBq) of 57Co for the transmission scan in conjunction with a 15 minute emission scan and coregistered with an MR scan (ajp.psychiatryonline.org). 157

10766-29_CH29.qxd

12/3/07

4:30 PM

Page 158

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Attenuation correction is also accomplished in SPECT by the use of an external line source with a long half-life, e.g., gadolinium-153 (153Gd) or americium-241 (241Am), that rotate on the opposite side of the patient during the SPECT acquisition. In PET cardiac studies, a rectilinear-style transmission scan using 2 mCi (74 MBq) of 68Ge is used in a circular ring source to identify the heart profile, then a 20-minute transmission scan recorded for attenuation correction (L. Choudhury et al: eurheartj.oxfordjournals.org). PET/MRI scans, in some cases, employ a 10 minute transmission scan for attenuation correction of gamma rays due to objects in the scanner e.g., the coil, coil mount, metal sheets, as well as permitting verification of the final position of the coil relative to the acquired PET and MRI images (www.loni.ucla.edu/ICBM/ICBM_Data.html). In PET/CT scanning, a rotating source of 137Cs of 20 mCi (750 MBq) (or 68Ge) is used in a 4 minute transmission scan for attenuation correction. Attenuation correction is used to get count rate values independent of tissue densities. Transmission scans date back to 1952 (Myneord) to compare anatomical contours to radiotracer distribution, similar to this lung transmission scan or body outlining, using a rectilinear scanner. Isotopes used along the way have been 125I, 131I, 170Tm, 99mTc, 133Ba, 137Cs, and 68Ge. The term is now more relegated to describing rotating sources in various modality combinations for attenuation correction of emission scans (www.pubmedcentral. nih.gov/articlerender.fcgi?artid=1164418). • Please note: Some institutions are combining the terms PE (pulmonary emboli) and DVT (deep vein thrombosis) and using the term VTE (venous thromboembolism). Lung transmission scan is usually performed with lung ventilation and perfusion.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

Y

N

Are you coughing up blood?

Y

N

Do you have a history of any lung diseases, e.g., pulmonary emboli, asthma, emphysema, chronic bronchitis, COPD?

Y

N

Do you now or have you ever smoked?

Y

N

Are you running a fever?

Y

N

Do you have fainting spells?

Y

N

Are you taking any oral contraceptives?

Y

N

If so, what type and for how long? Do you have any difficulty or pain with breathing? If so, where? Do you have shortness of breath? If so, for how long?

If so, how much and for how long?

158

10766-29_CH29.qxd

12/3/07

4:30 PM

Page 159

Chapter 29 — Lung Transmission (and Transmission Imaging)

Do you have a history of heart problems (tachycardia, atrial fibrillation, clots)?

Y

N

Do you have a history of deep vein thrombosis (DVT), phlebitis?

Y

N

Have you had any recent long-distance travel?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent related scans or x-rays?

Y

N

Are you on heparin, Coumadin, warfarin, aspirin, or other blood-thinning drugs?

Y

N

Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings There is not a lot of information in the literature about these techniques. These techniques were taken from the Nuclear Medicine Departments of the following institutions: Bayfront Medical Center, St. Petersburg, FL: 133Xe lung positioning. Columbia Doctor’s Hospital, Sarasota, FL: 57Co torso outlining. H. Lee Moffitt Cancer Center, Tampa, FL: 57Co torso outlining. James A. Haley Veterans Hospital, Tampa, FL: 99mTc lung transmission scan. Internet sources noted where applicable. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006.

Notes

159

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 160

chapter

30

Lung Ventilation: Gas and Aerosol (Usually Performed with Lung Perfusion) RADIOPHARMACY Radionuclide •

133

Xe t1/2: 5.3 days Energies: 32 x-ray, 81 keV Type: β−, γ, fission product • or: 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

133

Xe: gas Tc-DTPA (diethylenetriaminepentaacetic acid)

Quality Control • •

133

Xe: dose calibrate vial before use Tc-DTPA: chromatography >95%

99m

Adult Dose Range •

133

Xe: 10–20 mCi (370–740 MBq); Tb = ∼30 seconds • 99mTc-DTPA: 25–40 mCi (925–1480 MBq); Tb = >1 hour (less in smoker, IPF [idiopathic pulmonary fibrosis], ARDS patients).

99m

Localization • Compartmental by inhalation into lung space

160

Method of Administration • Inhalation through mask or mouth apparatus, PO.

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 161

Chapter 30 — Lung Ventilation: Gas and Aerosol (Usually Performed with Lung Perfusion)

INDICATIONS • Evaluation and detection of pulmonary embolism (PE) in conjunction with lung perfusion (mismatching defects). • Evaluation of chronic obstructive pulmonary disease (COPD) in conjunction with lung perfusion (matching defects). • Evaluation of obstructed or constricted airways, alveolar spaces, and air distribution, resulting in shortness of breath. • Evaluation of pulmonary retention. • Evaluation of chest pain. • Evaluation of low blood oxygen saturation. • Evaluation of adult respiratory distress syndrome (ARDS), emphysema, inflammation, chronic bronchitis, or pneumonia. • Evaluation of tracheobronchial epithelium function (aerosol). • Evaluation and staging of patients with COPD, lung carcinoma, and bronchial obstruction (aerosol). • Evaluation of pulmonary permeability in restrictive lung disease or pulmonary edema by observing clearance rates using submicrometer aerosols (DTPA).

CONTRAINDICATIONS • Studies on patients with known active pneumonia or other known debilitating lung disease will yield a nondeterminable result for PE.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Obtain recent (within 24 hours) chest x-ray or suggest that one is ordered.

EQUIPMENT Camera

Computer Set-up

• Large field of view

•

Collimator •

133

Xe: Low energy, all purpose, or low energy, high sensitivity • 99mTc-DTPA: Low energy, all purpose, or low energy, high resolution

PROCEDURE

133

Xe: dynamic, flow study, 20–60 sec/frame for 6–8 minutes (for wash-in, equilibrium, and wash-out study) • 99mTc-DTPA: static images (500,000–1 million counts) usually same views as perfusion

(TIME: ~15–30 MINUTES)

133

Xe: Gas

• Place patient in sitting position with camera on back, or in supine position, camera posterior (unless perfusion was done first, then use best projection that will show visualized defects). The imaging room should have negative pressure with appropriate exhaust. • If ventilation scan is first, position patient using the dose as a marker on the suprasternal notch or top of shoulders for the upper field of view (FOV), along sides of patient to ensure sides are in FOV, xiphoid process just below center. Lungs must be fully in FOV. If the dose is in a syringe, wave over thorax for a transmission-type view. Lungs will visualize on monitor. 161

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 162

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Explain and apply mask, ready apparatus depending on type and protocol. • Inject or pump in gas as patient takes a deep breath (and held, if protocol), start computer simultaneously. Adjust apparatus, e.g., Pulmanex®, as necessary for wash-in/wash-out phases if used. • Acquire dynamic images for inspiration (wash-in), equilibrium, and wash-out. Mask stays on for at least 60 seconds or longer as per protocol (if acquisition is for eight frames, some leave mask on for four frames or until count rate falls to a low level). • Remove mask and allow patient to breath room air. Remind patient to remain still. • If performed after perfusion scan, obtain a 99mTc background image using the 133Xe window. 99m

Tc-DTPA: Aerosol

• Place patient in supine position on bed, or upright (sitting or standing). • Inject 99mTc-DTPA into canister or aerosol dispenser (nebulizer). Place mouthpiece in patient’s mouth. Place nose clamp on patient. A mask can also be used. Attach nebulizer to ∼10 L/min of air from wall outlet or air canister. Only about 1 mCi (37 MBq) is actually inhaled into the lungs. • Instruct patient to breath normally for 5 minutes. • Remove equipment. • Obtain images as to protocol, the usual eight as in the perfusion, although some only require six in both (anterior, posterior, LLATs and RLATs, and LPOs and RPOs).

NORMAL RESULTS •

133

Xe gas: Uniform and symmetric wash-in, equilibrium, and wash-out pictures in both lungs with the left lung having the typically light cardiac notch. Wash-out fairly complete with no retention of gas. • Aerosol (e.g., 99mTc-DTPA): The pharynx shows bright from inhalation, the stomach and gut may show from swallowed contaminated saliva (have patient expectorate into a facial tissue as soon as the mouthpiece is removed and dispose to reduce this phenomenon). Trachea and bronchi show branching nicely with this method.

ABNORMAL RESULTS 133

Xe Gas

• Areas of decreased activity occur where lung was not ventilated. • Ventilation study usually presents as normal (uniform and symmetrical uptake and washout in all three phases) in cases of pulmonary embolism (PE). Mismatching areas of activity (usually two or more segmental defects) in the perfusion study are indicators for PE. • COPD and emphysema present as inhomogeneous wash-in, patchy equilibrium, and areas of trapping delaying wash-out (especially lower lobes). The same areas (matching defects) may present in the perfusion scan. • Bacterial pneumonia presents as markedly decreased ventilation and slightly decreased perfusion. • Localization and retention in liver with ventilation indicates liver fatty infiltrates prevalent with alcoholics and obese patients. 133Xe is fat-soluble and partially soluble in blood. • One lung not presenting or presenting very poorly indicates atelectasis (collapsed lung), complete or partial bronchial obstruction, e.g., tumor, mucus, or surgery to lung on that side (removal).

Aerosol (99mTc-DTPA) • Areas of decreased activity occur where lung was not ventilated. • Ventilation study usually presents as normal (uniform and symmetrical uptake) in cases of pulmonary embolism (PE). Mismatching areas of activity (usually two or more segmental defects) in the perfusion study is the indicator for PE. • Obstruction presents with bronchial branching missing or noticeably not as well ventilated distal to obstruction. 162

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 163

Chapter 30 — Lung Ventilation: Gas and Aerosol (Usually Performed with Lung Perfusion)

• Accelerated clearance of aerosols may present in patients with chronic interstitial lung disease or with inflammation of the lung such as ARDS and pneumocystic pneumonia. • One lung not presenting or presenting very poorly indicates collapsed lung or complete or partial bronchial obstruction, e.g., tumor or surgery to lung on that side (removal). • Particle deposition presents in large central airways with obstructive lung disease. Drug interactions • Liver uptake during 133Xe gas washout—TNP, clofibrate, also obesity, diabetes, liver disease, e.g., fatty liver, hyperlipidemia. • Upper lobe increased activity—diazepam, general anesthetic agents.

ARTIFACTS • Uptake in the liver may cause false-positive for trapping in right lower lobe. • Uptake may be seen in upper left quadrant of abdomen because of patient swallowing xenon during acquisition. • DTPA study may have activity in esophagus and stomach due to swallowing. • Some computers must be manually peaked for 133Xe. • Mask not fitting tightly over face, allowing gas to escape. This is more possible with very thin faces, facial hair, noncoherent patients. • Patient disrupting mask or mouthpiece by coughing or removing. • Lungs not properly positioned before start of ventilation. • Injection of gas made on patient’s exhale. • Missing proper start time on computer. • Patient not breathing well using aerosol apparatus. • Patient movement.

NOTE • Usually done in conjunction with lung perfusion study and recent (taken within 24 hours) chest x-ray. • Some institutions are combining the terms PE (pulmonary emboli) with DVT (deep vein thrombosis) and using the collective term VTE (venous thromboembolism). • 81mKr, obtained from 81Rb/81mKr generators and used for ventilation scans, is apparently no longer available on the market. • Please refer to the Lung Perfusion chapter for more information concerning lung scans and pulmonary emboli.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and for how long? Do you have any difficulty or pain with breathing? If so, where? (continued)

163

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 164

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have shortness of breath?

Y

N

Are you coughing up blood?

Y

N

Do you have a history of any lung diseases, e.g., pulmonary emboli, asthma, emphysema, chronic bronchitis, COPD?

Y

N

Do you now or have you ever smoked?

Y

N

Are you running a fever?

Y

N

Do you have fainting spells?

Y

N

Are you taking any oral contraceptives?

Y

N

Do you have a history of heart problems (tachycardia, atrial fibrillation, clots)?

Y

N

Do you have a history of deep vein thrombosis (DVT), phlebitis?

Y

N

Have you had any recent long-distance travel?

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent related scans or x-rays?

Y

N

Are you on heparin, Coumadin, warfarin, aspirin, or other blood-thinning drugs?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, for how long?

If so, how much and for how long?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Lung Scintigraphy, Version 3.0, February 7, 2004. SNM.org. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 164

10766-30_CH30.qxd

12/3/07

4:31 PM

Page 165

Chapter 30 — Lung Ventilation: Gas and Aerosol (Usually Performed with Lung Perfusion)

Notes

165

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 166

chapter

31

Lymphoscintigraphy (Lymphangiogram) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-sulfur colloid (filtered)

Localization • Compartmental, phagocytosis. Particles are cleared by lymphatic system, 30% at 3 hours.

Quality Control •

99m

Tc, chromatography >90%; sulfur colloid filtered to ≤0.22 µm

Adult Dose Range • 200 µCi to 2 mCi (7.4–74 MBq); 450 µCi to 1 mCi (16.65–37 MBq) is typical, two to six injections. Some use up to 7 mCi (259 MBq) total. 166

Method of Administration • For melanoma: Injections, two to six subcutaneous and/or intradermal, producing a wheal, placed around cancer site, surgery, or region of interest (ROI) (within 5 mm). Other routes are intradermal into the web of hand or foot. Volume should not exceed 0.25 mL per injection site (tuberculin syringe). • For breast lesions: Intraglandular injection, four to six injections placed into tissue surrounding lesion (within 1–3 mm) found by palpation, needle aspiration, or ultrasound, .1 to as much as 4 mL per syringe at (minimum) 3-, 6-, 9-, and 12-o’clock positions around tumor site. Injections may be done under ultrasound to locate tumor or to fluid sac if a surgical biopsy has already been performed. Some inject as they are retracting needle and also place a small amount of radiotracer into subdural space before removing needle. Intradermal injections: Because of the nature of the lymphatic system in the breast, injections can be done intradermally only and not deep at the position of the lesion or site. Peri-aureola intradermal injections can

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 167

Chapter 31 — Lymphoscintigraphy (Lymphangiogram)

be done at 3, 6, 9, and 12 o’clock positions. Some include lidocaine or sedation to reduce pain of injections. Some include hyaluronidase, a testicular enzyme, to limit time of pain with injection and increase radiotracer clearance time (distributes radiotracer faster).

• For lymphedema: Injections, two sites per limb, subcutaneous, producing a wheal, placed into the web between fingers or toes depending on the area of interest.

INDICATIONS • Evaluation of staging (spread) of cancers (e.g., lymphatic leukemia, reticulum cell carcinoma, Hodgkin’s disease, and melanomas) into the lymph system. • Evaluation of lymphatic kinetics, particularly for cancers. • Detection of metastatic invasion of the lymph nodes. • Evaluation of node resection as an alternative to removing an entire bed of lymph nodes, which may cause edema of that area and other related complications. It is designed to find the few sentinel nodes to which the cancer may drain. • Evaluation of pelvic and/or periaortic lymphatic drainage for blockage by trauma or tumor (e.g., rectal, prostatic, or vulvar cancer). • Evaluation for endolymphatic radiotherapy and radical surgery candidates. • Evaluation of chronic lymphedema of swollen extremity. • Differentiation of primary (neither lymphatic nor proximal lymph node visualization) and secondary (interstitial lymphatic uptake but poor visualization of proximal lymph vessels and nodes) lymphedema. • Evaluation of lymph vessel patency before lymphovenous anastomosis (connecting of vessels).

CONTRAINDICATIONS • None

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Wipe area with alcohol pad, shave if necessary; clean area with Betadine® or chosen sterilizing solution. • For breast study, patient is to bring mammograms and any related studies with her (outpatient) or make previous related studies available (inpatient). • For breast study, patient is instructed to massage area of injection after injections and between imaging sessions. • For lymphedema, physician to instruct patient to wear elastic stockings. These should be removed 3–4 hours before study.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• Peak for 99mTc at 140 keV and 57Co at 122 keV if cookie sheet is used for patient outline.

Collimator • Low energy, all purpose, or low energy, high resolution

Flow • 30–60 sec/frame, 10–15 minutes.

167

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 168

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Immediate Statics • Collect for 5 minutes (300 seconds) every 5 minutes for up to 30 minutes; 256 × 256 × 16 matrix; try 10% window to reduce scatter.

Whole Body • Set for 10–15 cm/min

Delays • 40,000–200,000 counts or 5 minutes each; try 10% window

PROCEDURE (PROCEDURES VARY GREATLY; SEE SAMPLE PROTOCOLS; TIME: ~1–6 HOURS) • Prepare the area of interest for the patient (e.g., shave, alcohol wipe, Betadine®). • Melanoma: Patient is injected around the ROI with two to six doses subcutaneously and/or intradermally. • Breast lesion: Patient is injected with four to six injections around lesion. • Lymphedema: Patient is injected subcutaneously in webs of feet or hands as indicated, two sites per limb. • Place patient in prone, supine, or sitting position depending on location of site to best obtain images of lymph drainage. • Flow: Position ROI under camera, image dynamic flow for 5–15 minutes. • Immediate statics: 5–10 minutes per view, with or without markers or transmission images. • Views: Anterior, posterior, obliques, and/or laterals to best image the direction of lymph node drainage. • Marker images: Use a point source outlining the body and/or a transmission image using a 57Co flood source (cookie sheet) placed behind the patient to help define the position of the nodes of interest. • Extremities: The inguinals or axillas should visualize within 10–30 minutes depending on how distal the site is. In these cases and trunk-oriented cancers, delays of the whole body (1–2 hours) may be required to visualize secondary drainage. Image in-transit nodes around knee(s) or elbow(s). • Abdominal lymph nodes: Subcutaneous injection in the interdigital webs of the feet. • Lymphatic internal mammary chain: Injection into the space behind the rectus abdominal muscle. • Presurgical patients: Position patient as he or she will be in surgery, e.g., arm up or down. When all related nodes are believed to be exposed, their locations are marked on the patient’s skin with indelible ink. Use point source and monitor or gamma probe for location. The patient can return just before surgery to have the spots reconfirmed and tattooed for the surgeon. • Delays: 1–4 hours after injection (see Protocols below), use same views as before. • Whole body: Sweep or statics to cover all drainage areas. • Single photon emission computed tomography (SPECT): Center area of interest, set parameters, and start camera.

NORMAL RESULTS • The radiotracer enters the lymphatic system through normal channels and proceeds through the system into the major lymphatic beds (e.g., retroperitoneal, the axillaries, inguinal, parasternal, and cervical lymph nodes). • Visualizing the sentinel node or nodes is normal within the first half hour. • After 4 hours, a chain of activity should visualize in the inguinal, iliac, and/or periaortic regions. • Liver should also present. • A biopsy of those nodes, once removed, will yield the result. If the dissected node contains no cancer cells, the patient may be spared removal of entire lymphatic bed. 168

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 169

Chapter 31 — Lymphoscintigraphy (Lymphangiogram)

ABNORMAL RESULTS • None or only some of the expected nodes visualizing. This may indicate malignant disease or blockage. Intervening surgical or trauma scars can block the normal progression of the lymph system. • Continuity of a chain interrupted or abnormal pathway created by tumor replacement of node or lymphatic obstruction. • Enlargement of a chain width because of lymphoma, congestion, or lymphadenitis. • Unexpected intensity difference; reduced in malignant lymphoma or increased in congestion and lymphadenitis. • Displacement of expected location by metastasis or collateral circulation. • Missing liver activity may indicate insufficient movement of the extremities or lymphatic blockade. • Malignant melanoma can metastasize through the lymphatic system to the liver, lung, brain, and bones. • Primary (congenital) lymphedema visualizes with an unobstructed few lymphatic channels. • Secondary (obstructive) lymphedema present with lack of migration of the radiotracer from the injection site, diffuse dermal activity, and/or multiple tortuous collateral pathways.

ARTIFACTS • A “star” artifact, caused by the intensity of the injection site(s), may obscure nodes in the proximity from presenting properly. • Injection sites that are too distant from the ROI may obscure primary nodes close to the lesion. • The injection(s) may not migrate as expected if there is intervening scar tissue from a prior surgery or injury. • One view of the presenting nodes may not be enough to properly locate the node or nodes. Multiple views, including anterior, posterior, oblique, and laterals may be needed. • Some nodes are small or weak in intensity. Enough counts and care must be taken to locate all that may be present. • If whole-body static images are necessary, there may be no visual clues on the monitor to position by, so careful visualization may be required. • Care must be taken when marking the affected nodes for presurgical candidates because that is where the surgeon will make the excisions. • Variables that can alter the image outcome include the total amount of radiotracer, volume of each injection, number of sites, distance of injections from lesion or ROI, depth of injections, flow, delay times, length of acquisitions, markers, silhouette, and region extraction or lead shields or both. Always check with physician about preferences. Time may also become a factor in cases where surgery is waiting for the patient.

INJECTION SITES FOR VISUALIZATION AND SUGGESTED DELAYED PICTURES • Surface lesion: Two to six injections around area of cancerous tissue or ROI. Delays 2–4 hours, 50,000–100,000 counts. Be sure to shield injection site or center counts on lymph nodes, not injection site. • Retroperitoneal lymph nodes: Injection into medial two interdigital webs of feet. Image at 4 hours with part of liver in view, lumbar lymph nodes are focal area, 100,000 counts. • Axillary and apical lymph nodes: Injection into medial two interdigital webs of the hands. Image at 2–4 hours, upper chest and neck in view, 40,000 counts. Axillary image, arm up, face turned away from ROI, 40,000 counts. • Cervical nodes: Injection into dorsum of the mastoid process. • Internal mammary chain: Injection into posterior rectus sheath below rib cage, angling toward diaphragm. Delays 2–4 hours, 50,000–100,000 counts. • Iliopelvic lymph nodes: Injection into perianal region just lateral to the anal margin at the 3- and 9-o’clock positions. Patient in knee-to-chest position. Delays 2–4 hours, 100,000 counts. 169

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 170

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

SAMPLE PROTOCOLS Protocol for Detecting Direction of Flow • Set-up • Flow: 10 sec/image for 300 seconds. • Immediate dynamics: 6 images for 300 seconds each. • Static: Immediate static (oblique for axilla) for 40,000 counts. • Patient placed on imaging table to allow access to ROI. Obtain lead shield just big enough to shield injection sites. • (Optional) With camera placed in approximate position making certain to include suspected drainage area of nodes, 57Co sheet placed under patient with camera over top. One or more images obtained with anatomic markers included and outline of body contours with 99mTc source. These can be filmed separately in the same format as the flow for superimposition (statics for 40,000 counts).

Breast Lesions • Inject four to six doses ∼200–500 µCi each with patient in place on imaging table. • Position ROI under camera, making certain to include closest suspected lymphatic bed. Shield injection sites. Start flow quickly as radiotracer begins migration quickly. Add anatomic markers if none have been done. • Note migration. Adjust camera for dynamics if necessary. (Add anatomic markers to one or more if camera is moved.) • Immediate static, especially oblique with axilla, adding anatomic marker(s) (e.g., xiphoid process, umbilicus, suprasternal notch [SSN], etc.) for 150,000 counts. • Delays: Static(s) at 1 or 2 hours; shield injection site, same position as dynamics and oblique if taken for 150,000 counts or 5 minutes each. Again at 3–4 hours. • Alternative delays: If computer has a region-extraction program, take an image without a lead shield, increase counts to 500,000 or so, using earlier images as a guide. Using computer program, extract injection sites and increase intensity to visualize possible nodes.

Alternative for Breast Lesions • After injection: flow 20 frames at 30 seconds each. Immediate static for 300 seconds with 57Co cookie sheet behind patient and/or using anatomical markers. Optional additional with shield and 57Co sheet behind patient. • At 1–2 hours with 57Co sheet: one 300-second image without shield, one with shield (anterior, posterior, obliques, laterals, or combination to get best picture of drainage). • At 3–4 hours with 57Co sheet: Same images. • Processing: if there is a region-extraction program or something similar, choose image without shield and extract injection sites (careful of not extracting possible proximal nodes) and increase intensity. Show films for possibility of performing more delays using same protocol.

Easiest Protocol for Breast Lesions • After injection: Patient massages injected breast with warm towels for 30 to 60 minutes after injection. • Imaging is begun at 30 to 90 minutes after injection. The 300 second images are anterior and oblique(s) of affected side(s) with the patient’s arm(s) up as it will be in surgery, using a “cookie sheet” behind the patient (for about 90 seconds) for outline. The patient may return 1.5 to 2 hours later for repeat statics if there is no visualization of lymph nodes. With visualization, patient can be “tattooed” or “inked” with a marker using the gamma probe and/or a 99mTc-marker locating the hot node(s) under the camera using the monitor. • If no visualization at that time, patient returns in 3 to 4 hours for repeat statics. 170

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 171

Chapter 31 — Lymphoscintigraphy (Lymphangiogram)

ROLE OF TECHNOLOGIST IN OPERATING ROOM (OR) • Many institutions are using these studies to localize and resect lymph nodes. The role of the technologist differs with the institution, but they generally perform the following tasks. • Prepare the dose syringes and bring them to physician doing injections. For subcutaneous and intradermal injections such as melanomas and some breast techniques, some institutions allow the technologists to inject. • Physicians may choose to use a Lymphazurin dye (1% isosulfan blue), which localizes in the lymphatic bed. Once surgery has begun, this dye gives surgeons a visual reference to the location of the lymph node(s) of interest. • Images taken as suggested above, patient and images are brought to preoperative area to prepare for surgery. • Physicians may choose to use a Lymphazurin dye (1% isosulfan blue), also known as azure blue, which localizes in the lymphatic bed. Once surgery has begun, this gives the surgeons a visual reference as to where the lymph node(s) of interest may be positioned. • In OR • Technologist uses gamma probe (usually a small hand-held gamma detector) to locate “hot” node(s). This is only in some institutions; others hire a company to manipulate the probe. • Activity in a sentinel node should typically register 10 times the background counts that are taken at a location remote from the injection site. • Technologist may be required to take resected nodes and material to pathology for inspection. • Technologist may have to take material to radiology for x-ray if requested for “needle loc (localization)” specimen. • Technologist assays material for storage (10 half-lives) if > 0.05 mR at 1 m or disposal if background ≤ 0.05 mR at 1 m. • Technologist assays pathology room and equipment for contamination. • Technologist assays OR for contamination after removal of patient.

NOTE • The sulfur colloid used in lymphoscintigraphy (a particle size of 3–220 nm or ≤ .22 um) is much smaller than the sulfur colloid used in liver spleen imaging (a particle size of 500–1,000 nm). 99mTc-sulfur colloid used in lymphoscintigraphy is formulated by combining hydrogen sulfide with antimony potassium tartrate resulting in Sb2S3. The colloid sulfide is stabilized by polyvinylpyrrolidone inhibiting particle growth.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and for how long? Is this a pre-surgery or post-surgery study? Have you had any surgery in area of interest? Where is the site (or sites) under scrutiny? (continued)

171

10766-31_CH31.qxd

12/3/07

4:32 PM

Page 172

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you had any recent biopsies?

Y

N

Have you had any past or recent related scans (mammography, PET, CT, NM, MRI, x-rays)?

Y

N

Do you have a history of lymphedema?

Y

N

Female: are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

172

10766-32_CH32.qxd

12/3/07

4:39 PM

Page 173

chapter

32

Meckel’s Diverticulum RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical

Quality Control • Moly breakthrough, Al breakthrough, chromatography

Adult Dose Range

• Na 99mTcO4− (pertechnetate)

• 10–15 mCi (370–555 MBq); 200–300 uCi/kg (7.4–11.1 MBq/kg) in pediatrics

Localization

Method of Administration

• Active transport, concentrated and rapidly secreted by the epithelial tissue of the (ectopic) gastric mucosa

• Intravenous injection

INDICATIONS • • • •

Localization of a Meckel’s diverticulum with functioning gastric mucosa. Detection of gastrointestinal bleeding. Evaluation of positive guaiac test (blood in feces). Evaluation of abdominal pain (especially in children). Usually early age onset from abnormal development of fetal intestine from yolk sac. Meckel’s is formed from incomplete closure of yolk duct and usually within 18 inches of the ileocecal valve. It may contain ileal, duodenal, colonic, pancreatic, or gastric tissue. • Evaluation of bleeding, diverticulitis, or intestinal obstruction caused by intussusception (intestinal invagination) and volvulus (twisting of bowel causing obstruction).

173

10766-32_CH32.qxd

12/3/07

4:39 PM

Page 174

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS • Patients with barium or contrast studies under way

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Ensure patient to be NPO for 4–12 hours. Infants: NPO equal to normal feeding time minus 30 minutes (study time). • Physician to discontinue thyroid blocking agents, e.g., perchlorate or saturated solution of potassium iodide 48 hours before study. • Instruct patient to void before procedure. • Ensure patient has no radiographic barium studies on same day or 48 hours before study. • If pentagastrin is to be used, ensure patient to be NPO for 8 hours. It must be ordered from pharmacy 24 hours in advance. Inject 15 minutes before 99mTcO4− injection. • Cimetidine suggested in difficult cases; about 300 mg adjusted for age, qid for 24 to 72 hours before exam. An additional dose may be administered 1 hour before exam. This H2 blocker inhibits the release of the radiotracer from the gastric mucosa.

EQUIPMENT Camera

Dynamic • 15 sec/frame for 29 minutes or 1 min/frame for 15 minutes

• Large field of view

Collimator • Low energy, all purpose, or low energy, high resolution

Statics • Acquire ∼500,000–1 million counts per image • Consider magnifying all types and views for pediatric patients.

Computer Set-up Flow • 1–5 sec/frame for 1 minute

PROCEDURE

(TIME: ~60 MINUTES)

• Place patient in supine position with camera anterior covering xiphoid to pubis. • Inject and start camera for flow and dynamic study. • Statics: Obtain immediate image(s) and, depending on length of dynamic, one image every 5 minutes up to 60 minutes after injection. Image posterior, laterals, and obliques as per protocol if possible area is visualized. • Drug interventions may be included. • Pentagastrin: (Peptavlon®) ∼6 µg/kg, stimulates ectopic gastric mucosal uptake of pertechnetate by 30–60% while decreasing emptying time into small bowel and decreasing background. Administered intramuscularly in children, subcutaneously in adults. Administer 15 minutes before 99mTcO4− injection. • Glucagon: ∼50 µg/kg, decreases peristalsis and increases persistence of activity in the ectopic mucosa. Administer intravenously 10 minutes post injection of 99mTc O4−. • Cimetidine: ∼300 mg qid adjusted for age, qid for 24 to 72 hours before exam. 20 mg/kg/day for pediatrics for 2 days before study. An additional dose may be administered 1 hour before exam. This inhibits the release of pertechnetate from the ectopic mucosa into the bowel lumen and increases gastric uptake (or use ranitidine: IV 1 mg/kg pediatrics and adults up to 50 mg 174

10766-32_CH32.qxd

12/3/07

4:39 PM

Page 175

Chapter 32 — Meckel’s Diverticulum

over 20 minutes or 2 mg/kg/dose PO pediatrics and 150 mg/dose adults, 1 hour before imaging). Pentagastrin and cimetidine should not be given together. • Potassium perchlorate: Blocks uptake of pertechnetate by thyroid and salivary glands. • If delays are required, instruct patient to void between imaging sessions.

NORMAL RESULTS • Increased gastric uptake and renal activity in first 10–20 minutes of study, decreasing as study progresses. • Bladder uptake increases with time.

ABNORMAL RESULTS • Focally increased activity not associated with normal structures, particularly in right lower quadrant or mid-abdomen. • Activity will appear anterior on a lateral view proving no relation to any ureteral activity. • Activity in Meckel’s will appear at the same time normal gastric mucosa presents and remains in same position despite peristalsis. • Usually appears within 30 minutes but may take up to 60 minutes depending on the amount of gastric mucosa present. • Other reasons for activity in a Meckel’s scan: other duplication cysts with ectopic gastric mucosa, renal (ectopic kidney, ureteral stenosis), very active bleeding sites, tumors, inflammatory bowel disease. • Drug interactions: Increased blood pool activity—aluminum containing antacids, sulfonamides, pyrophosphates, other radiopharmaceuticals present in system. Decreased uptake in Meckel’s tissue—the same list.

ARTIFACTS • Radiographic study before scan for Meckel’s may mask activity. • Barium studies and proctoscopy may present as false-positive results. • Early renal activity, unassociated ectopic gastric mucosa, malrotation of the ileum, blood pooling from inflammation, bladder, laxatives, endoscopy causing bowel irritation, or tumors may give false-positive reading for Meckel’s • Normal gastric activity, once transported to the bowel, can be mistaken for Meckel’s giving a false-positive. • Radiotracer may present in renal pelvis and duodenum, which are difficult to separate. This is done by lateral views. • False-negative results could be caused by small Meckel’s, no gastric mucosa (no activity), ischemia, necrosis, rapid radiotracer wash-out, barium enema, upper GI exam, recent NM bleeding study, or obscured by normal activity.

NOTE • “Rule of twos” for Meckel’s: • Occurs in 2% of population • Occurs within 2 feet of the ileocecal valve • Average length of 2 inches • Usually symptomatic by age of 2 175

10766-32_CH32.qxd

12/3/07

4:39 PM

Page 176

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Remnant of the omphalomesenteric duct. • Only 50% of Meckel’s diverticula contain gastric mucosa. Those that do not are undetectable using 99mTc O4−. • Most Meckel’s are asymptomatic (96%). Complications: Bleeding (95% of these have gastric mucosa), Intussusception, Intestinal obstruction (volvulus), Inflammation • Diverticulum is a sac or pouch formed at the weak point(s) in the walls of the alimentary canal. They are caused by internal pressure (pulsion diverticulum) or pulling from external pressure (traction diverticulum). They occur from the pharynx to the colon. Colonic diverticula, affecting primarily the lower portion, can be nonsymptomatic in causing abdominal pain and altered bowel habits. • Polyps—a growth with a pedicle, usually benign, protruding from mucus membrane. They can occur in the sinuses, ears, stomach, and bowel. Bowel polyps are usually removed during routine colonoscopies or surgery. If left unattended, however, the tissue may turn cancerous and is a leading cause of colon cancer.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

Are you actively bleeding?

Y

N

Do you have blood in your stool?

Y

N

Have you had any recent related examinations, e.g., NM GI bleeding scan or contrast radiographic examinations?

Y

N

Do you have any recent laboratory results with you?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long? Do you have any pain? If so, where and for how long?

If so, is it dark or bright red?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. 176

10766-32_CH32.qxd

12/3/07

4:39 PM

Page 177

Chapter 32 — Meckel’s Diverticulum

Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gastrointestinal Bleeding and Meckel’s Diverticulum Scintigraphy. Version 1.0, February 7, 1999. SNM.org. Weissleder R, Rieumont MJ, and Jack Wittenberg. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

177

10766-33_CH33.qxd

12/3/07

4:41 PM

Page 178

chapter

33

NeutroSpec®: Radioimmunoscintigraphy (RIS) for Infection NeutroSpec® was voluntarily removed from the market on December 19, 2005 following several adverse events caused by off-label use of the product. This chapter is included because the companies involved are currently seeking re-approval from the FDA.

RADIOPHARMACY Radionuclide •

99m

1/2

Tc: t 6.02 h Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-fanolesomab—a murine IgM monoclonal antibody.

Quality Control • Chromatography, radiochemical purity of ≥90%.

Adult Dose Range • 10–20 mCi (370–740 MBq) • Pediatrics 5 and older: 0.12 mCi/kg (4.44 MBq/kg) to a maximum of 20 mCi (740 MBq)

Localization • Compartmental. Blood flow. Fanolesomab targets the carbohydrate portion of 3-fucosylN-acetyllactosamine that defines the cluster of differentiation 15 (CD15) antigen. CD15 is expressed on the surface of polymorphonuclear neutrophils (PMNs), eosinophils, and monocytes. 99mTc-fanolesomab radiolabels white blood cells and myeloid precursors. Fanolesomab binds in vivo to white blood cells that migrate from the vascular space to the interstitial space by the process of diapedesis and then by chemotaxis, localize at the infection site. 178

Method of Administration • Intravenous injection using butterfly or IV catheter. The access must be patent with no possibility of extravasation. Flush with a minimum of 10 cc saline. • Monitor patient for hypersensitivity reaction to injection, e.g., redness in area of injection, flushing, nausea and vomiting, headache, dyspnea, hypotension, etc. • Injection may be administered under camera for immediate dynamic study.

10766-33_CH33.qxd

12/3/07

4:41 PM

Page 179

Chapter 33 — NeutroSpec®: Radioimmunoscintigraphy (RIS) for Infection

INDICATIONS • • • • • • • • • •

Detection and localization of acute appendicitis (in patients 5 years or older). Detection and localization of acute and chronic osteomyelitis. Assessment of pain in right lower quadrant of abdomen. Assessment of fever. Assessment of nausea. Assessment of elevated white blood cell count. Detection and localization of acute abscesses (e.g., liver, renal, intra-abdominal sepsis). Detection and localization of infection (fever of unknown origin [FUO]). Detection of inflammatory disease (e.g., bowel, cellulites, genitourinary). Differentiation of pulmonary infiltrates (infarct versus pneumonia).

CONTRAINDICATIONS • Hypersensitivity to murine products. • Patient susceptible to HAMA (human antibody to mouse antigen) reaction.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• 20% window, 140 keV • Dynamic: 10 frames for 4 minutes/frame • Statics: First for 1 million counts, remaining for time of first image. • Whole body: 10 cm/min or less. • SPECT: 360°, 64 steps, 20 sec/step.

Collimator • Low energy, all purpose or low energy, high resolution

PROCEDURE

(TIME: ~2 HOURS)

• Position patient supine on table. • Place camera anterior over abdomen, lower edge of liver in upper field of view (approximately the midline of the patient).

Immediate Imaging • • • •

Inject patient and start dynamic images. When complete, patient is to ambulate for 15 minutes, then void. Reposition patient supine on table. Acquire anterior, posterior, 10–25° RAO and LAO images of lower abdomen. Static anterior image for 1 million counts, remaining images for time of anterior image. • Acquire a standing image with camera anterior facing lower abdomen. • Whole body may be requested if assessing for fever, elevated white blood cell count, inflammation, or infection. Acquire images from head to mid thigh. Include extremities if that is an area of interest. 179

10766-33_CH33.qxd

12/3/07

4:41 PM

Page 180

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Other Options • 4 hour: Whole body, anterior/posterior and SPECT (for limited areas of interest and equivocal findings on whole body). • 24 hour: Whole body, anterior/posterior.

NORMAL RESULTS • Uptake in blood pool, liver, kidney, spleen, and red marrow. • Uptake in the uterus has been noted consistent with blood pool activity.

ABNORMAL RESULTS • Irregular, asymmetric uptake in abdominal right lower quadrant (appendix zone) in as little as 30 minutes to 60 minutes. Presentation at this time obviates the need for any more imaging. Imaging should be carried out to 90 minutes if initial imaging is negative. • Uptake remains constant or increases in intensity in follow up images. • Area of infection or inflammation will accumulate activity as white blood cells migrate over time by the process of diapedesis and chemotaxis to site(s).

ARTIFACTS • Bladder activity may hamper interpretation. • Patient may need urinary catheterization.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Are you diabetic?

Y

N

Have you had a previous scan using murine products?

Y

N

Are you allergic to murine products?

Y

N

Have you had a HAMA reaction to any study?

Y

N

Do you have abdominal pain or elsewhere?

Y

N

Do you have a fever?

Y

N

Have you experienced recent nausea and/or vomiting?

Y

N

Have you had any recent trauma to the abdomen?

Y

N

If so, what type and for how long?

If so, where and for how long?

180

10766-33_CH33.qxd

12/3/07

4:41 PM

Page 181

Chapter 33 — NeutroSpec®: Radioimmunoscintigraphy (RIS) for Infection

Do you still have your appendix?

Y

N

Has it ever been a problem in the past?

Y

N

Do you have any blood-borne infections?

Y

N

Have you had any recent infections?

Y

N

Have you had any abdominal surgery?

Y

N

Do you have a history of bowel disease?

Y

N

Have you had recent laboratory tests, e.g., WBC counts?

Y

N

Have you had any recent related studies, e.g., PET, MRI, CT, NM?

Y

N

Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Marieb EN. Human Anatomy and Physiology, 2nd ed. Redwood City, CA: Benjamin/Cummings, 1992. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. NeutroSpec™ (Fanolesomab): Package insert. Palatin Technologies, Inc. Cranbury, NJ. Mallinckrodt, Inc. St. Louis MO 2004. Thomas C, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: FA Davis, 1993. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

181

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 182

chapter

34

OctreoScan® RADIOPHARMACY Radionuclide •

111In t 1/2: 2.8 days Energies: 173, 247 keV Type: EC, γ, accelerator

Radiopharmaceutical •

Quality Control • Chemical tag must be >90%

Adult Dose Range • 6 mCi (222 MBq)

111

In-pentetreotide, a DTPA (diethylenetriaminepentaacetic acid) conjugate, or octreotide (labeled peptides), a long-acting analog of the hormone somatostatin

Method of Administration • Intravenous using butterfly catheter and 10 mL of flush

Localization • Extravasation and chemical bonding to somatostatin receptors, concentrating in tumor cells with a high density of receptors

INDICATIONS • Detection and localization of somatostatin receptors on primary and metastatic neuroendocrine tumors, e.g., carcinoid, pituitary, small cell carcinoma of the lung, medullary thyroid carcinoma, pheochromocytomas, incidentalomas, etc. (see Note). • Detection and localization of endocrine pancreatic tumors, e.g., Islet cell tumors, primary and metastatic gastrinomas, glucagonomas, and insulinomas (less sensitive). • Detection and localization of paragangliomas and neuroblastomas. • Evaluation of elevated tumor markers, patients with a history of cancers, or known somatostatin receptor-type cancers, and staging. 182

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 183

Chapter 34 — OctreoScan®

• Evaluation of pre- and/or post-surgery patients. • Evaluation of somatostatin receptor status (positive studies are more likely to respond to octreotide therapy). • Evaluation of patients with metastatic tumors for therapy and follow-up of peptide receptor radionuclide therapy (PRRT).

CONTRAINDICATIONS • Patients with severely impaired renal function. • Do not inject through total parenteral nutrition (TPN) admixtures or into TPN IV catheters because the sugars may cause a glycosyl-111In-pentetreotide conjugate to form.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to hydrate well (two eight-ounce glasses of water) before and after injection. • Octreotide therapy patients should suspend the medication for 72 hours before injection of radiopharmaceutical. • Physician to order mild laxative (cathartic) evening before injection and continued with light meals recommended and clear liquids until after all images are completed (refer to Patient Study Preparation).

EQUIPMENT Camera

Whole Body • 512 × 1024 matrix, 10 cm/min or longer (minimum 30 minutes) head to pelvis

• Large field of view

Collimator • Medium energy, general purpose, or medium energy, all purpose

Single Photon Emission Computed Tomography (SPECT) • 360°, 64 stops, 45–60 sec/stop, 64 × 64 word matrix

Computer Set-up Statics • Abdomen; 500,000 counts or 15 min/image

PROCEDURE

(TIME: ~1–1.5 HOURS EACH SCAN DAY)

• Instruct patient to void before scan begins. The patient also is instructed to void between scanning procedures. • Place patient in supine position on table, check for attenuating items. • Images: Obtain at 4 hours (whole body sweep or statics and/or planar of abdomen), 24 hours (whole body, planar, and/or SPECT with liver, spleen, and kidneys in field of view [FOV], some require SPECT of chest, abdomen, and pelvis), 48 hours (same), and 72 hours (same, as per radiologist).

NORMAL RESULTS • Excretion is almost exclusively renal: 50% at 6 hours, 85% at 24 hours, and 90% at 48 hours (hence the need for hydration). 183

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 184

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Uptake seen in blood pool, pituitary, liver, gall bladder, spleen, kidneys, and urinary bladder. • Planar images at 4 and 24 hours can differentiate bowel contents from true uptake as there is seldom fecal contamination at 4 hours. Clarify at 48 hours. • Pituitary gland and normal thyroid gland present at 24 hours as background vascularity clears. • Image at 48 hours may differentiate between radioactivity in a tumor and normal uptake in the bowel.

ABNORMAL RESULTS • Focal areas of uptake; particularly visible as time and biologic activity diminishes background distribution.

ARTIFACTS • Carefully monitor patients with impaired renal function. • Pediatric patients or patients with insulinoma (tumor of the islets of Langerhans of the pancreas) must consult with clinician before bowel cleansing. • Do not administer in TPN admixtures or inject into TPN IV catheters; an octreotide conjugate may form. • Sensitivity to 111In-pentetreotide may be reduced in patients receiving therapeutic doses of octreotide acetate and should consider suspending therapy before administering radiotracer. • False-positive results, especially in the lungs, can occur, possibly as a result of inflammatory reaction, radiation therapy, bleomycin in the nasal region, lung hila due to a cold virus or influenza, recent surgical and colostomy sites, somatostatin receptors located in non-neoplastic, chronic inflammatory processes, e.g., granulomatous lesions (sarcoidosis, tuberculosis), Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and/or a port that was used for the injection (ensure that the tubing is not in the field of view). • False-negatives may be possible from poor somatostatin tag, poor affinity to tumor, proximity to normal uptake. • SPECT and SPECT/CT, SPECT/MRI, SPECT/PET fusion imaging may be very helpful in diagnosis. • Patient with insulinoma may become severely hypoglycemic and should have IV infusion of glucose available.

PATIENT STUDY PREPARATION Day 1 1. Purchase four bottles of magnesium citrate at drug store. Dulcolax® and Metamucil® may also be used. 2. Eat a light breakfast on morning of injection and be well hydrated. 3. After injection, drink first bottle of magnesium citrate; drink plenty of clear liquids until after scan is completed. 4. Eat a light dinner that evening, followed by the second bottle of magnesium citrate. 5. Plenty of clear liquids until after the 24-hour scan.

Day 2 1. After the 24-hour scan, eat a light lunch and dinner. 2. After evening meal, drink third bottle of magnesium citrate; drink plenty of clear liquids until the 48-hour scan is completed.

Day 3 (72-hour scan if requested by radiologist) 1. After the 48-hour scan, eat a light lunch and dinner. 2. After the evening meal, drink the fourth bottle of magnesium citrate with plenty of clear liquids until the 72-hour scan is completed. 184

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 185

Chapter 34 — OctreoScan®

PROCESSING • Slice thickness to 2 mm. • Use a low-pass filter, e.g., Butterworth, 0.4 Nyquist cutoff, and seventh-order (or 0.5 cutoff and fifth-order).

NOTE • Somatostatin is a linked, 14-amino acid, cyclic polypeptide neuropeptide that inhibits growth hormone secretion. In doing so, it slows the growth of neuroendocrine tumors. It unfortunately has a short biologic half-life, meaning when used as a therapy, constant infusion is needed for the effect, with a strong rebound effect (recurrence) once therapy is stopped. • OctreoScan® (octreotide) is a somatostatin analog, binding to somatostatin receptors on tumor tissues to suppress hormonal hypersecretions from endocrine-secreting tumors, e.g., carcinoids, VIPomas (vasoactive intestinal peptide-related tumors—gastrinomas). It has reduced hepatobiliary excretion, primarily clearing through the kidneys. This lessens the gastrointestinal activity and allows for better visualization of abdominal tumors. • Positive OctreoScan® patients are candidates for octreotide therapy because there are somatostatin receptors that provide a high possibility of controlling hormonal hypersecretion. • Neuroendocrine tumors with APUD (amine precursor uptake and decarboxylation, neuroendocrine) characteristics include the following: • Carcinoids • Islet cell tumors • Paragangliomas • Medullary thyroid carcinomas • Pheochromocytomas • Small cell lung cancers • Pituitary tumors • Others that possess somatostatin receptors include the following: • Meningiomas • Neuroblastomas • Astrocytomas • Lymphomas • Merkel cell tumors • Breast cancers • Tumor markers • CA 19-9 Pancreas, colon, hepatobiliary, gastric cancer • CA 15-3 Metastatic breast cancer • CA 12-5 Ovary, colon, upper GI, other gynecologic cancers • CA 27-29 Ovary (primarily), breast (to a lesser degree) • CEA Colon (primarily), pancreas, lung, breast (to a lesser degree) • PSA Prostate cancer

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

If so, what type and for how long? (continued)

185

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 186

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have any pain?

Y

N

Are you on TPN?

Y

N

Have you ever had any therapeutic doses of octreotide acetate?

Y

N

Do you have a history of insulinomas?

Y

N

Do you have impaired renal function?

Y

N

Have you had any related studies, e.g., PET, MRI, CT, or NM?

Y

N

Y

N

Y

N

If so, where and for how long?

Female patients: Are you pregnant or nursing? When was your last menstrual period? Have you had a hysterectomy or are you in menopause? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with In-111 Pentetreotide. Version 1.0, February 21, 2001. SNM.org. Soudry G. Somatostatin Receptor Imaging. http://www.med.harvard.edu/JPNM/TF94_95/May30/ WriteUpMay30.html Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

186

10766-34_CH34.qxd

12/3/07

4:42 PM

Page 187

Chapter 34 — OctreoScan®

Notes

187

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 188

chapter

35

Parathyroid Scan (Dual-Isotope Subtraction Technique and Single-Isotope Two-Phase) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator • 201Tl t1/2: 73 hours Energies: 68–80 keV k x-ray, 135, 167 keV Type: EC, γ, accelerator • 123I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator.

Radiopharmaceutical • • •

99m

Tc as pertechnetate Tl as thallous chloride 99mTc-sestamibi (hexakis[2-methoxyisobutylisonitril]) • 99mTc-tetrofosmin (1,2-bis[bis(2-ethoxyethyl)phosphino]ethane) • 123I-sodium iodide 201

188

Localization TcO4−: Active transport into normal thyroid tissue. • 201Tl-chloride: Similar to potassium, distributes with Na/K pump and enters thyroid and parathyroid tissue with blood flow, as well as into adenomatous and hyperplastic tissue. • 99mTc-sestamibi/tetrofosmin: Passive transport in proportion to blood flow into thyroid and normal and abnormal parathyroid tissue, remaining longer in adenomatous and hyperplastic tissue. Prolonged sestamibi retention within the parathyroid adenoma is, to some, related to the presence of mitochondrial rich oxyphil cells within the lesion. • 123I-sodium iodide organified by thyroid and held in cells or follicular lumen. •

99m

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 189

Chapter 35 — Parathyroid Scan (Dual-Isotope Subtraction Technique and Single-Isotope Two-Phase)

Quality Control TcO4−: Chromatography, moly and Al breakthrough • 201Tl-chloride: Chromatography > 95%, use within 7 days • 99mTc-sestamibi/tetrofosmin: Chromatography > 90% • 123I-sodium iodide: Assay capsule(s) in dose calibrator to confirm amount of radioactivity •

99m

99m

Tc-sestamibi/tetrofosmin: 16–30 mCi (592–1110 MBq) • 123I-sodium iodide: 200–300 uCi (7.4–11.1 MBq)

•

Method of Administration • Intravenous injection, some use butterfly for subtraction method for patient comfort (instead of two injections) • 123I-sodium iodide: By mouth (PO)

Adult Dose Range • •

TcO4−: 5–12 mCi (185–444 MBq) Tl-chloride: 2–3 mCi (74–111 MBq)

99m 201

INDICATIONS • Detection and localization of primary and secondary parathyroid cancer. • Identification of single adenomas, multiple adenomas, or glandular hyperplasia in patients with newly diagnosed hypercalcemia and elevated parathyroid hormone (PTH) levels. • Localization of cancer for surgery candidates. Some, using probe, localize and bring straight to surgery. • Localization of parathyroid tissue (aberrant, ectopic hyperplastic or neoplastic glands) after surgery for persistent or recurrent hyperparathyroidism (elevated serum calcium and PTH).

CONTRAINDICATIONS • Patient on calcium medications. • Patient on thyroid medications and/or received recent iodine contrast studies (patient should be off thyroid medications for 5 days, contrast studies at 7–10 days). • Patient too agitated or prone to movement or claustrophobia.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. • Explain the procedure and the need to remain still during acquisitions. • Palpate neck to localize any abnormal parathyroid or thyroid tissue.

EQUIPMENT Camera • Large field of view

Collimator • Pinhole (5-mm insert) or low energy, all purpose, or low energy, high resolution

processing image subtraction, correct peak for radiotracer Single Photon Emission Computed Tomography (SPECT) • Circular or noncircular, 360°, 128 × 128 matrix, 64 stops, 20–25 sec/stop; centered for region of interest

Computer Set-up Planar • 128 × 128 × 8 or 64 × 64 × 16 matrix, 1 million counts or 300–900 sec/image, computer 189

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 190

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PROCEDURE (TIME: SUBTRACTION: ~1.5 HOURS; SESTAMIBI/ TETROFOSMIN: ~30 MINUTES, THEN DELAYS ~15–30 MINUTES)

Dual-Isotope Subtraction Technique • • • • •

Place patient in supine position, pillow under shoulders, head back, neck extended. Position camera anterior over extended neck and mediastinum. Remove any attenuating necklaces or pendants. Immobilize head if necessary. Instruct patient to remain motionless during acquisitions. Inject 201Tl.

Procedure A • Within 2–3 minutes of injection, obtain a 300-second image, preferably with a pinhole collimator, looking for focal uptake between heart and thyroid. • Immediately follow image with a 900-second image of thyroid centered in field of view (FOV). • Immediately follow image with injection of 5–10 mCi of 99mTcO4−. Wait 5 minutes. • Obtain a 900-second image of thyroid. • Run subtraction program, if necessary, to separate 201Tl accumulation from 99mTcO4− trapping. Procedure B • Position camera anterior with thyroid near top of FOV, looking for focal uptake between heart and thyroid using a high-resolution collimator, 128 × 128 matrix, zoom 1.3. • Obtain a 180-second image. • Reposition camera to center thyroid. • Obtain dynamic images; 1 frame/min for 15 minutes, zoom 2.6. No patient motion. • Inject 5–10 mCi of 99mTcO4− and begin dynamic images; 1 frame/min for 15 minutes, zoom 2.6. No patient motion. • Run subtraction program, if necessary, to separate 201Tl accumulation from 99mTcO4− trapping. Procedure C • • • • • •

Wait 30 minutes after injection before imaging. Acquire anterior image of neck and mediastinum with LEHR collimator, 100,000 counts. Acquire anterior image of thyroid with pinhole if available, 100,000 counts. Inject 99mTcO4−; wait 20 minutes. No patient motion. Acquire anterior image of thyroid, 100,000 counts. Run subtraction program, if necessary, to separate 201Tl accumulation from 99mTcO4− trapping.

Dual-Isotope with 123I-sodium iodide, 99mTc-O4−, and 99mTc-sestamibi/tetrofosmin: • •

• •

• • • •

123

I: Patient given 200–300 uCi 123I PO. Consideration should be given to an early start time because of the lengthy protocol. At 3–4 hours after administration, take a single image with 300,000 to 500,000 counts or 300 seconds using 10% window for 123I (at 159 keV). This image can be used for digital subtraction or qualitative visual comparison. Patient is then injected with 99mTc-sestamibi or 99mTc-tetrofosmin. At 15 minutes after injection, patient imaged with two 600 second anterior pictures, one using 10% windows for 99mTc (at 140 keV) and one using 10% window for 123I (at 159 keV). Imaging may also include right and left anterior oblique angles. At 3 hours after injection, image again using same parameters. Normalize 123I images of each acquisition time to the 99mTc images of each acquisition time. Subtract the normalized 123I images from the 99mTc images at each time. Images are evaluated at each imaging time for possible parathyroid adenoma residual activity.

190

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 191

Chapter 35 — Parathyroid Scan (Dual-Isotope Subtraction Technique and Single-Isotope Two-Phase)

Tc-O4− : inject 1–2 mCi (37–74 MBq) pertechnetate. At 15 minutes, take a 300-second image using 10% windows for 99mTc (at 140 keV). This image is used for digital subtraction. • Patient is then injected with 99mTc-sestamibi or 99mTc-tetrofosmin. • Imaging and processing as above. •

99m

Single-Isotope Two-Phase: (Thyroid Phase, Parathyroid Phase) • Inject patient with either sestamibi or tetrofosmin. Wait 15 minutes to obtain image. Remove any attenuating necklaces or pendants. • Place patient in supine position, pillow under shoulders, head back, neck extended. Immobilize head if necessary. • Position camera anterior over extended neck and mediastinum. • Using LEAP/LEHR collimator, acquire 300–600 second (≥ 1 million counts), anterior, RAO, and LAO 30° images. Obtain marker image: Thyroid cartilage and suprasternal notch (SSN) if protocol. Be sure to include salivary glands to mediastinum with anterior images. • Optional: Obtain repeat images after 15 more minutes if protocol. This may work depending on the size and weight of the suspected adenoma. If this accelerated method of imaging is to be used, give lemon to the patient on the day of procedure to reduce salivary uptake. • Repeat images at 1.5–3 hours after injection (especially if preoperatively). • Repeat images at 4–6 hours after injection if there are questionable areas. • SPECT acquisition may also be a consideration. Acquire at 30 minutes after injection and delay at 2 hours. Reconstruct with Butterworth filter, cutoff .5, power 10. Check with physician. • If a suspected adenoma fades on delayed images, patient can be re-injected with 99mTc-pertechnetate and imaged to compare for equivocal focus of tracer. Concentrated focus indicates a likely thyroid adenoma, or if it presents as a relative defect, an indication for parathyroid adenoma.

NORMAL RESULTS • Dual-isotope subtraction technique: • No increased 201Tl activity within or outside normal thyroid tissue. • Normal parathyroid tissue does not accumulate 201Tl or 99mTc-sestamibi/99mTc-tetrofosmin activity. • 99mTc-sestamibi/99mTc-tetrofosmin: initially; heterogeneous uptake by thyroid, salivaries, heart, gut. • Delays; heterogeneous washout, no focal points of lingering uptake. • 123I uptake in thyroid tissue as in normal thyroid uptake study. • Normal parathyroid tissue does not accumulate 123I-sodium iodide. • Single-isotope two-phase: • Initially; heterogeneous uptake by thyroid, salivary glands, heart, gut. • Delays; heterogeneous washout, no focal points of lingering uptake.

ABNORMAL RESULTS • Dual-isotope subtraction technique: Area(s) of increased 201Tl within and outside normal thyroid tissue. Increased focal area(s) of 99mTc-sestamibi/tetrofosmin uptake after subtraction of 123 I-sodium iodide especially on delays. • Single-isotope two-phase: Washout of thyroid tissue with focal area(s) of increased activity on delayed images anywhere from salivary glands to mediastinum. Obliques help define position of abnormal uptake in neck area. SPECT images especially in cine mode are known to be helpful for localization. • Surgery: Focal areas usually located by small hand-held gamma probe. Once resected, the tissue should register at least 20% to 50% (some say 10 times) higher than background thyroid tissue. • Parathyroid adenomas are usually well encapsulated, benign lesions. They are very small with ectopic lesions being somewhat larger. 191

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 192

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ARTIFACTS • • • • •

No patient movement is critical in subtraction method and with use of pinhole collimator. May not visualize ectopic parathyroid tissue. May not visualize abnormal tissue < 300 mg in size. Parathyroid adenomas can wash out quickly in two-phase studies or fail to present. False-positives: Patient motion, thyroid disease (cold nodule from thyroid neoplasm, adenoma/colloid cyst, carcinomas, focal Hashimoto’s thyroiditis, metastasis, lymphoma, sarcoid), MNG (multinodular goiter), uptake in a cervical lymph node, parathyroid carcinomas. Images should be correlated with an ultrasound. • False-negatives: Patients with parathyroid hyperplasia. • Interference from medications, recent radiographic contrast studies. • Depending on the camera, for severely claustrophobic patients, point the camera outward, seat the patient facing camera with chin on camera and area of interest in view, secure patient with tape to ensure no movement. This method has been useful in obtaining diagnostic images.

NOTE • The parathyroid glands synthesize, store, and secrete PTH. 80% of the normal population has four parathyroid glands: 15% have more, 5% have fewer. Normal glands are only a few millimeters in size. They are normally located one each on the two upper poles and two lower poles of the thyroid gland. There are occasions in which some inferior migrating gland continues with the thymus into the mediastinum. • Always check the anterior thorax, especially in women, for focal areas when using 99mTc-sestamibi/ 99mTc-tetrofosmin as they localize in breast cancer.

Parathyroid hormone (PTH—also parathormone) • 84-Amino-acid polypeptide. Quickly cleaved into an active amino-terminal fragment with a Tb of 3–5 minutes and an inactive carboxy-terminal fragment with a Tb of several hours. • Regulates serum calcium and phosphorus levels. • Increases osteoclastic activity in bone or increases release of ionic calcium from bone. • Decreases excretion of calcium from kidneys while increasing excretion of phosphates, sodium, and potassium. • Acts indirectly with vitamin D to increase intestinal absorption of calcium.

Hyperparathyroidism • Glandular disorder characterized by increased PTH synthesis and release causing a rise in serum calcium and drop in inorganic phosphates caused by: • Primary: Spontaneously and idiopathically. Seen in 1 in 700 adults usually between the ages of 40 to 70. The cause is single parathyroid adenoma 80–86%, two or more 1–4%, multiglandular hyperplasia in 12–15% and functioning parathyroid carcinoma 1–3%. • Secondary: Parathyroid glands hypertrophy due to chronic low serum calcium levels, e.g., chronic renal insufficiency. It characteristically presents with enlarged hyperplastic parathyroid glands. In patients with hyperplasia, the glands may be too small to image. • Tertiary: Long-standing secondary hyperparathyroidism becomes completely autonomous. • Head and neck radiation. • Hereditary disorders: Multiple endocrine neoplasia type I (MEN I), MEN IIa, and familial hypocalciuric hyperparathyroidism (FHH). • More common in females 3:1. Peaks in 5th decade of life. • Carcinoma is only rarely associated with hyperparathyroidism and these have markedly elevated calcium levels. Adenomas present with minimal elevation of their serum calcium levels and have complications from hypercalcemia, e.g., urolithiasis or nephrolithiasis. Most adenomas are near the thyroid gland with ectopic lesions located in the anterior mediastinum (parathymic tissues). 192

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 193

Chapter 35 — Parathyroid Scan (Dual-Isotope Subtraction Technique and Single-Isotope Two-Phase)

Hypercalcemia • > 10.5 mg/dL serum calcium. Release of Ca2+ from bone and absorption from intestine and kidneys with low serum phosphate. • In addition to abnormal labs, patients often present with osteoporosis, bone cavitation, and urinary calculi (nephrolithiasis). • Symptoms include muscle weakness, fatigue, incoordination, anorexia, constipation, nausea, vomiting, dehydration, muscle and/or bone pain.

Known Causes • Hyperparathyroidism: Excessive PTH secretion. • Neoplastic adenoma • Malignant neoplastic disease: PTH is suppressed—sarcoidosis, tuberculosis, polycythemia vera, multiple myeloma, lymphoma, leukemia, solid tumors, breast, lung, and kidney cancer bone metastasis. • Patient immobilization (rare): Paralysis, multiple fractures especially with adolescent people during growth spurts. • Thiazide diuretics: Cause PTH to act on kidneys reducing Ca2+ output or release. • Milk/alkali syndrome: Overabundance of antacids for ulcers. • Vitamin A and D intoxication. Lithium can also cause an increase in Ca2+.

Hypercalcemic Crisis • ≥ 17 mg/dL serum calcium. Symptoms: Thirst, polyuria, muscle weakness, intractable nausea, abdominal cramps, obstipation (severe constipation) or diarrhea, peptic ulcer symptoms, bone pain, lethargy, mental confusion, coma, seizures, and may lead to cardiac arrest.

Hypocalcemia • Hypoparathyroidism, demineralization of cell membrane electrical potential—muscle spasm and irritability, tetany, heart electrical conduction, hyperphosphatemia, anxiety, depression.

ROLE OF TECHNOLOGIST IN OPERATING ROOM (OR) • Many institutions are using these studies to localize and resect adenomas within the parathyroid glands. The role of the technologist differs with the institution, but they generally perform the following tasks. • Inject patient as per protocol of institution. One method is 10 mCi (370 MBq) 99mTc-sestamibi two hours before surgery, image at one hour post injection. • Images taken as suggested above, patient and images are brought to preoperative area to prepare for surgery. • In OR • Surgeon or technologist uses gamma probe to locate “hot” gland(s). (Only in some institutions, others hire a company to manipulate the probe.) • Technologist or nurse takes resected gland(s) and material to pathology for inspection. • Technologist assays material for storage (10 half-lives) if > 0.05 mR at 1 m or disposal if background ≤ 0.05 mR at 1 m. The material can be stored in the hot lab until background or in the pathology lab if there is a designated area. • Technologist assays pathology room and equipment for contamination. • Technologist assays OR for contamination after removal of patient. 193

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 194

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history or family history of parathyroid disease?

Y

N

Do you have a history or family history of thyroid disease?

Y

N

Do you have osteoporosis?

Y

N

Are you sensitive to pain?

Y

N

Do you have kidney disease or stones?

Y

N

Have you had recent thyroid or parathyroid surgery?

Y

N

Have you had head and neck radiation therapy?

Y

N

Have you noticed any swelling or tenderness in your neck?

Y

N

Have you had any recent iodine contrast studies?

Y

N

Have you had any related studies, e.g., NM, PET, MRI, CT, US?

Y

N

Do you have results of recent laboratory tests, particularly Ca2+ and PTH?

Y

N

Females: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

What medications are you taking?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Cardiac Scintigraphy. Revised 2004, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. 194

10766-35_CH35.qxd

12/3/07

4:43 PM

Page 195

Chapter 35 — Parathyroid Scan (Dual-Isotope Subtraction Technique and Single-Isotope Two-Phase)

Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Smeltzer SC, Bare BG. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 8th ed. Philadelphia: Lippincott, 1996. Wilson, MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

195

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 196

chapter

36

Positron Emission Tomography (PET) COINCIDENCE IMAGING: AN OVERVIEW Radiopharmacy • Positron emitters (partial listing) Radionuclide: t1/2 11

C (→11B)

18

F (→18O)

13

N (→13C) O (→15N) 82Rb (→82Kr) 15

Energies (MeV) (min) (max) (ave.) 20.4 0.96 .320

Type:

Decay:

Cyclotron

109.8

99.8% positron 0.2% EC 97% positron 3% EC 100% positron 99.9% positron 96% positron 4% EC

9.96 2.04 1.27

0.64

.202

Cyclotron

1.19 1.72 3.35

.432 .696 1.385

Cyclotron Cyclotron Generator

Range (water) (max) (mean) 4.1 mm 1.1 mm 2.4 mm

0.6 mm

5.1 mm 7.3 mm 14.1 mm

1.5 mm 2.5 mm 5.9 mm

Radiopharmaceutical

Localization

• Radiolabeled biochemical compounds. The number of usable isotopes is growing dramatically as are the chemical tags used in physiological processes. • 11C-acetate, choline, or methionine 20-minute half-life requires on-site cyclotron • 18F-fluorodeoxyglucose • 13N-ammonia • 15O-water, requires on-site cyclotron • 82Rb-chloride, requires on-site generator

• Biochemical metabolism within the cell. For 18F-FDG, tumor cells of many types use large amounts of glucose for energy and express glucose transporters, e.g., GLUT1 and increased hexokinase activity, e.g., HK2. FDG is transported into the cells and phosphorylated by hexokinase. The 18F-FDG is trapped in the cells in proportion to the glucose transport allowing imaging of normal and abnormal uptake within the different tissue.

196

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 197

Chapter 36 — Positron Emission Tomography (PET)

The exception is the liver because of enhanced dephosphorylation and washout. 18F-FDG reaches the peak of accumulation 45 minutes after injection. The best target to background ration is at 2 to 3 hours with high uptake in the brain, heart, and urinary system.

Quality Control • Similar to standard radiopharmaceuticals, performed at plant. • Solution must be clear and free of particulate matter when observed. • 18F for instance: The half-life must be within 105 to 115 minutes (radionuclide identity). • Must be at least 96% or better radiochemical purity from free 18F. • No less than 90% radiochemical purity from tagged chemical.

• Additional tests for impurities, sterility, and bacterial endotoxins must prove to be within limits.

Adult Dose Range • 4–20 mCi (148–740 MBq). • Lower doses are appropriate (4–5 mCi [148–185 MBq]) for gamma camera-based PET acquisitions because of the count rate.

Method of Administration • Standard intravenous injection quickly because of the kiloelectron volts (keV or KeV) of radiotracer. • Time, distance, and shielding considerations are of particular importance requiring special changes to the typical nuclear medicine department (packages available).

INDICATIONS BRAIN • Imaged patterns of metabolic activity can change depending on input at the time of the study (e.g., eyes open or closed, sounds, smells, movement, thought). • Evaluation of cerebrovascular disease: Physiologic affects of blood flow due to strokes and transient ischemic attacks (TIAs). • Evaluation of epilepsy: • Localization of focus of epilepsy. • Findings are similar to single photon emission computed tomography (SPECT) except more sensitive interictally (between attacks). • Evaluation of movement disorders: • Huntington’s; decreased metabolism in caudate nuclei, decreased D2 receptor density. • Parkinson’s; reduced basal ganglia uptake of 18F-DOPA (3,4-dihydroxyphenylalanine). • Evaluation of psychiatric disorders: Findings are still highly debated. • Localization of regional metabolic abnormalities and changes. • Schizophrenia: • Decreased perfusion and metabolism of frontal lobes. • Increased perfusion and metabolism in left hemisphere. • Increased subcortical:cortical ratio. • Mood disorders: • Globally diminished blood flow and metabolism in depressed patients. • Differences noted in scan appearance between unipolar and bipolar depressed patients. • Evaluation of dementia: Reveals regional metabolic patterns (e.g., Alzheimer’s). • Evaluation of tumors: • Evaluation of grade of glioma and true extent of brain tumor. • Differentiation of recurrent tumor from scar and radiation necrosis. • Evaluation of chemotherapy; effect on tumor metabolism. CARDIAC • Detection and evaluation of coronary artery disease (CAD) (10–15% more sensitive than SPECT, specificity improved because of less soft tissue attenuation). • Evaluation of intervention. • Differentiation of ischemia (increased FDG uptake) and infarction. Patient fasting while exercising. 197

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 198

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Differentiation of hypoperfused viable tissue from infarction. • PET will show enhanced FDG uptake and glycolysis in affected region and decreased 13N-NH3 (blood flow) if viable. • Decreased FDG and decreased 13N-NH3 indicates scar tissue. ONCOLOGY • Evaluation of grade and true extent of brain tumor for therapy intervention. • Differentiation of recurrent tumor from scar and radiation necrosis. • Evaluation of chemotherapy; effect on tumor metabolism.

CONTRAINDICATIONS • Patient too agitated, uncooperative, or claustrophobic to remain still for acquisition. • Because PET involves cellular metabolism, drug and food ingestion, or lack thereof, bears specific consideration for each study. • Too much muscle activity prior to examination. • Patient movement between transmission attenuation correction scan and emission scan (diagnostic PET study) will result in misalignment artifacts. • Free fluorine tends to go to the bones.

PATIENT HISTORY • Patient histories vary with the scan and are basically similar to the standard nuclear medicine procedures. • There is more emphasis on medications and food concerning glucose intake and physical activity before the studies.

PATIENT PREPARATION • • • • • • • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Instruct patient to remain NPO after midnight prior to exam. Instruct patient to refrain from exercise, caffeine, or tobacco from 12 hours prior to exam. Physician is to discontinue all medications on the morning of exam. Physician is to instruct diabetic patients take half dose. Instruct patient to be fully hydrated for exam (at least two glasses of water 1 hour before exam) unless contraindicated for other reasons. Instruct patient to bring or make available all medical records and prior exams. Instruct patient to arrive 3 hours in advance of scheduled exam time and to plan on half day for entire exam. Instruct patient to notify department immediately if there is a change in plans because of elaborate scheduling and radiopharmaceutical quality control and delivery. Instruct patient to remain calm and no movement throughout imaging. Instruct patient that once injected, to be extremely careful about urine and body fluid contamination.

EQUIPMENT • Camera and coincidence detection time • Bismuth germanium oxide (BGO, 12 nanoseconds), gadolinium oxyorthosilicate (GSO, 8 nanoseconds), lutetium oxyorthosilicate (LSO, 6 nanoseconds), and sodium iodide (NaI, 8 nanoseconds) crystal cameras (optimum thickness is .75 in.). • Energies are set for ∼250 to 600 keV. Others include a barium fluoride (BaF2) detector. 198

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 199

Chapter 36 — Positron Emission Tomography (PET)

• Collimator • Electronic collimation, high energy, high resolution (for 511 keV) for NaI cameras. • Detector array: rings (18–32), block detectors of crystal material, 10,000–20,000 crystals (4 × 4 × 30 mm), 36–64 crystals per block. • Other: Hexagonal array or a ring of large curved thallium-doped sodium iodide crystals, or dual opposed arcs of small detectors that rotate around the axis of the patient. • Computer set-up • PET and coincidence counting software necessary. • Limited field tomographic imaging: When abnormalities are localized to one area, e.g., lung carcinoma, hilar lymph node involvement. • Dynamic tomographic imaging: Multiple sequential three-dimensional imaging in a limited field, e.g., for quantitation of regional metabolic rates. • Whole body tomographic imaging: Sweep of entire body for abnormal FDG uptake. • Some cameras acquire similar to SPECT in that the cameras rotate around patient. • Attenuation correction: Loss of true events through photon absorption in tissue or scatter out of detector field of view. In a large person, attenuation of counts could be as high as 50% to 95% increasing image noise, distortion, and artifacts. Attenuation correction is needed for qualitative assessment of activity on regional or whole body imaging as well as quantitative measurements of tracer uptake, e.g., standardized uptake values (SUVs). • Methods: Calculated correction based on emission data of body contour and used primarily for brain/head scans and measured correction using transmission scans using an external source of radiation for chest, abdomen, pelvis, and whole body where attenuation is variable. Transmission attenuation correction involves acquiring a map of body density and applying the appropriate algorithms to the PET acquisition (see chapter on transmission scans). • PET/CT scanners can obtain maps using x-rays from CT during a single breath-hold as opposed to external radionuclide sources. Some PET/CT scanners include spiral CT and can be used for diagnostic imaging as well as attenuation correction. In some states, the nuclear medicine technologist can run the CT portion if it is for attenuation correction and anatomical localization. They must be appropriately trained and certified to do any type of diagnostic CT. Please also refer to the chapter on SPECT and Hybrid Imaging Overview. • SUV: Standardized uptake values. An index for FDG accumulation in tissue. It is used to normalize the measured FDG concentration to the injected activity per gram body mass. Factors that contribute to the moderation of radiotracer uptake in tissue are • Amount of radiotracer administered • Route of administration • Biochemical processes involved with radiotracer • Perfusion of tissue of interest • Body mass and fat content • Biological condition of body systems • Competition between body chemicals and radiotracer • Natural biochemical involvement within tissue • Biochemical involvement of labeled metabolites in plasma • Vascularization of tissue • Time that the measurement is taken after administration • SUV quantitation requires the total administered dose, the patient’s height and weight for measurement of lean body mass and/or body surface area. Tumor metabolism may require such factors as arterial input function, determination of the plasma FDG and glucose concentrations. A calibration factor must be obtained between scanner sessions including counts/pixel/sec and dose activity concentrations in counts/mL/sec. This is by a cylindrical phantom with known concentration of β+ radioisotope and by measuring and an aliquot of that same solution in a well counter. For extremely accurate measurements, it is suggested to use the same clock when recording the time of assays, injections, and re-assays of the radiopharmaceuticals. 199

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 200

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Normal SUV for 18F-FDG: Organ Blood Brain Liver Heart Kidneys Red marrow Lungs Spleen Breast Urine (2nd hour)

% Inj. Dose 6.9 4.4 3.3 1.3 1.7 0.9

Mean SUV 2.3

Mean SUV (lean body mass) 1.7

2.5

1.9

1.0 0.7 1.9 0.5

0.8 0.5 1.7 0.4

20–40

PROCEDURE (TIME: ~ HALF DAY) • Inject patient in advance of scan or as imaging is about to begin according to protocol for particular exam. Usually, after the injection, the patient must rest comfortably for about 45 minutes before imaging. This varies depending upon the exam. • Position patient supine on imaging table arms in appropriate scan position. • Remind patient to remain motionless during acquisition. • Position cameras centering area of interest. Set parameters and start cameras. • Obtain one set of images or more as to protocol. Some require two sets of images of same area, and then sum images. Some require multiple sets of images of various areas of interest.

PROCESSING • Gamma camera reconstructions include iterative programs and should be done as per recommendations from the manufacturer for best iterations and reconstruction choices. • Dedicated PET includes • Standard transaxial reconstruction: (usually) 128 × 128 pixels or 4–5 mm. Final resolution of 9–11 mm FWHM. Filter, e.g., Shepp-Logan, cutoff 0.1. If requested, coronal and sagittal slices. • SUV: Assign ROI to tumor and blood pool areas on dynamic images. Curves are fitted with analysis information to derive metabolic rate of radiotracer. Calibrations should be done typically once or twice a week with cylinder phantom. Also, administered dose to patient should be recorded as accurately as possible. • Whole body images: Attenuation corrected and uncorrected sequential sets for each bed position are corrected for decay, rearranged into various projection images, reconstructed into stacks of transaxial images, and resliced into a set of coronal whole body images. Slices may number from 15 to 45. As with SPECT, these images can also be presented in sagittal and transaxial views, as well as being displayed in 3D rotating images. Some software allows the separation of normal physiologic uptake from abnormal pathologic uptake.

PET SCANNING • PET imaging creates functional pictures of blood flow and/or metabolism. The isotopes used for tagging allow incorporation into the first step of cellular metabolism. It is more similar to the physiologic processes of routine nuclear medicine radiopharmaceuticals than the strictly anatomical images of CT, x-ray, MRI, or even SPECT. • Medicare/Medicaid coverage: Coverage was allowed on a conditional and temporary basis as of January 1, 1998. • Medicare coverage as of 2006 (see also Coding in reference section) • Solitary pulmonary nodule: Diagnosis (characterization of indeterminate single pulmonary nodule). • Non-small cell lung cancer: Biopsy-proven screening, diagnosis, staging, staging therapy assessment, reoccurrence assessment. 200

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 201

Chapter 36 — Positron Emission Tomography (PET)

• Colorectal cancer: Diagnosis, staging, staging therapy assessment, reoccurrence assessment, localization (with rising CEA levels). • Lymphoma: Diagnosis, staging, staging therapy assessment, reoccurrence assessment. • Melanoma (excludes evaluation of regional nodes): Diagnosis, staging, staging therapy assessment, reoccurrence assessment. • Esophageal cancer: Diagnosis, staging, staging therapy assessment, reoccurrence assessment. • Head and neck cancer (excluding CNS and thyroid): Diagnosis, staging, staging therapy assessment, reoccurrence assessment. • Breast cancer: Staging, restaging, and monitoring response to therapy. • Thyroid cancer: Restaging or recurrent or residual cancers of follicular origin. • Cervical cancer: Staging as an adjunct to conventional imaging. • Brain metabolic evaluation. • Brain perfusion evaluation. • Brain refractory seizures: Presurgical evaluation. • Brain dementia: Differential diagnosis of frontotemporal dementia (FTD) and Alzheimer’s disease (AD) or CMS approved practical clinical trial. • Myocardial perfusion: Stress and rest. • Myocardial viability: Primary or initial diagnosis, inconclusive SPECT prior to revascularization. • Myocardial metabolic evaluation. • Rubidium 82 heart perfusion: Noninvasive imaging of perfusion. • Ammonia N-13 heart perfusion: Noninvasive imaging of perfusion. • Insurance may also cover • Brain cancer • Hepatocellular cancer • Ovarian cancer • Pancreatic cancer

The Positron • Positrons are positive electrons emitted from the nucleus upon decay of an unstable proton-rich isotope as it changes a proton into a neutron. • Because of the abundance of electrons (negatively charged) in the electron cloud surrounding the nucleus of these large atoms, the escaping positron collides with an electron, resulting in annihilation of the positron and electron. Some travel varying distances in tissue before losing enough energy to interact with an electron. • The resulting annihilation radiation consists of two gamma photons both of 511 keVs and expelled from the atom at approximately 180° of each other (± .25 degrees).

TECHNICAL CONSIDERATIONS • • • • • • •

• •

Considerations must be made regarding safety to compensate for the higher energies involved. Time, distance, and shielding are extremely important when utilizing PET isotopes. Lead shielding must be thicker. 18F dose rate is six times that of the same activity of 99mTc. For 99mTc, the lead half-value layer is .2 mm while the half-value layer for 511 keV is 4.0 mm. This adds considerable thickness to shielding. Tungsten is more dense and is more suited to shielding the PET isotopes (provides 1.4 times the shielding as the equivalent thickness of lead). Shipping and receiving the isotopes presents its own problems. They are packaged in routine lead-lined containers and centered in large boxes to keep the surface mR/hr within Yellow Bar II shipping standards. It is imperative for the technologist that is receiving, assaying in the dose calibrator, and handling these isotopes to do so expeditiously. The isotopes should be stored in well-shielded areas to reduce exposure to personnel and patients. 201

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 202

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Because the half-lives of these isotopes are relatively short, e.g., 18F at 110 minutes, the 10 half-life rule for decay storage of spent syringes, tubing, stopcocks, saline flushes, wipes, etc., can be accomplished by 18 to 24 hours. • The imaging area needs special consideration as to room location, camera location, restroom facilities, and patient proximity to hospital staff and other patients and cameras. • Walls may need thicker lead to reduce exposure to adjoining rooms. • The injected patient adds to occupational risks of exposure. Dosing, waiting, and imaging areas should be isolated from other cameras and staff. • These areas and restroom facilities should be planned out to minimize patient movement within the department all in an effort to reduce exposure to others and interference with other scans. • The facility may have to amend its license to be authorized to receive and use the isotopes.

QUALITY ASSURANCE: RECOMMENDATIONS FROM THE AMERICAN COLLEGE OF RADIOLOGY • Daily: Attenuation blanks, detector operation, and any necessary normalization scans. • Annual (minimum) • Spatial resolution (radial, tangential, and axial). • Count rate performance including count loss correction factor: system dead time, count rate vs. activity (prompt, random, background, net true coincidences). • Sensitivity (cps/MBq/mL) in 2D and 3D modes. • Uniformity (plane by plane in 2D and 3D) • Attenuation-correction calibration accuracy (quantification). • Linearity of bed motion. • Reproducibility of transmission rod motion (extension and retraction). • Reproducibility of lead septa motion (extension and retraction). • Image contrast and full system test (phantom scan). • PET/CT daily QA (example, differs between manufactures) • Table in CT mode. • TIP all subsystems as per manufacturer’s specifications. • Landscape table by moving table vertically and horizontally, numbers should read about +150 or −10. • CT: Tube warm-up, accept tube warm-up, start (takes about 2 minutes). Fast calibration, start (about 20 minutes). • PET: Select full QA, daily QA, “take a current reading” for transmission source. Select table move button (about 2 minutes), a graph appears. Do weekly QA if not all green. Processing allows for visual inspection of blank scan and evaluation for abnormalities. Record and store results. • Weekly QA should be done before the daily QA. Select full QA, singles, select full QA, CTC (about 3 minutes). Select full QA, CTC, select most recent acquisition, calculate. Processes in a few minutes. Enter 30 minutes for blank scan on, e.g., DLS scanner. • Quarterly QA: 2D well counter, 3D well counter, 12-hour normalization.

DETECTION • Several methods have been and are being developed to detect and utilize this phenomenon. • Special ring- or doughnut-shaped cameras using arrays of photomultiplier (PM) tubes and surrounding the patient are currently in use to capture the gamma photons and pinpoint the location of the source. There are no collimators per se, they use electronic collimation and special crystals to absorb the energy (e.g., bismuth germinate [BGO], barium fluoride [BaF2], cesium fluoride [CsF]). These cameras are extremely expensive thus keeping them from many mainstream nuclear medicine departments. 202

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 203

Chapter 36 — Positron Emission Tomography (PET)

• Another method is to utilize the more common NaI crystals of a dual-head gamma camera with the addition of heavy collimation to accommodate the 511 keV photons and coincidence counting software in the computer. Modifications may also include changes to the electronics, a thicker crystal (5/8-inch as opposed to the standard 3/8-inch), and collimators changed out for scatter shields that contain a lining of lead around the perimeter to absorb oblique scattered radiation and horizontally aligned lead septa for absorbing low-energy photons. Improvements in hardware, software, and cost containment are making PET scanning more attractive and attainable to diagnostic departments. These can be used in planar, whole body, and tomographic imaging. • Techniques are being developed to utilize single-head gamma cameras with heavy collimation and specialized software to allow many departments to take some advantage of the metabolic imaging that PET scanning affords without the use of coincidence counting. In general, the resolution is considered too poor for accurate oncologic imaging. • Processing is similar to SPECT and is usually included with the software to run the imaging programs.

ISOTOPE • The isotope must be a pure β+ emitter. If not, the detector is busy sorting out single events, there is increased dead time, and there is marked decreased resolution of the image. • The isotopes of choice can be labeled with biologic and physiologic compounds used in the first step of metabolism of every cell. • The medical use is to find hypermetabolic lesions, metabolism in areas that were thought to have none, or differentiate between metabolic areas and no metabolism (necrotic or scar tissue).

Medical Importance Most medically significant compounds can be labeled with 11C, 18F, 13N, or 15O. These are physiologic, positron emitters, and readily produced in “baby” cyclotrons. They produce high resolution planar and tomographic images. There are no gamma-emitting isotopes of carbon, nitrogen, or oxygen that can label these biologic compounds for SPECT, nor can 99mTc be labeled to most of these compounds at this time. • Human disease is a biochemical process best diagnosed with a biochemical imaging modality. • • • •

Common Radiopharmaceuticals and Medical Applications 11

C-acetate C-glucose 11C-n-butanol 11C-N-methylspiperone 11C-palmitate 18F—sodium fluoride 18F-fluorodeoxyglucose (FDG) 11

18

F-fluoroethylcholine F-16α-fluoro-17β-estradiol 18F-spiperone 68G-citrate/transferrin 13N-NH 3 15O-CO 18

15

O-H2O

15

O-O2 Rb-chloride

82

Myocardial metabolism and prostate tumors Cerebral glucose metabolism Cerebral blood flow Dopamine receptor binding Myocardial metabolism Bone mineral metabolism Cerebral glucose metabolism Myocardial glucose metabolism Tumor localization Tumor localization (brain and prostate) Estrogen receptor binding Dopamine receptor binding Plasma volume Myocardial blood flow Cerebral blood volume Myocardial blood volume Cerebral blood flow Myocardial blood flow Cerebral oxygen extraction and metabolism Myocardial blood flow 203

10766-36_CH36.qxd

12/3/07

4:44 PM

Page 204

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Duncan K. Radiopharmaceuticals in PET imaging. J Nucl Med Technol 26:228–234, 1998. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Lombardi MH. Radiation Safety in Nuclear Medicine, 2nd ed. Boca Raton, FL: CRC Press LLC, 2007. Merlino DA, Majchrzak J. Nuclear Medicine Coder. St. Paul, MN: Medical Learning, Inc., 2006. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, et al. eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vol. 1 and 2. New York: Churchill Livingstone, 1994. Schulthess GK. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Tumor Imaging using F-18 FDG. Version 2.0, February 7, 1999. SNM.org. Westcoast Radiology Protocol for 18-F-FDG/CT, Clearwater, FL. 2007 Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

204

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 205

chapter

37

PET: Brain Imaging 18F-FDG RADIOPHARMACY Radionuclide •

18

F: t1/2: 109.77 min Energies: 635 (max) 202 (ave.) keV Type: EC, β+, γ, cyclotron

Radiopharmaceutical •

18

F-FDG (2-fluoro-2-deoxy-D-glucose) is a glucose analogue with a fluorine atom replacing a hydroxyl group in the C-2 position of d-glucose.

Localization • Distributed according to regional cerebral blood flow. • FDG is a substrate for the glucose transporter and hexokinase conversion to FDG6-phosphate, but goes no further than that first step and is not metabolized. 18F-FDG is trapped in the tissue as a phosphate with distribution mapped as glucose metabolism. • FDG does not undergo tubular reabsorption in the kidneys and is excreted in the urine.

Quality Control • Similar to standard radiopharmaceuticals, performed at plant. • Solution must be clear and free of particulate matter when observed. • The half-life must be within 105 to 115 minutes (radionuclide identity). • Must be at least 96% or better radiochemical purity from free 18F. • No less than 90% radiochemical purity from tagged chemical. • Additional tests for impurities, sterility, and bacterial endotoxins must prove to be within limits.

Adult Dose Range • 10–20 mCi (370–740 MBq) • Pediatric: See Pediatric Dosing, PET Pediatric Dose Chart in Reference Section

Method of Administration • Intravenous butterfly or indwelling catheter.

205

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 206

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • • • •

Evaluation of presurgical refractory seizure disorders. Localization of epileptic seizure focus in patients with intractable noncomplex seizure disorders. Detection of Alzheimer’s disease (AD). Differentiation between AD and frontotemporal dementia (FTD), and other dementia (e.g., dementia with Lewy bodies, Parkinson’s disease, and Huntington’s disease). • Differentiation between AD, normal aging, and neuropsychiatric conditions (e.g., depression). • Evaluation of recurrent brain tumors, e.g., postsurgery and/or radiation. • Evaluation of stroke, extent and recovery following therapy.

CONTRAINDICATIONS • Patient too agitated, uncooperative, or affected by disease to keep head completely still. • Severe claustrophobia. Some drugs interfere with a brain scan. Any remedy would have to be discussed with the physician. Antianxiety medication, e.g., diazepam 2–10 mg, or alprazolam 1 mg before imaging has been suggested. • Uncontrolled diabetes and/or blood sugar levels. High serum glucose levels hinder tumor uptake. • Patient who has not adhered to the preparations for the exam, e.g., ingested food, interfering medications, or drugs.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Patient to fast 4 to 6 hours before test with the exception of water. This reduces insulin levels to base levels and reduces uptake in certain organs, e.g., the heart. • Some procedures include monitoring the blood glucose level before injection. Blood glucose should read < 200 mg/dL. If glucose is > 200 mg/dL, authorized user must decide if injection and scan should be performed. There may be a request for glucose adjustments (see PET: Whole Body chapter). • No caffeine, alcohol, or nicotine products with 24 hours of exam suggested by some. • Patient placed in a quiet, darkened room at least 10 minutes before injection, and for 30 minutes or more following injection. Instruct patient to be still and not talk. • There are no contraindications for most medications, although patient should supply a list. Patient should discuss medication usage at the time of the exam with the physician.

EQUIPMENT Camera

Computer Set-up

• Large field of view (gamma camera) • Dedicated PET camera • PET/CT scanner

• Photopeak: 300- or 350–650 keV for BGO, 435–590 or 665 keV for NaI (CPET) • Attenuation correction can be done with cesium, germanium, or CT. • Images done in step-and-shoot protocol according to manufacturer’s specifications.

Collimator • Ultra-high energy, high resolution (gamma camera) • None in three-dimensional (3D) imaging, present in two-dimensional (2D) imaging.

206

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 207

Chapter 37 — PET: Brain Imaging 18F-FDG

PROCEDURE

(TIME: 90 MINUTES)

• PET scanner (dedicated). • Insert an intravenous catheter. • Inject the patient ensuring no extravasation. • Patient to void before imaging after a 30- to 45-minute uptake phase. • Image at 45 to 60 minutes after injection. • Place patient in supine position with arms down using a head restraint. • Position patient with Lazer beam. One step, cranium. • Acquire emission images of head (10 minutes), followed by transmission image (5 minutes). No movement of patient between emission and transmission. Some acquire transmission images first. • Acquisition: 2D: 15- to 20-minute emission; 5- to 10-minute transmission. • 3D: 10- to 15-minute emission; 5-minute transmission. • PET/CT (fused images): Dedicated PET scan may be fused with CT scans using MIM software. This could be done by network interface or CT on CD-ROM. The technologist may perform initial fusion procedure and submit or interpreting physician may perform the fusion. Using PET/CT scanners, the attenuation correction is usually performed first, and then applied to the processing. • PET/CT (scanner) • Contraindications: Elevated blood glucose levels. • Patient prep: NPO for 6 hours. • Dose: 15–20 mCi (555–740 MBq) 18F-FDG • 18F-FDG administered IV catheter at 45 minutes before exam time. • Patient arms to side, head in, cranium, use head holder. • At 30 minutes: CT scout (topogram) at 120 kV, 10 mA. • At 40 minutes: CT scan performed at 140 kV, auto mA. • At 45 minutes: PET scan 8 minutes for 3D, 20 minutes for 2D (3D = seizures; 2D = Alzheimer’s). • With CT imaging: Ex: 80 kV small pediatric, 100 kV large pediatric, 120 kV normal adult, 140 kV obese adult, 200–400 mA, depending on size. • Patient should empty bladder at end of imaging session. • CT scan standard radiation dose.

PROCESSING (EXAMPLE) • 2D processing with OSEM (2 iterations/28 subsets). Change diameter to 25–30 and increase the post filter 1.0 point. • 3D perform a reprojection. Display using an oval ROI and apply to all images. Save and reconstruct using calculated attenuation correction (factory defaults), change diameter to 25–30 and increase the post-filter 1.0 point. • The rotating maximum intensity projection (MIP) and surface-rendered 3D displays are used to enhance lesion evaluation. • Filter and reconstruct in transverse, coronal, and sagittal planes, according to manufacturer’s specifications. Images of head, neck and torso are to be reconstructed using “segmented attenuation correction” (SAC). SAC is also applied to extremities at the request of the reading physician. • Coronal and axial views, as well as additional views, can be printed out at the request of the reading physician.

NORMAL RESULTS • Highest uptake in the gray matter of cortex, basal ganglia, and thalami. Changes with aging particularly in the cortical area. • FDG uptake is reasonably uniform and constant in the cortex unless the patient is diabetic. • Decreased frontal lobe uptake with aging is not uncommon. 207

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 208

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Uptake in cerebellum and visual cortex and usually does not change with age. • Areas of the cortex are normally more metabolically active that the rest of the cortex, e.g., posterior cingulate cortex (anterior and superior to the occipital cortex), Wernicke region in the posterior superior temporal lobe, frontal eye fields (anterior to the primary motor cortex sometimes appearing asymmetric), and symmetric increased activity in the area of posterior parietal lobes. Cerebellum gray matter uptake is present but significantly less that seen on SPECT perfusion studies. • Areas stimulated during injection of FDG and during uptake process will have increased uptake on scan indicating increased metabolism, e.g., visual (occipital) and auditory cortical areas of increased activity if patient is so stimulated.

ABNORMAL RESULTS • • • •

• • • • • • • • •

High uptake in ictal seizure focus. Low uptake in interictal seizure focus, radiation necrosis. Variable uptake in recurrent tumors. Dementia: Alzheimer’s and Parkinson’s: Low uptake posterior temporoparietal cortical activity bilaterally. Tends to spare primary sensorimotor and occipital (visual) lobe, basal ganglia, thalamus, brainstem, and cerebellum. Early stages may be asymmetric and unilateral. Early findings include focal hypometabolism in posterior cingulate cortex and frontal cortical involvement may become prominent as the disease advances. Although similar, Parkinson’s exhibits hypometabolism in occipital (visual) cortex, sparing mesiotemporal cortical area. Dementia: Pick’s: low uptake frontal and frontotemporal lobe. Tends to spare sensorimotor and visual cortices. Dementia: Multi-infarct: Scattered small areas of decreased activity in cortical, subcortical, and cerebellar regions. Dementia: with Lewy bodies: Similar to Alzheimer’s, less sparing of occipital (visual) cortex. Cerebellar diaschisis (crossed): Low uptake area in one hemisphere, low activity in cerebellum contralateral to supratentorial stroke, tumor, or trauma. Huntington’s: Low activity in basal ganglia, particularly lentiform, caudate nucleus, and putamen. Diffuse cortical lesions. Focal areas of high uptake, high metabolism within the brain indicates malignancy. These can also be within low-grade gliomas. Recurrent tumor (after radiation) has increased activity whereas radiation necrosis (e.g., late radiation injury) will be decreased. A “flare” response after chemotherapy to the brain is possible, occurring a few days after treatment perhaps due to inflammation resulting from tumor death. Brain metastasis yields raised metabolism and is widely distributed mostly in the cerebral hemispheres and posterior fossa. Usually from carcinomas reaching brain through hematogenous spread from primaries of NSCLC, breast cancer, melanoma, renal cell cancer, and gastrointestinal tract cancer.

ARTIFACTS • Excessive physical or chemical stimuli before the exam will cause uptake in areas of brain to be affected. • Drugs may alter global and/or regional brain metabolism, including sedatives, antiepileptic and neuroleptic drugs, and barbiturates. • Some institutions require that, along with the log of the dispensed dose and patient, a physician’s report must be dictated, even if no images are acquired.

NOTE • Diaschisis (acute focal disturbance inhibiting function at a site in the brain that is remote from but attached by fiber from the original site of injury) may cause focal areas of hypoperfusion and hypometabolism in areas that are connected by neural pathways but remote from the site of the 208

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 209

Chapter 37 — PET: Brain Imaging 18F-FDG

•

•

•

•

•

•

lesion (tumor, stroke, and/or trauma). Typically presents in cerebellar hemisphere contralateral to the supratentorial session (crossed cerebellar diaschisis). It is typically asymptomatic, resolving when caused by stroke but persisting when associated with brain tumors. Subcortical/cortical cerebrals diaschisis, e.g., small thalamic strokes associated with ipsilateral depression of cortical metabolism, also occur. Mesial temporal lobe epilepsy is the most common form of seizure. Since FDG uptake of activity occurs over a few minutes, ictal seizures are difficult to localize and are often diffuse. A seizure during imaging may occur on the side of the lesion, making the contralateral side of the temporal lobe appear more hypometabolic. EEG during uptake and imaging may aid in preventing false localization of a presumed interictal focus. 18F-FDDNP (fluoro-ethyl methyl amino-2 naphthyl ethylidene malononitrile) crosses the blood–brain barrier, binding to senile plaques and neurofibrillary tangles afflicting Alzheimer’s patients. Plaques destroy neurons by lysis of cell membranes; tangles fill the cytoplasm of axons and dendrites and prevent glucose transport. 11C-nicotine follows nicotinic (cholinergic) receptor loss in Alzheimer’s disease. H215O shows reduced blood perfusion in areas of hypometabolism. 18F-FDG uptake and metabolism in brain tumors is generally an indicator of aggressiveness. High uptake is more likely to indicate high-grade lesions with poor patient survival; low uptake represents lower-grade tumors. Neuroreceptor imaging for distribution uses a number of receptor-specific radiotracers, e.g., muscarinic cholinergic receptors, dopamine D2 receptors, and benzodiazepine and serotonin-2 receptors. 11C-N-methylspiperone, a dopamine receptor seeker, maps neuromediator distribution in normal and pathologic states. Amino acid–linked tracers and analogs have shown low normal gray matter uptake, making them useful for diagnosis and follow-up imaging. These are known as MET-PET, e.g., 18F-methyltyrosine and 18F-ethyltyrosine. Others are nucleotides that link to DNA synthesis or tumor proliferation rate, e.g., 11C-thymidine. 11C-choline uses the essential building block of phospholipids in cell membranes with malignant tumors eliciting high proliferation and high metabolism of cell membrane components. This tracer has very fast uptake, allowing imaging to begin as quickly as 5 minutes after injection. PET/CT • PET imaging allows for the study of molecular biological function at the first step of metabolism within the cells. CT is extremely detailed in imaging anatomy. Combining the two allows an anatomic anomaly to be localized with a biologic disease process, potentially resulting in an earlier diagnosis and more accurate staging. Images, because they are on the same machine and with no patient movement or time variant, can be fused to allow functional abnormalities to be localized and distinguished from normal uptake of the PET tracer. At present, IV contrast-enhanced CT of the brain is not routinely used with PET/CT. Special software for attenuation calculations is needed because of the increased density of the contrast. When requested, CT is usually imaged separately and fused by software to the PET scan. As progress is made with imaging and processing software and types of contrast, there may be a more routine application for this form of information.

PATIENT HISTORY

The patient should answer the following questions. Ask relative or care taker if patient’s alertness is in question. Do you have a history or family history of cancer?

Y

N

If so, what type and for how long? What is your height and weight? (continued)

209

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 210

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

When was your last meal? Are you claustrophobic?

Y

N

Have you had any recent radiosurgery, brachytherapy (seed implants), chemotherapy, or radiation therapy?

Y

N

Have you had any recent surgery? If so, where?

Y

N

Are you diabetic and are you taking insulin?

Y

N

Have you had any caffeine, alcohol, or nicotine products in the last 24 hours?

Y

N

Has there been any recent memory loss?

Y

N

Is there a history of any brain disorders?

Y

N

Have there been any recent behavioral changes or confusion?

Y

N

Has there been any recent head trauma or headaches?

Y

N

Do you have incontinence?

Y

N

Has there been any recent infection?

Y

N

Has there been any recent seizures or balance problems?

Y

N

Do you have a shunt or metal plate?

Y

N

Are there any recent PET, NM, CT, or MRI scans? If so, what type and at what institution?

Y

N

Y

N

If so, is it long or short memory?

What is the patient taking for medications? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual, 2006–08. Englewood, CO: Wick, 2006. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. 210

10766-37_CH37.qxd

12/3/07

4:45 PM

Page 211

Chapter 37 — PET: Brain Imaging 18F-FDG

Schulthess GK. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Shared PET Imaging of Florida, Shared PET Imaging, Canton, OH. Administrative Policy & Procedure Manual. Smeltzer SC, Bare BG. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 11th ed. Philadelphia: Lippincott, 2007. Stedman TL. Stedman’s Medical Dictionary, 27th ed. Baltimore: Lippincott Williams & Wilkins, 2006. Thomas C, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: FA Davis, 1993. Westcoast Radiology Protocol for 18-F-FDG/CT, Clearwater, FL. 2007. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

211

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 212

chapter

38 PET:

Cardiac Perfusion and Viability RADIOPHARMACY Radionuclide F: t1/2: 109.77 min Energies: 635 (max) 202 (ave) keV Type: EC, β+, γ, cyclotron • 13N: t1/2: 9.96 min Energies: 1199 (max) 492 (ave) keV Type: β+, cyclotron • 15O: t1/2: 2.04 min Energies: 1732 (max) 696 (ave) keV Type: β+, cyclotron • 82Rb: t1/2: 1.27 min Energies: 3356 (max) 1385 (ave) keV Type: EC, β+, γ, generator •

18

Radiopharmaceutical •

18

F-FDG (2-fluoro-2-deoxy-d-glucose) is a glucose analogue with a fluorine atom replacing

a hydroxyl group in the C-2 position of d-glucose. Mean linear range in soft tissue is .2 mm, max is 2.4 mm. • 13N-ammonia. Formed from irradiation and from nitrate and nitrite forms. Mean linear range in soft tissue is 1.4 mm, max is 5.4 mm. • 15O-water. Produced by isotopic exchange or reduction reactions. 15O-carbon dioxide can be used as the labeling precursor bubbled through a water environment. Also by reduction of 15O-oxygen admixed with hydrogen gas. Mean linear range in soft tissue is 1.5 mm, max is 8.2 mm. • 82Rb-chloride. Daughter of 82Sr from generator by EC. Infused directly into patient for myocardial blood flow measurements. Mean linear range in soft tissue is 2.6 mm, max is 15.6 mm.

LOCALIZATION • FDG is a substrate for the glucose transporter and hexokinase conversion to FDG-6-phosphate, but goes no further than that first step and is not metabolized. 18F-FDG is trapped in the tissue as a phosphate with distribution mapped as glucose metabolism. FDG does not undergo tubular reabsorption in the kidneys and is excreted in the urine. Positron range is about 1.2 mm. 212

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 213

Chapter 38 — PET: Cardiac Perfusion and Viability

N-ammonia passively diffuses into myocytes and metabolizes into 13N-glutamine becoming unable to leave the cell. It has rapid blood clearance and >90% extraction. The extraction fraction decreases with high perfusion rates. Positron range is about .4 mm. • H2 15O passively diffuses freely across all capillary membranes, including the myocardium, and is unaffected by metabolism but remains in the blood pool. Accumulation is linear to blood flow with 100% extraction and quantitatively measures myocardial blood flow in stress and rest perfusion studies. Positron range is about 1.1 mm. Also used in cerebral blood flow. • 82Rb-chloride follows blood flow for cardiovascular PET measurements. Rubidium is an analogue of potassium and accumulates in the myocardium by active transport using the Na/K pump similar to 201T1. Infused directly into the patient via a pump at a continuous flow or bolus. Positron range is about 5.5 mm (mean). •

13

QUALITY CONTROL •

18

F-FDG: Solution must be clear and free of particulate matter when observed. The half-life must be within 105 to 115 minutes (radionuclide identity). Must be at least 96% or better radiochemical purity from free 18F. No less than 90% radiochemical purity from tagged chemical. Additional tests for impurities, sterility, and bacterial endotoxins must prove to be within limits. • 13N-ammonia: 95% radiochemical purity. Usually made with on-site cyclotron. • 15O-H2O: Short half-life requires it to be made and used on site. • 82Rb-chloride: None. From generator to patient.

ADULT DOSE RANGE • • • •

18

F: 10–15 mCi (370–555 MBq) N: 10–20 mCi (370–740 MBq) for each rest and stress test. 15 O: 30–100 mCi (1110–3700 MBq) for each rest and stress test. 82 Rb: 30–60 mCi (1110–2220 MBq) for each rest and stress test. 13

METHOD OF ADMINISTRATION • Intravenous butterfly or indwelling catheter. Ensure patency. Flush with at least 10 cc normal saline. • Because of the proximity of an antecubital injection to the detector for dynamic studies, foot veins may be preferred. • 18F: viability study: Glucose and insulin loading (typically around 50 mg) to find serum glucose plateau within 80 to 120 minutes for a time of 30 minutes. At this time the patient is injected with FDG and waits 30 minutes before imaging. Monitoring of glucose levels is maintained throughout and after imaging. • 13N: infused over a 20- to 30-second interval. • 15O: Bolus injection. • 82Rb: Directly infused from generator/pump over a 20- to 30-second interval.

INDICATIONS • Perfusion: Restricted to patients who are unable to exercise, with prior equivocal SPECT exam, or patients whose body habitus would degrade SPECT imaging. • Assessment of coronary artery disease (CAD) in symptomatic or asymptomatic patients including those with balanced three-vessel disease. • Assessment of physiologic stenosis for revascularization. • Determination of treatment for patients with ischemic heart disease and/or congestive heart failure, e.g., coronary artery bypass verses cardiac transplantation or conservative medical therapy such as anti-ischemic or thrombolytic treatment. 213

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 214

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Differentiation between viable tissue and infarcted or necrotic tissue in patients with suspected hibernating or stunned myocardium. • Evaluation of progression or regression of CAD during risk factor modification. • Assessment of microcirculatory dysfunction. • Quantification of myocardial blood flow.

CONTRAINDICATIONS • • • •

Patient too agitated, medically compromised, or uncooperative to remain completely still. Patient who has not adhered to the preparations for the exam. Patient with uncontrollable diabetes (for some exams). For stress test: Severe asthma, bronchospasm, COPD, unstable angina, recent myocardial infarction (within 48 hours), hypotension, sick sinus syndrome (abnormalities of ECG from malfunction of sinoatrial node), second- and third-degree AV block without pacemaker.

PATIENT PREPARATION • • • •

•

• • •

•

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain patient height and weight information. No caffeine, alcohol, or nicotine products within 24 hours of exam are suggested by some. Perfusion: Patient to eat light breakfast or lunch (non-fat, high carbohydrate) or is injected with glucose solution 1 to 3 hours before FDG injection. This changes the heart metabolism from fatty acid to glucose. Other tracers, e.g., 82Rb, demand NPO for 4 hours before exam. For perfusion, no caffeine or theophylline within 12 hours of exam. Some require all cardiac medications to be discontinued for test, e.g., beta-blockers, calcium channel blockers, nitrates, and nitroglycerin. Most procedures include monitoring the blood glucose level before injection. Diabetics need careful monitoring of blood glucose levels. Prepare patient with ECG setup if the study is gated. FDG viability: Patient must be NPO for 6 hours except for water prior to exam (nondiabetic prep). Other than blood sugar–related information, no other medication restrictions for patient. This method uses glucose-loading (see below). Or: high carbohydrate meal 2 hours before injection time. Diabetics should take their insulin or non-insulin diabetic medications along with a high carbohydrate meal. Monitor blood glucose levels before time if injection. If patient is claustrophobic, antianxiety medication can be administered, e.g., diazepam 2–10 mg, or alprazolam 1 mg before imaging.

EQUIPMENT Camera

Computer Set-up

• Large field of view • Dedicated PET scanner • PET/CT

• Gamma camera: Limited field tomography; 60–120 stops (360°), 20–25 sec/stop, window 511 keV ± 10%. • Photopeak: 300- or 350–650 keV for BGO, 435–590 or 665 keV for NaI (CPET), or 511 keV ± 30%. • Dynamic: 18 frames at 10 sec/frame or 5 minutes as per protocol. • Static: 6- to 15-minute image. Attenuation correction can be done with cesium, germanium, or CT. Enter heart rate, one group, 8 bins.

Collimator • Ultra-high energy, high resolution (gamma camera) • None in 3D imaging, present in 2D imaging. • 2D or 3D mode may be used. 214

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 215

Chapter 38 — PET: Cardiac Perfusion and Viability

PROCEDURE

(TIME: ABOUT 90 MINUTES TOTAL, SOME AS LONG AS 3 HOURS)

Perfusion (Examples) • Patient to void before imaging. • Place patient in supine position with arms up and feet first into gantry. If patient’s arms must be down, do both scans the same way and inform the reading physician. • Chest image to include heart. • Rest: Inject tracer, wait 70 seconds with patient at rest. • Acquire dynamic rest emission scan (3–5 minutes). • Acquire 6-minute rest emission scan. Other: Acquire 15-minute gated. • Transmission scan for attenuation correction (before or after emission, can take 10–20 minutes, landmark sternal notch, CT 120 kV, 10 mA, takes about 5 seconds). • 13N-ammonia • Static: Start imaging 5 minutes after injection to permit pulmonary background activity to clear. There must be a 50-minute pause between rest and stress injections to permit decay to background levels. Acquire in decay compensated mode. Post-treadmill exercise and gated imaging is feasible because of half-life. • Dynamic imaging starts simultaneously with the injection for 20-minute acquisition, followed by a 20-minute transmission scan (or short acquisition, low-dose CT attenuation scan for PET/CT). Following this, a pharmacologic stress test with ECG and blood pressure monitoring is started. • Wait appropriate time to begin stress test. There must be time enough for tracer to clear from background. • Patient to void before imaging unless beginning stress quickly. • Stress: Inject dipyridamole for 3 to 4 minutes (e.g., 0.14 mg/kg/min over 4 minutes) or adenosine (e.g., 0.14/kg/min over 7 minutes). Metoprolol 5–10 mg over 2–10 minutes as necessary for elevated heart rate (> 75 bpm). Have 50–150 mg aminophylline ready for end of test to counteract effects. More information in Chapter 14, Cardiac: Stress Test. • Dipyridamole: Wait 7 minutes from beginning of infusion, and then inject. • Adenosine: Inject at the 3-minute mark from beginning of infusion. • Dobutamine: Wait for physician’s command to inject. • Wait 70 seconds for uptake phase. • Acquire 6-minute stress emission scan. Other: Acquire 15-minute gated. • Transmission scan for attenuation correction before or after emission images. If patient has not moved from table, no second transmission scan or attenuation scan is needed. • 13N-ammonia PET/CT example • Rest: — Inject tracer. — Acquire CT anatomic scan for heart location. — 3 minutes from injection time, acquire 15 minute PET scan, one bed position, a longer delay may be required for CHF patients. — Acquire CT attenuation correction scan. — 30- to 50-minute delay for stress. Some allow patient to leave table. • Stress (example) — Patient to void. — Reposition patient as closely as possible to rest position. — Begin intravenous pharmacologic stress drug of choice. — Inject tracer at appropriate time after drug infusion (see above). — Acquire CT anatomic scan for heart location. — 3 minutes from injection time, acquire 15-minute PET scan, one bed position, a longer delay may be required for CHF patients. — Acquire CT attenuation correction scan. 215

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 216

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

•

•

• • • •

82

Rb tests are nearly identical procedures needing less time between rest and stress because of the shorter half-life and clearance. ECG if gated. Example with PET/CT. • Rest — Inject tracer. — Acquire CT anatomic scan for heart location. — 2 minutes from injection time, acquire 5-minute PET scan, one bed position; a longer delay may be required for CHF patients. — Acquire CT attenuation correction scan. • Stress (Example) — Begin intravenous pharmacologic stress drug of choice. — Inject tracer at appropriate time after drug infusion (see above). — Acquire CT anatomic scan for heart location. — 2 minutes from injection time, acquire 5-minute PET scan, one bed position; a longer delay may be required for CHF patients. — Acquire CT attenuation correction scan. With CT imaging: Example: 8 slice: 3.75-mm thick, pitch 1.67:1, 16.75 mm/rotation, 80 kV small pediatric, 100 kV large pediatric, 120 kV normal adult, 140 kV obese adult, 200–400 mA depending on size. Also used for LV volume and wall thickening assessment. Some include CT calcium scoring. See Cardiac: Stress Test. Some include CT cardiac contrast-enhanced angiography (patient to hyperventilate for breath-hold). Processing: Software specific. Example: Hanning transaxial filter, 128 × 128, cutoff 6.5, diameter 41.9 cm, center L 4.0 cm, measured attenuation, randoms correction by Singles, 3D PET Butterworth filtering. Usually: A nonattenuation corrected 3D data set with iterative construction, an attenuation corrected (transmission or CT) 3D data set, a maximum intensity projection (MIP) data set, transaxial tomograms of left ventricle are quantitatively analyzed, gated tomograms for left ventricular ejection fraction and wall motion (and wall thickening), printed rest and stress transaxial (transverse), sagittal, and coronal planes (or similar to SPECT using horizontal long axis, vertical long axis, and short axis views) with bullseye or polar images.

Metabolic Imaging: Viability 18F-FDG (Example: Nondiabetic Protocol, Diabetic, See Note) • Attain intravenous access. • Assess patient blood glucose level. • Patient to drink 16 oz sugared cola and eat doughnut or “sticky bun.” Other types: Oral glucose loading, hyperinsulinemic euglycemic clamping, administration of nicotinic acid derivatives. See note. • Wait 30–45 minutes, assess blood glucose level again. Should be 200 mg/dL or higher. • Assess blood glucose levels every 10 minutes. • When levels start declining (<200), inject 18F-FDG over 60 seconds. • Wait another 45–90 minutes for uptake. Record time of imaging, reproducibility is vital to accurate studies if repeated. • Place patient supine, arms up, center area over heart. (Arms down if incapable, increase length of transmission scan.) Remind patient to be very still. Have ECG in place if it is a gated exam. • Acquire 5-minute transmission scan. • Acquire 20-minute emission scan in 2D mode. • Process (e.g., GE software) directions of arrows in processing should be at 11, 5, and 12 o’clock, in that order. Process using filtered back projection and OSEM unless a protocol has been chosen. • Patient blood glucose level should be >80 mg/dL before discharge. • PET/CT: Wait 30 minutes after injection, acquire scout, then CT of chest for attenuation correction, 1 FOV over heart for 15 minutes. Arms over head if possible, arms down but out of detector view if arms up is not tolerated. • Can be done in combination with 82Rb-chloride or 13N-ammonia. • Dual isotope perfusion/viability studies can be acquired simultaneously using 18F-FDG and 99mTc-sestamibi or Myoview with a gamma camera equipped with the appropriate collimator. 216

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 217

Chapter 38 — PET: Cardiac Perfusion and Viability

Quantitation of Coronary Blood Flow • • • • • • •

•

Initial minutes of dynamic acquisition are used for quantitation. Place patient supine, arms up. Acquire transmission scan (10 to 20 minutes or with CT about 5 seconds). Inject bolus of tracer and start camera. 15O-water has a short half-life allowing for multiple measurements within 10 minutes and flow reserve measurements with total scan duration of 20 minutes. Dynamic scan for 5 minutes. Myocardial activity is determined by placing a region of interest (ROI) over the myocardium. Blood pool activity is measured from an ROI placed within the left atria or left ventricle and using various mathematical models to derive the information. Optimally, it would be measured at the level of the coronary ostia and the base of the ascending aorta. This is the point from which the blood pool perfuses into the myocardium. Limited resolution and small dimensions hinder this method. It can also be measured by a more invasive direct sampling of blood from an artery. PET/CT provides the most accurate results for qualification and quantification of myocardial perfusion. Using CT for attenuation correction and fusing the PET imaging with a coronary CTA study provides anatomic and physiologic information concerning atherosclerotic burden, identifying the functional significance of coronary stenoses, and patients for revascularization.

NORMAL RESULTS •

•

• • •

18

F-FDG: uniform uptake throughout most of the left ventricular myocardium. There is little or no uptake in the membranous septum. Right ventricular wall usually visualized. Less uptake in the apex (apical dip) due to increased motility of the heart in the apex, physiologic partial-volume averaging when imaging is not gated to the cardiac cycle. Diabetic patients can visualize with a marked inhomogeneous uptake in the myocardium because of inadequate glucose uptake from insulin resistance in diabetes mellitus type II patients or inadequate insulin blood levels in diabetes mellitus type I patients. Intraventricular activity up to about 20 minutes. Uptake into the myocardium needs about 30 to 40 minutes. Gated: globally synchronous. See Cardiac: Stress Test. 13N-ammonia: Perfusion reflects regional blood flow, decreases at high flow rates, plateaus at flow rates >2 mL/gm. Low uptake in lateral/posterolateral wall on stress and rest imaging due to attenuation. There is little or no uptake in the membranous septum. Often prominent liver accumulation. 15O-water: Uniform uptake in myocardium. Lingering uptake in blood pool image with uptake within the ventricular chambers and surrounding structures. 82Rb-chloride: Uniform uptake throughout myocardium. The higher energy degrades spatial resolution somewhat, but the generator (82Sr) eliminates the need of an on campus cyclotron. Myocardial blood flow (MBF): Mean resting 0.99 ± 0.23 mL/min/g (range 0.59–2.05 mL/min/g).

ABNORMAL RESULTS • • • • • •

Infarct: Focal areas of low uptake. Ischemia: Focal areas of reduced uptake. Scar: Focal areas of little or no uptake (<50% of normal myocardium uptake). Hibernating tissue: Normal to focal areas of increased uptake (>50% of normal myocardial uptake). Stunned tissue: Normal to focal areas of increased uptake. FDG viability: Right ventricular wall visualization means hypertrophy due to pressure overload for right heart in pulmonary hypertension or volume overload in congenital heart disease with shunt. • Myocardial blood flow (MBF): Mean hyperemic flow 3.54 ± 1.0. mL/min/g (range 1.11–5.99 mL/min/g). Hyperemic MBF declines with increasing age. Patients >65, increased baseline and reduction on hyperemic MBF means larger decrease in coronary flow reserve. Likely due to aging process (mechanical and neurohumoral factors) and increased arterial impedance, e.g., thickening of left ventricular myocardium, reduced catecholamine responsiveness, endothelial dysfunction, and deficient neuroendocrine regulation. 217

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 218

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ARTIFACTS • • • • • •

• • • •

Caffeine will cause increased cardiac uptake. Breast attenuation can be avoided by binding left breast up away from left ventricle. Excessive physical activity before the exam will cause muscle uptake. High-density barium may cause attenuation. Diabetes can seriously affect the interpretability of a scan. The patient with known diabetes may have to undergo imaging studies using a glucose clamp. Metal objects, e.g., pacemakers, defibrillators, can produce imaging artifacts when using CT for attenuation correction producing a hot spot. This is not found using conventional PET scanners with transmission sources. False-positives can occur from misregistration between transmission and emission scans. Acquiring separate stress and rest transmission scans can reduce misregistration artifacts. With 13N, tracer uptake in the liver and in the lungs of smokers and patients with CHF can interfere with interpretation. Motion from arms in up position may hinder interpretation. Arms down may necessitate longer transmission imaging time. With MBF, there are indications that aging modulates the effects of dipyridamole and adenosine and that peak vasodilation could occur at different times for younger patients compared to older patients.

NOTE • Stunned myocardium is a contractile abnormality in the area of a coronary occlusion (transient ischemia). The tissue involved exhibits segmental dysfunction and is not necrotic. The condition persists for about 2 weeks after the event as the tissue returns to full function. Stunning may also occur after exercise-induced ischemia. These may be areas of ischemic myocardium that appear on stress-gated images but not on rest images. Stunning may appear in postoperative CABG, unstable angina, following coronary angioplasty, and with pharmacologic stress imaging (coronary artery steal where normal artery flow siphons away from myocardial tissue distal to a high-grade stenosis via collateral channels). Possible mechanisms for wall motion abnormalities include abnormal energy utilization by myofibrils, production of cytotoxic oxygen free radicals, altered calcium flux, and accumulation of neutrophils in previously ischemic tissue. • Hibernating myocardium is a contractile abnormality of dysfunction, the wall of the segment affected exhibits hypokinesis, akinesis, or dyskinesis. The condition can lead to chronic ischemia and reversible by revascularization because the tissue is still viable and not necrotic. During periods of ischemia or hypoxia, the affected myocardium compensates for its normal fatty acid betaoxidation process by shifting to glucose utilization. It is enough to keep the tissue viable, but may not be enough to sustain mechanical work. This condition is hibernating myocardium. Some suggest that it is from repetitive episodes of myocardial stunning, which leads to chronic left ventricular dysfunction. If the condition worsens and blood flow is not enough to maintain glucose to the cell and remove metabolites, glycolysis is inhibited, resulting in loss of ion concentration gradients across the cell membrane followed by cell membrane disruption and cell death (necrosis). • Stress testing with PET is commonly done with pharmacology in nearly the same fashion as with standard SPECT imaging. Dipyridamole (1–2 h half-life) induces vasodilation indirectly by inhibiting the cellular uptake of adenosine, a natural enzyme in the body and a potent coronary vasodilator. This causes an increase in the levels of adenosine in blood and tissues and increases the coronary blood flow. Any decrease in flow from stenotic arteries can be detected with imaging. Using adenosine eliminates the first step of dipyridamole and acts directly on the coronary arteries with a very short biologic half-life (about 1 minute). Dobutamine (high doses, e.g., 20–40 ug/kg/min) increases the MBF by increasing heart rate, systolic blood pressure, and myocardial contractility. The overall effect may be less than dipyridamole or adenosine but still able to achieve sufficient blood flow for imaging. It is also used for patients with asthma, other types of pulmonary distress, or a hypersensitivity to adenosine. Although most studies are conducted with pharmacologic hyper218

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 219

Chapter 38 — PET: Cardiac Perfusion and Viability

emic stimuli, there are studies being done using a supine bicycle for physical stress tests finding the method as feasible and reproducible with comparable results. • Glucose loading and glucose/insulin clamping: • Oral: Nondiabetic fasting blood glucose 110 mg/dL or less, oral solution with 50 to 100 gm glucose about 60 minutes before injection or 10% dextrose in water solution at a rate of 15 umol/kg/min. • Diabetic: Following glucose loading, a bolus of regular insulin according to a sliding scale, checking plasma glucose every 15 minutes to maintain a stable serum glucose level of about 140 mg/dL. Image quality can be improved by waiting 2–3 hours after injection. • Non-insulin dependent diabetics: Use glucose loading and insulin boluses. For fasting plasma glucose level <7 mmol/L, give a 25 g oral glucose solution; for 7–11 mmol/L, give 5 IU of insulin IV; for >11 mol/L, give 10 IU of insulin IV. Measure plasma glucose level in 15 minutes. Insulin is given according to sliding scale. For 8 mmol/L, no insulin; for 8–11 mmol/L, 5 IU of insulin IV is given; for >11 mmol/L, give 10 IU of insulin IV. • Sliding scale for insulin dose Ideal body weight (IBW) — Female: (height – 152.4 cm) × 0.91 + 45.5 kg = IBW Actual weight (kg)/IBW × 100 = % of IBW — Male: (height – 152.4 cm) × 0.91 + 50.0 kg = IBW Actual weight (kg)/IBW × 100 = % of IBW • Insulin dose Units/kg actual body weight % of IBW 0.1 <120% 0.15 120–130% 0.20 >130% Add .05 units/kg if patient is taking >80 units/day combined forms of insulin. Adjust dose to patient weight and amount and type of insulin previously given that day. Final dextrose and insulin dosage for hyperglycemic patients should be decided by physician. • Hyperinsulinemic-euglycemic clamping: Simultaneous infusion of glucose and insulin. IV catheters in both arms, one for insulin (infused at 100 mU/kg/hr to achieve hyperinsulinemia), and one for glucose (500 mL of 20% glucose with 20 mL of 14.9% potassium chloride to prevent hypokalemia infused at 6 mg/kg/min). The rates are adjusted every 10 minutes to maintain normoglycemia. Inject after 60 minutes of clamping. • Nicotinic acid derivatives: Acipimox 250 mg is orally given 2 hours before injection. Some give carbohydrate and protein-enriched meal. • 62Cu-pyruvaldehyde-bis-(4N-thiosemicarbazone) (PTSM) is a neutral, lipophilic tracer and trapped by reduction within the cell by a non-lipophilic compound. It is generator produced and used for myocardial perfusion imaging. It has a t1/2 of 9.7 minutes. The positron range is about 2.7 mm. The dosage is 0.12–0.2 mCi/kg (4.44–7.4 MBq/kg) IV bolus followed by 10–15 minutes dynamic imaging.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

If so, what type and for how long? What is your height and weight? (continued)

219

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 220

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Are you diabetic?

Y

N

Do you have a history of or family history of heart disease?

Y

N

Do you have a history of heart attacks?

Y

N

Have you had any chest pain?

Y

N

Have you been short of breath, trouble breathing, or have asthma?

Y

N

Do you or did you smoke? How much? When did you quit?

Y

N

Do you have a nitro patch or are you taking nitroglycerin?

Y

N

Do you take insulin? If so when was your last treatment?

Y

N

Do you have any known heart conditions?

Y

N

Y

N

Have you taken aminophylline within the last 24 hours?

Y

N

Have you had any surgeries within the last 6 months?

Y

N

Do you have a pacemaker or any implanted devices?

Y

N

Have you had any recent chemo or radiation therapies?

Y

N

Have you had any recent diagnostic procedures?

Y

N

Do you have films or reports of prior exams?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, when and are you having chest pain now?

When did you eat last? Have you had any caffeine, alcohol, or nicotine products in the last 24 hours? What medications are you taking?

Bra cup size? Other department specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study? 220

10766-38_CH38.qxd

12/3/07

4:46 PM

Page 221

Chapter 38 — PET: Cardiac Perfusion and Viability

Suggested Readings Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual, 2006–08. Englewood, CO: Wick, 2006. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Schulthess GK. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Thomas C, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: FA Davis, 1993. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998. Westcoast Radiology Protocol for Cardiac Imaging, Clearwater, FL. 2007. www.auntminnie.com/index.asp?sec=ref&sub=ncm&pag=pet&itemid=54533 www.rad.msu.edu/research/gages/PET-CT/cardiac/ARRS/2004_files

Notes

221

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 222

chapter

39 PET:

Whole Body (Tumor) Imaging 18 F-FDG and PET/CT RADIOPHARMACY Radionuclide •

18

1/2

F: t : 109.77 min Energies: 635 (max) 202 (ave.) keV Type: EC, β+, γ, cyclotron

Radiopharmaceutical •

18

F-FDG (2-fluoro-2-deoxy-d-glucose) is a glucose analogue with a fluorine atom replacing a hydroxyl group in the C-2 position of d-glucose.

Localization • FDG is a substrate for the glucose transporter and hexokinase conversion to FDG6-phosphate, but goes no further than that first step and is not metabolized. 18F-FDG is trapped in the tissue as a phosphate with distribution mapped as glucose metabolism. • FDG does not undergo tubular reabsorption in the kidneys and is excreted in the urine.

222

Quality Control • Similar to standard radiopharmaceuticals, performed at plant. • Solution must be clear and free of particulate matter when observed. • The half-life must be within 105 to 115 minutes (radionuclide identity). • Must be at least 96% or better radiochemical purity from free 18F. • No less than 90% radiochemical purity from tagged chemical. • Additional tests for impurities, sterility, and bacterial endotoxins must prove to be within limits.

Adult Dose Range • 4–20 mCi (148–740 MBq) • Adjust by weight or body surface for pediatrics. See pediatric dosing in reference section.

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 223

Chapter 39 — PET: Whole Body (Tumor) Imaging 18F-FDG and PET/CT

Method of Administration • Intravenous butterfly or indwelling catheter. • Injection should be administered in a site contralateral to area of interest. • Assay dose, record amount and time. • Administer injection, flush with 10 cc normal saline, remove IV catheter, record time of injection. • Assay the syringe (and tubing if possible) after injection, record amount and time. • Patient should be kept warm, comfortable, and resting during uptake phase until imaging time. Remind patient not to move or speak during this time. • Brain study patients should be placed in a quiet, dimly lit room for 15 minutes before

•

•

• • •

injection and for 30 minutes following injection. A standard head-holder should be attached to the imaging bed. Breast patients should be injected in arm contralateral to side of interest. If both are in question, administer a foot injection. Head and neck studies must refrain from neck and jaw movement, e.g., talking, head movement. Patient is to remain in a holding room until imaging time. For dynamic imaging, injection by IV catheter is at time of acquisition start. In patients with no venous access, it is documented that 18F-FDG can be administered orally.

INDICATIONS • Detection, localization, and staging of primary, metastatic, and/or recurrent tumors. See Chapter 36, PET Overview. • Differentiation between benign and malignant tumors (e.g., bone, lung, adrenal). • Staging of patients with known malignant tumors. • Localization of lesions for biopsy or radiation therapy. • Differentiation of recurrent malignant disease from therapy-induced changes. • Evaluation of oncologic therapies on known or residual malignancies. • Detection of unknown primary disease when malignancies are present. • Evaluation of elevated tumor markers or symptoms. • Grading of malignant brain tumors and other cancer. • Evaluation of multiple myeloma. • Evaluation of dementia. • Evaluation of abnormalities detected on another modality.

CONTRAINDICATIONS • High serum glucose levels will hinder tumor uptake. Consult authorized user if blood glucose levels are >200 mg/dL. • FDG does not present well in all kinds of tumors. Evaluation of options is recommended. • Patient too agitated, uncooperative, or claustrophobic to remain still for acquisition. Some drugs interfere with a brain scan. Any remedy would have to be discussed with the physician. Antianxiety medication, e.g., diazepam 2–10 mg, or alprazolam 1 mg before imaging has been suggested. • Because PET involves cellular metabolism, drug and food ingestion, or lack thereof, bears specific consideration for each study. Either could be a contraindication to the study. • Too much muscle activity before the examination.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Determine that the primary indication is approved. • Patient NPO at least 6 hours except water before test. This reduces insulin levels to base levels and reduces uptake in certain organs, e.g., the heart. This includes no gum, candy, soda, or anything that may contain sugar. Some administer 20 mg Lasix orally. 223

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 224

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• No caffeine, alcohol, or nicotine products with 24 hours of exam is suggested by some. • Patient is to hydrate before scan (2 glasses of 8 oz water). • Some allow a high protein breakfast (egg, bacon, sausage, cup of orange juice) if it is an afternoon study. • Some procedures include monitoring the blood glucose level before injection. Blood sugar levels should be <200 mg/dL before injection. This allows better uptake of the FDG. For breast cancer, levels must be <150 mg/dL. • Some require that patients with blood sugar problems not take insulin the morning of the exam and be scheduled for the earliest morning exam time. • Some require a laxative the night before the exam to reduce bowel activity. • If a CT exam is involved, patient may need to drink oral contrast at appropriate time before acquisitions begin. • Administration of FDG may be as early as 2 hours following an administration of regular insulin (ideally 4 hours). • Patient is to avoid vigorous exercise within 24 hours of exam. • Brain tumor patient should sit in a quiet, dimly lit room for 15 minutes before injection. • Patient to remove all metal articles from person, e.g., glasses, jewelry, under wire bras, keys, change, wallet, belt buckle, pens, clips, knives, cellular phones, removable denture restraints or false teeth, etc. If there are metal zippers or buttons, the patient should change into a gown or lower pants below mid thigh level. • Patient may require Foley catheter to provide bladder drainage and evaluation of pelvis. • Remind patient of absolutely no movement during exam and that he or she will be given instructions as to breathing when imaging begins. • Record dosage administered to the patient for physician dictation whether or not patient is imaged.

EQUIPMENT Camera • Large field of view gamma camera • Dedicated PET camera

Collimator • Ultra-high energy high resolution (designed for 511 keV) for gamma camera applications. • None in three-dimensional (dedicated PET) imaging, present (septa in) in two-dimensional (dedicated PET) imaging.

•

•

• •

511 keV ± 10%. Whole body sweep; ant/post, head to foot, speed to achieve 450,000 to 1 million counts per image. Dedicated PET: Photopeak: 300– or 350– 650 keV for BGO, 435–590 or 665 keV for NaI (CPET) Limited field tomographic images: Most clearly defining metabolic activity in known lesions. Dynamic acquisition: Allows for quantification of metabolic rates of tumors. Whole body: Attenuation correction can be done with cesium, germanium, or CT.

Computer Set-up • Gamma camera: Limited field tomography; 60–120 stops (360°), 20–25 sec/stop, window

PROCEDURE (TIME : TOTAL IS ABOUT 2 HOURS) • Image at 45 minutes (range of 30–90 minutes) after injection (to allow for the metabolic uptake of the tracer). Some wait longer for target to background ratios to improve. • Patient to void before imaging. • Place patient in supine position. • Align patient and detector with inner laser to landmark. • Head and neck neoplasms: arms down, use head holder. 224

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 225

Chapter 39 — PET: Whole Body (Tumor) Imaging 18F-FDG and PET/CT

• Lesions of chest: Arms up. • If both areas could be involved, e.g., neck with mediastinal and/or pulmonary involvement, it may be necessary to do two imaging sessions using both positionings. • For dedicated PET cameras (and depending on areas of interest): • Limited field tomographic images: Acquire transmission image (some require 125 million counts over 15–20 minutes). On some systems, this can be done before or after emission imaging. Some allow patient to be removed from table before emission scan but careful note of patient’s position must be made for exact repositioning. Patient to void before emission scan. • Emission image: 6 to 15 minutes per bed position, collecting 5 to 15 million counts, depending on area of interest. • Suggested tumor site, scan range and emission/transmission times: Tumor Type All scans not listed below Head and Neck Melanoma

Brain

Scan Range Base of skull to mid-thigh Top of head to mid-thigh Top of head to toes, legs acquired on separate scan, emission only One bed-position landmark just superior to surface of skull. Do 60-second test image to confirm positioning

Emission Time (min) 6 6 6

Transmission Time (min) 3 3 3

10

5

• For solitary pulmonary nodule, perform delayed imaging (about 30 minutes after original imaging) of any pulmonary nodules with SUVs between 1.5 and 3.5. Acquire one bed position centered around the nodule of interest. • Semiquantitative analysis of tumor metabolism (SUVrelative—tumor activity normalized to injected dose and body weight). Static emission image at 30 minutes after injection. Computation requires information collected from patient and scan (see PET Overview). Use the same clock when entering the time information. • Dynamic image (determines metabolic rate of tumors): Acquire transmission image, acquire sequence of images beginning with injection of radiotracer for 60 to 90 minutes. • Whole body image: Transmission image (for attenuation correction). If patient is moved, exact repositioning is required. Head to foot unless a more specific area has been specified. • Bone mineral PET and PET/CT scan • 18F-sodium fluoride (10–20 mCi, 370–740 MBq) is used as a bone agent for whole body scans. Free 18F from other types of radiopharmacy tends to localize in the bones. • Indications are similar to Tc agent bone scans, e.g., metastasis, bone pain, bone grafts, Paget’s, but also differentiation of benign and malignant bone lesions. Patient prep is the same as above. • Image acquisition and attenuation correction are the same as listed. • 18F-sodium fluoride can be combined with 18F-FDG for a whole body, providing anatomic markers for localization of FDG avid tumors. • PET/CT: • Some scans require oral contrast upon arrival unless contraindicated. Studies that do not are, e.g., cardiac exams, brain studies, and head and neck cancer studies. • Patient to void before study. • Place patient supine on imaging bed reminding him or her to lie very still. • Use breath hold technique of choice, e.g., shallow for both, total for CT/shallow for PET, etc. • Scout image at 120 kV, 10 mA. • CT imaging at 140 kV, auto mA 100–200 lbs for normal size patient or 140 kV, auto mA 200–400 lbs for large. • PET imaging at 3 minutes FOV 100–200 lbs for normal or 5 minute FOV 200–400 lbs for large. • CT imaging lower extremities at 140 kV, 80 mA. • PET imaging lower extremities at 2 minutes FOV. • CT imaging brain at 140 kV, 80 mA. 225

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 226

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

•

•

• • • •

• PET imaging brain 3D at 10 minutes FOV and 20 minutes for 2D. • Skull to mid-thigh, arms down: Single pulmonary nodule, lung, colon, lymphoma (arms up if in head and neck area), breast, esophageal, head and neck (arms down, head holder, 2 FOV), thyroid (arms down, head holder, 2 FOV). • Melanoma: Top of head to lower extremities, arms down. • Seizures: 3D, entire head, arms down, use head holder. • Alzheimer’s: 2D, entire head, arms down, use head holder. • Myocardial viability: 2D, arms up. • Another CT set-up: Example: 8 slice: 3.75 mm thick, pitch 1.67:1, 16.75 mm/rotation, 80 kV small pediatric, 100 kV large pediatric, 120 kV normal adult, 140 kV obese adult, 200–400 mA depending on size. Using IV and oral CT contrast can be used with PET/CT: Barium should be oral glucose-free 1.3% to 2.1% barium sulfate 500–750 mL, administered 60 to 90 minutes before FDG injection. A second administration of oral barium is given 30 minutes after the FDG injection. The patient rests quietly for 30 minutes. CT is performed just before PET, using IV contrast (300 mg I/mL) 80 mL at 3 mL/sec for arterial contrast, followed by 60 mL at 2 mL/sec for venous and parenchymal enhancement. Example: Oral contrast 450 mL Redi-Cat (1 bottle) at 60 minutes before exam time if used. At exam time, IV contrast Optiray (320), 2 mL/sec, 80 mL total. Then saline 2 mL/sec, 30 mL total (dual injector). At 55 seconds, CT scan is performed with contrast. Allergy: If patient is allergic to Redi-Cat, use Gastroview (10 mL/450 mL H2O). At 55 seconds: CT scan from base of skull to mid-thigh (5 mm cuts) (25 second breath-hold if possible. If patient cannot hold breath for entire study, begin slow exhale). PET scan from mid-thigh up to skull base (shallow breathing). Whole body CT used for attenuation correction of PET scan.

Oral Contrast Protocol (Example) • • • • • • •

For colon, ovarian, cervical, bladder cancers. Mix 10 mL Gastrografin in 1 L H2O (or 1 oz Gastrografin in 12 oz water or lemonade Crystal Light®). Administer one third upon arrival (or 1 12-oz cup). Administer one third (or 1 12-oz cup) 20 minutes after injection of 18F-FDG. Administer one third (or 1 6-oz cup) just before imaging session. If patient cannot tolerate contrast, water should be administered before scan. Pretreatment protocol for iodine allergy patients (by physician’s order): For morning exams, prednisone 50 mg oral, three doses, 6 p.m. day before, 12 midnight, 1 hour before exam. Afternoon exams, 12 noon day before, 7 a.m. morning of exam, 1 hour before exam. Also, administer Benadryl® 50 mg oral 1 hour before exam.

Processing • Images filtered and reconstructed in transverse, coronal, and sagittal planes, according to manufacturer’s specifications. Images of head, neck and torso reconstructed using segmented attenuation correction (SAC). SAC may also be applied to images of extremities at physician’s request. • Coronal and axial views of the scan filmed on printer, additional views as per physician. • PET/CT: At authorized user’s request, PET studies can be fused with CT using, e.g., MIM software if scanner is not a fusion camera. • A rotating maximum intensity projection (MIP) can be useful in detection and localization of tumors. • There may be four groups of images in each study (example): Scout, 2D AC, 2D NAC, and CTAC. Erase scout before sending/saving images. Send/save in chosen format and protocol.

NORMAL RESULTS • Uptake in brain (high in gray, low in white matter, cortex, basal ganglia), Soft palate, tongue, vocal cords, palatine tonsils, adenoids, parotids, submandibular glands (decreases with age), thyroid (can be high with Graves’ disease or thyroiditis), and neck muscle. 226

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 227

Chapter 39 — PET: Whole Body (Tumor) Imaging 18F-FDG and PET/CT

• Myocardium (even despite fasting in some), aorta (bandlike in thoracic aorta), liver, spleen, stomach, small and large bowel (ascending colon appearing tubular), esophagus (usually diffuse), thymus in children and young adults, kidneys, ureter, bladder, urine (contributing to contamination), and bone marrow (can be high after stimulating agents). Skeletal muscle will present if recently active or tense. Brown or USA fat (females and cold environment), e.g., supraclavicular, paravertebral, intercostal. Uterus during menses. • Low level uptake in lung, breast (more in young women and with lactation), testes, and penis. • Increased uptake in surgical wounds (up to 6 months after surgery). • No activity usually seen in pancreas, prostate, lymph nodes, or around breast implants. • After cancer therapy, uptake common in the axial skeleton, brown fat (posterior neck and shoulders), costovertebral joints of cervicothoracic spine, and around large upper abdomen organs. • Normal SUVs: see Chapter 36, PET Overview.

ABNORMAL RESULTS • High uptake in neoplasms in, e.g., larynx, esophagus, colorectal, melanoma, non-small cell lung, lymphoma. • Moderate uptake in neoplasms in, e.g., thyroid (follicular, medullary, papillary, Hürthle cell), lung, breast. • Low uptake in neoplasms in, e.g., brain metastasis, hepatoma, renal and bladder, prostate, carcinoid, mucinous. • Variable uptake in neoplasms in, e.g., head and neck (squamous cell and adenoid cystic carcinoma), skeletal metastasis, uterine, cervical, testicular. • Increased uptake in infections and inflammatory type tissue, e.g., pneumonia, cellulitis, osteomyelitis. • High uptake in granulomas, e.g., sarcoidosis, tuberculosis. • Increased uptake in trauma from, e.g., recent surgery, fracture, aortic graft, radiation therapy. • An SUV of >2.5 is suggestive of malignancy.

ARTIFACTS • • • • • • • • • • • • •

Excessive physical activity before the exam will cause muscle uptake. Food intake before the exam will cause diffuse global uptake. Elevated glucose levels will cause decreased tumor uptake, increased muscle and cardiac uptake. Caffeine and nicotine will cause decreased cardiac uptake. Light and noise during or shortly after injection will cause focally increased brain uptake. High density barium may cause attenuation. Free fluorine tends to accumulate on the bones. Marrow uptake may occur in patients undergoing GCSF therapy. Axilla lymph nodes may visualize with dose extravasation. Inability to lie still or place arms over head may hamper acquisition. Claustrophobia may be relieved by adavan or valium by physician’s order. Patient positioning and movement are crucial to imaging outcome. Patient movement or relocation between transmission attenuation correction scan and emission scan (diagnostic PET study) may result in misalignment artifacts. • Repositioning, if needed, must be exact to eliminate alignment artifacts. • Residual bowel activity and urinary tract activity may hamper interpretation of local FDG accumulation in the pelvis and/or abdomen. Foley catheter, diuretic, and/or hydration may be helpful. • False-positive: Infections and inflammatory disease (nearly any “–itis”). Uptake in thymus, especially in younger patients. Increased uptake of pulmonary parenchyma after radiation in pneumonitis and the pleura. Uptake in paraspinal and other skeletal muscles. Others: granulomatous disease, aortic atherosclerosis, hiatal hernia, empyema, pleurodesis, pneumonia, other bacterial infections, biopsy sites, bypass grafts, endometriosis, benign bone lesions, healing fractures, 227

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 228

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

wound healing, ostomies, etc. Focal, often symmetric uptake in neck, supraclavicular, and axillary areas may indicate brown fat. • False-negative: Chemotherapy and radiation may decrease tumor uptake. Other: low-grade gliomas, bronchioalveolar cancer, carcinoid, solitary pulmonary nodule <1 cm, lobular carcinoma, carcinoma in situ, tubular carcinoma, hepatocellular cancer, small lesions, renal cell cancer, chondrosarcoma, plasmacytoma, low-grade sarcomas, sclerotic metastasis, small lesions and metastases located next to FDG-avid primary cancer site or high activity organ. • Appearance of peripheral body or skin activity with reconstruction without attenuation correction.

NOTE • Another method of grading hypermetabolic lesions (other than SUVs) is a 0 to 4 grading system and reading the images in gray scale. The brain cortex, because it displays consistent FDG uptake (except for diabetic patients) is set at black and is the 4 reference point. Grade 0 is no uptake. Grade 1 is a comparably weak uptake (general body uptake). Grade 2 is moderate uptake (comparable to liver). Grade 3 is high uptake (between brain and liver). Grade 4 is very high uptake, and comparable to (equal to) the brain uptake. The method works well for initial staging of tumors but may fall short in analyzing more subtle changes after therapies. SUVs may be more accurate in those cases. Comparably, SUV ranges have the liver around 1.5 and the brain is above 4. See Chapter 36, PET: Overview. • Also, see Chapter 38, PET: Cardiac for glucose adjustment protocols.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Are you claustrophobic?

Y

N

Can you hold your arms over your head?

Y

N

Are you diabetic or have blood sugar problems?

Y

N

Do you take insulin? If so when was your last treatment?

Y

N

Are you fasting? If not, when did you eat last?

Y

N

Have you had vigorous exercise in the last 24 hours?

Y

N

Have you had any surgeries within the last 6 months?

Y

N

Have you had any recent sickness or infections?

Y

N

Do you have a pacemaker or any implanted devices?

Y

N

If so, what type and for how long? What is your height and weight?

What medications are you taking?

228

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 229

Chapter 39 — PET: Whole Body (Tumor) Imaging 18F-FDG and PET/CT

Have you had any recent chemo or radiation therapies (area)?

Y

N

Have you had any recent diagnostic procedures?

Y

N

Do you have films or reports of prior exams?

Y

N

Do you have any problems with micturition, or incontinence?

Y

N

With CT: are you allergic to iodine?

Y

N

Do you have any allergies or asthma?

Y

N

Do you have any pathology or laboratory reports?

Y

N

Female: Are you pregnant or nursing?

Y

N

Are you in menses? LMP?

Y

N

Are you pre/post menopausal?

Y

N

Are you taking any hormone therapy?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of FDG-PET Scintigraphy in Oncology. Revised 2006, acr.org. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Schulthess GK. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Shared PET Imaging of Florida/Shared PET Imaging, Canton, OH. 2007. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Tumor Imaging using F-18 FDG. Version 2.0, February 7, 1999. SNM.org. Westcoast Radiology Protocol for 18-F-FDG/CT, Clearwater, FL. 2007

229

10766-39_CH39.qxd

12/3/07

4:47 PM

Page 230

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notes

230

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 231

chapter

40

ProstaScint® Scan (Radioimmunoscintigraphy [RIS]) RADIOPHARMACY Radionuclide 111In t 1/2: 2.8 days Energies: 173, 247 keV Type: EC, γ, accelerator • 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

•

Radiopharmaceutical In-capromab pendetide, or 111In-CYT-356, a whole murine monoclonal antibody, 7E11-C5.3 conjugated to the linker-chelator, glycyl tyrosyl-(N, ∈-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYKDTPA-HCL). • 99mTc: Tagged red blood cells by pyrophosphate (pyp) or stannous chloride to 99mTc 04− by in vivo, in vitro or kit, e.g., UltraTag®.

•

111

Localization •

lium known as prostate-specific membrane antigen (PSMA). PSMA is located in the cytoplasmic domain and is not expressed on any other adenocarcinomas or transitional cell cancers. • 99mTc: Compartmental, tagged to and circulating with blood

Quality Control •

111

In-capromab pendetide: Produced by serumfree in vitro cultivation, purified by sequential protein isolation and chromatography. Chemical tag must be > 90%. • 99mTc 04−; chromatography. Tagging; 90% in vivo, 95% in vitro.

Adult Dose Range •

111

In-capromab pendetide: 4.5–7 mCi (166.5–256 MBq). • 99mTc: 5 mCi (185 MBq).

111

In-capromab pendetide: Chemical bonding to glycoprotein expressed by prostate epithe231

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 232

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Method of Administration • Intravenous large-bore butterfly catheter (18–22 ga) over 5 to 20 minutes in up to 30 mL saline with 10-mL flush. • Vital signs monitored before injection and at 5, 15, 30, and 60 minutes after injection

(some simply observe patient for 15 to 30 minutes looking for redness at injection site or signs of nausea and vomiting). • Physician or nurse should be available for possible allergic reaction (1 mg epinephrine IV available).

INDICATIONS • Detection and localization of clinically suspected prostate cancer (via abnormal biopsy, x-ray, PET, CT, MRI, ultrasonography [US]) with a high risk of metastasis. Metastatic growth occurs by both lymphatic and hematogenous routes. • Evaluation of elevated prostate specific antigen (PSA; 8–10 times normal upper limit, normals are 0–6.0 ng/mL in most cases, or Gleason sum of 3–7). Patients with a history of cancers, suspicious biopsy, or known cancers are candidates. • Evaluation of patients with a high risk for lymph node metastasis, e.g., elevated prostatic acid phosphatase and PSAs (≥8 times upper normal limits), corroborating PET, CT, MRI, and/or US. Lymphatic metastasis first appears in areas of the obturator and internal and external iliac nodes. • Evaluation of patients with a high clinical suggestion of occult recurrent or residual prostate cancer, elevated PSAs after radical prostatectomy, negative bone scan, and/or negative PET, CT, MRI, or US, ≥0.8 ng/mL PSA levels and increasing. • Evaluation of pre-surgical, post-surgical, and therapy treatments.

CONTRAINDICATIONS • • • • • • •

Patients who are sensitive to this or any other product of murine. Patients who are not at high risk for developing prostate cancer. Patients at risk of human anti-mouse antibody (HAMA) reaction. Patients who have had a recent positive bone scan. Patient unable to tolerate lying immobile in a supine position. Not for screening for carcinomas. Patients who are female.

PATIENT PREPARATION Before Day of Injection • Physician to instruct patient to take a mild laxative (cathartic) evening before imaging. Also, it may be required to have a cleansing enema 1 hour before each imaging session. Patient should receive a written copy of the bowel preparations. • Ensure that patient can remain in supine position and motionless for extended periods of time. • Instruct patient to increase fluid uptake for duration of examination. • Obtain preinjection blood sample and baseline vital signs if protocol.

Day of Injection • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure and possible HAMA reaction. Obtain a written consent from patient. Administer injection to patient and wait according to protocol to image. Monitor patient’s vital signs after injection, 15–60 minutes as to protocol. Instruct patient to empty bladder completely (catheterize if necessary) before each imaging session.

232

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 233

Chapter 40 — ProstaScint® Scan (Radioimmunoscintigraphy [RIS])

• Injection should be planned for Monday, Thursday, or Friday to accommodate the 96-hour (day 4) return for imaging sessions.

Day Prior to Imaging • It is exceptionally important that the patient’s bowels contain as little digesting food as possible. For this reason, strict regimens must be followed for exam. • One suggested regimen: • 12:00: Liquids only for the next 24 hours, e.g., broth, gelatin, juices, soups, tea, coffee, sodas, etc. • 4:00 p.m.: Drink entire contents of magnesium citrate over ice. • 5:00 p.m.: 8 ounces of water. • 6:00 p.m.: Liquid dinner. • 7:00 p.m.: Take three laxative tablets with 8 ounces of water. • 8:00 p.m.: Drink 8 ounces of clear liquid. • 9:00 p.m.: Drink 8 ounces of clear liquid. • 10:00 p.m.: Insert one suppository into rectum as far as possible, retain as long as comfort will allow, usually 10–15 minutes, before defecating. • Next morning, take Fleet Kit® enema approximately 1 hour prior to leaving home for exam. • Instruct patient to empty bladder completely (catheterize if necessary) before each imaging session.

EQUIPMENT Camera • Large field of view

Collimator • Medium energy, general purpose

Computer Set-up • To ensure quality, peak camera for isotope energies before each imaging session. Planar (Statics) Torso • 111In: 800,000 counts or 10 min/image; extremities and skull, 5 min/image 99mTc: If

done separately, 5 minutes/image. 256 × 256 × 16 matrix Whole Body • 512 × 1024 matrix, 4–10 cm/min (minimum 35 minutes) head to mid-thigh Single Photon Emission Computed Tomography (SPECT) • Noncircular 360°, 64 stops/head, 25–60 sec/stop, 128 × 128 matrix, 99mTc window; 140 keV–5%, 111In windows; 173–15%, 247–20%. Weiner or Butterworth filter, cutoff 0.5, order 5, slice thickness 6 to 12 mm.

PROCEDURE (TIME: ~1–2.5 HOURS EACH SCAN DAY) Single Isotope Procedure: 111In • • • • • •

Instruct patient to void before each imaging session. Place patient supine on table, check for attenuating items. Instruct patient as to no movement during acquisition. Position camera as to images desired. Obtain images as to protocol (options below). Acquire two SPECT imaging sessions: • Pelvis at 30 minutes after injection to identify blood pool. Use 25 seconds/stop. • Pelvis and abdomen to include lower liver margin to prostatic fossa at 72 or 96 to (if necessary) 120 hours after injection. Use 50 seconds/stop. 233

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 234

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Acquire 72- or 96- and (if necessary) 120-hour delays. • Whole body or planar views of pelvis, abdomen, and thorax at these times.

Optional Imaging Protocols • Immediates: Inject and wait 30 minutes, and then obtain planar or whole body sweep. • Delays: 48-, 72-, 96-, and/or 120-hour delays as to protocol. Include planar, whole body, and/or SPECT. Check with nuclear physician or radiologist. • Planar: 800 k counts or 10 minutes at 6 to 8 hours, and 24 hours postinjection. • Acquire marker planar image of bony prominences or other for reference. • Acquire anterior/posterior thorax, abdomen/pelvis, and tail-on-detector (TOD) for 10 minutes/ image. Also images of proximal humeri, femurs and skull for 5 minutes/image. • Whole body sweep can be taken at each session. • SPECT: 6 to 8 hours and 24, 48, 72, 96, and/or 120 hours. • Clinical trials used two sessions between 2 and 5 days postinjection.

Dual Isotope Procedure: 111In and 99mTc • 96 hour (day 4) and optional 120 hour (day 5) images used to verify any bowel activity from day 4 images. The use of tagged red blood cells is to help identify the blood pool areas in the pelvic basin and abdomen. • Patient: Same bowel preparation as before. • Injection is administered as above on day of injection. • Day 4 (96 hours): Planar then SPECT • Cameras are set up to take indium and technetium images • When patient arrives, draw blood and do a standard tag with UltraTag®. • Instruct patient to void before imaging begins. • Statics: Cameras set with 111In windows at 20%, 99mTc at 20%. 600 seconds per image. 256 × 256 × 16 matrix. • Anterior/posterior pelvis. Penile blood pool (pubic symphysis) at lower limit of view. • Anterior/posterior abdomen. Slight overlap. • Anterior/posterior thorax. Mid-face/top of ears at upper limit of view. • Whole body sweep: Head to mid-thigh, using a 35-minute acquisition (total cm length 4 35 = cm/minute). • Patient to void again before next imaging session. • Reinject 99mTc tagged red blood cells containing 5 mCi (185 MBq) of activity. • SPECT images: 111In windows at 173 keV–15%, 247 keV–20%, 99mTc at 5%, 64 stops/head, 60 seconds/ stop, 128 × 128 matrix. • Pelvis. Penile blood pool (pubic symphysis) at lower limit of view. • Abdomen. Slight overlap. • If patient was not reinjected before first static images were taken and 99mTc window was not included, then patient is to void again and the following images acquired. Camera set to 99mTc window at 20%, 300 seconds per image, 256 × 256 × 16 matrix. • Anterior/posterior pelvis. Penile blood pool (pubic symphysis) at lower limit of view. • Anterior/posterior abdomen. Slight overlap. • Anterior/posterior thorax. Mid-face/top of ears at upper limit of view. • Day 5, SPECT only (optional). Patient to void before imaging. Cameras set to 111In windows at 173 keV–15%, 247 keV–20%, 64 stops/head, 70 seconds/stop, 128 × 128 matrix. • Pelvis. Penile blood pool (pubic symphysis) at lower limit of view. • Abdomen if necessary. Slight overlap.

PROCESSING • Static images are separated if necessary for the 99mTc images and 111In images. • They are processed with 111In and 99mTc side by side on same film for comparison of areas. 234

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 235

Chapter 40 — ProstaScint® Scan (Radioimmunoscintigraphy [RIS])

• • • •

SPECT images are separated for the 99mTc images and 111In images. Try a Butterworth filter with a cutoff 5, order .5 (6.22 also a suggestion). They should be filmed all the same size and intensity. New users of ProstaScint® must send a duplicate set of films of the first five patients to corporate over-readers to concur findings.

NORMAL RESULTS 111

In

• Excretion is relatively slow: 10% after 72 hours is excreted in the urine. • Uptake in immediates present blood pool, liver, spleen, bone marrow, kidneys, urinary bladder, and genitalia. Blood pool image differentiates blood vessels that can be confused with lymph node uptake in delayed images. • Bowel activity changes between sessions. • Blood pool, liver, spleen, kidney, and bone marrow diminish activity with time. • Increased activity at the base of the penis serves as landmark for SPECT transaxial and sagittal images, identifying the inferior level of the prostatic fossa. 99m

Tc

• Heart and great vessels prominent. • Bladder, bowel and penile activity not unlikely.

ABNORMAL RESULTS • Focal areas of uptake, particularly visible as time progresses and biologic activity diminishes background distribution. • Focal areas of activity in the region of the prostatic fossa, distinct from activity in the bladder or rectum. • Focal areas of uptake in bladder and/or seminal vesicles. • Focal areas of activity may also show in bone, pelvic lymph node chains, extrapelvic or abdominal lymph nodes, neck nodes, and distant lesions throughout. Lymphatic metastases first appear in pelvic vessels, e.g., the obturator, internal and external iliac, femoral, paraaortic nodes, etc. • Skip lesions: Positive abdominal (or more distant) lymph nodes in the absence of disease within the pelvic bed.

ARTIFACTS • There were high rates of false-positive and false-negative results in some clinical trials. This could result in the following: • Inappropriate surgical intervention to confirm results. • Inappropriate denial of curative therapy if results are not confirmed. • Inadequate surgical staging if only areas of uptake are sampled. • False-positives: ProstaScint® nonspecifically localizes to colostomy, degenerative joint disease, aneurysms, postoperative bowel adhesions, inflammatory masses associated with inflammatory bowel disease or secondary to surgery or radiation. • Staging pelvic lymphadenectomy, a sampling procedure that can miss metastatic spread, is still the standard for assessing the status of pelvic lymph nodes. Noninvasive modalities, e.g., PET, US, CT, and MRI, are also used for evaluation. Correct staging is critical to the selection of patients and primary therapy. • Bone scans are more sensitive to skeletal metastasis and should always be included. • There is urology literature stating that if a patient’s PSAs are < 15, then in most cases the bone scan will be negative for metastasis, thus negating the need for a bone scan before a ProstaScint® scan. 235

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 236

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Metastasis to the bone is very uncommon if PSAs are < 20 and there is no bone pain. • Acid phosphatase levels elevated in patients with metastatic prostate cancer. • As well as using PSA levels as an indicator, Gleason Grading for prostate cancer is a method employed by pathology labs, using tissue from biopsy, to determine the histologic grade (degree of aggressiveness) of a tumor.

Grades • Grades are numbered 1 through 5, with grade 1 most well differentiated cancer (slow-growing), and grade 5 most poorly differentiated (fast-growing). They assign one number to the primary grade (the most common pattern) and another number to the secondary grade (the next most common pattern). • Grade 1: Least common, especially in needle biopsies. Circumscribed mass of evenly placed uniform glands. Closely resembles normal prostate glands. • Grade 2: Similar to grade 1 but do not form a circumscribed mass. • Grade 3: Most common. Considerable variation in size, shape, and spacing of glands. • Grade 4: Fusion of glands forming anastomosing network punctuated by glandular lumens. Glands no longer recognized as individual units. • Grade 5: Cancer cells are solid sheets and clusters, may infiltrate prostate as individual cells. Necrosis may be present. No attempt at gland formation by cancer. • By adding the two grades (e.g., 3 + 2 = 5), a Gleason Score is obtained. The scale of combined grades is from 2 to 10. • Cytogen encourages sites using ProstaScint® to enroll in their Partners in Excellence (PIE) program to ensure that the scans will be interpreted only by physicians who have had specific training in the interpretation of these images. • Note: ProstaScint® is being used in conjunction with PET, CT, and MRI in fusion studies that can be used to direct external beam or cryotherapy therapy and surgical removal of some of the disease. Trials are being conducted by Cytogen Corporation using CYT-500, the same ProstaScint® antibody, as a therapy agent. It is labeled with lutetium-177 [177Lu: t1/2: 6.71 d, 208 keV (γ), 497 keV(β−)] allowing therapy for smaller tumors and imaging. As well as delivering radiation to tumors expressing PSMA within prostate cancer cells, CYT-500 also targets the same protein found on newly forming blood vessels that feed solid tumors in breast, lung, and colorectal cancers.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

Have you had any chemotherapy or radiation therapy?

Y

N

Have you had a recent ECG?

Y

N

Are there any recent or planned bone scans, other nuclear medicine, PET, CT, MRI, US, x-ray, or biopsy?

Y

N

If so, what type and for how long? Do you have any pain? If so, where and for how long?

236

10766-40_CH40.qxd

12/3/07

4:48 PM

Page 237

Chapter 40 — ProstaScint® Scan (Radioimmunoscintigraphy [RIS])

Are there any recent laboratory results (e.g., PSA levels,Gleason sum, electrolytes, glucose, blood urea nitrogen [BUN], creatinine, calcium, phosphorus, uric acid, total bilirubin, total protein, albumin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, acid phosphatase, urinalysis, HAMA titer, complete blood cell count [CBC])?

Y

N

Do you have any bowel disease, e.g., diverticulitis, colitis, Crohn’s disease, etc.?

Y

N

What medications are you presently taking? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Cytogen Corporation. http://www.cytogen.com/professional/prostascint/pi.php Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Sartori K. Prostate Agent Benefits from Technology Advances. Adv Imag Radiat Ther Prof 19(18), 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

237

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 238

chapter

41

Red Blood Cell Studies: Plasma Volume, Red Blood Cell Volume, Red Blood Cell Survival, and Splenic Sequestration RADIOPHARMACY Radionuclide 51Cr: t 1/2: 27.7 d Energies: 320 keV Type: EC, γ, accelerator • 125I: t1/2: 60.14 d Energies: 27, 16, 35 keV Type: EC, x and γ, accelerator

•

Radiopharmaceutical • •

51

Cr (Na2CrO4)-labeled red blood cells (RBCs) I-human serum albumin

125

Localization • Compartmental, tagged to, and circulating with blood.

Quality Control •

51Cr (Na CrO ) sodium chromate > 90%. 2 4 Tagging; 90% in vivo, 95% in vitro.

238

•

125

I-human serum albumin (HSA) is supplied as a unit dose. Assay the syringe in dose calibrator to confirm amount of radioactivity. Radiochemical purity > 97%.

Adult Dose Range • Plasma volume measurement: 125I: 10 uCi (.37 MBq) • Red blood cell volume measurement: 51 Cr: 10–30 uCi (0.37–1.11 MBq) • Red blood cell survival: 51Cr: 60 uCi (2.22 MBq) • Splenic sequestration: 51Cr: 10–30 uCi (0.37–1.11 MBq)

Method of Administration • Intravenous injection of tagged RBCs or 125I-HSA.

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 239

Chapter 41 — Red Blood Cell Studies

INDICATIONS • Plasma volume measurement: Evaluation for polycythemia vera, anemia, trauma and burns, blood loss/replacement therapy, preoperative elderly patient. • Red blood cell volume: Evaluation for polycythemia vera, anemia, trauma and burns, blood loss/replacement therapy, preoperative elderly patient. • Red blood cell survival: Evaluation of lifespan of homologous red blood cells, effect of therapy on patients with hemolytic anemia. • Splenic sequestration: Evaluation of spleen in deceased red cell survival.

CONTRAINDICATIONS • All: Patient having transfusion or phlebotomy within last 4 weeks. • Residual activity from previous radioisotope procedure.

PATIENT PREPARATION • • • • •

Identify the patient. Verify doctor’s order(s). Explain the procedure. Obtain consent for blood work. Ensure that the patient has had no transfusions or phlebotomy within the last 4 weeks. Ensure that the patient has not had a radioisotope test in recent past. These studies are often done in conjunction with each other.

EQUIPMENT Gamma Well Counter • •

125

I: Energy: 20–80 keV Cr: Energy: 285–365 keV

Collimator • Straight bore

51

Camera: Splenic Sequestration Only

Computer Set-up • Energy: 285–365 keV

• Scintillation probe

PROCEDURE

(TIME: 30–60 MINUTES PER SESSION)

• Most of these tests are now only done by special radiopharmacies that complete the tests at designated laboratories and send the results to the ordering physician. Check with the radiopharmacy for availability of these procedures.

Plasma Volume Measurement • Inject radiopharmaceutical with patient supine. Flush syringe well to ensure that all of the dose has been injected. • Using opposite arm, at 10 and again at 20 minutes, withdraw 20 mL of blood. • Transfer samples to heparin-containing tubes. • Remove a small sample of blood from each specimen for determination of micro-hematocrits. • Centrifuge the 10- and 20-minute specimens. • Label three counting vials: 10-minute plasma, 20-minute plasma, background. • Pipette 4 mL plasma from 10- and 20-minute samples to appropriate counting vials.

239

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 240

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Pipette 4 mL water into background vial. • Count vials and standard vial each for 1 minute (>10,000 counts). If the time needs to be longer to reach the count minimum, count them all the same. • Perform calculations and plot on semilog graph paper (refer to Klingensmith).

Red Blood Cell Volume Measurement • Place patient in supine position. • Draw 5 mL of acid-citrate-dextrose (ACD) anticoagulant solution into 50-mL syringe. • Using appropriate gauge (19-gauge) butterfly or indwelling catheter, withdraw 40 mL blood into 50-mL syringe. Gently mix capped syringe. • Flush infusion catheter and inject small amount of heparin to ensure patency for reuse. • Withdraw 30 mL from 50-mL syringe into ACD tagging vial. • Withdraw 5 mL from 50-mL syringe into “background” counting vial. Count for 1 minute in well counter: 285–365 keV. • Inject 100 uCi (3.7 MBq) 51Cr into ACD vial and let stand for 20 minutes. • At 20 minutes, inject 50 mg ascorbic acid into ACD vial and let stand for 10 minutes. • Start 21-gauge IV set in opposite arm and “heparinize.” • Withdraw 20 mL blood from ACD vial and inject through 21-gauge IV set. Save remaining blood in ACD vial for standard. • Wait 20 minutes for circulation. • Using 19-gauge IV set, withdraw 20 mL blood into heparinized syringe. • Patient is done and may be released. • Determine microhematocrit of standard and 20-minute collection in duplicate. • Label five vials: Standard whole blood dilute, standard plasma dilute, 20-minute blood specimen, 20-minute plasma specimen, background. • Pipette 1 mL standard whole blood from ACD tagging vial into dilution flask and add 99 mL water, mix. • Centrifuge remaining whole blood standard and pipette 1 mL of plasma into second dilution flask, add 99 mL of water, mix. • Pipette 5 mL of diluted whole blood standard and 5 mL of plasma standard into counting vials. • Pipette 5 mL of the 20-minute blood specimen into counting vial. • Centrifuge the 20-minute blood specimen and pipette 5 mL of plasma into counting vial. • Count vials each for 10,000 counts and reduce the results to cpm/mL, well counter at 285–365 keV. • Calculate red blood cell volume using work sheet (refer to Klingensmith).

Red Blood Cell Survival (12-Day Procedure) • Place patient supine. • Follow above steps through waiting for 20 minutes while reinjected patient circulates tagged blood. Withdraw 20 mL tagged blood into heparinized syringe. • Pipette 5 mL of blood into test tube and label tagged patient blood. • Centrifuge remainder of blood specimen and pipette 5 mL of plasma into a test tube and label tagged patient plasma. • Repeat the blood draw procedure on days 3, 5, 8, 10, and 12. • Refrigerate all collected specimens and vials. Ensure that they are all properly labeled. • Determine microhematocrits on each sample of blood. • Count all samples in well counter (swirl each sample first for homogeneity and geometry of counting, 10,000 counts or 5 minutes [whichever comes first], energy at 285–365 keV) and carefully document the results of each. • Reduce counting data to cpm/mL. • Record results on work sheet (refer to Klingensmith). • Plot the results on semilog graph paper. 240

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 241

Chapter 41 — Red Blood Cell Studies

Splenic Sequestration (12-Day Procedure) • • • • •

• • • • •

Usually performed in conjunction with Red Blood Cell Survival study. Use Red Blood Cell Survival study for labeling method (above). This study requires no labeled blood draw for calculation. Patient is placed supine for heart and liver counting or prone for spleen counting. Imaging area: Heart; center over left third intercostal space at sternal border, liver; center over ninth and tenth ribs in the midclavicular line, spleen; center two thirds of the way from the back to the left side of the patient at the level of the ninth and tenth ribs. Can use ultrasound to localize organs for use with counting probe. Acquire minimum of 300 counts from each site on each of day 1, 3, 5, 8, 10, and 12. Data processing: for each day; spleen count rate over heart count rate, liver count rate over heart count rate, spleen count rate over liver count rate. Plot spleen to heart ratios and liver to heart ratios on linear graph paper with days on x-axis (0–12 days) and organ ratio on y-axis (0–3). Can be done with gamma camera and processing using counts in areas of interest.

NORMAL RESULTS Plasma Volume Measurement • Males and females: 30–45 mL/kg. • 9% of human serum albumin diffuses into extravascular space within first 10 minutes.

Red Blood Cell Volume Measurement • Males–25–35 mL/kg • Females–20–30 mL/kg

Red Blood Cell Survival • Normal RBC t1/2 = 25 to 35 days. • Normal RBCs have 120-day lifespan; 0.8% are lost through senescence per day. • Measured 51Cr RBC survival half-time not 60 days as predicted because of additional 1% loss of elution of tag from RBCs.

Splenic Sequestration • Spleen:liver ratio of 1:1 • Ratio remains about 1:1 over course of study.

ABNORMAL RESULTS Plasma Volume Measurement • Polycythemia vera: Usually normal, may be mildly increased or decreased. • Stress polycythemia vera: Diminished plasma volume, elevated hematocrit due to diminished plasma volume given normal RBC mass. • In diseased states, increase protein loss or increase vascular permeability, greater amount of HSA may be lost. More accurate plasma determination can be obtained by drawing more samples at 20, 30, and 60 minutes, then extrapolating back to time zero.

Red Blood Cell Volume Measurement • Polycythemia vera: Males > 36 mL/kg, females > 32 mL/kg. • Stress polycythemia: Normal or reduced RBC mass. 241

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 242

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Red Blood Cell Survival • <25- to 35-day survival. • Patient must be in a steady-state with no recent hemorrhage or transfusion. • If the hematocrit varies significantly (recent hemorrhage or transfusion), closer determinations of survival can be obtained by plotting whole blood cell counts without hematocrit correction.

Splenic Sequestration • Increased spleen:liver ratio. • Increasing spleen:liver ratio over course of study. • Splenomegaly without pathologic sequestration, can yield spleen:liver ratios of 2:1 to 4:1. Rising ratio is the best evidence of significant sequestration.

ARTIFACTS • Blood volume is plasma and red blood cell mass. White cells and platelet volumes are miniscule and do not affect these studies. • Plasma tracers exhibit leakage into extravascular fluids. Splenomegaly patients must be sampled early enough before leakage but late enough to ensure uniform circulatory and organ mixing. • Plasma volume is affected by congestive heart failure, low serum protein conditions, and debilitating illnesses. • If there is a possibility that the blood contains residual radioisotope, draw 4 mL and count in well counter. It should not measure above background. • For RBC volume, if extravasation of some cells occurs with reinjection, calculations will be falsely high. Check for extravasation by comparing counts in injection site to opposite arm with handheld probe. • For RBC survival, poor handling of the labeling process and nonhemolytic loss (gastrointestinal and genitourinary blood loss) may result in false-positive (abnormally reduced half-life). • False-negatives exist from transfusions prolonging normal survival times.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Have you had any recent transfusions or phlebotomy?

Y

N

Have you had any recent radioisotope studies?

Y

N

Do you have known splenomegaly?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long? What are your height and weight?

Other department-specific questions.

242

10766-41_CH41.qxd

12/3/07

4:50 PM

Page 243

Chapter 41 — Red Blood Cell Studies

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. General Electric. Nuclides and Isotopes, 14th ed. San Jose, CA: General Electric Company, 1989. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1992–93. Englewood, CO: Wick, 1993. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

243

10766-42_CH42.qxd

12/3/07

4:51 PM

Page 244

chapter

42 Renal:

Cortical Imaging (99mTc-DMSA) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

Quality Control • Chromatography, >90%. DMSA: Relatively unstable; a more stable form has been recently developed. Draw immediately after mixing into syringe. No O2 introduction. Use within 30 minutes of preparation. GH: Use up to 5 hours after preparation.

99m

Tc-DMSA (dimercaptosuccinic acid) Tc–GH (D-glycero-D-glucoheptonate complex, gluceptate, or glucoheptonate)

99m

Localization • Compartmental, blood stream; DMSA: 90% binds to plasma proteins, preventing any significant glomerular filtration, hence slow clearance from renal cortex (proximal convoluted tubules). Only 10% excreted through the urine in the first several hours. GH: a carbohydrate cleared from kidneys by renal tubules and glomerular filtration; 10% to 15% of injected dose remains bound to renal tubules.

244

Adult Dose Range • DMSA: 1–6 mCi (37–222 MBq), • GH: 10–20 mCi (370–740 MBq).

Method of Administration • Direct intravenous injection or IV catheter with saline flush.

10766-42_CH42.qxd

12/3/07

4:51 PM

Page 245

Chapter 42 — Renal: Cortical Imaging (99mTc-DMSA)

INDICATIONS • • • • • • •

Evaluation of renal cortex. Evaluation and quantitation of regional relative function. Evaluation and quantitation of differential function. Detection and localization of renal mass. Detection and differentiation of acute and chronic pyelonephritis. Evaluation for renal blood supply obstruction and/or trauma. Evaluation of renal transplant.

CONTRAINDICATIONS • None

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure, especially the delay between injection and imaging. Patient is to be well hydrated and should void before test begins. Patient is to discontinue angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB).

EQUIPMENT Camera

Computer Set-up

• Large field of view.

• Flow: 2–4 seconds/frame for 60–180 seconds. • Statics: 500,000–1 million counts. • Single Photon Emission Computed Tomography (SPECT); circular or noncircular, 360, 64 stops, 20–25 seconds/stop. ROI centered.

Collimator • Pinhole or low energy, all purpose, or low energy, high resolution.

PROCEDURE (VARIES GREATLY; TIME: INJECTION ~15 MINUTES, IMAGES ~45 MINUTES) • Place patient in supine position, camera under table, except for kidney transplant patients for whom camera is placed above the abdomen. Prone for pinhole collimator, kidneys in field of view (FOV). • Position camera with upper abdomen centered in FOV. • Obtain images: Wide variation in protocols for imaging; 50% of injected DMSA dose is in kidneys within 1 hour. • Some may require a flow study as in renogram studies. • Inject, take immediate statics (500,000–800,000 counts), then delays at 1 hour, using this 1-hour posterior view for processing. Also 4- to 6-hour delays, and 24-hour delays if requested. • Inject, patient returns in 2–6 hours for delay imaging, and again for 24-hour delays if requested. • Select imaging technique. Check with the radiologist. • Optional images: 500,000–800,000 counts, posterior (at least). Some take RPOs and LPOs 30°, RLATs and LLATs, and/or anterior if horseshoe kidneys are suspected or kidney transplant. 245

10766-42_CH42.qxd

12/3/07

4:51 PM

Page 246

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

(May need to magnify views for pediatric patients.) RAOs and LAOs and prone RPOs and LPOs have also been suggested. Whole body and single photon emission computed tomography (SPECT) have been suggested as well. Check with radiologist for views. • Generate percent uptake for each kidney. Select posterior static taken at least at 1 hour. Software differs: some have automatic programs; some will allow regions of interest to be drawn, giving counts within area. Add two counts together for total, divide each by total to give percent uptake for each kidney: Combined percents should equal 100. • Generate pictures of static images (and flow, whole body, and/or SPECT if taken).

NORMAL RESULTS • Assuming two kidneys, both kidneys visualizing about the same size and intensities if flow is performed. • Static images should yield bilateral smooth renal contour. • Hepatic uptake visualized, varies with degree of renal function. • Because of extremely slow rate of clearance of DMSA, collecting system may not visualize.

ABNORMAL RESULTS • • • • •

One or both kidneys are not visualized. One or both enlarged kidneys or decreased activity indicates pyelonephritis. Asymmetric activity indicates renal artery stenosis or hydroureteronephrosis. Gallbladder and gut are visualized in renal failure. Decreased renal distribution, increased liver uptake—ammonium chloride, sodium bicarbonate, mannitol. • Decreased DMSA uptake in HTN or RAS kidney patients—ACE inhibitors, e.g., captopril.

ARTIFACTS • Increased liver uptake with decreased renal uptake may be caused by chemical breakdown of radiotracer. • Acidic urine may produce similar results as above. • Some patients do not have both kidneys. • Patient still on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before test. • With dehydration, decreased kidney:liver ratio. • DMSA and GH are usually used for anatomic studies. Maintain patient hydration. • Misalignment on positioning.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of kidney disease (e.g., stones, infections)?

Y

N

Do you have both kidneys?

Y

N

If so, what type and for how long?

246

10766-42_CH42.qxd

12/3/07

4:51 PM

Page 247

Chapter 42 — Renal: Cortical Imaging (99mTc-DMSA)

Are there any recent or planned operations?

Y

N

Have you had a kidney transplant?

Y

N

Do you have any pain?

Y

N

Are you experiencing nausea or vomiting?

Y

N

Are you experiencing urinary frequency or urgency?

Y

N

Do you have any blood in your urine?

Y

N

Are you a diabetic?

Y

N

Do you have any cardiac diseases?

Y

N

Do you have high blood pressure?

Y

N

Do you have the results of any recent laboratory tests?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, where and for how long?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

247

10766-42_CH42.qxd

12/3/07

4:51 PM

Page 248

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notes

248

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 249

chapter

43

Renal: Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator • 131I t1/2: 8.1 days Energies: 364 keV Type: β−, γ, fission product

Radiopharmaceutical •

Quality Control Tc: chromatography, 99mTc-MAG3®: >95%, DTPA: chromatography >90%, use within 1 hour. • 131I: chemical purity test for 131I iodide (<1.5%), 131I-OIH (orthoiodohippurate) >97%, and 131I orthoiodobenzoic acid; radionuclide purity for anything other than 131I, spectrometer test for tracer tag.

•

99m

99m

Tc-DTPA (diethylenetriaminepentaacetic acid) • 99mTc-MAG3® (mercaptoacetyltriglycine) • 131I-OIH (orthoiodohippurate)

Localization

Adult Dose Range •

99m

Tc: 3–20 mCi (111–740 MBq) generally 10 mCi (370 MBq) for most studies. • 131I: 150–300 uCi (5.55–11.1 MBq)

• Compartmental, blood flow

249

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 250

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Method of Administration • Bolus intravenous injection • If study includes a diuretic use butterfly or IV catheter (furosemide 20–40 mg).

• ACE inhibitor study: • Captopril (Capoten® 50 mg) is given PO 1 hour before exam. • Enalapril maleate (Vasotec® .04 mg/kg intravenous over 3–5 minutes).

INDICATIONS • Evaluation for renal artery stenosis, obstruction, and/or trauma. • Evaluation of renal tubular function and perfusion (glomerular filtration) for blood flow, parenchyma, and excretion. • Evaluation of renal vascular flow (effective renal plasma flow). • Evaluation of renal obstructive nephropathy and/or hydronephrosis (study with furosemide). • Evaluation for renal (renovascular) hypertension (captopril study). • Evaluation of renovascular hypertension therapy. • Evaluation of abdominal or flank bruits, azotemia, pulmonary edema, retinopathy, and unexplained renal dysfunction. • Detection of acute tubular necrosis. • Evaluation of a kidney transplant.

CONTRAINDICATIONS • Iodine IV contrast study on same day. • Patient still on adrenal cortical extract (ACE, or angiotensin-converting enzyme) inhibitors (although some scans require the inclusion of their intake and function with the test) or angiotensin receptor blocker (ARB). These accomplish a similar action as an ACE inhibitor by a different mechanism. • If the test is ordered as a captopril study and the patient has taken an ACE inhibitor or ARB within hours before, some suggest taking a blood pressure. If it is normal or high, give the captopril and continue with the test. Check with the radiologist if it can be used as or with the captopril. If the blood pressure is low, the test may be rescheduled. • Food intake too close to a captopril study will decrease the sensitivity of the test and slow the absorption of the ACE inhibitor. • Captopril/enalaprilat challenge studies should be used advisedly, especially in cases of known severe stenosis. • Beta blockers may affect production of renin.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to hydrate well (water; up to 10 mL/kg) and void just before test. If it is a 1-day two-study test, the hydration should continue between studies. • Physician is to instruct patient to discontinue ACE inhibitors for several days (3–7) before examination depending on the half-life of the drug (e.g., captopril 48 hours, enalapril and lisinopril 1 week). There are cases where the patient cannot discontinue medication. • Physician may also choose to discontinue ARBs, diuretics, beta blockers, and calcium channel blockers. • Instruct patient to be NPO for at least four hours on morning before captopril study. • Post study voiding is recommended to lessen bladder exposure.

250

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 251

Chapter 43 — Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR

EQUIPMENT Camera

Computer Set-up

• Large field of view

Flow • 1–5 sec/frame for 1 minute.

Collimator • •

131

I: medium to high energy 99mTc: low energy, all purpose, or low energy, high resolution

Dynamic • 20–60 sec/frame for 1800 seconds. Statics • 500,000–1 million counts at 1, 3, 5, 10, 15, 20, 25, and 30 minutes (out to 60 minutes, depending on protocol).

PROCEDURE

(VARIES GREATLY; TIME: ~30 [BASELINE] TO 180 MINUTES [WITH CAPTOPRIL])

Baseline • If GFR is to be included, count the syringe before and after injection for 1 minute at 20–30 cm from camera face (use same distance both times). • Place patient in supine position, camera under table, except for kidney replacement patients for whom camera is placed anterior over the abdomen to include lower abdomen. • Position camera by point source over xiphoid, umbilicus, pubic symphysis, and sides in field of view. Some inject 100–200 µCi of 99mTc-MAG3® before starting camera to visualize kidney placement. • Bolus intravenous injection, start camera. Note: some wait until they see activity blush in abdomen (the “umbrella” effect caused by the heart-liver-spleen and descending aorta) before starting camera. To be sure, set flow for 120 seconds; start camera just before injection. • Diuretic (furosemide) study, use following options: • Insert intravenous butterfly with 3-way stopcock, inject furosemide, flush and inject a bolus of radiotracer. Protocols vary for furosemide injection time. Some wait until 10 to 15 minutes for obstruction studies. • For 1-minute flow: Inject bolus, start camera, inject furosemide, and flush. • Acquire statics at 2- to 5-minute intervals for 30 minutes or serial (dynamic) 1-minute images for 30 minutes. (Most systems have a preset for renogram, renal qualitative, or renal perfusion.) • If furosemide is separate (only study), take images for 5 minutes, inject over 2 minutes, and follow every 5 minutes for 30 minutes. • Always note the time in study when diuretic was administered.

Processing • Generate time/activity curve graph(s); renogram, differential function. • Generate percent uptake of each kidney. Select frame of dynamic study or static that has or appears to have the most counts. Software differs, some have automatic programs, some allow ROIs to be drawn, giving counts within area. Add two counts together for total, divide each by total to give percent uptake for each kidney, combined percents should equal 100. • Generate pictures of dynamic or static images. • Calculate GFR and/or ERPF (see below) if ordered.

Captopril • Patient is connected to blood pressure cuff machine, arm level with machine and a baseline blood pressure measurement is taken or done with a manual cuff and stethoscope. Note blood pressure. 251

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 252

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Administer 50 mg captopril (Tb = 48 hours) tablet PO with water (as much as 1 L). An option is to crush the tablet and dissolve in 150–250 mL of water. It may enhance absorption. • Patient is monitored closely (record blood pressures every 15 minutes by machine or manually, watch for reactions) for 1 hour, at which time patient is to void. • Patients may have reactions to the captopril. • Hypotension: Small women or patient already on BP medicines; elevate legs, hydrate patient. • Allergic reaction: Antihistamine (e.g., Benadryl® IV by nurse). • Position or reposition patient (1-day study) and repeat baseline procedure from start, including diuretic if ordered. • Take delays as per physician’s order. • These can be done as same day or separate day procedures. Captopril study can be performed first; if normal, it negates the need for a baseline study. Most want to see a baseline study regardless.

Enalaprilat • • • • • • • •

Start intravenous catheter or butterfly. Take blood pressure. Enalaprilat (Tb = 72 hours) use .04 mg/kg. This gives the total number of mg to use. Divide that number by 1.25 mg/mL to give the total amount of fluid to infuse using normal saline to fill to that amount. The patient should not receive more than 2.5 mg per 2 mL. Infuse slowly over 5 minutes. Monitor blood pressure. Begin imaging 15 to 20 minutes after infusion is complete.

Pre- and Post 1-Day Studies • Position patient for a baseline study. Medication restrictions and hydration still apply. • The combined study is usually accomplished using a low dose/high dose combination, e.g., 1–3 mCi (37–111 MBq) 99mTc-DTPA or MAG3® for the baseline, 8–10 mCi (296–370 MBq) 99mTc-DTPA or MAG3® for the captopril study. • Follow the baseline instructions above. • When study is complete, allow patient to void. Continue with hydration. • Take a baseline blood pressure. If blood pressure is suitable as described above, give 50 mg captopril tablet (or inject enalaprilat). • Follow captopril (enalaprilat) instructions above.

NORMAL RESULTS • Assuming two kidneys, both kidneys visualizing about the same size and intensities. Both graphs peaking with parallel up-slope and within 3 seconds of aortic peak and dropping off (excretion) at the same rate. • Static images should yield a smooth renal contour. • Time-to-peak concentration is 3 to 5 minutes. • Clearance t1/2 is 12 to 15 minutes. • Furosemide suggested normals: t1/2 washout time from injection is suggested at < 15 minutes; 15–20 minutes is indeterminate. Curves are declining and continue to do so after administration of diuretic. • A normal captopril or enalaprilat renogram obviates the need for a baseline study. • GFR (glomerular filtration rate) = 125 mL/minute. • ERPF (effective renal plasma flow) 500–600 mL/min. • Filtration fraction (GFR ÷ ERPF) = .2 252

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 253

Chapter 43 — Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR 99m

Tc-MAG3® Renogram

• • • • •

Renal cortical activity (RCA) at 20 minutes .3 or < 30%. Time to peak activity (Tmax) is 3 to 5 minutes. Relative renal uptake ratios at 2 to 3 minutes is 50%. T1/2 of peak activity is 8 to 12 minutes. Differential cortical activity at 15 minutes should be equal.

99m

Tc-DTPA or 99mTc-MAG3® with Captopril

• Captopril renal cortical activity (RCA) at 20 minutes < 30%. • Captopril time to peak activity (tmax) is 3–6 minutes. • Captopril renal function: tubular excretion rate (TER) ratio is 40:60.

ABNORMAL RESULTS • • • • •

• • • •

•

• • •

One or both kidneys not visualizing. One or both enlarged kidneys, decreased activity—pyelonephritis. Asymmetrical activity—renal artery stenosis, hydroureteronephrosis. Graphs not having parallel input and excretion drop-off rates. Slow up slope and/or down slope in one or both kidneys. Corrected slopes after captopril may mean renal artery stenosis. Uncorrected slopes after captopril may mean obstruction or nephrosis of tissue, problems other than but perhaps as well as stenosis. Increased spleen and liver activity indicates renal failure. Relative renal uptake ratios at 2 to 3 minutes of 40% or less. Lasix® (furosemide) distinguishes benign dilated systems from mechanical obstruction. Furosemide: Suggested abnormal t1/2 washout time is 20 minutes or greater from injection. With dilated nonobstructive studies (curves rising), after diuretic injection the system releases urine (curves decline). In mechanical obstruction, the curves rise and continue to do so after diuretic is administered. Captopril: Renal uptake at 2 to 3 minutes by one kidney > 40% if total, retained cortical activity at 20 minutes differing from contralateral kidney > 20% or increase from baseline of 0.15, time to peak activity in affected kidney > 2 minutes compared to baseline or nonaffected kidney. Bilateral changes after captopril are more likely associated with hypotension, salt depletion, calcium channel blockers, and/or low urine flow rate. Acute rejection of transplanted kidney: Delayed DTPA, diminished 131I-hippuran. Transplants as above. 99mTc-sulfur colloid can be used to confirm acute rejection because the agent localizes in fibrin thrombi of rejecting transplant. It is not so sensitive in chronic rejection.

ARTIFACTS • • • •

Some patients do not have both kidneys. Injection problems for flow or bad start. Misalignment on positioning. Infiltration at the injection site can alter renography curves, food within 4 hours of study, pelvic retention, dehydration, hypotension, or full bladder at the start of the study. • Spleen may overlie left kidney giving increased left kidney perfusion or “phantom kidney” in patients with left nephrectomy. • Because DTPA in small amounts (5–10%) binds to plasma protein, it tends to underestimate the GFR. 253

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 254

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Patient still taking ACE inhibitors or ARB before test. • The Teveten® Internet site states that its research indicates that the black population (generally a low renin population) responds less to ACE inhibitors and angiotensin II inhibitors than other populations. • False-positives of mechanical obstruction: poor hydration and/or poor underlying renal function eliciting poor diuretic response, noncompliant or rigid renal pelvis, high filling pressure of bladder, overcompliant or patulous (open) renal pelvis allowing pelvis to fill and not wash out, large hydronephrotic volume (reservoir effect).

NOTE •

•

•

•

•

99m

Tc-MAG3® is used more in clinical practice than 99mTc-DTPA because 99mTc-MAG3® is 95% cleared by the proximal tubules with 5% filtration and behaves more like the classic gold standard of orthoiodohippurate. It has an extraction fraction of 40% to 50%, which is more than double 99mTc-DTPA (about 20%). This is particularly useful in the diagnosis of obstruction or impaired renal function. DTPA is more cost effective, however. Baseline and captopril studies are routinely performed on a 1- or 2-day protocol. If a 1-day protocol is desired, usually a baseline renogram is performed, captopril is given (or enalaprilat; .04 µg/kg IV for 3–5 minutes) with the patient monitored closely for 1 hour (peak activity for captopril), 20 minutes for enalaprilat, then a second injection and renogram are performed. Furosemide studies (diuretic renography) distinguishes between obstructive hydronephrosis and nonobstructive collecting system dilatation. Dilatation can be caused by vesicoureteral reflux, urinary tract infection, congenital malformation, previous obstruction, or a noncompliant bladder. A functional obstruction may be overcome by the diuretic with the production of more urine causing the ureteropelvic junction to open, permitting flow where a fixed anatomic obstruction would not be expected to allow the flow even with the diuretic. Injection of the diuretic should be delayed until the collection systems are full, usually 15 to 20 minutes after the injection of the radiotracer (even later in known hydronephrotic renal systems). 20 to 40 mg may be administered (1 mg/kg up to 40 mg for pediatric patients) and up to 80 mg for patients with known impaired renal function. Response to furosemide is usually within 2 to 5 minutes peaking at 15 minutes after injection. Reporting renal hypertension is high, intermediate and low probabilities. High probability; > 90% for renovascular hypertension (RVHTN), marked changes on the renogram after ACEI compared with the baseline, Intermediate; 50–75% RVHTN, abnormal baseline findings, renogram unchanged after ACEI, Low; < 10% RVHTN, normal ACEI findings and/or abnormal baseline findings that improve after ACEI. 123I-orthoiodohippurate is available in some countries and acts very similar to 131I-OIH and 99mTc-MAG ®. 3

Calculating the Glomerular Filtration Rate (GFR) • Some software have automatic programs, just enter the information. This is a simple method for the “do-it-yourself-ers.” • Gates method (one rendition). • Using about 3 mCi (111 MBq), count syringe for 1 minute. • Inject and get flow, then at least a 5-minute dynamic or five 1-minute static images. • Choose the 2- or 3-minute picture for processing. • If a renogram is also involved, let it run out. Either way, take a 1-minute postinjection count of syringe. Follow these easy steps: • Net dose counts = preinjection syringe counts − postinjection syringe counts. • Tonnesen method of kidney depth calculation: • Right kidney depth (cm) = [13.3 × pt. weight (kg) ÷ pt. height (cm)] + .7 • Left kidney depth (cm) = [13.2 × pt. weight (kg) ÷ pt. height (cm)] + .7 254

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 255

Chapter 43 — Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR

• Where weight is the patient’s weight in kilograms and height is the patient’s height in centimeters. • Percent renal uptake of kidney (counts taken from ROIs of kidneys and backgrounds using the 3-minute image). Rt kidney counts − bkg counts + Lt kidney count − bkg counts 2.718 − [ 0.153 × ( kidney depth )] 2.7 718 − [ 0.153 × ( kidney depth )] × 100 = % uptake preinjection counts − postinjection counts • GFR in mL/min = (% renal uptake) × 9.81270 6.82519

Effective Renal Plasma Flow (ERPF) • There are many methods to calculate ERPF: Here are two. ERPF = −51.1 + ( 8.21X ) − ( 0.019X 2 ) in mL/min where X = dose injected (counts/s) ÷ counts/s per liter of plasma from blood specimen taken 45 minutes after injection.

Schegel Method for 131I-OIH • Take 1-minute counts of preinjection and postinjection syringe at 20–30 cm from camera face (same distance for both). • Preinjection counts − postinjection counts = net injected counts. • From the 2-minute image regions of interest: ERPF =

( kidney counts − bkg counts × Y

2

× 100 )

net injected counts

where Y = kidney depth.

Tonnesen Method of Kidney Depth Calculation Right kidney depth ( cm ) = [13.3 × weight/height ] + .7 Left kidney depth ( cm ) = [13.2 × weight/heeight ] + .7 where weight is the patient’s weight in kilograms, and height is the patient’s height in centimeters.

Renin/Angiotensin/Aldosterone System • The kidneys, much like the liver, are important filters for the blood. All of the blood in the body’s circulation passes through the kidneys. The kidneys also help to regulate blood pressure along with neural controls and chemical controls. In the nephrons located in the cortex of the kidneys, a region called the juxtaglomerular apparatus exists in which the afferent arteriole and distal tubule come into contact. Granular cells in the afferent arterioles produce the enzyme renin and secret it into the bloodstream. Renin catalyzes the protein angiotensin into angiotensin I. Angiotensin I is then converted to angiotensin II by a “converting enzyme” as it passes through the lungs and other organs. Angiotensin II stimulates the secretion of aldosterone causing the reabsorption of Na+ into the distal convoluted tubules and thus back into the bloodstream. Na+ helps regulate blood volume and blood pressure. A drop in blood volume is accompanied by a drop in blood pressure. Na+ in the bloodstream maintains blood volume by controlling water content. A detected decrease in blood volume by the juxtaglomerular apparatus stimulates the granular cells to release renin and by the above mechanism increases blood volume and blood pressure. 255

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 256

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ACE Inhibitors • ACE inhibitors block the formation of angiotensin II. Angiotensin II is the potent vasoconstrictor that constricts the efferent glomerular arteriole. The normal renin-angiotensin II system helps maintain arterial blood pressure within normal limits, among other things. With renal artery stenosis, blood flow to the kidneys is reduced, stimulating the release of more than normal renin. This catalyzes the production of angiotensin I, which leads to angiotensin II. Angiotensin II then causes arterial constriction and sodium retention, resulting in increased systemic arterial pressure and blood flow to the stenotic kidney(s).

Angiotensin Receptor Blockers (ARBs) • Angiotensin II is formed from angiotensin I in a reaction catalyzed by ACE (kininase II). • Angiotensin II is the principal pressor agent of the angiotensin/renin system. Effects include vasoconstriction, stimulates synthesis and release of aldosterone, cardiac stimulation, and renal absorption of sodium. ARBs (. . . sartan) block vasoconstriction and aldosterone secretion of angiotensin II by selectively blocking and binding of angiotensin II to the AT1 receptor in many tissues, e.g., vascular smooth muscle and the adrenal glands. ACE inhibitors inhibit biosynthesis of angiotensin II from angiotensin I. ARB blockade of angiotensin II receptors inhibits the negative regulatory feedback of angiotensin II on renin secretion. The following is a partial list of ACE inhibitors and ARBs: Accupril® quinapril Accuretic® with furosemide Aceon Tablets® perindopril Altace® ramipril Atacand® candesartan Avapro® irbesartan Avalide® irbesartan Benicar® olmesartan Capoten® captopril Capozide® with furosemide Cozaar® losartan Diovan® valsartan Hyzaar® losartan Lotensin® benazepril Mavik® trandolapril Micardis® telmisartan Monopril® fosinopril Prinivil® lisinopril Prinzide® with furosemide Teveten® eprosartan Univasc® moexipril Uniretic® with furosemide Vasotec® enalaprilat Vaseretic® with furosemide Zestril® lisinopril Zestoretic® with furosemide Ace inhibitors with calcium channel blockers: Lexxel® enalapril Lotrel® benazepril Tarka® trandolapril

256

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 257

Chapter 43 — Renogram, Diuretic, and Captopril: Tubular Function, ERPF, and GFR

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of kidney disease (e.g., stones, infections)?

Y

N

Do you have both kidneys?

Y

N

Are there any recent or planned operations?

Y

N

Do you have any pain?

Y

N

Are you experiencing nausea or vomiting?

Y

N

Are you experiencing urinary frequency or urgency?

Y

N

Do you have any blood in your urine?

Y

N

Are you diabetic?

Y

N

Do you have any cardiac diseases?

Y

N

Do you have high blood pressure?

Y

N

Do you have the results of any recent laboratory tests?

Y

N

Y

N

If so, what type and for how long?

If so, where and for how long?

What medications are you currently taking (please list)? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. 257

10766-43_CH43.qxd

12/3/07

4:52 PM

Page 258

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Diagnosis of Renovascular Hypertension. Version 3.0, June 20, 2003. SNM.org. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

258

10766-44_CH44.qxd

12/3/07

4:54 PM

Page 259

chapter

44

Salivary Gland Imaging RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical

Quality Control • Moly-Al breakthrough, chromatography > 90%

Adult Dose Range • 8–12 mCi (296–444 MBq)

• Na 99mTcO4− (pertechnetate)

Localization

Method of Administration • Intravenous injection, good bolus for flow

• Compartmental to blood supply. 99mTcO4− is taken up by the parenchyma cells of the parotid and salivary glands.

INDICATIONS • Differentiation of Warthin’s tumor (benign parotid gland lesion, usually in elderly men and bilateral in presentation) from other malignant or benign salivary tumors. • Evaluation of function of palpable masses in parotid or salivary tissue. • Evaluation of salivary gland function, especially after head and neck irradiation. • Evaluation of anatomic size and position of salivary glands. • Evaluation and assessment of salivary glands for pre-external or interstitial radiotherapy candidates.

CONTRAINDICATIONS • None 259

10766-44_CH44.qxd

12/3/07

4:54 PM

Page 260

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Withhold thyroid-blocking agents (e.g., iodide or perchlorate) for 48 hours before examination. • Administer gum or citrus-flavored candy to stimulate salivary glands.

EQUIPMENT Camera

Flow • 1 sec/image for 60 seconds

• Large field of view

Dynamic • 1- to 3-minute images for 30–60 minutes

Collimator • Low energy, all purpose, or low energy, high resolution

Statics • 300,000 counts or 180 seconds per view

Computer Set-up • 128 × 128 matrix, some magnify at ×2 − ×4

PROCEDURE

(TIME: 60–90 MINUTES)

• Place patient in supine position on table, pillow under shoulders, neck extended, camera anterior over face and neck, as close as possible. For markers e.g., right side, suprasternal notch (SSN), tip of nose. • Administer injection to patient; start camera. • Obtain one of the following: • Flow and dynamics for 30–60 minutes. Then, obtain anterior marker image, left and right laterals. • Flow with statics at 15 minutes after injection, 3 minutes per view. Some obtain images at 2, 5, 10, 15, 20, and 30 minutes. Obtain anterior marker, anterior, left and right laterals. • Statics only at least at 15 minutes after injection, 3 minutes per view. Some obtain images at 2, 5, 10, 15, 20, and 30 minutes. Obtain anterior marker, anterior, left and right laterals. • Lemon phase for function: • Place lemon extract or lemon juice–soaked gauze on both sides of patient’s mouth. (Or patient can suck lemon juice through straw and hold in mouth to stimulate salivaries.) • Some do this during dynamics at 40 minutes or after dynamics and statics. Use 2 mL of lemon juice through straw (intraorally). • Remove gauze after 5 minutes, allow patient to expectorate excess saliva and rinse with water. • Repeat static anterior, left, and right lateral images at 15 and 30 minutes after lemon administration. • Salivary function evaluation processing: • Draw regions of interest around thyroid, submandibular, parotid glands, and backgrounds on appropriate lateral or anterior view. • Record counts and repeat for all sequential timed images.

NORMAL RESULTS • Symmetric uptake in the parotid and submandibular glands. • Uptake in sublingual and thyroid glands and nasal cavity. • Significant reduction of activity in salivary glands after lemon administration.

ABNORMAL RESULTS • Increased uptake nonsymmetrically on one side or both sides of face, different from the bilateral uptake of the salivary glands. 260

10766-44_CH44.qxd

12/3/07

4:54 PM

Page 261

Chapter 44 — Salivary Gland Imaging

• Activity remains local after lemon administration. • Benign tumors, e.g., Warthin’s, present with increased concentration of radiotracer and will retain tracer within the mass. • Space-occupying lesions or filling defects: 1.5–2 cm in diameter, patchy decreases in activity in Sjögren’s syndrome (autoimmune disease affecting the salivary and lacrimal glands, occurs in postmenopausal women; presents with rheumatoid arthritis, xerostomia [dryness of mouth caused by malfunctioning salivary glands], and keratoconjunctivitis sicca [dryness in eyes]). • Mixed tumors of the parotid: Patchy decrease in activity in area of lesion; lesion may have normal or even increased count rate. • Lymphomatous infiltration: Patchy areas of decreased concentration and may have normal count rates; with increasing infiltration, count rate decreases. • Metastatic lesions (only 20% of cases): space-occupying and slightly ragged with no activity. Examples are mucoepidermoid carcinoma, adenocarcinoma, squamous cell carcinoma, malignant degeneration of a pleomorphic adenoma, and adenoid cystic carcinoma. • Abscesses: Smooth and round with no activity, tender to palpation. • Cysts: Smooth and round, no activity, not tender to palpation. • Bacterial or viral acute sialadenitis (inflammation of the salivary glands): Marked increase in uptake of affected gland(s).

ARTIFACTS • Patient movement will blur images. • Patients with Sjögren’s syndrome (immunologic–postmenopausal women, patient who presents with rheumatoid arthritis, xerostomia, and keratoconjunctivitis sicca) may present with decreased accumulation of uptake relative to the thyroid and with delayed, possibly asymmetric clearance of activity from the glands. • Patients with Graves’ disease may present with decreased salivary uptake because of the activity going to the thyroid. • Note: The salivary glands include the parotid, submandibular, and sublingual glands. 99mTc O − trapping begins at 1 minute and peaks at about 5 to 10 minutes. 4

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history or family history of salivary dysfunction?

Y

N

Do you have “dry mouth”?

Y

N

Do you have any palpable lumps in or under your jaw?

Y

N

Do you have any pain in or under your jaw?

Y

N

Have you had a labial biopsy (minor salivary gland tissue)?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

Other department-specific questions.

261

10766-44_CH44.qxd

12/3/07

4:54 PM

Page 262

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Thomas C, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: FA Davis, 1993. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

262

10766-45_CH45.qxd

12/3/07

4:55 PM

Page 263

chapter

45

Schilling Test RADIOPHARMACY Radionuclide •

57

Co t1/2: 270 days Energies: 122 keV Type: EC, γ, accelerator

Radiopharmaceutical •

57

Co-cyanocobalamin (vitamin B-12)

Localization

Quality Control • Capsule(s) come with kit. Calibrate the dose.

Adult Dose Range • .3–1 µCi (11.1–37 kBq)

Method of Administration • Oral (PO); intrinsic factor (IF) given intramuscular (IM).

• Bound to plasma proteins. Combined to intrinsic factor in the gastric mucosa, absorbed into the bloodstream in the terminal ileum, and stored in the liver.

INDICATIONS • Diagnosis of pernicious anemia (decreased red blood cells, muscular weakness, gastrointestinal and neural disturbances). • Diagnosis of macrocytic (megaloblastic) anemia (degenerative disease of spinal cord). • Evaluation of gastrointestinal absorption of B-12 and/or low B-12. • Evaluation of small intestinal malabsorption. • Evaluation of thrombocytopenia and/or leukopenia.

CONTRAINDICATIONS • Pregnant women or nursing mothers. 263

10766-45_CH45.qxd

12/3/07

4:55 PM

Page 264

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to be NPO from midnight before test (NPO at least 4 hours before test) and continue to do so for 2 hours after ingestion of radiotracer. • Instruct patient to discontinue parenteral B-12 for 3 or more days before test. • Complete all patient paperwork. • Instruct patient to collect all urine in container during the 24-hour period after ingestion of radiotracer. • Instruct patient to drink only water for liquid. • Instruct patient to have no other tests, enemas, or laxatives for the duration of this test.

EQUIPMENT Detector

Computer Set-up

• Well counter

• Energy window set at 114–144 keV. Count for 5–10 minutes per sample (count all the same way).

Collimator • N/A

PROCEDURE

(TIME: ~30 MINUTES)

Before Dosing Patient • • • • •

Obtain kit supplied by radiopharmacy. Assay patient dose; record. Assay standard dose (if separate); record. Label paperwork, collection container, and doses. Collect a predose urine sample from patient if background test tube is indicated. Label and store for 24-hour count; also needed if patient has had recent nuclear scan.

Stage 1: Without Intrinsic Factor • Instruct patient to empty bladder. Collect some urine for testing for radioactivity if previous nuclear medicine tests have been performed. • Instruct patient to ingest capsule containing 57Co-labeled B-12. Note time on paperwork. • Patient is given 24-hour urine collection container to begin collection, still fasting. • Instruct patient to return in 1–2 hours for IM “flushing dose” of 1000 µg of cold B-12, which saturates the remaining B-12 binding sites in body so whatever labeled (hot) B-12 was absorbed from intestine is excreted in the urine. • Instruct patient to return in 24 hours with collection container(s). Some collect for 48 hours if serum creatinine levels are more than 2.5 mg/dL. Record total amount of urine brought in. Stage 2: With Intrinsic Factor • Instruct patient to return in 5 days. • Same test is repeated with patient receiving a capsule containing intrinsic factor (30 mg) along with the 57Co-labeled B-12 capsule. Stage 3: After Antibiotic Treatment • Physician prescribes antibiotic therapy to patient. • Instruct patient to return in 5 days. • Same test as in Stage 2. 264

10766-45_CH45.qxd

12/3/07

4:55 PM

Page 265

Chapter 45 — Schilling Test

Stage 4: Dual-Isotope Study • Use 58Co with study. • 58Co t1/2: 72 d. Energies: 810 keV. Type: EC, β+, γ, accelerator • Administer 57Co-labeled B-12 and 58Co-labeled B-12 and intrinsic factor at the same time (kit form). • Count using two standards and two windows. • Counting, procedure, and results are same as above, just performed in one step.

PROCESS INFORMATION • • • •

Check lot numbers for correctness. Record total amount of urine in sample. Pipet two patient samples, 4 mL each, into test tubes. Place standard into test tube, or pour into test tube to make 4 mL (typically 0.5 mL of labeled B-12 and 3.5 mL of water, check kit insert). • Count samples using program provided by probe. Usually something similar to counting background sample (or room background) for 5 minutes, count two patient 24-hour samples for 5 minutes each, count reference standard for 5 minutes. Some go 10 minutes for each. • Manual calculations (all in cpm): • Net standard counts (net std cts) = standard − background (bkg) • Corrected patient (pt) sample counts 1 = pt sample 1 − bkg • Corrected patient sample counts 2 = pt sample 2 − bkg • Net corrected patient sample counts (net corr pt sample cts) = (corrected 1 + corrected 2)/2 % excreted in urine =

net corr pt sample cts × total urine vol (mL) × 100 net std cts × 4

• or (using counts per milliliter [divide counts by 4]): pt urine cts/mL × total urine vol × 100 = % excreted labeled B-12 diluted standard cts/mL × dilution factor where dilution factor is calculated as follows: if 4 mL of dilute standard contains 1% of the standard (check kit insert), 1 mL will contain .25%. The dilution factor will then be 400.

NORMAL RESULTS • ≥7% of dose excreted in urine at 24 hours. Some use > 10% with 6–10% indeterminate. Less than 7% is abnormal, indicating failure to absorb B-12. • Others: >10% excreted at 24 hours (10–40%) is normal; 5–9.9% indeterminate. Less than 5% is abnormal, indicating failure to absorb B-12.

ABNORMAL RESULTS • Stage 1: < 7% of dose excreted in urine at 24 hours. Deficient absorption because of either intrinsic factor or intestinal deficiency. • Stage 2: ≥ 7% of dose excreted in urine at 24 hours indicates malabsorption due to intrinsic factor deficiency (ulcers, cancer, etc.). • < 7% indicates malabsorption caused by intestinal illness (sprue, regional enteritis, bacterial, viral, blind-loop syndrome, etc.). 265

10766-45_CH45.qxd

12/3/07

4:55 PM

Page 266

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ARTIFACTS • It is extremely important that the patient collects all urine into the collection container. Missing any causes falsely low results. • Medications and vitamin supplements, recent food intake, etc., are all important to the outcome of the test. Patient history is a must. • Impaired renal function makes test inappropriate. Physical problems with renal system, e.g., benign prostatic hypertrophy that results in urinary retention, can affect the 24-hour collection. Elderly patients with slowed renal function will similarly affect the 24-hour collection. In these and other situations, a second 24-hour collection is indicated.

NOTE • Vitamin B-12 and folic acid (B-complex vitamins) are involved with the production of red blood cells. B-12 is naturally absorbed from meats and dairy products, is bound to intrinsic factor by gastric mucosa, and is a coenzyme needed, along with folic acid from vegetables, for DNA synthesis and cell division in all tissues, especially bone marrow. Normal nutritional requirements are 1 µg/d. Normal diets usually provide 2–30 µg/d. B-12 is stored for up to 800 days. Neurologic changes are often associated with severe B-12 and folate deficiencies. These may not be reversible. Deficiencies (malabsorption) of B-12 can be caused by lack of intrinsic factor from pernicious anemia or gastrectomy, dietary lack of the vitamin, bacterial overgrowths within the bowel that consume the vitamin, or inability to absorb the intrinsic factor–B-12 complex in the terminal ileum because of resection or disease states, e.g., Crohn’s disease.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history or family history of low B-12?

Y

N

Do you have a history of intestinal disease?

Y

N

Have you had any recent abdominal trauma?

Y

N

Have you had any stomach disease or surgery (e.g., ulcers, tapeworm, gastrectomy)?

Y

N

Are you a strict vegetarian?

Y

N

Are you taking vitamins?

Y

N

Do you feel that you are tired?

Y

N

Are you on any drug therapy?

Y

N

If so, what type and for how long? When was your last meal?

What medications are you taking?

266

10766-45_CH45.qxd

12/3/07

4:55 PM

Page 267

Chapter 45 — Schilling Test

Have you received any vitamin B-12 recently?

Y

N

Have you had any recent nuclear medicine or related tests?

Y

N

Do you have the results of any recent laboratory tests (especially serum creatinine)?

Y

N

Female: Are you pregnant or nursing?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

267

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 268

chapter

46

Scintimammography RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

99m

Tc-sestamibi (hexakis[2-methoxyisobutylisonitril]), 99mTc-tetrofosmin (1,2-bis[2-ethoxyethyl]phosphino)ethane

Localization • Passive transport through cell membranes in proportion to blood flow, active transport into myocardial mitochondria. High affinity to myocytes and carcinoma cells.

Quality Control • Chromatography > 90%

Adult Dose Range • 20–30 mCi (740–1110 MBq)

Method of Administration • Intravenous injection in hand contralateral to breast with suspected lesion. • If bilateral lesions suspected or post bilateral mastectomy, inject in foot vein. • For hand or arm injections, use IV catheter or butterfly and stopcock to avoid infiltration (very important), which may appear as falsepositive axillary node uptake. • Flush with at least 10 mL of saline.

INDICATIONS • Detection and localization of breast carcinoma, particularly in women with palpable breast mass. Usually done in conjunction with and to help improve the sensitivity and specificity of mammography, and aid in decisions about biopsy. • Evaluation of women with mammographically dense breasts, palpable mass, and negative fine needle aspiration (FNA). • Detection and localization of metastases in the axillary lymph nodes. Test helps breast cancer patients decide between lumpectomy and mastectomy: for high-risk patients with prior history or family history of premenopausal breast cancer, patients with palpable lumps or abnormal lesions on mammography, and patients with dense, as opposed to fatty, breast tissue. 268

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 269

Chapter 46 — Scintimammography

• Evaluation of known but nonpalpable breast lesions. • Evaluation of elevated tumor markers. • Differentiation between true-positives (e.g., invasive ductal carcinoma, ductal carcinoma in situ, colloid carcinoma, medullary carcinoma, and infiltrating lobular carcinoma) and true negatives (e.g., fibrocystic changes, fibroadenoma, atypical ductal hyperplasia, florid epithelial hyperplasia, stromal sclerosis, complex sclerosing lesion, cysts, and combinations thereof). • Evaluation of therapy. • Evaluation of breast implants. • Evaluation of breasts because of abnormal findings on other related diagnostic images, e.g., PET, MRI, CT, US, mammography.

CONTRAINDICATIONS • None.

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure; midmenstrual cycle is best time for exam. Patient dressed in hospital gown open to the front, no bra or jewelry. Obtain recent mammogram or other relevant scans and results for lesion correlation.

EQUIPMENT Camera

Computer Set-up

• Large field-of-view or dedicated scintimammography camera (SPEM: single photon emission mammograph)

• 10% window (to reduce scatter from table, which appears as a vertical line during processing), centered on 140 keV, 128 × 128 matrix, zoom as allowed to include large breasts and anterior chest wall in field of view. Acquisition time 600 sec/image.

Collimator • Low energy, high resolution

PROCEDURE

(TIME: ~90 MINUTES)

Prone Dependent-Breast Position • Patient is injected; imaging begins 10 minutes after injection. Consider dorsal foot injection to minimize extravasation and false-positive lymph node presentation. • Images: All pictures are 10-minute (600-second) views. • Place patient in prone position on imaging bed, sternum on edge of bed, arms comfortably over head, shoulder flat on bed, head to one side, one breast pendant. • On table with dual-pendant cushion, include an attachment for a lead shield to be placed between the breasts to eliminate shine-through from opposite breast. • Maintain collimator face as close to the patient’s side and breast as possible to improve image resolution and patient safety. • Reposition patient and camera as needed for the acquisitions. • Other images: All pictures are 10-minute (600-second) views. • Place patient in sitting position or standing upright with camera positioned for anterior chest image, arms up (around detector) for evaluation of axillae (ipsilateral). This can also be done supine, arms up with breasts taped up and away from interfering liver-spleen-gut-cardiac activity. 269

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 270

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Obtain 180-second marker image (nipples and known lesions, with or without 57Co transmission image). • Obtain left and right laterals with patient prone (if both breasts are pendant, a lead shield is placed between to eliminate shine-through). • Optional view: Position camera under table, patient prone, to take the “anterior” picture. • Obtain 30° posterior obliques, arms up, for better separation if deep lesion is visualized close to chest wall.

Single Photon Emission Computed Tomography (SPECT) Scintimammography (usually 20–30 minutes after injection) • • • • •

Place patient in prone position, with breast(s) dependent. 180° acquisition; 32 30-second frames. 45° anterior oblique to 45° posterior oblique. 64 × 64 matrix with zoom as permitted. Reconstruct using Hamming/Hanning or Butterworth filter. Transverse, coronal, and sagittal images in gray scale, masking chest and abdominal organs. • SPECT is said not to improve sensitivity of test because of the high counts in heart and gut.

NORMAL RESULTS • Homogeneous diffuse, mild, or no uptake of sestamibi or tetrofosmin in normal breast tissue. • Uptake in myocardium, thyroid, salivary glands, spleen, kidneys, bladder, lungs, skeletal muscle, liver, gallbladder, and small and large intestines.

ABNORMAL RESULTS • Focal area(s) of increased uptake in tissue of either or both breasts and/or axillary lymph nodes. • Localization in tumors in thorax, neck, or abdomen. • A negative scan with a palpable lesion makes breast cancer possible but unlikely.

ARTIFACTS • Infiltration of injection may cause a false-positive because of movement through lymphatic system. Injection should be done in contralateral arm using a butterfly catheter; or if there is bilateral breast involvement, a foot vein injection should be considered. • One or both breasts may present as diffusely increased in some patients as a result of hormone levels at imaging time. The occurrence is lowest during midcycle of premenopausal women, especially those younger than 30 years. Considered benign, it still may mask a lesion. • False-positives are generally the result of fibroadenomas, fibrocystic change, inflammation, epithelial hyperplasia or sclerosing adenosis. • False-negatives are usually caused by small (< 1 cm) or deep, medial lesions, lesions obscured by myocardial activity or other organs with normal uptake, and tumors with less avidity for the radiotracer. • Imaging of prone dual dependent breasts (dual- or single-head camera) without lead shield between breasts allows for shine-through. • Supine anterior views require taping of breasts up and away from interfering liver-spleen-gut-cardiac activity. • Be aware of possible thyroid shine-through on laterals. • Extreme kyphosis can result in poor images. Supporting the patient’s lower extremities with pillows allows chest wall to be as close to the imaging table as possible. • Cannot detect lesions < 5–8 mm; hence, those with malignant calcifications may be missed; however, at present, very accurate with lesions ≥ 1 cm. 270

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 271

Chapter 46 — Scintimammography

• Artifacts caused by perspiration, table, clothing, jewelry, heart monitors, movement, non-fully dependent breast, and shine-through from background organs. • Implants may mask possible sites. • Care must be taken with positioning of pendant breast, patient, and camera. Stay with patient throughout study.

BIOPSY TABLE • Surgeons may use gamma probe to localize uptake and remove site.

ROLE OF TECHNOLOGIST IN OPERATING ROOM (OR) • Many institutions are using these studies to localize and resect suspected lesions. The role of the technologist differs with the institution, but they generally perform the following tasks. • Inject patient as per protocol of institution. • Images taken as suggested above; patient and images are brought to preoperative area to prepare for surgery. • In OR • Surgeon or technologist uses gamma probe to locate “hot” lesion(s). (Only in some institutions, others hire a company to manipulate the probe.) • Technologist or nurse takes resected material to pathology for inspection. • Technologist assays material for storage (10 half-lives) if > 0.05 mR at 1 m or disposal if background ≤ 0.05 mR at 1 m. • Technologist assays pathology room and equipment for contamination. • Technologist assays OR for contamination after removal of patient.

NOTE • Compared with normal breast or adipose tissue, sestamibi and tetrofosmin accumulate in malignant breast tumors with a contrast ratio of 6:1. Palpable lesion specificity is 85–90%, less for nonpalpable lesions. • Mammograms find normal tissue, fibroglandular breast pattern, architectural distortion, mass, fatty tissue, dense tissue, calcification, and combinations thereof, along with a lesion of 1 cm in size or larger if present. • Other helpful tracers are 99mTc-MDP, 111In-octreotide, 18F-fluorodeoxyglucose, various monoclonal antibodies, 99mTc-sulfur colloid, 99mTc-dextran, 99mTc-O4−, 67Ga-citrate, 201Tl, and estrogen and progesterone receptor markers. Stereotactic needle biopsy has also become useful for assessing suspicious breast lesions. • There are companies manufacturing dedicated scintimammography tables and/or cushions that accommodate the patient very well.

PATIENT HISTORY (or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

If so, what type and for how long? (continued) 271

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 272

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you have any palpable nodules?

Y

N

Do you have any tenderness in your breasts?

Y

N

Have you had any discharge from your breasts?

Y

N

Have you had any recent trauma to your chest area?

Y

N

Have you had any recent surgery or mastectomy?

Y

N

Do you have or have you had any implants?

Y

N

Have you received any chemotherapy or radiation therapy?

Y

N

Have you had any recent mammograms, PET, CT, MRI, NM, US, biopsy, x-rays, or laboratory work?

Y

N

Female: Are you pregnant or nursing?

Y

N

Y

N

If so, since when?

When was your last menstrual period? Have you had a hysterectomy or are you in menopause? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy. Version 2.0, June 2, 2004. SNM.org. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

272

10766-46_CH46.qxd

12/3/07

4:56 PM

Page 273

Chapter 46 — Scintimammography

Notes

273

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 274

chapter

47

SPECT Imaging (Single Photon Emission Computed Tomography) and Hybrid Imaging Overview RADIOPHARMACY Radionuclide and Radiopharmaceutical • SPECT (also known as SPET and many times ordered as SPEC) imaging can be performed with any in vivo nuclear medicine radiotracer given the proper collimation for the chosen isotope and software for collection and processing of data. They are performed by acquiring a series of planar images and reconstructing the images into planes (angles), e.g., transverse, coronal, and sagittal. SPECT/CT adds the capability of a very quick scan for attenuation correction and anatomic localization.

Localization • Any radiopharmaceutical used in general planar imaging can be used in a SPECT procedure. 274

• Adjustments in time per stop is a consideration to compensate for photon flux and count rate depending on the radiopharmacy and the activity injected.

Adult Dose Range • uCis to many mCis (same for MBq). • On the low end, the dosage must provide adequate photon flux from the region of interest (ROI) for the collection of data for processing into an image within the amount of time given for each step. • On the high end, the amount should not be so much as to create dead time, in which the camera electronics are saturated and not recording counts. • There remains a considerable range.

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 275

Chapter 47 — SPECT Imaging and Hybrid Imaging Overview

Method of Administration • Radiotracer administration is the same for SPECT as it is for planar imaging.

• Most administrations are intravenous for the type of studies requiring SPECT imaging; although it is possible, if requested, to perform SPECT after oral doses of, e.g., iodine.

INDICATIONS • SPECT is often done if planar images turn up negative when a lesion or abnormality is highly suspected. • Visualization of “buried” or blocked lesions within an organ or hidden by other structures. • Additional information to planar (20% benefit from adding SPECT study). • Gated SPECT for cardiac studies provide three-dimensional (3D) images of heart and motion assessment. • Fusion with other modalities, e.g., MRI, PET, and CT for transmission scans used in attenuation correction and integrated diagnostic imaging, allow for higher-quality imaging and more accurate localization.

Advantages • • • • • •

3D localization of radiopharmaceutical distribution and processing. Better target to non-target ratio than planar. Improved resolution in any given plane. Better definition of lesion shape. Accurate quantification. Wide selection of radiotracers.

CONTRAINDICATIONS • Patient unable to cooperate physically or psychologically for scan. • Radiographic exams underway or recent using contrast that would hamper interpretation in the ROI.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct patient to void before exam. • Instruct patient to remain motionless for duration of imaging.

EQUIPMENT Camera • Single, dual, triple, or quadruple head large field of view gamma camera. • Camera(s) positioned as close as possible to body surface without brushing. • Patient comfort is a consideration.

Collimator • Matched to radioisotope. Generally, low energy, high resolution or medium energy, general purpose or high resolution.

• Make sure a center of rotation (COR) has been done for the collimators of choice and flood tables loaded for the radioisotope.

Quality Control for the SPECT Camera: 99mTc source, 57Co flood disc (cookie sheet), cylindrical phantom • Quality control differs for every manufacturer. Factory protocols for specific cameras should always be followed. They are usually provided in a manual. 275

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 276

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Daily floods: 2 to 4 million counts for camera uniformity, intrinsic or extrinsic. • Gantry index search or alignment: Daily to maintain gantry positioning. • Table-camera alignment: Daily, axis of rotation must be absolutely parallel to table. • Weekly bar phantoms: For linearity and spatial resolution (ability to resolve fine lines in bar phantoms). • A SPECT or cylindrical phantom study should be performed to assess tomographic uniformity, contrast, and spatial resolution. • COR: Weekly to monthly, 500 uCi (18.5 MBq) point source on end of imaging table, 1 mm in diameter. SPECT performed. Center should not vary more than .5 pixel (2 mm). • Uniformity correction: 30 million counts (64 × 64 matrix) or 120 million counts (128 × 128 matrix) every 3 months for uniformity matrix. • Overall performance: Every 3 months, SPECT performed on cylindrical phantom containing radioisotope of choice. Examine images for artifacts, adjustments made to table leveling, reconstruction, display, or components. • Extrinsic floods: Every 3 months, bar phantom floods with collimators on for system resolution. • Manufacturer’s recommendations should be followed for assessing the geometric and electronic alignment of detectors on multiplehead cameras. • The gamma camera should have an intrinsic resolution of at least 3 to 4 mm, a linear deviation of < 1 mm, and a basic uncorrected uniformity deviation of 3% to 5% or less within the useful field of view of the detector head(s).

Computer Set-up • Circular, noncircular (elliptical), peanutshaped, helical (whole body), or mapped orbit.

• Gated SPECT: Three- or five-lead used on patient, acquisition triggered by R wave of ECG. • Matrix is 64 × 64 for single head, 64 × 64 or 128 × 128, or more for multi-head. The larger the matrix, the higher the resolution of the image, and more computer memory is used. • Rotation usually covers 360°, although cardiac studies cover 180° (RAO to LPO except for those with dextrocardia). Some use double or triple orbits; others utilize a helix orbit to cover whole body. • Projections usually 32 (180°) or 64 steps (360°) for step-and-shoot mode: 120 views for high-resolution imaging (360°) or 60 views for 180°. Acquisition can also be done in continuous mode if stepping time is > 10% of imaging time per stop. • Acquisition time usually 20 to 40 seconds per step. This depends on the study (usually preset) and patient (size and cooperation). Each step or view must have sufficient counts per pixel for adequate reconstruction. A consideration to patient motion limits the optimal total imaging time to < 30–45 minutes. • Acquisition attenuation correction is possible on some systems by obtaining a transmission scan or map of body thickness and contour. This entails the use of an external line source with a long half-life, e.g., gadolinium-153 (153Gd) or americium-241 (241Am), that rotate on the opposite side of the patient during the SPECT acquisition. • SPECT/CT employs a very quick (about 5-second) attenuation correction and/or anatomic location scan. • Reconstruction filters, attenuation correction, and slice thickness are usually preset, although most software presents opportunities to change these during processing.

PROCEDURE

(TIME: ~ 15 TO 40 MINUTES, DEPENDING ON NUMBER OF CAMERA HEADS) • Position patient supine (in most cases). Prone or with some camera systems, seated is not out of the question. No attenuating items in field of view. Make note of any surgically implanted devices. • Position arm(s) over head if ROI requires it. • Secure head to table with ace bandage for cranial studies to minimize movement or use head attachment. • Verify the existence of the raw data on computer before the patient leaves. 276

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 277

Chapter 47 — SPECT Imaging and Hybrid Imaging Overview

PROCESSING • General: Processing is very camera/software specific and department specific as to what the radiologists or nuclear physicians wish to see. Basically, the following must always be performed.

General SPECT • Pick SPECT reconstruction, pick patient, and select raw data. • Select an image or series of images for reconstruction. • Select a filter(s). Most have defaults already set. You may be able to pick prefilters (affect the twodimensional raw data) and reconstruction filters. A simple ramp or filtered back projection is used after the prefilter. Postprocessing filters can be applied and usually only affect or smooth the 3D image. Adjustments can be made as to the strength of the filter. Choose one that is not too smooth or too grainy. • Motion correction is possible with many software companies to heighten the quality of the study. • Most computers now allow for iterative construction using the more efficient ordered subsets expectation maximization (OSEM) algorithms, to replace the use of filtered back projection by applying digital filters to eliminate artifacts. • Attenuation correction compensates for photon origination and absorption by body materials before being detected. Homogeneous body boundaries may need to be defined to use the software or some have nonuniform attenuation correction. Some cameras use transmission scans to accomplish this, whereas others, e.g., SPECT/CT cameras, use the CT portion for attenuation correction and/or anatomic location. • Transverse (transaxial) slices: Move parameter lines to cover ROI. Software differs greatly but usually gives instructions on screen. Set slice thickness, attenuation correction, working color, and intensity. When parameters are set, there is usually a “complete reconstruction,” “exit and save,” or similar command. • Some now complete sagittal and coronal slices automatically, whereas others ask you to click reconstruct, reformat, continue, etc. • At the end of the procedure, always save your work. Some will automatically annotate the slices. If not (usually but not always, software differs): • Transverse: Slices: If superior to inferior, then images usually top is anterior, right is right side of patient, bottom is posterior, and left is left side of patient. • Sagittal: Slices: If right side to left side of patient, then images usually left is posterior, top is superior, right is anterior. • Coronal: Slices: If anterior to posterior, then images usually left is right side of patient, top is superior, right is left side of patient. • If there is a 3D command, complete this and save to create a 3D rotational or cine picture for review. • Reformatting is used to align reconstructed images along the primary axis of specific organs, e.g., brain (parallel to the orbital–meatal line) and heart (long and short axis).

To Display Images • Usually there is a SPECT display or dynamic display command. • Select patient, select proper data set (there should be at least four—raw, transverse, sagittal, coronal—and maybe more). • You may still be able to sum images for slice numbers, mag images if needed, and adjust intensity. • Annotate (type of slices, direction, dose, hospital, etc.). • Usually one screen or page apiece for transverse, sagittal, and coronal slices. • Some ask for a separate screen or page for positive study of frame or frames best depicting affected area. • Display 3D by choosing cine or 3D cine or similar for physicians. Select 3D data set. Select create cine data. Adjust intensity, speed, and color (usually gray). 277

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 278

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Cardiac SPECT • Because of the orientation of the heart within the body, names of slices are unique. • Most systems have dedicated software for heart processing that allows the stress and rest or stress and redistribution data sets of the patient to be processed in the same session. • A correlation of general to cardiac SPECT planes is: • Transverse (transaxial) = horizontal long axis (Slices: superior to inferior, image: left is septal wall, top is apex, right is lateral wall). • Sagittal = vertical long axis (Slices: right side of heart to left, image: top is anterior wall, right is apex, bottom is inferior wall). • Coronal = short axis (Slices: apex to base, image: top is anterior wall, right is lateral wall, bottom is inferior wall, left is septal wall). • Software differs greatly but again, certain things must be accomplished. Many have auto-SPECT programs and most have instructions on screen. • Select cardiac SPECT processing, select patient, select raw data group(s). • For each set, select working color, intensity, orientation, and parameters for processing. • Adjust filter(s) and set line(s) for masking (to remove background), slice thickness, and magnification. • Proceed, complete, or save and exit, etc. • Bull’s eye images (a flattened apical view, center is apex, edges are base) may also be processed from data. • Gated views for wall motion and ejection fraction are usually required and processed. These put the heart in motion and most software allows rotation of image for different perspectives.

To Display Images (refer to cardiologist’s preferences) • Select image display type (full-page 3-axes stress/rest slices, single-page single axis stress/rest slices), select patient, select appropriate data set(s). • Align stress/rest images, adjust intensities, annotate. • Film up slices, gated view, and bull’s eye as well if requested. Physician may want to view cine of gated study for wall motion.

ARTIFACTS • • • • • • • • • •

“Star” artifact: Caused by overlap of projections, removed by ramp filter. Concentric rings: Nonuniform flood source. Image blurring: Camera not leveled. Mottled image: Insufficient count density. “Starburst” effect: Injection site in slice. Arm shadows: Attenuation from extremities, patient not positioned correctly. Blurring: Wrong COR. Loss of resolution: Improper use of filters. Ring around the edge: Little or no attenuation correction due to uniformity problems. “Buckshot” look to one or more slices: Overcompensating for rejected beats by accepting 100% PVCs, etc., in patients with irregular heart beat.

HYBRID IMAGING: AN OVERVIEW • Most everyone agrees that hybrid cameras and fused imaging are the future of nuclear medicine and diagnostic imaging—and for good reason. Combining modalities offers the best of the imaging community. Anatomic imaging by CT or MRI can locate an abnormality and indicate the size of the lesion while providing extremely accurate anatomic markers. Proving that it is hypermetabolic with PET imaging or that the lesion combines with a certain labeled nuclear medicine radiopharmaceutical allows an accurate diagnosis. Some of the benefits of hybrids are faster, more accurate diagnosis, better detection of metastasis from the primary cause, prevention of unneeded surgeries 278

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 279

Chapter 47 — SPECT Imaging and Hybrid Imaging Overview

or other invasive procedures, more precise localization of lesions for biopsy or needed surgeries, treatment, therapies (e.g., radiation, chemo, brachytherapy, drug), efficiency in time for diagnosis, overall view of information for staging of disease, better departmental throughput, better patient comfort and convenience, and eventually perhaps less overall cost of diagnosis, to name a few. It will be interesting to see if the ultimate gantry is manufactured that incorporates gamma cameras, CT, MRI magnets, and PET detectors (with perhaps an ultrasound probe attachment?). The technologist of that future is the multitrained diagnostic technologist in a department of one or two, depending on the number of machines. Education is standardized to cover all areas with one degree. They will receive a single (no doubt extremely expensive) license and certificate(s) to operate the machinery and handle the various radiotracers. After a thorough history that covers all of the combined modalities to be used on that patient, the patient is prepared and/or injected, at the appropriate time positioned, the diagnostic technologist activates the requested detection, and all scans are completed simultaneously. Beyond that, the ultimate hybrid would have the patient positioned in front of a point or line detector measuring atomic or molecular interaction that scans the entire body in seconds, simultaneously processing for display any anomaly within the body system, e.g., “The UltimaCam,” perhaps a Star Trek–inspired “Bones” McCoy likeness. • SPECT imaging as described above represents the less costly alternative for most tumor localization because of the lower energy isotopes, and better spatial resolution than, e.g., PET; other sources site PET having better resolution. More than likely it is camera dependent.

PET/SPECT • PET applications are presently 90% oncology for soft tissue tumors, the remainder being cardiac studies with a small amount of neurologic imaging. SPECT is used for cardiac studies (55%), bone imaging (25%), and others; brain, prostate, and thyroid studies make up the rest. Both utilize radiopharmaceuticals and represent function of tissue and organ with PET going one step further into metabolism. It makes either of these two modalities helpful counterparts when combined with the anatomic modalities. This is being accomplished on a routine basis and will be more so in the future. Although both are being adapted to fuse with other modalities, there is apparently very little fusion using PET and SPECT images. Fusing PET cardiac perfusion and viability studies with SPECT perfusion studies may have some merit. Fusing PET with SPECT for tumor localization and with labeled nuclear medicine radiotracers for identification of tumor receptors can be useful. The Cytogen Corporation is working with ProstaScint and PET fusion for prostate cancer to name one. Fusing or comparing brain SPECT with PET metabolic imaging is another advantage. PET/SPECT imaging using FDG PET and 201Tl SPECT for localization of brain tumor has been encouraging, but the success appears institution-specific. Work is being conducted to label the plaque and amyloid binding associated with Alzheimer’s disease. Chemical and biological tagging of PET and gamma-emitting isotopes is changing the face of imaging and therapy. The more specific the tag or label, the more precise the modality can be at localizing or demonstrating a disease process as well as treating the disease. At this time, there is not much in the literature describing hybrid machinery incorporating gamma and PET detectors into the same machine. Most of the technology, it appears, is in the software used to blend or fuse the images once taken individually.

SPECT/CT • Both modalities produce tomographic images with nuclear medicine SPECT imaging reflecting function, and CT that of anatomy. SPECT and CT images have been fused for years with computer assistance. There are cameras that have both capabilities, sharing a common imaging table and allowing for more accurate image registration and fusion of combined images. The combined cameras are multihead gamma cameras with a multidetector CT scanner mounted in the same gantry. Much like PET/CT, the CT portion can be used for attenuation correction (AC) using its transmission data, anatomic localization (AL), or diagnostic imaging (depending on the camera) and fused or not with SPECT. Usually, though not always, the CT AC/AL acquisition is first, followed by SPECT, followed by the diagnostic CT. Patient breathing is problematic for proper registration and usage of transmission scans for SPECT. Some are settling on shallow breathing during AC acquisition, depending on the area of interest in an attempt to match the registration between 279

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 280

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

the CT/AC and the SPECT emission images. The fused images can be a whole body, limited region, or an organ. Examples of clinical use and research are tumors, thyroid disorders, parathyroid disorders, skeletal disorders, inflammation, infection, lymphatic system, heart disorders, brain disorders, and other body organs. Patient preparation includes concerns for both modalities and must all be considered before a fused exam. Contraindications of a combined scan must include both modalities for patients, medications, drug or contrast interventions, laboratory results, etc. Artifactual problems can be from (but not limited to) movement of patient between SPECT and CT imaging, whole body or extremity motion during acquisition, diaphragmatic motion with breathing, bowel motility, contrast motion or change in contrast concentration, rapid filling of urinary bladder, attenuation artifacts such as dense materials like dental work, metallic implants, lack of data for CT technique, software misalignment, display errors such as inadequate windowing on separate or fused images, cursor misalignment, or inappropriate color table selection for SPECT data.

SPECT/MRI • Presently, not commercially available. There are companies developing fusion software. Gamma Medica-Ideas of Toronto, Canada has applied for a grant to build a SPECT/MR fusion machine using cadmium zinc telluride (CZT) semiconductor detectors that are not susceptible to magnetism. They may be developed in the world of small animals at first. MR is very much into small. This company already offers micro-CT, micro-PET, and micro-SPECT for animal study.

PET/CT • PET/CT has become routine in many diagnostic settings. It can be accomplished by separate systems interfacing and fusing with each other using software programming, e.g., MIM, Clarity, DICOM, etc. Images are taken on both modalities and combined into overlays and/or individual views for comparison. New cameras have combined modalities. Regulations vary from state to state as to licensing and certification for running both modalities. Because the technology is changing quickly, so are the regulations. It is advised for technologists involved with the fusing modalities to ensure that they have the most current regulations. • PET adds the functional (metabolic) aspect to any of the anatomic (e.g., CT) modalities. Between the two, the readers can easily compare the anatomic location to the metabolic physiology in progress at that location. To get these images, however, it is of utmost importance that the patient does not move position between imaging (emission, transmission, CT, or other modality if the camera is fused). Misregistration between images is a cause of imaging artifacts as well and false-positives and -negatives. • PET/CT is routinely involved with oncology in the detection and localization of many cancers, e.g., breast, cervical, colon, esophageal, head and neck, lung, ovarian, thyroid, lymphoma, and melanoma. Cardiac imaging allows the visualization of blockage in arteries, precise perfusion, delineating viable, metabolizing muscle tissue with scarred or necrotic tissue even if the tissue is hibernating or stunned (metabolizing but not moving). Brain imaging is used for tumor localization, trauma, and discerning disease processes, e.g., dementia, epilepsy. • The benefits of combined PET/CT are considerable: Improved tumor detection and localization, precise initial staging, diagnosis, restaging, treatment planning, maximum sensitivity, image quality, spatial resolution, electronic fusion of CT and MRI for more accurate interpretation (e.g., avoiding false-positives and -negatives), evaluation of difficult-to-image regions of the body, coverage by Medicare, convenience of a single scan, and patient comfort to name a few. Limited patient motion using combined scanners allows for ideal fusion of anatomic and metabolic images, anatomic landmarks provided by CT enhance the assignment of functional abnormalities to anatomic structures, and fused images can be used to plan and target radiation treatment (isolates location so that a higher dose can be delivered to a smaller area) and monitor effects of surgeries, chemo, and radiation treatment. When 3D volume rendering is used in processing using the fused images of PET/CT, there is a significant improvement of lesion location. Virtual 3D tours through and around organs are possible. • Technical limitations for PET/CT include but are not limited to software incompatibility, misregistration from acquisition to acquisition caused by patient positioning or movement, respiratory motion, and artifacts from metal objects. 280

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 281

Chapter 47 — SPECT Imaging and Hybrid Imaging Overview

• PET/CT combination scanners are commercially available. CTI, GE, Phillips, and Siemens are a few companies producing these machines.

PET/MRI • Presently, this is not commercially available, although companies are developing fusion software. Much of the work is being done with animals and the development of drugs. PET and MRI are compatible for simultaneous acquisition and it is possible that the physical attributes of MR may improve the specificity of PET acquisitions. In a magnetic field, the positron tends to spiral and remain closer to its point of origin. Combining MR with PET may produce images with higher resolution. Coregistration with PET and MRI is presently most useful in brain tumor imaging. University of California, Davis researchers have developed machinery and methods that can acquire simultaneously. PET provides sensitive assays of biological processes. MRI provides high-resolution anatomical information as well as access to volume-specific chemical and physical information such as metabolite concentrations. These two modalities are highly complementary. The gantry is compact, needing only a simple insert for dual modality. Acquisitions are made simultaneously instead of via separate scans, and they have near perfect registration and extremely high resolution anatomical context for PET imaging. Also, PET radiopharmacy and acquisition hardware can withstand high magnetic fields. Applications for this hybrid include medical imaging, cell tracking in vivo using reporter genes or multimodal labels visible to both PET and MRI, tumor detection and staging (e.g., prostate, breast, etc.), in vivo assessment of neuronal cerebral metabolic rate of glucose, and dual modality labeling to study atherosclerotic plaque formation. Research institutions have built systems, and Siemens is developing a PET insert for its 3 tesla Trio MR system.

PET/CT/SPECT • A tri-modality camera developed by Gamma Medica-Ideas in Toronto, Canada combines three powerful modalities: PET, CT, and SPECT imaging. It can image separately, any combination of the three, or all three to best achieve research objectives. From the researchers’ point of view, imaging systems like this could speed the development of life-saving drugs by allowing them to work faster and more efficiently. Commercially, it could provide information faster to the physician for patient care, reduce the amount of time the patient spends in diagnostic settings, and allow greater throughput for diagnostic departments. It brings us one step closer to the “UltimaCam.”

PATIENT HISTORY

The patient should answer the following questions.

Are you physically or psychologically challenged in any way that would impede this study?

Y

N

Can you lay flat on your back and remain motionless for about 20 minutes?

Y

N

Are you claustrophobic?

Y

N

Do you have any monitors, pumps, pacemakers, surgically implanted devices, or prostheses?

Y

N

Do you have any attenuating articles on or in clothing?

Y

N

Have you had any recent diagnostic exams with contrast?

Y

N

Other scan specific questions. Other department-specific questions.

281

10766-47_CH47.qxd

12/3/07

4:57 PM

Page 282

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, et al. eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vol. 1 and 2. New York: Churchill Livingstone, 1994. Schulthess GK. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for SPECT/CT Imaging. Version 1.0, May 16, 2006. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for General Imaging. Version 3.0, May 30, 2004. SNM.org. Ward J. Fusion, taking cancer diagnosis, therapy to the next level. Advance. September 4, 2006. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998. http://interactive.snm.org/index.cfm?PageID=4096&RPID=627 www.iame.com/learning/PETimagre/petimage_cintro.html www.medicalimagingmag.com/issues/articles/2005-06_01.asp?mode=print www.medscape.com/viewarticle/521668 www.research.ucdavis.edu/ncd.cfm?caseno=2005-584 www.umm.edu/petct/

Notes

282

10766-48_CH48.qxd

12/3/07

4:58 PM

Page 283

chapter

48

Testicular Scan (Scrotal Imaging) RADIOPHARMACY Radionuclide •

99m

Tc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • Na 99mTcO4− (pertechnetate) • 99mTc-DTPA (diethylenetriaminepentaacetic acid).

Quality Control • Na 99mTc O4−: Moly-Al breakthrough, chromatography > 90% • 99mTc-DTPA: chromatography > 90%, use within 1 hour.

Adult Dose Range • 8–20 mCi (296–740 MBq) • 99mTc-DTPA: 30 mCi (1110 MBq).

Localization

Method of Administration

• Compartmental to blood supply

• Intravenous injection, good bolus for flow

INDICATIONS • • • •

Evaluation of groin pain. Evaluation of patency of blood supply to testes. Evaluation of increased perfusion caused by inflammatory disease. Differentiation between acute testicular torsion (twisting and lack of blood supply to one or both testes), acute epididymitis (infection or trauma to epididymis or scrotum), and orchitis (infection of testes). • Evaluation of scrotal mass.

283

10766-48_CH48.qxd

12/3/07

4:58 PM

Page 284

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS • None

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Instruct the patient to empty bladder if possible. • Use discretion as patient is usually experiencing some degree of pain; modesty will be compromised.

EQUIPMENT Camera

Computer Set-up

• Small field of view (FOV) is best; if large FOV, use magnification

Flow • 2–6 sec/frame for 1 minute

Collimator

Statics • Collect 500,000–700,000 counts at immediate, 5, 10, 15, 20, 25, and 30 minutes as per protocol. Magnification, 1.5 to 2 times.

• Low energy, high sensitivity, or low energy, all purpose (flow) and low energy, high resolution (statics); pinhole for pediatric statics.

PROCEDURE (TIME: ~30 MINUTES) • • • • • • •

Place patient in supine position on table, legs abducted or frogleg. Secure penis to abdomen (or chest in some cases) with tape. Position towel or tape sling under testicles for support while imaging. Drape privacy cloth after set-up. Ensure tape cannot stick to legs, scrotum, or penis. Insure testes are separated. Position camera anterior, as close as possible, with scrotum centered in FOV. Position lead shielding over thighs and abdomen and/or under scrotum to reduce background vascularity. • Inject and wait a few seconds to start flow study. • Image immediate blood pool, then statics every 5 minutes for 30 minutes or as per protocol. • Optional imaging includes right and left anterior obliques, magnified views, and placement of a thin marker on raphe of scrotum in one static.

NORMAL RESULTS • • • •

Flow: Medial border of iliac artery is smooth. No significant activity is seen in area of testicular, deferential, or pudendal artery. Scrotal perfusion, if present, is seen only as poorly marginated, minimally intense area of activity. Tissue phase: Scrotum and contents with homogeneous activity.

ABNORMAL RESULTS • Torsion (acute) • Flow (perfusion) scan will be missing perfusion to affected side. Tissue phase (statics) will show photopenic area with activity less than opposite testicle and less than that of thigh. Increased activity may be seen high in cord. 284

10766-48_CH48.qxd

12/3/07

4:58 PM

Page 285

Chapter 48 — Testicular Scan (Scrotal Imaging)

• • • • • •

• Infarcted tissue: Flow (perfusion) scan will show increased blood flow through pudendal vessels. Tissue phase will have halo sign on affected side. • Spontaneous detorsion: Flow and tissue phase will have increased perfusion. Epididymitis (acute—bacterial or viral): Flow and tissue phase will show increased activity in region of epididymis with normal testicular activity in simple epididymitis. Orchitis: Similar but more medial testicular involvement. Increased activity in both the epididymis and testicle. If there is excessive edema, testicle may present with decreased activity. Trauma: Diffuse increase with decreased areas (hematoma, hematocele, hydrocele). Tumor: Diffuse increase with decreased areas. Vascular tumor: Increased flow, increased tissue phase. Hydrocele: Normal to increased flow, decreased tissue phase.

ARTIFACTS • • • • • • •

Lead shielding can be used to block out background vascularity from torso and legs. Testicles not separated for imaging. Sticky side of tape on scrotum or penis. 99mTcO − in a filled bladder could interfere with interpretation. 4 Patient movement will blur images. Female or previously castrated patients make visualization a long and tedious process. Note: This test has been replaced by ultrasound in most cases particularly for chronic or painless scrotal mass. Scintigraphy is still used for differentiation of between acute testicular torsion and acute epididymoorchitis. The test evaluates the blood flow to the testes and surrounding tissue. Testicular torsion presents with pain and swelling and is usually related to recent trauma. Earlyphase torsion may be normal but with a “nubbin sign” (vascular activity bulging from the ipsilateral iliac artery into the spermatic cord vessels, terminating at the site of torsion). Late-phase torsion (delayed or missed) increases the perfusion around the affected testicle presenting the “halo effect” from the pudendal vessels (also called “ring sign” or “bull’s eye” sign). Increased rim activity with photopenic central zone may indicate inflammation of dartos and infarcted/necrotic testicle. Testicular neoplasms, trauma with hematoma, and scrotal abscesses may mimic delayed testicular torsion.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Y

N

If so, what type and for how long? Are you in pain now? How long since pain started? Where exactly is the pain? What was the activity at the onset of pain (e.g., fighting, lifting, exercising, walking, sexual calisthenics)? Do you have a history of this type of pain?

(continued) 285

10766-48_CH48.qxd

12/3/07

4:58 PM

Page 286

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you had any recent trauma to that region?

Y

N

Have you had any prostate problems?

Y

N

Have you had a recent ultra sound of your testicles?

Y

N

Have you had a recent lower abdominal/pelvic CT or MRI?

Y

N

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

286

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 287

chapter

49

Therapy: BEXXAR® (Radioimmunotherapy: RIT for B-cell non-Hodgkin’s Lymphoma) RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV (γ), 606 keV(β−) Type: β−, γ, fission product.

Radiopharmaceutical •

131

I-Tositumomab. A murine IgG2a lambda monoclonal antibody composed of two murine gamma 2a heavy chains of 451 amino acids each and two lambda light chains of 220 amino acids with a molecular weight of approximately 150 kD and covalently linked to 131I. The 131I beta particles travel about 1 mm in soft tissue (about 20–40 cell diameters).

Localization • Compartmental, blood flow; dose dependent, antibody binding. Targets CD20 (human

B-lymphocyte-restricted differentiation antigen, Bp 35 or B1) antigen, a transmembrane phosphoprotein located on the surface of normal and malignant B lymphocytes of non-Hodgkin’s lymphoma (NHL).

Quality Control • If made from kit, chromatography, ≥ 95% radiochemical purity. Store in refrigerator before use. • Tositumomab solution can be stored refrigerated for 24 hours at 2 to 8°C (26–46°F) or 8 hours at room temperature.

Adult Dose Range • Dosimetric: 5 mCi (185 MBq) • Therapy: Based on patient specific dosimetry. Paperwork supplied by Bexxar®. Expect dosages ranging from 30–200 mCi (1110–7400 MBq). Calculation of patient 287

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 288

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

specific activity is based on delivery of 75 cGy TBD (in mCi) or 65 cGy TBD in patients with platelets ≥ 100,000 and < 150,000 platelets/mm3.

Method of Administration • Intravenous butterfly (large-bore, 18–22 ga) over 20 minutes with a .22-um micropore filter on the syringe.

• 20-mL saline flush. • Should have physician or nurse available for possible allergic reaction (1 mg epinephrine available). • Follow vital signs: Baseline, 5 minutes postinjection, 15, 30, and 60 minutes. (Some simply observe patient for 15 minutes looking for redness at injection site or signs of nausea and vomiting.)

INDICATIONS • Confirm biodistribution of 131I-tositumomab for 131I-tositumomab therapy. • Treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, with or without transformation, B-cell non-Hodgkin’s lymphoma. • Treatment of patients with Rituximab-refractory non-Hodgkin’s lymphoma. • Treatment of patients with chemotherapy-refractory disease. • Treatment for nonmyeloablative and (higher dose) myeloablative therapies.

CONTRAINDICATIONS • Not indicated for the initial treatment of patients with CD20 positive non-Hodgkin’s lymphoma. • Patient with known Type 1 hypersensitivity or anaphylactic reactions to murine proteins or to any component of this product. • Patients with ≥ 25% lymphoma marrow involvement and/or impaired bone marrow reserve caused by myeloablative surgery, platelet count of <100,000 cells/mL, neutrophil count < 1500 cells/mL. • Impaired renal function (>1.5 times upper normal creatinine level [1.5 mg/dL]). • Patient who is pregnant. • Patient unable to tolerate thyroid-blocking agents. • Patient who has not received thyroid-blocking agent at least 24 hours before dosimetric dose. • 131I-Tositumomab therapy should not be administered to patients with altered biodistribution as determined by the outcome of the 131I-tositumomab images.

PATIENT PREPARATION • • • • • • • • •

• • •

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain a signed consent form from patient for the 131I therapy. Obtain appropriate written directives for iodine dosages. Ensure patient supplies list of history of allergies and prior exams. Female patients of childbearing age should be advised to avoid becoming pregnant during therapy. Pregnant females should be counselled as to the potential hazard to the fetus. Patients who have had a previous Moab test should have a HAMA titer (human anti-mouse antibody) performed before another injection. Patient should have > 50,000/mm3 platelet count and ANC > 800/mm3. Patient to receive thyroid-blocking medication at least 24 hours before receiving the dosimetric dose and continuing until 14 days after the therapeutic dose. Patient to be medicated with 650 mg acetaminophen and 50 mg diphenhydramine PO before receiving the cold tositumomab. The cold tositumomab must be given before the injection of the 131I-tositumomab (Bexxar®). Platelet counts should be taken before regimen and continued for 10 weeks or longer. TSH levels and serum creatinine should be monitored. Patient should be well hydrated before 131I dosing.

288

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 289

Chapter 49 — Therapy: BEXXAR®

EQUIPMENT Camera • Large field of view

Collimator

Whole Body • 10 cm/minutes or slower, check patient for length. • Or: day of use camera calibration using 131I source and 20 cm/min images per scan.

• Medium or high energy, general purpose or medium or high energy, all purpose

Computer Set-up Statics • Iodine peak (364 keV), 15–20% windows, 128 × 128 or 256 × 256 matrix, 600 seconds or more per view (> 1 million counts).

PROCEDURE

(TIME: 30 MINUTES FOR DOSAGE, 1 HOUR EACH SCAN DAY) Patient is injected with dosimetric 131I-tositumomab on “day 0.” Record time of injection. Scan day: Instruct patient to void before imaging, check clothing for possible artifacts. Place patient supine on table, arms to sides, remind patient of no movement during imaging. Image at 2–24 hours, 48–72 hours, and possibly 96–120 hours postinjection (as per protocol). Statics: 10 minutes (600 seconds) per view. Anterior/posterior; thorax, abdomen, pelvis, extremities if protocol. • Whole body (preferred method): 30-minute (1800 seconds) anterior/posterior. • Patient infused with 131I-tositumomab therapy approximately 7 to 10 days after 131I-tositumomab diagnostic/dosimetric injection. This takes about 30 minutes and is done by radiation oncologist or nuclear medicine technologist in department under supervision. • Using camera calibration: • Same camera used for each acquisition, same field of view, calibration source, and background. • Calibrate camera sensitivity each day of use by placing a sealed vial containing 200–250 uCi (7.4–9.25 MBq) 131I in 20 mL saline on the table. Acquire a digital image of the vial using a NIST traceable calibrated dose calibrator by scanning the vial in whole body mode with the same field of view to be used for the patient. Use 128 × 128 matrix minimum, 20 cm/minute. • Acquire a digital image with no vial (background) using the same parameters. • Calculate the sensitivity of the gamma camera: Counts per µCi = background corrected source counts/calibrated I-131 activity. • At 1 hour postinjection, acquire whole body anterior/posterior at 20 cm/min. • Repeat images on day 2, 3, or 4 and then again on day 6 or 7. Use same parameters. • Follow manufacturer’s instruction pack using spreadsheet that is provided with the radiopharmaceutical to calculate residence time, activity hours, and therapeutic dose of 131 I-tositumomab. • • • • •

NORMAL RESULTS • First day imaging: Activity in blood pool. • Focal areas of tumor uptake may visualize in soft tissue. Tumor-bearing areas in normal organs by visualizing as increased and/or decreased areas of intensity. This is normal in the sense that the test is attempting to confirm biodistribution to tumors for therapy. 289

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 290

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ABNORMAL RESULTS • Altered biodistribution of 131I-tositumomab, including the following: • First-day imaging: Blood pool not visualized, diffuse uptake in liver and/or spleen, evidence of urinary obstruction and diffuse lung uptake. • Second- and third-day imaging: Evidence of urinary obstruction and diffuse lung uptake. • Total body residence times of < 50 hours and > 150 hours.

ARTIFACTS • Observe patient for allergic reaction, e.g., anaphylactic shock, nausea, redness or rash at injection site. Typically, the reaction happens with the first Rituximab injection. Severe reactions include hypotension, angioedema, hypoxia, and bronchospasm, and cause a manifestation of pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, hemorrhage, and mucocutaneous reactions. The most common side effects are thrombocytopenia, neutropenia, anemia, nausea, vomiting, diarrhea, abdominal pain, cough, dyspnea, dizziness, arthralgia, anorexia, and ecchymosis. • Should do HAMA titer if patient has had previous Moab test. • Impaired renal function may be a consideration. • Myelodysplastic syndrome (MDS), secondary leukemia, and solid tumors have been observed in patients receiving this product. • Therapeutic dose should be modified for patients with mild thrombocytopenia or obesity. • Patient motion may distort or obscure possible sites. • Dose infiltration: Immediately stop infusion and start a new site in opposite arm. Use same IV tubing set and filter for either dosimetric or therapeutic infusion. • Patients may respond with hypothyroidism. • Free iodine may present in normal thyroid tissue.

NOTE • Bexxar® monoclonal antibody therapy is a multistep treatment regimen. The patient receives a thyroid blockade 24 hours before the dosimetric injection and continues 14 days after the therapeutic dosage. On day 0, the patient receives an intravenous injection of cold Tositumomab (450 mg) over 1 hour to clear peripheral B cells and improve biodistribution of 131I-tositumomab. Patient takes acetaminophen 650 mg orally and diphenhydramine 50 mg orally 30 minutes before imaging dose. This is done at the oncology physician’s office. This is followed by an infusion of the dosimetric dose, ideally within 1 hour after the injection of the cold tositumomab. This is done in the nuclear medicine department and is used for images and assessment of biodistribution. Whole body images are taken and the therapeutic dose is determined using supplied formula paperwork. If the biodistribution is deemed acceptable, 7–14 days later the patient is again injected with cold Tositumomab (450 mg) over 1 hour followed by the therapeutic dosage over 20 minutes, again ideally within 1 hour after the infusion of the cold tositumomab in the nuclear medicine department. The patient takes acetaminophen 650 mg orally and diphenhydramine 50 mg orally 30 minutes before the therapy dose. After the iodine scans and injection of the iodine therapy, the physician’s office follows the patient’s blood work and physical wellbeing. The technologist’s role is limited to injection of the iodine and imaging, and may be involved with the infusion of the therapy. The patient can be released immediately and should be instructed to follow similar guidelines as 131I therapies. (Refer to Patient Information for Hyperthyroid Therapy in the reference section for a list.) Bexxar® Service Center 877-423-9927 fax: 877-279-1512 290

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 291

Chapter 49 — Therapy: BEXXAR®

Unit doses: Pharmacy Services of Rockford 4330 Charles St. Rockford, IL 61108 815 484-0500 • Thyroid blocking agents: Saturated solution of potassium iodide (SSKI) 4 drops orally t.i.d., Lugol’s solution 20 drops orally t.i.d., potassium iodide tablets 130 mg orally q.d. 234–777 mCi (8.658–28.749 GBq) of the 131I-tositumomab regimen were administered to myeloablative patients with 16 of 19 showing complete response and later 16 of 21 with complete remission. • Other 131I therapy: 131I-LYM-1 is an IgG2a murine monoclonal antibody targeting HLA-DR expressed on the surface of most malignant B-cell lymphocytes. It is not internalized. It has also been tagged with 67Cu in the form of BFCA2-iminothiolanebromoacetamidobenzyl TETA to yield the antibody conjugate 67Cu-2IT-BAT-LYM-1.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy or radiation therapy?

Y

N

Have you had any recent Moab type exams?

Y

N

Do you have any allergies (especially to murine products)?

Y

N

Do you have a history of pulmonary or cardiac problems?

Y

N

Are there any recent or planned CT, PET, MRI, X-Ray, US, or NM exams?

Y

N

Have you had any recent abnormal labs (CEA, CA-125, HAMA, other)?

Y

N

Do you have the results of your platelet counts?

Y

N

Do you have thyroid and blood chemistry laboratory results?

Y

N

Have you received the cold tositumomab therapy?

Y

N

Women: Are you pregnant or nursing?

Y

N

If so, what type and for how long? Do you have any pain? If so, where and for how long?

If so, what type?

Other department-specific questions.

291

10766-49_CH49.qxd

12/3/07

4:59 PM

Page 292

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Bexxar® (tositumomab): Package insert. Corixa Corp, Seattle, WA, June 2003. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Sandler MP et al., eds. Diagnostic Nuclear Medicine, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2003. www.medscape.com/viewarticle/440526 www.radiology.wisc.edu/divisions/nucmed/protocols/files/therapies/BexxarBMTStudy0401.pdf

Notes

292

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 293

chapter

50

Therapy: Bone Pain (Palliation) RADIOPHARMACY Radionuclide •

89

Sr t1/2: 50.5 days Energies: 1463 keV (max), 583.3 keV (mean) Type: β−, fission product • 153Sm t1/2: 46.7 hours Energies: β− 632, 702, 805 keV (max), 198, 224, 263 keV (mean), γ 103 keV Type: β−, γ, fission product (neutron irradiation of 152Sm) 32 • P t1/2: 14.26 days Energies: 1710 keV (max), 694.9 keV (mean) Type: β−, fission product

Radiopharmaceutical • •

153

Sm: Phosphonate compounds concentrate in bone mineral. Metallic ions are chelated with phosphonate complexes, with the resulting compound used to deliver metallic radioactive ions to bone mineral turnover in association with hydroxyapatite. Quadramet® (153Sm-lexidronam) accumulates in osteoblastic lesions at a 5:1 ratio compared with normal bone. • 32P: Phosphate compound with similar characteristics of other phosphate products. A concern is with involvement in metabolic processes, especially within the hematopoietic system causing a high level of myelosuppression.

89

Sr-chloride Sm-lexidronam (ethylenediamine tetramethylene phosphonate [EDTMP]) • 32P-sodium phosphate 153

Localization •

•

89

Sr: Uptake of strontium at sites of osteoblastic skeletal metastases remaining in the same concentration for 100 days after injection. Metastron® (89Sr-chloride) behaves like calcium analogs, preferentially localizing in areas of active osteogenesis.

Quality Control • Radiochemical purity must be ≥ 90% • 32P: 100% radiochemical purity

Adult Dose Range •

89

Sr: 4 mCi (148 MBq) or 40–60 µCi (1.48–2.22 MBq) per kg • 153Sm: 1 mCi (37 MBq) per kg • 32P: 5–10 mCi (185–370 MBq) intravenously or 10–12 mCi (370–740 MBq) PO 293

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 294

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Some calculate doses on lean body mass, reducing for azotemia or increasing with diffuse widespread metastasis. Some divide the administrations over a period of time.

Method of Administration • It is suggested that the syringe be shielded with a lead syringe shield rather than plastic, even though Sr-89 is a pure β emitter.

• Existing IV catheter or 21-gauge butterfly. • Three-way stopcock. • Ten milliliters of flush or more. It is suggested to flush the radiopharmaceutical syringe several times to ensure the entire dose is administered. • Performed by authorized user: nuclear physician, radiologist, or ordering physician.

INDICATIONS • Palliation of intractable bone pain for patients with two or more osseous metastases (osteoblastic metastatic bone lesions) documented by bone scan from primary cancer. Candidates should have multiple bone metastases sites, bone pain, white blood cell (WBC) count of > 2400, and a platelet count of > 60,000. Other candidates are those who have failed hormonal therapy for prostate cancer management. • Assessment of painful bone metastases for the use of palliation in conjunction with, or instead of, radiotherapy.

CONTRAINDICATIONS • Patients with no bone pain, multiple sites of metastases, WBC counts of < 2400, platelet counts of < 60,000, or doing well with other methods of pain palliation. • A solitary metastatic site. • Pregnancy. • Patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration. • Quadramet®: Patients who have a known hypersensitivity to EDTMP or similar phosphonate compounds. • No contraindications are indicated for the following: • Previous heavy external beam irradiation. • Previous failure of 89Sr therapy. • Anemia; can be corrected by infusion. • Conventional methods of pain palliation (e.g., analgesics, nonsteroidal antiinflammatory drugs, hormonal therapy, and radiotherapy) that have not yet been used or are being used and have not yet failed.

PATIENT PREPARATION • • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Ensure patient has and reads package insert information. Obtain a signed, informed consent from patient. Patient to bring results of latest laboratory tests. Patient to bring images and results of latest bone scan (within the last 6 weeks). Instruct patients with incontinence as to toilet instructions and if necessary, catheterize 2 days before injection. • Instruct patient to ingest 500 mL of fluid before injection and to void often before and after injection.

294

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 295

Chapter 50 — Therapy: Bone Pain (Palliation)

EQUIPMENT Camera

Computer Set-up

• Large field of view

•

Collimator

Statics • 500,000–750,000 counts

• Low energy, all purpose, or low energy, high resolution

153

Sm; peak for 103 keV, 20% window

Whole Body • 10 cm/min, head to toe

PROCEDURE (TIME: INJECTION, 20 MINUTES; IMAGES, ~30–50 MINUTES) • Place patient in supine position on table or sitting upright in chair. • The following is in preparation for the injection: • Place a butterfly needle in (preferably) the antecubital fossa, secure with tape, or use indwelling catheter. • Attach a three-way stopcock to the line. • Attach a syringe containing 10 mL (or more) of saline to the straight port. • Ensure that the needle is properly in the vein by withdrawing and reinjecting small amounts of blood; the blood should flow freely. • Cover area with absorbent material in case of spill or leak. • The injection is performed by an authorized user (e.g., nuclear physician): • Attach the syringe containing the radiopharmaceutical to the side port. • Turn the stopcock to connect the radiopharmaceutical syringe to the patient and inject the radiopharmaceutical for 30–60 seconds. • Turn the stopcock to connect the saline syringe to the patient and flush the radiopharmaceutical syringe three times to ensure the entire dose has been injected into the patient. • Observe injection site for extravasation; apply warm compresses to area if detected to encourage venous and lymphatic absorption. • The IV catheter (once removed), the saline syringe, tubing, and radiopharmaceutical syringe can be counted before proper disposal to ensure that there is not an abundance of residue. • Samarium-153: Optional imaging: • Obtain whole body scan or statics of areas of bone pain at 3–48 hours after injection, if desired, to confirm success of skeletal uptake and lesion affinity. These have been shown to be very comparable to routine bone imaging agents. • Compare results with most recent bone scan.

NORMAL RESULTS • Decreased bone pain beginning in 7–20 days and lasting 10–24 weeks or more. • Increased quality of life, decreased dependency on opiates. • Patients can be treated again as early as 10 weeks if symptoms reappear.

ABNORMAL RESULTS • No change or short-term change in pain levels and/or deteriorating conditions. • Platelet count should be monitored as 80% of patients experience a 20–30% decrease by 6 weeks.

295

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 296

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ARTIFACTS • Nonpatent IV site leading to leakage or extravasation of radiopharmaceutical, causing local tissue radiation injury and less than desired or no therapeutic amount delivered to patient. • Myelosuppression (bone marrow toxicity) is one of the major concerns with therapy, and the patient should be monitored for any signs during this and other types of therapy. • In cases in which spinal cord compression from vertebral metastasis or pathologic fractures may occur, therapy should only be used in conjunction with other forms of management that address those issues.

NOTE • The carcinomas that account for most of the metastatic bone disease are breast, prostate, bronchial, renal, lung, and thyroid. Research is presently under way to develop therapeutic administrations to use in conjunction with pain palliation. Typical strategies include non-narcotic analgesics, narcotic analgesics, nonsteroidal anti-inflammatory drugs, hormone therapy, chemotherapy, local-field external beam radiotherapy, and wide-field external beam radiotherapy. Although palliation has been the intention of using these agents, there is now serious attention given to the use of these agents as tumor-controlling therapeutic drugs. • Other bone palliation agents include the following: • 32P-orthophosphate; t1/2 14.3 days, 1.710 MeV (max), 0.695 MeV (mean). • 186Re-etidronate (hydroxyethylidenediphosphonate [HEDP or etidronate]), chelate; t1/2 3.8 days, 1.077 MeV (max), 0.362 MeV (mean), γ, 137 keV. • 188Re-phosphonate, chelate; t1/2 16.98 hours, 2.120 MeV (max), 0.795 MeV (mean), γ, 155 keV. • 131I-diphosphonate; t1/2 8.0 days, 0.606 MeV (max), 0.191 MeV (mean), γ, 365 keV. • 90Y-citrate; t1/2 2.7 days, 2.284 MeV (max), 0.935 MeV (mean). • 117mSn-chelate; t1/2 13.6 days, isomeric transition, γ, 159 keV.

THE ROLE OF THE NUCLEAR MEDICINE TECHNOLOGIST IN THERAPY • Order and receive the radiopharmaceutical from the radiopharmacy into the department. • Properly prepare patient and paperwork for physician and therapy. • Some institutions have other personnel to start IV catheter. If not, the nuclear medicine technologist must start and test the IV catheter and tubing for patency. • Provide a sterile area and proper equipment for the injection. • Assay the therapy dose and confirm the amount of activity with the injecting physician. • Record the time, dose, patient, doctor, and any pertinent information about the therapy.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer? If so, what type and for how long? When was your last chemotherapy? When was your last radiotherapy?

296

Y

N

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 297

Chapter 50 — Therapy: Bone Pain (Palliation)

Are you on any other type of therapy for pain?

Y

N

Have you had a recent chest radiograph?

Y

N

Do you have a copy of the images and/or results with you?

Y

N

Do you have recent laboratory results with you (hemoglobin, WBC [> 2500], platelets [> 60,000])?

Y

N

Do you have bone pain at present?

Y

N

Do you have the results of any related examinations with you?

Y

N

Are you taking any pain medication?

Y

N

Have you received and read your information sheet?

Y

N

Female: Are you pregnant or nursing?

Y

N

When was your last bone scan?

If so, where and for how long?

Please list.

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases. Version 3.0, January 25, 2003. SNM.org. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

297

10766-50_CH50.qxd

12/3/07

5:00 PM

Page 298

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notes

298

10766-51_CH51.qxd

12/3/07

5:01 PM

Page 299

chapter

51

Therapy: Intra-articular (Joint); Synovectomy RADIOPHARMACY Radionuclide •

32

P t1/2: 14.26 days Energies: 1710 keV (max), 694.9 keV (mean) Type: β−, fission product • 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

32

P-chromic phosphate as a colloid, .6–2.0 µm Tc-sulfur colloid (SC)

99m

Localization

Adult Dose Range (weight-based) •

32

P-chromic phosphate: • 10–25 kg: knee, .500 mCi (18.5 MBq); elbow/ankle, .250 mCi (9.25 MBq) • 25–40 kg: knee, .750 mCi (27.75 MBq); elbow/ankle, .375 mCi (13.875 MBq) • >40 kg: knee, 1.000 mCi (37.0 MBq); elbow/ankle, .500 mCi (18.5 MBq) • 99mTc-SC: 1 mCi (37 MBq)

Method of Administration • Injection through needle placement into a joint (synovial) cavity.

• Compartmental to synovial cavity

Quality Control •

32

P-chromic phosphate: > 95% radiochemical purity • 99mTc-SC: > 92% radiochemical purity

299

10766-51_CH51.qxd

12/3/07

5:01 PM

Page 300

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Palliation of joint pain caused by rheumatoid arthritis. • Palliation of joint pain caused by hemophilic arthropathy (hemorrhage into synovial space because of hemophilia). • Palliation of joint pain caused by villonodular synovitis (nodular projections of the synovial membrane into the synovial cavity).

CONTRAINDICATIONS • None

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. The written directive must be signed by an authorized user. Obtain a signed consent from the patient. Patients with hemophilia are usually given factor VIII before therapy (50 U/kg) and at 24 and 72 hours after therapy (20 U/kg). This is also required in known cases of factor IX deficiency. • Patient must bring laboratory results and recent x-ray films of area of interest.

EQUIPMENT Camera

Computer Set-up

• Large field of view

•

99m

Tc-SC: 140 keV, 20% window Statics: 250,000 counts or 180-second images

Collimator • Low energy, all purpose, or low energy, high resolution

PROCEDURE

(WITH OPTIONAL 99MTC-SC IMAGING; TIME: INJECTION, ~30 MINUTES; IMAGING, ~15 MIN/SESSION) • Place patient in supine position on table or in a suitable position for proper placement of injection needle. • Procedure is performed by authorized user (physician) under fluoroscopy guidance. • Wipe area to be injected with povidone-iodine solution (Betadine®). • Anesthetize the skin in area to be injected using 1% lidocaine. • Enter the synovial (joint) space with needle. For the knee, the needle is placed beneath the lateral side of the patella. • Connect tubing and three-way stopcock to the needle. • Attach a 50-mL syringe to the stopcock and aspirate the synovial fluid. Optional: instill iothalamate (Conray®) through needle to ensure needle is in the joint space using fluoroscopy. • Attach the syringe containing the 32P-chromic phosphate, or, optionally, 99mTc-SC if imaging is desired, to the stopcock. • Optional: inject 1 mCi (37 MBq) 99mTc-SC into synovial space for imaging. (This ensures therapeutic agent will not loculate, but disperse throughout joint space.) Obtain static images: anterior, posterior, and laterals both before therapy dose and after therapy dose. 300

10766-51_CH51.qxd

12/3/07

5:01 PM

Page 301

Chapter 51 — Therapy: Intra-articular (Joint); Synovectomy

• Inject the 32P-chromic phosphate and (optionally) any remaining 99mTc-SC. Again optional: Image area again to ensure thorough dispersal within the joint. • Flex the joint to ensure thorough distribution of therapy dose. Optional: Image area of interest as before. • Attach the syringe containing 1% lidocaine and dexamethasone. • Inject 3–5 mL of 1% lidocaine/dexamethasone along the needle track while withdrawing the needle from the joint to prevent inflammation and leakage of the therapy dose. • Immobilize joint in a protective splint for 2 days (helps to minimize leakage into lymphatics and blood vessels). • Optional • At 24 and 72 hours and optionally at 7 days, patient may be counted by Geiger-Müller (GM) counter to assess nodal uptake of therapeutic colloid in draining lymphatic nodes and liver. • Imaging using bremsstrahlung radiation from 32P can be performed to document distribution within the synovial cavity. Use a high-energy collimator and energy window of 150–450 keV. • Blood and urine samples may be obtained every few hours after injection and counted for radioactivity to document presence or absence of leakage.

NORMAL RESULTS • • • • •

Reduction of pain associated with the affected joint. Reduction of inflammation within the affected joint. Reduction of degradation of cartilage and bone within the affected joint. Improvement of function of the affected joint. With the use of 99mTc-SC imaging, joint space presents as thoroughly and evenly perfused with radiotracer.

ABNORMAL RESULTS • Little or no palliative effect felt in affected joint. • Images may have clumping or subspaces with more activity than others (inhomogeneous mixture within the synovial cavity).

ARTIFACTS • Extravasation of therapy dose or misplacement of needle will, depending on extent, negatively affect the usefulness of the therapy. • Do not use as IV injection. Radiotherapy colloid will localize in liver. The preparation should be a cloudy, brownish-green colloidal suspension, not the clear 32P solution used for IV injection for polycythemia vera.

NOTE • Other radiopharmaceuticals used in synovectomy include the following: • 165Dy-FHMA (ferric hydroxide macroaggregates): t1/2, 2.3 hours; energies, 1285, 1190 keV (max), 453, 414 keV (mean). • 90Y-calcium oxalate or FHMA: t1/2, 64.1 hours; energies, 2284 keV (max), 935 keV (mean). • 198Au: t1/2, 2.7 days; energies, 961 keV (max), 315 keV (mean), 412 keV.

301

10766-51_CH51.qxd

12/3/07

5:01 PM

Page 302

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

THE ROLE OF THE NUCLEAR MEDICINE TECHNOLOGIST IN THERAPY • • • • •

Order and receive the radiopharmaceutical from the radiopharmacy into the department. Properly prepare patient and paperwork for physician and therapy. Provide a sterile area and proper equipment for the injection. Be prepared to take pretherapy dose images of area of interest if that avenue is being pursued. Assay the therapy dose and confirm the amount of activity with the injecting physician. Pure beta emitters do not dose calibrate well. Low-energy bremsstrahlung radiation can be used to assay the dose. The radiopharmacist can be contacted for verification. • Record the time, dose, patient, doctor, and any pertinent information about the therapy. • Be prepared to take posttherapy dose images of area of interest if that avenue is being pursued.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of rheumatoid arthritis?

Y

N

Do you have a history of joint disease?

Y

N

Are you experiencing pain at present?

Y

N

Do you have the results of recent laboratory tests and recent x-ray films with you?

Y

N

Have you had any recent operations?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type and for how long?

What other means of therapy are currently or recently under way (e.g., aspirin, nonsteroidal anti-inflammatory agents, steroids, remission-inducing agents [gold or D-penicillamine], intra-articular corticosteroid injections, osmic acid, alkylating agents [thiotepa-T])?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

302

10766-51_CH51.qxd

12/3/07

5:01 PM

Page 303

Chapter 51 — Therapy: Intra-articular (Joint); Synovectomy

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

303

10766-52_CH52.qxd

12/3/07

5:02 PM

Page 304

chapter

52

Therapy: Intracavitary (Serosal) RADIOPHARMACY Radionuclide •

32

P t1/2: 14.26 days Energies: 1710 keV (max), 694.9 keV (mean) Type: β+, fission product • 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical •

32

P-Chromic phosphate as a colloid, 0.1–0.3 µm in size • 99mTc-sulfur colloid (SC)

Localization • Compartmental to serosal cavity. Macrophages consume colloid particles and become fixed on serosal compartment lining. Confined to lining, beta emitters deliver ablation energy to serosal and lymphatic deposits. Some reach the local lymph nodes and are deposited there.

304

Quality Control •

32

P-Chromic phosphate: >95% radiochemical purity • 99mTc-SC: >92% radiochemical purity

Adult Dose Range • •

99m

Tc-SC: 2–3 mCi (74–111 MBq) P-Chromic phosphate • Pleura: 10–15 mCi (370–555 MBq) • Pericardium: 5–10 mCi (185–370 MBq) • Peritoneum: 15–20 mCi (555–740 MBq) 32

Method of Administration • Intracath placement into cavity of concern through which the therapy is administered. The method is listed below. The site could be a patent access left from surgical treatments or a new installation.

10766-52_CH52.qxd

12/3/07

5:02 PM

Page 305

Chapter 52 — Therapy: Intracavitary (Serosal)

INDICATIONS • Palliation by reduction of recurrent effusions in serosal cavities (e.g., peritoneal, pericardial, and pleural) secondary to malignant disease, especially those not successfully treated with sclerosing agents such as tetracycline. • Prevention of recurrence of malignant disease on serosal surfaces. • Treatment of cystic neoplasms. • Treatment of malignant ascites (especially ovarian source). • Treatment, in limited role, of ovarian cancer. Patients with stage I or II ovarian carcinoma are treated with 15 mCi (555 MBq) of 32P-chromic phosphate colloid premixed with 250 mL of normal saline.

CONTRAINDICATIONS • Patients with intraperitoneal infection. • Patients with > 6 months’ life expectancy. • Detection of the presence of loculated fluid (through the use of 99mTc-SC).

PATIENT PREPARATION • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. The written directive must be signed by an authorized user. Obtain a signed consent from the patient. Patients receiving intrapleural administration must have a thoracentesis to remove the effusion.

EQUIPMENT Camera

Computer Set-up

• Large field of view

•

Collimator

Statics • 250,000 counts or 180-second images

99m

Tc-SC: 140 keV, 20% window

• Low energy, all purpose, or low energy, high resolution

PROCEDURE

(WITH OPTIONAL 99mTc-SC IMAGING; TIME: INJECTION, ~30 MINUTES; IMAGING, ~15 MIN/SESSION) • Place patient in supine position on table or in a suitable position for proper placement of injection needle. • Injection • Using aseptic technique and 1% lidocaine to anesthetize the skin, place the intracatheter into the cavity and secure with tape. (Ultrasound imaging may be helpful in documenting the location of ascites.) • Attach a connecting tube to the intracatheter. • Attach a three-way stopcock to the connecting tube. • Attach the second connecting tube to the three-way stopcock. • Attach the collecting bag to the free end of the connecting tube. • Attach the 50-mL syringe to the stopcock and withdraw the bulk, but not all, of the fluid. 305

10766-52_CH52.qxd

12/3/07

5:02 PM

Page 306

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

•

• • • •

• Document free flow of injected fluid within the cavity by injecting iodinated contrast material and obtaining a radiograph or by injecting 99mTc-SC or 99mTc-macroaggregated albumin (MAA) and acquiring a gamma camera image. • Attach the syringe containing the 99mTc-SC, if imaging is desired, to the stopcock. • Optional: Inject 1 mCi (37 MBq) 99mTc-SC into serosal cavity for imaging. (This ensures therapeutic agent will not loculate, but will disperse throughout serosal cavity.) Obtain static images: anterior, posterior, and laterals both before and after therapy dose. • Some attach up to 500-mL (for peritoneum) bag of saline to tubing leading into cavity. • Inject the 32P-chromic phosphate (into saline bag if used) and (optionally) any remaining 99mTc-SC. Again optional: Image area again to ensure thorough dispersal within the cavity. Peritoneum or pleural cavity: Have the patient roll from side to side and lie prone to ensure adequate distribution of the radiotherapy throughout the cavity. Heart motion ensures adequate distribution in the pericardial cavity. Confirmation that fluid will disperse can be obtained by injecting a water-soluble radiopaque agent and taking a KUB (kidneys, ureter, and bladder x-ray). Optional: Image peritoneum or pleural cavity using bremsstrahlung radiation from 32P to confirm dispersal. Use a high-energy collimator and energy window of 150–450 keV. Cystic volume measurement in brain neoplasms can be obtained with computed tomography (CT). After injection, patient is repositioned repeatedly in first hour, then several times each hour for the next 24 hours.

NORMAL RESULTS • Palliation of the pain caused by excess fluid within affected cavity. Maximum effect occurs at 3 months. Dose may need repeating. • Temporary therapeutic treatment (remission) of cancer causing the production of excess fluid within the affected cavity. • With the use of 99mTc-SC imaging, serosal cavity presents as thoroughly and evenly perfused with radiotracer.

ABNORMAL RESULTS • Little or no palliative relief of pain and/or cancer causing the production of excess fluid within the affected cavity. • Images may have clumping or subspaces with more activity than others (inhomogeneous mixture within the serosal cavity).

ARTIFACTS • Do not use as IV injection. Radiotherapy colloid will localize in liver. The preparation should be a cloudy, brownish-green colloidal suspension, not the clear 32P solution used for IV injection for polycythemia vera. • Any leakage from the therapy site must be treated as a radioactive spill and cleaned in accordance with precautions pertaining to beta emitters. • There are newer nonradioisotopic drugs being used for therapy as well as newer 90Y-labeled monoclonal antibody and microsphere therapies.

NOTE • Tumors in the peritoneal or pleural cavity cause serosal irritation, resulting in excess cavity transudate. This excess fluid can be a source of extreme discomfort to the patient. The beta emitter 306

10766-52_CH52.qxd

12/3/07

5:02 PM

Page 307

Chapter 52 — Therapy: Intracavitary (Serosal) 32

P-chromic phosphate is used as a palliative treatment, irradiating the surfaces of cavity and reducing the amount of fluid production. Macrophages within the system engulf the colloid particles and settle on the surfaces. Little systemic colloid absorption occurs.

THE ROLE OF THE NUCLEAR MEDICINE TECHNOLOGIST IN THERAPY • • • •

Order and receive the radiopharmaceutical from the radiopharmacy into the department. Properly prepare patient and paperwork for physician and therapy. Provide a sterile area and proper equipment for the injection. Assay the therapy dose and confirm the amount of activity with the injecting physician. Pure beta emitters do not dose calibrate well. Low-energy bremsstrahlung radiation can be used to assay the dose. The radiopharmacist can be contacted for verification. • Record the time, dose, patient, doctor, and any pertinent information about the therapy. • Be prepared to take post-therapy dose images of area of interest if that avenue is being pursued.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Y

N

Do you have the results of any other related examinations?

Y

N

Do you have the results of any recent laboratory tests?

Y

N

Have you had any other therapy?

Y

N

Y

N

If so, what type and for how long? Are you presently experiencing pain? If so, where and for how long? Do you feel you have fluid build-up? If so, where and for how long?

If so, what type and when? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

307

10766-52_CH52.qxd

12/3/07

5:02 PM

Page 308

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

308

10766-53_CH53.qxd

12/3/07

5:19 PM

Page 309

chapter

53

Therapy: Polycythemia Vera RADIOPHARMACY Radionuclide •

32

P t1/2: 14.26 days Energies: 1710 keV (max), 694.9 keV (mean) Type: β−, fission product

Radiopharmaceutical •

32

P-sodium phosphate (clear, injectable solution)

Localization • Approximately 85% of administered dose metabolically localizes in bone tissue (bone marrow and trabecular bone) because of its high inorganic phosphorus content. Incorporates into DNA with subsequent damage from beta particles and decays to 32S, altering nucleic acid structure.

Adult Dose Range • 2.3 mCi (85.1 MBq) per square meter body surface. • 3–5 mCi (111–185 MBq), dosage not to exceed 7 mCi (259 MBq) during any 6-month period. • If no response within 3 months, repeat dose at 25% of original dose. • If no response in subsequent 3 months, repeat dose at 25% of previous dose (dose not to exceed 7 mCi [259 MBq]).

Method of Administration • Intravenous injection through butterfly or indwelling catheter with a 10-mL saline flush.

Quality Control • No other radiochemical forms are present. Administered dose must be within 10% of requested dose.

309

10766-53_CH53.qxd

12/3/07

5:19 PM

Page 310

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Palliation of erythrocytosis not controllable by phlebotomy alone. • Treatment of thrombocytosis with platelet counts approaching 1 million. • Treatment of extramedullary hematopoiesis with painful spleen, hypersplenism, abdominal pain, or splenic infarct. • Palliation of pruritus or hyperuricemia not controlled by phlebotomy, allopurinol, or antihistamines. • Treatment of cardiovascular problems contraindicating frequent phlebotomies. • Treatment of patients with a risk of thrombosis. • Treatment is reserved for the elderly (>75 years old) to minimize concerns of possible subsequent development of acute leukemia. • Treatment of patients who cannot tolerate or be relied on to take hydroxyurea according to instructions.

CONTRAINDICATIONS • Treatment should not be used if • Platelet count is < 15,000. • Reticulocyte count is < .2%. • White blood cell count is < 3000.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • The written directive must be signed by an authorized user. • Obtain a signed consent from the patient.

EQUIPMENT Camera

Computer Set-up

• N/A

• N/A

Collimator • N/A

PROCEDURE (TIME: ~20 MINUTES) • Place patient in supine position on table or sitting upright in chair. • The following is in preparation for the injection • Place a butterfly needle in (preferably) the antecubital fossa and secure with tape, or use indwelling catheter. • Attach a three-way stopcock to the line. • Attach a syringe containing 10 mL (or more) of saline to the straight port. • Ensure that the needle is properly in the vein by withdrawing and reinjecting small amounts of blood; the blood should flow freely. • Cover area with absorbent material in case of spill or leak. • The injection is performed by an authorized user (e.g., nuclear physician) • Attach the syringe containing the radiopharmaceutical to the side port. • Turn the stopcock to connect the radiopharmaceutical syringe to the patient and inject the radiopharmaceutical for 30 to 60 seconds. 310

10766-53_CH53.qxd

12/3/07

5:19 PM

Page 311

Chapter 53 — Therapy: Polycythemia Vera

• Turn the stopcock to connect the saline syringe to the patient and flush the radiopharmaceutical syringe three times to ensure the entire dose has been injected into the patient. • Observe injection site for extravasation; apply warm compresses to area if detected to encourage venous and lymphatic absorption. • The IV catheter (once removed), the saline syringe, tubing, and radiopharmaceutical syringe can be counted before proper disposal to ensure that there is not an abundance of residue. • Extravasation can be checked with a Geiger-Müller counter moving up the arm. The count rate should remain pretty much the same all the way.

NORMAL RESULTS • Patient’s blood chemistry returns to normal levels within 4 to 6 weeks. It may stay in remission for 2 years or more.

ABNORMAL RESULTS • No reduction of production of red blood cells even after repeated doses of the therapy.

ARTIFACTS • Extravasation of the therapy dose may cause collateral tissue damage and lessen the desired therapeutic affect. This can occur up to 2 weeks after injection. • 10% to 20% of 32P patients contracted acute leukemia as opposed to 1% with phlebotomy alone. • Median survival of patients treated with 32P is 10 to 16 years, 7 to 8 years with phlebotomy only, and 1.5 years without any therapy. • Myelofibrosis with myeloid metaplasia occurs in 10% to 20% of polycythemia patients and is considered a natural outcome, unrelated to therapy. • There are newer non-radioisotopic drugs being used for therapy of polycythemia vera.

NOTE • Other treatment plans include phlebotomy and chemotherapy with chlorambucil. Polycythemia rubra vera is a chronic hematologic disease characterized by increased proliferative activity of erythroid, myeloid, megakaryocytic, and fibroblastic cells. The early phase often progresses to the myelofibrosis phase with myeloid metaplasia (spent phase). This entails anemia, a leukoerythroblastic blood condition, and hepatosplenomegaly. This evolves into an accelerated malignant phase closely resembling acute myeloblastic leukemia.

THE ROLE OF THE NUCLEAR MEDICINE TECHNOLOGIST IN THERAPY • Order and receive the radiopharmaceutical from the radiopharmacy into the department. • Properly prepare patient and paperwork for physician and therapy. • Some institutions have other personnel to start IV catheter. If not, the nuclear medicine technologist must start and test the IV catheter and tubing for patency. • Provide a sterile area and proper equipment for the injection. • Assay the therapy dose and confirm the amount of activity with the injecting physician. Pure beta emitters do not dose calibrate well. Low-energy bremsstrahlung radiation can be used to assay the dose. The radiopharmacist can be contacted for verification. • Record the time, dose, patient, doctor, and any pertinent information about the therapy. 311

10766-53_CH53.qxd

12/3/07

5:19 PM

Page 312

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have documentation of a bone disorder?

Y

N

Do you have the results of any related examinations?

Y

N

Do you have the results of recent laboratory tests?

Y

N

Have you received any recent therapy?

Y

N

Y

N

If so, what type and for how long?

If so, what type and when? Female: Are you pregnant or nursing? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

312

10766-54_CH54.qxd

12/3/07

5:20 PM

Page 313

chapter

54

Therapy: Zevalin® (Radioimmunotherapy for B-cell non-Hodgkin’s Lymphoma) RADIOPHARMACY Radionuclide 111 In: t1/2: 2.8 d Energies: 173, 247 keV Type: EC, γ, accelerator • 90Y: t1/2: 64.1 h Energies: 2.284 MeV Type: β−, fission product

ted on the normal and malignant B-lymphocytes of non-Hodgkin’s lymphoma (NHL).

•

Radiopharmaceutical •

Quality Control • If made from kit, chromatography, ≥ 95% radiochemical purity for both. Store in refrigerator before use. • 111In: Use within 12 hours. • 90Y: Use within 8 hours.

111

In-chloride: Isothiocyanatobenzylderivatized DTPA linker, Ibritumomab (intact IgG1 kappa murine monoclonal antibodies [Moabs]), and tiuxetan, MX-DTPA. Zevalin® • 90Y-chloride: Same. Zevalin®. 90Y beta particles travel about 5 mm in soft tissue (100–200 cell diameters)

Adult Dose Range • •

111

In: 5 mCi (185 MBq) Y: .4 mCi/kg (14.8 MBq/kg) for therapy, not to exceed 32 mCi (1184 MBq) 90

Method of Administration Localization • Compartmental, blood flow; dose dependent, antibody binding. Targets CD20 antigen loca-

• Intravenous butterfly (large bore, 18–22 ga.) over 10 minutes with a .2-um micropore filter on the syringe. 313

10766-54_CH54.qxd

12/3/07

5:20 PM

Page 314

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• 10-mL saline flush. • Should have physician or nurse available for possible allergic reaction (1 mg epinephrine available).

• Follow vital signs: Baseline, 5 minutes postinjection, 15, 30, and 60 minutes. (Some simply observe patient for 15 minutes looking for redness at injection site or signs of nausea and vomiting.)

INDICATIONS • Confirm biodistribution of 111In-Zevalin® for 90Y-Zevalin® therapy. • Treatment of patients with relapsed or refractory low grade, follicular or transformed B-cell nonHodgkin’s lymphoma. • Treatment of patients includes Rituxan (rituximab)-refractory follicular NHL.

CONTRAINDICATIONS • Patients with known Type 1 hypersensitivity or anaphylactic reactions to murine proteins or any component of this product, including but not limited to yttrium chloride and indium chloride. • Patients with ≥ 25% lymphoma marrow involvement and/or impaired bone marrow reserve caused by myeloablative surgery, low platelet counts, neutrophil count < 1500 cells/mL. • Patients having bone marrow transplantation or radioimmunotherapy. • Patients with leukemia, HIV, or AIDS. • 90Y-Zevalin® should not be administered to patients with platelet counts < 100,000/mm3. If counts are 100,000 to 149,000/mm3, activity should be adjusted to .3 mCi/kg (11.1 MBq/kg). • 90Y-Zevalin® should not be administered to patients with altered biodistribution as determined by the outcome of the 111In-Zevalin® images.

PATIENT PREPARATION • • • • • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Obtain a signed consent form from patient for the 90Y therapy. Obtain appropriate written directive for therapy dosage. Ensure patient supplies list of history of allergies and prior exams. Female patients of childbearing age should be advised to avoid becoming pregnant during therapy. Pregnant females should be counseled as to the potential hazard to the fetus. Patients who have had a previous Moab test should have a HAMA titer (human anti-mouse antibody) performed before another injection. Verify patient’s platelet count. For 90Y, not less than 100,000/mm3. Patient to receive Rituxan (cold ibritumomab) therapy at physician’s office 4 hours before receiving the 111In dosage and again before the 90Y therapy dose. Patient should be well hydrated before 111In and 90Y dosing.

EQUIPMENT Camera

Computer Set-up

• Large field of view

Statics • Indium peaks (172 and 247 keV), 15% to 20% windows, 128 × 128 or 256 × 256 matrix, 600 seconds or more per view (> 1 million counts).

Collimator • Medium energy, general purpose or medium energy, all purpose. 314

10766-54_CH54.qxd

12/3/07

5:20 PM

Page 315

Chapter 54 — Therapy: Zevalin® (Radioimmunotherapy for B-cell non-Hodgkin’s Lymphoma)

Whole Body • 10 cm/min or slower, check patient for length. At least a 30-minute image.

PROCEDURE (TIME: 30 MINUTES FOR 111IN DOSAGE, 1 HOUR EACH SCAN DAY) • • • •

Instruct patient to void before imaging, check clothing for possible artifacts. Position patient supine on table, remind patient of no movement during imaging. Image at 2 to 24 hours, 48 to 72 hours, and possibly 96 to 120 hours postinjection (as per protocol). Statics: 10 minutes (600 seconds) per view. Anterior/posterior; thorax, abdomen, pelvis, extremities if protocol. • Whole body (preferred method): 30 minute (1800 seconds) anterior/posterior. • Patient infused with 90Y-Zevalin® approximately 7 to 10 days after 111In-Zevalin® injection. This takes about 30 minutes and is done by radiation oncologist or nuclear medicine technologist in department under supervision.

NORMAL RESULTS • Activity in heart, vascular areas of head, lungs, pelvis, and abdominal blood vessels on first images (day 1). Less blood pool activity thereafter. • Moderately high to high uptake in liver and spleen on all imaging days. • Moderately low to very low uptake in kidneys, urinary bladder, and bowel on first and second day imaging. • Focal areas of tumor uptake may visualize in soft tissue. Tumor-bearing areas in normal organs by visualizing as increased and/or decreased areas of intensity. This is normal in the sense that the test is attempting to confirm biodistribution to tumors for therapy.

ABNORMAL RESULTS • Altered biodistribution of 111In-Zevalin® including the following • Diffuse uptake in lung space that is more intense than the cardiac blood pool on first day imaging, or more intense than liver on the subsequent imaging days. • Kidneys present with greater intensity than liver in posterior view on second and third day imaging. • Increased uptake in normal bowel compared to liver on second- and third-day imaging.

ARTIFACTS • Observe patient for allergic reaction, e.g., anaphylactic shock, nausea, redness or rash at injection site. Typically, the reaction happens with the first Rituximab injection. Severe reactions include hypotension, angioedema, hypoxia, bronchospasm, and cause a manifestation of pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, hemorrhage, and mucocutaneous reactions. Most commonly are thrombocytopenia, neutropenia, anemia, nausea, vomiting, diarrhea, abdominal pain, cough, dyspnea, dizziness, arthralgia, anorexia and ecchymosis. • Should do HAMA titer if patient has had previous Moab test. • Patient motion may distort or obscure possible sites. • Dose infiltration: Increase acquisition times. • Plastic or acrylic syringe shield should be used on the 90Y dose. Lead shielding, as is used with the 111In, causes more penetrating bremsstrahlung radiation from the beta-emitting yttrium. 315

10766-54_CH54.qxd

12/3/07

5:20 PM

Page 316

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

NOTE • Zevalin® monoclonal antibody therapy is a three-step treatment regimen. The patient should already have had Rituxan before being injected for the indium scan. After the indium scan and injection of the yttrium therapy, the physician’s office follows the patient’s blood work and physical well-being. The technologist’s role is limited to injection of the indium and imaging, and may be involved with the infusion of the yttrium. • The regimen begins when the patient on day 1 receives unlabeled rituximab (Rituxan), 250 mg/m2 intravenously (to saturate readily available CD20 sites in spleen and B cells) followed in 4 hours by the 111In-Zevalin® imaging dose over 10 minutes. At least two imaging sessions (as described above) are performed to assess biodistribution. If the biodistribution is deemed acceptable, on day 7, 8, or 9, another injection of unlabeled Rituxan is followed within 4 hours by a 90Y-Zevalin® injection over 10 minutes. They can be released immediately and should be instructed to follow similar guidelines as 131I therapies (refer to Patient Information for Hyperthyroid Therapy in the reference section for a list). IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego, CA 92121 www.biogenidec.com www.zevalin.com • Other 90Y therapy: • 90Y-labeled microspheres (SIR-Spheres) are being used in palliative treatment of nonresectable hepatoma and liver metastases. They are 20–60 µm in diameter and delivered through an angiographic catheter into the hepatic artery. They localize in the hypervascular tumors and less so in normal parenchyma. They remain in the liver and do not degrade, retrievable only by surgery. Patients are screened to ensure that the liver is the source of the life-threatening disease, shunting to the lung (> 20%) as well as portal vein thrombosis may be contraindications to this therapy. SPECT images may be obtained using the bremsstrahlung radiation from the 90Y to confirm localization. Acceptable NRC dose rates allow the patient to be released after administration. • 90Y-LymphCide® (epratuzumab hLL2) by Immunomedics, Inc., San Antonio, TX, humanized monoclonal antibody of the murine IgG2a antibody (mLL2), binds to CD22 sites in B cells. It does not react with normal peripheral blood cells but does react with germinal B cells of normal lymph nodes and the white pulp of the spleen. It becomes internalized in the cell after its CD22 interaction, allowing for subsequent CD22 synthesis and additional antibody localization. It has also been tagged to 131I, 111In, 90Y, and 186Re.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent chemotherapy or radiation therapy?

Y

N

If so, what type and for how long? How much do you weigh? Do you have any pain? If so, where and for how long?

316

10766-54_CH54.qxd

12/3/07

5:20 PM

Page 317

Chapter 54 — Therapy: Zevalin® (Radioimmunotherapy for B-cell non-Hodgkin’s Lymphoma)

Have you had any recent Moab type exams?

Y

N

Do you have any allergies (especially to murine products)?

Y

N

Do you have a history of pulmonary or cardiac problems?

Y

N

Have you had any recent abnormal labs (CEA, CA-125, HAMA, other)?

Y

N

Do you have the results of your platelet counts?

Y

N

Have you received your Rituxan therapy?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, what type? Are there any recent or planned CT, PET, MRI, X-Ray, US, or NM exams?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Klingensmith W, Eshima D, Goddard J. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Zevalin® (ibritumomab tiuxetan): Package insert. IDEC Pharmaceuticals Corporation, San Diego, CA, August 2005. www.medscape.com/viewarticle/440526

Notes

317

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 318

chapter

55

Thyroid: Ablation RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV (γ), 606 keV (β−) Type: β−, γ, fission product

Radiopharmaceutical •

131

I as sodium iodide capsule or liquid

Localization • Active transport. Organified by thyroid and held in cells or follicular lumen. Te = 3–5 days.

Adult Dose Range • 29.9 mCi (1106.3 MBq) or less if primary tumor is < 1.5 cm (low risk for reoccurrence) • 30–300 mCi (1.11–11.1 GBq)

Method of Administration • Oral (PO) capsule, through straw from lead container for liquid. The procedure may require the radiation safety officer (RSO), nuclear physician, or resident nuclear physicist to be present.

Quality Control • Assay the capsule or vial in the dose calibrator to confirm amount of radioactivity

INDICATIONS • Ablation of residual functioning thyroid carcinoma. • Ablation of residual functioning normal thyroid tissue after total or partial thyroidectomy.

318

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 319

Chapter 55 — Thyroid: Ablation

CONTRAINDICATIONS • • • • •

Pregnancy or nursing. Allergy to iodine. Iodinated studies under way or performed recently. Patient taking thyroid medications or vitamins, or not on low-iodine diet. Patient extremely likely to regurgitate dose.

PATIENT PREPARATION • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Low-iodine diet 1 week before therapy. Patient should discontinue thyroid medication for 2 to 4 weeks before therapy. No iodinated radiographic studies 3 weeks before therapy. Female patients cannot be pregnant or nursing nor should they have plans to be until the therapy and follow-up studies are completed. • Additional preparation is considerable with this therapy. Examples are given below.

EQUIPMENT Camera

Computer Set-up

• N/A

• N/A

Collimator • N/A

PROCEDURE (TIME: DOSING, ~15 MINUTES; HOSPITAL STAY, ~3–5 DAYS) • Because of the changed NRC regulations as to release of therapy patients, hospitalization is based on dosage and resulting exposure rates to the public or physician’s discretion. See note. • Obtain initial room clearance from hospital admitting (see Note). • Prepare patient’s room (see Note). • In-service the nurses involved with that patient (see Note). • Admit patient into room. • Explain therapy and answer all questions (see Note). • Obtain signed consent from patient and signature in log book. • Assay the capsule or vial in the dose calibrator and bring to room (see Note). • Remove family and friends from patient’s room. • Administer Reglan® to patient as antivomitus if deemed necessary. • Obtain the written directive (prescription) from physician. • Administer dose to patient quickly (in the presence of RSO or physician). Watch for signs of vomiting. • Obtain an initial assay of patient, room, doorway, adjoining wall, record results. • Monitor and record assays of patient and room b.i.d. until readings fall below limits (usually 5–7 mR at 1 m from patient’s chest and/or < 30 mCi remaining in body. As of 1998, the Nuclear Regulatory Commission has made changes to the rules for handling 131I about the need for patient hospitalization and release (see Note). Not all of the agreement states have instituted these changes. (Check the hospital and state protocol.) Have patient void before taking the reading. • Release patient when appropriate, clean and assay room for residual contamination (see Note). 319

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 320

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

NORMAL RESULTS • Residual thyroid tissue and thyroid carcinoma tissue ablated. Patient is treated with thyroid medication. • No naturally occurring elevated levels of thyroid hormones. • No residual thyroid tissue or carcinoma is found on follow-up whole body scan. • Upon re-evaluation, patient is naturally hypothyroid, but with medication, can be adjusted to proper levels of hormones.

ABNORMAL RESULTS • On re-evaluation, elevated levels of thyroid hormones in laboratory tests. • Whole body scan reveals areas of uptake in neck and/or thorax, perhaps other places as well, suggesting insufficient ablation, metastasis, or recurrence.

ARTIFACTS • Patient may vomit dose immediately or some time soon after dosing. Prepare for that type of radioactive spill (gloves, absorbent cloths, some type of containment). • Distances from patient must be consistent when recording readings. • Patient must force hydration and empty bladder often.

NOTE • Scheduling patient: Something similar to the following must occur to admit the patient into the hospital for the therapy. • Get a signed prescription from the authorized user along with written order from physician. • Call ordering physician to confirm order. • Call the chief radiologist to confirm dose ordered. • Call admitting office and/or floor to confirm room availability (usually a corner room). • Call patient to confirm date and time for dosing. • Confirm that patient has completed all laboratory and other tests before being admitted to the hospital or before dosing. • Call pharmacy to order dose. • Call ordering doctor’s office to have them confirm admitting orders by calling admitting office. • Prepare the room (next section). • Room preparation: Some form of the following is needed for room preparation. • Bring radiation signs, therapy patient log book, dosimeter(s), tape measure, several packs of “chucks,” masking tape, 3 mL of stable iodine, two waste containers double lined with signs for linen and trash, small and large plastic bags. • Use small plastic bags to cover phone and call button or other small items likely to be held and used, e.g., TV controller. • Cover floor by bed, bathroom floor, back of toilet bowl, table tops, the chair of use. If the patient is incontinent or unstable, it is not out of the question to cover the floor and walls with chucks and plastic. • Place chucks on bed under sheets. • Wrap pillows in plastic bag under pillow case. • Squirt 3 mL of stable iodine into toilet and sink (this takes up possible iodine sites). • Store plenty of linen in room. • Mark a tape line on the floor behind which visitors must remain (usually 10 feet from where patient will usually be). 320

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 321

Chapter 55 — Thyroid: Ablation

•

•

•

•

• Some hospitals supply a cooler stocked with patient’s choice of soft drinks and juices. • Set a small table outside room for charting dosimeter and Geiger counter readings. Nursing in-service: Check specific hospital rules for nursing status. • No pregnant nurses. • These patients are not sick unless they are already inpatients for something else, hence no daily care or vital signs are needed. They will be there for about 3 days on average. • No housekeeping personnel are permitted. • Explain dosimeter, how to read, and how to log with each visit. • Explain time, distance, and shielding for radiation safety. • Explain what the 131I does to the patient and that 95% of the dose will be excreted in bodily fluids and urine. • Always glove up and discard just before leaving room. • Chart all orders, medications, and visual assessments. Document each visit. • Nurse is usually allowed 2 mR/day, or about 1 min/visit at 3 feet. • Make sure patient remains completely hydrated and encourage using the bathroom frequently. • Food trays should contain only disposable utensils, all must stay in room. • Everything must remain in the room, either placed in the waste cans or flushed (three times) down the toilet. • Try to do whatever needs to be done quickly, then leave and chart. • Any problems, call nuclear medicine department, the RSO, or a nuclear physician. Patient explanation • Most institutions have forms explaining their specific protocols for the therapy. • Patient may experience a dry mouth or soreness in the salivary glands and throat. • Patient may experience nausea and vomiting and neck swelling and pain. These symptoms should be reported immediately and are treatable. • Whatever the patient brings into the room must remain in the room until checked out by Geiger counter after patient leaves. If articles are found to be “hot,” they must remain in storage until decayed to background. • Once dosed, the patient is restricted to the room until released. • Stay hydrated and use the facilities often. Flush three times after each use. • After eating, rinse out milk and juice containers before throwing into waste cans, rinse off disposable plates and utensils. Flush sink or toilet well after each use. Nothing leaves the room. • Report any sickness immediately. • Visitors may only stay for 20 minutes per day and at a distance of (usually) 10 feet or at the door. • No pregnant visitors or those < 18 years old. • Have patient sign the informed consent and allow for any questions. • Call the RSO or physician, get the dose. Dosing patient: Bring these items • Assay the dose, replace into lead container; therapy log book; Geiger counter; dosimeter(s); tape measure; masking tape and signs; cup for water if capsule; straw and 12-mL or more syringe for water to rinse vial if liquid; gloves and booties; absorbent cloths for possible accident; stable iodine for toilet and sink; dose of Reglan® (antivomitus) if required. • With RSO or physician present and signed consent, administer dose to patient as quickly as possible. Watch for any signs of regurgitation. Take initial readings of patient, 1 m, 2 m, doorway, adjacent walls (follow hospital protocols). Make sure signs are posted. Inform nursing staff that patient is dosed. Room decontamination • The patient may be released from the room and the hospital when the NRC guidelines listed below are achieved. • Nothing is to leave the room except the patient (hopefully in a new set of clothes brought for that purpose). • Glove up; put booties on. • With a Geiger counter, survey the room and its contents. Articles in drawers, phone, buttons, books, linen, chairs, tables, closet, bed, etc. Anything that registers > 5 mR/hr at 1 m must be stored for decay. 321

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 322

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• • • • • • •

•

•

•

•

All chucks must be surveyed and disposed of properly and according to activity. The bathroom must be surveyed and scrubbed until levels are < 5 mR/hr at 1 m. Check the sink and plumbing below for activity; it may have to be dismantled and stored. Check the waste cans for activity and store or discard. Mark for storage and decay any containers and bags that remain contaminated. Mark separate bag(s) for personal items left by patient that need storage. When room is below levels of contamination, let the floor know that the room is ready and that housekeeping can go in. • Call admitting department to let them know the room is now available. Most of the destruction is caused by the 606 keV of the β− particles causing ionization and chromosomal damage. Cells cannot replicate. Delay in effect is caused by remaining thyroid tissue that is still functional, although not replicating, until natural cell death. Built-up hormone produced from before therapy must be metabolized. Some physicians, for postsurgery and posttherapy follow-up, opt for a regular thyroid uptake and scan, prescribe < 30 mCi therapy if something is found, then follow laboratory results before they attempt an ablation. Some say this sensitizes the remaining tissue, which becomes more resistant, making it more difficult to eradicate. Some also suggest a whole body iodine scan 5 to 7 days, several weeks, or months after the treatment to follow the progress of the therapy. Effective 131I treatment doses: Graves’ disease—10 to 15 mCi (370–555 MBq), toxic nodular goiter— 15 to 29 mCi (555 MBq–1.1 GBq), follicular cancer depending on size and stage—100 to 150 mCi (3.7–5.5 GBq), functioning tissue in thyroid bed—50 to 100 mCi (1.85–3.7 GBq), cervical node metastasis—150 mCi (5.5 GBq), lung or skeletal metastases—200 mCi (7.4 GBq). Please note: The NRC has changed the requirements for release of 131I patients from hospitals. Before 1998, the patient could be discharged when readings at 1 meter from patient fell < 5 mR/hr. Some states retain those recommendations. Others use the more recent criteria or a version of it. Instead of the patient-based dosage and external exposure rate regulations for retaining/releasing the patient, the criteria is now based on the exposure to the public with higher external exposure and releasable dosage limits. The patient may be released from the hospital following a therapeutic administration of radiopharmaceuticals when the total effective dose equivalent (TEDE) to any other individual is not likely to exceed 0.5 rem (5 mSv). If the total effective dose could exceed 0.1 rem (1 mSv), then the patient is given verbal and written instructions as to how to maintain exposure to others following ALARA procedures. The NRC guideline states when the survey meter reading is < 48.5 mrem/h (or equivalent mR/h) at one meter or when the oral 131I dosage is 221 mCi (8177 MBq) or less. The unit mR/h is equivalent to mrem/h but only for x- or gamma rays in the range of .1 to 10 MeV. The reason is because 1R of exposure = .97 rads in soft tissue, and since the radiation weighting factor for gamma rays is 1, then 1 rad = 1 rem. The same applies to exposure rates and dose rates. Not all agreement states have accepted the new guidelines. Some allow the use of the minimum of the most stringent requirements but must amend the Radioactive Materials License to state their policy and procedure. Consideration is also given to patient safety instruction and the home environment of the patient once discharged, e.g., are they likely to expose children and others to radiation. Requirements can be obtained from the individual state’s regulatory board.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history of adenocarcinoma?

Y

N

Do you have a history or family history of any cancer?

Y

N

Y

N

If so, what type and for how long? Have you recently had thyroid surgery?

322

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 323

Chapter 55 — Thyroid: Ablation

Do you feel that there is a possibility of nausea or vomiting?

Y

N

Do you have the results of recent laboratory tests?

Y

N

Have you had any recent iodinated radiographic studies?

Y

N

Are you presently taking any thyroid medications?

Y

N

Do you have any questions about the stay in the hospital, procedure, or possible side effects?

Y

N

Y

N

Y

N

Female patients: Are you pregnant or nursing? When was your last menstrual period? Have you experienced amenorrhea (suppression of menstruation)? Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements. Revised 2006, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Lombardi MH. Radiation Safety in Nuclear Medicine, 2nd ed. Boca Raton, FL: CRC Press LLC, 2007. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide). Version 2.0. SNM.org. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

323

10766-55_CH55.qxd

12/3/07

5:21 PM

Page 324

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Patient Information for > 30 mCi Thyroid Therapy 1. You are not here because you are sick. The nursing staff will not be coming in to take daily vital signs like blood pressure and temperature. 2. This room is to keep you isolated during your therapy. Please confine yourself to the room. 3. The usual stay is about 3 days, depending on how much of the iodine is excreted as measured by a Geiger counter. 4. No visitors under the age of 18 or pregnant persons are allowed. 5. Visiting time permitted is no more than 20 minutes per visitor per day. The time increases slightly as the days progress. 6. Visitors must remain at the doorway (at least 10 feet from patient). 7. Iodine is released from the body in perspiration as well as waste so everything brought into the room and touched stays in the room. The clothes you wear and possessions handled will be bagged and stored for 3 months. Games and other items can be wrapped in plastic before being handled, then released once checked by the Geiger counter. 8. You will be given disposable plates and utensils. These must be stored for 3 months, then opened and surveyed with the Geiger counter. Please thoroughly rinse off dishes; rinse out cans and milk cartons before placing them in the storage bag. 9. Flush what you do not finish down the toilet (except for larger items like chicken bones, etc.). If you do not touch a meal at all, it can be surveyed and removed from the room. 10. When using the toilet, be careful not to contaminate the surrounding area, and, when done, flush three times to ensure dilution within the plumbing system. Wash hands often. 11. Questions: Call the nuclear medicine department.

324

10766-56_CH56.qxd

12/3/07

5:22 PM

Page 325

chapter

56

Thyroid: Ectopic Tissue Scan (Substernal) RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV (γ), 606 keV(β−) Type: β−, γ, fission product • 123I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator • 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

123

I and 131I: Sodium iodide as capsules TcO4−: (Pertechnetate)

99m

Quality Control •

99m

Tc: chromatography, moly, and Al breakthrough. • 123I and 131I: Assay capsules in dose calibrator to confirm amount of radioactivity.

Adult Dose Range • • •

131

I: 10–100 uCi (0.37–03.7 MBq) I: 200–400 uCi (7.4–14.8 MBq) 99mTcO −: 10–20 mCi (370–740 MBq) 4 123

Method of Administration • •

131

I, 123I: Capsules PO TcO4−: Intravenous injection

99m

Localization • Active transport • 131I and 123I organified by thyroid and held in cells or follicular lumen. Te = 3–5 days. • 99mTcO4− trapped but not organified.

325

10766-56_CH56.qxd

12/3/07

5:22 PM

Page 326

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • • • • •

Detection and localization of substernal and other ectopic thyroid tissue. Differentiation of anterior mediastinal mass from substernal thyroid tissue. Evaluation of suspected autonomously functional ectopic thyroid tissue in hyperthyroidism. Evaluation of ectopic thyroid tissue in hypothyroidism. Evaluation of normally positioned thyroid gland.

CONTRAINDICATIONS • Allergy to iodine if that is being used. • Patient still taking thyroid medication. • Contrast studies under way.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Obtain a prescription signed by physician for iodine studies.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• • •

Collimator • High energy, parallel hole for 131I • Low energy, high resolution, or low energy, all purpose, and pinhole for 99mTc and 123I

131

I: 30% window at 364 keV I: 20% window at 159 keV 99m Tc: 20% window at 140 keV 123

Statics • 131I: 10-minute images (600 seconds) • 123I, 99mTcO4−: 50,000–100,000 counts

PROCEDURE (TIME: ~45–60 MINUTES) 131

I Capsule

• Images taken at 24 hours after ingestion. • Place patient in supine position, chin hyperextended (very important when looking for ectopic tissue), camera anterior. • Obtain all images, taking one with and one without markers. • Obtain anterior view, centered over thyroid, markers on chin, thyroid cartilage, and suprasternal notch (SSN). • Position camera centered over thorax, markers on SSN and xiphoid process. • Position camera over lower abdomen. If ectopic tissue is suspected in ovaries (struma ovarii), markers on xiphoid, umbilicus, and pubic symphysis. 123

I Capsule

• Images taken at 4–6 hours after ingestion. • Same procedure as above. Be sure camera is peaked for radiotracer. • Counts or time to get good images (10 minutes or 50,000–100,000 counts).

326

10766-56_CH56.qxd

12/3/07

5:22 PM

Page 327

Chapter 56 — Thyroid: Ectopic Tissue Scan (Substernal)

TcO4−

99m

• Images taken at 15–30 minutes after injection • Administer injection to patient; give patient water (some use lemon water to decrease uptake in salivary glands). • Place patient in supine position with pillow under shoulders and chin up (Water’s position). • Utilizing LEHR collimator, obtain images (300 seconds or 100,000 counts) with and without markers as above. Optional study: Any of these can be performed in conjunction with a routine thyroid uptake and scan.

NORMAL RESULTS • Increased activity within normal thyroid gland tissue around the trachea between the thyroid cartilage and the SSN. • Some have left lobe smaller than right lobe and/or a pyramidal lobe.

ABNORMAL RESULTS • Increased activity higher or lower on the trachea, usually separated from the normal thyroid gland tissue (not to be confused with salivary gland uptake if 99mTcO 4− is being used). • Increased activity beneath and shining through the sternum. • Increased activity around one or both ovaries is not unlikely in cases of struma ovarii. • The thyroid gland embryonically migrates from the base of the tongue caudally into the neck. Remnants are possible anywhere along this path (usually hypofunctioning lingual thyroid tissue at the midline base of the tongue, thyroglossal duct cyst superior to thyroid and slightly off midline, and, occasionally, further caudally beneath sternum to the diaphragm and perhaps the abdomen).

ARTIFACTS I and 99mTcO4− will allow imaging although they are easily attenuated by the sternum. TcO4− lingers in many places, making visualization of ectopic tissue an uncertainty or obscured by uptake in other systems. • 131I is the best for substernal, although there is the consideration of β− radiation and 364 keV gamma radiation to the tissue.

• •

123

99m

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

If so, what type and for how long? Why does the physician suspect ectopic tissue? Do you have a history of thyroid disease?

(continued) 327

10766-56_CH56.qxd

12/3/07

5:22 PM

Page 328

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Are you presently taking any iodine-containing medications, thyroid hormones, or antithyroid drugs?

Y

N

Have you had any surgery?

Y

N

Do you have difficulty swallowing?

Y

N

Do you have any swelling or tenderness in the neck?

Y

N

Have you had any recent weight loss or gain?

Y

N

Have you had any recent change in your appetite?

Y

N

Have you recently experienced fevers?

Y

N

Have you had any recent change in your overall energy levels?

Y

N

Have you had any thyroid therapy, chemotherapy, or radiation therapy?

Y

N

Are you taking vitamins?

Y

N

Have you had any tests using iodine or radiographic contrast?

Y

N

Have you had (or do you have planned) any recent related US, CT, x-ray, or nuclear medicine examinations?

Y

N

Do you have any recent laboratory work results?

Y

N

Are you pregnant or nursing?

Y

N

If so, what type and when?

How does cold or heat affect you?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. 328

10766-56_CH56.qxd

12/3/07

5:22 PM

Page 329

Chapter 56 — Thyroid: Ectopic Tissue Scan (Substernal)

Notes

329

10766-57_CH57.qxd

12/3/07

5:23 PM

Page 330

chapter

57

Thyroid: Hyperthyroid Therapy (<30 mCi) RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV (γ), 606 keV (β−) Type: β−, γ, fission product

Radiopharmaceutical •

131

I as sodium iodide capsule or liquid

Localization • Active transport. Organified by thyroid and held in cells or follicular lumen. Te = 3–5 days.

Quality Control • Assay capsule or vial in dose calibrator to confirm amount of radioactivity.

Adult Dose Range • 1 to < 30 mCi (37 to < 1110 MBq). Diffuse goiter (Graves’ disease) 5–10 mCi, nodular (Plummer’s disease) usually 10–29 mCi.

Method of Administration • Oral (PO), usually administered by physician or technologist under supervision.

INDICATIONS • • • • • •

Treatment of hyperthyroidism. Treatment of Graves’ disease (thyrotoxicosis, diffuse toxic goiter). Treatment of toxic (multiple) nodular goiter. Treatment of Plummer’s disease (true autonomous toxic nodular goiter). Treatment of toxic nodule (toxic adenoma). Treatment of recurrent hyperthyroidism.

330

10766-57_CH57.qxd

12/3/07

5:23 PM

Page 331

Chapter 57 — Thyroid: Hyperthyroid Therapy (<30 mCi)

• Treatment of subclinical hyperthyroidism. • Low dose ablation of residual thyroid tissue after surgery.

CONTRAINDICATIONS • • • • •

Pregnancy. Allergy to iodine. Interfering iodine medications or vitamins. Interfering food sources. Interfering radiographic tests underway or recently performed.

PATIENT PREPARATION Before Ingestion • • • • •

Identify the patient. Verify doctor’s order. Explain the procedure. Physician to instruct patient to discontinue all thyroid medication for at least 2 days. Ensure there has been no iodinated radiographic studies for 3 weeks before test. Instruct patient to consume no food or vitamins containing large amounts of iodine. For patients who have presented with an extremely high percent on the uptake and scan, and who may be candidates for thyroid storm, there is the suggestion that the patient take a beta-blocker, e.g., Inderal®, for 1 week before dosing.

After Ingestion • Instruct patient not to have close contact with anyone for 48 hours after ingestion. • Instruct the patient not to share food or utensils. • Instruct the patient to flush toilet twice (some suggest 3 mL of normal iodine into toilet to take up possible iodine sites). • Instruct the patient to wash clothes and linen thoroughly. • Inform the patient that they may feel a scratchy throat. • Inform the patient that there is no immediate benefit; it takes a week or more to feel effect. • Instruct the patient to contact department immediately if dose is vomited.

EQUIPMENT Camera

Computer Set-up

• N/A

• N/A

Collimator • N/A

PROCEDURE (TIME: ~20 MINUTES) • Ensure procedure is preceded by uptake and scan procedures within 2 weeks. • Obtain a signed informed consent form (some have a booklet to read) from patient. • Obtain a written prescription prepared and signed by ordering physician before ordering the dose from the radiopharmacy. (The amount the patient receives is a decision made by the ordering physician and/or physician who is an authorized user.) • Obtain a signature from physician on requisition and appropriate paperwork, e.g., the written directive that is stored in the department. 331

10766-57_CH57.qxd

12/3/07

5:23 PM

Page 332

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Ensure that the patient receives an explanation from the physician or technologist of the benefits and disadvantages of the therapy and has a clear understanding of the instructions to follow after the administration of the capsule. • Provide a glass of water to the patient. • Assay the capsule to be administered. • Ensure that the dose is administered by physician (or technologist under the supervision of a physician who is an authorized user). Some institutions will allow the technologist to administer the dose after the patient has had a consultation with the radiologist or nuclear physician. • Inform the patient that they will be re-evaluated in 2 to 3 months. This is usually done with serum laboratory results, nuclear medicine uptake and scan, or various other diagnostic imaging modalities. • Instruct the patient to exit the department immediately (after making sure patient does not vomit capsule).

NORMAL RESULTS • Goiter shrinks and symptoms decrease with earliest effect 2 to 6 weeks after ingestion. • Patient becomes euthyroid after 2 to 6 months (follow-up laboratory tests and/or uptake and scan to confirm).

ABNORMAL RESULTS • In 3 months to a year, patient does not become euthyroid as confirmed by follow-up tests; retreatment may be ordered. • Hypothyroidism that is rectified by thyroid medications.

ARTIFACTS • Ensure that the patient has signed consent form for treatment. Paperwork, including a signed written directive, is a must for Nuclear Regulatory Commission (NRC) and agreement state regulations for radioiodine. • Patient regurgitates dose shortly after dosing and/or is reluctant to inform department of loss. • Patient does not discontinue thyroid medications. • Effectiveness of therapy can be affected by nodular thyroids that are usually more resistant and require larger doses, large thyroid glands that will result in less response, previous anti-thyroid drugs increase resistance, and severely hyperthyroid patients will have less response presumably because of rapid turnover of the iodine within the gland. • Approximately half of the patients experience hypothyroidism 10 years after treatment regardless of dose received. • Thyroid storm from the treatment occurs in < .1% of the patients.

NOTE • Most of the destruction is caused by the 606 keV (89%) of the β− particles causing ionization and chromosomal damage. Cells cannot replicate. Delay in effect is caused by remaining thyroid tissue that is still functional until cell death although not replicating. Built-up hormone produced before therapy must be metabolized. • Graves’ disease (exophthalmic goiter): Autoimmune disease usually of middle age and women. Antibodies attach to thyroid-stimulating hormone (TSH) receptors of thyroid cells, causing glandular hypertrophy and increased production of thyroid hormone (T4 and T3). Toxic diffuse goiter, elevated T3 and T4, and low TSH produces LATS (long-acting thyroid stimulator, an autoantibody). Signs of Graves’ disease are caused by excessive deposits of mucopolysaccharides. • Toxic nodular goiter: Higher doses are used as there is little uptake in nodules. Estimation of gland size is difficult because of irregularity and retrotracheal and substernal extensions. Relapse occurs more frequently with this disease. 332

10766-57_CH57.qxd

12/3/07

5:23 PM

Page 333

Chapter 57 — Thyroid: Hyperthyroid Therapy (<30 mCi)

• Plummer’s disease: Toxic nodular goiter, solitary or multiple autonomous nodules, elevated T3 and T4, low TSH, no LATS, normal suppressed gland receives little radiation. • Dosages are usually decided by gland size, presence or absence of nodularity, and the results of the iodine uptake study. Hyperthyroid, large glands, significant nodularity, or cardiac disease aggravated by thyrotoxicity cases are dosed with the upper end of the range. Diffuse goiter may be in the range of 15 mCi (555 MBq). Large multi-nodular goiters require doses higher than 30 mCi (1110 MBq). Solitary toxic nodules are in the 15–25 mCi (555–925 MBq). Graves’ disease requires 15 mCi (555 MBq) and toxic nodular goiter needs 25 mCi (925 MBq). Some endocrinologists are treating for “subclinical” hyperthyroidism (patients likely to develop the physiology and symptoms) and are usually treated with the higher end of the range. • Thyroid storm occurs when T4 is being converted into T3 and excess thyroid hormone is being produced. It is a complication of thyrotoxicosis and can be fatal. Symptoms include abrupt onset of fever (>103º), tachycardia (>130 bpm), sweating, pulmonary edema or congestive heart failure, tremulousness, and restlessness. It usually follows infection, trauma, or surgery. Thyroid storm is usually avoided by pretreatment of the patient with an antithyroid drug (ATD) e.g., PTU. Also, corticosteroids are useful (e.g., propranolol).

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Y

N

Y

N

Have you had any previous treatments?

Y

N

Do you have the results of any recent laboratory tests (elevated thyroid function tests)?

Y

N

Y

N

Y

N

If so, what type and for how long? Have you had any of the following (Graves’ disease): exophthalmos, lid lag, goiter, fine tremor in extremities, tachycardia, high metabolism, vomiting, diarrhea, nervousness, anxiety, perspiration, hot feeling, brittle thinning hair, heat intolerance, weight loss, pretibial myxedema (swelling of legs), acropachy (clubbing of fingers and toes)? What medications are you currently taking? Are you taking any thyroid medications? If not, how long have you been off them? What were the results of your nuclear medicine uptake and scan?

Female patients: Are you pregnant or nursing? When was your last menstrual period? Have you experienced amenorrhea (suppression of menstruation)? Other department-specific questions.

333

10766-57_CH57.qxd

12/3/07

5:23 PM

Page 334

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

NOTE Patient Information for (<30 mCi) Hyperthyroid Therapy 1. 2. 3. 4. 5. 6. 7. 8. 9.

10. 11.

12.

For at least 2 days, keep a distance of 3 feet or more between you and any persons. Do not hug or hold children close for 2 days. Do not share utensils at home with anyone. Wash the ones you use thoroughly. Keep your clothes and linen separate and wash them thoroughly. The iodine exits your body over time by bowel movements, urine, saliva, and perspiration. Sleep alone for the first two nights. When using the toilet, be careful not to contaminate the surrounding area, and, when done, flush two times to ensure dilution within the plumbing system. Wash hands often. You may feel a scratchy throat within a few days but that will subside. It may take a couple of weeks to feel any benefit related to your condition from the capsules. If you get sick and throw up the capsule(s), try to do so in a toilet, sink, or, at last resort, on the pavement. Call the nuclear medicine department so that they will know you no longer have the capsule(s) inside you. This is extremely rare and is usually caused by food or sickness unrelated to the iodine capsules. Although any allergic reaction to the iodine capsules is extremely rare, if you feel you are having one, contact your doctor’s office. You have taken a capsule that contains radioactive iodine that emits beta and gamma rays. It is designed to do its therapeutic work on your thyroid and does not present a danger to anyone. These steps are taken only to reduce unnecessary exposure to people with whom you may come in contact. Questions: Call the nuclear medicine department.

Notes

334

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 335

chapter

58

Thyroid: Scan RADIOPHARMACY Radionuclide •

123

I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator • or 131I t1/2: 8.1 days Energies: 364 (γ), 606 keV (β−) keV Type: β−, γ, fission product • or 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

123

I and 131I as capsules TcO4− (pertechnetate)

99m

Quality Control •

99m

Tc: Chromatography, moly and Al breakthrough • 123I and 131I: Assay capsule(s) in dose calibrator to confirm amount of radioactivity

Adult Dose Range I: 1µCi −10 mCi (0.037–370 MBq) depending on patient and reason for scan. Usually 5–30 µCi (0.185–1.110 MBq) for uptake and scan, 2–5 mCi (74–185 MBq) for whole body imaging and/or treatment of patients. • 123I: 100–450 µCi (3.7–16.65 MBq) • 99mTcO4−: 2–10 mCi (74–370 MBq)

•

131

Localization

Method of Administration

• Active transport. 99mTcO4− trapped but not organified. Iodine organified by thyroid and held in cells or follicular lumen. Te = 3–5 days.

• •

123

I and 131I capsule Oral (PO) Tc by intravenous injection

99m

335

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 336

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Evaluation of thyroid anatomy, e.g., position, goiter (enlarged gland due to inadequate iodine supply), surgery, cold or hot nodule(s). • Detection and evaluation of hyperthyroidism and hypothyroidism. • Detection and localization of metastases from thyroid cancer. • Differentiation of benign from malignant nodules. • Detection, localization, and evaluation of independent functioning nodule(s). • Evaluation of heterogeneity of function within a hyperthyroid gland. • Detection and localization of benign ectopic thyroid tissue. • Evaluation of abnormal thyroid serum laboratory results. • Evaluation of subclinical (before appearance of typical symptoms of disease) and subacute (between acute and chronic) disease processes, e.g., toxic goiter, thyroiditis. • Evaluation of thyroid because of abnormal findings on other diagnostic images, e.g., US, x-ray images, PET, MRI, CT.

CONTRAINDICATIONS • Allergy to iodine if that is being used. • With iodine, interfering recent contrast studies. • With iodine, patient has not discontinued thyroid or interfering medication, vitamins, or iodinated food products.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • 99mTc: None other. • Patient to discontinue thyroid medications and avoid contrast material, Betadine®, or amiodarone. • Refrain from eating foods containing iodine such as cabbage, turnips, greens, seafood, kelp, or large amounts of table salt. • 123I and 131I: Patient will be returning at 4 to 6 hours and 24 hours for scan. 131I: Patient will usually be returning at 24 hours and beyond for imaging. This iodine is not routinely used for uptake and scans. See appropriate thyroid chapters.

EQUIPMENT Camera

Computer Set-up

• Large field of view

• • •

Collimator • Low energy, high resolution, or low energy, all purpose and pinhole for 99mTc and 123I. • High energy, parallel hole for 131I.

336

131

I: 30% window at 364 keV I: 20% window at 159 keV 99mTc: 20% window at 140 keV; 50,000 to 100,000 counts 123

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 337

Chapter 58 — Thyroid: Scan

PROCEDURE

(USUALLY TWO PARTS; TIME: ~40 MINUTES)

TcO4−

99m

• Administer injection to patient; wait 15 to 20 minutes before imaging. Give patient water (optional lemon to clear salivary glands). • Place patient in supine position with pillow under shoulders and chin up (Water’s position). • Using the LEHR collimator, obtain anterior views (300 seconds or 100,000 depending on protocol) with and without markers as per protocol (thyroid cartilage and suprasternal, marker strip, right side, etc.). RAO and LAO and perhaps a “pull-back” image (more distant) for ectopic thyroid tissue are optional images if a pinhole collimator is not available. • Using a pinhole collimator if available, obtain anterior views with and without markers as per protocol, then RAO and LAO and perhaps a “pull-back” image (more distant) for ectopic thyroid tissue. 123

I Capsule

• Same procedure as above without injection. Image 50,000 to 100,000 counts or 8 to 10 minutes per image. Images can be taken from 3 to 36 hours after administration of capsule (usually at 4–6 hours or 24 hours). Peak camera for radiotracer. 131

I Capsule

• Same procedure as above without injection. Usually used to locate residual and recurrent cancers. 24-, 48-, and 72-hour pictures may be the most useful. Collect 100,000 counts over thyroid and whole body if cancer is suspected. Check peak and collimator(s).

NORMAL RESULTS • • • •

Euthyroid: Homogeneous uptake of radiotracer. Left lobe smaller than right lobe or having pyramidal lobe. Straight or convex outer margins. Uptake equal to or greater than that of salivary glands (water or lemon given to reduce salivary uptake). • 99mTc also shows in soft tissue, brain, stomach mucosa, nasopharynx, bladder. • 123I and 131I will present in nasopharynx, salivary glands, stomach, colon, bladder, lactating breasts. • The test is usually performed in conjunction with the thyroid uptake test.

ABNORMAL RESULTS • Plummer’s disease: Autonomous multinodular goiter; nodules, solitary or multiple: cold and/or hot (solitary: adenoma, thyroiditis; multiple: goiter). • Nonvisualization of thyroid gland caused by, e.g., subacute thyroiditis, patient on contraindicated medications (see list in reference section). • Graves’ disease: Enlarged gland, high uptake (LATS [long-acting thyroid stimulator, an autoantibody]). • Hashimoto’s thyroiditis: Enlarged gland, mottled (checkerboard) areas. • Thyroid carcinoma: Usually solitary cold nodule (4% show high uptake). • Cold nodule on iodine scan can be clarified by 99mTc O4− scan. Cold on 99mTc O4− scan is nonvascular and more than likely benign though not always. Hot on 99mTc O4− scan is vascularized and more likely to be malignant (20% chance of carcinoma). Usually followed by biopsy and/or surgery.

337

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 338

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Increased blood pool activity or decreased or absent uptake in thyroid–aluminum containing antacids, sulfonamides, pyrophosphates, other radiopharmaceuticals present in system.

ARTIFACTS • Compton scatter and downscatter from contaminates may contribute to 123I spectrum. • 99mTcO4− not as accurate because of low absolute uptake, high neck background, changing biodistribution, concentrations in extrathyroid tissues, and trapping without organification. • High collar metal buttons or medallions may interfere with pictures. • Improper collimator and computer changes. • Careless marker placement. • Patient movement (particularly with pinhole collimator). • Depending on the camera, for severely claustrophobic patients, point the camera outward, seat the patient facing camera with chin on camera and area of interest in view (or head back and pinhole aimed properly), secure patient with tape to ensure no movement. This method has been useful in obtaining diagnostic images.

NOTE Definitions T3 = triiodothyronine = Cytomel® (most metabolically active). T4 = thyroxine (highest concentration in blood). TSH = thyrotropin, anterior pituitary hormone stimulates thyroid to release T3 and T4. TRH = thyrotropin-releasing hormone from hypothalamus, stimulates release of TSH from anterior pituitary. Calcitonin = from the C cells or parafollicular cells; regulates calcium or bone building. Parathormone = parathyroid hormone; breaks down calcium in bone (resorption).

Hypothyroidism • Hypothyroidism may be the result of iodine deficiency (large, endemic goiter), inherited enzyme deficiency, postradioiodine ablation (iatrogenic), end-stage toxic goiter, metastatic cancer, chronic thyroiditis, iodine excess, or pituitary or hypothalamic injury. • Hypothyroidism is characterized by myxedema (end-stage hypothyroidism, puffy face, fluid retention, and lethargy) or cretinism in infants (lethargy, pot belly, enlarged tongue, stunted growth, and mental retardation). Hashimoto’s thyroiditis is characterized by inflammation, chronic lymphocytic thyroiditis, lymphoid goiter, and struma lymphomatosa; autoimmune thyroiditis is diffuse lymphocytic infiltration.

Hyperthyroidism • Plummer’s disease (toxic nodular goiter) is characterized by solitary or multiple autonomous nodules (goiter), elevated T3 and T4, low TSH, and no LATS. Graves’ disease (exophthalmos, pretibial myxedema, and acropachy) results in hyperthyroidism, thyrotoxicosis, toxic diffuse goiter, elevated T3 and T4, and low TSH, and produces LATS. Subacute thyroiditis is the absence of uptake illustrating shutdown of the thyroidal iodine extraction and hormonal synthesis pathway. Patient presents sporadically with (among other things) sore neck, difficulty in swallowing, fever, dehydration, and slightly elevated white blood cell count. Serum thyroid hormone levels may present as normal or elevated to the point of hyperthyroidism or even “thyroid storm” (a complication of thyrotoxicosis presenting with sudden fever, sweating, tachycardia, pulmonary edema or congestive heart failure, tremulousness, and restlessness all of which can be fatal and is treated by, or prevented by guanethidine and/or propanolol). 338

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 339

Chapter 58 — Thyroid: Scan

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of thyroid disease?

Y

N

Are you presently taking any iodine-containing medications, thyroid hormones, antithyroid drugs, or antiarrhythmics?

Y

N

Have you had any surgery?

Y

N

Do you have difficulty swallowing?

Y

N

Do you have any swelling or tenderness in the neck?

Y

N

Have you had any recent weight loss or gain?

Y

N

Have you had any recent change in your appetite?

Y

N

Have you recently experienced fevers?

Y

N

Have you had any recent change in your overall energy levels?

Y

N

Have you had any thyroid therapy, chemotherapy, or radiation therapy?

Y

N

Are you sensitive to cold or heat?

Y

N

Are you taking vitamins?

Y

N

Have you had any tests using iodine or radiographic contrast?

Y

N

Have you had (or do you have planned) any recent related US, CT, x-ray, PET, or nuclear medicine examinations?

Y

N

Do you have any recent laboratory work results?

Y

N

Are you pregnant or nursing?

Y

N

If so, what type and for how long?

If so, what type and when?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

339

10766-58_CH58.qxd

12/3/07

5:25 PM

Page 340

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Suggested Readings American College of Radiology. ACR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements. Revised 2006, acr.org. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Steves AM. Review of Nuclear Medicine Technology, 2nd ed. Reston, VA: Society of Nuclear Medicine, 1996. Thomas C, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: FA Davis, 1993. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

340

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 341

chapter

59

Thyroid: Uptake (Usually in Conjunction with Thyroid Scan) RADIOPHARMACY Radionuclide •

Quality Control

123

I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator • or 131I t1/2: 8.1 days Energies: 364 (γ), 606 keV (β−) keV Type: β−, γ, fission product • or 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

123

I and 131I as capsules TcO4− (pertechnetate)

99m

Localization

•

99m

Tc: Chromatography, moly and Al breakthrough • 123I and 131I: Assay capsule(s) in dose calibrator to confirm amount of radioactivity

Adult Dose Range •

131

I: 1µCi–10 mCi (0.037–370 MBq) depending on patient and reason for scan. Usually 5–30 µCi (0.185–1.110 MBq) for uptake and scan, 2–5 mCi (74–185 MBq) for whole body imaging and/or treatment of patients. • 123I: 100–450 µCi (3.7–16.65 MBq) • 99mTcO4−: 2–10 mCi (74–370 MBq)

Method of Administration 99m

− 4

• Active transport. TcO trapped but not organified. Iodine organified by thyroid and held in cells or follicular lumen. Te = 3–5 days.

• •

123

I and 131I capsule Oral (PO) Tc by intravenous injection

99m

341

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 342

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

INDICATIONS • Evaluation of thyroidal radioactive iodine uptake (RAIU). This provides an index of thyroid trapping and organification of iodide measured as a percentage of radiotracer actively transported into thyroid tissue during a period of time. It is dependent on thyroid function and the body’s iodine pool. • Evaluation of hyperthyroidism and hypothyroidism. • Evaluation of independently functioning nodule(s). • Evaluation of subclinical (before appearance of typical symptoms of disease) and subacute (between acute and chronic) disease processes, e.g., toxic goiter, thyroiditis. • Evaluation of thyroid because of abnormal findings on other diagnostic images, e.g., US, x-ray images, PET, MRI, CT. • Evaluation of abnormal thyroid serum laboratory results. • Differentiation of Graves’ disease from subacute thyroiditis or factitious hyperthyroidism.

When Used with the Thyroid Scan • • • •

Detection and localization of metastases from thyroid cancer. Differentiation of benign from malignant nodules. Evaluation of heterogeneity of function within a hyperthyroid gland. Detection and localization of benign ectopic thyroid tissue.

CONTRAINDICATIONS • Allergy to iodine if that is being used. • Patient has not discontinued thyroid medication or other interfering medications. • Patient discontinued thyroid medication too long.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • 99mTc: None other. • Verify written directive for iodine signed by authorized user prior to administration. • Physician to instruct patient to discontinue thyroid medications, contrast material, Betadine®, or amiodarone (antiarrhythmics). • Instruct patient to refrain from eating iodine-containing foods such as cabbage, turnips, greens, soybeans, shellfish seafood, kelp, or large amounts of table salt. Some require this as a 3 to 10 day protocol before administration of the capsule(s). • Instruct patients taking 123I to return at 4–6 hours and 24 hours for scan and uptake. • 99mTc is rarely used for uptakes but would be done 20 minutes after injection.

EQUIPMENT Camera

Computer Set-up

• Thyroid probe or small or large field of view.

• • •

Collimator • Flat-field scintillation probe with pulseheight analyzer or low energy, all purpose, or low energy, high resolution.

342

131

I: 30% window at 364 keV I: 20% window at 159 keV 99mTc: 20% window at 140 keV 123

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 343

Chapter 59 — Thyroid: Uptake

PROCEDURE (TIME: ~15 MINUTES) • Assay capsule(s) in dose calibrator (or syringe with 99mTc). • 99mTc: count in neck phantom for “standard,” inject and wait 20 minutes. Calculate 20 minute decay of 99mTc. Math is same as below. 99mTc is rarely used for uptake. • Count capsule in neck phantom with thyroid probe or gamma camera; record count(s) (this can also serve as the “standard” or count standard capsule if separate). Count room background; record count(s). • Ensure that the patient has discontinued all interfering medications (e.g., thyroid medications, antiarrhythmics) for the appropriate amount of time. • Administer the capsule with water (or inject the 99mTcO4−). Instruct patient to return in 4–6 hours and 24 hours (for capsules) or counted under camera at 20 minutes (for 99mTcO4−). If performed in conjunction with scan, take images along with the 4- to 6-hour uptake. Peak camera for use with iodine. • Probe for thyroid: Facing thyroid gland (usually 25–30 cm from patient’s neck), 1-minute count, can be counted twice, and then averaged. Record counts. • Camera for thyroid: Place patient in supine position, pillow under shoulders to extend neck with camera anterior and close, e.g., 10 cm (record position to use for 24-hour uptake), thyroid centered; start count or camera (1-minute count, can be twice, then averaged); record count(s). • Probe for patient background: Position as per protocol for patient background, usually facing thigh, 25–30 cm, start count, 1-minute count, can be twice, and then averaged. Record count(s). (This applies to 24-hour uptake as well.) • Camera for patient background: Position camera over patient thighs. Use same distance as from thyroid (e.g., 10 cm). Start count or camera (1-minute count, can be twice, then averaged), record count(s). • Camera or probe for standard: Count standard in neck phantom at same distance as patient as per protocol. (This applies to 24-hour uptake as well.) If there is no standard capsule, use original count of capsule(s) and apply the appropriate decay factors. • Camera or probe for room background: Ensure no patient under camera or probe not facing any source of activity. Start count or camera (1-minute count, can be twice, and then averaged), record count(s). • Calculate uptake (two examples of the many methods).

Probe (Most New Probes Automatically Calculate after Thyroid and Thigh Counts): Using This Manual Method • • • •

The patient is given one capsule and one standard capsule is retained. Or two capsules are given to the patient and two are retained as standard. Or two capsules are given to the patient and one is retained as standard and counted twice. Or one or two capsules are counted first, and then given to the patient, then mathematically decayed using the decay factors. [ patient thyroid CPM − patient background (thigh) CPM] % uptake = × 100 (standard count or original capsule CPM × decay factor) − original background (room)

Camera: Using This Manual Method • Two capsules are given to the patient and one standard capsule is retained. • Or count one or two capsules first, then give them to patient, then mathematically decay the original count as the standard as in the example above.

343

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 344

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

% uptake =

Two 60-sec patient counts/2 × 100 Two 60-sec standard counts added together

• Whichever method is used, one must end up using the same number of standard capsules (real, counted twice, or mathematically derived) as is given to the patient. • Repeat count procedure at 24 hours and calculate uptake. • Decay factors: These are for decaying the counts, not the activity. 4 hours: 0.810548 6 hours: 0.72974 24 hours: 0.283578

NORMAL RESULTS

(PERCENTS VARY GREATLY BETWEEN HOSPITALS ACCORDING TO LOCAL POPULATIONS) • 4–6 hours = 5% to 20% • 24 hours = 7% to 35% • 99mTcO4−: 20 minutes = ∼4% • The test is usually performed in conjunction with a thyroid scan.

ABNORMAL RESULTS • At 24 hours, less than ∼7% indicates hypothyroidism, especially with concordant history. • More than ∼35% indicates hyperthyroidism with concordant history. • Factors that increase uptake: hyperthyroidism, early Hashimoto’s, recovery from subacute thyroiditis, rebound from antithyroid drugs, enzyme defects, starvation, iodine deficiency, hypoalbuminemia, TSH, tumor-secreted stimulators, pregnancy. • Factors that decrease uptake: hypothyroidism, iodine overload (radiographic contrast), subacute or autoimmune thyroiditis, thyroid hormone therapy, ectopic secretion of thyroid hormone, renal failure.

ARTIFACTS • Capsule not assayed in dose calibrator for activity and/or counted before administration. • Compton scatter and downscatter from contaminates may contribute to 123I spectrum. • 99mTcO4− not as accurate because of low absolute uptake, high neck background, changing biodistribution, concentrations in extrathyroid tissues, and trapping without organification. • High collar metal buttons or medallions may interfere with counts. • Placement of probe must be consistent with department protocol or readings can be false-positive or false-negative. • Patient on interfering food or medications, e.g., shellfish, thyroid or antiarrhythmic medications. • Patients with a tracheotomy may be on Lugol’s solution (a thyroid antagonist) and/or bronchodilators, which may affect test results. • Depending on the camera, for severely claustrophobic patients, point the camera outward, seat the patient facing camera with chin on camera and area of interest in view (or head back and pinhole aimed properly), secure patient with tape to ensure no movement. This method has been useful in obtaining diagnostic images.

ADDITIONAL INTERVENTIONS • Thyrotropin-releasing hormone (TRH) and thyrotropin (thyroid-stimulating hormone, TSH) stimulating tests can be performed to indicate suppressed tissue, functioning metastasis, and functional reserve. 344

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 345

Chapter 59 — Thyroid: Uptake

• Perchlorate washout test to diagnose organification defects such as Hashimoto’s thyroiditis or congenital enzyme deficiencies. • Triiodothyronine (T3, Cytomel®) suppression test to diagnose borderline hyperthyroidism.

NOTE Hypothyroidism • Hypothyroidism may be the result of iodine deficiency (large, endemic goiter), inherited enzyme deficiency, postradioiodine ablation (iatrogenic), end-stage toxic goiter, metastatic cancer, chronic thyroiditis, iodine excess, or pituitary or hypothalamic injury. • Hypothyroidism is characterized by myxedema (end-stage hypothyroidism, puffy face, fluid retention, and lethargy) or cretinism in infants (lethargy, pot belly, enlarged tongue, stunted growth, and mental retardation). Hashimoto’s thyroiditis is characterized by inflammation, chronic lymphocytic thyroiditis, lymphoid goiter, and struma lymphomatosa; autoimmune thyroiditis is diffuse lymphocytic infiltration.

Hyperthyroidism • Plummer’s disease (toxic nodular goiter) is characterized by solitary or multiple autonomous nodules (goiter), elevated T3 and T4, low TSH, and no LATS (long-acting thyroid stimulator, an autoantibody). Graves’ disease (exophthalmos, pretibial myxedema, and acropachy) results in hyperthyroidism, thyrotoxicosis, toxic diffuse goiter, elevated T3 and T4, and low TSH, and produces LATS. Subacute thyroiditis is the absence of uptake illustrating shutdown of the thyroidal iodine extraction and hormonal synthesis pathway. Patient presents sporadically with (among other things) sore neck, difficulty in swallowing, fever, dehydration, and slightly elevated white blood cell count. Serum thyroid hormone levels may present as normal or elevated to the point of hyperthyroidism or even “thyroid storm” (a complication of thyrotoxicosis presenting with sudden fever, sweating, tachycardia, pulmonary edema or congestive heart failure, tremulousness, and restlessness—all of which can be fatal—and is treated by, or prevented by, guanethidine and/or propanolol).

Definitions T3 = triiodothyronine = Cytomel® (most metabolically active). T4 = thyroxine (highest concentration in blood). TSH = thyrotropin, anterior pituitary hormone stimulates thyroid to release T3 and T4. TRH = thyrotropin-releasing hormone from hypothalamus, stimulates release of TSH from anterior pituitary. Calcitonin = from the C cells or parafollicular cells; regulates calcium or bone building. Parathormone = parathyroid hormone; breaks down calcium in bone (resorption).

Thyroid Stimulators • Levothyroxine sodium (T4 or L-thyroxine sodium): Eltroxin, Levo-T, Levothroid, Levoid, Levoxine, Levoxyl, Oroxine, Synthorax, Synthroid®. • Liothyronine sodium (T3): Cytomel®, Tertroxin, Triostat, Cyronine. • Liotrix (combination products): Euthyroid, Thyrolar, Thyroid Tabs. • Thyroglobulin: Proloid. • Thyroid (desiccated): Armour Thyroid, S-P-T, Thyrar, Thyroid Strong, Thyroid USP, Enseals, ThyroTeric, Westhroid. • Thyrotropin (thyroid-stimulating hormone, TSH): Thytropar.

345

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 346

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Thyroid Antagonists • • • • • •

Methimazole: Tapazole. Potassium iodide: Pima, Thyro-Block. Potassium iodide saturated solution: SSKI. Strong iodine solution: Lugol’s solution. Propylthiouracil (PTU): Propyl-Thyracil. Radioactive iodine (sodium iodide) 131I: Iodotope therapeutic, sodium iodide 131I therapeutic.

See complete listings in the Nursing 2007 Drug Handbook, Philadelphia: Lippincott, Williams & Wilkins, 2006 or the listing in the reference section of this manual. Refer to the “Drugs and Studies affecting 123I and 131I Uptake” table in this manual for a partial listing and suggested withholding times.

RELATED THYROID SERUM LABORATORY RANGES Test

Normal Range

Clinical Significance

Calcitonin

400 ng/L

High: Medullary carcinoma of the thyroid, some nonthyroid tumors, Zollinger-Ellison syndrome

T4 (thyroxine)

4.5–11.5 ug/dL

T3 (triiodothyronine) uptake

25–35%

T3 (total circulating)

75–200 ng/dL

T7 (free T4 index)

1–2.2 ng/dL

TPOAb (Thyroperoxidase antibody) TSH (Thyroid Stimulating Hormone) TSI (Thyroid-Stimulating Immunoglobulin) Thyroid-binding globulin

< 1:100 titer or ~<70 UI/mL .3–5 m/IU/L

High: Hyperthyroidism, thyroiditis, pregnancy, oral contraceptives Low: Hypothyroidism, hypoproteinemia, nephrotic syndrome, androgenic and anabolic steroids High: Hyperthyroidism, TBG deficiency, androgens, and anabolic steroids Low: Hypothyroidism, pregnancy, TBG excess, estrogens and antiovulatory drugs High: Pregnancy, hyperthyroidism Low: Hypothyroidism High: Euthyroid patients with normal free thyroxine levels may have abnormal T3 and T4 levels caused by drug preparations Presence: Graves’, Hashimoto’s thyroiditis

Thyroglobulin (serum) normal thyroid athyroid PTH (parathyroid hormone) 346

High: Primary hypothyroidism Low: Hyperthyroidism

<130% basal activity

High: Graves’ Disease, toxic multinodular goiter

10–26 ug/dL

High: Hypothyroidism, pregnancy, estrogen therapy, oral contraceptives, genetic and idiopathic Low: Androgens and anabolic steroids, nephritic syndrome, marked hypoproteinemia, hepatic disease

59.4 ng/mL < 5 ng/mL 160–350 ng/L

High: Active thyroid tissue High: Hyperparathyroidism

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 347

Chapter 59 — Thyroid: Uptake

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Do you have a history of thyroid disease?

Y

N

Are you presently taking any iodine-containing medications, thyroid hormones, antithyroid drugs, or antiarrhythmics?

Y

N

Have you had any surgery?

Y

N

Do you have difficulty swallowing?

Y

N

Do you have any swelling or tenderness in the neck?

Y

N

Have you had any recent weight loss or gain?

Y

N

Have you had any recent change in your appetite?

Y

N

Have you recently experienced fevers?

Y

N

Have you had any recent change in your overall energy levels?

Y

N

Have you had any thyroid therapy, chemotherapy, or radiation therapy?

Y

N

Are you sensitive to cold or heat?

Y

N

Are you taking vitamins?

Y

N

Do you have a list of all medications presently being taken?

Y

N

Have you had any tests using iodine or radiographic contrast?

Y

N

Have you had (or do you have planned) any recent related US, CT, x-ray, or nuclear medicine examinations?

Y

N

Do you have any recent laboratory work results?

Y

N

Are you pregnant or nursing?

Y

N

If so, what type and for how long?

If so, what type and when?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study? 347

10766-59_CH59.qxd

12/3/07

5:26 PM

Page 348

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Suggested Readings Brener T, ed. Nursing 2007 Drug Handbook, 27th edition. Philadelphia: Lippincott, Williams & Wilkins, 2006. Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Nuclear Medicine Handbook. Princeton, NJ: ER Squibb & Sons, 1990. Smeltzer SC, Bare BG. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 8th ed. Philadelphia: Lippincott, 1996. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

348

10766-60_CH60.qxd

12/3/07

5:28 PM

Page 349

chapter

60

Thyroid: Whole Body 131I Cancer Study and rTSH Augmentation RADIOPHARMACY Radionuclide •

131

I t1/2: 8.1 days Energies: 364 keV (γ), 606 keV (β−) Type: β−, γ, fission product 123 • I t1/2: 13.1 hours Energies: 159 keV Type: EC, γ, accelerator

Radiopharmaceutical •

131

I and 123I as sodium iodide capsule(s) or liquid

Quality Control • Assay the capsule(s) or vial in the dose calibrator to confirm amount of radioactivity.

Adult Dose Range • •

131

I: 1 to 5 mCi (37–185 MBq) I: 1 to 2 mCi (37–74 MBq)

123

Method of Administration • Oral (PO)

Localization • Active transport. Organified by thyroid and held in cells or follicular lumen. Te = 3–5 days.

INDICATIONS • Localization and evaluation for metastasizing or recurrent thyroid carcinoma. • Localization and evaluation for residual functioning thyroid tissue after total thyroidectomy. 349

10766-60_CH60.qxd

12/3/07

5:28 PM

Page 350

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONTRAINDICATIONS • Allergy to iodine. • Iodinated radiographic studies recently or under way. • High-iodine diet or taking thyroid medications.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure. • Obtain a written directive signed by authorized user before administration. • Physician is to discontinue thyroid medication (hormone supplements or antithyroid medication). Patient must be clinically hypothyroid with elevated TSH levels at time of study unless it is an rTSH study. • Instruct patient to refrain from eating iodine-containing foods such as cabbage, turnips, greens, soybeans, shellfish seafood, kelp, or large amounts of table salt. Some require this as a 3- to 10-day protocol before administration of the capsule(s). • Instruct patient to be NPO for at least 4 hours before ingestion of dose and remain so for 1 hour after ingestion of dose. • Instruct patient to bring results of recent laboratory tests. • For rTSH augmentation study, 131I or 123I administration: 24 hours after the final Thyrogen® injection. Patient need not discontinue medication.

EQUIPMENT Camera

Computer Set-up

• Large field of view, single or dual head

Statics • 131I (364 keV) or 123I (159 keV) peaks, 15% to 20% windows, 128 × 128 or 256 × 256 matrix, 600 seconds or more per view (>1 million counts). Anterior-posterior; head, thorax, abdomen, and pelvis.

Collimator • •

131

I: Medium- or high-energy parallel hole I: Low energy, high resolution, or low energy, all purpose

123

Whole Body (usually head to thigh) • 10 cm/min or slower

PROCEDURE

(TIME: DOSING, ~15 MINUTES; IMAGING, ~30–60 MINUTES) • • • • •

Administer dose to patient as to protocol, by physician or technologist. Instruct patient to return at appropriate time for images, according to protocol. Place patient in supine position, remove attenuating articles from clothing. Instruct patient to remain motionless during acquisition. 131I: Obtain images at 72 hours (and 96 if requested). These present with better target to background ratios. Optional: Obtain images at 24 and/or 48 hours after ingestion of dose if protocol. • 123I: Obtain images at 24 hours. • Obtain whole body statics (10 min/image) and/or whole body sweep, anterior-posterior from head to thigh. • Obtain optional statics with anatomic markers if possible, if suspicious areas are found. Laterals may be helpful. 350

10766-60_CH60.qxd

12/3/07

5:28 PM

Page 351

Chapter 60 — Thyroid: Whole Body 131I Cancer Study and rTSH Augmentation

NORMAL RESULTS • No focal areas of iodine uptake. • Salivary glands may present dim to bright. • Mouth, stomach (may extend into intestine), and bladder present well.

ABNORMAL RESULTS • Focal areas of uptake, especially in thyroid bed, although other places (lymph metastases, etc.) are not unlikely. • Areas of lungs and breasts may have uptake, suggesting pulmonary or breast metastases, etc. Lateral images may better define area. • False-positive focal uptake in liver, indicating metastatic lesion and may be caused by retention in intrahepatic duct dilation, particularly in patients with history of biliary tract disease.

ARTIFACTS • Patient has not discontinued medications or not on low-iodine diet. • Patient not clinically hypothyroid or with elevated TSH levels. This may preclude the test because there must be autonomous tissue producing hormone.

WHOLE BODY SCANS WITH rTSH AUGMENTATION • This test is based on serum thyroglobulin levels and stimulation of thyroid tissue with a recombinant form of TSH to detect recurring thyroid cancer or residual functioning thyroid tissue in patients without necessitating the discontinuation of thyroid hormone medications (e.g., Synthroid®).

Description • Thyrogen® (thyrotropin alfa for injection) is a highly purified, heterodimeric glycoprotein, recombinant form of human pituitary TSH. It is synthesized using a genetically modified Chinese hamster ovary cell line.

Localization • Thyrotropin alfa binds to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue, stimulating iodine uptake and organification, and synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4).

Adult Dose Range • ≥ 4 mCi (148 MBq) 131I-sodium iodide. ≥ 2 mCi (96 MBq) 123I-sodium iodide. Clearance of radioiodine is 50% greater when euthyroid (posttreatment patient taking thyroid medications) as opposed to hypothyroid (post-treatment patient not taking thyroid medications). This may be a consideration when selecting the activity for imaging.

Procedure • Thyrogen® injections: 0.9 mg IM into buttock every 24 hours for two injections, every 72 hours for three injections. 351

10766-60_CH60.qxd

12/3/07

5:28 PM

Page 352

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• 131I or 123I administration: 24 hours after the final Thyrogen® injection. • Scanning: whole body images are obtained at 72 hours after 131I administration (96 hours after final Thyrogen® injection) or 24 hours after 123I administration (48 hours after final Thyrogen® injection). • Parameters: • Whole body: ≥30 minutes and/or minimum of 140,000 counts. • Statics: 10 to 15 minutes each or 60,000 counts for large field-of-view cameras or 35,000 counts for small field of view cameras. • For a serum Tg test: A blood sample is obtained at 72 hours after final Thyrogen® injection.

NOTE • The scan should only be done after ablation of normal thyroid tissue. TSH levels should be > 40 mU/mL. Scan may also be done 7 to 10 days after a therapy 131I treatment. Using 123I may prevent stunning of thyroid remnants and/or metastasis. • Once the residual thyroid tissue has been ablated, it takes about 4 to 6 weeks for sufficient endogenous TSH stimulation by the pituitary to allow functioning of distant metastatic sites. Seldom do metastatic lesions visualize if there is functioning thyroid tissue remaining in the neck. Once ablated, follow-up with the iodine whole body sweep may be performed at 6-month to 1-year intervals until the scan is negative for 2 years. Patient should withhold thyroid hormones for 4 to 6 weeks for TSH levels to reach > 30 mU/mL, which enhances possible detection. • The whole body cancer study can also be performed with 99mTc-sestamibi (and perhaps 99mTctetrofosmin) using ∼20 mCi (740 MBq), image 15 minutes after injection, or 201Tl (∼4 mCi [148 MBq] IV, image 20 minutes after injection), for localization of nonfunctioning metastasis and alleviating the need to discontinue thyroid medication. Also imaged with 131I-meta-iodobenzylguanidine (131I-mIBG, same as pheochromocytoma study with emphasis on neck and chest). • Some physicians, for postsurgery or therapy follow-up, opt for a regular thyroid uptake and scan, < 30 mCi therapy if something is found, then monitor laboratory results before they attempt an ablation. Some say this sensitizes the remaining tissue, which becomes more resistant, making it more difficult to eradicate. • One way for markers if using film, if a 131I marker is not available, is to make up a 99mTc marker (a drop on a cotton-tipped swab stuffed into a needle cap works well) and take a quick marker image on 99mTc peak, then switch to 131I peak and take image. Do this for all views, put 99mTc images on one film and 131I images in same order on one film to allow direct overlay.

PATIENT HISTORY

The patient should answer the following questions.

Do you have a history or family history of cancer?

Y

N

Do you have a history of adenocarcinoma?

Y

N

Do you have a history of thyroid problems?

Y

N

Have you had any recent pain or problems in neck or throat area?

Y

N

Have you had any thyroid surgery?

Y

N

If so, what type and for how long?

If so, when?

352

10766-60_CH60.qxd

12/3/07

5:28 PM

Page 353

Chapter 60 — Thyroid: Whole Body 131I Cancer Study and rTSH Augmentation

Have you had any thyroid therapy, chemotherapy, or radiation therapy?

Y

N

Do you have any recent laboratory results?

Y

N

If rTSH (recombinant thyroid-stimulating hormone) study, do you have Tg (thyroglobulin) results?

Y

N

Have you had any recent iodinated radiographic studies (IV pyelogram, CT with contrast, x-ray with contrast, myelogram, angiogram, nuclear medicine)?

Y

N

Female: Are you pregnant or nursing?

Y

N

If so, when and what type?

When was your last injection of Thyrogen®?

Other department-specific questions.

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Genzyme Therapeutics. Thyrogen®, thyrotropin alfa for injection. Pamphlet. Cambridge, MA: Genzyme and Knoll, 1999. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

353

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 354

chapter

61

White Blood Cell Scan (111In-oxime and 99m Tc-HMPAO) RADIOPHARMACY Radionuclide •

111

In t1/2: 2.8 d Energies: 173, 247 keV Type: EC, γ, accelerator • or 99mTc t1/2: 6 hours Energies: 140 keV Type: IT, γ, generator

Radiopharmaceutical • •

proteins. Plasma half-life is about 7 hours. 99mTc-HMPAO is lipophilic entering the leucocyte and is converted to a hydrophilic complex becoming trapped within the cell (prefers eosinophils and is stored in the secretory granules). Plasma half-life is about 4 hours.

111

In-oxine (oxyquinoline) Tc-HMPAO (D,L-hexamethylpropyleneamine oxime) Ceretec®, exametazime

99m

Localization • White blood cell (WBC) migration through chemotaxis. 111In-oxine is lipophilic and enters the leukocyte cell membrane, dissociates with the indium binding to cytoplasmic

354

Quality Control • •

111

In-oxine: >90% Tc-HMPAO: >95% radiochemical purity

99m

Adult Dose Range • •

111

In-oxine: 500 µCi (18.5 MBq) Tc-HMPAO: 10–24 mCi (370–888 MBq)

99m

Method of Administration • Slow intravenous injection or hep-lock catheter with flush.

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 355

Chapter 61 — White Blood Cell Scan (111In-oxime and 99mTc-HMPAO)

INDICATIONS • Detection and localization of acute and chronic osteomyelitis (especially acute) and other musculoskeletal infections, e.g., septic arthritis. • Detection and localization of acute abscesses (e.g., liver, renal, intra-abdominal sepsis). • Detection and localization of infection (especially in fever of unknown origin [FUO]). • Detection of acute inflammatory disease (e.g., bowel, cellulitis, genitourinary, appendicitis). • Evaluation for prosthesis rejection. • Differentiation of pulmonary infiltrates (infarct versus pneumonia). • Detection of mycotic (fungal) aneurysms, shunt, and graft infections.

CONTRAINDICATIONS • Antibiotics decrease leukocyte chemotaxis and have negative effect on leukocytes. • Not particularly effective on spinal cord infections. • Patient should not be leukopenic.

PATIENT PREPARATION • Identify the patient. Verify doctor’s order. Explain the procedure (especially blood draw, reinjection, and then delay for pictures). • Document name, date, and time for procedure to begin. • Obtain a signed consent for blood work. • Obtain lab work and information concerning recent blood transfusions if any.

EQUIPMENT Camera • Large field of view

Collimator •

111

In: Medium energy; general purpose, or medium energy, high resolution • 99mTc: Low energy, all purpose, or low energy, high resolution

Computer Set-up •

111

In: 20% windows centered at 173 and 247 keV • 99mTc: 20% window centered at 140 keV

(cover head to pelvis, extremities may be required; patient comfort and compliance may be a factor in length of each spot) Whole Body • 512 × 1024 matrix, 10 cm/min or longer (minimum 30 minutes) head to pelvis and extremities in some cases. Single Photon Emission Computed Tomography (SPECT) • 360°, 64 stops, 45–60 sec/stop, 64 × 64 word matrix. Butterworth, cutoff .4, power 5, slice thickness 1–2 mm

Statics (spots) • 111In: 500,000 counts, 10–20 min/image, 99mTc: 800,000 to 2 million counts, 5–10 min/image

355

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 356

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PROCEDURE

(TIME: BLOOD DRAW, ~15 MINUTES; SPOTS, ~30–60 MINUTES; WHOLE-BODY, ~30–60 MINUTES; SPECT, ~30 MINUTES)

Blood Preparation • Order a blood sample collection kit from the radiopharmacy. • Arrange for time of pickup (takes ∼4 hours for turnaround time, 1–2 hours is preferable). • Identify patient. Using a large enough syringe (60–100 mL) for collection, add ∼4 to 8 mL of ADC or heparin. • Withdraw 50–80 mL of blood from patient (100 mL if patient’s WBC count is low). Use a large-gauge needle (18–20 gauge). • Invert gently for ∼1 minute to mix. • Fill out all necessary paperwork; label syringe and patient. • Store collected blood sample in supplied or fabricated container with needle or red cap facing up. • Send to radiopharmacy for processing. Turnaround is 1 to 4 hours. • Identify patient. Reinject tagged WBCs slowly, using large-bore needle. Flush IV well, if one is used. • Wait for appropriate amount of time to image (see below).

Imaging • Instruct patient to void; remove attenuating articles from patient’s clothing. • Place patient in supine position. • Acquire whole body sweep or statics, and/or SPECT as per protocol and radiologist’s request. Laterals and obliques may also be required, particularly with visualized suspicious areas. Check with radiologist before releasing patients (especially outpatients). 111

In-Oxine • Image at 1–6 hours and/or 24 hours after reinjection (usually only 24 hours). • Optional: Image at 48 hours. 99m

Tc-HMPAO (Ceretec®) • Because of higher photon flux, times for images can be reduced. • Image at .5–4 hours after reinjection (usually ∼2 hours, although optimum time is 1 hour). 10 min/image statics for osteomyelitis. • 18- to 24-hour delays may be the most helpful and required in cases of chronic infections. 15 min/image statics for osteomyelitis. • With 99mTc-HMPAO, it is essential to image the abdomen and pelvis early due to hepatobiliary excretion and bowel transit. 15 minute images at 8 hours may be needed to visualize pulmonary infection or osteomyelitis. • SPECT images can include chest, abdomen/pelvis, and/or spine.

NORMAL RESULTS 111

In-Oxine

• Up to 4 hours, pulmonary uptake. • 18–24 hours, liver, spleen, and bone marrow activity. • No renal, bladder, or gastrointestinal activity. 99m

Tc-HMPAO • Initial uptake in lung, liver, spleen, major blood vessels. • 1–hours: Liver, spleen, bladder, and kidney, some gall bladder.

356

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 357

Chapter 61 — White Blood Cell Scan (111In-oxime and 99mTc-HMPAO)

• 4 hours: Lung activity reduced, gallbladder brighter, bone marrow, and bowel activity presents. • 24 hours: Colonic activity, usually terminal ilium and right colon, others reduced.

ABNORMAL RESULTS • Osteomyelitis: Areas of focal activity outside normal areas, greater than adjacent or contralateral background. Increase in activity around orthopedic hardware for infection, normal or decreased for simple loosening. • Abscess activity compared with liver: More than or equal to liver indicates infectious process; less than liver indicates noninfectious process. • Splenic activity changes may indicate inflammatory bowel disease. • True-positive results: Abscesses communicating with bowel, pseudomembranous colitis, inflammatory bowel disease, or necrotic bowel. Best seen on early imaging (.5–3 hour). May visualize by 15–30 minutes and increase in intensity for next 2–3 hours. • Lung activity lingering after 4 hours may indicate pulmonary edema, diffuse inflammatory lung disease, atelectasis, renal failure, sepsis, or ARDS. • Focal abdominal uptake outside the liver/bowel area may indicate infection or inflammation. Correlation with other modalities is recommended. • Cold defects in spine may indicate osteomyelitis, compression fracture, neoplasm, postirradiation changes, postsurgical changes, or anatomic deformities.

ARTIFACTS • If an existing IV catheter is used for reinjection, it should be flushed before administration. Dextrose solutions can cause clumping of labeled cells. Labeled cells suffer significant loss of cell viability after 3 hours and cell damage if exposed to temperatures > 70°F. • Attenuation from clothing or articles. • False-positive results: Inflammation from tracheal tubes, pneumonia, emphysema, sinusitis, pulmonary embolism, congestive heart failure, adult respiratory distress syndrome (ARDS), accessory spleen, myositis ossificans, ulcers, diverticula, endometritis, tumors, metastases, IV catheters, colostomies, vaginitis, postsurgical wounds, acute bleeds, hematomas, arthritis, arthropathy, bone infarcts, or fractures. Also, cellulitis next to some bones e.g., maxilla, mandible, or pelvis. • False-negative results: Patient on antibiotics or with altered chemotaxis may suppress tagged leucocyte migration (especially for osteomyelitis, should be discontinued for 2–4 weeks), chronic abscess older than 3 weeks, lymphocytic infection (e.g., tuberculosis, sarcoidosis, granulomatous process, viral infection), hepatic or splenic abscesses or adjacent abscesses, chronic osteomyelitis (vertebral), low-grade infections, residual lung uptake from heart or renal disease, masking renal and/or bladder activity (Tc).

NOTE • Donor WBCs (ABO matched) can be used in leukopenic patients. • WBC studies may be chosen to follow up an equivocal 3-phase bone scan for osteomyelitis. Combined planar or SPECT indium/bone scans or indium/SC marrow scans may be more useful in difficult osteomyelitis sites that have bone alteration and/or adjacent cellulitis (increased indium activity/no corresponding SC uptake). Using the appropriate energy windows, dual-isotope Tc/Indium images can be done at the same time or as separate images. • 99mTc-sulfur colloid (8–10 mCi [296–370 MBq]) can be injected after the 111In-oxine study is complete for a standard liver/spleen study taken to compare and help evaluate upper abdomen for abscesses and/or a bone marrow study for distribution to assess pattern of uptake at suspected infection sites to differentiate between soft tissue and bone uptake and especially for hip prosthesis evaluation. Image sites at 30 minutes after injection, 10-minute views for medium energy collimator using Tc windows. 357

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 358

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Tc-MDP or HDP (20–25 mCi [740–925 MBq]) can be injected after the 111In-oxine study is complete for a combined bone scan of areas of interest. Inject at the appropriate time before the indium scan. If using a medium energy collimator (indium), use a 10% window, 140 keV, 300 second or 400,000 counts for spots. With SPECT Tc/In, osteomyelitis is indicated when abnormal focal indium uptake corresponds to abnormal bone uptake in two or more 6- to 8-mm slices and identified in at least one plane. Cellulitis will not have the corresponding bone uptake. • 99mTc-HMPAO is particularly useful for osteomyelitis detection in extremities and in cases in which there is a concern for time. Also best for evaluation of inflammatory bowel, particularly small bowel. • 111In-oxine is more useful for infection and inflammation in abdomen/pelvis region because of no excretion into gastrointestinal or urinary tracts. Also better in chest infection with patients who have prolonged lung blood pool uptake due to congestive heart failure, septic shock, and renal failure. Graft or shunt infection may be better visualized because of less blood pool activity. •

99m

PREPARATION FOR INJECTION Kits (from the radiopharmacy) • Included (usually): container, 60-mL syringe, ADC (or other) blood thinner, wrist label and extra number stickers, cap, butterfly, plastic bag, and paperwork. • Start IV or butterfly. • Draw ∼7 mL of ADC into syringe (or ∼1 mL heparin). • Draw 50 mL of blood into syringe (more, up to 100 mL in two syringes, if WBC count is known to be low). • Cap syringe and label with number tag; place into plastic bag. • Place into shipping container so that cap is up when case is upright (to facilitate settling). • Fill out paperwork and place a number tag on paper. • Affix the wrist band onto the patient’s arm. • Send blood sample back to radiopharmacy. The turnaround time varies but may be ∼3 to 4 hours. • Upon return, identify and reinject patient with tagged WBCs after checking number tags and paperwork. • Wait specified time for particular scan and image.

For the “Do-It-Yourselfers” (home-spun injections) • Withdraw 50 to 100 mL of whole blood with 1 to 8 mL of blood thinner (e.g., 7 mL acid citrate dextrose [ADC]). • Clamp syringe at 10° to 30° angle, needle side (or red cap side) up. • Add 10 mL of 6% hetastarch to settle RBCs or let sit for 45 to 60 minutes. • Reclamp syringe straight up. • Remove upper layer containing leukocyte-rich plasma (LRP, buffy coat) and place slowly into sterile plastic tubes or one 50-mL centrifuge tube. • Centrifuge at 300 g for 15 minutes or at 450 g for 5 minutes. (Makes leukocyte “button” at bottom.) • Remove leukocyte-poor plasma layer (LPP) and place into fresh plastic tube(s). • Centrifuge tube(s) at 100 g for 15 minutes. (Separates out platelets.) • Remove and save all platelet-poor plasma. • Combine leukocyte buttons and add 5 mL of normal saline to resuspend. • At this point, for 111In-oxine, some wash buttons by centrifuging again at 450 g for 5 minutes to remove the plasma transferrin, remove and discard supernatant, then resuspend with 5 mL of normal saline. • Add .5 to 1 mCi (18.5–37 MBq) 111In-oxine or 30 mCi (1110 MBq) 99mTc-HMPAO slowly to suspension while swirling tube, then incubate at room temperature for 15 to 30 minutes to effect cell labeling. • Add 5 mL of the previously saved platelet-poor plasma to suspension to bind any free indium or 99m Tc-HMPAO. 358

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 359

Chapter 61 — White Blood Cell Scan (111In-oxime and 99mTc-HMPAO)

• Centrifuge at 300g for 5 minutes, remove, assay, and save supernatant layer for quality control. • Add 2 mL of the platelet-poor plasma to wash labeled WBCs without resuspending, and then remove, assay, and discard. • Add 5 mL of the platelet-poor plasma and resuspend labeled WBCs; assay. % bound =

µCi or mCi in WBCs × 100 µCi or mCi in WBCs + µCi or mCi in supernatant

• Check with microscope for clumps and foreign particles. • Perform trypan blue exclusion test to determine cell viability. • Draw 500 µCi (18.5 MBq) 111In-oxine or 24 mCi (888 MBq) 99mTc-HMPAO of labeled WBCs into syringe; assay. • It is now ready for injection. Reinject patient and wait specified time for particular scan for imaging.

PATIENT HISTORY

(or use complete patient history in reference section) The patient should answer the following questions. Do you have a history or family history of cancer?

Y

N

Y

N

Have you had any recent surgery?

Y

N

Have you had any recent infections?

Y

N

Do you have any blood-borne infections?

Y

N

Do you have any pain?

Y

N

Are you taking antibiotic therapy?

Y

N

Have you had recent fevers?

Y

N

Have you had any recent trauma?

Y

N

Are you a diabetic?

Y

N

Are there any recent or planned related studies (e.g., US, CT, MRI, PET, nuclear medicine, x-ray, biopsy)?

Y

N

Y

N

If so, what type and for how long? Do you have a history of bowel disease? If so, what type and for how long?

If so, where and for how long?

Discern discreetly whether the study is AIDS-related. Female: Are you pregnant or nursing? Other department-specific questions.

359

10766-61_CH61.qxd

12/3/07

5:31 PM

Page 360

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Students Explain the relevancy of each of the above patient history questions to this particular scan. Can you think of others that would be helpful for the interpretation of this type of study?

Suggested Readings Datz FL. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Early PJ, Sodee DB. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. Kowalsky RJ, Falen SW. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation. Version 3.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for 111In-Leukocyte Scintigraphy for Suspected Infection/Inflammation. Version 3.0, June 2, 2004. SNM.org. Weissleder R, Rieumont MJ, Wittenberg J. Primer of Diagnostic Imaging. St. Louis: Mosby, 1997. Wilson MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998.

Notes

360

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 361

section

2

Quick Reference A. B. C. D. E. F. G. H. I. J. K. L.

Conversion Tables Radiopharmaceuticals Decay Tables of Common Radionuclides Standard Drug Interventions Laboratory Tests Language Barrier Buster™/Interpretech™ Regulations Patient Release Methods and Information for Thyroid Therapies Patient History Sheets Abbreviations Commonly Used in Nuclear Medicine Coding Anatomical Images

361

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 362

QUICK REFERENCE A

Conversion Tables lb/kg in/cm Target Heart Rates (Cardiac Studies) mCi/MBq

362

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 363

Quick Reference A — Conversion Tables

CONVERSION TABLE FOR POUNDS TO KILOGRAMS Weight (in lb) ÷ 2.2 = kg (rounded off to nearest number)

lb

kg

lb

kg

lb

kg

lb

kg

lb

kg

lb

kg

lb

kg

lb

kg

65

30

90

41

115

52

140

64

165

75

190

86

215

98

240

109

66

30

91

41

116

53

141

64

166

75

191

87

216

98

241

110

67

31

92

42

117

53

142

64

167

76

192

87

217

99

242

110

68

31

93

42

118

54

143

65

168

76

193

88

218

99

243

110

69

31

94

43

119

54

144

65

169

77

194

88

219

100

244

111

70

32

95

43

120

55

145

66

170

77

195

89

220

100

245

111

71

32

96

44

121

55

146

66

171

78

196

89

221

100

246

112

72

33

97

44

122

55

147

67

172

78

197

90

222

101

247

112

73

33

98

45

123

56

148

67

173

79

198

90

223

101

248

113

74

34

99

45

124

56

149

68

174

79

199

90

224

102

249

113

75

34

100

46

125

57

150

68

175

80

200

91

225

102

250

114

76

35

101

46

126

57

151

69

176

80

201

91

226

103

251

114

77

35

102

46

127

58

152

69

177

80

202

92

227

103

252

115

78

36

103

47

128

58

153

70

178

81

203

92

228

104

253

115

79

36

104

47

129

59

154

70

179

81

204

93

229

104

254

115

80

36

105

48

130

59

155

70

180

82

205

93

230

105

255

116

81

37

106

48

131

60

156

71

181

82

206

94

231

105

256

116

82

37

107

49

132

60

157

71

182

83

207

94

232

105

257

117

83

38

108

49

133

60

158

72

183

83

208

95

233

106

258

117

84

38

109

50

134

61

159

72

184

84

209

95

234

106

259

118

85

39

110

50

135

61

160

73

185

84

210

95

235

107

260

118

86

39

111

50

136

62

161

73

186

85

211

96

236

107

261

119

87

40

112

51

137

62

162

74

187

85

212

96

237

108

262

119

88

40

113

51

138

63

163

74

188

85

213

97

238

108

263

120

89

41

114

52

139

63

164

75

189

86

214

97

239

109

264

120

363

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 364

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONVERSION TABLE FOR INCHES TO CENTIMETERS Height (inches) × 2.54 = cm Feet

Inches

Centimeters (rounded off)

4′9″

57″

145 cm

4′10″

58″

147 cm

4′11″

59″

150 cm

5′

60″

152 cm

5′1″

61″

155 cm

5′2″

62″

157 cm

5′3″

63″

160 cm

5′4″

64″

163 cm

5′5″

65″

165 cm

5′6″

66″

168 cm

5′7″

67″

170 cm

5′8″

68″

173 cm

5′9″

69″

175 cm

5′10″

70″

178 cm

5′11″

71″

180 cm

6′

72″

183 cm

6′1″

73″

185 cm

6′2″

74″

188 cm

6′3″

75″

191 cm

6′4″

76″

193 cm

6′5″

77″

196 cm

6′6″

78″

198 cm

6′7″

79″

200 cm

6′8″

80″

203 cm

6′9″

81″

206 cm

6′10″

82″

208 cm

364

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 365

Quick Reference A — Conversion Tables

CONVERSION TABLE FOR TARGET HEART RATES (CARDIAC STUDIES) 220 − age = 100% target rate

Age

100%

85%

Age

100%

85%

Age

100%

85%

18

202

172

42

178

151

66

154

131

19

201

171

43

177

150

67

153

130

20

200

170

44

176

150

68

152

129

21

199

169

45

175

149

69

151

128

22

198

168

46

174

148

70

150

128

23

197

167

47

173

147

71

149

127

24

196

167

48

172

146

72

148

126

25

195

166

49

171

145

73

147

125

26

194

165

50

170

145

74

146

124

27

193

164

51

169

144

75

145

123

28

192

163

52

168

143

76

144

122

29

191

162

53

167

142

77

143

122

30

190

162

54

166

141

78

142

121

31

189

161

55

165

140

79

141

120

32

188

160

56

164

139

80

140

119

33

187

159

57

163

139

81

139

118

34

186

158

58

162

138

82

138

117

35

185

157

59

161

137

83

137

116

36

184

156

60

160

136

84

136

116

37

183

156

61

159

135

85

135

115

38

182

155

62

158

134

86

134

114

39

181

154

63

157

133

87

133

113

40

180

153

64

156

133

88

132

112

41

179

152

65

155

132

89

131

111

365

10766-62_ST2-QuickRef-A.qxd

12/3/07

5:32 PM

Page 366

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CONVERSION TABLE FOR MILLICURIES (MCI) TO MEGABECQUERELS (MBQ) mCi × 37 = MBq µCi

MBq

mCi

MBq

mCi

1 (0.001 mCi)

0.037

1

37

26

962

350

12,950

2

0.074

2

74

27

999

400

14,800

5

0.185

3

111

28

1,036

450

16,650

10

0.370

4

148

29

1,073

500

18,500

25

0.925

5

185

30

1,110

550

20,350

50

1.85

6

222

31

1,147

600

22,200

75

2.775

7

259

32

1,184

650

24,050

100

3.70

8

296

33

1,221

700

25,900

150

5.55

9

333

34

1,258

750

27,750

200

7.40

10

370

35

1,295

800

29,600

250

9.25

11

407

36

1,332

850

31,450

300

11.10

12

444

37

1,369

900

33,300

350

12.95

13

481

38

1,406

950

35,150

400

14.80

14

518

39

1,443

1,000

37,000

450

16.65

15

555

40

1,480

1,500

55,500

500

18.50

16

592

50

1,850

2,000

74,000

550

20.35

17

629

60

2,220

2,500

92,500

600

22.20

18

666

70

2,590

3,000

111,000

650

24.05

19

703

80

2,960

3,500

129,500

700

25.90

20

740

90

3,330

4,000

148,000

750

27.75

21

777

100

3,700

4,500

166,500

800

29.60

22

814

150

5,550

5,000

185,000

850

31.45

23

851

200

7,400

7,500

277,500

900

33.30

24

888

250

9,250

10,000

370,000

950

35.15

25

925

300

11,100

50,000

1,850,000

366

MBq

mCi

MBq

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 367

QUICK REFERENCE B

Radiopharmaceuticals Standard Adult Nuclear Medicine Dose Ranges Routine Medical Radionuclides Equations Kit Preparations (Overview) Pediatric Dosing in Nuclear Medicine Radioactive Isotopes

367

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 368

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

STANDARD ADULT NUCLEAR MEDICINE DOSE RANGES Standard Dose ± 10%

Range ± 10%

I-Iodomethylnorcholesterol

2 mCi

2 mCi

I-tositumomab (dosimetric)

5 mCi

5 mCi

25 mCi

20–30 mCi

15 mCi

10–20 mCi

25 mCi

20–30 mCi

99m

25 mCi

20–30 mCi

99m

25 mCi

7–30 mCi

one day, first study

99m

8 mCi

7–10 mCi

second study

99m

25 mCi

20–30 mCi

two day

99m

Tc, Cardiolite® or Myoview®

25 mCi

20–30 mCi

201

Tl-chloride

3.5 mCi

2.5–3.5 mCi

Stress reinjection

1 mCi

1 mCi

201

3.0 mCi

2.5–3.5 mCi

Tc, Cardiolite® or Myoview®

25 mCi

20–30 mCi

In-DTPA

1 mCi

.5–1.5 mCi

500 uCi

.5–1 mCi

Procedure

Radiopharmaceutical

Adrenocortical Scan

131

Bexxar®

131

Bone Scan

99m

Bone Marrow Scan

99m

Brain Scan

99m

Brain Scan—SPECT Cardiac First Pass

Tc-MDP, HDP Tc-Sulfur Colloid −

Tc-04 , DTPA, GH Tc-Ceretec® or Neurolite® Tc, Cardiolite® or Myoview®

Cardiac Rest/Stress Tc, Cardiolite® or Myoview® Tc, Cardiolite® or Myoview®

Cardiac Stress/Redistribution Redistribution and/or 24 hour delay Cardiac Dual-isotope: Rest Stress

Tl-chloride

99m

Cisternogram

111

Cystogram (voiding)

99m

Dacryoscintigraphy

99m

100 uCi

50–200 uCi

Gallium Scan (infection)

67

7 mCi

5–10 mCi

Gallium Scan (tumor)

67

10 mCi

5–10 mCi

Gastric Emptying

99m

500 uCi

.5–1 mCi

G.I. Bleed

99m

25 mCi

20–30 mCi

HIDA (hepatobiliary scan)

99m

Tc-Choletec®

8 mCi

5–10 mCi

Liver/Spleen Scan

99m

Tc-S.C.

4 mCi

2–7 mCi

Liver SPECT(hemangioma)

99m

25 mCi

20–30 mCi

Lung Perfusion Scan

99m

Tc-MAA

4 mCi

3–5 mCi

Lung Ventilation Scan

133

Xe

10 mCi

10–20 mCi

Lung Ventilation Scan

99m

35 mCi

25–40 mCi

Lymphoscintigraphy

99m

Tc-S.C.

500 uCi

100–800 uCi

Meckel’s Diverticulum

99m

Tc-04−

10 mCi

10–15 mCi

MUGA Scan

99m

25 mCi

20–30 mCi

Myocardial (MI) Scan

99m

25 mCi

20–30 mCi

NeutroSpec™

99m

15 mCi

10–20 mCi

368

Tc-S.C.,

99m

Tc-04

−

Tc-04−

Ga-citrate Ga-citrate Tc-S.C. Tc-pyp-RBC’s

Tc-pyp-RBC’s

Tc-DTPA (aerosol)

Tc-pyp-RBC’s Tc-pyp Tc-fanolesomab

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 369

Quick Reference B — Radiopharmaceuticals

(Continued) Standard Dose ± 10%

Range ± 10%

6 mCi

6 mCi

99m

Tc-Cardiolite®

25 mCi

16–30 mCi

201

Tl-chloride

2 mCi

2–3 mCi

99m

Tc-04−

5 mCi

5–12 mCi

18

15 mCi

10–20 mCi

13

10 mCi

10–20 mCi

15

40 mCi

30–100 mCi

82

30 mCi

30–60 mCi

5 mCi

3–10 mCi

500 uCi

.5–1 mCi

5 mCi

5–17 mCi

Procedure

Radiopharmaceutical

OctreoScan®

111

Parathyroid Scan Subtraction:

PET

In-pentetriotide

F-FDG N-ammonia O-water Rb-chloride

Pheochromocytoma Scan

123

I and 131I-mIBG

123

I

131

I

ProstaScint®

111

Renal Scan

99m

10 mCi

10–15 mCi

Renal Scan

99m

5 mCi

3–10 mCi

Renal Scan

99m

Tc-MAG-3®

7 mCi

3–10 mCi

Renogram

131

I-OIH

300 uCi

150–300 uCi

Schilling

B-12-57Co

.3 uCi

.3–.5 uCi

Scintimammography

99m

Tc-Cardiolite®

20 mCi

20 mCi

Testicular Scan

99m

Tc-04−

20 mCi

10–25 mCi

Thyroid Ablation

131

I

150 mCi

30–300 mCi

Thyroid Hyperthyroid Tx

131

I

diffuse

10 mCi

1–10 mCi

nodular

29 mCi

< 33 mCi

In-CYT-356 Tc-DTPA Tc-DMSA

Thyroid Scan

99m

Tc-04−

10 mCi

5–10 mCi

Thyroid Uptake and Scan

123

I

140 uCi

100–450 uCi

or 131I

50 uCi

1–100 uCi

Thyroid Scan (Substernal)

131

50 uCi

15–100 uCi

WBC Scan

99m

10 mCi

10–15 mCi

99m

Tc-Ceretec®

10 mCi

10–24 mCi

111

In-WBC

500 uCi

500 uCi

Wholebody 131I CA work-up

131

I

1 mCi

1–5 mCi

Zevalin®

111

In-Ibritumomab (dosimetric)

5 mCi

5 mCi

I Tc-WBC

369

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 370

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ROUTINE MEDICAL RADIONUCLIDES Name

t1/2

Emitter

Energies (keV’s)

Medical Uses

Ac-225

10.0d

α

5829

MoAb for radioimmunotherapy (RIT)

Am-241

432y

α

5486

osteoporosis detection, heart imaging

As-72

26h

β+

511

planar, SPECT, or PET

As-74

17.8d

β ,β

1353, 511

biomedical applications

At-211

7.21h

α

5867

MoAb for RIT, used with F-18

Au-195m

30.6s

γ

200, 262

first-pass angiography

Au-198

2.69d

β

961

ovarian, prostate, brain cancer tx

Be-7

53.2d

γ

478

berylliosis studies

Bi-212

1.1h

α, β−, γ

6051, 2246, 727

MoAb RIT, cellular dosimetry

45.6m

α, β , γ

5870, 5550, 1430, 979, 440

MoAb RIT

Br-75

1.62h

β ,γ

511, 286.5

Planar, SPECT, PET

Br-77

57h

γ

239

MoAb labeling, hypoxia in tumors

20m

β

511

brain PET, cardiac PET

C-14

5730y

β

156.5

H. Pylori breath test

Co-55

17.5h

β+, γ

511, 931, 477, 1408

Planar, SPECT, PET (brain)

Co-57

270d

γ

122

“mock Tc,” markers, vit. B-12

Bi-213

C-11

−

+

−

−

+

+ −

Schilling’s Test Co-58

70.8d

β+, γ

Cr-51

27.7d

γ

29.2m

Cs-137 Cu-61

511, 811

Schilling’s Test

320

RBC survival, dosimetry

β ,β ,γ

511, 440, 536

myocardial localizing agent

30y

−

β ,γ

662

calibration of machines

3.35h

β+

511

planar, SPECT, PET

12.7h

β

511

PET brain, cardiac

Cu-67

61.9h

β ,γ

390, 481, 575, 185

CA Tx, MoAb, RIT, planar, SPECT, PET

Dy-165

2.33h

β−

1205

radiation synovectomy, rheumatoid arthritis treatment

Eu-152

13.6y

γ

122

medical

Eu-155

4.71y

β ,γ

141, 160, 87, 105

osteoporosis detection

F-18

110m

β+

511

brain, cardiac, tumor PET (fluorodeoxyglucose FDG, etc.)

Fe-59

45d

β−, γ

1100, 1290

ferrokinetics, formation of RBC’s

Ga-64

2.63m

β ,γ

511, 991, 808, 3366

treatment of pulmonary diseases

Ga-67

78.3h

γ

93, 184, 300

tumors, infections, lymphomas, hepatomas, bronchogenic carcinomas, osteomyelitis

Ga-68

68.1m

β+

511

PET, thrombosis, atherosclerosis, pancreatic cancer, attenuation correction

Gd-153

242d

γ

97

dual photon source, osteoporosis detection, SPECT

Cs-130

Cu-62

370

+

+ −

−

+

−

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 371

Quick Reference B — Radiopharmaceuticals

(Continued) Name

t1/2

Emitter

Energies (keV’s)

Medical Uses

Ge-68

271d

γ

9

attenuation correction

H-3

12.26y

β−

18.6

body composition: total body water intra- and extra-cellular water

I-122

3.6m

β+

511

PET brain blood flow

I-123

13.1h

γ

159

thyroid, brain, kidney, cardiac, cerebral blood flow, dementia

I-124

4.17d

β+

511

thyroid, PET

I-125

60d

γ

27 x&γ

in vitro therapy, seed implants, RIA, GFR, plasma volume, tumor, osteoporosis detection, MoAb, brain cancer, prostate cancer, planar, SPECT

I-131

8.1d

β−, γ

606, 364

thyroid therapy, uptake 1–10µCi, hyperthyroid − 30mCi, follicular cancer 100–300mCi

I-132

2.28h

β−, γ

1185, 2140, 668, 773

brain tumor mapping

In-111

2.8d

γ

173, 247

tag WBC’s for infections, MoAb, tumors, cisternography, transplant rejection, leukemia tx,

Ir-192

73.8d

β−, γ

672, 208, 309

tx for prostate, brain, breast, etc.

Kr-81m

13.1s

γ

191

pulmonary ventilation

Lu-177

6.68d

β−

497, 144

tx cancer, heart (restinosis)

Mn-51

46.2m

β+, γ

511, 749, 1148, 1164

myocardial localizing agent

Mn-52

5.59d

β

511

PET imaging

Mo-99

66h

β−, γ

740, 780

generator for Tc imaging

N-13

9.97m

β ,β

511, 1199

brain PET, myocardial perfusion

Nb-95

35d

β−, γ

159, 766

PET, myocardial tracer, studies of effects on pregnant females/fetus

O-15

2.1m

β+

511

SPECT, PET brain, cardiac

Os-191

15.4d

β−, γ

143, 129

generator for Ir-191m for cva

Os-194

6y

β−, γ

96, 540, 43

MoAb for RIT

P-32

14.3d

β

1710

RBC’s for polycythemia vera or sodium phosphate solution for bone metastases

P-33

25d

β−

249

labeling

Pb-203

2.16d

γ

279

planar, SPECT, PET, MoAb, dosimetry

Pb-212

10.6h

β−, γ

334, 239

RIT, cellular dosimetry

Pd-103

16.9d

γ

39.8, 357.5

prostate seed implant therapy

Pd-109

13.4h

β−

1028

therapy agent

Pu-238

87.8y

α

5457

pacemaker (no Pu-236 contaminants)

Ra-223

11.4d

α, γ

5606, 84

MoAb for RIT

Ra-226

1.6e3y

α

4785

production alpha emitters for RIT

+

+

−

−

(continued) 371

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 372

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

(Continued) Name

t1/2

Emitter

Energies (keV’s)

Medical Uses

Rb-81

4.7h

β+, γ

190, 446, 511

generators for Kr

Rb-82

1.3m

β+

511

cardiac PET, from generator

3.9d

β

939.4

cancer tx, MoAb, arthritis tx, imaging

17h

β

1965

cancer tx, MoAb

Rh-105

35.4h

β ,γ

248, 567, 319

tx, MoAb

Ru-97

2.89d

γ

216

planar, SPECT, MoAb

Ru-103

39d

β−, γ

226, 497

PET, cardiac, microspheres

87.2d

β

1675

nucleic acid labeling, dosimetry

84d

β ,γ

357, 889

PET regional blood flow

Sc-47

3.34d

β ,γ

441, 600, 657, 984

cancer tx, MoAb for RIT

Se-75

120d

γ

136, 265, 279

brain, pancreatic imaging

Sm-153

46.7h

β−, γ

632, 702, 805, 103 γ

bone pain and metastases

Sr-85

65d

γ

518

brain, bone lesions

50.5d

β

1463

bone pain and metastases tx

28.6y

β

546

generator, MoAb RIT

Ta-178

9.3m

β ,γ

511, 93, 1350, 1341

PET cardiac and blood vessels

Ta-182

114.7d

β−, γ

258, 522, 68, 1121, 1221

bladder cancer tx, internal implants

Tb-149

4.13h

α, β+, γ

3969, 511, 352, 165, 389

MoAb for RIT

Tc-99

6h

γ

140

general imaging

Th-228

1,9y

α

5341

cancer tx, MoAb

Th-229

7340y

α, γ

4845, 89

origin for Bi-213, Ac-225, RIT

Tl-201

73h

γ

135, 167 γ

myocardial perfusion

69–83 Hg K x-rays

hibernating tissue

129d

β

884, 968

leukemia, lymphoma tx

Tm-171

1.9y

−

β

967

medical applications

W-188

69.4d

β−

349

cancer tx, MoAb, generator parent

Xe-127

36.4d

γ

28, 172, 203

brain (schizophrenia, dementia), pulmonary ventilation, SPECT

Xe-133

5.3d

β−, γ

346, 81, 32 x-ray

pulmonary ventilation, brain flow, liver, SPECT brain, lung

Y-88

107d

γ

898

cancer tx

64h

β

2284

radiation tx, MoAb for RIT, rheumatoid arthritis

Y-91

58.5d

β

1543

MoAb for RIT, cellular dosimetry

Yb-169

32d

γ

63, 98

g i tract, cisternography

Zn-62

9.2h

γ

41

brain and cardiac flow

Zn-65

244.4d

γ

1120

medical applications

Zr-95

64d

β−, γ

366, 724

medical applications

Re-186 Re-188

S-35 Sc-46

Sr-89 Sr-90

m

Tm-170

Y-90

372

− − −

− − −

− − +

−

− −

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 373

Quick Reference B — Radiopharmaceuticals

EQUATIONS 1. Pediatric doses:

wt. in kg × adult dose = pediatric dose 70 kg

2. Drawing doses:

what you want = what you will get what you have

Or: 3. 4. 5. 6.

dose needed (mCi) = V1 (volume to draw up in mL) C1 (concentration on hand in mCi/mL)

Weight: weight in lb ÷ 2.2 = kg; weight in kg × 2.2 = lb Height: height in inches × 2.54 = cm; height in cm ÷ 2.54 = inches Activity: mCi × 37 = MBq; MBq ÷ 37 = mCi Cardiac functions: Target heart rates: 220 − age = 100% target heart rate (HR) % Ejection fraction:

ED − ES × 100, ED

where ED is end-diastolic volume, and ES is end-systolic volume SV (stroke volume) = ED − ES CO (cardiac output in mL) = SV × HR 7. Decay: A t = A 0 e

−

.693 (t) t1 2

8. Inverse square law: I1 D12 = I2 D22 (I = intensity in mR/time, D = distance) 9. Concentrations: C1 V1 = C2 V2 (C = concentration in mCi/mL, V = volume in mL) 10. Doses from concentrations: −

Decay concentration: C2 = C1 e Draw from concentration: C1 =

11. Shielding: I2 = I1 e

−

.693 (x) HVL

.693 (t) t1 2

A0 V1

(X = thickness of material) (HVL = half value layer of radionuclide) (I = intensity of radionuclide)

12. Effective/biologic half-lives: t e =

t1 2 × t b t1 2 + t b

tb =

t1 2 × t e t1 2 − t e

13. Temperature: F ° = 1.8C° + 32 or C° =

(F ° − 32) 1. 8

14. Liquid: 1 ounce = 29.57352956 mL mL = Ounces × 29.57 Ounces = mL ÷ 29.57 Also see Conversion Tables and Drug Interventions, Calculations for more examples. 373

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 374

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

KIT PREPARATIONS (OVERVIEW) General Considerations • Most kit preparations are for use with 99mTc-pertechnetate, which is usually supplied in bulk form from the radiopharmacy or from department generators. • Bulk Tc is usually supplied in a vial containing from 50 mCi (1850 MBq) to hundreds of mCi (thousands of MBq) on a daily basis with usually two deliveries or more depending on the department. • Ensure that you have the proper kit or vial with an unexpired date on the label and that it is placed in a lead shield container. • If more than one is being prepared at the same time, label each lead container properly. • When reconstituting the chemical by adding the 99mTc-pertechnetate to the kit(s), with few exceptions, it is important not to introduce any O2 from the syringe into the vial as this may oxidize the 99mTc or seriously affect the stannous ions. If you add, e.g., 2 mL of 99mTc-pertechnetate and/or normal saline to a kit vial, withdraw the 2 mL of air before removing syringe. This will help to remove any unwanted O2 and leave the vial with negative pressure. This is a desired result. • Use only normal nonbacteriostatic 0.9% NaCl without preservatives to dilute the pertechnetate and kits for dilution to proper concentration. • Some “cold” kits (those for non-radioactive intravenous drugs e.g., sincalide) require the use of sterile water. Ensure that the proper additive is used. • Once the additions have been made, invert the lead container or vial several times to ensure complete mixture and allow to incubate for suggested time. • Follow instructions on kit package inserts if available, paying close attention to suggested mCi, volumes, and incubation time before injection. • On the label, note the name of the kit, total activity, total volume, concentration (mCi/mL), date, time made, expiration date, and time. • Record this same information as well as lot numbers from the kit (vial) and pertechnetate, into the computer or log book. • Perform quality control on the product for radiochemical purity before injection. • Some kits require heating. Extreme caution should be used if preparing the kit and heating with a microwave. There are instances of sparking from the metal cap and vials exploding.

Rules of Thumb • Never use < 30 mCi in a kit. Some require or suggest more (30–100 or more mCi per kit). • Most are diluted to (queued to) a total of about 2–4 mL with normal saline after the pertechnetate is added for a workable concentration. • If you need ∼25 mCi and a small bolus (quantity) is preferred, use 50–70 mCi of pertechnetate and bring up to 2–3 mL for concentration. If you need 5 mCi, use less pertechnetate and 3–4 mL of saline. Most institutions have established protocols to follow for each type of kit. • Always remember to label the lead container(s). Example: Say you get bulk 99mTc, 100 mCi/2 mL. Assay the vial in a dose calibrator, it is now 72 mCi/ 2 mL (36 mCi/mL). You want 40 mCi for a Choletec® kit. What you want ÷ what you have = what you will get; or 40 mCi ÷ 36 mCi/mL = 1.1 mL. Draw 1.1 mL into a 3-mL (or 5-mL) syringe. Assay the syringe in the dose calibrator. It comes out to 38 mCi. Perhaps you want to bring it up to (dilute it to) 3 mL for total kit volume. Draw 1.9 mL normal saline. It is now 38 mCi/3 mL (12.6 mCi/mL). Inject into kit, withdraw air, swirl, run quality control, and incubate for proper time. If your protocol calls for 5 mCi of Choletec®: What you want ÷ what you have = what you will get; or 5 mCi ÷ 12.6 mCi/mL = 0.39 or 0.4 mL. In a fresh syringe, draw ∼0.4 mL from kit. Assay the syringe in the dose calibrator, it should be 5 mCi ± 10%. If you do not like the math, common sense and eye balling will get you pretty much to the same place. 374

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 375

Quick Reference B — Radiopharmaceuticals

Note Chromatography Chromatography is a technique used to separate the components of a newly reconstituted kit into its separate components to ensure that enough of the desired mixture or “tag” is present in the desired form for injection. Thin-layer chromatography (TLC) is usually the recommended quality control although there are other methods. TLC is the procedure using a drop of the reconstituted radiopharmaceutical on a quality control strip (Gelman ITLC-SG, Instant Thin Layer Chromatography Silica Gel Paper) in which the mobile component (solvent) migrates up a stationary component (paper) and moves individual substances to varying distances. Protocols for each kit, supplies on hand, and specific instructions vary slightly among institutions. Most kits on hand are for routine on-call procedures or radiopharmacy after-hours routine procedures. Radiochemical purity is the percent of the total radioactivity in the reconstituted kit which is in the form of the desired radiochemical. Most of these involve 99mTc-pertechnetate and must have 90–95% radiochemical purity for their use. Most need to incubate (reconstitute) for about 5 minutes after radioactivity and normal saline are added to the vial. Follow protocols supplied by the department or hospital (or package insert if none are available). Here is just one example of a hospital protocol for mixing up kit preparations. Bone Lung

Gallbladder Tagged RBC Cardiac

Osteolite® diethylenetriaminepentaacetic acid (DTPA) Pulmolite®* Choletec® Cold Pyp Myoview®

up to 200 mCi

2–8 mL

stand for 2 min

up to 100 mCi up to 50 mCi up to 100 mCi

2–8 mL 2–8 mL 1–5 mL 1.5–2.5 mL 4–8 mL

stand for 2 min stand for 2 min stand for 15 min stand for 3–5 min stand for 15 min

up to 30 mCi/mL

There are some kits that require heating during the mixing process. Many institutions opt for relying on “unit doses” (prepared at the radiopharmacy and sent to the department at the desired amount). Other labs have the required heating units or some use microwave ovens. Although many institutions rely on unit doses for their radiopharmaceutical needs, there are still many that possess their own generators and make nearly everything they need in their on campus hot lab.

Protocols There are many protocols and supply companies with different products and kits that can be used at various institutions. Most have a list with specific instructions in the hot lab. *One that must be handled with care is the macroaggregated albumin kit. If a kit is reconstituted early in the evening and more out of the same vial is required much later, care must be taken not to inject the patient with too many particles.

Particles in Kits • • • •

Particles in kits range from 2–8 million/vial. Average, 5 million. Accepted range of particles injected per dose, 200,000 to 700,000. Average, 450,000. Accepted range of activity is 3–5 mCi (111–185 MBq). Average, 4 mCi (148 MBq). A workable concentration for this scenario (assuming an uncompromised adult patient): • Withdraw 50 mCi from bulk 99mTc; it is (for instance) in 1 mL. • Add 4 mL (or whatever to equal a total of 5 mL) normal saline. Place the macroaggregated albumin vial into a lead container and inject the radioisotope into the vial. Perform chromatography and allow to incubate. • Results: 50 mCi/5 mL or 10 mCi/mL. • Particle number is now (on average) 5,000,000/5 mL or 1,000,000/mL. • A 4 mCi dose drawn immediately is 0.4 mL, having 400,000 particles (on average). Well within accepted limits. • In 6 hours, the kit has decayed to 25 mCi/5 mL or 5 mCi/mL. These concentration ratios remain pretty much the same whether the kit has been used earlier or not. A 4 mCi dose then is 0.8 mL and 800,000 particles (on average) and at the upper recommended limit of particles per dose. 375

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 376

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• 75–100 mCi at the start is not unlikely for busy departments. • A rule of thumb in the case of using aging kits is to never draw up more than 1 mL into the injection syringe. It’s better to give a low dose than to jeopardize the patient’s mortality. Better yet, if more bulk 99mTc is available, make a new kit.

Methods of Thin Layer Chromatography • The general TLC methods utilized are the Single Strip/Single Solvent and the Two Strip/Two Solvents methods which are outlined below. • The newer radiopharmaceutical agents may require additional procedures which are more involved than the simple TLC methods. • When determining the net activity or counts in a quality control procedure, the background activity or counts should be subtracted in order to determine the net counts.

Single Strip/Single Solvent Method • Materials required • The solvent typically used is 0.9% NaCl. • The TLC paper to be used is Gelman ITLC-SG. (Instant Thin Layer Chromatography Silica Gel Paper) • Methods • Withdraw a small aliquot of the prepared Tc-99m radiopharmaceutical kit into a 1 mL syringe using a 27 gauge needle. • Prepare a clean empty vial with an opening large enough to hold the paper strip so that there is minimal contact between the strip and the sides of the vial. • Place approximately 1–2 mL of 0.9% NaCl into the vial or enough solvent to measure 2 to 3 mm in height. • Cut an appropriate size strip of chromatography paper to fit into the opening of the vial, whose length should measure 5–8 cm. • With a pencil, mark a line onto one side of the strip. This mark is the position at which the radiopharmaceutical will be spotted (origin). The line should be clearly above the level of the solvent. • While holding the syringe vertically, place 1 drop of the radiopharmaceutical agent at the level of the pencil mark. • Using tweezers, gently place the strip into the vial so as not to have it splash or disturb the solvent. • Allow the solvent to migrate up the strip till it migrates 80% up the strip. This is called the solvent front. • Cut the strip 50% of the distance between the origin and the solvent front. • Count the activity at the origin (O) and the solvent front (SF) to determine the total activity in µCi or counts on each portion. • To determine the radiochemical purity: % Purity =

Activity at O × 100% Activity at SF + O

• This procedure separates the free pertechnetate from bound Tc-99m particles and the reduced/hydrolysed Tc-99m (TcO2).

Two Strip/Two Solvent Method • Materials • The solvents typically used are 0.9% NaCl and an organic solvent (Methyl Ethyl Ketone [MEK] or Acetone). • The TLC paper used is typically ITLC-SG paper. 376

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 377

Quick Reference B — Radiopharmaceuticals

• Methods • Withdraw a small aliquot of the Tc-99m radiopharmaceutical into a 1 mL syringe with a 27 gauge needle attached. • Prepare two clean empty vials with an opening large enough to hold the paper strip so that the strips do not touch the sides of the vial. • Place approximately 1 to 2 mL of 0.9% NaCl into one vial or enough solvent to measure 2 to 3 mm in height. • Place approximately 1 to 2 mL of an organic solvent (MEK) into the second vial or enough solvent to measure 2 to 3 mm in height. • Cut two strips of chromatography paper into appropriate width to fit into the opening of the vials and which is 5–8 cm in length. • With a pencil, mark a line on one side of each of the strips. This mark is the position at which the radiopharmaceutical will be spotted (origin). The line should be high enough on the strip so that the radiopharmaceutical spot will not be below the level of the solvent. • While holding the syringe vertically, place 1 drop of the radiopharmaceutical agent on both strips at the level of the pencil mark. • Using tweezers, gently, place the strips into the vials so as not to have it splash or disturb the solvent. • Allow the solvent to migrate up the strip till it migrates 80% up the strip. This is called the solvent front (SF). • To determine the percent free pertechnetate: • remove the strip from the organic solvent gently. • cut the strip 50% of the distance between the origin and the solvent front. • count the activity on the origin (O) and the solvent front (SF) to determine the total activity in µCi or counts on each portion. % Free =

Activity at SF × 100% Activity at SF + O

• To determine the percent reduced/hydrolysed Tc-99m (%Red/Hyd) or the insoluble Tc-99m forms • gently, remove the strip from the 0.9% NaCl solvent. • cut the strip 50% of the distance between the origin and the solvent front. • count the activity at the origin (O) and the solvent front (SF) to determine the total activity in µCi or counts on each portion. % Red/Hyd =

Activity at O × 100% % Activity at SF + O

• Calculate the percent radiochemical purity: % Radiochemical purity = 100% − (%Free + %Red/Hyd)

Radiochemical Purity • The radiochemical purity must be within the USP and manufacturer’s limits. • Do not inject a patient with a radiopharmaceutical agent which has a low radiochemical purity. • Low radiochemical purities may be due to: • Poor reagent kit. • Reconstitution problems. • Improper techniques in the quality control procedure. • Improper techniques have been reported to result in a low radiochemical purity: • Grease on hands while preparing the paper. • The strip touching the side of the vial. • Incorrect solvent used. • Fresh solvents not used—contaminated with other Tc-99m radiopharmaceuticals 377

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 378

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• • • • • •

Contaminated instruments i.e., scissors, tweezers, paper. Too large a spot or too large a solvent volume which contaminates the solvent system. Solvent evaporates and does not flow to the top or a solvent that migrates past the top of the strip. Reoxidation of the Tc-99m radiopharmaceutical on the chromatography paper. Moving the vial while developing the strip causing abrupt movement of the solvent. In a mixed solvent system, the solvent systems may have been poorly mixed or one solvent may have evaporated at a faster rate than the other which changes the concentration of the two solvents. • The chromatography strips may absorb moisture, therefore, the age and condition of the chromatography strips should be carefully monitored. • Spotting the strip below the solvent level. • Counting the chromatography strips in an inappropriate counting devise. • If a low radiochemical purity is obtained: • Review your techniques and redo the chromatography being careful to follow the procedures exactly. • If the radiochemical purity is still low, discard the kit and reconstitute another kit. • If several vials from the same lot number have poor tags, contact the manufacturer. Methods of chromatography are taken from Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006.

378

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 379

Quick Reference B — Radiopharmaceuticals

PEDIATRIC DOSING IN NUCLEAR MEDICINE Standard Pediatric Dose (Clark’s Rule) (Patient weight in kg × standard adult dose) ÷ 70 kg = pediatric dose. (Patient weight in lb × standard adult dose) ÷ 154 lb = pediatric dose. The standard adult dose assumes a 70 kg or 154 lb person ± 20% (56–84 kg, 123–185 lb).

Dose by body surface area (modified Talbot’s nomogram) kg

lb

Surface Area (m2)

% of Adult Dose

1

2.2

0.09

5

2

4.4

0.15

8

3

6.6

0.20

11

4

8.8

0.24

13

5

11.0

0.28

16

6

13.2

0.32

18

7

15.4

0.35

20

8

17.6

0.39

22

9

19.8

0.42

24

10

22.0

0.46

26

11

24.2

0.49

27

12

26.4

0.52

29

13

28.6

0.55

31

14

30.8

0.58

32

15

33.0

0.61

34

20

44.0

0.74

42

25

55.0

0.87

49

30

66.0

0.98

55

35

77.0

1.10

62

40

88.0

1.20

68

45

99.0

1.31

73

50

110.0

1.41

79

55

121.0

1.50

84

60

132.0

1.60

90

65

143.0

1.69

95

70

154.0

1.78

100

body surface area (BSA) = (body weight)0.7/11 For 70 kg adult, BSA = 1.779 m2 % of adult dose = BSA/1.779 × 100 (from the Mayo Clinic Manual of Nuclear Medicine) Also: See below. 379

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 380

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Note A child’s physiology and metabolism is not a miniature adult’s; uptake of radiopharmaceuticals vary greatly. For instance, a child’s thyroid is perhaps 50% smaller than an adult’s but has the same uptake. Bone uptake in children is ∼80% compared with that of adults at ∼40%. The weight of a 1-year-old child’s brain may be 80% of the adult weight, whole body ∼15%, and liver ∼25%. Many methods to calculate proper doses have been considered. As well as the standard weight method and body surface area methods above, others have considered the mass of target organs.

PET PEDIATRIC DOSE CHART (SUPPLIED BY SHARED PET IMAGING OF FLORIDA, EXTRAPOLATED) Wt. in kg

380

Wt. in lbs

% Adult dose

2

4.4

9

3

6.6

11.5

4

8.8

14

5

11

16.5

6

13.2

19

7

15.4

21

8

17.6

23

9

19.8

25

10

22

27

15

33

36

20

44

48

25

55

55

30

66

62

35

77

69

40

88

75

45

99

81

50

110

87

55

121

91

60

132

95

65

143

98

70

154

100

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 381

Quick Reference B — Radiopharmaceuticals

WEIGHT/METABOLIC RULE Pediatric dose =

( Mp)2 3 × adult dose ( Ma)2 3

where Mp = mass of pediatric organ, and Ma = mass of adult organ Webster’s rule (age/mass approximation) Pediatric dose =

x +1 × adult dose x+7

where x is the age of the child

ADJUSTED WEBSTER’S OR WELLMAN <5 years old: 5–10 years old: 10–15 years old: >15 years old:

25% of adult dose 50% of adult dose 75% of adult dose adult dose

YOUNG’S RULE Pediatric dose =

age (in yrs) × adult dose age + 12

MODIFIED WRIGHT’S FORMULA (OLD FORMULA AND RADIOTRACERS BUT IT IS BASED IN KILOGRAMS)

Child Dose Study

Radiotracer

Amount

Bone

99m

0.240 mCi/kg

Bone marrow

99m

Cardiac

99m

Cerebral

Tc-PP

Minimum/Patient

Tc-SC

0.100 mCi/kg

Tc-O4

−

0.240 mCi/kg

99m

Tc-O4−

0.240 mCi/kg

2 mCi

Cerebral

99m

Tc-DTPA

0.280 mCi/kg

2 mCi

Cisternogram

131

I-IHSA-H

1.5 µCi/kg

25 µCi/max = 100 µCi

Cisternogram

111

In-DTPA

0.030 mCi/kg

GI bleed

99m

Tc-O4−

0.240 mCi/kg

2 mCi

Hepatic

99m

0.050 mCi/kg

200 µCi

Pulmonary

99m

Tc-MS

0.030 mCi/kg

Pulmonary

133

Xe

0.147 mCi/kg

Renal

131

I-OIH

1.5 µCi/kg per kidney:

Tc-SC

25 µCi/max = 200 µCi (continued) 381

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 382

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Study

Radiotracer

Amount

Renal

99m

Tc-DTPA

0.070 mCi/kg per kidney

Thyroid

123

I-sodium iodide

1.5 µCi/kg

Thyroid

99m

Tc-O4−

0.030 mCi/kg

Spleen

99m

0.050 mCi/kg

child dose +

Tc-SC

Minimum/Patient

0.5 mCi/max = 2.0 mCi

(child weight in kg´standard adullt dose) adult weight in kg*

*63.63 kg for hepatic study; 58.18 kg for cerebral study; 72.72 kg for all other studies

As indicated in the above table, there are minimum doses to consider (to ensure enough counts [photon flux] for a diagnostic examination). Here is a more current list based in pounds from the Children’s Memorial Hospital in Chicago: Procedure

Radiotracer

Dose

Minimum

Maximum

Angiogram

99m

200 µCi/lb

2.5 mCi

15 mCi

Bone scan

99m

300 µCi/lb

5 mCi

20 mCi

LTD bone scan

99m

200 µCi/lb

5 mCi

20 mCi

Brain scan

99m

Tc-DTPA

400 µCi/lb

10 mCi

20 mCi

Cystogram

99m

Tc-O4−

1 mCi

1 mCi

1 mCi

Dacryoscintigraphy

99m

Tc-O4−

200 µCi/drop

400 µCi

800 µCi

Gallium scan

67

3–10 mCi

3 mCi

10 mCi

GE reflux

99m

Tc-SC

150 µCi

150 µCi

150 µCi

GI bleed

99m

Tc-SC

5 mCi

1 mCi

5 mCi

HIDA

99m

1.0–8.0 mCi

1 mCi

8 mCi

Liver scan

99m

25 µCi/lb

500 µCi

2 mCi

Lung scan

99m

25 µCi/lb

500 µCi

2 mCi

Meckel’s

99m

Tc-O4

100 µCi/lb

2.5 mCi

15 mCi

mIBG scan

131

I-mIBG

500 µCi

2 mCi

MUGA

99m

Tc-RBCs

350 µCi/lb

10 mCi

20 mCi

Plasma volume

123

I-HSA

3 µCi

1 µCi

3 µCi

Renal scan

99m

50 µCi/lb

2.5 mCi

15 mCi

99m

Tc-MAG3

22 µCi/lb

1 mCi

5 mCi

Renogram

131

I-IOH

100 µCi

50 µCi

100 µCi

Subarachnoid scan

111

In-DTPA

300 µCi

100 µCi

300 µCi

Testicular scan

99m

Tc-O4−

200 µCi/lb

5.0 mCi

15 mCi

Thyroid uptake

123

I-sodium iodide

100 µCi

2 µCi

100 µCi

Thyroid scan

99m

Tc-O4−

1–2 mCi

1 mCi

2 mCi

382

Tc-O4− Tc-MDP/HDP Tc-MDP/HDP

Ga-citrate

Tc-disofenin Tc-SC Tc-MAA −

Tc-DTPA

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 383

Quick Reference B — Radiopharmaceuticals

And as more proof that printed data vary from source to source, the following scans and minimum doses are taken from the Mayo Clinic Manual of Nuclear Medicine: Procedure

Radiopharmaceutical

Minimum Dose

Brain SPECT

99m

Tc-HMPAO or ECD

2 mCi (74 MBq)

CSF imaging (cisternography/ ventriculography)

111

In-DTPA

100 µCi (3.7 MBq)

Recurrent brain tumor

201

Tl-thallous chloride

50 µCi (1.85 MBq)

Brain death

99m

2 mCi (74 MBq)

Cardiac left to right shunt

99m

2 mCi (74 MBq)

Angiography

99m

5 mCi (185 MBq)

Perfusion study

99m

Tc-sestamibi/tetrafosmin

3 mCi (111 MBq)

201

Tl-thallous chloride

300 µCi (11.1 MBq)

Central nervous system

Tc-HMPAO

Cardiovascular system

MI study

Tc-DTPA Tc-RBCs

99m

Tc-pyp

4 mCi (148 MBq)

131

I-sodium iodide

20 µCi (0.740 MBq)

123

I-sodium iodide

30 µCi (1.11 MBq)

Endocrine system Substernal thyroid

Thyroid scan

99m

131

−

Tc-O4

1 mCi (37 MBq)

131

I-sodium iodide

2 µCi (0.074 MBq)

131

131

I-sodium iodide

150 µCi (5.55 MBq)

131

131

I-sodium iodide

150 µCi (5.55 MBq)

I Uptake I Neck scan I Total body scan

Parathyroid scan

Adrenal medulla scan

Adrenal cortex scan

99m

−

Tc-O4

250 µCi (9.25 MBq)

99m

Tc-sestamibi/tetrafosmin

3 mCi (111 MBq)

131

I-mIBG

500 µCi (18.5 MBq)

123

I-mIBG

2 mCi (74 MBq)

131

I-NP-59

500 µCi (18.5 MBq)

Tc-O4−

Gastrointestinal system Salivary gland scan

99m

1 mCi (37 MBq)

Esophageal study

99m

150 µCi (5.55 MBq)

GE reflux

99m

500 µCi (18.5 MBq)

Gastric empty

99m

Tc-sulfur colloid

500 µCi (18.5 MBq)

111

In-DTPA

250 µCi (9.25 MBq)

GI bleed

Tc-sulfur colloid Tc-sulfur colloid

99m

Tc-RBCs

Meckel’s

99m

Protein-losing enteropathy

99m

−

Tc-O4

Tc-human serum albumin

2 mCi (74 MBq) 2 mCi (74 MBq) 2 mCi (74 MBq) (continued) 383

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 384

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Procedure

Radiopharmaceutical

Minimum Dose

Liver/spleen scan

99m

500 µCi (18.5 MBq)

Liver SPECT

99m

2 mCi (74 MBq)

HIDA

99m

1 mCi (37 MBq)

99m

1 mCi (37 MBq)

99m

2.5 mCi (9.25 MBq)

Renal cortical scan

99m

500 µCi (18.5 MBq)

Cystography

99m

Tc-DTPA Age 0–1

1 mCi (37 MBq)

Age > 1

2 mCi (74 MBq)

Tc-sulfur colloid Tc-RBCs Tc-disofenin

Genitourinary system Renal scan

Tc-MAG3 Tc-DTPA Tc-DMSA

Residual urine study

99m

Testicular scan

99m

Tc-DTPA −

500 µCi (18.5 MBq)

Tc-O4

2 mCi (74 MBq)

In-WBCs

50 µCi (1.85 MBq)

Infection/bone WBC scan

111

99m

1 mCi (37 MBq)

Gallium scan

67

Tc-HMPAO

1 mCi (37 MBq)

Bone marrow scan

99m

500 µCi (18.5 MBq)

Bone scan

99m

Tc-MDP

4 mCi (148 MBq)

Joint scan

99m

Tc-O4−

1 mCi (37 MBq)

Lung ventilation

133

Xe gas

1 mCi (37 MBq)

aerosol

99m

100 µCi (3.7 MBq)

pertechnegas

99m

none established

Lung perfusion

99m

500 µCi (18.5 MBq)

Gallium scan

67

1 mCi (37 MBq)

Oncoscint®

111

Ga-gallium citrate Tc-sulfur colloid

Respiratory system

Tc-DTPA Tc-pertechnegas Tc-MAA

Tumor imaging Ga-gallium citrate In-Oncoscint®

none established

Tc-O4−

Special imaging Dacryoscintigraphy

99m

200 µCi (7.4 MBq)/eye

LeVeen shunt

99m

100 µCi (3.7 MBq)

Tc-MAA (into shunt tubing) (intraperitoneal)

Note Pediatric Breast Feeding delays: 99mTc-based products: suggestion is 24 to 36 hours. 67Ga-gallium citrate products: suggestion is 72 hours. Sodium iodide products: suggestion is up to 3 weeks. 384

1 mCi (37 MBq)

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 385

Quick Reference B — Radiopharmaceuticals

Ablations with sodium iodide: suggestion is permanent discontinuation of breast feeding. Gadolinium from MRI: not radioactive, pump and discard milk after procedure, resume feeding. From keepkids healthy.com

Body Surface Area Calculations Mosteller: (recommended) BSA (m2) = ([height in cm × weight in kg]/3600)1/2 or: BSA (m2) = ([height in inches × weight in pounds]/3131)1/2 DuBois and variation: BSA (m2) = 0.20247 × height(m)0.725 × weight(kg)0.425 BSA (m2) = 0.007184 × height(cm)0.725 × weight(kg)0.425 Haycock: BSA (m2) = 0.024265 × height(cm)0.42246 × weight(kg)0.51456 Gehan and George: BSA (m2) = 0.0235 × height(cm)0.42246 × weight(kg)0.51456 Boyd: BSA (m2) = 0.0003207 × height(cm)0.3 × weight(g)(0.7285 − [0.0188 × LOG(g)])

SUGGESTED READINGS Bernier, DR, Christian PE, Langan JK, eds. Nuclear Medicine: Technology and Techniques. 3rd ed. St. Louis: Mosby, 1994. O’Connor, MK. The Mayo Clinic Manual of Nuclear Medicine. New York: Churchill Livingstone, 1996. Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vols. 1 and 2. New York: Churchill Livingstone, 1994. Shared PET Imaging of Florida, Shared PET Imaging, Canton, OH. Administrative Policy & Procedure Manual. Wilson, MA. Textbook of Nuclear Medicine. Philadelphia: Lippincott-Raven, 1998. www.halls.md/body-surface-area/refs.htm

385

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 386

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

RADIOACTIVE ISOTOPES (highest % of significant energies)

Isotope Ac-225

Ac-227

Ac-228

Ag-106m

Name Actinium

Actinium

Actinium

Silver

T1/2 10.00 d

21.77 y

✓ = emissions but no significant % or energies

a MeV

%

5.731

10

5.792

18

5.829

52

✓

6.130 h

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

Silver

2.370 min

Ag-108m

Silver

127.0 y

%

0.12

22

0.0344

0.0087

35

0.0437

0.0111

54

1.168

0.3860

32

0.338

11

1.741

0.6110

12

0.911

28

0.969

17

0.451

28

0.512

88

0.616

22

0.717

29

1.05

30

✓

8.460 d

Ag-108

g MeV

1.650

0.6290

96

✓

✓ 0.434

90

0.614

90

0.723

91

0.022

19

Ag-109m

Silver

39.60 s

Ag-110

Silver

24.57 s

2.893

1.199

95

✓

Ag-110m

Silver

249.9 d

0.0839

0.0218

67

0.658

94

0.5307

0.1656

31

0.764

22

0.885

73

0.937

34

1.38

24

Ag-111

Silver

7.460 d

Al-26

Aluminum

7.20 × 105 y

Al-28

Aluminum

2.240 min

Am-241

Americium

432.2 y

Am-242

Am-242m 386

Americium

Americium

1.028

92

✓ 1.174

2.864 5.486

16.02 h

152.0

0.3604

✓

1.242

100

85

0.6190

0.1848

42

0.6612

0.1990

41

0.5439

82

0.511 166 1.81

99

1.78

100

0.014

43

0.060

36

0.015

20

0.015

30

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 387

Quick Reference B — Radiopharmaceuticals

Isotope Am-243

Am-244

Name Americium

Americium

T1/2 7.380 × 10 y 3

a MeV

%

5.275

88

10.10 h

b2 Max MeV

0.3870

b2 Ave MeV

0.1096

%

b1 Max MeV

b1 Ave MeV

%

100

g MeV

%

0.014

39

0.075

66

0.015 117 0.746

67

0.900

28

Am-245

Americium

122.4 min

0.8961

0.2810

77

✓

Am-246

Americium

25.00 min

1.221

0.4000

38

0.015

39

0.799

25

1.08

28

0.003

9

1.29

99

Ar-37

Argon

35.02 d

Ar-39

Argon

269.0 y

0.5650

0.2188

100

Ar-41

Argon

1.827 h

1.198

0.4593

99

As-72

Arsenic

26.00 h

As-73

Arsenic

80.30 d

As-74

Arsenic

17.77 d

As-76

Arsenic

2.495

1.353

26.32 h

0.5309

19

2.410

0.9963

35

2.969

1.267

51

0.6904

0.2318

97

0.9445

1.115

0.4080

65

27

0.511 176 0.834

80

0.010

90

0.511

59

0.596

60

0.559

45

As-77

Arsenic

38.80 h

At-211

Astatine

7.214 h

5.867

42

0.079

At-217

Astatine

0.032 s

7.066

100

✓

Au-194

Gold

39.50 h

Au-195

Gold

183.0 d

Au-195m

Gold

30.60 s

Au-196

Gold

6.183 d

✓

✓

✓

21

0.328

64

0.065

29

0.067

50

0.076

22

0.262

68

0.065

22

0.067

38

0.333

23

0.355

88

Au-198

Gold

2.696 d

0.9607

0.3146

99

0.412

96

Au-199

Gold

3.139 d

0.2448

0.0673

21

0.158

37

0.2946

0.0824

66 0.123

29

0.216

20

0.496

47

Ba-131

Barium

11.80 d

387

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 388

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope Ba-133

Name Barium

T1/2

a MeV

%

b2 Max MeV

b2 Ave MeV

%

10.50 y

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.031

97

0.035

23

0.081

33

0.356

61

Ba-133m

Barium

38.90 h

0.032

28

Ba-135m

Barium

28.70 h

0.032

28

Ba-137m

Barium

2.552 min

0.662

90

Ba-139

Barium

83.10 min

0.166

17

0.537

26

Ba-140

Ba-141

Barium

Barium

12.79 d

18.27 min

Ba-142

Barium

10.70 min

Be-7

Beryllium

53.44 d

Be-10

Beryllium

1.6 × 106 y

Bi-206

Bismuth

6.24 d

Bi-207

Bi-208

Bi-210 388

Bismuth

Bismuth

Bismuth

2.140

0.8370

22

2.306

0.9120

78

0.4539

0.1360

26

0.9912

0.3400

37

1.005

0.3570

22

2.382

0.9470

25

0.190

49

2.563

1.029

19

0.277

25

0.304

27

0.255

18

0.478

10

0.011

49

0.073

32

0.075

54

0.085

24

0.344

23

0.516

41

0.538

31

0.803

99

0.881

66

1.72

32

0.011

36

0.073

22

0.075

37

0.570

98

1.06

75

0.011

31

0.075

21

2.62

100

0.9960

0.5558

0.3400

0.2025

40

100

33.40 y

368.0 × 103 y

5.013 d

1.161

0.3890

100

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 389

Quick Reference B — Radiopharmaceuticals

Isotope Bi-211

Name Bismuth

T1/2 2.130 min

a MeV

%

b2 Max MeV

6.279

16

✓

6.623

84 25

Bi-212

Bismuth

60.55 min

6.051

Bi-213

Bismuth

45.65 min

✓

Bi-214

Bismuth

19.90 min

b2 Ave MeV

%

0.3190

32

0.440

28

1.420

0.4910

64

1.506

0.5250

18

1.540

0.5390

18

3.270

1.269

17

0.609

46

0.989

45

1.03

35

0.239

23

0.521

22

Bk-250

Berkelium

3.222 h

0.7483

0.2280

83

Br-80

Bromine

17.40 min

Br-80m

Bromine

4.420 h

Br-82

Bromine

35.30 h

13

0.9796

100

57.04 h

0.351

12

0.0330

Bromine

%

0.727

0.1264

Br-77

g MeV

48

320.0 d

57.0 min

%

0.8316

Berkelium

Berkelium

b1 Ave MeV

2.246

Bk-249

Bk-251

b1 Max MeV

1.120

0.3611

100 ✓

2.006

0.4443

0.8050

0.1378

85

✓

✓

98

0.037

39

0.554

71

0.619

43

0.698

28

0.776

83

0.828

24

1.04

27

1.32

27

Br-83

Bromine

2.390 h

0.9184

0.3230

99

✓

Br-84

Bromine

31.80 min

4.673

2.072

32

0.882

Br-85

Bromine

172.0 s

2.495

1.030

96

✓

C-11

Carbon

20.48 min

C-14

Carbon

5.730 × 10 y

0.1565

0.0495

100

C-15

Carbon

2.449 s

4.510

2.000

68

9.820

4.354

32

0.9601 3

0.3856

100

42

0.511 200

✓

Ca-41

Calcium

103.0 × 103 y

Ca-45

Calcium

162.7 d

0.2569

0.0772

100

✓

Ca-47

Calcium

4.536 d

0.6905

0.2409

82

1.30

75

Ca-49

Calcium

8.719 min

2.184

0.9086

92

3.08

92

Cd-109

Cadmium

464.0 d

0.022

35

Cd-111m

Cadmium

48.70 min

0.151

31

0.245

94

0.003

12

389

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 390

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Name

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

Cd-113

Cadmium

9.3 × 10 y

0.3220

0.0933

100

Cd-113 m

Cadmium

13.70 y

0.5857

0.1854

100

Cd-115

Cadmium

53.46 h

0.5834

0.1846

35

1.111

0.3944

60

15

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.528

29

Cd-115m

Cadmium

44.60 d

1.621

0.6150

98

✓

Cd-117

Cadmium

2.490 h

0.6361

0.2040

32

0.273

28

2.213

0.8820

21

0.5694

0.1790

26

1.07

23

0.6671

0.2160

47

2.00

26

0.166

80

0.145

48

Cd-117 m

Cadmium

3.360 h

Ce-139

Cerium

137.7 d

Ce-141

Cerium

32.50 d

Ce-143

Cerium

33.0 h

0.4346

0.1296

71

0.5800

0.1807

30

1.104

0.3846

48

0.036

32

1.398

0.5075

38

0.293

42

0.3182

0.0911

77

✓

Ce-144

Cerium

284.3 d

Cf-248

Californium

333.5 d

6.260

83

✓

Cf-249

Californium

350.6 y

5.814

84

0.388

Cf-250

Californium

13.08 y

6.031

83

✓

Cf-251

Californium

900.0 y

5.677

35

0.015

60

5.852

27

0.109

25

82

✓

66

Cf-252

Californium

2.639 y

6.118

Cf-253

Californium

17.81 d

✓

Cf-254

Californium

60.50 d

Cl-36

Chlorine

301.0 × 10 y

0.7096

0.2513

99

✓

Cl-38

Chlorine

37.21 min

1.107

0.4203

33

1.64

33

4.917

2.244

56

2.17

44

Cm-242

Curium

0.2870

0.0790

100

✓

✓

3

163.2 d

✓

6.070

26

6.113

74

✓

Cm-243

Curium

28.50 y

5.785

73

0.104

Cm-244

Curium

18.11 y

5.763

24

✓

5.805

76

Curium

8.50 × 10 y

5.362

93

Curium

4.750 × 10 y

5.343

21

5.386

79

✓

Cm-245 Cm-246

3

3

0.104

Curium

15.60 × 106 y

4.868

71

0.402

Cm-248

Curium

339.0 × 10 y

5.079

75

✓

Cm-249

Curium

64.15 min

Cm-247

390

3

0.8912

0.2790

96

✓

23

22

72

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 391

Quick Reference B — Radiopharmaceuticals

Isotope

Name

T1/2

Cm-250

Curium

6.90 × 10 y

Co-56

Cobalt

78.76 d

3

a MeV

%

b2 Max MeV

b2 Ave MeV

%

5.190

25

0.0370

0.0090

14

b1 Max MeV

b1 Ave MeV

%

g MeV

%

1.461

0.6319

19

0.511

40

0.847 100

Co-57

Cobalt

270.9 d

Co-58

Cobalt

70.80 d

Co-58m

Cobalt

9.150 h

Co-60

Cobalt

5.271 y

Co-60m

Cobalt

10.47 min

Co-61

Cobalt

1.650 h

Cr-49

Chromium

42.09 min

0.4750

0.2012

15

1.24

67

0.122

86

0.511

30

0.811

99

✓ 0.3179

0.0958

100

✓ 1.255

1.17

100

1.33

100

✓ 0.4744

96

0.067

85

1.453

0.6255

46

0.091

53

1.515

0.6537

35

0.153

30

0.511 184 Cr-51

Chromium

27.70 d

Cs-126

Cesium

1.640 min

Cs-129

Cesium

✓ 3.419

1.560

24

0.389

3.808

1.740

51

0.511 164

32.06 h

38

0.372

31

0.412

23

0.030

60

0.668

97

Cs-131

Cesium

9.688 d

Cs-132

Cesium

6.475 d

✓

Cs-134

Cesium

2.062 y

0.0885

0.0231

27

0.605

98

0.6578

0.2101

70

0.796

85

✓

Cs-134 m

Cesium

2.90 h

Cs-135

Cesium

2.30 × 106 y

0.2050

0.0563

100

Cs-136

Cesium

13.16 d

0.3410

0.0988

95

✓

0.341

49

0.819 100

Cs-137

Cesium

30.17 y

0.5115

0.1568

95

Cs-138

Cesium

32.20 min

2.884

1.179

44

4.204

0.463

31

1.01

30

1.44

76

Cesium

9.40 min

Cu-61

Copper

3.408 h

1.216

0.5242

51

0.511 123

Cu-62

Copper

9.740 min

2.927

1.316

98

0.511 196

Cu-64

Copper

12.70 h

0.6529

0.2781

18

0.511

0.1902

84

80

Cs-139

0.5782

1.794

1.05

37

✓

36 391

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 392

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope Cu-67

Name Copper

T1/2

a MeV

%

61.88 d

b2 Max MeV

b2 Ave MeV

%

0.3904

0.1210

57

0.4817

0.1540

22

0.5750

0.1890

20

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.185

49

0.326

94

Dy-157

Dysprosium

8.060 h

Dy-165

Dysprosium

2.334 h

1.285

0.4531

83

✓

Dy-166

Dysprosium

81.60 h

0.4015

0.1175

92

0.047

Er-169

Erbium

9.40 d

0.3418

0.0979

45

✓

0.3502

0.1006

55

1.066

0.3622

94

Er-171

Erbium

7.520 h

0.112

21

0.296

29

0.308

64

Es-253

Einsteinium

20.47 d

6.633

90

✓

Es-254

Einsteinium

275.7 d

6.429

93

✓

Es-254m

Einsteinium

39.30 h

✓

Es-255

Einsteinium

39.80 d

Eu-152

Europium

13.60 y

✓

37

0.4373

0.1247

19

0.649

34

0.4772

0.1373

67

0.694

29

0.2800

0.0767

92

✓

✓

0.122

28

0.344

27

1.41

21

Eu-152m

Europium

9.320 h

1.865

0.7041

67

✓

Eu-154

Europium

8.80 y

0.2474

0.0688

27

0.123

41

0.5694

0.1757

37

1.28

36

0.1407

0.0374

46

0.087

31

0.1595

0.0428

26

0.105

21

0.4871

0.1470

32

✓

2.453

0.9660

27

Eu-155

Eu-156

Europium

Europium

4.960 y

15.19 d

F-18

Fluorine

109.7 min

0.6335

0.2498

97

0.511 194

Fe-52

Iron

8.275 h

0.8036

0.3400

56

0.169

97

0.511 112 Fe-55

Iron

Fe-59

2.70 y

✓

44.63 d

0.2734

0.0810

45

1.10

57

0.4658

0.1492

53

1.29

43

Fm-254

Fermium

3.240 h

7.189

85

✓

Fm-255

Fermium

20.07 h

7.022

93

✓

Fm-256

Fermium

157.6 min

✓

Fr-221

Francium

2.80 min

6.340

83

✓

Fr-223

Francium

21.80 min

392

1.098

0.3611

57

0.050

32

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 393

Quick Reference B — Radiopharmaceuticals

Isotope Ga-66

Ga-67

Name Gallium

Gallium

a MeV

T1/2

68.0 min

Ga-72

Gallium

14.10 h

Gadolinium

1.1 × 1014 y

Gd-153

Gadolinium

241.6 d

Gadolinium

%

b1 Max MeV

b1 Ave MeV

%

g MeV

4.153

1.904

49

0.511 115

1.899

Gd-152

Gd-162

b2 Ave MeV

3.261 d

Gallium

Gadolinium

b2 Max MeV

9.40 h

Ga-68

Gd-159

%

18.56 h

9.70 m

2.150

0.8630

88

%

1.04

39

2.75

24

0.093

36

0.185

20

0.300

16

0.511 178

0.6666

0.2235

22

0.630

24

0.9561

0.3418

28

0.834

96

2.20

26

0.097

31

0.103

22

100

0.9167

0.3057

21

0.9747

0.3286

70

0.9584

0.3200

100

✓

0.403

46

0.411

53

Ge-68

Germanium

288.0 d

✓

Ge-71

Germanium

11.80 d

✓

Ge-77

Germanium

11.30 h

1.512

0.5835

19

0.211

31

2.070

0.8389

21

0.216

28

2.226

0.9117

17

0.264

53

0.416

22

0.133

42

0.482

83

H-3

Hydrogen

12.28 y

0.0186

0.0057

100

Hf-181

Hafnium

42.39 d

0.4072

0.1187

93

Hg-197

Mercury

64.14 h

✓

Hg-197m

Mercury

23.80 h

0.134

34

Hg-203

Mercury

46.60 d

0.2122

0.0577

100

0.279

77

Ho-166

Holmium

26.80 h

1.774

0.6511

48

✓

1.854

0.6938

51

Holmium

1.20 × 10 y

0.0724

0.0187

73

Ho-166m

I-122

Iodine

3

3.620 min

3.118

1.414

63

0.184

73

0.281

30

0.712

54

0.810

57

0.511 152 0.564

21 393

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 394

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Name

I-123

Iodine

13.13 h

I-124

Iodine

4.180 d

I-125

I-126

I-128

Iodine

Iodine

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

✓

60.14 d

24.99 min

I-129

Iodine

I-130

Iodine

%

g MeV

%

0.159

83

0.511

47

0.603

59

0.027 112

12.93 d

Iodine

b1 Ave MeV

0.8624

0.2897

27

✓

0.031

25

0.389

29

0.666

40

2.127

0.8357

80

✓

15.70 × 10 y

0.1524

0.0409

100

✓

12.36 h

0.6219

0.1970

47

0.418

34

1.034

0.3610

48

0.536

99

0.669

96

0.740

82

6

I-131

Iodine

8.040 d

0.6063

0.1916

89

0.365

81

I-132

Iodine

2.30 h

1.185

0.4220

19

0.668

99

2.140

0.8410

17

0.773

76

I-133

Iodine

20.80 h

1.230

0.4410

84

0.530

86

I-134

Iodine

52.60 min

1.283

0.4600

33

0.847

95

0.884

65

I-135

I-136

In-111

Iodine

Iodine

Indium

6.610 h

83.0 s

Indium

1.658 h

In-114

Indium

71.90 s

In-114m

Indium

49.51 d

In-115

Indium

4.6 × 1015 y

In-115m

Indium

4.360 h

In-116m

Indium

54.15 min

In-117m 394

Indium

Indium

0.3590

22

1.13

23

1.451

0.5350

24

1.26

29

4.366

1.880

36

1.31

69

5.687

2.500

30

1.32

26

0.171

90

0.245

94

0.392

65

2.830 d

In-113m

In-117

1.033

43.80 min

116.5 min

1.984

0.7769

99

✓ ✓

0.4950

0.1520

100

✓

0.336

47

0.8711

0.2950

33

0.417

28

1.009

0.3510

51

1.10

55

1.29

89

0.159

86

0.553

99

0.315

19

0.7435

1.770

0.2450

0.6800

100

35

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 395

Quick Reference B — Radiopharmaceuticals

Isotope Ir-190

Name Iridium

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

11.78 d

b1 Ave MeV

%

g MeV

%

0.187

50

0.371

22

0.407

23

0.519

32

0.558

29

0.569

27

0.605

38

Ir-190m1

Iridium

1.20 h

✓

Ir-190m2

Iridium

3.20 h

0.063

35

Ir-192

Iridium

74.02 d

0.5361

0.1612

41

0.296

29

0.6724

0.2089

48

0.309

30

0.317

83

0.468

48

Ir-193m

Iridium

11.90 d

Ir-194

Iridium

19.15 h

2.251

0.8475

85

✓

Ir-194m

Iridium

171.0 d

0.2525

0.0697

100

0.329

93

0.339

55

0.391

35

0.483

97

0.562

70

0.601

62

0.689

59

✓

K-40

Potassium

1.277 × 109 y

1.312

0.5085

89

✓

K-42

Potassium

12.36 h

3.521

1.564

82

1.53

18

K-43

Potassium

22.60 h

0.8267

0.2980

92

0.373

87

0.618

81

0.511

14

Kr-79

Krypton

35.04 h

Kr-81

Krypton

210.0 × 10 y

✓

Kr-83m

Krypton

1.830 h

✓

Kr-85

Krypton

10.72 y

0.6870

0.2514

100

✓

Kr-85m

Krypton

4.480 h

0.8407

0.2904

79

0.151

75

Kr-87

Krypton

76.30 min

3.486

1.502

47

0.403

50

3.889

1.695

30

0.5209

0.1560

67

0.196

26

2.39

35

0.221

20

Kr-88

Kr-89

Krypton

Krypton

✓ 3

2.480 h

3.160 min

4.970

2.210

23

395

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 396

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope Kr-90

La-140

Name Krypton

Lanthanum

a MeV

T1/2 32.32 s

40.22 h

%

b2 Max MeV

b2 Ave MeV

%

2.610

1.086

4.390

1.935

b1 Max MeV

b1 Ave MeV

g MeV

%

62

0.122

32

29

0.540

30

1.12

37

%

1.348

0.4874

45

0.329

21

1.677

0.6295

21

0.487

46

0.816

24

1.60

96

La-141

Lanthanum

3.940 h

2.430

0.9670

97

La-142

Lanthanum

95.40 min

1.974

0.7610

20

2.119

0.8260

22

✓

Lu-177

Lutetium

6.710 d

0.4971

0.1489

79

✓

Lu-177m

Lutetium

160.1 d

0.1518

0.405

79

0.113

22

0.208

61

0.228

37

0.379

28

0.419

20

Mg-27

Mg-28

Mn-52

Mn-52m

Magnesium

Magnesium

Manganese

9.458 min

20.91 h

1.595

0.6457

29

0.844

72

1.765

0.7244

71

1.01

28

0.4589

0.1559

95

0.401

37

0.942

38

1.34

53

0.511

59

0.744

90

0.936

95

1.43

100

5.591 d

0.5753

Manganese

21.40 min

Mn-53

Manganese

3.70 × 10 y

Mn-54

Manganese

312.7 d

Mn-56

Manganese

2.578 h

2.633

0.2416

1.174

29

96

0.511 193 1.43

6

Mn-57

Manganese

1.470 min

Mo-91

Molybdenum

15.49 min

Mo-93

Molybdenum

3.50 × 103 y

Mo-99

Molybdenum

66.02 h

Mo-101 396

Molybdenum

14.61 min

98

✓ 0.835 100 1.038

0.3819

28

0.847

99

2.849

1.217

56

1.81

27

2.678

1.135

81

✓ 3.416

1.553

93

0.511 188 ✓

0.4360

0.1330

17

1.214

0.4427

83

0.740

13

0.7633

0.2560

21

0.192

19

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 397

Quick Reference B — Radiopharmaceuticals

Isotope

Name

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

N-13

Nitrogen

9.970 min

1.199

0.4918

100

N-16

Nitrogen

7.13 s

4.288

1.941

68

Na-22

Sodium

2.602 y

Na-24

Nb-90

Sodium

Niobium

b1 Max MeV

1.390

0.5539

%

6.13 0.2155

90

100

14.60 h

g MeV

%

0.511 200

0.5455

15.0 h

b1 Ave MeV

1.500

0.6622

53

69

0.511 180 1.28

100

1.37

100

2.75

100

0.141

69

0.511 106

Nb-91

Niobium

10.0 × 103 y

Nb-91m

Niobium

61.0 d

Niobium

36.0 × 10 y

Nb-92

✓

1.13

92

2.32

82

✓ ✓

6

0.561 100 0.935 100

Nb-92m

Niobium

10.15 d

Nb-93m

Niobium

14.60 y

Niobium

20.30 × 10 y

Nb-94

0.935

99

✓ 3

0.4715

0.1458

100

0.703 100 0.871 100

Nb-94m

Niobium

6.260 min

Nb-95

Niobium

35.06 d

0.1598

Nb-95m

Niobium

86.60 h

✓

Nb-96

Niobium

23.35 h

0.7486

✓ 0.0434

0.2406

96

0.236

25

0.460

28

0.569

56

0.778

97

0.850

21

1.09

49

1.20

20

0.658

98

0.743

98

72.10 min

Nb-97m

Niobium

60.0 s

Nd-147

Neodymium

10.98 d

0.8047

0.2640

81

0.091

28

Nd-149

Neodymium

1.730 h

1.151

0.4024

24

0.211

27

1.478

0.5398

26 0.158

99

0.270

37

0.480

37

0.750

50

0.812

86

6.10 d

98

0.766 100

Niobium

Nickel

0.4698

100

Nb-97

Ni-56

1.275

✓

397

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 398

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope Ni-57

Name Nickel

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

36.08 h

Ni-59

Nickel

75.0 × 103 y

Ni-63

Nickel

100.1 y

0.0659

0.0171

100

Ni-65

Nickel

2.520 h

0.6552

0.2209

28

2.137

0.8757

61

Np-235

Neptunium

396.1 d

Np-236

Neptunium

115.0 + 103 y

Np-236m Np-237

Np-238

Np-239

Np-240

Np-240m

22.50 h

Neptunium

2.140 × 10 y

Neptunium

Neptunium

Neptunium

%

g MeV

%

0.8434

0.3590

33

0.511

80

1.38

78

✓

1.48

✓

0.5360 6

4.771

25

4.788

47

2.117 d

2.355 d

65.0 min

7.40 min

O-15

Oxygen

122.24 s

Os-185

Osmium

93.60 d

Os-186

Osmium

2.0 × 10 y

Os-190m

Osmium

9.90 min

15

0.1580

40

24

21

0.098

34

0.160

28

✓

0.2634

0.0722

42

0.985

24

1.248

0.4124

45

0.3298

0.0921

35

0.104

24

0.4360

0.1253

52

0.106

23

0.7814

0.2410

100

0.566

27

0.601

20

0.974

21

0.554

22

1.513

0.5140

32

2.067

0.7330

52 1.732

2.756

0.094

✓

0.7352

100

0.511 200 0.646

80

0.187

70

0.361

95

0.503

98

0.616

99

0.129

26

100

Os-191

Osmium

15.40 d

Os-191m

Osmium

13.03 h

Os-193

Osmium

30.00 h

1.132

0.3831

53

P-32

Phosphorus

14.29 d

1.710

0.6949

100

P-33

Phosphorus

25.40 d

0.2490

0.0766

100

Pa-230

Protactinium

17.40 d

✓

398

b1 Ave MeV

✓

Neptunium

Neptunium

b1 Max MeV

0.1388

0.0367

100

✓ ✓

0.093

31

0.952

29

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 399

Quick Reference B — Radiopharmaceuticals

Isotope Pa-231

Pa-233

Pa-234

Name Protactinium

Protactinium

Protactinium

T1/2 32.76 × 10 y 3

27.00 d

6.70 h

a MeV

%

4.950

23

5.011

25

5.028

20

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

✓

0.1565

0.0415

24

0.2318

0.0630

28

0.2604

0.0714

33

0.6887

0.1410

24

2.281

0.8254

99

0.312

39

0.098

25

0.131

20

Pa-234m

Protactinium

1.170 min

Pb-203

Lead

52.02 h

0.279

77

Pb-204m

Lead

66.90 min

0.375

94

0.899

99

0.912

91

0.010

23

0.011

24

Pb-205

Lead

15.10 × 106 y

Pb-209

Lead

3.253 h

0.6646

0.1976

100

Pb-210

Lead

22.26 y

0.0165

0.0041

80

0.0630

0.0161

20

✓

Pb-211

Lead

36.10 min

1.373

0.4733

93

✓

Pb-212

Lead

10.64 h

0.3342

0.0944

85

0.239

45

Pb-214

Lead

26.80 min

0.6721

0.2070

48

0.352

37

0.7288

0.2270

43

Pd-103

Palladium

16.96 d

Pd-107

Palladium

6.5 × 106 y

0.0331

0.0093

100

Pd-109

Palladium

13.45 h

1.028

0.3610

100

Pm-143

Promethium

265.0 d

0.742

38

Pm-144

Promethium

363.0 d

0.477

42

0.618

99

✓

✓

0.697 100 Pm-145

Promethium

17.70 y

Pm-146

Promethium

5.534 y

✓ 0.7949

0.2599

34

0.454

63

0.736

22

0.747

36

Pm-147

Promethium

2.623 y

0.2247

0.0620

100

✓

Pm-148

Promethium

5.370 d

0.9989

0.3400

33

0.550

22

2.464

0.9750

56

1.47

22

0.4072

0.1200

54

0.550

95

0.6953

0.2220

22

0.630

89

Pm-148m

Promethium

41.30 d

399

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 400

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Pm-149

Name

Promethium

Pm-151

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.726

33

1.01

20

53.08 h

1.071

0.3690

96

✓

28.40 h

0.8431

0.2780

43

0.340

Po-209

Polonium

102.0 y

4.882

99

✓

Po-210

Polonium

138.4 d

5.305

100

✓

Po-211

Polonium

0.5160 s

7.450

99

✓

Po-212

Polonium

0.000 s

8.785

100

Po-213

Polonium

0.000 s

8.377

100

✓

Po-214

Polonium

0.000 s

7.687

100

✓

Po-215

Polonium

0.001 s

7.386

100

✓

Po-216

Polonium

0.146 s

6.779

100

✓

Po-218

Polonium

3.050 min

6.003

100

Pr-142

Praseodymium

19.13 h

2.159

0.8328

96

✓

Pr-143

Praseodymium

13.56 d

0.9353

0.3156

100

✓

Pr-144

Praseodymium

17.28 min

2.996

1.221

98

✓

Pr-144m

Praseodymium

7.20 min

✓

Pt-191

Platinum

2.710 d

0.065

Pt-193

Platinum

50.00 y

✓

Pt-193m

Platinum

4.330 d

✓

Pt-195m

Platinum

4.020 d

0.067

Pt-197

Platinum

18.30 h

Pt-197m

Platinum

94.40 min

Pu-236

Plutonium

2.851 y

Pu-237

Plutonium

45.30 d

Pu-238

Plutonium

87.75 y

0.6417

0.1977

82

5.722

32

5.770

68

28

5.499

72

Plutonium

24.131 × 103 y

5.155

73

✓

Pu-240

Plutonium

6.537 × 103 y

5.123

26

✓

5.168

74

Pu-242

Pu-243

400

Plutonium

14.40 y

Plutonium

375.80 × 10 y

Plutonium

0.208 3

4.956 h

4.856

22

4.901

78

23

21

✓

Pu-239

Pu-241

38

✓

0.101 5.457

65

✓ 0.067

✓

23

0.0052

100 ✓

0.4980

0.1451

29

0.5820

0.1727

59

0.084

23

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 401

Quick Reference B — Radiopharmaceuticals

Isotope Pu-244

Name Plutonium

T1/2 82.60 × 10 y 6

a MeV

%

4.546

20

4.589

81

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

✓

Pu-245

Plutonium

10.57 h

0.9326

0.2950

57

0.327

27

Pu-246

Plutonium

10.85 d

0.1503

0.0400

73

0.224

28

0.3302

0.0920

27

Ra-222

Radium

38.00 s

6.556

97

✓

Ra-223

Radium

11.43 d

5.606

24

0.084

5.715

53

5.686

95

Ra-224

Radium

3.620 d

Ra-225

Radium

14.80 d

Ra-226

Radium

1.60 × 10 y

Ra-228

Radium

5.750 y

Rb-81

Rubidium

4.580 h

3

1.250 min

Rb-83

Rubidium

86.20 d

Rb-86

32.90 d

Rubidium

18.66 d

Rb-87

Rubidium

Rb-88 Rb-89

0.3220

0.0900

72

0.3620

0.1030

28

95

✓ ✓

✓

0.4580

1.524

31

83

0.190

66

0.511

66

0.511 191 0.520

46

0.530

30

0.511

54

0.882

68

1.774

0.7093

91

4.7 × 10 y

0.2733

0.0788

100

Rubidium

17.80 min

5.315

2.372

78

1.84

21

Rubidium

15.44 min

1.275

0.4736

33

1.03

58

2.223

0.9031

34

1.25

42

4.503

1.987

25

2.976

37

0.832

33

0.832

93

0.059

87

1.12

21

0.059

52

1.21

32

1.22

25

0.059

60

0.162

23

0.059

44

10

157.0 s

6.553

Rb-90m

Rubidium

258.0 s

✓

Rb-182

Rhenium

64.0 h

Re-184

100

✓

Rubidium

Re-183

0.0099

3.356

Rb-90

Re-182m

✓

1.050

Rubidium

Rubidium

✓

0.0389

Rb-82

Rb-84

4.785

25

Rhenium

Rhenium

Rhenium

12.70 h

70.00 d

38.00 d

✓

✓

401

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 402

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Name

T1/2

Re-184m

Rhenium

169.0 d

Re-186

Rhenium

90.64 h

a MeV

%

b2 Max MeV

b2 Ave MeV

%

0.9394

0.3088

22

1.077

0.3620

71

Re-187

Rhenium

4.7 × 1010 y

0.0026

0.0006

100

Re-188

Rhenium

16.98 h

1.965

0.7286

25

2.120

0.7951

71

Rh-103m

Rhodium

56.12 min

Rh-105

Rhodium

35.36 h

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.792

37

0.903

38

0.061

24

✓

✓

✓ 0.2480

0.0699

20

0.5669

0.1794

75

0.319

19

0.130

20

0.512

21

Rh-105m

Rhodium

45.00 s

Rh-106

Rhodium

29.92 s

Rn-218

Radon

0.035 s

7.133

100

✓

Rn-219

Radon

3.960 s

6.819

80

✓

Rn-220

Radon

55.61 s

6.288

100

✓

Rn-222

Radon

3.823 d

5.490

100

✓

Ru-97

Ruthenium

2.90 d

Ru-103

Ruthenium

39.35 d

0.2261

0.0632

Ru-105

Ruthenium

4.440 h

1.112

3.541

1.509

79

0.216

86

90

0.497

89

0.3975

20

0.725

49

1.193

0.4322

50

0.159

86

0.564

71

Ru-106

Ruthenium

368.2 d

0.0394

0.0100

100

S-35

Sulfur

87.44 d

0.1675

0.0488

100

Sb-117

Antimony

2.800 h

Sb-122

Antimony

2.700 d

Sb-124

Antimony

60.20 d

✓ 1.417

0.5224

67

1.981

0.7721

26

0.6113

0.1940

53

0.603

98

2.302

0.9186

22

1.69

49

Sb-125

Antimony

2.770 y

0.3034

0.0870

40

0.428

29

Sb-126

Antimony

12.40 d

0.3714

0.1090

29

0.415

83

1.068

0.3740

16

0.666

97

1.789

0.6890

19

0.695 100

Sb-126m

402

Antimony

19.00 min

1.807

0.6940

81

0.697

29

0.721

54

0.415

86

0.666

86

0.695

86

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 403

Quick Reference B — Radiopharmaceuticals

Isotope

Name

Sb-127

Antimony

Sb-128

Antimony

4.400 h

Scandium

3.927 h

Sc-46

Scandium

83.80 d

Sc-46m

Scandium

18.72 s

Sc-47

Scandium

3.422 d

Scandium

%

3.850 d

Sc-44

Sc-48

a MeV

T1/2

Scandium

54.40 min

Sc-73

Selenium

7.150 h

b2 Ave MeV

%

0.8959

0.3041

1.108

b1 Max MeV

b1 Ave MeV

g MeV

%

35

0.473

25

0.3909

22

0.685

36

0.5344

0.1660

23

0.813

46

0.6497

0.2080

27

0.915

21

1.476 0.3573

43.67 h

Sc-49

b2 Max MeV

0.1120

0.1427

68

0.6005

0.2040

32

0.6569

0.2265

90

0.8231

94

100

0.4411

2.004

0.6329

%

0.511 189 0.889 100 1.12

100

0.142

63

0.159

68

0.984 100

100

1.04

98

1.31

100

✓ 1.290

0.5620

65

0.067

77

0.361

97

0.511 132 Se-75

Selenium

119.8 d

0.136

59

0.264

60

0.280

25

Se-79

Selenium

65.00 × 10 y

0.1490

0.0522

100

Si-31

Silicon

157.3 min

1.491

0.5956

100

Si-32

Silicon

330.0 y

0.2130

0.0647

100

Sm-147

Samarium

6.900 × 10 y

Sm-151

Samarium

90.00 y

0.0761

0.0197

99

✓

Sm-153

Samarium

46.70 h

0.634

0.1986

34

0.103

0.7020

0.2244

44

0.8052

0.2634

21

3

9

2.248

✓

100

28

Sn-113

Tin

115.1 d

✓

Sn-117m

Tin

13.60 d

0.159

Sn-119m

Tin

293.0 d

✓

Sn-123

Tin

129.2 d

1.397

0.5231

99

✓

Sn-125

Tin

1.640 d

2.350

0.9380

83

✓

Sn-126

Tin

100.0 × 103 y

0.2501

0.0700

100

0.088

Sr-82

Strontium

25.00 d

✓

Sr-85

Strontium

64.84 d

0.514

99

Sr-85m

Strontium

67.66 min

0.232

85

86

37

403

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 404

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.388

82

Isotope

Name

Sr-87m

Strontium

2.805 h

Sr-89

Strontium

50.55 d

1.491

0.5830

100

Sr-90

Strontium

28.60 y

0.5460

0.1958

100

Sr-91

Strontium

9.500 h

1.104

0.3989

34

0.750

23

1.379

0.5180

24

1.02

33

2.684

1.121

31

✓

Sr-92

Strontium

2.710 h

0.5461

0.1740

96

1.38

90

Sr-93

Strontium

7.30 min

1.692

0.6600

18

0.710

22

2.733

1.140

16

0.876

24

0.888

22

Ta-182

Tantalum

114.7 d

Tb-157

Terbium

150.0 y

Tb-160

Terbium

72.30 d

Tb-162

Terbium

Technetium

20.00 h

Tc-95m

Technetium

61.00 d

Tc-96

Tc-96m

Technetium

0.716

29

0.068

42

0.4375

0.1286

21

1.12

35

0.5222

0.1572

41

1.22

27

✓

7.760 min

Tc-95

0.2581

0.5687

0.1750

46

0.299

27

0.8673

0.2860

25

0.879

29

0.966

24

0.808

42

0.888

38

0.766

94

0.204

62

0.582

29

0.835

26

1.382

0.4900

96

✓

4.280 d

0.778 100 0.813

82

0.850

98

Technetium

51.50 min

Tc-97

Technetium

2.600 × 10 y

0.018

36

Tc-97m

Technetium

89.00 d

0.018

27

Tc-98

Technetium

4.200 × 106 y

Tc-99

Technetium

213.0 × 10 y

Tc-99m

Technetium

6.020 h

Tc-101

Technetium

14.20 min

Te-121

Tellurium

16.80 d

Te-121m

Tellurium

154.0 d

Tellurium

1.0 × 10 y

✓ 6

0.3942

0.1180

100

0.652 100 0.745 100

Te-123 404

3

13

0.2936

1.318

0.0846

0.4870

100

89

✓ 0.140

89

0.307

88

0.573

80

0.212

81

0.026

38

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 405

Quick Reference B — Radiopharmaceuticals

Isotope

Name

a MeV

T1/2

%

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

Te-123m

Tellurium

119.7 d

0.159

84

Te-125m

Tellurium

58.00 d

0.027

92

Te-127

Tellurium

9.350 h

0.6940

Te-127m

Tellurium

109.0 d

✓

Te-129

Tellurium

69.60 min

1.470

0.5445

90

✓

Te-129m

Tellurium

33.60 d

1.604

0.6073

33

✓

Te-131

Tellurium

25.00 min

1.687

0.6220

22

0.150

69

2.099

0.8250

59

0.2247

99

✓ 0.027

29

Te-131m

Tellurium

30.00 h

0.4510

0.1362

37

0.774

38

Te-132

Tellurium

78.20 h

0.2151

0.0594

100

0.228

88

Te-133

Tellurium

12.45 min

2.250

0.8900

33

0.312

71

2.658

1.080

29

0.408

30

1.528

0.5700

20

0.864

20

1.744

0.6700

29

0.913

87

2.392

0.9600

38

0.3766

0.1108

43

0.079

21

0.4533

0.1370

41

0.210

22

0.278

21

0.767

30

Te-133m

Te-134

Th-226

Th-227

Th-228

Tellurium

Tellurium

Thorium

Thorium

55.40 min

41.80 min

30.90 min

18.72 d

6.234

23

6.338

76

5.757

20

5.978

23

6.038

25

5.341

27

5.423

73

✓

✓

Thorium

1.913 y

Th-229

Thorium

7.340 × 10 y

4.845

56

0.089

Th-230

Thorium

77.00 × 103 y

4.621

23

✓

4.688

76

Th-231

Th-232

Th-233

3

Thorium

25.52 h

Thorium

1.4 × 10 y

Thorium

10

22.30 min

Th-234

Thorium

24.10 d

Ti-44

Titanium

47.30 y

3.953

23

4.010

77

✓

0.2876

0.0796

41

0.3047

0.0848

35

27

✓

✓

1.239

0.4121

51

1.245

0.4146

30

0.1886

0.0506

73

✓

✓ 0.068

92

0.078

98 405

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 406

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Name

a MeV

T1/2

Ti-45

Titanium

3.080 h

Ti-51

Titanium

5.752 min

Tl-200

Thallium

26.10 h

Tl-201

Tl-202

Thallium

Thallium

%

b2 Max MeV

2.146

b2 Ave MeV

0.8882

%

b1 Max MeV

b1 Ave MeV

%

g MeV

1.041

0.4391

85

0.511 170

92 ✓

73.06 h

12.23 d

%

0.320

93

0.069

24

0.071

40

0.368

87

1.21

30

0.069

27

0.71

47

0.080

21

0.167

10

0.069

23

0.071

39

0.440

92

Tl-204

Thallium

3.779 y

0.7634

0.2439

97

✓

Tl-207

Thallium

4.770 min

1.422

0.4941

100

✓

Tl-208

Thallium

3.053 min

1.284

0.4387

23

0.511

22

1.517

0.5325

23

0.583

84

1.794

0.6465

49

2.62

100

1.825

0.6590

100

0.117

77

0.465

97

1.57

100

Tl-209

Tl-210

Tm-170

Thallium

Thallium

Thulium

2.200 min

1.300 min

128.6 d

Tm-171

Thulium

1.920 y

U-230

Uranium

20.80 d

U-231

Uranium

4.200 d

U-232

Uranium

72.00 y

5.818

32

5.889

67

1.317

0.4500

25

0.298

79

1.867

0.6800

56

0.800

99

2.337

0.8700

19

1.31

21

0.8837

0.2904

24

✓

0.9679

0.3231

76

0.0967

0.0252

98

✓ ✓

0.096

3

5.264

31

5.320

69

✓

U-233

Uranium

159.20 10 y

4.824

84

✓

U-234

Uranium

244.50 × 103 y

4.724

27

✓

4.776

72

Uranium

703.80 × 10 y

4.396

55

U-235 406

6

28

0.184

54

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 407

Quick Reference B — Radiopharmaceuticals

Isotope U-236

U-237

U-238

U-239

Name Uranium

Uranium

Uranium

Uranium

T1/2 3.415 × 10 y 6

a MeV

%

4.445

26

4.494

74

6.750 d

4.468 × 10 y 9

23.40 min

U-240

Uranium

14.10 h

V-48

Vanadium

15.97 d

4.147

23

4.196

77

b2 Max MeV

b2 Ave MeV

%

b1 Max MeV

b1 Ave MeV

%

g MeV

%

✓ 0.2381

0.0648

53

0.060

34

0.2519

0.0688

44

0.101

26

0.208

22

✓

1.191

0.3920

68

1.266

0.4206

28

0.4360

0.1250

100

0.075

48

✓ 0.6974

0.2914

50

0.511 100 0.984 100 1.31

98

V-49

Vanadium

330.0 d

V-52

Vanadium

3.750 min

W-181

Tungsten

121 d

W-185

Tungsten

75.10 d

0.4324

0.1268

100

✓

W-187

Tungsten

23.83 h

0.6267

0.1935

59

0.480

23

1.313

0.4571

25

0.686

29

0.3490

0.0997

99

✓

W-188

Tungsten

69.40 d

Xe-122

Xenon

20.10 h

Xe-123

Xenon

2.140 h

Xe-125

Xe-127

Xe-129m

Xenon

Xenon

Xenon

1.074

99

1.505

✓

36.41 d

8.890 d

Xenon

11.84 d

Xe-133

Xenon

5.245 d

Xenon

2.542

16.80 h

Xe-131m

Xe-133m

✓

2.190 d

0.6740

17

1.43

100

0.057

33

0.028

63

0.028

60

0.149

48

0.511

45

0.028

81

0.188

55

0.243

29

0.028

71

0.172

25

0.203

68

0.029 103

0.3463

0.1006

99

0.034

24

0.029

43

0.030

38

0.081

36

0.029

45 407

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 408

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Isotope

Name

T1/2

Xe-135

Xenon

9.110 h

Xe-135m

Xenon

15.36 min

Xe-137

Xenon

3.830 min

Xe-138

Y-86

Xenon

Yttrium

14.13 min

a MeV

%

b2 Max MeV

b2 Ave MeV

%

0.9092

0.3080

96

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.250

90

0.527

81

0.456

31

3.889

1.649

30

4.344

1.862

67

0.7133

0.2310

33

0.258

32

2.290

0.9080

20

0.435

20

0.511

66

0.628

33

0.777

22

1.08

83

1.15

31

1.92

21

14.74 h

1.254

0.5500

12

Y-87

Yttrium

80.30 h

✓

0.485

94

Y-88

Yttrium

106.6 d

✓

0.898

93

1.84

99

0.203

97

0.480

91

Y-90

Yttrium

64.10 h

Y-90m

Yttrium

3.190 h

2.284

Y-91

Yttrium

58.51 d

Y-91m

Yttrium

49.71 min

Y-92

Yttrium

3.540 h

3.634

1.563

Y-93

Yttrium

10.10 h

2.890

1.214

Yb-169

Ytterbium

31.97 d

Yb-175

Ytterbium

4.190 d

Zn-62

Zinc

9.260 h

1.543

0.9348

0.4679

0.6038

0.1392

100

100

✓ 0.558

95

86

0.935

14

90

✓

87

0.050

53

0.051

93

0.058

38

0.063

44

0.177

21

0.198

35

✓ ✓

0.041

27

0.597

28

1.12

51

Zn-65

Zinc

244.4 d

Zn-69

Zinc

55.60 min

Zn-69m

Zinc

13.76 h

0.439

95

Zr-86

Zirconium

16.50 h

0.243

96

Zr-88

Zirconium

83.40 d

0.393

97

408

✓ 0.9045

0.3209

100

✓

10766-63_QuickRef-B.qxd

12/3/07

5:33 PM

Page 409

Quick Reference B — Radiopharmaceuticals

Isotope Zr-89

Name Zirconium

T1/2

a MeV

%

b2 Max MeV

b2 Ave MeV

%

78.43 h

b1 Max MeV

b1 Ave MeV

%

g MeV

%

0.9047

0.3969

23

0.511

46

0.909

99

Zr-93

Zirconium

1.530 × 106 y

0.0615

0.0195

100

Zr-95

Zirconium

64.02 d

0.3664

0.1093

55

0.724

44

0.3989

0.1204

44

0.757

55

1.914

0.7566

86

✓

Zr-97

Zirconium

16.90 h

Excerpted from Hacker C. Radiation Decay: Emissions Tables and Spectra. 3.5-inch floppy disk program, Rockville, MD: Grove Engineering, 1995. Most isotopes have many more emissions than are listed. For a complete list, please refer to the program mentioned or one that is similar. If discrepancies are noted, be aware that published energy and half-life values vary slightly from source to source.

409

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 410

QUICK REFERENCE C

Decay Tables of Common Radionuclides 137

Cs

57

Co

18

F

67

Ga

111

In

123

I

131

I

99

Mo

99m

Tc

201

Tl

133

Xe

410

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 411

Quick Reference C — Decay Tables of Common Radionuclides

CESIUM-137 DECAY TABLE Radionuclide: 137Cs t1/2: 30.17 years Energies: Beta (maximums): 511.6 keV (94.6%), 1173.2 keV (5.4%) Gamma: 661.7 keV (89.98% from 137mBa, t1/2 2.55 minutes) − Type: β , γ emitter, fission product Decays to: 137mBa → 137Ba (100%) Original amount × decay factor (DF) for years and/or days = factored amount Ex: 10 mCi after 6 years 35 days: 10 × 0.8713 (6 years) × 0.9978 (35 days) = 8.69 mCi Days

DF

Days

DF

Days

DF

Years

DF

Years

DF

Years

DF

Years

DF

1

0.9999

13

0.9992

50

0.9968

2

0.9551

14

0.7250

26

0.5503

50

0.3171

2

0.9999

14

0.9991

60

0.9962

3

0.9334

15

0.7085

27

0.5378

55

0.2827

3

0.9998

15

0.9991

70

0.9956

4

0.9122

16

0.6925

28

0.5256

60

0.2520

4

0.9997

16

0.9990

80

0.9950

5

0.8915

17

0.6767

29

0.5137

65

0.2247

5

0.9997

17

0.9989

90

0.9943

6

0.8713

18

0.6614

30

0.5020

70

0.2003

6

0.9996

18

0.9989

100

0.9937

7

0.8515

19

0.6463

32

0.4795

75

0.1786

7

0.9996

19

0.9988

150

0.9906

8

0.8321

20

0.6317

34

0.4580

80

0.1592

8

0.9995

20

0.9987

200

0.9875

9

0.8132

21

0.6173

36

0.4374

85

0.1419

9

0.9994

25

0.9984

250

0.9844

10

0.7948

22

0.6033

38

0.4178

90

0.1265

10

0.9994

30

0.9981

300

0.9813

11

0.7767

23

0.5896

40

0.3990

95

0.1128

11

0.9993

35

0.9978

350

0.9782

12

0.7591

24

0.5762

42

0.3811

100

0.1006

12

0.9992

40

0.9975

365

0.9773

13

0.7419

25

0.5631

45

0.3557

150

0.0319

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas (1 year = 365.24 days): e e

−

.693 × time in days 11019.2908

.693 − × time in years 30.17

for days

for years

411

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 412

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

COBALT-57 DECAY TABLE Radionuclide: 57Co t1/2: 271.8 days Energies: 14.4 keV (9.5%), 122.1 keV (85.5%), 136.5 keV (10.6%) Type: electron capture, γ emitter, accelerator Decays to: 57Fe (100%) Original amount × decay factor (DF) for days and/or hours = factored amount Ex: 10 mCi after 60 days 15 hours: 10 × 0.8581 (60 days) × 0.9984 (15 hours) = 8.57 mCi Hours

DF

Hours

DF

Days

DF

Days

DF

Days

DF

Days

DF

Days

DF

1

0.9999

13

0.9986

2

0.9949

14

0.9649

26

0.9359

70

0.8365

160

0.6650

2

0.9998

14

0.9985

3

0.9924

15

0.9625

27

0.9335

75

0.8259

170

0.6483

3

0.9997

15

0.9984

4

0.9899

16

0.9600

28

0.9311

80

0.8155

180

0.6320

4

0.9996

16

0.9983

5

0.9873

17

0.9576

29

0.9287

85

0.8052

190

0.6160

5

0.9995

17

0.9982

6

0.9848

18

0.9551

30

0.9264

90

0.7950

200

0.6005

6

0.9994

18

0.9981

7

0.9823

19

0.9527

35

0.9146

95

0.7849

250

0.5286

7

0.9993

19

0.9980

8

0.9798

20

0.9503

40

0.9030

100

0.7749

275

0.4960

8

0.9992

20

0.9979

9

0.9773

21

0.9479

45

0.8916

110

0.7554

300

0.4654

9

0.9990

21

0.9978

10

0.9748

22

0.9455

50

0.8803

120

0.7364

365

0.3943

10

0.9989

22

0.9977

11

0.9723

23

0.9430

55

0.8692

130

0.7179

400

0.3606

11

0.9988

23

0.9976

12

0.9699

24

0.9406

60

0.8581

140

0.6998

450

0.3175

12

0.9987

24

0.9975

13

0.9674

25

0.9382

65

0.8473

150

0.6822

500

0.2795

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in hours 6523.2

.693 − × time in days 271. 8

412

for hours

for days

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 413

Quick Reference C — Decay Tables of Common Radionuclides

FLUORINE-18 DECAY TABLE Radionuclide: 18F t1/2: 109.77 minutes or 1.83 hours Energies: Beta (maximum): 1.65 MeV (97%) Gamma: 511 keV (annihilation radiation) Type: electron capture, β+, γ emitter, accelerator Decays to: 18O (100%) Original amount × decay factor (DF) for hours, and/or minutes = factored amount Ex: 15 mCi after 2 h 25 min: 15 × .4689 (2 h) × .8540 (25 min) = 6.01 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9689

2

0.4689

13

0.0073

24

0.0001

10

0.9388

3

0.3211

14

0.0050

25

0.0001

15

0.9096

4

0.2199

15

0.0034

26

0.0001

20

0.8813

5

0.1506

16

0.0023

27

0.0000

25

0.8540

6

0.1031

17

0.0016

30

0.8275

7

0.0706

18

0.0011

35

0.8017

8

0.0483

19

0.0007

40

0.7768

9

0.0331

20

0.0005

45

0.7527

10

0.0227

21

0.0004

50

0.7293

11

0.0155

22

0.0002

55

0.7066

12

0.0106

23

0.0001

60

0.6847

13

0.8840

25

0.7889

Hours

DF

Hours

DF

Hours

DF

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 109.77

.693 × time in hours − 1.83

for minutes

for hours

413

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 414

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

GALLIUM-67 DECAY TABLE Radionuclide: 67Ga t1/2: 78.24 hours or 3.26 days Energies: 93.3 keV (35.7%), 184.6 keV (19.7%), 300.2 keV (16%), 393.5 keV (4.5%) Type: electron capture, γ emitter, accelerator Decays to: 67Zn (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 8.5 mCi after 6 h 35 min: 8.5 × 0.9482 (6 h) × 0.9948 (35 min) = 8.02 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9993

2

0.9824

14

0.8834

26

0.7943

38

0.7142

52

0.6309

78

0.5011

10

0.9985

3

0.9738

15

0.8756

27

0.7873

39

0.7079

54

0.6198

80

0.4923

15

0.9978

4

0.9652

16

0.8679

28

0.7804

40

0.7017

56

0.6090

85

0.4710

20

0.9971

5

0.9567

17

0.8602

29

0.7735

41

0.6955

58

0.5983

90

0.4506

25

0.9963

6

0.9482

18

0.8526

30

0.7667

43

0.6833

60

0.5878

95

0.4311

30

0.9956

7

0.9399

19

0.8451

31

0.7599

44

0.6772

62

0.5774

100

0.4124

35

0.9948

8

0.9316

20

0.8377

32

0.7532

45

0.6713

64

0.5673

105

0.3945

40

0.9941

9

0.9234

21

0.8303

33

0.7465

46

0.6654

68

0.5476

110

0.3775

45

0.9934

10

0.9152

22

0.8229

34

0.7400

47

0.6595

70

0.5379

115

0.3611

50

0.9926

11

0.9072

23

0.8157

35

0.7334

48

0.6537

72

0.5285

120

0.3455

55

0.9919

12

0.8982

24

0.8085

36

0.7270

49

0.6479

74

0.5192

125

0.3305

60

0.9912

13

0.8912

25

0.8014

37

0.7206

50

0.6422

76

0.5101

130

0.3162

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 4694.4

.693 × time in hours − 78.24

414

for minutes

for hours

10766-64_QuickRef-C.qxd

12/3/07

5:34 PM

Page 415

Quick Reference C — Decay Tables of Common Radionuclides

INDIUM-111 DECAY TABLE Radionuclide: 111In t1/2: 67.92 hours or 2.83 days Energies: 23 keV (68.2%), 171.3 keV (90.2%), 245.4 keV (94%) Type: electron capture, γ emitter, accelerator Decays to: 111Cd (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 0.450 mCi after 6 h 35 min: 0.450 × 0.9406 (6 h) × 0.9941 (35 min) = 0.421 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9992

2

0.9798

14

0.8669

26

0.7670

38

0.6786

52

0.5883

78

0.4512

10

0.9983

3

0.9699

15

0.8581

27

0.7592

39

0.6717

54

0.5764

80

0.4421

15

0.9975

4

0.9600

16

0.8494

28

0.7515

40

0.6649

56

0.5675

85

0.4201

20

0.9966

5

0.9503

17

0.8408

29

0.7439

41

0.6581

58

0.5533

90

0.3992

25

0.9958

6

0.9406

18

0.8322

30

0.7363

43

0.6449

60

0.5416

95

0.3793

30

0.9949

7

0.9311

19

0.8238

31

0.7288

44

0.6383

62

0.5312

100

0.3605

35

0.9941

8

0.9216

20

0.8154

32

0.7214

45

0.6318

64

0.5205

105

0.3426

40

0.9932

9

0.9123

21

0.8071

33

0.7141

46

0.6254

68

0.4997

110

0.3255

45

0.9924

10

0.9030

22

0.7989

34

0.7069

47

0.6191

70

0.4896

115

0.3092

50

0.9915

11

0.8938

23

0.7908

35

0.6997

48

0.6128

72

0.4797

120

0.2939

55

0.9907

12

0.8848

24

0.7828

36

0.6926

49

0.6066

74

0.4700

125

0.2793

60

0.9898

13

0.8758

25

0.7749

37

0.6856

50

0.6004

76

0.4605

130

0.2654

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 4075.2

.693 × time in hours − 67.92

for minutes

for hours

415

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 416

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

IODINE-123 DECAY TABLE Radionuclide: 123I t1/2: 13.13 hours Energies: 159 keV (83.3%), 27.5 keV (45.9%), 27.2 keV (24.7%) Type: electron capture, γ emitter, accelerator Decays to: 123Te (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 0.250 mCi after 6 h 35 min; 0.250 × 0.7286 (6 h) × 0.9697 (35 min) = 0.177 mCi or: 0.250 mCi after 6 h 35 min: 0.250 × 0.7065 (6 h + 35 min) = 0.177 mCi. Min

DF

2 h + DF

4 h + DF

6 h + DF

8 h + DF

10 h + DF

Hours

DF

0

1.0000

0.89982

0.80968

0.72856

0.65557

0.58990

—

—

5

0.9956

0.8959

0.8061

0.7254

0.6527

0.5873

12

0.5308

10

0.9912

0.8919

0.8026

0.7222

0.6498

0.5847

14

0.4776

15

0.9869

0.8880

0.7991

0.7190

0.6470

0.5822

16

0.4298

20

0.9826

0.8841

0.7956

0.7159

0.6441

0.5796

18

0.3867

25

0.9782

0.8802

0.7921

0.7127

0.6413

0.5771

20

0.3480

30

0.9739

0.8764

0.7886

0.7096

0.6385

0.5745

22

0.3131

35

0.9697

0.8725

0.7851

0.7065

0.6357

0.5720

24

0.2818

40

0.9654

0.8687

0.7817

0.7034

0.6329

0.5695

26

0.2535

45

0.9612

0.8649

0.7783

0.7003

0.6301

0.5670

28

0.2281

50

0.9670

0.8611

0.7748

0.6972

0.6274

0.5645

30

0.2053

55

0.9528

0.8573

0.7714

0.6942

0.6246

0.5620

48

0.0794

60

0.9486

0.8536

0.7681

0.6911

0.6219

0.5596

60

0.0421

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 787.8

.693 × time in hours − 13.13

416

for minutes

for hours

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 417

Quick Reference C — Decay Tables of Common Radionuclides

IODINE-131 DECAY TABLE Radionuclide: 131I t1/2: 192.96 hours or 8.04 days Energies: Beta (maximums): 606.3 keV (89.3%) Gamma: 364.5 keV (81.2%), 636.9 keV (7.3%) Type: β−, γ emitter, fission product Decays to: 131Xe (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 29 mCi after 6 h 35 min: 29 × 0.9787 (6 h) × 0.9979 (35 min) = 28.3 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Days

DF

5

0.9997

2

0.9928

14

0.9510

26

0.9108

38

0.8724

52

0.8296

4

0.7084

10

0.9994

3

0.9893

15

0.9476

27

0.9076

39

0.8630

54

0.8237

5

0.6499

15

0.9991

4

0.9857

16

0.9442

28

0.9043

40

0.8662

56

0.8178

6

0.5962

20

0.9988

5

0.9822

17

0.9408

29

0.9011

41

0.8631

58

0.8120

7

0.5470

25

0.9985

6

0.9787

18

0.9374

30

0.8979

43

0.8569

60

0.8062

8

0.5018

30

0.9982

7

0.9752

19

0.9340

31

0.8946

44

0.8538

62

0.8004

9

0.4604

35

0.9979

8

0.9717

20

0.9307

32

0.8914

45

0.8508

64

0.7947

10

0.4223

40

0.9976

9

0.9682

21

0.9274

33

0.8882

46

0.8477

68

0.7833

15

0.2745

45

0.9973

10

0.9641

22

0.9240

34

0.8851

47

0.8447

70

0.7777

20

0.1784

50

0.9970

11

0.9613

23

0.9207

35

0.8819

48

0.8416

72

0.7721

25

0.1159

55

0.9967

12

0.9578

24

0.9174

36

0.8787

49

0.8386

74

0.7666

30

0.0753

60

0.9964

13

0.9544

25

0.9141

37

0.8756

50

0.8352

76

0.7611

40

0.0318

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 11577.6

.693 × time in hours − 192.96

for minutes

for hours

417

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 418

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

MOLYBDENUM-99 DECAY TABLE Radionuclide: 99Mo t1/2: 66.02 hours or 2.75 days Energies: Beta (maximums): 436 keV (17.3%), 1214 keV (82.7%) Gamma: 140.5 keV (3.8%), 181 keV (6.2%), 739.6 keV (12.8%), 778 keV (4.5%) Type: β−, γ emitter, fission product Decays to: 99Tc (11%), 99mTc → 99Tc (89%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 120 mCi after 6 h 35 min: 120 × 0.9390 (6 h) × 0.9939 (35 min) = 111.99 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9991

2

0.9792

14

0.8633

26

0.7612

38

0.6711

52

0.5794

78

0.4410

10

0.9983

3

0.9690

15

0.8543

27

0.7532

39

0.6641

54

0.5673

80

0.4318

15

0.9973

4

0.9589

16

0.8454

28

0.7453

40

0.6571

56

0.5555

85

0.4097

20

0.9965

5

0.9489

17

0.8366

29

0.7376

41

0.6503

58

0.5440

90

0.3888

25

0.9956

6

0.9390

18

0.8378

30

0.7299

43

0.6368

60

0.5327

95

0.3689

30

0.9948

7

0.9292

19

0.8192

31

0.7288

44

0.6301

62

0.5216

100

0.3500

35

0.9939

8

0.9195

20

0.8106

32

0.7147

45

0.6235

64

0.5108

105

0.3322

40

0.9930

9

0.9099

21

0.8022

33

0.7072

46

0.6170

68

0.4898

110

0.3152

45

0.9922

10

0.9004

22

0.7938

34

0.6998

47

0.6106

70

0.4796

115

0.2991

50

0.9913

11

0.8910

23

0.7855

35

0.6925

48

0.6042

72

0.4696

120

0.2838

55

0.9904

12

0.8816

24

0.7773

36

0.6853

49

0.5979

74

0.4599

125

0.2693

60

0.9896

13

0.8724

25

0.7692

37

0.6782

50

0.5916

76

0.4503

130

0.2555

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 3961.2

.693 × time in hours − 66.02

418

for minutes

for hours

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 419

Quick Reference C — Decay Tables of Common Radionuclides

TECHNETIUM-99M DECAY TABLE Radionuclide: 99mTc t1/2: 6.01 hours Energies: 140.5 keV (89.1%), 18 keV (6%), 20.6 keV (1%) Type: isomeric transition, γ emitter, generator Decays to: 99Tc (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 25 mCi after 2 h 35 min: 25 × 0.7940 (2 h) × 0.9349 (35 min) = 18.56 mCi or: 25 mCi after 2 h 35 min: 25 × 0.7424 (2 h + 35 min) = 18.56 mCi. Min

DF

1h + DF

2 h + DF

3 h + DF

4 h + DF

5 h + DF

Hours

DF

5

0.9904

0.8826

0.7865

0.7008

0.6245

0.5565

7

0.4461

10

0.9809

0.8741

0.7789

0.6941

0.6185

0.5511

8

0.3975

15

0.9716

0.8658

0.7715

0.6875

0.6126

0.5459

9

0.3542

20

0.9623

0.8575

0.7641

0.6809

0.6067

0.5407

10

0.3157

25

0.9531

0.8493

0.7568

0.6744

0.6009

0.5355

11

0.2813

30

0.9439

0.8412

0.7496

0.6679

0.5952

0.5304

12

0.2507

35

0.9349

0.8331

0.7424

0.6615

0.5895

0.5253

13

0.2234

40

0.9260

0.8252

0.7353

0.6552

0.5839

0.5203

14

0.1990

45

0.9172

0.8173

0.7283

0.6489

0.5783

0.5153

15

0.1774

50

0.9084

0.8096

0.7213

0.6427

0.5727

0.5104

16

0.1580

55

0.8997

0.8017

0.7144

0.6366

0.5673

0.5055

17

0.1408

60

0.8911

0.7940

0.7076

0.6305

0.5618

0.5006

18

0.1255

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 360.6

.693 × time in hours − 6.01

for minutes

for hours

419

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 420

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

THALLIUM-201 DECAY TABLE Radionuclide: 201Tl t1/2: 73.06 hours or 3.04 days Energies: 68.9 to 80.3 keV (94.3%), 135.3 keV (2.6%), 167.4 keV (10%) Type: electron capture, γ emitter, accelerator Decays to: 201Hg (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 3.5 mCi after 6 h 35 min: 3.5 × 0.9447 (6 h) × 0.9945 (35 min) = 3.29 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9992

2

0.9812

14

0.8756

26

0.7814

38

0.6974

52

0.6106

78

0.4772

10

0.9984

3

0.9719

15

0.8674

27

0.7741

39

0.6908

54

0.5992

80

0.4682

15

0.9976

4

0.9628

16

0.8592

28

0.7668

40

0.6843

56

0.5879

85

0.4465

20

0.9968

5

0.9537

17

0.8511

29

0.7591

41

0.6778

58

0.5769

90

0.4258

25

0.9961

6

0.9447

18

0.8404

30

0.7523

43

0.6651

60

0.5660

95

0.4178

30

0.9953

7

0.9358

19

0.8351

31

0.7452

44

0.6588

62

0.5554

100

0.3873

35

0.9945

8

0.9269

20

0.8272

32

0.7382

45

0.6526

64

0.5449

105

0.3694

40

0.9937

9

0.9182

21

0.8194

33

0.7312

46

0.6464

68

0.5247

110

0.3523

45

0.9929

10

0.9095

22

0.8117

34

0.7243

47

0.6403

70

0.5148

115

0.3359

50

0.9921

11

0.9009

23

0.8040

35

0.7175

48

0.6343

72

0.5051

120

0.3204

55

0.9913

12

0.8924

24

0.7964

36

0.7107

49

0.6283

74

0.4956

125

0.3055

60

0.9906

13

0.8840

25

0.7889

37

0.7040

50

0.6223

76

0.4863

130

0.2914

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 4380.6

.693 × time in hours − 73.06

420

for minutes

for hours

10766-64_QuickRef-C.qxd

12/3/07

5:35 PM

Page 421

Quick Reference C — Decay Tables of Common Radionuclides

XENON-133 DECAY TABLE Radionuclide: 133Xe t1/2: 126 hours or 5.25 days Energies: Beta (maximums): 346.3 keV (99.3%) Gamma: 81 keV (36.5%) Type: β−, γ emitter, fission product Decays to: 133Cs (100%) Original amount × decay factor (DF) for days, hours, and/or minutes = factored amount Ex: 10 mCi after 6 h 35 min: 10 × 0.9675 (6 h) × 0.9968 (35 min) = 9.6 mCi Min

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

Hours

DF

5

0.9995

2

0.9891

14

0.9259

26

0.8715

38

0.8114

52

0.7513

78

0.6512

10

0.9990

3

0.9836

15

0.9208

27

0.8620

39

0.8069

54

0.7430

80

0.6440

15

0.9986

4

0.9782

16

0.9158

28

0.8715

40

0.8025

56

0.7349

85

0.6266

20

0.9982

5

0.9729

17

0.9107

29

0.8526

41

0.7981

58

0.7269

90

0.6096

25

0.9977

6

0.9675

18

0.9057

30

0.8479

43

0.7894

60

0.7189

95

0.5930

30

0.9973

7

0.9622

19

0.9008

31

0.8432

44

0.7851

62

0.7111

100

0.5769

35

0.9968

8

0.9570

20

0.8958

32

0.8386

45

0.7808

64

0.7033

105

0.5613

40

0.9963

9

0.9517

21

0.8909

33

0.8340

46

0.7765

68

0.6880

110

0.5461

45

0.9959

10

0.9465

22

0.8803

34

0.8294

47

0.7722

70

0.6805

115

0.5313

50

0.9954

11

0.9413

23

0.8812

35

0.8249

48

0.7680

72

0.6730

120

0.5169

55

0.9950

12

0.9361

24

0.8763

36

0.8204

49

0.7638

74

0.6656

125

0.5028

60

0.9945

13

0.9310

25

0.8715

37

0.8159

50

0.7596

76

0.6584

130

0.4892

Values for t1/2, energies, and percentages vary from data source to data source. These numbers were derived from the following formulas: e e

−

.693 × time in minutes 7560

.693 × time in hours − 126

for minutes

for hours

421

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 422

QUICK REFERENCE D

Standard Drug Interventions Calculations, Preparations, and Administration Infusion Rate Tables Side Effects of Common Drugs Drugs and Studies Affecting 123I and 131I Uptake Drug Lists: Anticoagulants and ACE Inhibitors

422

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 423

Quick Reference D — Standard Drug Interventions

CALCULATIONS, PREPARATIONS, AND ADMINISTRATION ACETAZOLAMIDE (DIAMOX®) (BRAIN SPECT) Potent cerebral vasodilator. Shows affected area as regional decreased perfusion in patients suffering from TIA’s (frequently a precursor to cerebral infarction). A normal brain will show shunting and is referred to as the “reversed Robin Hood” affect. Dosage: 1.0 g in 10 mL sterile water, administer I.V. over 2 minutes (adults), or 14 mg/kg pediatric 10 to 20 minutes before injection of radiotracer. Or, 1.0 g orally before radiotracer injection.

ADENOSINE (CARDIAC STRESS TEST) Wt. in Lbs_____ ÷ 2.2 = _____ kg × 140 mcg/min =_____kg/mcg/min × 6 min = _____mcgs × 1000 (to convert to mgs) = _____ mgs ÷ 3 mg/cc = _____cc. or: Wt. in kg × .83 (already converted to mgs) ÷ 3 = ______ cc’s to draw up. or: Wt. in kg × .28 = ____cc’s to draw up, × 3 = total mg’s given to patient. Usually diluted to 30 cc’s with saline or 60 cc’s if weight is more than 235.7 lbs. Administer slowly over 6 minutes. Although the half-life is less than 10 seconds, antidote, if needed, is aminophylline. Or: 50 ug/kg/min increased to 75, 100, and 140 ug/kg/min each minute for 7 minutes.

BETHANECHOL (URECHOLINE—GASTRIC EMPTYING) 2.5–5 mg subcutaneously.

CAPTOPRIL (CAPOTEN®) (RENAL HYPERTENSION STUDIES) 25–50 mg capsule or tablet usually given orally an hour before renal imaging as standard dose in hypertension study.

CHOLECYSTOKININ (CCK, SINCALIDE, KINEVAC®) (HIDA/GALLBLADDER STUDIES) Wt. in Lbs____ ÷ 2.2 = ____ kg × 0.02 mcg/kg = _____ mcg ÷ 1 mcg/cc = _____ cc. Administer I.V., in up to 10 mL saline slowly over 3 to 10 minutes. Vials supplied with 5 mcg. Add 5 mL sterile water. Some administer 1.5 mcg for gallbladder studies or 1.5 mL in a 3 cc syringe.

CIMETIDINE (TAGAMET®): (MECKEL’S DIVERTICULUM STUDY) Supply: 300 mg tablets, 300 mg/5 ml oral liquid, 300 mg/2 mL I.V. Dosage: 300 mg tablets qid, 300 mg in 20 mL saline I.V., no dilution if I.M. Administer: P.O. for 24 hours before exam, I.V. push slowly over 5 minutes, or I.M., qid 24 hours before exam. Pediatric 20 mg/kg in 20 mL saline I.V. over 20 minutes. 423

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 424

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

DIPYRIDAMOLE (PERSANTINE®) (CARDIAC STRESS TEST) Wt. in Lbs_____ ÷ 2.2 = _____ kg × 0.57 mg/kg = ______ mg ÷ 5 mg/cc = _____cc. Maximum dose per patient: 60 mg Maximum patient size/vial: 105.5 kg or 232 Lbs. 0.57 mg × Wt. in kg = pt. dose 0.259 mg × Wt. in Lbs = pt. dose 10 mL vials @ 5 mg/mL 8 minute protocol: Dilute with saline to total of 50 mL. Administer I.V. slowly over 8 minutes. 4 minute protocol: Dilute with saline to total of 30 mL. Administer I.V. slowly over 4 minutes. Maximum dose is 60 mg. Antidote is aminophylline.

DOBUTAMINE (CARDIAC STRESS TEST) Administer in increments of three minutes, I.V., based on patient weight and age (max and submax heart rates). Cardiologist calls the test. Start with 250 mg dobutamine mixed in 250 cc normal saline (or D5W) in a final solution of 1000 ugm/cc. 5 mcg/kg/min for 3 minutes 10 mcg/kg/min for 3 minutes Continue by 5 mcg/kg/min to 40 mcg. Some prefer 15 mcg/kg/min up to 40 mcg/kg/min every 3 minutes. Antidote is Inderol® (atropine, Lopressor®, Proventil® also used). Propranolol or Lopressor® may be administered (0.1 mg/kg) I.V. to interrupt ischemia. Atropine may be administered (0.6 mg) I.V. to increase heart rate if dobutamine is failing.

ENALAPRILAT (VASOTEC®) ACE INHIBITOR (RENAL STUDIES) Wt. in Lbs_____ ÷ 2.2 = _____kg × 0.04 mg/kg = _____ mg ÷ 1.25 mg/cc = _____cc. Administer I.V. slowly in 10 mL saline over 3–5 minutes. Maximum 2.5 mg.

ERYTHROMYCIN (GASTRIC EMPTYING) Supply: 500 mg and 1 g vials. Reconstitute with 10 cc sterile water. Draw the equal of 250 mg from vial and mix with more sterile water if necessary to equal 5 cc. Mix that amount into a 50 cc normal saline bag. Attach to patient and drip (10–16 drips per minute) for 20 minutes.

FUROSEMIDE (LASIX®) (RENAL SCANS) Wt. in Lbs_____ ÷ 2.2 = ______ kg × 0.3 mg/kg = _____ mg ÷ 10 mg/cc = ______cc. 20 to 40 mg given in some renal studies as standard dose. Pediatric: 1.0 mg/kg. Vials supplied with 40 mg in 4 mL. Administer I.V. slowly over 1–2 minutes. 424

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 425

Quick Reference D — Standard Drug Interventions

GLUCAGON (MECKEL’S DIVERTICULUM STUDY) Adult: 0.5 mg. Pediatric: 5 mcg/kg I.V. or I.M.

METOCLOPRAMIDE (REGLAN®) (GASTRIC EMPTYING) Supply: 10 mg/2mL ampule. Add 2 cc saline. If 5 mg needed, draw 1 cc and add 1 cc saline to equal 2 cc. Adult dose: 5–10 mg I.V. Administer slowly over 2 minutes by nurse or doctor. Response in 1 to 3 minutes P. I.

MORPHINE SULFATE (HIDA/GALLBLADDER STUDIES) Wt. in Lbs____ ÷ 2.2 = ____ kg × 0.04 mg/kg = _____mg ÷ 10 mg/cc =______cc. Wt. in Lbs____ ÷ 2.2 = ____ kg × 0.04 mg/kg = dose Dilute with saline to 10 cc. Administer I.V., slowly over 3–5 minutes. Some administer between 2 to 4.5 mg per patient as a standard dose.

PENTAGASTRIN (PEPTAVLON®): (MECKEL’S DIVERTICULUM STUDY) Supply: 0.25 mg/ml (2.0 ml volume) = 250 mcg/ml. Total in one vial = 500 mcg. Dosage: Pt. wt. in Lb’s ÷ 2.2 = _____ kg × 6 mcg pentagastrin = dose. Administer I.V. 5 to 15 minutes before study.

PHENOBARBITAL (HIDA/GALLBLADDER STUDIES) 5 mg/kg/day for 5 days.

PYROPHOSPHATE (PYP OR PYROLITE®) (RBC TAGGED STUDIES) Warm to room temperature. Inject 2 to 3 mL’s normal saline into vial. Mix, set sit for 5 minutes. Draw back into syringe, (some draw only the equivalent of 1.2 mg Pyp), administer I.V.

ULTRA TAG® Draw .3 to 1 cc heparin into 3 to 6 cc syringe. (10–15 units/cc) Draw 2 to 3 cc patient blood into syringe, (more if RBC count is low), mix well. Inject contents into package vial, let sit for 5 minutes, swirl once or twice. Inject package syringe I, swirl, Inject package syringe II, swirl. 425

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 426

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Inject 99mTc-04− (amount as per protocol, 20 to 50 mCi) into vial, let sit for 20 minutes. Withdraw amount of activity as per protocol. Reinject into patient.

BODY SURFACE AREA Mosteller: (recommended) BSA (m2) = ([height in cm × weight in kg] / 3600)1/2 or: BSA (m2) = ([height in inches × weight in pounds] / 3131)1/2 DuBois and variation: BSA (m2) = 0.20247 × height (m)0.725 × weight (kg)0.425 BSA (m2) = 0.007184 × height (cm)0.725 × weight (kg)0.425 Haycock: BSA (m2) = 0.024265 × height (cm)0.42246 × weight (kg)0.51456 Gehan and George: BSA (m2) = 0.0235 × height (cm)0.42246 × weight (kg)0.51456 Boyd: BSA (m2) = 0.0003207 × height (cm)0.3 × weight (g)(0.7285 − [0.0188 × LOG(g)]) www.halls.md/body-surface-area/refs.htm

DRIP CONVERSIONS 15 drops = 1 cc. Some tubing has drip factor (on package) of 10, micro-tubing at 60. # cc’s in bag ÷ time to drip into patient in minutes = cc’s / minute. Cc’s / min × 15 = drops per minute. (Or divide by 2 for drops per 30 seconds or etc.)

IDEAL BODY WEIGHT (IBW) IN CONJUNCTION WITH INSULIN DOSAGE FOR PET SCANS Female: (Ht in cm − 152.4 cm) × 0.91 ÷ 45.5 kg = Ideal body weight (IBW) Actual weight in kg ÷ IBW × 100 = % of IBW Male: (Ht in cm − 152.4 cm) × 0.91 ÷ 50.0 kg = Ideal body weight (IBW) Actual weight in kg ÷ IBW × 100 = % of IBW Insulin dose: units/kg actual body weight percent of Ideal Body Weight 0.1 <120% 0.15 120–130% 0.20 >130% Add 0.05 units/kg if patient is taking >80 units/day in any combined form of insulin. Dose is then adjusted for patient weight with consideration to amount and type of insulin previously administered that day. Determination of final dextrose and insulin dose for hyperglycemic diabetic patients will be assessed by nuclear physician or PET specialist.

PEDIATRIC DOSE (Patient weight in kg’s × adult dose) ÷ 70 kg = pediatric dose. (Patient weight in lb’s × adult dose) ÷ 154 lb = pediatric dose. See Pediatric Doses in Reference Section. 426

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 427

Quick Reference D — Standard Drug Interventions

Suggested Readings Chohan, Naina. ed. Nursing 99 Drug Handbook. Springhouse, PA: Springhouse, 1999. Datz, Frederick L. Handbook of Nuclear Medicine. 2nd ed. St. Louis: Mosby, 1993. Duffy, Marjorie A. ed. Physicians’ Desk Reference. 46th ed. Montvale, NJ: Medical Economics Company, 1992. Early, Paul J. and D. Bruce Sodee. Principles and Practice of Nuclear Medicine. 2nd ed. St. Louis: Mosby, 1995. Mettler, Fred A. Jr., and Milton J. Guiberteau. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray, I.P.C. et al. eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol. 1 and 2. New York: Churchill Livingstone, 1994. Wilson, Michael A. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

427

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 428

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

4 MINUTE PROTOCOL ADENOSINE INFUSION TABLE lbs

kgs

mg

95

43.1 24.2

8.0 128 58.2 32.6 10.9 161 73.2 41.1 13.7 194

88.2 49.5 16.5 227 103.1 57.9 19.3

96

43.6 24.5

8.1 129 58.6 32.9 11.0 162 73.6 41.3 13.8 195

88.6 49.7 16.6 228 103.6 58.1 19.4

97

44.1 24.7

8.3 130 59.1 33.2 11.1 163 74.1 41.6 13.9 196

89.1 50.0 16.7 229 104.1 58.4 19.5

98

44.6 25.0

8.3 131 59.6 33.4 11.1 164 74.6 41.8 13.9 197

89.6 50.2 16.8 230 104.6 58.7 19.6

99

45

8.4 132 60

90

25.2

mL lbs kgs

mg

mL lbs kgs

33.7 11.2 165 75

mg

mL lbs

42.1 14.0 198

kgs

mg

mL lbs

kgs

50.5 16.8 231 105

mg

mL

58.9 19.6

100 45.5 25.5

8.5 133 60.5 33.9 11.3 166 75.5 42.3 14.1 199

90.5 50.8 16.9 232 105.5 59.2 19.7

101 46

25.7

8.5 134 60.9 34.2 11.4 167 75.9 42.6 14.2 200

90.9 51.0 17.0 233 105.9 59.4 19.8

102 46.3 26.0

8.8 135 61.4 34.4 11.5 168 76.4 42.8 14.3 201

91.4 51.3 17.1 234 106.4 59.7 19.9

103 46.8 26.2

8.8 136 61.8 34.7 11.6 169 76.8 43.1 14.4 202

91.8 51.5 17.2 235 106.8 59.9 20.0

104 47.2 26.5

8.8 137 62.3 34.9 11.7 170 77.3 43.4 14.5 203

92.3 51.8 17.3 236 107.3 60.2 20.0

105 47.7 26.7

8.9 138 62.7 35.2 11.7 171 77.2 43.6 14.5 204

92.7 52.0 17.3 237 107.7

106 48.1 27.0

9.0 139 63.2 35.5 11.8 172 78.2 43.9 14.6 205

93.2 52.3 17.4 238 108.2

107 48.6 27.2

9.1 140 63.6 35.7 11.9 173 78.6 44.1 14.7 206

93.6 52.5 17.5 239 108.6

108 49.1 27.5

9.2 141 64.1 36.0 12.0 174 79.1 44.4 14.8 207

94.1 52.8 17.6 240 109.1

109 49.5 27.8

9.3 142 64.5 36.2 12.1 175 79.6 44.6 14.9 208

94.6 53.0 17.7 241 109.6

110 50

9.4 143 65

95

28.0

36.5 12.2 176 80

44.9 15.0 209

53.3 17.8 242 110

111 50.5 28.3

9.4 144 65.5 36.7 12.2 177 80.5 45.1 15.1 210

95.5 53.6 17.9 243 110.5

112 50.9 28.6

9.5 145 65.9 37.0 12.3 178 80.9 45.4 15.1 211

95.9 53.8 17.9 244 110.9

113 51.3 28.8

9.6 146 66.4 37.2 12.4 179 81.4 45.7 15.2 212

96.4 54.1 18.0 245 111.4

114 52.3 29.3

9.8 147 66.8 37.5 12.5 180 81.8 45.9 15.3 213

96.8 54.3 18.1 246 111.8

115 52.3 29.3

9.8 148 67.3 37.7 12.6 181 82.3 46.2 15.4 214

97.3 54.6 18.2 247 112.3

116 52.7 29.6

9.9 149 67.7 38.0 12.7 182 82.7 46.4 15.5 215

97.7 54.8 18.3 248 112.7

117 53.2 29.8

9.9 150 68.2 38.3 12.8 183 83.2 46.7 15.6 216

98.2 55.1 18.4 249 113.2

118 53.6 30.1 10.0 151 68.6 38.5 12.8 184 83.6 46.9 15.6 217

98.6 55.3 18.5 250 113.6

119 54.1 30.3 10.1 152 69.1 38.8 12.9 185 84.1 47.2 15.7 218

99.1 55.6 18.5 251 114.1

120 54.5 30.6 10.2 153 69.6 39.0 13.0 186 84.6 47.4 15.8 219

99.6 55.9 18.6 252 114.6

121 55

30.9 10.3 154 70

39.3 13.1 187 85

47.7 15.9 220 100

56.1 18.7 253 115

122 55.5 31.1 10.4 155 70.5 39.5 13.2 188 85.5 47.9 16.0 221 100.5 56.4 18.8 254 115.5 123 55.9 31.4 10.5 156 70.9 39.8 13.3 189 85.9 48.2 16.1 222 100.9 56.6 18.9 255 115.9 124 56.4 31.6 10.5 157 71.4 40.0 13.4 190 86.4 48.5 16.2 223 101.4 56.9 19.0 256 116.4 125 56.8 31.9 10.6 158 71.8 40.3 13.4 191 86.8 72.9 16.2 224 101.8 57.1 19.0 257 116.8 126 57.3 32.1 10.7 159 72.3 40.6 13.5 192 87.3 49.0 16.3 225 102.3 57.4 19.1 258 117.3 127 57.7 32.4 10.8 160 72.7 40.8 13.6 193 87.7 49.2 16.4 226 102.7 57.6 19.2 259 117.7 4 minute protocol: Wt. in lbs 2.2 = wt. in kgs × .187 (= mL’s adenosine to withdraw) × 3 = total mgs adenosine. Queue to 20 mL’s with normal saline and infuse over 4 minutes. Maximum infusion is 20 mL’s (60 mg) at 236 lbs and heavier. 428

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 429

Quick Reference D — Standard Drug Interventions

6 MINUTE PROTOCOL ADENOSINE INFUSION TABLE lb

kg mg/6 mL/6

lb

kg mg/6 mL/6

lb

kg mg/6 mL/6

lb

kg mg/6 mL/6

lb

kg mg/6 mL/6

95

43 36.1 12.0 128 58 48.9

16.3 161 73 61.5 20.5 194 88 74.1 24.7 227 103 86.7 28.9

96

44 36.7 12.2 129 59 49.3

16.4 162 74 61.9 20.6 195 89 74.5 24.8 228 104 87.1 29.0

97

44 37.0 12.3 130 59 49.6

16.5 163 74 62.2 20.7 196 89 74.8 24.9 229 104 87.4 29.1

98

45 37.4 12.5 131 60 50.0

16.7 164 75 62.6 20.9 197 90 75.2 25.1 230 105 87.8 29.3

99

45 37.8 12.6 132 60 50.4

16.8 165 75 63.0 21.0 198 90 75.6 25.2 231 105 88.2 29.4

100 45 38.2 12.7 133 60 50.8

16.9 166 75 63.4 21.1 199 90 76.0 25.3 232 105 88.6 29.5

101 46 38.6 12.9 134 61 51.2

17.1 167 76 63.8 21.3 200 91 76.4 25.5 233 106 89.0 29.7

102 46 38.9 13.0 135 61 51.5

17.2 168 76 64.1 21.4 201 91 76.7 25.6 234 106 89.3 29.8

103 47 39.3 13.1 136 62 51.9

17.3 169 77 64.5 21.5 202 92 77.1 25.7 235 107 89.7 29.9

104 47 39.7 13.2 137 62 52.3

17.4 170 77 64.9 21.6 203 92 77.5 25.8 236 107 90.1 30.0

105 48 40.1 13.4 138 63 52.7

17.6 171 78 65.3 21.8 204 93 77.9 26.0 237 108 90.5 30.2

106 48 40.5 13.5 139 63 53.1

17.7 172 78 65.7 21.9 205 93 78.3 26.1 238 108 90.9 30.3

107 49 40.9 13.6 140 64 53.5

17.8 173 79 66.1 22.0 206 94 78.7 26.2 239 109 91.3 30.4

108 49 41.2 13.7 141 64 53.8

17.9 174 79 66.4 22.1 207 94 79.0 26.3 240 109 91.6 30.5

109 50 41.6 13.9 142 65 54.2

18.1 175 80 66.8 22.3 208 95 79.4 26.5 241 110 92.0 30.7

110 50 42.0 14.0 143 65 54.6

18.2 176 80 67.2 22.4 209 95 79.8 26.6 242 110 92.4 30.8

111 50 42.4 14.1 144 65 55.0

18.3 177 80 67.6 22.5 210 95 80.2 26.7 243 110 92.8 30.9

112 51 42.8 14.3 145 66 55.4

18.5 178 81 68.0 22.7 211 96 80.6 26.9 244 111 93.2 31.1

113 51 43.1 14.4 146 66 55.7

18.6 179 81 68.3 22.8 212 96 80.9 27.0 245 111 93.5 31.2

114 52 43.5 14.5 147 67 56.1

18.7 180 82 68.7 22.9 213 97 81.3 27.1 246 112 93.9 31.3

115 52 43.9 14.6 148 67 56.5

18.8 181 82 69.1 23.0 214 97 81.7 27.2 247 112 94.3 31.4

116 53 44.3 14.8 149 68 56.9

19.0 182 83 69.5 23.2 215 98 82.1 27.4 248 113 94.7 31.6

117 53 44.7 14.9 150 68 57.3

19.1 183 83 69.9 23.3 216 98 82.5 27.5 249 113 95.1 31.7

118 54 45.1 15.0 151 69 57.7

19.2 184 84 70.3 23.4 217 99 82.9 27.6 250 114 95.5 31.8

119 54 45.4 15.1 152 69 58.0

19.3 185 84 70.6 23.5 218 99 83.2 27.7 251 114 95.8 31.9

120 55 45.8 15.3 153 70 58.4

19.5 186 85 71.0 23.7 219 100 83.6 27.9 252 115 96.2 32.1

121 55 46.2 15.4 154 70 58.8

19.6 187 85 71.4 23.8 220 100 84.0 28.0 253 115 96.6 32.2

122 55 46.6 15.5 155 70 59.2

19.7 188 85 71.8 23.9 221 100 84.4 28.1 254 115 97.0 32.3

123 66 47.0 15.7 156 71 59.6

19.9 189 86 72.2 24.1 222 101 84.8 28.3 255 116 97.4 32.5

124 56 47.3 15.8 157 71 59.9

20.0 190 86 72.5 24.2 223 101 85.1 28.4 256 116 97.7 32.6

125 57 47.7 15.9 158 72 60.3

20.1 191 87 72.9 24.3 224 102 85.5 28.5 257 117 98.1 32.7

126 57 48.1 16.0 159 72 60.7

20.2 192 87 73.3 24.4 225 102 85.9 28.6 258 117 98.5 32.8

127 58 48.5 16.2 160 73 61.1

20.4 193 88 73.7 24.6 226 103 86.3 28.8 259 118 98.9 33.0

Total mg given: mg/6 min = weight in kg × 0.14 × 6 min Total adenosine to withdraw: mL/6 min = (kg × 0.14 × 6) ÷ 3 429

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 430

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

DOBUTAMINE DRIP INFUSION TABLE lb

kg mg/3 mL/h lb kg mg/3 mL/h lb kg mg/3 mL/h lb

kg mg/3 mL/h lb

kg mg/3 mL/h

95

43 64.8 77.8 128 58

87.3 105 161 73 109.8 132 194

88 132.3 159 227 103 154.8 186

96

44 65.5 78.5 129 59

88.0 106 162 74 110.5 133 195

89 133.0 160 228 104 155.5 187

97

44 66.1 79.4 130 59

88.6 106 163 74 111.1 133 196

89 133.6 160 229 104 156.1 187

98

45 66.8 80.2 131 60

89.3 107 164 75 111.8 134 197

90 134.3 161 230 105 156.8 188

99

45 67.5 81.0 132 60

90.0 108 165 75 112.5 135 198

90 135.0 162 231 105 157.5 189

100 45 68.2 81.8 133 60

90.7 109 166 75 113.2 136 199

90 135.7 163 232 105 158.2 190

101 46 68.9 82.6 134 61

91.4 110 167 76 113.9 137 200

91 136.4 164 233 106 158.9 191

102 46 69.5 83.5 135 61

92.0 110 168 76 114.5 137 201

91 137.0 164 234 106 159.5 191

103 47 70.2 84.3 136 62

92.7 111 169 77 115.2 138 202

92 137.7 165 235 107 160.2 192

104 47 70.9 85.1 137 62

93.4 112 170 77 115.9 139 203

92 138.4 166 236 107 160.9 193

105 48 71.6 85.9 138 63

94.1 113 171 78 116.6 140 204

93 139.1 167 237 108 161.6 194

106 48 72.3 86.7 139 63

94.8 114 172 78 117.3 141 205

93 139.8 168 238 108 162.3 195

107 49 73.0 87.5 140 64

95.5 115 173 79 118.0 142 206

94 140.5 169 239 109 163.0 196

108 49 73.6 88.4 141 64

96.1 115 174 79 118.6 142 207

94 141.1 169 240 109 163.6 196

109 50 74.3 89.2 142 65

96.8 116 175 80 119.3 143 208

95 141.8 170 241 110 164.3 197

110 50 75.0 90.0 143 65

97.5 117 176 80 120.0 144 209

95 142.5 171 242 110 165.0 198

111 50 75.7 90.8 144 65

98.2 118 177 80 120.7 145 210

95 143.2 172 243 110 165.7 199

112 51 76.4 91.6 145 66

98.9 119 178 81 121.4 146 211

96 143.9 173 244 111 166.4 200

113 51 77.0 92.5 146 66

99.5 119 179 81 122.0 146 212

96 144.5 173 245 111 167.0 200

114 52 77.7 93.3 147 67 100.2 120 180 82 122.7 147 213

97 145.2 174 246 112 167.7 201

115 52 78.4 94.1 148 67 100.9 121 181 82 123.4 148 214

97 145.9 175 247 112 168.4 202

116 53 79.1 94.9 149 68 101.6 122 182 83 124.1 149 215

98 146.6 176 248 113 169.1 203

117 53 79.8 95.7 150 68 102.3 123 183 83 124.8 150 216

98 147.3 177 249 113 169.8 204

118 54 80.5 96.5 151 69 103.0 124 184 84 125.5 151 217

99 148.0 178 250 114 170.5 205

119 54 81.1 97.4 152 69 103.6 124 185 84 126.1 151 218

99 148.6 178 251 114 171.1 205

120 55 81.8 98.2 153 70 104.3 125 186 85 126.8 152 219 100 149.3 179 252 115 171.8 206 121 55 82.5 99.0 154 70 105.0 126 187 85 127.5 153 220 100 150.0 180 253 115 172.5 207 122 55 83.2 99.8 155 70 105.7 127 188 85 128.2 154 221 100 150.7 181 254 115 173.2 208 123 56 83.9 101

156 71 106.4 128 189 86 128.9 155 222 101 151.4 182 255 116 173.9 209

124 56 84.5 101

157 71 107.0 128 190 86 129.5 155 223 101 152.0 182 256 116 174.5 209

125 57 85.2 102

158 72 107.7 129 191 87 130.2 156 224 102 152.7 183 257 117 175.2 210

126 57 85.9 103

159 72 108.4 130 192 87 130.9 157 225 102 153.4 184 258 117 175.9 211

127 58 86.6 104

160 73 109.1 131 193 88 131.6 158 226 103 154.1 185 259 118 176.6 212

mg/3 min = kg × 0.5 mg × 3 min mL/h = (kg × 0.5 × 3) ÷ 0.83 430

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 431

Quick Reference D — Standard Drug Interventions

PERSANTINE® INFUSION TABLE lb

kg

mg/4

lb

kg

mg/4

lb

kg

mg/4

lb

kg

mg/4

96

44

24.8

131

60

33.8

166

75

42.9

201

91

51.9

97

44

25.0

132

60

34.1

167

76

43.1

202

92

52.2

98

45

25.3

133

60

34.3

168

76

43.4

203

92

52.4

99

45

25.6

134

61

34.6

169

77

43.6

204

93

52.7

100

45

25.8

135

61

34.9

170

77

43.9

205

93

52.9

101

46

26.1

136

62

35.1

171

78

44.1

206

94

53.2

102

46

26.3

137

62

35.4

172

78

44.4

207

94

53.4

103

47

26.6

138

63

35.6

173

79

44.7

208

95

53.7

104

47

26.9

139

63

35.9

174

79

44.9

209

95

54.0

105

48

27.1

140

64

36.1

175

80

45.2

210

95

54.2

106

48

27.4

141

64

36.4

176

80

45.4

211

96

64.5

107

49

27.6

142

65

36.7

177

80

45.7

212

96

54.7

108

49

27.9

143

65

36.9

178

81

46.0

213

97

55.0

109

50

28.1

144

65

37.2

179

81

46.2

214

97

56.3

110

50

28.4

145

66

37.4

180

82

46.6

215

98

55.5

111

50

28.7

146

66

37.7

181

82

46.7

216

98

55.8

112

51

28.9

147

67

38.0

182

83

47.0

217

99

56.0

113

51

29.2

148

67

38.2

183

83

47.2

218

99

56.3

114

52

29.4

149

68

38.5

184

84

47.5

219

100

56.5

115

52

29.7

150

68

38.7

185

84

47.8

220

100

56.8

116

53

29.9

151

69

39.0

186

85

48.0

221

100

57.1

117

53

30.2

152

69

39.2

187

85

48.3

222

101

57.3

118

54

30.5

153

70

39.5

188

85

48.5

223

101

57.6

119

54

30.7

154

70

39.8

189

86

48.8

224

102

57.8

120

55

31.0

155

70

40.0

190

86

49.1

225

102

58.1

121

55

31.2

156

71

40.3

191

87

49.3

226

103

58.3

122

55

31.5

157

71

40.5

192

87

49.6

227

103

58.6

123

56

31.8

158

72

40.8

193

88

49.8

228

104

58.9

124

56

32.0

159

72

41.1

194

88

50.1

229

104

59.1

125

57

32.3

160

73

41.3

195

89

50.3

230

105

59.4

126

57

32.6

161

73

41.6

196

89

60.6

231

105

59.6

127

58

32.8

162

74

41.8

197

90

50.9

232

105

59.9

128

58

33.0

163

74

42.1

198

90

51.1

233

106

60

129

59

33.3

164

75

42.3

199

90

51.4

234

106

60

130

59

33.6

165

75

42.6

200

91

51.6

235

107

60

Reverse with aminophylline: 100–125 mg at 50 mg/min Maximum dose = 60 mg mg/4 = kg × 0.142 × 4 min 431

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 432

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

UROKINASE INFUSION TABLE Rate (mL/h) 1

Dosage (U/min) 83.3333

Rate (mL/h)

Dosage (U/min)

Dosage (U/h)

5,000

31

2583.33

155,000

Dosage (U/h)

2

166.667

10,000

32

2666.67

160,000

3

250

15,000

33

2750

165,000

4

333.333

20,000

34

2833.33

170,000

5

416.667

25,000

35

2916.67

175,000

6

500

30,000

36

3000

180,000

7

583.333

35,000

37

3083.33

185,000

8

666.667

40,000

38

3166.67

190,000

9

750

45,000

39

3250

195,000

10

833.333

50,000

40

3333.33

200,000

11

916.667

55,000

41

3416.67

205,000

12

1000

60,000

42

3500

210,000

13

1083.33

65,000

43

3583.33

215,000

14

1166.67

70,000

44

3666.67

220,000

15

1250

75,000

45

3750

225,000

16

1333.33

80,000

46

3833.33

230,000

17

1416.67

85,000

47

3916.67

235,000

18

1500

90,000

48

4000

240,000

19

1583.33

95,000

49

4083.33

245,000

20

1666.67

100,000

50

4166.67

250,000

21

1750

105,000

51

4250

255,000

22

1833.33

110,000

52

4333.33

260,000

23

1916.67

115,000

53

4416.67

265,000

24

2000

120,000

54

4500

270,000

25

2083.33

125,000

55

4583.33

275,000

26

2166.67

130,000

56

4666.67

280,000

27

2250

135,000

57

4750

285,000

28

2333.33

140,000

58

4833.33

290,000

29

2416.67

145,000

59

4916.67

295,000

30

2500

150,000

60

5000

300,000

For lysis of pulmonary emboli, usually 4400 IU/kg for 10 minutes, then 4400 IU/kg per hour for 12–24 hours.

432

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 433

Quick Reference D — Standard Drug Interventions

SIDE EFFECTS OF COMMON DRUGS Adrenergics: nausea and vomiting, anorexia, headache, anaphylaxis, hypotension, insomnia, angina, anxiety, dizziness, pallor, flushing, dysuria, bradycardia, tachycardia, asthmatic episodes.

Antidiabetics: nausea, vomiting, and diarrhea, headache, abdominal pain, dizziness, jaundice, rash, weakness, anemia, hematologic changes, anaphylaxis.

Electrolytes, vitamins, or minerals: nausea, vomiting, and diarrhea, headache, confusion, arrhythmia, abdominal pain, hypotension, palpitations, hematologic and hepatic changes, weakness, anaphylaxis, wheezing, rash, diaphoresis.

Adrenocortical steroids: nausea and vomiting, headache, pancreatitis, seizures, hypertension, congestive heart failure, rash, poor wound healing, glaucoma, shock, weakness.

Antiemetics: nausea, vomiting, and diarrhea, headache, dry mouth, dizziness, confusion, blurred vision, drowsiness, hypotension, palpitations, tachycardia, wheezing, anaphylaxis.

Inotropics or cardiac glycosides: nausea, vomiting, and diarrhea, headache, fatigue, anorexia, cramps, confusion, visual disturbance, dizziness, arrhythmia, muscular weakness.

Antacids: nausea, vomiting, and diarrhea, constipation, fecal impactions, Ca2+ imbalance, anorexia, encephalopathy, mental depression, osteomalacia, muscle weakness.

Antihistamines: nausea, vomiting, and diarrhea, headache, drowsiness, dizziness, dry mouth, epigastric pain, anorexia, constipation, urinary frequency or retention, nervousness, palpitations, hypotension, tachycardia, anaphylaxis.

Laxatives or stool softeners: nausea, vomiting, and diarrhea, dizziness, cramps, weakness, dehydration.

Antianginals: nausea, vomiting, and diarrhea, headache, rash, arrhythmia, abdominal pain, tachycardia, hypotension, dizziness, weakness, dyspnea.

Antihypertensives: nausea, vomiting, and diarrhea, headache, congestive heart failure, constipation, abdominal pain, tachycardia, bradycardia, orthostatic hypotension, angina, rash.

Muscle relaxants: nausea, vomiting, and diarrhea, headache, dizziness, fatigue, hypo/hypertension, constipation, tachycardia, bradycardia, arrhythmia, blurred vision, diaphoresis, urinary frequency or retention.

Antiarrhythmics: nausea and vomiting, headache, abdominal pain, liver disorders, bitter taste, rash, CHF, hypotension, flushing, blurred vision, chest pressure, dyspnea.

Antilipemics: nausea, vomiting, and diarrhea, headache, constipation, flatulence, dizziness, fatigue, syncope, tinnitus, GI bleed, abdominal pain, hematuria, dysuria, rash.

Narcotic analgesics: nausea and vomiting, headache, dry mouth, constipation, urinary retention, dyspnea, bradycardia, tachycardia, hypertension, dizziness, sedation.

Anti-Infectives/Antivirals: nausea, vomiting, and diarrhea, headache, fever, confusion, anorexia, skin disorders, respiratory disorders, dizziness, hypotension, weakness.

Antineoplastics: nausea, vomiting, and diarrhea, headache, dizziness, abdominal pain, renal & hepatic disorders, hematologic changes, rash, alopecia.

Nonnarcotic analgesics: nausea, vomiting, and diarrhea, headache, anorexia, GI bleed, rash, leukopenia, increased prothrombin time, tinnitus, dizziness, confusion, thirst, thrombocytopenia, hepatitis, shortness of breath.

Anticholinergics: nausea and vomiting, headache, heartburn, constipation, blurred vision, urinary hesitancy and retention, tachycardia, rash, nervousness.

Antiparkinsons: nausea, vomiting, and diarrhea, headache, constipation, hallucinations, confusion, blurred vision, GI cramps, insomnia, weakness, nervousness, anxiety, tachycardia, orthostatic hypotension.

Sedatives or hypnotics: nausea, vomiting, and diarrhea, headache, abdominal pain, rash, dizziness, delirium, excitement, confusion, hypotension, apnea.

Anticoagulants: nausea, vomiting, and diarrhea, headache, fever, hemorrhage, liver disorders, GI bleed, rash, thrombocytopenia, decreased renal flow.

Bronchodilators: nausea, vomiting, and diarrhea, headache, hypertension, seizures, anorexia, restlessness, tachycardia, arrhythmia, anxiety, tremor, bronchospasms.

Thyroid hormones: nausea, vomiting, and diarrhea, headache, palpitations, arrhythmia, angina, tachycardia, tremors, insomnia, depression, nervousness, anorexia, weight loss, edema. 433

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 434

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

(Continued) Anticonvulsants: nausea, vomiting, and diarrhea, nystagmus, constipation, confusion, dizziness, rash, fatigue, nervousness, palpitations, hypotension, hypertension.

Cholinergics: nausea, vomiting, and diarrhea, headache, blurred vision, dizziness, weakness, abdominal cramps, rash, urinary urgency, hypotension, bradycardia, diaphoresis.

Tranquilizers or antipsychotics: nausea, vomiting, and diarrhea, anorexia, psychosis, dry mouth, constipation, liver disorders, postural hypotension, hypertension, tachycardia, cardiac arrest, urine retention, diaphoresis, rash.

Antidepressants: nausea, vomiting, and diarrhea, headache, seizures, delusions, constipation, orthostatic hypotension, hypertension, arrhythmia, tachycardia, confusion, anxiety, dry mouth, rash.

Diuretics: nausea, vomiting, and diarrhea, headache, confusion, syncope, weakness, dizziness, orthostatic hypotension, dysuria, hematuria, constipation, abdominal pain, pancreatitis, dehydration, rash.

Vasodilators: nausea and vomiting, dizziness, weakness, abdominal pain, hypotension, tachycardia, rash.

These are only excerpts. See complete listings of particular drug in Nursing 2007 Drug Handbook, LWW, PA ©2007

434

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 435

Quick Reference D — Standard Drug Interventions

DRUGS AND STUDIES AFFECTING 123I AND 131I UPTAKE: SUGGESTED WITHHOLDING TIMES Treatment

Off

Treatment

Off

Anticoagulants

1 week 3 to 6 months

3 days

Antiarrythmics: Amiodarone HCL; Aratac, Cordarone, Pacerone

Seafood

3 days

Antiepileptics

1 week

Shellfish

3 days

Antihistamines

1 week

Soy products

3 days

Antiparasitics

1 week

Table salt (large amounts)

3 days

Antiprotozoan

1 month

Low iodine diet 7–14 days before radioiodine therapy.

Aspirin (large doses of)

1 week

Benzodiazapines

4 weeks

No food 2 h before and 2 h after dosing if early uptake is planned.

Birth Control pills (↓ uptake)

2 weeks

Butazolidin

1 week

Butizalidine (Butizol)

3 weeks

Cobalt

1 week

Combid

1 week

Cough Medicines

2 week

Ibuprofin

1 week 2 to 7 weeks 2 weeks 1 week

Food Cabbage

3 days

Kelp (seaweed, agar, carageen)

Iodine Preparations Antitussives

3 weeks

Betadine

2 weeks

Diodoquin

3 weeks

Enterosept

3 weeks

Enterovioform

3 weeks

Iodides (topical)

1 to 9 months

Iodine ointments (topical)

3 weeks

Multi-vitamins Theragram M Vitamin preps M

Iodine suppositories

3 weeks

NSAID (all)

1 week

Iodine tincture (topical)

3 weeks

Nitrate

1 week

Iodoform (topical)

3 weeks

Orinase

1 week

Iodoquinol (Yodoxin)

3 weeks

Ornade

1 week

Lugol’s solution (strong iodine solution)

3 weeks

PAS and Isoniacid

1 week

Potassium iodide (Pima, Avadrinal, Thyro-Block)

3 weeks

Penicillin (antibiotics) (1 g doses of) e.g., Neo-penil

3 weeks

SSKI (potassium iodine, saturated solution)

3 weeks

Pentothal

1 week

Perchlorate

up to 6 weeks

Therapy dose

3 months

Phenothiazine

3 days

Vaginal suppositories w/iodine

3 weeks

Phenylbutazone

1 to 2 weeks

Chemicals and Drugs ACTH

Progesterone

1 month

1 week

Resorcinal

1 week

Salicylates

1 week

Sulfonamides

1 week

Thiocyanates

10 days

131

I

Adrenal Cortical Steroids e.g., cortisone, corticosterone, desoxycorticosterone, prednisone, prednisolone

1 week

Amphenone

3 days

435

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 436

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

(Continued) Treatment

Off

Treatment

Off

Thiopental

1 week

Thioxolon

3 weeks

Tolbutamide

1 week

Contrast Media Aqueous solutions e.g., Diodrast, Hypaque, Medopaque Neo-iopax, Urokon, Miokon, Thixokon, Dionosil

Urokon

30 days

Ateriography

up to 3 months

Visciodol

1 year or more

Oily solutions; Lipiodol, Visciodol, Oil-based iodinated contrast agents Bronchographic Myleographic

6 to 12 months

Ethiodol, Iodochlorol, Pantopaque

up to 1 year plus

Cholecystopaques and Cholangiopaques Telepaque—gallbladder Cholografin Priodax Gallbladder w/contrast

up to 9 months 3 months 3 months 3 months 3 months

CT scan w/contrast Gastrographin Isoview

3 months 3 months 3 months

Antithyroid Drugs Carbimazole

3 days to 1 week

3 months

2 to 10 years 2 to 10 years

Iothiouracil (Itromil)

1 month

Lithium

1 month

Mercazole

1 month

Methylthiouracil

1 month

Muracil

1 month

Propylthiouracil (PTU) Propyl-Thyracil

3 days to 1 week

Tapazole (methimazole)

3 days to 1 week

Conray

16 days

Heart Cath

3 months

Thiouracil

1 month

IVP

6 weeks

Thyroid Hormones Cytomel (T3—liothyronine sodium), Tertroxin, triostat

Myelogram

up to 6 months

2 weeks Renografin—kidney

2 months

Upper and lower GI x-ray Contrast

4 to 6 weeks

Uterosalpingopaques e.g., Salpingography Salpix Skiodan acacia Ekiodan, acacia

2 months 1 month 1 month 1 month

Dessicated Thyroid grains; Armour Thyroid, S-P-T, Thyrar, Thyroid Strong, Westhroid

6 weeks

Liotrix (T3, T4) Euthyroid, Thyrolar

4 weeks

Proloid (thyroid)

3 weeks

Thyroid caps (T3, T4 supplements)

4 weeks

Synthroid (T4—levothyroxine sodium), Levo-T, Levothyroid, Levoxine, Levoxyl, Oroxine

3–6 weeks

Thyroglobulin

3 weeks

Thyronine (T3)

2 weeks

Thyroxine (T4)

4–6 weeks

Thypinone—(TRH) normal pre-treatment Increases prior to thyroid scan and uptake uptake TSH (thyrotropin)

Increases uptake

Estrogens

Increases uptake (not persistently)

Times vary greatly from source to source. These are only suggested suspensions. Please check with endocrinologist or radiologist. Http://nuclearpharmacy.uams.edu/nicki.html www.uphs.upenn.edu/radiology/reso/handbook/nm.html Leven, David. Understanding Drug-Radiopharmaceutical Interactions. Veterans Administration Medical Center, Bay Pines, FL. February, 1990. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement. Version 3.0, September 5, 2006. SNM.org. 436

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 437

Quick Reference D — Standard Drug Interventions

ANTICOAGULANT DRUGS (IV: intravenous, SQ: subcutaneous, PO: by mouth) Argatroban (IV) Aggrastat (IV or SQ) Bivalirudin (IV) Angiomax ASA (PO) aspirin Ardeparin (IV) Normiflo Clopidogrel (PO) Plavix Dalteparin sodium (SQ) Fragmin Danaparoid (SQ) Orgaran Desirudin (SQ) Iprivask Dipyridamole (PO, IV) Persantine, Dipridacot Enoxaparin sodium (SQ) Lovenox Fondaparinux sodium (SQ) Arixtra Heparin Calcium (IV) Calcilean, Calciparine, Caprin, Uniparin-Ca Heparin Sodium (IV) Hepalean, Heparin Leo, Hep-Lok, Liquaemin, Uniparin Intergrillin (IV or SQ) Pletol (PO) Reo-Pro (IV or SQ) Ticlopidine (PO) Ticlid Tinzaparin (SQ) Innohep Warfarin sodium (IV or PO) Coumadin, Panwarfin, Sofarin, Warfilone Sodium, Jantoven Thrombin Inhibitors (e.g., ATryn, a human protein antithrombin made by a transgenic animal).

Sources Choi, Charles Q. Old MacDonald’s Pharm. Scientific American, September 2006. Brener, Toby. ed. Nursing 2007 Drug Handbook. 27th edition. Philadelphia: Lippincott, Williams and Wilkins, 2006. PDR. Physicians’ Desk Reference, 57th ed. Montvale, NJ: Thompson PDR, 2003.

437

10766-65_QuickRef-D.qxd

12/3/07

5:36 PM

Page 438

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ACE I AND ARB DRUGS FOR RENAL SCANS A Partial List of ACE Inhibitors Accupril/quinapril

Lotensin/benazepril

Uniretic

Accuretic

Mavik/trandolapril

Vasotec/enalapril

Aceon Tablets/perindopril

Monopril/fosinopril

Vaseretic

Altace/ramipril

Prinivil/lisinopril

Zestril/lisinopril

Capoten/captopril

Prinzide

Zestoretic

Capozide

Univasc/moexipril ACE Inhibitors with Calcium Channel Blockers

Lexxel/enalapril

Lotrel/benazepril

Tarka/trandolapril

A Partial List of ARB’s (angiotensin receptor blockers) Atacand/candesartan

Benicar/olmesartan

Hyzaar/losartan

Avalide/irbesartan

Cozaar/losartan

Micardis/telmisartan

Avapro/irbesartan

Diovan/valsartan

Teveten/eprosartan

Brener, Toby. ed. Nursing 2007 Drug Handbook. 27th edition. Philadelphia: Lippincott, Williams and Wilkins, 2006.

438

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 439

QUICK REFERENCE E

Laboratory Tests Normal Ranges Enzymes and Hormones

439

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 440

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Test (serum, plasma)

Normal Range

Clinical Significance

Acid phosphatase

0–11 ng/mL

High: carcinoma of the prostate, advanced Paget’s disease, hyperparathyroidism, Gaucher’s disease (lipid accumulation in the RES)

Adrenocorticotropic hormone (ACTH)

<50 pg/mL

High: pituitary-dependent Cushing’s syndrome, ectopic ACTH syndrome, primary adrenal atrophy Low: adrenocortical tumor, adrenal insufficiency secondary to hypopituitarism

Aldosterone

Supine: 3–10 ng/dL Upright: 5–30 ng/dL Adrenal vein: 200–800 ng/dL

High: primary aldosteronism (Conn’s syndrome), secondary aldosteronism Low: Addison’s disease

Alkaline phosphatase

30–115 mU/mL

High: increased osteoblastic activity of bone, carcinoma of the bones, phosphatase rickets, Paget’s disease (osteitis deformans), hyperparathyroidism, liver disease, obstructive jaundice

Amylase

111–296 U/L

High: acute pancreatitis, mumps, duodenal ulcer, carcinoma of pancreas, drugs that constrict the sphincter of Oddi e.g., morphine, codeine, cholinergics Low: chronic pancreatitis, pancreatic fibrosis and atrophy, cirrhosis of liver, pregnancy

10–40 U/mL 8–35 U/mL

High: liver disease (better marker), myocardial infarction, skeletal muscle disease

AST (SGOT) Males: Females:

10–40 U/L 15–30 U/L

High: liver disease, myocardial infarction, skeletal muscle disease

Bilirubin: total

0.3–1.0 mg/dL

High: biliary obstruction and disease, hepatocellular damage (hepatitis), pernicious anemia, hemolytic anemia

Direct bilirubin:

0.1–0.4 mg/dL

High: biliary obstruction and disease

Indirect bilirubin:

0.1–0.4 mg/dL

High: hepatocellular damage (hepatitis), pernicious anemia, hemolytic disease of newborn

BUN (urea nitrogen)

10–20 mg/dL

High: decreased kidney function, acute glomerulonephritis, obstructive uropathy, diet or strenuous nephrotic syndrome, dehydration, high protein exercise, mercury poisoning Low: severe hepatic failure, pregnancy liver damage, pregnancy, low protein-high carbohydrate diet

Ca-15-3 tumor marker

<30 IU/mL

increased in breast cancer

Ca-19-9 tumor marker

<37 IU/mL

increased in pancreatic, hepatobiliary, gastric, and colorectal cancer, gallstones, and cirrhosis

Ca 125

0–35 IU/mL

increased in colon, upper GI, ovarian, and other gynecologic cancers, pregnancy, peritonitis

Calcitonin Stimulation test Male: Female:

Basal: 19 pg/mL <350 pg/mL <100 pg/mL

High: medullary carcinoma of the thyroid, some nonthyroid tumors, Zollinger-Ellison syndrome

ALT (SGPT)

440

Males: Females:

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 441

Quick Reference E — Laboratory Tests

Test (serum, plasma)

Normal Range

Clinical Significance

Calcium

8.6–10.2 mg/dL

High: tumor or hyperplasia of parathyroid, hypervitaminosis D, multiple myeloma, nephritis with uremia, malignant tumors, sarcoidosis, hyperthyroidism, skeletal immobilization, excess calcium intake: milk-alkali syndrome Low: hypoparathyroidism, diarrhea, celiac disease, vitamin D deficiency, acute pancreatitis, nephrosis

Catecholamines (plasma) Epinephrine: 24 hr urinary excretion: Norepinephrine: plasma concentration Dopamine:

<100 pg/mL 3–18 mg <400 pg/mL 165–460 ng/L <143 pg/mL

High: pheochromocytoma

CEA (carcinoembryonic antigen)

0.0–2.5 ng/mL (nonsmoker) 0.0–5 ng/mL (smoker)

High: repeated elevated levels indicate possible ca of colon, rectum, pancreas, stomach

Cholesterol

150–200 mg/dL

High: increased risk of coronary heart disease, lipemia, obstructive jaundice, diabetes, hypothyroidism Low: pernicious anemia, hemolytic anemia, hyperthyroidism, severe infection, terminal stage illnesses

CO2 (venous)

Adults: 24–32 mEq/L Infants: 18–24 mEq/L

High: tetany, respiratory disease, intestinal obstruction, vomiting Low: acidosis, nephritis, eclampsia, diarrhea, anesthesia

Creatine

0.2–0.8 mg/mL

High: skeletal muscle necrosis or atrophy, pregnancy, starvation, hyperthyroidism

Creatinine

0.7–1.5 mg/dL

High: renal dysfunction, nephritis, destruction of muscle tissue, hyperthyroidism, active rheumatoid arthritis Low: kidney diseases

Folic acid

2.5–20 ng/mL

Low: megaloblastic anemias of infancy or pregnancy, inadequate diet, liver disease, malabsorption syndrome, sever hemolytic anemia

Gastrin

fasting 50–155 ng/L postprandial 80–170 ng/L

High: Zollinger-Ellison syndrome, peptic ulcer (postprandial) of the duodenum, pernicious anemia

GGTP (γ glutamyl transferase) Males: 20–30 U/L Females: 1–24 U/L

High: hepatobiliary disease, anicteric alcoholics, drug therapy damage, myocardial infarction, renal infarction

Glucose Guidelines: normal fasting: Pre-diabetes/impaired glucose: Diabetes: A1C Test: normal <6%, diabetes >6.5% postprandial (2 hrs)

fasting: 60–110 mg/dL <100 mg/dL

High: diabetes, nephritis, hyperthyroidism, early hyperpituitarism, cerebral lesions, infections, pregnancy, uremia Low: hyperinsulinism, hypothyroidism, late hyperpituitarism, pernicious vomiting, Addison’s disease, extensive hepatic damage

Guaiac test

positive/negative

101–125 mg/dL >126 mg/dL

65–140 mg/dL

HDL (high-density lipo-protein male: 35–70 mg/dL “good” cholesterol) female: 35–85 mg/dL

positive: occult blood present in stool Low: increased risk of CAD (continued) 441

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 442

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Test (serum, plasma)

Normal Range

Clinical Significance

Insulin

5–25 uU/mL

High: insulinoma, acromegaly Low: diabetes mellitus

Iron

50–160 ug/dL

High: pernicious anemia, aplastic anemia, hemolytic anemia, hepatitis, hemochromatosis Low: iron deficiency anemia

LDL (low-density lipoprotein “bad” cholesterol)

High: increased risk for coronary artery, coronary heart disease

optimal 50–70 mg/dL

<160 mg/dL no CAD <130 mg/dL no CAD but two risk factors <100 mg/dL w/CAD

Lipase

<200 U/mL

High: acute and chronic pancreatitis, biliary obstruction, cirrhosis, hepatitis, peptic ulcer

Lipids

400–800 mg/dL

High: hypothyroidism, diabetes, nephrosis, glomerulonephritis, hyperlipoproteinemias Low: hyperthyroidism

O2 sat

94–100%

Low: cardiac obstruction, COPD

Phosphorous

2.4–4.5 mg/dL

High: chronic nephritis, hypoparathyroidism Low: hyperparathyroidism, vitamin D deficiency

Total protein

6.3–8.2 gm/dL

High: hemoconcentration Low: malnutrition

Protein/albumin

3.5–5.0 gm/dL

High: shock Low: malnutrition, hemorrhage, proteinuria

Protein/globulin

1.5–3.0 gm/dL

High: multiple myeloma, chronic infections, liver disease Low: malnutrition, hemorrhage, proteinuria

PaO2 (partial pressure)

85–95 mm Hg

High: polycythemia, anhydremia Low: anemia, cardiac decompensation, chronic obstructive pulmonary disease

PaCO2 (partial pressure)

35–45 mm Hg

High: respiratory acidosis, metabolic alkalosis Low: respiratory alkalosis, metabolic acidosis

pH

7.35–7.45

High: vomiting, hyperpnea, fever, intestinal obstruction Low: uremia, diabetic acidosis, hemorrhage, nephritis

PSA

<4 ng/mL

High: indication of prostate cancer, benign prostatic hyperplasia, prostatitis

pO4

2.5–4.5 mg/dL

High: chronic nephritis, hypoparathyroidism Low: hyperparathyroidism, vitamin D deficiency

Renin (plasma) Supine: Upright:

normal diet: 0.3–1.9 ng/mL/h 0.6–3.6 ng/mL/h Low-salt diet: 0.9–4.5 ng/mL/h 4.1–9.1 ng/mL/h

High: renovascular hypertension, malignant hypertension, untreated Addison’s disease, primary salt-losing nephropathy, low-salt diet, diuretic tx, hemorrhage

Sodium

135–145 mEq/l

High: hemoconcentration, nephritis, pyloric obstruction Low: alkali deficit, Addison’s disease, myxedema

Triglycerides

100–200 mg/dL Diabetic: <100 mg/dL

High: increased risk of artherosclerosis

Supine: Upright:

442

Low: primary aldosteronism, high salt intake, salt retaining steroid tx, ADH tx, blood transfusion

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 443

Quick Reference E — Laboratory Tests

Test (serum, plasma)

Normal Range

Clinical Significance

Thyroid T3 (triiodothyronine) uptake

24–34%

High: hyperthyroidism, TBG deficiency, androgens and anabolic steroids Low: hypothyroidism, pregnancy, TBG excess, estrogens and anti-ovulatory drugs

T3 (total circulating)

70–204 ng/dL

High: pregnancy, hyperthyroidism Low: hypothyroidism

T4 (thyroxine)

5–11 ug/dL

High: hyperthyroidism, thyroiditis, pregnancy, oral contraceptives Low: hypothyroidism, hypoproteinemia, nephrotic syndrome, androgenic and anabolic steroids

T7 (free T4 index)

.8–2.7 ng/dL

High: euthyroid patients with normal free thyroxine levels may have abnormal T3 and T4 levels caused by drug preparations

TSH (thyroid stimulating hormone)

0.4–4.2 mIU/L

High: primary hypothyroidism Low: hyperthyroid

Thyroid-binding globulin

10–26 ug/dL

High: hypothyroidism, pregnancy, estrogen therapy, oral contraceptives, genetic and idiopathic Low: androgens and anabolic steroids, nephritic syndrome, marked hypoproteinemia, hepatic disease

Thyroglobulin (serum) normal thyroid athyroid

# 59.4 ng/mL <5 ng/mL

PTH (parathyroid hormone)

160–350 ng/L

High: hyperparathyroidism, hypercalcemia, renal stones, calcinosis Low: hypoparathyroidism, hypocalcemia, demineralization of cell membrane electrical potential—muscle spasm and irritability, heart electrical conduction

PTH—Intact

10–65 pg/mL

High: primary hyperparathyroidism, (with high calcium levels), secondary hyperparathyroidism (with normal to low calcium levels) Low: hypoparathyroidism (with low calcium levels), non-parathyroid hypercalcemia (with high calcium levels)

males: 42–52% Females: 35–47%

High: erythrocytosis, dehydration, shock Low: anemia, blood loss, pregnancy

HGB (hemoglobin)

males: 13–18 gm/dL females: 12–16 gm/dL

High: chronic obstructive pulmonary diseases, polycythemia, failure of oxygenation because of congestive heart failure, high altitude Low: anemia, pregnancy, hemorrhage, excessive fluid intake

Platelets

0.15–0.45 × 1012/L or: 150,000–450,000/mm3

High: malignancy, myeloproliferative disease, rheumatoid arthritis, postoperative Low: thrombocytopenic purpura, acute leukemic aplastic anemia, infections, drug reactions, and during chemotherapy

Blood HCT (hematocrit)

High: active thyroid tissue

(continued)

443

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 444

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Test (serum, plasma)

Normal Range

Clinical Significance

Prothrombin time INR

9.5–12 sec 1.0

Prolonged by deficiency of factors I, II, V, VII, and X, fat malabsorption, severe liver disease, coumarinanticoagulant therapy. INR used to standardize the prothrombin time and anti-coagulation therapy

RBC

males: 4.6–6.2 × 1012/L females: 4.2–5.4 × 1012/L or: males: 4.6–6.2 million/mm3 females: 4.2–5.4 million/mm3

High: severe diarrhea, dehydration, polycythemia, acute poisoning, and pulmonary fibrosis Low: anemia, leukemia, post hemorrhage

WBC

4.5–11.0 × 109/L or: 4,500–11,000/mm3

High: acute infections, acute leukemia, following surgery, trauma, menstruation Low: aplastic anemia, chemotherapy High: acute infection, trauma, surgery, leukemia, malignant disease, necrosis Low: viral infection, bone marrow suppression, primary bone marrow disease High: allergy, parasitic disease, collagen disease, subacute infections Low: stress, use of some medications (ACTH, epinephrine, thyroxine) High: acute leukemia, following surgery or trauma Low: allergic reaction, stress, allergy, parasitic disease, use of corticosteroids High: infectious mononucleosis, viral and some bacterial infections, hepatitis Low: aplastic anemia, SLE, immunodeficiency including AIDS High: viral infection, parasitic disease, collagen and hemolytic disorders Low: use of corticosteroids, RA, HIV infection

Neutrophils

45–73%

Eosinophils

0–4%

Basophils

0–1%

Lymphocytes

20–40%

Monocytes

2–8%

Cardiac enzymes CK (creatine kinase)

MM band present (skeletal muscle) MB band absent (heart muscle)

High: (MB band-positive), myocardial infarction, ischemia

CPK (creatine phosphokinase) males: 50–324 mU/mL females: 50–250 mU/mL

High: (MB band-positive), myocardial infarction, ischemia (MM band), skeletal muscle diseases, intramuscular injections, crush syndrome, hypothyroidism, delirium tremens, alcoholic myopathy, cerebrovascular disease

LDH

90–176 U/L

High: myocardial infarction, pulmonary infarction, liver disease, untreated pernicious anemia

Troponin

I: <0.35 ng/mL T: <0.2 ng/mL

High: myocardial infarction, rhabdomyolysis, severe crushing injuries

Myoglobin

5–70 ng/mL

High: myocardial infarction, ischemia, muscle necrosis, rhabdomyolysis, malignant hyperthermia Low: rheumatoid arthritis, myasthenia gravis

Note: Normal ranges vary from institution to institution. These are to be used only as a reference. Please refer to the institution’s current laboratory ranges. 444

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 445

Quick Reference E — Laboratory Tests

Suggested Readings Smeltzer, Suzanne C., and Brenda G. Bare. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing. 11th ed. Philadelphia: Lippincott, 2007. Van De Graaff, Kent M., and Stuart Ira Fox. Concepts of Human Anatomy and Physiology. Dubuque, IO: Brown, 1986.

Notes

445

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 446

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ENZYMES AND HORMONES Name

Production Site

Substrate

Action

SALIVARY AMYLASE

Salivary glands of the mouth

Starches

Catabolizes starch to polysaccharides

PANCREATIC AMYLASE

Pancreas

Carbohydrates

Released into the small intestine, catabolizes polysaccharides mostly to maltose

MALTASE

Small intestine

Maltose

Hydrolyzes maltose to its constituent two glucoses

LACTASE

Small intestine

Lactose

Hydrolyzes lactose to galactose and glucose

SUCRASE

Small intestine

Sucrose

Hydrolyzes sucrose to fructose and glucose

PEPSIN

Stomach

Proteins

Activated in the stomach by pepsinogen, catabolizes proteins to amino acids

TRYPSIN

Pancreas

Proteins

Cleaves proteins into smaller peptides

CHYMOTRYPSIN

Pancreas

Proteins

Cleaves proteins into smaller peptides

CARBOXYPEPTIDASE

Pancreas and small intestine

Peptides

Splits off one amino acid at a time from end of polypeptide

PANCREATIC LIPASE

Pancreas

Unemulsified fats

In the small intestine, catabolizes fats to monoglycerides, glycerol, and fatty acids

PANCREATIC DEOXYRIBONUCLEASE

Pancreas

Deoxyribonucleic acid

Hydrolyzes DNA to nucleotide monomers

PANCREATIC RIBONUCLEASE

Pancreas

Ribonucleic acid

Hydrolyzes RNA to nucleotide monomers

RENIN

Kidneys (juxtaglomerular cells)

Angiotensinogen

Forms angiotensin I; regulates aldosterone release, extracellular fluid volume, and systemic blood pressure

Duodenal mucosa and small intestine

Liver/pancreas

In the presence of fatty chyme, potentiates secretin’s actions on these organs

Pancreas

Increases output of pancreatic juice

Gall bladder

Stimulates contraction and expulsion of bile

ENZYMES

HORMONES CHOLECYSTOKININ (CCK)

446

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 447

Quick Reference E — Laboratory Tests

Name

Production Site

SECRETIN

Duodenal mucosa and small intestine

GASTRIN

Stomach mucosa

Substrate

Action

Hepatopancreatic sphincter

Relaxes sphincter to allow pancreatic juice into duodenum

Autonomic nervous system

Invokes feeling of satiety

Stomach

In the presence of acidic chyme inhibits gastric gland secretion (HCl)

Pancreas

Increases bicarbonate ions in pancreas, potentiates CCK action

Liver

Increases bile output

Stomach

Increases output of gastric glands (HCl)

Small intestine

Stimulates contraction of intestinal muscle

Ileocecal valve

Relaxes valve

Large intestine

Stimulates mass movements

BILE

Hepatocytes in liver

Small intestine

Transports bile salts; emulsifies fats, and facilitates absorption of fats and cholesterol by micelles

hGH (HUMAN GROWTH HORMONE)

Somatotropic cells of adenohypophysis

Bones and skeletal muscles, most body cells

Stimulates growth and cellular uptake of amino acids and sulfur to cartilage, mobilizes stored fat, and inhibits oxidation of glucose

DISORDERS: Hypersecretion: In children, results in gigantism or abnormally tall individuals In adults, when bone growth has stopped, it results in acromegaly, enlargement, and thickening of bony area Hyposecretion:

In children, results in pituitary dwarfism or abnormally small individuals

TSH (THYROIDSTIMULATING HORMONE)

Thyrotropic cells of adenohypophysis

Thyroid

Stimulates release of thyroid hormones

ACTH (ADRENOCORTICOTROPIC HORMONE)

Corticotropic cells of adenohypophysis

Adrenal cortex

Stimulates adrenal cortex to release corticosteroid hormones (anti-stressors)

ADH (ANTIDIURETIC HORMONE, VASOPRESSIN)

Hypothalamus

Kidney tubules

Controls urine production and reabsorption of water

DISORDERS: Hypersecretion: Water retention, weight gain Hyposecretion: Diabetes insipidus—intense thirst, large urine output MSH (MELANOCYTESTIMULATING HORMONE)

Pineal gland

Children: hypothalamus, dermis

Inhibits gonadotropin-releasing hormone release, controls pigmentation (continued)

447

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 448

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Name

Production Site

Substrate

Action

THYROXINE

Thyroid

Most cells in follicles

Increases metabolic body rate and body heat, tissue growth, adrenergic receptors

DISORDERS: Hypothyroidism: In adults, myxedema—low metabolic rate, chills, constipation, lethargy, water retention In infants, cretinism—short disproportionate body, thick tongue and neck, mentally retarded Lack of iodine causes endemic goiter, enlargement of thyroid Hyperthyroidism: Grave’s disease—autoimmune system, hypertension CALCITONIN

Parafollicular cells

Bone

Inhibits Ca2+ release

PTH (PARATHYROID HORMONE)

Parathyroid

Bone, kidneys, and intestine

Stimulates release of Ca2+ into bloodstream by releasing from bone, and removing from urine and food

ALDOSTERONE (MINERALOCORTICOID)

Zona glomerulosa of adrenal cortex

Kidney tubules

Regulates Na+ and K+ in extracellular fluids

DISORDERS: Hypersecretion: Aldosteronism—hypertension, edema Hyposecretion: Addison’s syndrome—weight loss, drop in glucose and Na+ levels, rise in K+ levels, dehydration, and hypotension CORTISOL (GLUCOCORTICOID)

Zona fasciculata of adrenal cortex

Body cells

Promotes gluconeogenesis, hyperglycemia, mobilizes fat, stimulates protein catabolism, resists stressors, depresses immune system

DISORDERS: Hypersecretion: Cushing’s syndrome—hyperglycemia, loss of muscle and bone protein, edema, hypertension, and “moon face” Hyposecretion: ANDROGENS (GONADOCORTICOID)

Addison’s syndrome Women’s libido

Zona reticulata of adrenal cortex

CATECHOLAMINES: EPINEPHRINE

Chromaffin cells of medullary cortex

Organs stimulated by sympathetic nervous system

Intensifies action of sympathetic nervous system, stimulates heart and metabolic activity

NOREPINEPHRINE

Chromaffin cells of medullary cortex

Organs stimulated by sympathetic nervous system

Vasoconstricts

DISORDERS: Hypersecretion: Hyperglycemia, palpitation, hypertension, sweating GLUCAGON

448

Alpha cells of pancreas (islets of Langerhans)

Liver

Hyperglycemic agent: raises blood glucose levels by glycogenolysis (glycogen to glucose) and glyconeogenesis (glucose from fatty acids and amino acids)

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 449

Quick Reference E — Laboratory Tests

Name

Production Site

Substrate

Action

INSULIN

Beta cells of pancreas (islets of Langerhans)

Body cells

Hypoglycemic agent; inhibits action of glucagon and uptake of glucose

DISORDERS: Hyposecretion: Diabetes mellitus (hyperglycemia)—hypoglycemic state, making even more glucose available by glycogenolysis, lipolysis, and gluconeogenesis; results in high blood levels (> 200 mg/dL), excess sugar in urine, dehydration, hunger, thirst, frequent urination, dry skin, blurred vision, drowsiness, and nausea Hypersecretion: Hypoglycemia—low blood sugar (< 70 mg/dL), anxiety, nervousness, hunger, shaking, weakness, tachycardia, sweating, headache, irritability, dizziness, and disorientation THYMOSIN

Thymus

Immune system, targets itself

Responsible for normal development of immune system, T lymphocytes only

FSH (FOLLICLESTIMULATING HORMONE)

Anterior pituitary (adenohypophysis)

Gonads (testes, ovaries)

Stimulates gamete seminiferous production, ovarian tubules, and follicle development and spermatogenesis

LH OR ICSH (LUTEINIZING HORMONE; INTERSTITIAL CELL-STIMULATING HORMONE)

Anterior pituitary

Gonads (interstitial cells and ovaries)

Promotes production of gonadal hormones, maturation of egg and ovulation, and formation of corpus luteum, stimulates interstitial cells

PROLACTIN

Anterior pituitary lactotrophic cells

Mammary glands (lobules)

Stimulates production of milk, lactation

OXYTOCIN

Hypothalamus neurohypophysis

Uterus (myometrium) and breasts

Stimulates uterine contractions and milk secretion from breasts (milk letdown)

PROGESTERONE

Ovaries, also placenta and corpus luteum

Reproductive organs, endometrial lining

Stimulates breast development and sets menstrual cycle, during pregnancy readies for implantation

ESTROGEN

Ovaries

Reproductive organs, endometrial lining

Causes maturation of reproductive organs during puberty, breasts, secondary characteristics and shedding and rebuilding endometrial lining

TESTOSTERONE

Testes (interstitial cells)

Male reproductive organs, seminiferous tubules

Causes maturation of reproductive organs at puberty, promotes sperm production

hCG (HUMAN CHORIONIC GONADOTROPIN)

Blastocyte of early pregnancy

Pituitary gland and corpus luteum

Promotes viability of corpus luteum for 4 months, stops menses (continued)

449

10766-66_QuickRef-E.qxd

12/3/07

5:37 PM

Page 450

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Name

Production Site

Substrate

Action

RELAXIN

Placenta

Pelvic ligaments and pubic symphysis

Causes ligaments and symphysis to relax, widen, and become more flexible

INHIBIN

Seminiferous tubules

Anterior pituitary and hypothalamus

Shuts down FSH and LH production

Suggested Readings Marieb, Elaine N. Human Anatomy and Physiology. 2nd ed. Redwood City, CA: Benjamin/ Cummings, 1992. Van De Graaf, Kent M, and Stuart Ira Fox. Concepts of Human Anatomy and Physiology. Dubuque, IA: Brown, 1986.

450

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 451

QUICK REFERENCE F

Language Barrier Buster™/Interpretech™ Chinese French German Italian Portuguese Russian Spanish Japanese Polish

451

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 452

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

This section is a derivative work in progress, taken from many books and people who speak these languages. It is to be considered only as a stop-gap source for communication where no other alternative is available. Because of variations in accents and dialects, it may or may not serve your specific needs. Some are more complete than others. Please bear in mind that, unless it involves a highly unusual circumstance, if the patient cannot understand what procedure is about to take place, the procedure should be postponed until they do understand or completely terminated.

CHINESE Introductions

American Phonetics Only: Mandarin

Hello / Good bye.

Nee how / Jigh-jee-in

Excuse me.

Mah-fahn nee. Dway-buu-shee.

My name is . . . . . .

Waw-duh meeng-dzu shir . . . . . . .

I am a technologist.

Waw shir jee-shuu-ywen.

What is your name? / Is your name . . . . . ?

Nee jee-ow shuun-muh meeng-dzu?

How are you?

Neen how mah?

What is your date of birth?

Tsuu sheng ree chee?

Do you speak English?

Nee jee-ahng Eeng-wun mah?

I cannot speak Chinese.

Waw buu hway jee-ahng Joong-wun (Gwah-ee).

Answer yes or no.

Shir / Buu shir

Speak slowly.

Cheeng jee-ahng mahn ee-dan.

I do not understand.

Waa buu doong.

Do you understand?

Ne doong mah?

Please.

Cheeng

Thank you / You’re welcome

Shay shay / Hwahn ee nee (or Boo-ka-see)

You will get an injection in the vein of your arm.

Gei nee so bee dzu she.

The injection will not affect you.

Mei gwan sheh.

You will get a pill.

Gei nee yao.

Assessments

What’s up? What’s going on?

Hey?

Are you O.K.?

Ne-je et-ta jam yung?

How do you feel right now?

Shee-an dzai jwe de dzen meh yung?

Calm down, it’s O.K.

Boo yow pop, ma-soo.

Good / Bad

How / bu how

Are you pregnant or nursing?

Nee hwai ywun lee? buu ruu?

Do you have any pain?

Ne yoe tung mah? Hin-tung?

Where?

Chigh na-ah-lee?

452

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 453

Quick Reference F — Language Barrier Buster™/Interpretech™

How?

Dzen meh?

For how long?

Yo dor joe?

When?

Shen meh shi hou?

How long? 1–10 min / hrs / days / wks / months / years.

Ee, err, sahn, suh, wuu, leo, chee, bah, jeo, shuh. Fin, shee-ow-shr, tee-in, sheeng-chee, yeh, nay-in.

Show me.

Cheeng gay waw kahn.

Do you have a history of cancer?

Yo gwo ai dzeng mah?

Have you had any chemotheraphy or radiation therapy?

Hwa le-ao farng le-ao gwo mah?

Are you a diabetic?

Nee yo tang le-ao bing mah?

When was your last full meal?

Shang Tsee Tsee fun shen meh shi hou?

What medications are you taking?

Nee dzai tsee shen meh yao?

Have you had a recent diagnostic test?

Dzwei jin je-an tshaa gwo mah?

Do you have the report?

Yo bing lee mah?

Have you had any surgery?

Dzwo gwo shou su mah?

Have you broken any bones or hurt yourself recently?

Dzwei jin guu dze gwo mah? sou gwo sang mah?

Were you involved in an accident?

Tsuu gwo tse hwo mah?

Are you allergic to morphine/iodine/eggs?

Dwei mafei/dee-an joe/ jee-dan gwo min mah?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Gwo chee ee te-an foo gwo ka-fei-yin, joe jin, ni-gwo-tin mah?

Do you have high blood pressure?

Yo gao shwe ya mah?

Chest pain?

Shee-ong-koe tuung?

Shortness of breath?

?

Are you hot / cold?

Ruh? / Lung?

Water, a blanket, a pillow, a urinal, a bed pan?

Soiy, chwahng tahn-dzu, jing-toe, . . . . . , . . . . . . ?

Would you like to use the bathroom?

Tsuh-swaw?

Try to empty you bladder.

Pie lee-ow.

Directions

Sign here.

Chen main.

Left / Right

Jore / Yoe

Up / Down

Shahng / She-eh

Stand up.

Ze-shang.

Come towards me / Back up

Gan-wa-lie / Twoi-hoe

Turn around

Gwie-wahn

Sit down / here / up.

Jaw se-eh / Jaw-lee / Jaw-shahng 453

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 454

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Let me help.

Cheeng, wo lie bang lee.

Lay down on your back / on your stomach.

?

Lay on your right/left side.

She-ang yo/dzo tah-ang.

Put your head on the pillow.

Ni toe fahn sang, jin-toe.

Lift your feet / head.

Na nee jeo sahn / toe sahn.

Arms up / down.

Na sho shang / fan so she-eh.

Look straight up.

Can ju.

Shut your eyes.

Bee she-ang yen.

Turn your head to the left / right.

Cheeng ju-ahng jaw / yoe zwahn.

Left / right arm over head.

Jaw show / Yoe show fahn quat toe.

Deep breath. Hold it. Let it out.

Foo-shee. Boo foo-shee. Foo-shee.

Breathe normal.

Foo-shee ping-sher.

Do not move. Hold still.

Poo ya dong!

We are taking a picture.

Wah-mun kuh-ee gay nee jah-oh-shee-ahng.

You are doing great.

Ne chaw ha-now.

It will go faster soon.

?

Walk faster.

Shee qui-tan.

We are almost done.

Wa man sah-poo-toe how.

We are all done.

Dzwo wan leh.

You are all done.

Nee ee-ching how.

Wait here.

Cheeng dung ee shee-ah.

You can go home now.

Ne kah-ye whay jee-ah.

You are going back up to your room, now.

Ne kah-ye fahn-jee ne ta fan.

FRENCH Introductions

Translation

Hello / Good bye.

Bonjour / Au revoir

Excuse me.

Pardon or Excuse-moi.

My name is . . . . . .

Je m’appelle. . . .

I am a technologist.

Je suis technologue.

What is your name? / Is your name . . . . . ?

Comment vous appelez-vous?

How are you?

Comment allez-vous? Comment ca va?

What is your date of birth?

Quel est votre date de naissance?

Do you speak English?

Parlez-vous anglais?

I speak very little French.

Je parle très peu le français.

Answer yes or no.

Répondez seulement oui ou non.

454

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 455

Quick Reference F — Language Barrier Buster™/Interpretech™

Speak slowly.

Parlez plus lentement, s’il vous plaît.

I do not understand.

Je ne comprends pas.

Do you understand?

Comprenez-vous?

Please.

S’il vous plaît.

Thank you / You’re welcome

Merci / de rien

How do you say [—] in French?

Comment dit-on [——] en Français?

You will get an injection in the vein of your arm.

Vous obtiendrez une injection dans la veine de votre bras.

The injection will not affect you.

L’injection ne vous affectera pas.

You will get a pill.

Vous obtiendrez une pilule.

Assessment

What’s up? What’s going on?

Ca va? Qu’est-ce qu’il y a donc?

Are you O.K.?

Allez-vous bien?

How do you feel right now?

Comment vous vous sentez maintenant?

Calm down, it’s O.K.

Calmez-vous, c’est bien.

Good / Bad

Bon / Mal

Are you pregnant or nursing?

Êtes-vous enceinte ou soigner?

Do you have any pain?

Avez-vous mal?

Where?

Où?

How?

Comment?

For how long?

Pour comment longtemps?

What kind?

Quel genre?

When?

Quand?

1–10 min / hrs / days / wks / months / years.

un, deux, trois, quatre, cinq, six, sept, huit, neuf, dix. Une minute, une heure, un jour, une semaine, un mois, une année.

Show me.

Montrez-moi.

Have you ever had cancer?

Vous jamais avez eu le cancer?

When was your last full meal?

Quand était votre dernier repas plein?

What medications are you taking?

Quels médicaments prenez-vous?

Are you a diabetic?

Etes-vous un diabétique?

Have you had a recent diagnostic test?

Avez-vous eu un test diagnostique récent?

Do you have the report?

Avez-vous le rapport?

Do you have high blood pressure?

Avez-vous de l’hypertension?

Have you had any chemotherapy or radiation therapy?

Avez-vous eu la thérapie de chimiothérapie ou rayonnement?

Have you had any surgery?

Avez-vous eu la chirurgie? 455

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 456

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Have you broken any bones or hurt yourself recently?

Avez-vous cassé des os ou vous blesses récemment?

Were you involved in an accident?

Avez-vous été impliqué dans un accident?

Are you allergic to morphine/iodine/eggs?

Etes-vous allergique à la morphine/l’iode/les oeufs?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Avez-vous eu la caféine, l’alcool, ou la nicotine dans le dernier 24 heures?

Chest pain?

Avez-vous mal à la poitrine?

Shortness of breath?

Avez-vous mal à respirer?

Are you hot / cold?

Avez-vous chaud / froid?

Would you like water, a blanket, a pillow, urinal, a bed pan?

Voulez-vous de l’eau, une couverture, un oreiller, l’urinoir, un bassin (de lit).

Would you like to use the bathroom?

Voulez-vous aller à la toilette?

Try to empty your bladder.

Essayer de vider votre vessie.

Directions

Sign here.

Signez ici.

Left / Right

à gouche / à droite (ah goshe / ah dwat)

Up / Down

Haut / bas

Stand up.

Levez-vous.

Come towards me / Back up

Tout droit / marchez en renverse

Turn around

Tournez-vous.

Sit down / here / up.

Asseyez-vous / ici / vertical

May I help you?

Est-ce que je peux vous aider?

Lay down on your back / on your stomach.

Allongez-vous sur le dos / l’estomac

Lay on your right/left side.

Poser sur votre côté de droite/parti.

Put your head on the pillow.

Ensuite votre tête sur l’oreiller.

Lift your knees / feet / head.

Décrochez les genous / les pieds / la tête.

Arms up / arms down.

Levez les bras / baissez les bras

Look straight up.

Regardez en haut.

Shut your eyes.

Fermer vos yeux.

Turn your head to the left / right.

Tournez la tête à gauche / à droit.

Left / right arm over head.

Levez le bras gauche / droit sur la tête.

Deep breath. Hold it. Let it out.

Respirez à fond. Retenez. Soufflez (expirez)

Breathe normal.

Respirez normalement.

Do not move. Hold still.

Ne bougez pas. Immobile.

We are taking a picture.

Nous allons prendre un photo.

You are doing great.

Vous faites très bien.

It will go faster soon.

Ça va marcher plus vite.

456

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 457

Quick Reference F — Language Barrier Buster™/Interpretech™

Walk faster.

Marchez plus vite.

We are almost done.

Nous sommes presque finis.

You are almost / all done.

Vous êtes presque / tout fini.

We are all done.

Nous tout sont fait.

Wait here.

Attendez ici.

You can go home now.

Vous pouvez rentrer chez vous maintenant

You are going back up to your room, now.

Vous allez rentrer à votre chambre, maintenant.

GERMAN Introductions

Translation

Hello // Good bye.

Guten Morgen / Tag // Gute Nacht / Auf Wiedersehen

My name is . . . . . .

Ich heiss(e) . . . . . . .

I am a technologist.

Ich bin ein(e) Technologe ? (. .login /)

What is your name? / Is your name . . . . . ?

Wie heissen Sie? / Heissen Sie. . . . . . . ?

How are you?

Wie geht es Ihnen? or Wie geht’s?

What is your date of birth?

Was ist Ihr Geburtsdatum?

Do you speak English?

Sprechen Sie Englisch?

I speak very little German.

Ich sprech(e) nur ein bisschen Deutsch.

Answer yes or no.

Antworten Sie nur ja (yah) oder nein (nine).

Speak slowly.

Sprechen Sie langsamer, bitte.

I do not understand.

Ich verstehe Sie nicht.

Do you understand?

Verstehen Sie das? or Verstehen Sie mich?

Please.

Bitte

Thank you / You’re welcome

Danke / Bitte or Dankeschön / Bitteschön

How do you say [——] in German?

Wie sagt man [–—] auf Deutsch?

You will get an injection in the vein of your arm.

Sie werden eine Einspritzung in der Vene von Ihrem Arm erhalten.

The injection will not affect you.

Die Einspritzung wird Sie nicht beeinflussen.

You will get a pill.

Sie werden eine Pille erhalten.

Assessment

What’s up?

Was ist los?

Are you O.K.?

Geht es Ihnen? Geht’s?

How do you feel right now?

Wie fühlen Sie jetzt gleich?

Calm down, it’s O.K.

Beruhigen Sie sich, alles wird klappen.

Good / Bad

Gut / Schlecht 457

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 458

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Are you pregnant or nursing?

Sind Sie schwanger oder Krankenpflege?

Do you have any pain?

Haben Sie schmerzen?

Where?

Wo? (Vo)

How?

Wie?

For how long?

Für wie lang?

What kind?

Welche Art?

When?

Wann?

1–10 min / hrs / days / wks / months / years.

Ein, zwei, drei, vier, fünf, sechs, sieben, achts, neun, zehn. Minuten / Stunden / Tage / woken / Monate / Jahre.

Show me.

Zeigen Sie es mir.

Have you ever had cancer?

Haben Sie je Krebs gehabt?

When was your last full meal?

Wann war Ihre letzte volle Mahlzeit?

What medications are you taking?

Welche Medikationen nehmen Sie?

Are you a diabetic?

Sind Sie ein Diabetiker?

Have you had a recent diagnostic test?

Haben Sie eine neue diagnostische Prüfung gehabt?

Do you have the report?

Haben Sie den Bericht?

Do you have high blood pressure?

Haben Sie hohen Blutdruck?

Have you had any chemotherapy or radiation therapy?

Haben Sie eine Chemotherapie oder Bestrahlungstherapie gehabt?

Have you had any surgery?

Haben Sie eine Chirurgie gehabt?

Have you broken any bones or hurt yourself recently?

Haben Sie Knochen gebrochen oder verletzt sich kürzlich?

Were you involved in an accident?

Wurden Sie in einem Unfall verwickelt?

Are you allergic to morphine/iodine/eggs?

Sind Sie allergisch zu Morphium/Jod/Eiern?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Haben Sie ein Koffein, Alkohol, oder Nikotin in den letzten 24 Stunden gehabt?

Chest pain?

Haben Sie schmerzen in der Brust?

Shortness of breath?

Sind Sie atemlos?

Are you hot / cold?

Ist Ihnen heiss / kalt?

Would you like . . . water, a blanket, a pillow, a urinal, a bed pan?

Möchen Sie . . . Wasser, eine Decke, ein Kopfkissen, ein Urinal, eine Bettpfanne.

Would you like to use the bathroom?

Möchten Sie auf die Toilette gehen?

Try to empty your bladder.

Versuch, Ihre Blase zu entleeren.

Directions

Sign here.

Unterschreiben Sie bitte hier.

Left / Right

Links / Rechts

Up / Down

Herauf / Herab

458

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 459

Quick Reference F — Language Barrier Buster™/Interpretech™

Stand up.

Stehen Sie auf.

Come towards me / Back up

Kommen Sie hier / Gehen Sie rückwärts.

Turn around

Drehen Sie Sich bette herum.

Sit down / here / up.

Setzen Sie sich / hier / herauf

Let me help.

Lassen Sie mich Ihnen helfen.

Lay down on your back / on your stomach.

Legen Sie sich auf den Rücken / auf den Magen.

Lay on your right/left side.

Legen Sie auf Ihr richtiges/linke Seite.

Put your head on the pillow.

Legen Sie bitte Ihren Kopf auf das Kopfkissen.

Lift your knees / feet / head.

Heben Sie Bitte Ihr(e) Knien / Füβe / Kopf.

Arms up / down.

Arme rauf / runter.

Look straight up.

Aufsehen.

Shut your eyes.

Schlieβen Sie Ihre Augen.

Turn your head to the left / right.

Wenden Sie den Kopf nach Links / Rechts

Left / right arm over head.

Linken / Rechten Arm über den Kopf.

Deep breath. Hold it. Let it out.

Tief Einatmen. Anhalten. Ausatmen.

Breathe normal.

Normal atmen.

Do not move. Hold still.

Bewegen Sie sich nicht. Momentchen.

We are taking a picture.

Wir machen ein Foto.

You are doing great.

Sie machen das ganz gut.

It will go faster soon.

Bald geht es schneller.

Walk faster.

Gehen Sie bitte schneller.

You are almost / all done.

Sie sind fast / ganz fertig.

We are all done.

Wir sind alle gemacht.

You can go home now.

Sie können jetze nach Hause gehen.

You are going back up to your room, now.

Jetze gehen Sie wieder in Ihr Zimmer.

ITALIAN Introductions

Translation

Hello / Good bye.

Ciao or pronto / addio (arrivederci)

Excuse me.

Mi scusi.

My name is . . . . . .

Mi chiamo . . . . . . .

I am a technologist.

Sono un Technologo.

What is your name? / Is your name . . . . . ?

Come ti chiami? / Suo nome è . . . . . ?

How are you?

Come va?

What is your date of birth?

Che è la sua data di nascita? 459

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 460

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Do you speak English?

Parla Inglese?

I speak very little Italian.

Parlo poco Italiano.

Answer yes or no.

Responde si o no.

Speak slowly.

Parla lento.

I do not understand.

No capisco.

Do you understand?

Hai capito?

Please.

Per favore.

Thank you / You’re welcome

Grazie / Prego

How do you say [——] in Italian?

Como se dice [——] in Italiano?

You will get an injection in the vein of your arm.

Lei prenderà un’iniezione nella vena del suo braccio.

The injection will not affect you.

L’iniezione non la riguarderà.

You will get a pill.

Lei prenderà una pillola.

Assessment

What’s up? What’s going on?

Cosa che?

Are you O.K.?

Stai bene?

How do you feel right now?

Come lei sente proprio ora?

Good / Bad

Buono / Cattivo

Are you pregnant or nursing?

Siete incinti o l’allattamento?

Do you have any pain?

Hai dolore?

Where?

Dove?

How?

Come?

For how long?

Per quanto tempo?

What kind?

Che il tipo?

When?

Quando?

How long? 1–10 min / hrs / days / wks / months / years

Quanto tempo? Uno, due, tre, quattro, cinque, sei, sette, otto, nove, dieci. Minuto, ora, giorno, settimana, mese, anno.

Show me.

Fa me vedere.

Have you ever had cancer?

Lei mai ha avuto il cancro?

When was your last full meal?

Quando il suo ultimo era il pasto pieno?

What medications are you taking?

Che le medicazioni lei porta?

Are you a diabetic?

Lei è un diabetico?

Have you had a recent diagnostic test?

Lei ha avuto un test recente diagnostico?

Do you have the report?

Lei ha la relazione?

Do you have high blood pressure?

Lei ha l’ipertensione?

Have you had any chemotherapy or radiation therapy?

Lei ha avuto qualunque terapia di chemioterapia o radiazione?

460

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 461

Quick Reference F — Language Barrier Buster™/Interpretech™

Have you had any surgery?

Lei ha avuto qualunque chirurgia?

Have you broken any bones or hurt yourself recently?

Lei ha rotto qualunque ossa o te stesso è doluto recentemente?

Were you involved in an accident?

Lei era coinvolto in un incidente?

Are you allergic to morphine/iodine/eggs?

Lei è allergico alla morfina/l’iodio/le uova?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Lei ha avuto qualunque caffeina, qualunque alcool, o qualunque nicotina nell’ultimo 24 ore?

Chest pain?

Dolore del petto?

Shortness of breath?

Respirazione difficile? Difficolta con respiro?

Are you hot / cold?

Hai caldo / freddo?

Would you like water, a blanket, a pillow, a urinal, a bed pan?

Acqua, una coperta, un cushino, un orinale, padella da letto?

Would you like to use the bathroom?

Hai bisogno del bagno?

Try to empty your bladder.

Tentare di vuotare la sua vescica.

Directions

Sign here.

Firma.

Left / Right

Sinistra / Destra

Up / Down

Su / Giù

Stand up.

In piedi.

Come towards me / Back up

Vieni qui / Vai in dietro

Turn around

Gira

Sit down / here / up.

Siedi / qui / su.

Let me help.

Hai bisogno.

Lay down on your back / on your stomach.

Soria ti sulla schiena / sullo stomaco.

Lay on your right/left side.

Applicare il suo lato destra/lasciato.

Put your head on the pillow.

Metti giù la testa sull cushino.

Lift your knees / feet / head.

Alza le ginocchi / piedi / la testa.

Arms up / down.

Bracce su / giù

Look straight up.

Guarda diritto.

Shut your eyes.

Chiudere i suoi occhi.

Turn your head to the left / right.

Gira la testa a sinistra / destra.

Left / right arm over head.

Alza il braccia sinistra / destra sopra la testa.

Deep breath. Hold it. Let it out.

Respira profundo. Tiene lo. Lascia lo fuori.

Breathe normal.

Respira normale.

Do not move. Hold still.

Non muovere. Stai fermo.

We are taking a picture.

Facciamo le foto.

You are doing great.

Fa bene. 461

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 462

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

It will go faster soon.

Fa piu rapido subito.

Walk faster.

Camina piu rapido.

We are almost done.

Siamo quasi finiti.

You are almost / all done.

Stai quasi finito.

We are all done.

Siamo tutto fatto.

Wait here.

Aspetta qui.

You can go home now.

Puoi andare a casa adesso.

You are going back up to your room, now.

Adesso ritoni alla tua stanza.

PORTUGUESE Introductions

Translation

Hello / Good bye.

Alô / Adeus

Excuse me.

Excuséme.

My name is . . . . . .

Meu nome é

I am a technologist.

Sou um tecnôlogo.

What is your name? / Is your name . . . . . ?

Qual é seu nome?

How are you?

Como vai?

What is your date of birth?

O que é sua data de nascimento?

Do you speak English?

Você fala Inglés?

I speak very little Portuguese.

Falo um poco Portugués.

Answer yes or no.

Responda sim o no.

Speak slowly.

Fale devagar.

I do not understand.

Não entendo.

Do you understand?

Entende?

Please.

Por favor.

Thank you / You’re welcome

Obrigado / De nada

How do you say [––] in Portuguese?

Como se diz [–—] em Portugués?

You will get an injection in the vein of your arm.

Receberá um injeção na veia do seu braço.

The injection will not affect you.

O injeção não o afetará.

You will get a pill.

Receberá uma pílula.

Assessment

What’s up? What’s going on?

Que acontece?

Are you O.K.?

Esta bom?

How do you feel right now?

Como sente-se agora mesmo?

462

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 463

Quick Reference F — Language Barrier Buster™/Interpretech™

Calm down, it’s O.K.

Seja calmo, tudo vai bem.

Good / Bad

Bom / Mal

Are you pregnant or nursing?

Estão grávido ou cuida?

Do you have any pain?

Sente dor?

Where?

Onde?

How?

Como?

For how long?

Para como longo?

What kind?

Que espécie?

When?

Quando?

How long? 1–10 min/hrs/days/ wks/months/years

Quanto tempo? Um, dois, três, quatro, cinco, seis, sete, oito, nova, dez. Minutos / horas /dias / semanas / anos.

Show me.

Me mostre.

Have you ever had cancer?

Você jamais teve câncer?

When was your last full meal?

Quando era sua última plena refeição?

What medications are you taking?

Que medicamentos tomam?

Are you a diabetic?

São diabético?

Have you had a recent diagnostic test?

Teve uma prova diagnóstica recente?

Do you have the report?

Tem o relatório?

Do you have high blood pressure?

Tem pressão arterial alta?

Have you had any chemotherapy or radiation therapy?

Teve qualquer quimioterapia ou terapia de radiação?

Have you had any surgery?

Teve qualquer cirurgia?

Have you broken any bones or hurt yourself recently?

Quebrou qualquer ossos ou se machuca recentemente?

Were you involved in an accident?

Foram envolvidos num acidente?

Are you allergic to morphine/iodine/eggs?

São alérgico a morfina/iodine/ovos?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Teve qualquer cafeína, álcool, ou nicotina nas últimas 24 horas?

Chest pain?

Dor do peito?

Shortness of breath?

Respiracão difícil?

Are you hot / cold?

Sente calor / frio?

Would you like water, a blanket, a pillow, a urinal, a bed pan?

Quer agua, um cobertor, uma almofada, urinol, panda de leito?

Would you like to use the bathroom?

Precisa do quarto de banho?

Try to empty your bladder.

Tente de esvaziar sua bexiga.

Directions

Sign here.

Firme aquí.

Left / Right

Esquerdo / Direito 463

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 464

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Up / Down

Arriba / Em baixo

Stand up.

Esté em pé.

Come towards me / Back up

Venha aqui / vai para atrás

Turn around

Dei volta.

Sit down / here / up.

Sentese / aqui / Esté em pé.

Let me help.

Deixe ajudar-lhe.

Lay down on your back / on your stomach.

Deitese nas costas / no stômago.

Lay on your right/left side.

Coloque em seu lado de direito/partiu.

Put your head on the pillow.

Ponha a testa na almofada.

Lift your knees / feet / head.

Levante os joelhos / pés / a testa.

Arms up / down.

Levante os braços / baixe os braços.

Look straight up.

Olhe arriba.

Shut your eyes.

Feche os seus olhos.

Turn your head to the left / right.

Volte a testa à esquerda / direita.

Left / right arm over head.

Ponha o braço esquerdo / direito sob a testa.

Deep breath. Hold it. Let it out.

Respire profundo / Tem ar e contenha / Respire

Breathe normal.

Respire normalmente.

Do not move. Hold still.

Não mover, por favor.

We are taking a picture.

Estamos tirando uma imagem.

You are doing great.

Você está fazendo bem.

It will go faster.

Agora virá mais rápido.

Walk faster.

Caminhe mais rápido.

We are almost done.

Quase teminamos já.

You are almost / all done.

Você estará pronto já.

We are all done.

Têm todo ano feito.

Wait here.

Espere aquí.

You can go home now.

Pôde ir à casa já.

You are going back up to your room, now.

Você Vai para seu quarto agôra.

RUSSIAN Note: Superscript y (XyXX) pronounces as a “ye” within the word. Accented syllable of word is capitalized. Introductions

Phonetics Only

Hello / Good bye.

Pryee VyEHT / Duh-svyee-DAHNy-yuh

Excuse me.

Eez-vyee-NYEE-tyih.

My name is . . . . . .

Mah-YOH EE-myuh . . . . . . . .

464

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 465

Quick Reference F — Language Barrier Buster™/Interpretech™

I am a technologist.

Yah tecknico . . .

What is your name? / Is your name . . . . . ?

Kahk vahs zah-VOOT?

How are you?

Kahk puh-zhi-VAH-yih-tyih?

What is your date of birth?

NazovEEtih VAHshu DAHtu rozhDEHnya?

Do you speak English?

Vee guh-vah-RyEE-tyih pah-ahn-GLyEE-shyee?

I speak very little Russian.

Yah nyihm-NOH-guh guh-vah-RyOO ROO-skyee.

Answer yes or no.

Aht-VyEHTy-tyih dah EE-lyee nyeht.

Speak slowly.

Guh-vah-RyEE-tyih MyEH-dlyihn-nyih-yih.

I do not understand.

Yah nyih-puh-nyee-MAH-yoo.

Do you understand?

Vee puh-nyee-MAH-yih-tyih-NyAH?

Please.

Pah-ZHAH-lee-stuh.

Thank you / You’re welcome

Spah-SyEE-buh / Pah-ZHAH-lee-stuh

How do you say [––] in Russian?

Kahk skah-ZAHTy pah-ROO-skyee [–]?

You will get an injection in the vein of your arm.

Vahm sDELayooht vnootrihVEHnney ooKOHL vROOKoo.

The injection will not affect you.

ooKOHL neh oKAHZHet na VAHS NeekahKOHvah vleeYAHneeya.

You will get a pill.

Vahm dahDOOT tahblEHTkoo.

Assessments

What’s up? What’s going on?

Shtoh NOH-vuh-vuh?

Are you O.K.?

Khuh-rah-SHOH?

How do you feel right now?

Kahk SEEbya CHOOStvuteh na DAHniy moMENt?

Calm down, it’s O.K.

Ee-Ge so-DAH.

Good / Bad

DOH-bree-ee / plah-KHAH-yuh

Are you pregnant or nursing?

Vee beREHmeneh EELi KOHrmiteh gRUHdyuh?

Do you have any pain?

Bah-LYEET?

Where?

Gdyeh?

How?

Kahk?

For how long?

Kahk DOHlgo?

When?

KagDAH?

How long? 1–10 min / hrs / days / wks / months / years.

Kahk DOHL-guh? Ah-DYEEN, dvah, tryee, chih-TI-ryih, pyahty, shehsty, syehmy, VOH-syihmy, DYEH-vyihty, DYEH-syihty. Myee-NOOT, chahs, dyeny, nyih-DYEH-lyih, MYEH-syih-tsi, goht.

Show me (please point).

Puh-kah-ZHI-tyih, pah-ZHAH-lee-stuh.

Are you diabetic?

U VAHS ESTy deeaBET?

When was your last full meal?

KagDAH YEli v posLEDnih RAHz? 465

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 466

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

What medications are you taking?

KahKEEyih leKAHrstva priniMAHeetih?

Have you had a recent diagnostic test?

KagDAH u VAHS BEEloh pahsLEDnyee obsLEDvaneeyeh u vraCHAH?

Do you have the report?

U VAHS ESTy rezoolTAHTee obsLEDvaneeyah?

Do you have a history of cancer?

U VAHS beel RAHK?

Have you had any chemotherapy or radiation therapy?

VAHM DEHlali HIHmeoteraPIHyu EELi radeetsiOHneh leCHEnye

Have you had any surgery?

U VAHS BEELah opeeRAHtsiyah?

Have you broken any bones or hurt yourself recently?

U VAHS BEELlih pereLOHmee EELi druhGEEye povrehZHDENyah?

Were you involved in an accident?

VEE BEELlih v ahVAHree kagDAH neeBOOTy?

Are you allergic to morphine/iodine/eggs?

U VAHS ESTy ahlerHEEYah na MORfeeh/YOHD/YAHeetsah?

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Vee priniMAHleeh kahfehEEn, alkahGOHLy EELi neekahTEEN zah posLEDneeh SOOHTkee?

Do you have high blood pressure?

U VAHS veeSOHKaye dahvLENiyeh kroVIH?

Chest pain?

Grooty bah-LYEET?

Shortness of breath?

Vey-ee-may, ta-BOLE Grodyee

Are you hot / cold?

Tyih PLOH / KHOH-luhd-nuh?

Would you like water, a blanket, a pillow, a urinal, a bed pan?

Vah-DAH, ah-dyih-YAH-luh, pah-DOOSH-kuh, ?

Would you like to use the bathroom?

Tou-ah-LyEHT?

Try to empty your bladder.

PahZHAHloostah, s-HoDEETih v tooh-ahLET pah MAHLenykamooh.

Directions

Sign here.

Ruhs-pyee-SHI-tyihsy zdyehsy.

Left / Right

Nah-LYEH-vuh / nah-PRAH-vuh

Up / Down

vvyehrkh / vnyees

Stand up.

v=STANTyah.

Come towards me (come here) / Back up

Puh dah-ee-DYEE-tyih syoo-DAH /

Turn around

?

Sit down / here / up.

Sah-DyEE-tyihsy / Siz dis /

Let me help.

Mnyeh pah-MOHCH.

Lay down on your back / on your stomach.

...

Lay on your right/left side.

LoZHEETeesy nah pRAHVyooh/LEHVyooh sTOHrahnoo.

Put your head on the pillow.

?

Lift your knees / feet / head.

Kah-LYEH-nuh / nah-GAH / guh-lah-VAH

466

Spyee-NAH / Zhee-LOO-duhk

guh-lah-VAH

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 467

Quick Reference F — Language Barrier Buster™/Interpretech™

Arms up / down.

Roo-KAH vvyehrkh / vnyees.

Look straight up.

?

Shut your eyes.

ZakROHytih glaZAH.

Turn your head to the left / right.

guh-lah-VAH Nah-LYEH-vuh / nah-PRAH-vuh

Left / right arm over head.

Nah-LYEH-vuh / nah-PRAH-vuh Roo-KAH guh-lah-VAH

Deep breath. Hold it. Let it out.

V’dakneeti GROba core.

Breathe normal.

Dashet yeh namala.

Do not move. Hold still.

Nyih-DVYEE-guh-ee-tyih.

We are taking a picture.

Sfuh-tuh-grah-FYEE-ruh

You are doing great.

?

It will go faster soon.

?

Walk faster.

?

We are almost done.

?

You are almost / all done.

?

We are all done.

vsYOH, zaKOHnychelih.

Wait here.

Zdyehsy zhdahty.

You can go home now.

?

You are going back up to your room, now.

?

SPANISH Introductions

Translation

Hello / Good bye.

Hola / Adiós

Excuse me.

Excuseme.

My name is . . . . . .

Me llamo . . . . . or Mi nombre es . . . . . . . .

I am a technologist.

Yo soy un tecnólogo.

What is your name? / Is your name . . . . . ?

Cómo se llama Usted?

How are you?

Cómo se siente Usted hoy? Cómo estás?

What is your date of birth?

Cuál es la fecha de su nacimiento?

Do you speak English?

Habla inglés?

I speak very little Spanish.

Hablo un poco de español.

Answer yes or no.

Responda Sí o No.

Speak slowly.

Habla despacio.

I do not understand.

No Comprendo, or No entiendo.

Do you understand?

Entiende? 467

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 468

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Please.

Por favor.

Thank you / You’re welcome

Gracias / de nada

How do you say [––] in Spanish?

Cómo se dice [––] en español

You will get an injection in the vein of your arm.

Vamos a ponerle una inyección en la vena del brazo.

The injection will not affect you.

La inyección no le va a afectará nada.

You will get a pill.

Usted recibirá una píldora.

Assessment

What’s up? What’s going on?

Qué Pasa?

Are you O.K.?

Está bien?

How do you feel right now?

Cómo se siente usted ahora?

Good / Bad

Bueno / Malo

Are you pregnant or nursing?

Está usted embarazada o está amamantando?

Do you have any pain?

Siente dolor?

Where?

Dónde?

How?

Cómo?

For how long?

Por cuánto tiempo?

What kind?

Qué clase?

When?

Cuándo?

How long? 1–10 min / hrs / days / wks / months / years

Cuánto tiempo? Uno, dos, tres, cuatro, cinco, seis, siete, ocho, nueve, diez. Minutos / horas / días / semanas / meses / años.

Show me.

Muéstreme

Do you have a history of cancer?

Ha tenido usted cáncer?

When was your last full meal?

Cuándo fue su última comida?

What medications are you taking?

Qué medicamentos está tomando?

Are you a diabetic?

Es usted diabético / diabética?

Have you had a recent diagnostic test?

Ha tenido recientemente una prueba diagnóstica?

Do you have the report?

Tiene usted el informe?

Do you have high blood pressure?

Tiene usted tensión arterial alta?

Have you had any chemotherapy or radiation therapy?

Ha tenido usted quimioterapia o radioterapia?

Have you had any surgery?

Ha tenido usted cirugía?

Have you broken any bones or hurt yourself recently?

Le ha roto usted algún hueso o sufrido algún daño recientemente?

Were you involved in an accident?

Ha tenido un accidente?

Are you allergic to morphine/iodine/eggs?

Es usted alérgico/alérgica a morfina/yodo/huevos?

468

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 469

Quick Reference F — Language Barrier Buster™/Interpretech™

Did you have any caffeine, alcohol, or nicotine in the last 24 hours?

Ha tomado usted cafeína, alcohol, o nicotina en las últimas veinticuatro horas?

Chest pain?

Dolor en el pecho?

Shortness of breath?

Cortad de aliento? Respira difícil?

Are you hot / cold?

Siente calor? / Siente frío?

Would you like water, a blanket, a pillow, a urinal, a bed pan?

Quiere agua, una frazada, una almohada, un orinal, cuña

Would you like to use the bathroom?

Quiere usar el baño?

Try to empty your bladder.

Trate de vaciar su vejiga.

Directions

Calm down, it’s OK.

Cálmese, todo está bien.

Sign here.

Firme aquí.

Left / Right

Izquierdo / Derecho

Up / Down

Arriba / Abajo

Stand up.

Párese or Páraté

Come towards me / Back up

Venga / Retroceda

Turn around

Dé la vuelta.

Sit down / here / up.

Siéntese / Siéntese aquí / Párese

Let me help.

Déjeme ayudarle

Lay down on your back / on your stomach.

Échese de espaldas / bocaabajo

Lay on your right/left side.

Acuéstese en su derecho / en su izquierdo.

Put your head on the pillow.

Ponga la cabeza en la almohada.

Lift your knees / feet / head.

Levante las rodillas / los pies / la cabeza.

Arms up / down.

Levante los brazos / Baje los brazos.

Look straight up.

Mire hacia arriba.

Shut your eyes.

Cierre los ojos.

Turn your head to the left / right.

Voltee la cabeza a la izquierda / derecha.

Left / right arm over head.

Ponga el brazo izquierdo / derecho sobre la cabeza.

Deep breath. Hold it. Let it out.

Respire profundo. Contenga la respiración. Expire.

Breathe normal.

Respire normalmente.

Do not move. Hold still.

No se mueva. Esté quieto.

We are taking a picture.

Estamos tomando una imagen.

You are doing great.

Usted está portándose muy bien.

It will go faster.

Ahora irá más rápido.

Walk faster.

Camine más rápido.

We are almost done.

Ya casi terminamos. 469

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 470

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

You are almost / all done.

Usted ya está listo / todo está listo.

We are all done.

Estamos terminados.

Wait here.

Espere aquí.

You can go home now.

Ahora puede ir a casa.

You are going back up to your room, now.

Ahora quede ir a su cuarto.

JAPANESE Introductions

Phonetics Only

Hello / Good-bye.

Ko-nee-she-wah or Moe-she moe-she / Sah-yo nara.

Excuse me.

Sue-me-mah-sin, koo-dah-sigh.

My name is. . . .

Wah-tock-she no nag-my wah . . . dess.

I am a technologist.

Wah-tock-she wa tek-no dess.

What is your name? / Is your name . . . ?

Oh-nah-my wah? / Oh-nah-tah wah? . . .—san dess kah?

How are you?

Ee-kaa-gaa dess kah?

Do you speak English?

Aa-ee-go gah han-nah-say-mah-sin?

I cannot speak Japanese.

Hee-hone-go gah han-nah-say-mah-sin.

Answer yes or no.

Hane-jee high / Ee-eh

Speak slowly.

Mot-toe yoo-koo-ree hah-nah-ssh-tay, koo-dah-sigh.

I do not understand.

Wah-kah-ree-mah-sin.

Do you understand?

Wah-kah-ree-mas ka?

Please.

Koo-dah sigh.

Thank you / You’re welcome.

Doe-moe ah-ree-gah-toe go-zee-mahss / Doe-ee-tah-she-mahsh-tay.

How do you say [—] in Japanese?

Nee-hon-go de [—] wah doe eye-mas kah?

Assessment

Phonetics Only

What’s the matter?

Doe she-mah-sshta kah?

Are you okay?

Die-joe-boo dess kah?

Good / Bad.

Ee-ee / Wah-roo-ee.

Do you have any pain?

Ee-tam-ee?

Where?

Doe-koe?

How long? 1–10 minutes / hours / days / weeks / months / years

Doe nah-gy? ee-chee, nee, san, she, go, roe-koo, she-chee, hachee, koo, juu. Poon / jie-kan / nichi / shah / gah-tsoo / toe-she.

Show me.

Oh-she-eh-mas.

Chest pain?

Ee-tah-mee moo-nay?

470

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 471

Quick Reference F — Language Barrier Buster™/Interpretech™

Are you hot / cold?

Aht-sue-ee / Sah-moo-ee dess kah?

Would you like water, a blanket, a pillow, a toilet?

Mee-zoo, moe-foo, mah-koo-rah, twa-ree?

Would you like to use the bathroom?

Oh-tay-ah-rie?

Directions

Phonetics Only

Sign here.

Koe-koe day nah-my oh kite-tay, koo-dah-sigh.

Left / Right

Hee-dah-ree / mee-gee

Up / Down

Ooh-eh / Shrtah

Stand up.

Tat-te-pay, koo-dah-sigh.

Come towards me / Back up.

Ko-cheer-ah eh / ooh-sheer-oh eh

Turn around.

Mah-wat-the, koo-dah-sigh.

Sit down

Swat-tay, koo-dah-sigh.

May I help you?

Tat-soo-die mah-show kah?

Lay down on your back / on your stomach.

Say-nah-kah / oh-nah-kah nar-ee-tay.

Put your head on the pillow.

Mah-koo-rah ni oh ir-et-tay, koo-dah-sigh.

Lift your knees / feet / head.

He-zah / ah-she / ah-tah-mah oh.

Arms up / down.

Ooh-day ooh-eh / shrtah

Turn your head to the left / right.

Ah-tah-ma de hee-dah-ree / mee-gee ee mah-gah-roo no dess.

Deep breath. Hold it.

Foo-kah-yee koke-yoo / Ee-kee oh to-met-tay.

Breathe normal.

Foo-tsoo no koke-yoo

Do not move.

Chote-toe mot-tay.

We are taking a picture.

Wah-tock-she-tah-chee shah-sheen.

You are doing great.

Go-kuu-roe-sahn.

Wait here.

Koe-koe day mot-tay, koo-dah-sigh.

POLISH Introductions

Translation

Hello / Good-bye.

Dzien ´dobry / Do widzenia.

Excuse me.

Przepraszam.

My name is. . . .

Nazywam sie˛. . . .

I am a technologist.

Jestem technologiem.

What is your name? / Is your name . . . ?

Jak sie˛ pan (pani) nazy wal´ / Czy pan (pani) . . . ?

How are you?

Jak sie˛ pan (pani) czuje?

Do you speak English?

Czy mówi pan (pani) po angielsku? 471

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 472

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

I speak very little Polish.

Ja mówie˛ bardzo slabó po polsku.

Answer yes or no.

Prosze˛ odpowiedziec´ tak ubl´ nie.

Speak slowly.

Mów wolno prosze˛.

I do not understand.

Ja nie rozumie˛.

Do you understand?

Czy pan (pani) rozumie˛?

Please.

Prosze˛.

Thank you / You’re welcome.

Dzie˛kuje˛ / Nie ma za co.

How do you say [—] in Polish?

Jak powiedziec´ [—] po polsku?

Assessment

Translation

What’s up? What’s going on?

Co slychac´? Co sie˛ dzieje?

Are you okay?

Czy wszystko z pania / panem dobrze?

Calm down, it’s okay.

Prosze˛ sre˛ uspokoic´, jest dobrze.

Good / Bad.

Dobrze / Z´le.

Do you have any pain?

Czy ma pan (pani) jakis´ ból?

Where?

Gdzie?

How long? 1–10 minutes / hours / days / weeks / months / years.

Jak dtugo? (1–10?) Minute / godziny / dni / tygodnie / miesia / lata.

Show me.

Prosze˛ pokazac´.

Chest pain?

Ból w klatce piersiowej?

Shortness of breath?

Krótki oddech?

Are you hot / cold?

Czy jest pan (pani) goraco / zimno?

Would you like water, a blanket, a pillow, a urinal, a bed pan?

Czy chce pan (pani) wody, koc, poduszke˛, kaczke˛, kaczke˛.

Would you like to use the bathroom?

Chce pan (pani) is´c´ do ´lazienki?

Directions

Translation

Sign here.

Prosze˛ tu podpisac´.

Left / Right.

Lewa / Prawa.

Up / Down.

Góra / Dol´.

Stand up.

Prosze˛ wstac´.

Come toward me / Back up.

Prosze˛ is´c´ do mnie / Do tyl´u.

Turn around

Prosze˛ obrócic´ sie˛.

Sit down / here / up.

Prosze˛ usiaˇs´c´ / tutaj / wstac´.

Let me help.

Pomoge˛ panu (pani).

Lay down on your back / on your stomach.

Prosze˛ pol´uzyc´ sie˛ na plecach / na brzuchu.

Put your head on the pillow.

Prosze˛ pol´uzyc´ gl´owe˛ na poduszce.

472

10766-67_QuickRef-F.qxd

12/3/07

5:39 PM

Page 473

Quick Reference F — Language Barrier Buster™/Interpretech™

Lift your knees / feet / head.

Prosze˛ unies´c´ kolona / stopy / gl´owe˛.

Arms up / down.

Ramiona do góry / do dol´u.

Look straight up.

Prosze˛ do góry (ppzed siebie).

Turn your head to the left / right.

Prosze˛ obrócic´ gl´owe˛ w lewa / prawo.

Left / right arm over head.

Lewa / prawe ramie˛ nad gl´owe˛.

Deep breath. Hold it. Let it out.

Gle˛boki wdech. Zatrzymac´. Wypus´cic´.

Breathe normal.

Oddychac´ normalnie.

Do not move. Hold still.

Prosze˛ nie ruszac´ sie˛. Sie˛ dziec´ bez ruchu.

We are taking a picture.

Robimy zdje˛cie.

You are doing great.

Spisuje sie˛ pan (pani) s´wietnie.

It will go faster soon.

To be˛dzie prosac´ przyspieszyc´ nied?ugo.

Walk faster.

Prosze˛ is´c´ szybciej.

We are almost done.

Pranie sko{aan}czylis´my.

You are almost / all done.

Pranie wszystko zrobione.

Wait here.

Prosze˛ poczekac´ tutaj.

You can go home now.

Moze pan (pani) is´c´ do domu.

You are going back up to your room, now.

Teraz wraca pan (pani) do pokoju.

473

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 474

QUICK REFERENCE G

Regulations Misadministration Radiation Safety

474

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 475

Quick Reference G — Regulations

MISADMINISTRATION CURRENT NRC REGULATIONS The Nuclear Regulatory Commission (NRC) and consequently licensing agencies in agreement states (e.g., the Bureau of Radiation Control [BRC] in Florida) have, by issuance of their regulation changes (January 27, 1992), made it extremely difficult to cause a bona fide misadministration. The regulations concern fission by-product material only e.g., 131I, 125I, 99Mo, 99mTc, 133Xe, 32P, 51Cr, etc. Most incidents fall under recordable events or reportable only within the individual department. Always consult your RSO if there is any question or if the situation warrants it.

MISADMINISTRATION Diagnostic • Only for doses > 30 uCi (1.11 MBq) of 131I NaI or 125I NaI: wrong patient, or radiopharmaceutical, or a larger dose than prescribed with a difference > 20% and that difference is >30 uCi. • Other RP’s (including 99mTc): wrong patient, or radiopharmaceutical, or route, or dose amount, and the dose administered resulting in DDE >5 rem (50uSv) or TODE >50 rem (500 uSv).

Therapeutic • Wrong patient, or radiopharmaceutical, or route, and a larger dose than prescribed with a difference >20%. Records must be kept for 20 years.

RECORDABLE EVENT Diagnostic • Only for doses > 30 uCi of 131I NaI or 125I NaI: no written directive for administration, no record of directive, and the dose differs by more than 10% and that difference is >15 uCi (555 MBq).

Therapeutic (any therapeutic radiopharmaceuticals) • No written directive for administration, no record of directive, and the dose differs by more than 10%. Records must be kept for 5 years.

REPORTABLE EVENT • All misadministrations are reportable to the licensing agency (NRC or agreement state agency). 475

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 476

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Notification • Within 24 hours: Telephone call to RSO, referring physician, and NRC/(e.g., BRC) and to the parent or guardian if the patient is a minor. • Within 15 days: Written report to NRC, referring physician, and parent or guardian if the patient is a minor. • The department is to file a Quality Management Program with the NRC describing actions taken to prevent recurrence and its procedures for prescribing, calculating, dispensing, verifying, and administering radiopharmaceuticals, and revised every 12 months. Records must be kept for 3 years.

ALL OTHER INCIDENTS • Spills, wrong patients, wrong radiopharmaceutical, wrong dose, wrong route of by-product material that do not meet the above criteria and accelerator produced radiopharmaceuticals should be brought to the attention of the supervisor and/or RSO along with a departmental incident report.

Suggested Readings Early, Paul J. and D. Bruce Sodee. Principles and Practice of Nuclear Medicine. 2nd ed. St. Louis: Mosby, 1995. Lombardi, Max H. Radiation Safety in Nuclear Medicine. 2nd ed. Boca Raton, FL: CRC Press LLC, 2007. Wilson, Michael A. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

RADIATION SAFETY This section is intended only to serve as a limited review addressing some of the more common sources of confusion. Consult department policies and procedures for specific information concerning area surveys, spills, decontamination, and waste disposal. If there are any questions, contact your RSO.

RADIATION • Particles: Alpha (α), Beta+ (β+, positron), Beta− (β−, negatron), e− (electron), p+ (proton), d+ (deuteron), t+ (triton), He++ (helium ion beams), heavy nuclei (n—neutron beams). 476

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 477

Quick Reference G — Regulations

• Photons (electromagnetic waves): cosmic energy, gamma (γ), x-ray, ultra-violet (UV), visible light, infra-red (IR), radar (microwaves), radio, electric waves.

MODES OF DECAY • Alpha (α): origin-nuclear; monoenergetic (discrete energies); soft-tissue penetration, 10–40 um. Alpha decay is the stabilizing process of nuclei that have too many nucleons, e.g., neutrons and protons. The energy range is about 1.8 to 11.7 MeV. Alphas travel at about 1⁄30th the speed of light. • Beta+ (β+, positron): origin-nuclear; continuum of energy, average energy = 1⁄3 Emax; >1.02 MeV for annihilation radiation, produces two gammas of .511 MeV’s at 180° (coincidence radiation) and neutrino. Positron decay is the stabilizing process of nuclei that have too many protons (or not enough neutrons). In the nucleus, a negative and a positive electron are produced. The positron is emitted with a neutrino and the electron joins with a proton to form a neutron. Positrons have the same mass and charge as an electron but are positive. The average energy ranges from 0.1 to 14 MeV. Positrons at emission travel a about 1⁄3 the speed of light. The neutrino travels at the speed of light. The positron spends its energy traveling through matter, slows or stops and attracts an electron (the opposite charge) and annihilates. E = mc2 where matter is converted to energy. • Beta− (β−, negatron): origin-nuclear; continuum of energy, average energy = 1⁄3 Emax; antineutrino; soft-tissue penetration, 10 um—1 cm. Negatron decay is the stabilizing process of nuclei that have too many neutrons. A neutron is converted to a proton. They have the same mass and charge of orbital electrons. The average energy ranges from a few keV to 14 MeV. Negatrons at emission travel at about 1⁄3 the speed of light. • Gamma (γ): origin-nuclear; discrete energies, followed by prompt gammas or delayed gammas; soft-tissue penetration is infinite. Gamma decay follows other decay processes e.g., electron capture and positron annihilation radiation. The gammas emitted are the functional photons involved in nuclear medicine diagnostic imaging. The range for gammas is negligible to 6.1 MeV. The normally used range for nuclear medicine imaging is from about 20 to 511 keV. Gammas, being electromagnetic radiation, have no mass and carry no electrical charge. Through a vacuum, they travel at or close to the speed of light. • Electron Capture (EC): usually K electron capture, changes proton to neutron, releases gamma, neutrino, x-ray, and/or Auger electron (a second electron emitted caused by the emission of the first), soft-tissue penetration is infinite. Electron capture is the stabilizing process of nuclei with too many protons. If the energy available at the time of transition is less than 1.02 MeV, the atom decays by EC. If the energy available is more than 1.02 MeV, it can decay by EC or positron emission. Gammas, x-rays, and neutrinos travel at or close to the speed of light. • Isomeric Transition (IT): delayed gamma emission from metastable state, soft-tissue penetration is infinite. IT is the stabilizing process that involves an excited nucleus de-exciting by emitting a delayed gamma. The resulting daughter is a nuclear isomer of the parent atom. 99mTc is the most applicable example of this process. The “m” stands for metastable meaning a temporary condition leading to a more stable configuration. Gammas, being electromagnetic radiation and through a vacuum, travel at or close to the speed of light.

INTERACTIONS • Bremsstrahlung: braking radiation, secondary photon emission (x-ray) from negative acceleration of Beta particles passing closely to nucleus of atom. As it slows, the kinetic energy lost is released in the form of an x-ray. This is the source of most radiographic imaging. • Compton Effect: gamma emission interacts with a loosely bound or free electron. The energy transfer sends both on altered trajectories. The Compton electron gains energy, the gamma loses energy. 477

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 478

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Internal Conversion: gamma emission interacts with orbital electron of the same atom, monoenergetic, conversion electron emitted, x-rays may do the same with Auger electron emitted. • Pair Production: gamma emission with energy of at least 1.02 MeV interacts with the electrical field of a nucleus. The gamma ray is completely absorbed with a resulting positive electron and negative electron produced. Both are ejected from the atom but the positron immediately undergoes annihilation. • Photoelectric Effect: high energy gamma emission interacts with a tightly bound orbital electron (usually K-shell). The gamma is completely absorbed and the electron is ejected (ionized) from the atom. The vacancies are immediately filled with resulting emission of x-rays and/or Auger electrons. Probability of occurrence decreases with lessening energy.

RADIATION SAFETY External Exposure • Time: reduce time spent near radioactive sources, e.g., patients, loaded syringes, open pigs, generators, hot lab, therapy doses (especially 131I even when shielded), PET doses. Total exposure is directly and linearly related. Total mrem = mrem/hr × hr. • Distance: step back from any hot source, the more distance, the less exposure. Inverse Square Law; I1 × D12 = I2 × D22. • Shielding: use syringe shields, lead-lined carry cases, pigs, leaded glass shields, etc., when manipulating or transporting radiopharmaceuticals. Exposure rate is an exponential function of shield thickness.

Internal Exposure • Ingestion: For radiation workers, most departments and laboratories have rules that do not permit food products, drinks, cosmetics, etc. anywhere in the area, particularly those areas where radiopharmacy is worked with and/or stored. This is in an effort to lessen the risk of inadvertent contamination. Patients ingest radioactive food as in a gastric emptying exam or pills for thyroid uptake and scans, or therapy/ablations, and apparently an oral route may be used with 18F-FDG if there is no suitable venous access. • Inhalation: For radiation workers, departments that work with gaseous substances such as 133Xe and/or liquid 131I that sublimes, must provide a fume hood in the hot lab and a “negative pressure” closed system room or department where these studies will be carried out. Patients receive radioactivity in this manner while doing 133Xe and 99mTc-DTPA ventilation studies for example. • Percutaneous: For radiation workers, any radiopharmacy that contacts the skin is a source of radiation exposure to that area. Gloves, lab coats, scrubs, leather shoes, etc., are suggested to limit this type of contamination. Exposure of this type is doubly troublesome for the patient. Not only does the patient receive unwanted exposure but that area (or areas) becomes a source of artifact during the imaging process. Any contamination of this type requires the person to remove the clothing that may also be contaminated and the area washed in an attempt to reduce the exposure to background. Nuclear medicine presently has no studies that require a radiopharmacy to be applied to the surface of the skin. Dacryoscintigraphy uses drops to the eye and lymphoscintigraphy uses subcutaneous injections. In these cases as with all injections, the risk of skin contamination around the site must be carefully monitored. • Injection: For radiation workers, accidental actual injection into a vein is a low probability but nevertheless a possible risk because of the common use of needles within any nuclear medicine department. There is more risk involved with inadvertent piercing of the skin with a needle that has radioactivity in or on it. Extreme care must always be taken when working with needles and 478

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 479

Quick Reference G — Regulations

radiopharmacy. For the patients, this method is used for nearly all imaging studies and most therapeutic procedures. To prevent unnecessary exposure, the dosages must be carefully calibrated in the hot lab before injection and extreme care must be taken as the injection is made to ensure that the proper dosage is infused safely into the vein without extravasation into surrounding tissue.

REGULATORY RADIATION SAFETY The Quality Management Program (QMP) is a yearly report to the licensing agency of an institution documenting the details of the usage of radiopharmacy in an effort to prevent misadministration of radioactive materials to patients. The QMP must include the method of reporting, documentation, and recording of misadministrations, and procedures for prescribing, preparing, dispensing, administering, and recording the dosage of the radiopharmaceuticals. The Radiation Safety Officer (RSO) can be anyone selected by management for the position that possesses the appropriate qualifications and experience to perform, enforce, and maintain a radiation safety program in a hospital, clinic, or other medical institution. Candidates include but are not limited to physician (e.g., radiologist), physicist (medical or health), radiopharmacist, or nuclear medicine technologist. The Radiation Safety Committee (RSC) is a group of selected personnel from a medical institution that oversees and supervises the radiation safety program. Candidates include but are not limited to the RSO, members from nursing, management, and authorized users (those licensed to dispense radioactive materials e.g., physicians with a nuclear license and radiopharmacists). The Radiation Safety Program (RSP) is a set of rules to govern the operation of the dispensing and usage of radioactivity within the institution. It is based on the license issued to that institution, usually prepared by the RSO, documented and approved by the RSC, and revised once a year. Units

Special Units

S.I. Units

Equivalents

Activity

Curie

Becquerel

1 mCi = 37 MBq

Exposure

Roentgen

Coulomb/kg Air

C/kg air = 3876 R

Absorbed Dose

Rad

Gray

1 Gy = 100 Rads

Dose Equivalent

Rem

Sievert

1 Sv = 100 Rems

Biological Effects • Stochastic: chronic, low level, over long period. Measure of probability of linear and nonthreshold effect. The effects increase as the dose received increases with no threshold. • Non-stochastic: acute, high level, short term. Measure of severity of effect. Linear with saturation level, reaching threshold results in degrees of radiation sickness or as in the case of radiation therapy, a desired effect. • Hormesis: radiation-induced cell repair/response allowing resistance to future radiation damage upon receiving minimal “triggering” dose. It concerns low levels above background (2 to 10 times background) and the existence is controversial. By intracellular communication, cells in the vicinity of a radiation induced injured cell react in a similar fashion as the injured cell causing an enhanced adaptive response to radiation. In studies with animals, plants, and humans, there is evidence of no radiation injury, increased growth, longer life span, less illness, among other things. It flies in the face of the linear non-threshold hypothesis (LNT) of late effects which assumes that the risk to low-level exposer is linear and proportional to the dose with no certain amount that has to be overcome to initiate the process. Those that agree with hormesis say that the LNT hypothesis overestimates the risks at low doses and attempting to reduce this type of exposure to background levels is futile. 479

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 480

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Readings • Lens (eye) Dose Equivalent (LDE): external radiation exposure at .3 cm depth into eye, taken from TLD or film badge. • Shallow Dose Equivalent (SDE): effective dose equivalent of external radiation exposure at 70 um depth in tissue averaged over 1 square cm of whole body skin or extremity, taken from TLD or film badge. • Deep Dose Equivalent (DDE): external radiation exposure at 1 cm depth, for tissue or internal organs taken from TLD or film badge. • Total Effective Dose Equivalent (TEDE): the sum of DDE for external exposure and the CEDE for internal exposure and accounts for radiation exposure from both sources. • Total Organ Dose Equivalent (TODE): the sum of DDE and CEDE to the organ receiving the highest dose of exposure. • Dose Equivalent: the product of absorbed dose and effective quality factor (EQF-differences in biological effectiveness for various types of radiation e.g., x-ray, gamma, beta, electrons, the EQF is unity). Expressed in rem or sievert. • Effective Dose Equivalent: sum of the weighted dose equivalents (weighting factors) accounting for various risks of radiation exposure to different organs and tissues. Expressed in rem or sievert. • Committed Dose Equivalent (CDE): organ radiation over 50 years of a radionuclide that has a long (several months or more) half-life, and the dose equivalent is spread over many years. It is not applicable to routine nuclear medicine. • Committed Effective Dose Equivalent (CEDE): sum of the weighted CDE of ingested radiation for each affected organ or tissue. It is not applicable to routine nuclear medicine. • Annual Limit on Intake (ALI): the annual limit of a radionuclide administered to the body that would result in a CEDE of 5 rem or a TODE of 50 rem. Expressed in millicurie or becquerel. • Derived Air Concentration (DAC): the annual limit of the concentration of a radionuclide in the air, breathed in for one working year (2000 hours). Expressed in uCi/mL or becquerel/mL.

ANNUAL DOSE LIMITS Occupational Whole body TEDE (DDE):

5 rems/yr

50 mSv/yr

Internal TODE (organ):

50 rems/yr

500 mSv/yr

SDE (skin and extremity):

50 rems/yr

500 mSv/yr

Lens LDE (eye):

15 rems/yr

150 mSv/yr

Pregnant worker:

50 mrems/9 months

.5 mSv/9 months

If the embryo/fetus has reached limit by the time of declaration of pregnancy or is within 5 mrems of the limit, then the worker must remain within 5 mrems for the remainder of the pregnancy. Minors <18 years old:

10% of occupational adult limits

Cumulative dose equivalent:

Age of worker × 1 rem

10 mSv × age

Whole body TEDE (DDE):

100 mrem/yr

1 mSv/yr

Whole body (infrequent exposure)

500 mrem/yr

5 mSv/yr

SDE (skin and extremity):

5 rem/yr

50 mSv/yr

General Public

480

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 481

Quick Reference G — Regulations

Lens LDE (eye):

1.5 rem/yr

15 mSv/yr

Unrestricted area:

2 mrem/hour

20 mSv/hr

Embryo/fetus:

500 mrem/9 months

5 mSv/9 months

Women of childbearing age:

Physician approval, procedure at 10 days following menses. A pregnancy test may be required.

Women breast feeding:

Physician approval.

Negligible dose:

National Council on Radiation Protection (NCRP) has deemed 1 mrem (.01 mSv) is negligible.

A pregnant employee must declare her pregnancy in writing. At the time of declaration, if the estimated dose to the fetus is ≥50 mrems or within 5 mrems of the limit, the dose for the remaining time of the pregnancy must not exceed 5 mrem. If this is an infringement on her right to work, she can simply “un-declare” her pregnancy and continue working.

ALARA (AS LOW AS REASONABLY ACHIEVABLE) The policy for ALARA extends to all those working in the ionizing radiation usage industry to reduce the probability of stochastic effects of low level ionizing radiation. In nuclear medicine, workers must minimize radiation exposure to themselves and their cohorts. The practice may extend to patients and public as well. Time, distance, and shielding play an important role to this end. Also being mindful of dosages, where they are, who is exposed to the radiation, and how can the exposure be minimized, should always be considered when working with radioactivity. It should be nearly an instinctive behavior to minimize the radiation exposure to everyone in the vicinity of any radioactive source. Within the nuclear medicine community, it is the responsibility of the Radiation Safety Officer (RSO) to enforce the ALARA program. Recommendations for radiation worker exposure levels are as follows: Level 1: Investigate and report. Quarterly reading (average over 3 month period), 10% of NRC limit. • Whole body (head, trunk, gonads, arms above elbow, legs above knee): 125 mrems • Extremities (elbows and distal, knees and distal) or skin: 1250 mrems • Lens (eye): 375 mrems Level 2: Action level. Quarterly reading, 30% of NRC limit. • Whole body (head, trunk, gonads, arms above elbow, legs above knee): 375 mrems • Extremities (elbows and distal, knees and distal) or skin: 3750 mrems • Lens (eye): 1125 mrems These can be reviewed on a cumulative annual basis as well.

PACKAGES Label

Surface (mrem/hr)

1 Meter (mrem/hr)

White I

0.5

background

Yellow II

Transportation IndexH –—

50

1

0.1 mrems/hr (typically)

Yellow III nuc-med:

100

3

1.2 mrems/hr (typically)

Other industries:

200

10

(Applies to type II and III only. Actual exposure rate at 1 meter from surface of package at time of shipment.)

H

481

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 482

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Suggested Readings Early, Paul J. and D. Bruce Sodee. Principles and Practice of Nuclear Medicine. 2nd ed. St. Louis: Mosby, 1995. Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Lombardi, Max H. Radiation Safety in Nuclear Medicine. 2nd ed. Boca Raton, FL: CRC Press LLC, 2007. Wilson, Michael A. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998.

Notes

482

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 483

Quick Reference G — Regulations

STATE INSPECTION SELF-ASSESSMENT FOR NUCLEAR MEDICINE FACILITIES The following is an excerpt from information distributed during a presentation by the State of Florida’s Bureau of Radiation Control at a Florida nuclear medicine conference. Every state will vary slightly, but whether the state follows the NRC directly or is an Agreement State, inspectors must look for similar information to ensure that any department is running within the expectations of that state and does so consistently. If the department has the following information available, they will be well on the way to a successful inspection. Reference numbers are from a CD issued by the State of Florida, Department of Health, Bureau of Radiation Control (3/8/05). Retain records for the appropriate amount of years and keep the documentation complete and up to date. The names of the sections under Reference have been included hopeful that they are similar to titles in other states.

Subject

Information Needed

Reference—Where to Find It (Name of section, numbers are from FL—BRC)

I. License and Facility

Have a copy of the license and licence application available

Control of Ionizing Radiation (64-E-5 unless otherwise specified)

Review license for accuracy

Name & corporation

State License

Building & structure

Use of Radionuclides in the Healing Arts (601, 602)

Location Uses Check postings

Emergency procedures

Standards for Protection

Safe use procedures

Notices, Instructions and Reports to Workers; Inspections (322, 323, 901)

1081 & regulations CRAM signs NMT certificates Clearance times II. Instrumentation Survey Instruments

Operable Up-to-date calibration by appropriate vendor

Dose Calibrator

License Application Use of Radionuclides in the Healing Arts (615)

(is it) Used as required

License Application

Constancy

Use of Radionuclides in the Healing Arts (614)

Accuracy Geometric variation Camera

Mfr. QC procedures must be available

License Application

Show that QC procedures are followed

Use of Radionuclides in the Healing Arts (613)

Records Maintenance

483

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 484

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Information Needed

Reference—Where to Find It (Name of section, numbers are from FL—BRC)

Responsibilities

License

Licensure

Use of Radionuclides in the Healing Arts (607)

Visiting A/U

Documentation of license to read NM

Use of Radionuclides in the Healing Arts (609)

Physician In Training

Documentation

Use of Radionuclides in the Healing Arts (608)

Radiation Safety Officer

Duties and Responsibilities

License Application

Licensure

Use of Radionuclides in the Healing Arts (605)

Subject III. Personnel Authorized Users

Required Reviews Nuclear Medicine

Training

Technologist

Certifications

Nurses and others

Training

Notices, Instructions and Reports to Workers; Inspections (902)

Dose Evaluation

License Application

Documentation

Standards for Protection

DP Workers

Notices, Instructions and Reports to Workers; Inspections (308, 311, 315, 903)

Meetings on time

Use of Radionuclides in the Healing Arts (606)

Notices, Instructions and Reports to Workers; Inspections 64-E-3 (Radiologic Technology), 468.302 (Use of radiation; identification of certified persons; limitations; exceptions) 49-CFR-172

IV. Personnel Monitoring Program Badge Usage

V. Radiation Protection Programs Radiation Safety Committee (if applicable)

Organization/Membership Duties Accomplishments Documentation of meetings

Members of the Public Study

ALARA Program Review

Documentation available

License Application

Accurate

Standards for Protection (303)

Documentation available

License Application

Contents

Standards for Protection Use of Radionuclides in the Healing Arts (303, 606) (continued)

484

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 485

Quick Reference G — Regulations

Subject

Information Needed

Reference—Where to Find It (Name of section, numbers are from FL—BRC)

Quality Management Program (QMP)

Used properly

License Application

Complete records

Use of Radionuclides in the Healing Arts (611)

Summarized reviews VI. Day-to-Day Operations Inventory

All sources inventoried Timely documentation

Radioactive Materials

Proof of origin (radiopharmacy)

Receipt and Transfer

Transfer documentation

Disposal

Decay in storage (records) Storage areas

Safe Use of Radioactive Materials

Leak Tests

Hand survey

Use of Radionuclides in the Healing Arts

License Application

Assay and injection records

Use of Radionuclides in the Healing Arts (616)

All required sources tested

Use of Radionuclides in the Healing Arts (618)

All RAM storage containers marked

License Application

No hot waste products in trash can

Standards for Protection Use of Radionuclides in the Healing Arts (320, 321, 620)

End of day reports Documentation

Weekly Surveys

Wipes results Documentation

Waste Storage Area Surveys

General good practices (619)

Dose calibrator usage

Security (proper areas lockable)

Daily Surveys

Use of Radionuclides in the Healing Arts (623) License Application

Timely documentation Radioactive Materials Markings and Labels

Standards for Protection (328, 340)

Protective clothes

Syringe shields (observed during inspection to ensure these are being done) Radiopharmaceutical Administration

Use of Radionuclides in the Healing Arts (618)

Weekly radiation and wipe results if applicable

Use of Radionuclides in the Healing Arts (621) Use of Radionuclides in the Healing Arts (621) Use of Radionuclides in the Healing Arts (621)

Documentation Quarterly Surveys

Sealed source storage area results Documentation

Shipping and Transportation

Use of Radionuclides in the Healing Arts (618)

Package receipt and return

License Application

Documentation up-to-date

49-CFR-172 49-CFR-173 49-CFR-174 485

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 486

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Information Needed

Reference—Where to Find It (Name of section, numbers are from FL—BRC)

Aerosols & Gases

Documentation for equipment and venting for aerosols and gases

Use of Radionuclides in the Healing Arts (629)

Radiopharmaceutical Therapy

General requirements

License Application

Outpatient and Inpatient requirements and documentation

Use of Radionuclides in the Healing Arts (622, 625)

General requirements

License Application

Outpatient and Inpatient requirements and documentation

Use of Radionuclides in the Healing Arts (618, 622, 625, 633)

Required documentation

Use of Radionuclides in the Healing Arts (610)

Subject VII. Additional Modules

Brachytherapy

Mobile Systems

Surveys RAM Control Type A shipments

The above criteria for inspections are suggestions to be used only as an example. Check with your local state regulations for specific requirements. There are many examples of computer software available for departments that record and calculate the activities of the department, patient dosage, receipt and transport, waste storage, etc. Much of the hot lab testing, e.g., the dose calibrator, and related tasks are or can be outsourced to physicists and their companies for testing, collecting data, and filing reports.

SOME PREPARATIONS FOR INSPECTION • Ensure that the department is in order: no personal items out, no food, no “hot” waste in waste baskets e.g., contaminated gloves, cotton balls, gauze, etc. • Ensure that the lock on the door of the department and/or hot lab is in working order. • Ensure that sign placements (postings e.g., “Caution: Radioactive Materials” or Warning, “Emergency Procedures,” “Notice to Employees,” “Rules for Safe Use of Radiopharmaceuticals,” pregnancy signs, survey hands sign) and technologists’ certifications and license are visible, appropriate, and current. Some include the list of radiopharmaceuticals and dosages for the specific department. • Ensure that all authorized users’ documentation is current; old ones removed, new ones added. • Ensure that the technologists have proper attire. Some states will accept scrubs in lieu of lab coats as removable safe clothing. Use of gloves, syringe shields, hand surveys, and safe practices are observed by the inspectors during the inspection. • Wear exposure badges when working making sure that the extremity badge (ring) is facing inside (palm side of hand) when working. • Ensure HAZMAT (with security awareness training) and annual exposure records are current and available. • Ensure that there is a copy of the License Application and License available. • Ensure that there is a department policy and procedure manual available, complete, and signed by all of the authorized users. • Ensure that ALL of the documentation for radiopharmacy and patients include the appropriate information. The NRC or state supplies lists of criteria, an example is given in the following pages. 486

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 487

Quick Reference G — Regulations

• Ensure that manufacturers’ specifications (operating manuals) concerning quality control (QC) of that equipment is available. • Patient information e.g., written directives, must be complete and match the dates on the patient’s record. Thyroid uptake machine quality control dates must match dates on patient’s records. Released thyroid patients of greater than 30 mCi must have documentation of the results of their survey and/or method of release. • Ensure that quality control tests of all equipment are accurate, up-to-date, and readily accessible on film or digital, or logged in some fashion with the appropriate information included. • Ensure that the RSO is properly listed (in the license and posted on door of department) and that RSO is aware of and has performed all duties and signed all appropriate documentation. • All records, with only a few exceptions, must be kept for 3 years. Exceptions include but are not limited to visiting AU’s for 5 years, recordable events for 5 years, misadministrations for 20 years, written directives for the duration of the license. • An often overlooked requirement (by techs, not the inspectors) is that the survey meter gets an operational check before EACH use. • Inspectors can and will look at all aspects of the department including the hot lab and technologists’ performance. They want to ensure that the department is safe, that it is operating within federal/state specifications, and that the department can function continuously in that manner.

USE OF RADIOPHARMACEUTICALS DOCUMENTATION If the department does not have patient/radiopharmaceutical software that automatically tracks, stores, and/or prints out the information required, here is what is required for records concerning radioactive materials use: A. Unit dose received from a supplier. • Radionuclide. • Generic name or its abbreviation or trade name. • Date of receipt. • Supplier. • Lot number or control number, if assigned. • Activity in µCi or mCi as recorded on the unit dosage or packing slip and its associated time. • Date of administration or disposal. • If administered: • prescribed dosage (unless already recorded in clinical procedure manual). • measured activity in µCi or mCi and date and time of measurement. • If discarded, the date and method of disposal. • Initials of the individual who made the record. B. Multidose vial received from a supplier or that is prepared on campus. • Radionuclide. • Generic name or its abbreviation or trade name. • Date of receipt or preparation. • Date and time of initial assay and amount in µCi or mCi, and milliliters (mL). • Supplier or kit manufacturer and lot number. • If administered: • prescribed dosage (unless already recorded in clinical procedure manual). • date and time dosage was drawn and measured. • calculated volume that is needed for the prescribed dosage. • measured activity in µCi or mCi. • patient name and identification number if one has been assigned. • If discarded, the method of disposal and date. • Initials of the individual who made the record. 487

10766-68_QuickRef-G.qxd

12/3/07

5:40 PM

Page 488

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

C. Measuring and recording molybdenum concentration—each time a generator is eluted, make a record of the: • Date the generator was received. • Date and time of elution. • Measured Mo-99 activity obtained from a dose calibrator in µCi. • Product of the measured Mo-99 activity and the correction factor noted by the molybdenum breakthrough pig manufacturer. • Measured Tc-99m activity in mCi. • Ratio of the total µCi of Mo-99 per mCi of Tc-99m and check mark that the ratio is less than 0.15 µCi of Mo-99 per mCi of Tc-99m. (If it isn’t, stop and notify the RSO. In conformance with 10 CFR 21.21(b), the licensee must notify the NRC or State Agency if a leaking generator is detected.) • Note: The regulations specify that no more than 0.15 µCi of Mo-99 per mCi of Tc-99m be present at the time of administration of the material to the patient. Due to the more rapid decay of Tc-99m compared to Mo-99, the ratio of Mo-99 to Tc-99m will approximately double during a six hour time period. Therefore, to ensure that no more than the 0.15 µCi limit of Mo-99 is administered at the end of a six hour day of use of the material, it is necessary to ensure that no more than 0.07 µCi per mCi of Mo-99 is present at the time of elution. • Initials of the person who made the record. The pages following this section are examples of data sheets for record keeping. If a software program is not available, these examples can be used as a guide for recording daily data. The examples were made using a standard Excel® spreadsheet. There are many ways the information can be organized to best suit a department. The information needed for storage and inspections may vary slightly from state to state.

Suggested Readings State of Florida, Department of Health, Bureau of Radiation Control, CD entitled Radiation Control (March 08, 2005). For information about the NRC (www.nrc.gov) and their requirements: http://www.nrc.gov/reading-rm/ doc-collections/cfr/part035/full-text.html NRC—10 CFR Part 19.14 NRC—10 CFR Part 30.52 NRC—10 CFR Part 20 NRC—10 CFR Part 35—Medical Use of Byproduct Material NRC—49 CFR Parts 172, 173, 174 Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Lombardi, Max H. Radiation Safety in Nuclear Medicine. 2nd ed. Boca Raton, FL: CRC Press LLC, 2007.

488

100002

Shackett, Brandy

0.02 0.02 0.02 0.02 0.02 0.02 0.02

5. Non-RAM Waste

6. Injection Chair

7. Uptake Probe

8. Camera

9. Imaging Table

10. Acquisition Console

11. Processing Station

Ludlum Ludlum

Svy Meter A:

Svy Meter B:

Srvy Meter:

14C

14C

Model #

0.02

4. Work Area

Mfr:

0.02

3. RAM Storage

PS

0.04

2. RAM Waste/Sharps

Tech Init.

0.05

1. Hot Lab Work Area

44-9

44-9

Dosage Assay

2190002

2190001

Ser. #

uncontrolled areas:

controlled areas:

Bkg:

10:00

8:05

Assay Time

Feb-09

Jul-09

Nxt cal date

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

0.5 mR/hr

2 mR/hr

2 mR/hr

2 mR/hr

B mR/hr

18F-FDG

99mTc-ECD

Radiopharmaceutical

Survey Meter: Action Limit:

17.8mCi/ml

28.7mCi/ml

Pancake

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

mR/hr

PET scan

Brain SPECT

Daily Surveys 0.02

Givesabunch

Helpsalot

Type of Exam

15.0mCi

25.0mCi

Prescrib. Dosage

pass

234766

234765

Rx #

3.5 mR/hr

mR/hr

Ck source

CPM

CPM

CPM

CPM

CPM

CPM

CPM

CPM

CPM

CPM

ps

ps

Tech Init.

CPM

8/8/2008

8/8/2008

RP Exp. Date

100 sq.cm Action Limit: It Above bkg:

15.2mCi

26.7mCi

Admin. Dosage

8/8/2008

Pete Shackett, BA, CNMT, ARRT(N) c2008

Battery

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

60 CPM

Weekly Wipes 60 CPM

10:03

8:10

Admin. Time

Date:

DAILY DRAW DOSE REPORT

5:40 PM

2 8/8/2008 Bkg:

100001

Shackett, Carolyn

Referring Physician

LIPPINCOTT RADIOLOGY CENTER

12/3/07

Total # Patients: DATE:

MR ID #

Patient Name

Logo

10766-68_QuickRef-G.qxd Page 489

489

490

Radiopharm. 99mTc-HDP

Date rcvd.

8/7/2008

Rtnd to pharm.

Type of Disposal:

203379

Rx #

Returned to Radiopharmacy

Wolters Kluwer Radiopharmacy

Supplier:

Case Number:

Surface: mR/hr

0.02

Survey 1 meter: mR/hr

22.0mCi

Act.at Cal.

11:00

Time

Surface: mR/hr

Condition:

pass

Battery

0.02

ok

0.1

II

0.02

ok

600546

Type:

% error: 0

Feb-09

Jul-09

Nxt cal date

Cs-137 Vial E ser.#:

2190002

2190001

Ser. #

Case Number:

206 uCi

44-9

44-9

Pancake

Ser. #: 14433970

14C

14C

Unused RP’s:

TRANSFER:

RECEIVING:

137Cs:

AtomLab 100

Ludlum

Survey Meter B:

Dose Calibrator:

Ludlum

Survey Meter A:

Model #

Surface: mR/hr

Condition:

Surface: mR/hr

Type:

mR/hr

0.02

B

0.02 mR/hr

0.02

B

0.02

B

0.02 mR/hr

0.02

B

PS

60 CPM

60 CPM

PS

PS

PS

60 CPM

Wipe: Technologist:

60 CPM

Bkg Wipe:

Background: mR/hr

Technologist:

Wipe:

Bkg Wipe:

Technologist:

207 uCi

Technologist:

PS

60 CPM

Wipe: Technologist:

60 CPM

PS

60 CPM

60 CPM

Bkg Wipe:

Technologist:

Wipe:

Bkg Wipe:

Pete Shackett, BA, CNMT, ARRT(N) c2008

Bkg mR/hr

Survey Meter:

Empty pkg:

Bkg mR/hr

Survey Meter:

Decay Corr. Activity:

3.5 mR/hr

Ck source

Bkg mR/hr

Survey Meter:

Empty pkg:

Bkg mR/hr

Survey Meter:

Date: 8/8/2008

5:41 PM

Mfr:

Returned to Radiopharmacy

Type of Disposal:

Wolters Kluwer Radiopharmacy

Supplier:

37

0.02

Survey 1 meter: mR/hr

Case Number:

37

Case Number:

LIPPINCOTT RADIOLOGY CENTER RADIOPHARMACEUTICAL RECEIVING AND DISPOSAL

12/3/07

INSTRUMENT:

TRANSFER:

RECEIVING:

Logo

10766-68_QuickRef-G.qxd Page 490

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

10766-69_QuickRef-H.qxd

12/3/07

5:41 PM

Page 491

QUICK REFERENCE H

Patient Release Methods and Information for Thyroid Therapies Methods of Patient Release Inpatient Information Outpatient Information

491

10766-69_QuickRef-H.qxd

12/3/07

5:41 PM

Page 492

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

METHODS OF PATIENT RELEASE Administered Activity • Patients may be released using the guidelines below based on the activity administered to them for the study. They receive instructions upon release based on the activity minimums in the table below. Activity Above Which Patient Instructions are Required

Activity at or Below Which Patients May be Released Radionuclide

GBq

mCi

GBq

mCi

Au-198

3.5

93.0

0.69

19.0

Cr-51

4.8

130.0

0.96

26.0

Ga-67

8.7

240.0

1.7

47.0

I-123

6.0

160.0

1.2

33.0

I-125

0.25

7.0

0.05

1.0

I-131

1.2

33.0

0.24

7.0

In-111

2.4

64.0

0.47

13.0

P-32

n/a

n/a

n/a

n/a

Re-186

28.0

770.0

5.7

150.0

Re-188

29.00

790.0

5.8

160.0

Sc-47

11.0

310.0

2.3

62.0

Sm-153

26.0

700.0

5.2

140.0

Sn-117m

1.1

29.0

0.21

Sr-89

n/a

n/a

n/a

Tc-99m

28.0

760.0

5.6

150.0

Tl-201

16.00

430.0

3.1

85.0

Y-90

n/a

n/a

n/a

Yb-169

0.39

10.0

0.073

6.0 n/a

n/a 2.0

N/A: limits not applicable because exposure is deemed too minimal to affect general public given activity normally administered for diagnostic or therapeutic reasons.

• Agreement state regulations may vary. Check values with state regulations before usage. • Release documentation is not required unless the patient is nursing and the radiation dose to the infant or child is likely to exceed 5 mSv (0.5 rem).

Retained Activity • The patients may be retained at the institution if their activity exceeds the levels listed above until the amount of activity decays to at or below the listed levels. Activity levels are based on decay tables for the given particular radioisotope. There is an assumption of no biological excretion in the calculation. 492

10766-69_QuickRef-H.qxd

12/3/07

5:41 PM

Page 493

Quick Reference H — Patient Release Methods and Information for Thyroid Therapies

• Instructions given to the patient are based on the table above and the calculated activity of the patient at the time of release. • Release documentation is needed for release as well as additional documentation if the patient is nursing.

Measured Dose Rate • Patients may be released based on the measured dose rate at 1 meter from the surface of the patient using a survey meter. The release is based on the table below. The patient is required to receive instructions if the dose rate is above the levels listed in the table. Dose Rate at 1 m, at or Below Which Patients May be Released Radionuclide

Dose Rate at 1 m, Above Which Patient Instructions are Required

mSv/hr

mrem/hr

mSv/hr

mrem/hr

Au-198

0.21

21.0

0.04

4.0

Cr-51

0.02

2.0

0.004

0.4

Ga-67

0.18

18.0

0.04

4.0

I-123

0.26

26.0

0.05

5.0

I-125

0.01

1.0

0.002

0.2

I-131

0.07

7.0

0.02

2.0

In-111

0.2

20.0

0.04

4.0

P-32

n/a

n/a

n/a

n/a

Re-186

0.15

15.0

0.03

3.0

Re-188

0.20

20.0

0.04

4.0

Sm-153

0.3

30.0

0.06

6.0

Sr-89

n/a

n/a

n/a

n/a

Tc-99m

0.58

58.0

0.12

12.0

Tl-201

0.19

19.0

0.04

4.0

Y-90

n/a

n/a

n/a

n/a

Yb-169

0.02

2.0

0.004

0.4

N/A: limits not applicable because exposure is deemed too minimal to affect general public given activity normally administered for diagnostic or therapeutic reasons.

• Agreement state regulations may vary. Check values with state regulations before usage. • Release documentation is needed for release as well as additional documentation if the patient is nursing.

Patient-Specific Dose Calculations • The patient may be released if the maximum likely patient-specific dose to the individual is no greater than 0.5 rem (5 mSv). The patient is to receive instructions if the patient-specific dose to the individual is greater than 0.1 rem (1 mSv). • The method for determining the patient-specific dose is complicated and best served by involving a medical physicist and nuclear physician. The methods for calculation can be found in appendix A to NRC Regulatory Guide 8.39. 493

10766-69_QuickRef-H.qxd

12/3/07

5:41 PM

Page 494

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

• Release documentation is needed for release as well as additional documentation if the patient is nursing. • As examples for 131I, taken from appendix A to NRC Regulatory Guide 8.39: • Hyperthyroidism Dose = Q0 (1.62 + 9.0 F2) Where: Dose = total effective dose equivalent (in mrem) to an individual from the radioactive patient Q0 = initial administered activity (in mCi) F2 = thyroid uptake fraction of radioiodine Use the measured value for the thyroid uptake if it is known, otherwise a value of 0.8 may be substituted. Remaining consistent with the 500 mrem limit of immediate patient release and an uptake of 0.8, then 56 mCi is the maximum dose that can be administered. • Thyroid Cancer Dose = Q0 (1.62 + 12.9 F2) Use the measured value for the thyroid uptake if it is known, otherwise a value of 0.05 may be substituted. Remaining consistent with the 500 mrem limit of immediate patient release and an uptake of 0.05, then 220 mCi is the maximum dose that can be administered. • Release documentation includes the patient name, identification number, activity administered with date and time, date and time of patient release, the method chosen for release and documented calculation of method used, the maximum amount allowed for release, the signature of the patient being released and the signature of the person doing the calculations. • Information concerning the release of female patients who are nursing can also be found in appendix A to NRC Regulatory Guide 8.39. • Agreement States: As an example, Florida is an Agreement State. From a discussion with the Bureau of Radiation Control (BRC), Agreement States must have a policy/procedure in place determining the early release of patients receiving greater than 30 mCi of radioactive iodine. The policy/procedure will concern the safety of the individual and the public and instructions to the individual. The policy/procedure must meet the minimum of the most stringent requirements for release. Institutions and clinics may amend their license with their chosen protocols by contacting, in Florida’s case, the Materials Program Office. Other Agreement States will have a similar bureau or office.

Suggested Readings Appendix A to NRC Regulatory Guide 8.39. Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Mettler, Fred A. Jr., and Milton J. Guiberteau. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006.

Notes

494

10766-69_QuickRef-H.qxd

12/3/07

5:41 PM

Page 495

Quick Reference H — Patient Release Methods and Information for Thyroid Therapies

PATIENT INFORMATION FOR THYROID THERAPY (INPATIENT) 1. You are not here because you are sick. The nursing staff will not be coming in to take daily vital signs like blood pressure and temperature. 2. This room is to keep you isolated during your therapy. Please confine yourself to the room. 3. The usual stay is about 3 days, depending on how much of the iodine is excreted as measured by a Geiger counter. 4. No visitors under the age of 18 or pregnant women are allowed. 5. Visiting time permitted is no more than 20 minutes per visitor per day. The time increases slightly as the days progress. 6. Visitors must remain at the doorway (at least 10 feet from patient). 7. Iodine is released from the body in perspiration, as well as waste, so everything brought into the room and touched stays in the room. The clothes you wear and possessions handled will be bagged and stored for 3 months. Games and other items can be wrapped in plastic before being handled, then released once checked by the Geiger counter. 8. You will be given disposable plates and utensils. These must be stored for 3 months, then opened and surveyed with the Geiger counter. Please thoroughly rinse off dishes and rinse out cans and milk cartons before placing them in the storage bag. 9. Flush what you do not finish down the toilet (except for larger items like chicken bones, etc.) If you do not touch a meal at all, it can be surveyed and removed from the room. 10. When using the toilet, be careful not to contaminate the surrounding area, and, when done, flush three times to ensure dilution within the plumbing system. Wash hands often. 11. Questions: call the nuclear medicine department.

PATIENT INFORMATION FOR HYPERTHYROID THERAPY (OUTPATIENT) 1. 2. 3. 4. 5. 6. 7. 8. 9.

10. 11.

12. 13.

For at least 2 days, keep a distance of 3 feet or more between you and any people. Do not hug or hold children or animals close for 2 days. Do not share utensils at home with anyone. Wash the ones you use thoroughly. Keep your clothes and linen separate and wash them thoroughly. The iodine exits your body over time by bowel movements, urine, saliva, and perspiration. Sleep alone for the first 2 nights. When using the toilet, be careful not to contaminate the surrounding area and, when done, flush two times to ensure dilution within the plumbing system. Wash hands often. You may feel a scratchy throat within a few days but that will subside. It may take a couple of weeks to feel any benefit related to your condition from the capsules. If you get sick and throw-up the capsule(s), try to do so in a toilet or sink or, at last resort, on the pavement. Call the nuclear medicine department so that they will know you no longer have the capsule(s) inside you. This is extremely rare and is usually caused by food or sickness unrelated to the iodine capsules. Although any allergic reaction to the iodine capsules is extremely rare, if you feel you are having one, contact your doctor’s office. You have taken a capsule that contains radioactive iodine that emits beta and gamma rays. It is designed to do its therapeutic work on your thyroid and does not present a danger to anyone. These steps are taken only to reduce unnecessary exposure to people with whom you may come in contact. Questions: call the nuclear medicine department. Note: Times and distances may vary with dosage administered.

495

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 496

QUICK REFERENCE I

Patient History Sheets Adrenal Scans, mIBG, and NP59 Bexxar® and Zevalin® Bone Scan Brain Scan (SPECT) Cardiac/MUGA Scan Rest/Stress/Redistribution Gallium/Indium/Ceretec® Scan Gastric Emptying Scan GI Bleed/Meckel’s HIDA Scan Lung Scan (Aerosol) Lung Scan (Gas) Liver/Spleen Scan Miscellaneous Worksheet NeutroSpec® Octreoscan® PET Scan ProstaScint® Renal/Renogram/Captopril Scan Scintimammography Thyroid Uptake and Scan Please feel free to copy these history sheets for department use. 496

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 497

Quick Reference I — Patient History Sheets

History for Adrenal Scans, mIBG, and NP59 Date of exam _____________________________ ❑ OP

❍M

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site __________________________ Time __________________________ Scans _______ /_______ /______ Diagnosis ______________________________________________________________________________________ Chief complaint __________________________________________________________________________________ Date symptoms began ______________________________ Recent weight gain ______________________________ Pain ________________________________________ Since when ________________________________________ Lugol or perchlorate (thyroid blocker) last night ________________________________________________________ Meds: list (both Rx and OTC) _______________________________________________________________________ Meds withheld for exam: how long __________________________________________________________________ ______________________________________________________________________________________________ Hx of CA (type) ______________________________________ When Dx ____________________________________ Allergy to iodine ___________________ Nausea and vomiting ___________________ Anxiety ___________________ Hyper- or hypotension ______________________________ Oral contraceptives _______________________________ Palpitations _______________________ Sweating ______________________ Headaches ______________________ Flushed face ________________________________ Tingling in hands or feet ________________________________ Radiation or chemo Tx _________________________________ Diabetic ____________________________________ Hirsutism (abnormal hair growth) ______________________________ Since when ____________________________ Recent surgery __________________________________________________________________________________ ______________________________________________________________________________________________ / Pt.: LMP _______ /_______ /_______Hysterectomy _____________________ Menopause ____________________ Previous scans or related studies (type, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Other diagnosed diseases _________________________________________________________________________ Labs: ______________________________________ Date _______________________________________________ Technologist ______________________________

497

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 498

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Bexxar® and Zevalin® Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant/nursing _________________________ Physician: Dr. ____________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site ________________________ Time ________________________ Scan time _______________________ Diagnosis ______________________________________________________________________________________ Chief complaint __________________________________________________________________________________ Have you had your cold Bexxar (tositumomab) injection? _______________________ When _____________________ Reaction to the injection ________________________ What ______________________________________________ Have you taken thyroid blocking agents (what, when) ____________________________________________________ Have you had your cold Zevalin (rituxan) injection? ________________________ When ________________________ Reaction to the injection ________________________ What ______________________________________________ Any known allergies (murine products, etc.) ___________________________________________________________ Previous MoAb tests ____________________________________ HAMA ___________________________________ Primary type CA/FHx of CA _________________________________________ When Dx _______________________ Pain (where, since when) __________________________________________________________________________ Chemo or Radiation _________________________________________________ When _______________________ Surgery (type, when) _____________________________________________________________________________ Cardiac or pulmonary problems (type, when) __________________________________________________________ Related scans (previous, pending, e.g., NM, PET, MRI, CT, US, x-ray)________________________________________ ______________________________________________________________________________________________ Labs:

Date: _______________________ HAMA _____________ CEA, ______________ CA-125 ________________

Thyroid ______________________ Platelet count ______________________ WBC count ______________________ Abnormal labs __________________________________________________________________________________ Diabetic ______________________ Medications _______________________________________________________ ______________________________________________________________________________________________ Injection monitoring Time

HR

BP

Resp. Rate

Comments

Baseline 5 min 15 min 30 min 60 min RN _______________________________ Technologist __________________________ 498

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 499

Quick Reference I — Patient History Sheets

History for Bone Scan Whole Body

❍M Limited

Date of exam _____________________________ ❑ OP

3-Phase ❑ ER

❍F

SPECT (Circle One)

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Diagnosis ______________________________________________________________________________________ Chief complaint __________________________________________________________________________________ Bone Pain ________________________ Where ________________________ Radiating ________________________ ______________________________________________________________________________________________ Broken bones _______________________________ Recent trauma (falls, etc) _______________________________ ______________________________________________________________________________________________ Arthritis _____________________________ Prosthesis _________________________________________________ Infections _______________________ Swelling _______________________ Open sores _______________________ Hx of cancer (type, where, when Dx) _________________________________________________________________ Chemo, radiation Tx _______________________ When _________________________________________________ Recent surgery, related information __________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _______________________ Medications ______________________________________________________ Labs: _________________________ Date ____________________________________________________________ Alk Phos _______________ LDH _______________ BUN _______________ Creat ____________________________ Ca2+ __________________ PO4 ________________PSA _______________ Acid Phos _________________________ Comments _____________________________________________________________________________________ Technologist ______________________________

499

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 500

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Brain Scan (SPECT) Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ Chief complaint _________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Head pain (head aches, other area, pressure) __________________________________________________________ Since when ________________________________________ Where _______________________________________ Head trauma ____________________________________________________________________________________ CVA ________________________ When _________________________ What affected _________________________ Infection (e.g., meningitis, encephalitis) _______________________________________________________________ Memory problems (short-term, long-term) _____________________________________________________________ Since when _____________________________________________________________________________________ Seizures ________________________ Since when _____________________________________________________ Surgeries (any) _________________________________________________________________________________ FHx of pain, CVA, memory loss _____________________________________________________________________ Shunt, metal plate ________________________ Location ________________________________________________ Previous scans or related studies (EEG, MRI, CT, when, where, Dx) __________________________________________ ______________________________________________________________________________________________ Diabetic ________________________ Medications_____________________________________________________ ______________________________________________________________________________________________ Labs: ______________________________________ Date _______________________________________________ Comments _____________________________________________________________________________________ Technologist ______________________________

500

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 501

Quick Reference I — Patient History Sheets

History for Cardiac/MUGA Scan Rest/Stress/Redistribution Date of exam _____________________________ ❑ OP

❑ ER

❍M

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant _____________ Bra Size _____________ Physician: Dr. __________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Drug interventions (type, amount) ___________________________________________________________________ Injection sites __________ /__________ Times __________ /__________ Scan times ___________ /___________ Diagnosis ______________________________________________________________________________________ Chief complaint _________________________________________________________________________________ Date symptoms began _____________________ Pain _____________________ How long _____________________ Where _________________________ SOB _________________________ How long __________________________ With exertion _________________________ Diet pills (type) _____________________________________________ Viagra® ______________________ Cholesterol-reducing drugs ___________________________________________ Hx of cancer _____________________ When Dx _____________________ Evaluation for chemo Tx ______________ Hx of cardiac disease _____________________________________________________________________________ What type (MI, CHF, CAD) _________________________________________________________________________ Family Hx of cardiac disease _______________________________________________________________________ Who, what type _________________________________________________________________________________ Hypertension ______________________ When Dx ______________________ EtOH intake _____________________ Smoker (how much, how long) ______________________________________ Diabetic ________________________ Pacemaker _____________________ Nitro patch or meds _____________________ Asthma ____________________ Cardiac cath report (where, when) ___________________________________________________________________ Prior EKG _____________________________ Results __________________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ Medications ____________________________________________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ CPK _____________ LDH _____________ Chol _____________ Troponin _____________ Myoglobin _____________ Comments _____________________________________________________________________________________ Technologist(s) ________________________ /________________________

501

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 502

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Gallium/Indium/Ceretec® Scan Date of exam _____________________________ ❑ OP

❍M

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site ________________________ Time _________________________ Scan time ______________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Pain ______________________________________ Location _____________________________________________ Fever ______________________ Since when ______________________ Frequency __________________________ Recent surgery _____________________________ When _______________________________________________ Where ________________________________________________________________________________________ Hx of cancer _______________________________ What type _____________________________________________ When Dx __________________________________ Radiation or chemo Tx __________________________________ Diabetes __________________________________ Hx bowel disease ______________________________________ Biopsy or aspiration ______________________________________________________________________________ Previous scans or related studies (type, when, where, Dx):________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Antibiotic therapy (what, when) _____________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ WBC ________________ AST (SGOT) ________________ ALT (SGPT) ________________ GGTP ________________ BUN ________________ LDH ______________________ Alk Phos __________________ Creat _________________ Comments _____________________________________________________________________________________ Technologist ______________________________

502

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 503

Quick Reference I — Patient History Sheets

Gastric Emptying Scan Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Administration ______________________ PO Time ______________________ Scan time ______________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Last solid meal _______________________________ Feel full soon after eating _______________________________ Abdominal pain _______________________________ Where ____________________________________________ Bloating ________________________ Acid burning ________________________ Ulcers _______________________ Diabetic ____________________________ Nausea and vomiting __________________________________________ Hx of cancer _______________________________ Where _______________________________________________ Recent surgery (where, when) ______________________________________________________________________ Allergic to Reglan ________________________ Allergic to eggs ___________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Medications ____________________________________________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ Intrinsic factor ___________________ Gastrin _________________________ Pepsin _________________________ Amylase ________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________

503

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 504

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for GI Bleed/Meckel’s Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Abdominal pain _______________________________ Where ____________________________________________ Active bleeding ________________________________ How long __________________________________________ Color of blood in stool (bright red, burgundy, dark) ______________________________________________________ Active or HX of internal and external hemorrhoids (non-bleeding or bleeding) _________________________________ Hx of cancer ___________________________ Diverticulitis ___________ Crohn’s ____________________________ Colostomy _________________ Site _________________ Surgery _________________ Site ___________________ Recent transfusion ________________________________ How many units _________________________________ Receiving KCI IV fluids ____________________________________________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ RBC ________________________ Hematocrit _____________ Hemoglobin _________________________________ WBC _______________________ Guaiac Test _________________________________________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________

504

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 505

Quick Reference I — Patient History Sheets

History for HIDA Scan

❍M

Date of exam _____________________________ ❑ OP

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Last solid meal __________________________________________________________________________________ Abdominal pain _______________________________ Where ____________________________________________ Nausea/vomiting ________________________ EtOH intake ________________ Smoke ________________________ Jaundice ____________________________________ Intolerance to fatty food _______________________________ Abnormal blood tests _____________________________________________________________________________ Allergic to morphine ______________________________________________________________________________ Hx of liver/GB disease or surgery (hepatitis, cancer, gallstones) ____________________________________________ ______________________________________________________________________________________________ Recent sonogram ________________________ Results __________________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ T. Bili ____________ Alk. Phos ___________ ALT (SGPT) ___________ AST (SGOT) __________________________ GGTP ____________ LDH _____________ Amylase ______________ CPK _____________ WBC ________________ Creat _____________________________ BUN ________________________________________________________ Comments _____________________________________________________________________________________ FOR EF (Circle):

CCK

Fatty meal

Pulmocare

Other at ___________________ minutes into study.

Patient reaction to intervention: _____________________________________________________________________ Max EF: ___________% at ______________ minutes post CCK injection. Technologist ______________________________

505

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 506

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Lung Scan (Aerosol) Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical:

99m

Tc-DTPA

Radiopharmaceutical:

99m

Tc-MAA

Dose _______________ Time ________________________________ Dose ___________________________________________________

Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ______________________ Oral contraceptives ______________________________________ Recent (within 24 hours) chest x-ray _________________________________________________________________ Chest pain ____________________ Where _____________________ Syncopy _______________________________ SOB ___________________ Fever __________________ Hemoptysis ______________________________________ Smoker (how much) ____________________ Recent long trips ___________________________________________ Recent or upcoming surgery _______________________________________________________________________ Hx of any lung disease (prior PE, emphysema, bronchitis, pneumonia, pleurisy)________________________________ ______________________________________________________________________________________________ Hx of cancer, deep vein thrombosis, phlebitis, heart disease _______________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Previous scans or related studies (type, when, where, Dx) ________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Heparin, Coumadin, Lovenox, Ticlid __________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ PaCO2 __________________ PaO2 __________________ pH__________________ O2Sat _____________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________ 506

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 507

Quick Reference I — Patient History Sheets

History for Lung Scan (Gas)

❍M

Date of exam _____________________________ ❑ OP

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical:

133

Xe

Radiopharmaceutical:

99m

Tc-MAA

Dose _______________ Time ________________________________ Dose ___________________________________________________

Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Recent (within 24 hours) chest x-ray _________________________________________________________________ Date symptoms began ______________________ Oral contraceptives ______________________________________ Chest pain ____________________ Where ____________________ Syncopy _______________________________ SOB _________________________ Fever _____________________ Hemoptysis _____________________________ Smoker (how much) ____________________ Recent long trips ___________________________________________ Recent or upcoming surgery _______________________________________________________________________ Hx of any lung disease (prior PE, emphysema, bronchitis, pneumonia, pleurisy) _______________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Hx of cancer, deep vein thrombosis, phlebitis, heart disease ______________________________________________________________________________________________ ______________________________________________________________________________________________ Previous scans or related studies (type, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Heparin, Coumadin, Lovenox, Ticlid __________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ PaCO2 __________________ PaO2 __________________ pH__________________ O2Sat _____________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________ 507

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 508

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Liver/Spleen Scan Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Abdominal pain _______________________________ Where ____________________________________________ Nausea/vomiting _______________________________ Jaundice ____________________________________________ Hx of surgery or disease of liver, GB, spleen (hepatitis, cancer, abnormal blood tests) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Alcohol consumption ___________________________ Smoking __________________________________________ Previous scans or related studies (type, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ T. Bili ____________ Alk. Phos ___________ ALT (SGPT) ___________ AST (SGOT) __________________________ GGTP ________ LDH _________ Hgb __________ HCT _________ Platelets _____________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________

508

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 509

Quick Reference I — Patient History Sheets

Miscellaneous Worksheet

❍M

❍F

Scan ____________________________________ Date of exam _____________________________ ❑ OP

❑ ER

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Clinical Scan Data _______________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________ 509

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 510

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for NeutroSpec®

❍M

Date of exam _____________________________ ❑ OP

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site __________________________ Time __________________________ Scans _______ /_______ /______ Diagnosis ______________________________________________________________________________________ Chief complaint __________________________________________________________________________________ Any known allergies (murine products, etc.) ___________________________________________________________ Previous MoAb tests ______________________________________ HAMA _________________________________ Hx/FHx of CA (type, when Dx) ______________________________________________________________________ Pain (where, since when) __________________________________________________________________________ Nausea/vomiting ____________________ Trauma to abdomen ____________________________________________ Diabetic ___________ Fever ___________ Do you have your appendix _______________________________________ Any recent infections _____________________________ Bowel disease ____________________________________ Surgery (type, when) _____________________________________________________________________________ ______________________________________________________________________________________________ Related scans (previous, pending, e.g., NM, PET, MRI, CT, US, x-ray) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Problems with micturition ______________________________ Hx of cellulitis _______________________________ Labs:

Date: ____________________ HAMA _________ BUN _________ WBC count _________________________

Medications ____________________________________________________________________________________ ______________________________________________________________________________________________ Injection monitoring Time

HR

BP

Resp. Rate

Comments

Baseline 5 min 15 min 30 min 60 min RN _______________________________ Technologist _______________________________ 510

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 511

Quick Reference I — Patient History Sheets

History for Octreoscan® Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _________________________ Time _________________________ Scan time _____________________ Diagnosis ______________________________________________________________________________________ ______________________________________________________________________________________________ Chief complaint _________________________________________________________________________________ ______________________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Pain ______________________________________ Since when __________________________________________ Hx of CA (type) ______________________________ When Dx _____________________________________________ Tx of octreotide acetate _______________________ Since when __________________________________________ Other Tx _______________________________________________________________________________________ Hx of insulinoma ____________________________ Since when __________________________________________ Hx of impaired renal function ___________________ Since when __________________________________________ Pt. on total parenteral nutrition __________________ Since when __________________________________________ Recent surgery __________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ / Pt.: LMP _____/_____/_____

Hysterectomy ________________________ Menopause _____________________

Previous scans or related studies (type, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _________________________ Medications ____________________________________________________ ______________________________________________________________________________________________ Labs: _______________________ Date ______________________________________________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Patient needs to purchase 4 cans of magnesium citrate. Technologist ______________________________ 511

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 512

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for PET Scan Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Name of Study __________________________________________________________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site ______________________ Time _______________________ Residual Activity ____________________ Uptake time ___________________ Emission time ____________________ Transmission time __________________ Diagnosis ______________________________________________________________________________________ Chief complaint ________________________________________ Date symptoms began _______________________ NPO since _________________________________Contents of last meal ____________________________________ Diabetic _________________________ Medications ____________________________________________________ Blood sugar ______________/ Time________________ Blood sugar ________________/ Time__________________ Claustrophobia ____________ Incontinence _____________ Physical problems ______________________________ Hx of Cancer (type, when diagnosed) _________________________________________________________________ Primary site ________________________________ Pain (where, since when) _______________________________ Hx of surgery ___________________________________________________________________________________ Radiation (when, area)____________________________________Chemo __________________________________ Recent trauma or infections ________________________________________________________________________ Related scans (type, when, where, Dx e.g., NM, MRI, CT, PET, biopsy) _______________________________________ ______________________________________________________________________________________________ Allergies (e.g., shellfish)____________________________________________ Asthma ________________________ Oral contrast ____________________________________ Water __________________________________________ Cardiac: Bra cup size ________________ Chest pain ________________________ Smoke ______________________ Heart disease _______________________________________ Pacemaker _______________ SOB ________________ Medications ______________________________________ Nitro ______________ Aminophylline _______________ Previous or pending heart procedures ________________________________________________________________ Brain: Caffeine, alcohol, or nicotine in the last 24 hours ___________________________________________________ Seizures or balance problems ___________________________ Plates or other surgery _________________________ Memory loss ___________________ Confusion ___________ Headaches ___________________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________ 512

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 513

Quick Reference I — Patient History Sheets

History for ProstaScint®

❍M

Date of exam _____________________________ ❑ OP

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Physician: Dr. ___________________________________________________________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _____________________________________________________ Time __________________________ Scan days/time __________________________ /___________________________ /___________________________ Diagnosis ______________________________________________________________________________________ Chief complaint __________________________________________________________________________________ Any known allergies (murine products, indium, etc.) _____________________________________________________ Biopsy ___________________________________ Previous MoAb tests ____________________________________ Pain (where, since when) __________________________________________________________________________ Hx/FHx of CA (type, when Dx) ______________________________________________________________________ Bowel disease (Crohn’s, colitis, diverticulitis, etc.) _______________________________________________________ Surgery (type, when) _____________________________________________________________________________ ______________________________________________________________________________________________ (radical, cryosurgery) _____________________________________________________________________________ Radiation Tx _______________________________________ Chemo _______________________________________ Hormonal _________________________________________ Brachytherapy __________________________________ Related scans (previous, pending, e.g., bone, PET, MRI, CT, US, x-ray) ______________________________________________________________________________________________ Labs:

Date: ________ PSA ________ HAMA ________ BUN ________ Creat ________ Ca2+ ___________________

Acid Phos ______________ Phosphorus ______________ T. Bili ______________ T. Protein ___________________ Albumin ______________ AST ______________ ALT ______________ Glucose _________ CEA _________________ Diabetic ____________________________ Medications _________________________________________________ ______________________________________________________________________________________________ Laxative/enema ordered ___________________________________________________________________________ Injection monitoring Time

HR

BP

Resp. Rate

Comments

Baseline 5 min 15 min 30 min 60 min RN _______________________________ Technologist _______________________________ 513

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 514

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Renal/Renogram/Captopril Scan Date of exam _____________________________ ❑ OP

❑ ER

❍M

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical: _____________________ Dose 1st _____________________ 2nd _______________________ Injection site _______________________ Time _______________________ Time ____________________________ Diagnosis ______________________________________________________________________________________ Chief complaint _________________________________________________________________________________ Date symptoms began _____________________________ Pain ___________________________________________ Hematuria _____________________ Nausea and vomiting _____________________ Dialysis ___________________ Hx of cancer _____________________ When Dx _____________________ Allergy to IVP dye ___________________ Hx of stones, infections (bladder or kidneys), obstructions, surgery _________________________________________ ______________________________________________________________________________________________ Hypertension _____________________ Meds __________________________ Diabetes ________________________ Urinary frequency _________________ Urgency _______________________ CHF, cardiac disease _______________ Previous scans or related studies (type, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Medications ____________________________________________________________________________________ ______________________________________________________________________________________________ Labs:

Date __________________ Furosemide __________________ mg

Time ____________________________

BUN ________________________ Protein/albumin ____________________ Creat ____________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ Captopril/enalaprilat ______________________________ mg Time _______________________________________ Time

HR

BP

Resp. Rate

Comments

Baseline 5 min 15 min 30 min 60 min RN _______________________________ Technologist _______________________________ 514

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 515

Quick Reference I — Patient History Sheets

History for Scintimammography Date of exam _____________________________ ❑ OP

❍M ❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant _____________ Bra Size _____________ Physician: Dr. __________________________________ Radiopharmaceutical: ______________________________________________ Dose __________________________ Injection site _____________________ Time ______________________ Scan time ____________________________ Diagnosis ______________________________________________________________________________________ Chief complaint _________________________________________________________________________________ Date symptoms began ____________________________________________________________________________ Palpable nodules _______________________ When _______________________ Where ______________________ Pain or tenderness in breasts (where, how often) _______________________________________________________ __________________________________ Discharge (side, how often) ______________________________________ Implants __________________________ Type __________________________ Side(s) _________________________ Recent surgery or mastectomy _____________________________________________________________________ Where _______________________________________ When ____________________________________________ Recent trauma to chest (type, when, where) ___________________________________________________________ Hx of CA (type, when Dx) __________________________________________________________________________ FHx of CA (type, who) ____________________________________________________________________________ Radiation or chemo Tx ____________________________________________________________________________ Recent or previous scans (mammogram, PET, MRI, CT, x-rays, biopsy, date, where, Dx) _________________________ ______________________________________________________________________________________________ ______________________________________________________________________________________________ Diabetic _______________________________________ Medications ______________________________________ ______________________________________________________________________________________________ Labs: ________________________ Date _____________________________________________________________ Comments _____________________________________________________________________________________ ______________________________________________________________________________________________ Technologist ______________________________

515

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 516

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

History for Thyroid Uptake and Scan

❍M

Date of exam _____________________________ ❑ OP

❑ ER

❍F

Room # ________________________________

Patient name _________________________________________ Age ____________ DOB _______ /_______ /_______ MR number __________________________ Height _______________________ Weight _______________________ Females: Pregnant __________________________ Physician: Dr. _________________________________________ Radiopharmaceutical:

Tc O4−

99m

Dose _______________ mCi _________________________________

Injection site _____________________ Time _____________________ Scan Time ____________________________ 123

I or 131I Dose __________________________ µCi

Time ________________ Standard count _____________

4- to 6-h uptake ____________________________ %

Normal range _________________ to ________________ %

24-h uptake _______________________________ %

Normal range _________________ to ________________ %

Diagnosis ______________________________________________________________________________________ _____________________________________________ Date symptoms began ______________________________ Lumps or swelling in neck ________________________ Tenderness _______________________________________ Exactly where ___________________________________________________________________________________ Difficulty swallowing _____________________ Nervous ______________________ Tired _______________________ Weight gain/loss ________________________ How much ____________________ Since when __________________ Appetite good/bad ______________________ Perspire more _________________ Fevers ______________________ Heat/cold bother __________________________________ Heart palpitations ________________________________ Menstrual problems (irregular, infrequent, heavy) _______________________________________________________ Past Hx of thyroid disease _______________ When ________________ Type ________________________________ Treatment ___________________________ When ________________ Type ________________________________ Hx goiter ____________________________ Hx nodules ____________ Hx surgery ___________________________ Hx thyroid CA ________________________ When ________________ Type __________________________________ FHx of thyroid disease ______________________________ Type _________________________________________ Recent iodine contrast, dye studies (CT, IVP, GB, arteriogram, venogram, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________ Previous scans, studies, biopsy (US, Labs, when, where, Dx) ______________________________________________________________________________________________ ______________________________________________________________________________________________

516

10766-70_QuickRef-I.qxd

12/3/07

5:42 PM

Page 517

Quick Reference I — Patient History Sheets

Palpate patient’s thyroid Draw (anterior view) position of lump(s) or tenderness if found

Check list questions for patient (circle those that apply) Hyperthyroid

Hypothyroid

Neck swelling

Lethargy

Increased nervousness

Increased tiredness

Weight loss (amount)

Weight gain (amount)

Increased appetite

Decreased appetite

Heat intolerance

Cold intolerance

Diarrhea

Constipation

Increased irritability

Drowsiness

Hand tremors

Edema

Warm, moist skin

Dry skin

Hair loss

Dry, coarse hair

Hoarseness

Weakness

Sore throat Difficulty swallowing Heart palpitations Exophthalmus (bulging eyes, do a visual check) Thyroid medications _____________________________________________________________________________ When taken off __________________________________________________________________________________ (Synthroid 3 wk, Cytomel 2 wk, PTU 2 wk, thyroid grains 6 wk) Other meds, vitamins, antiarrhythmics ________________________________________________________________ Labs _____________________ Date ________________________________________________________________ RT3U _____________________ T4 _____________________ T7 _____________________ TSH __________________ Parathyroid disease (↑ Ca, ↑ PTH, Surgery, +FH) _______________________________________________________ Sensitive to pain _______________________ Ca _______________________ PTH ____________________________ Diabetic ______________________________________ Comments ________________________________________ Technologist ______________________________ 517

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 518

QUICK REFERENCE J

Abbreviations Commonly Used in Nuclear Medicine

518

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 519

Quick Reference J — Abbreviations Commonly Used in Nuclear Medicine

a

alpha

AFB

acid-fast bacillus

b2

beta—negatron

a-fib

atrial fibrillation

b1

beta—positron

AFP

alpha-feto-protein

g

gamma

Ag

antigen

l

decay constant

AGES

age, tumor grade, extent, and size

>

greater than

AGN

acute glomerulonephritis

<

less than

AIDS

auto immune deficiency syndrome

~

about, approximately

a.k.a.

also known as

99m

pertechnetate

Al

aluminum

28

secondary to

ALARA

as low as reasonably achievable

38 _ a

tertiary to

ALI

annual limit on intake

before

Alk

alkaline

A

activity, mass number

ALND

axillary lymph node detection

AAA

abdominal aortic aneurysm

ALT

alanine amino transferase (SGPT)

AB

antibody

Am

americium

ABC

airway, breathing, circulation

AMA

against medical advice, American Medical Association

ABNM

American Board of Nuclear Medicine

AMES

Acc. or accel

accelerator

age, metastasis, tumor extent, and size

Abd

abdomen

AMI

acute myocardial infarction

ABN

abnormal

ANS

American Nuclear Society

AC

acromioclavicular (joint)

Ant.

anterior

ACC

acalculous cholecystitis

A/O

alert and oriented

ACD

anticoagulant-citrate-dextrose; citric acid, sodium citrate, dextrose—blood thinner

AP

anteroposterior

APhA

American Pharmaceutical Association

Tc-O24

ACE

adrenal cortical extract, angiotensinconverting enzyme

APUD

amine precursor uptake and decarboxylation

ACEI

angiotensin-converting enzyme inhibitor

ARC

aids related complex

ACF

antecubital fossa

ARDS

adult (acute) respiratory distress syndrome

ACNP

American College of Nuclear Physicians

ARF

acute renal failure

ACP

acute conditioned necrosis

ARNP

ACR

American College of Radiology

Advanced Registered Nurse Practitioner

ACS

American College of Surgeons

ARS

acute radiation sickness

ACTH

adrenocorticotropic hormone

ASA

aspirin (acetylsalicylic acid)

AD

Alzheimer’s disease

ASAP

as soon as possible

ADR

adverse drug reaction

AST

aspartate amino transferase (SGOT)

ADH

antidiuretic hormone

ATD

antithyroid drug 519

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 520

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ATN

acute tubular necrosis

CAS

coronary artery stenosis

ATPase

adenosine triphosphatase

CAT

computerized axial tomography

ATOH

alcohol

CBC

complete blood count

AV

arteriovenous, atrial/ventricular

CBD

common bile duct

AVN

avascular necrosis

CBF

coronary blood flow

BaF2

barium fluoride

cc

cubic centimeter

BAL

bronchoalveolar lavage

CC

chief complaint

BATO

boron adducts of technetium di oximes

CCK

cholecystokinin

BBB

blood brain barrier

CDC

Center for Disease Control

B Bx

breast biopsy

CDE

committed dose equivalent

BCD

benign cortical defects

CEA

carcinoembryonic antigen

BE

barium enema

CEDE

committed effective dose equivalent

BERT

background equivalent radiation time

CFOV

center field of view

BGO

bismuth germanate

CFR

Code of Federal Regulations

b.i.d.

bis in die, twice daily

cGy

centigray

bilat

bilateral

chemo

chemical therapy

bili

bilirubin

CHF

congestive heart failure

Bkg

background

Chol

cholesterol

bm

bone marrow, bowel movement

Ci

curie

BMC

bone marrow content

ck

check

BMD

bone marrow density

Cl

chloride

BP

blood pressure

cm

centimeters

Bq

becquerel

CMJ

carpometacarpal joint

BR

bilirubin

CMV

cytomegalovirus

BRBPR

bright red blood per rectum

CNS

central nervous system

BRC

Bureau of Radiation Control (Florida)

Co

cobalt

BRIDA

mebrofenin

CO

cardiac output

BUA

broad-band ultrasound attenuation

C/O

complains of

BUN

blood, urine, nitrogen

Comp Fx

compression fracture

BW

Butterworth (filter)

COPD

chronic obstructive pulmonary disease

C _ c

carbon

COR

center of rotation

with

CP

chest pain

C1–C8

cervical spine

CPA

costophrenic angle

CA

cancer

CPB

competitive protein binding

Ca

calcium

CPK

creatine phosphokinase

CABG

coronary artery bypass graft

CPM, c/m

counts per minute

CAD

coronary artery disease

CPR

cardiopulmonary resuscitation

11

520

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 521

Quick Reference J — Abbreviations Commonly Used in Nuclear Medicine

CPS, c/s

counts per second

DPS

disintegrations per second

CPT

coding, current procedural terminology

Dr.

doctor

Creat

creatinine

DRE

digital rectal examination

Cs

cesium

DRG

diagnosis-related group

CsF

cesium fluoride

D/S

CSF

cerebrospinal fluid

(D5W normal saline) 5% dextrose, 0.9% normal saline mixture

CT

computerized tomography, cat scan

D/T

due to

cts.

counts

DTPA

diethylene triamine penta acetic acid

CV

coefficient of variation

DVT

deep vein thrombosis

CVA

cerebrovascular accident

Dx

diagnosis

Cx

cancelled

EBR

external beam radiotherapy

CXR

chest x-ray

EC

electron capture

CYT

conjugate of antibody 7E11-C5.3glycyl-tyrosyl-(N,e-diethylenetriamine pentaacetic acid)-lysine

ECD

ethyl cysteinate dimer

ECF

extracellular fluid

ECG/EKG

electrocardiogram

ECHO

echocardiogram

ECT

emission computed tomography

ED

end diastole

EDE

effective dose equivalent

EDTA

ethylenediaminetetriacetic acid

EDTMP

ethylene diamine tetramethylene phosphonic acid

d

day(s)

DAC

derived air concentration

D bili

direct bilirubin

DC

discontinue

DDD

degenerative disc disease

DDE

deep dose equivalent

DE

dose equivalent

DEXA

dual-energy x-ray absorptiometry

EDV

end diastolic volume

DI

dual isotope

EEG

electroencephalogram

DISIDA

di-isopropyl-imino-diacetic acid

EF

ejection fraction

DJD

degenerative joint disease

E/F

evaluate for

DMSA

2,3-dimercaptosuccinic acid

e.g.

exempli gratia, for example

DNR

do not resuscitate

ELISA

enzyme-linked immunosorbent assay

D/O

doctor’s order

EM

electromagnetic radiation

DOA

dead on arrival

Emax

maximum energy of beta emission

DOB

date of birth

EMIA

enzyme-multiplied immunoassay

DOE

Department of Energy

EMS

emergency medical services

DON

director of nurses

EP

electrophysiology

DOPA

dihydroxyphenylalanine

EPA

Environmental Protection Agency

DOT

Department of Transportation

ER

emergency room

DPA

dual photon absorptiometry (gamma rays)

ERCP

endoscopic retrograde cholangiopancreatography

DPM

disintegrations per minute

ERPF

effective renal plasma flow 521

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 522

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ES

end systole

GE

gastroesophageal

ESR

erythrocyte sedimentation rate

GERD

gastroesophageal reflux disease

ESRD

end stage renal disease

GeV

giga electron volt

ESV

end systolic volume

GFR

glomerular filtration rate

esp.

especially

GGTP

gamma glutamyl transpeptidase

etc.

etcetera

GH (GHA)

glucoheptonate

ETT

exercise treadmill test

GI

gastrointestinal

eV

electron volt

GIT

gastrointestinal tract

eval

evaluate

GM

Geiger-Mueller

F

fluorine

GUR

glucose uptake rates

FA

fore arm, fatty acid

Gy

gray

Fab

antibody fragment (papain)

h, hr

hour

F(ab′)2

antibody fragment (pepsin)

H/A

headache

FBP

filtered background projection

HAA

hepatitis associated antigen

Fc

antibody fragment (papain)

HAHA

human anti-human antibody

FDA

Food and Drug Administration

HAM

human albumin microspheres

FDG

fluorodeoxyglucose

HAMM

human albumin minimicrosphere

Fhx

family history

HAMA

human antimouse antibodies

FHH

familial hypercalciuric hyperparathyroidism

HAP

hydroxyapatite

fibula

HAT

hypoxanthine aminopterin thymidine

fib

false negative

HBP

high blood pressure

FN

fine needle aspiration

HCT

hematocrit

FNA

focal nodular hyperplasia

HCFA

Health Care Financing Agency

FNH

field of view

HCG

human chorionic gonadotropin

FOV

false positive

HCL

hydrochloric acid

FP FTI

free thyroxine index

HCPCS

coding, healthcare common procedure coding system

FT4

free thyroxine

HD

Hodgkin’s disease, Harley Davidson

F/U

follow up

HDL

high density lipoprotein

FUO

fever of unknown origin

HDP (HMDP) hydroxymethylene diphosphonate

FWHM

full width, half maximum

HEHR

high energy high resolution

g, gm

gram

Hg

mercury

Ga

gallium

HGB

hemoglobin

GAD

gadolinium

HIDA

GBq

gigabecquerel

2,6-dimethylacetanilidoiminodiacetic acid (lidofenin)

GB

gallbladder

HIV

human immunodeficiency virus

Gd

gadolinium

HMPAO

d,1-hexamethyl propylene amine oxime

522

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 523

Quick Reference J — Abbreviations Commonly Used in Nuclear Medicine

HNP

herniated nucleus pulposus

ITLC

instant thin layer chromatography

HPLC

high performance (pressure) liquid chromatography

IU

international units

IV

intravenous

HPS

Health Physics Society

IVC

inferior vena cava

HR

heart rate

IVP

intravenous pyelogram

hrs

hours

JCAH

HSA

human serum albumin

Joint Commission on Accreditation of Hospitals

HTN

hypertension

JCAHO

HVL

half-value layer

Joint Commission on Accreditation of Healthcare Organizations

hx

history

JRA

juvenile rheumatoid arthritis

I

iodine

K or k

kilo

IBD

inflammatory bowel disease

K

potassium, equilibrium constant

IBS

irritable bowel syndrome

KeV

kilo electron volts

ICD

implantable cardioverter defibrillator

Kg

kilogram

ICP

Institute of Clinical PET

Kr

krypton

ICRP

International Commission on Radiation Protection

KS

Kaposi’s sarcoma (syndrome)

KUB

kidney-ureter-bladder x-ray

L

liter

L or Lt

left

L1–L5

lumbar spine

LAD

left anterior descending

LAO

left anterior oblique

lats

laterals

LATS

long acting thyroid stimulator

LBBB

left bundle branch block

LBP

low back pain

Lbs

pounds

LCP

Legg-Calvé-Perthes disease

LCX

left circumflex coronary artery

LDH

lactic dehydrogenase

LDE

lens dose equivalent

LDL

low density lipoprotein

LEAP

low energy all purpose

ICRUM

International Commission on Radiation Units and Measurements

IDA

iminodiacetic acid

IDDM

insulin dependent diabetes mellitus

i.e.

id est, that is

IF

intrinsic factor

IHD

intrahepatic duct

inj

injection

IM

intramuscular

IMF

idiopathic myelofibrosis

IMP

iodoamphetamine

immed.

immediate

In

indium

IND

investigational new drug

IP

in patient

IPF

idiopathic (interstitial) pulmonary fibrosis

IPG

impedance plethysmography

LEGP

low energy general purpose

IRMA

immunoradiometric assay

LEHR

low energy high resolution

IT

isomeric transition

LEM

low energy mobile

ITP

idiopathic thrombocytopenic purpura

LEP

lower extremity pain 523

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 524

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

LET

linear energy transfer

MEHR

medium energy high resolution

LEHS

low energy high sensitivity

MEN

multiple endocrine neoplasia

LFA

left fore arm

mets

metastases

LFOV

large field of view

MeV

mega electron volt

LFT

liver function test

M/F

male/female

LI

large intestine

mg

milligram

LIP

lymphocytic interstitial pneumonitis

MI

myocardial infarction

LLAT or LL

left lateral

mIBG

-meta-iodobenzylguanidine

LLE

left lower extremity

MIBI

methoxyisobutylisonitrile (sestamibi)

LLI

lower left intestine

min

minute(s)

LLQ

lower left quadrant

MIRD

medical ionizing radiation dosimetry

LMP

last menstrual period

mL

milliliter

LPO

left posterior oblique

MNG

multi-nodular goiter

LRP

leukocyte rich plasma

MoAb

monoclonal antibody

L/S

liver/spleen

moly

molybdenum

LSC

liquid scintillation counter

MPI

myocardial perfusion imaging

LSO

lutetium oxyorthosilicate

mR

milliroentgen

LTD

limited

mR/h

milliroentgen per hour

LUE

left upper extremity

mrem

millirem

LV

left ventricle

MRI

magnetic resonance imaging

LVEF

left ventricular ejection fraction

MRA

magnetic resonance angiography

LVH

left ventricle hypertrophy

MRCP

magnetic resonance cholangiopancreatography

m

meter macro aggregated albumin

MRSA

MAA

methicillin-resistant Staphylococcus aureus

MACIS

metastasis, age, completeness of resection, invasion, and size

MRSE

methicillin-resistant Staphylococcus epidermidis

MAG3

mercaptoacetyltriglycine

msec

millisecond(s)

MAI

mycobacterium avium intracellular

mSv

millisievert

max.

maximum

MTC

medullary thyroid carcinoma

MBF

myocardial blood flow

MUGA

multi-gated acquisition

MBq

megabecquerel

MUGA-X

multi-gated acquisition with stress

mCi

millicurie

MVA

motor vehicle accident

mcg

micrograms

MVP

mitral valve prolapse

MDP

methylene diphosphonate

NA (N/A)

not applicable

MEAP

medium energy all purpose

Na

sodium

meds

medications

NaCl

sodium chloride

MEGP

medium energy general purpose

NaI

sodium iodide

524

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 525

Quick Reference J — Abbreviations Commonly Used in Nuclear Medicine

NAS-BEIR

National Academy of Sciences— Biological Effects of Ionizing Radiation

orig.

original

OSHA

Occupational Safety and Health Administration

OTC

over the counter

P _ p

phosphorus

NBS

National Bureau of Standards

NCA

nonspecific cross-reacting antigen

NCCLS

National Commission for Clinical Laboratory Standards

NCRP

National Council on Radiation Protection and Measurement

PA

posteroanterior

PASS

pull pin, aim, squeeze trigger, sweep

nCi

nano curie

PAP

prostatic acid phosphatase

NDA

new drug application

PBI

protein bound iodine

NEMA

National Electronic Manufacturers Association

PE

pulmonary embolism

ped(s)

pediatric (children)

NG

nasogastric PET

positron emission tomography

ng

nanogram(s) pulmonary function test

non-Hodgkin’s lymphoma

PFT

NHL

National Institute of Health

pH

power hydrogen (acidity/basicity)

NIH

no known allergies

PHA

pulse height analyzer

NKA

nuclear medicine

PHx

previous history of

NM

nuclear physician

phos

phosphatase

NMD

nuclear pharmacist

PI

post injection

NMP, NPh

nuclear medicine technologist

pics

pictures

NMT NP-59

beta-iodo-methyl 19-norcholesterol

PIOPED

prospective investigation of pulmonary embolism diagnosis

NPH

normal pressure hydrocephalus

PMH

past medical history

NPO

non (nil) per os, nothing by mouth (fasting)

PMT

photomultiplier tube

NRC

Nuclear Regulatory Commission

PPD

packs per day, purified protein derivative (tuberculin)

NSAID

non-steroidal anti-inflammatory drugs

PPE

personal protective equipment

NSCLCA

non-small cell lung cancer

PR

pulse rate

NSF

National Science Foundation

PRN

pro re nata, as necessary

N/V/D

nausea, vomiting, and diarrhea

PO

per os, by mouth

O2

oxygen

pos.

position

O2 sats

blood oxygen saturation

Post.

posterior

OH

hydroxyl ion

PSA

prostate specific antigen

OIH

orthoiodohippurate

p-scope

persistence scope

OP

out patient

PSMA

prostate specific membrane antigen

OPF

outpatient facility

pt.

patient

OREF

open reduction, external fixation

PTA

ORIF

open reduction, internal fixation

percutaneous transluminal angioplasty

after

525

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 526

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

PTCA

percutaneous transluminal coronary angioplasty

RIT

radioimmunotherapy

RLAT or RL

right lateral

RLE

right lower extremity

RLQ

right lower quadrant

R/O

rule out

ROI

region of interest

RP

radiopharmaceutical

RPF

renal plasma flow

RPO

right posterior oblique

RSC

radiation safety committee

RSD

reflex sympathetic dystrophy

RSO

radiation safety officer

RSP

radiation safety program

RTN

return

RUE

right upper extremity

PTH

parathyroid hormone

PTHC

percutaneous transhepatic cholangiography

PTT

parenchymal transit time

PTU

propylthiouracil

PVD

peripheral vascular disease

pyp

pyrophosphate

QA

quality assurance

QC

quality control

q.i.d.

quater in die, four times daily

QMP

quality management plan

r or rt

right

R

roentgen

R to R

ECG peaks

RV

right ventricle

RACE

rescue, alarm, contain, extinguish (evacuate)

RVEF

right ventricular ejection fraction

rad

radiation absorbed dose

RVG

radionuclide ventriculography

RAIU

radioactive iodine uptake

RVH

renovascular hypertension

RAO

right anterior oblique

Rx

prescription

RAS

renal artery stenosis

second(s)

RBBB

right bundle branch block

s or sec _ s

red blood cell

SA

sinoatrial (node, heart)

RBC

read back telephone order

S&S

signs and symptoms

RBTO

renal blood flow

sal.

saline

RBF

SBAR

RCA

renal cortical activity, right coronary artery

rCBF

regional cerebral blood flow

situation, background, assessment, recommendation (information to have ready for any discussion with a doctor about his patient)

RCRPM

National Council on Radiation Protection and Measurement

SC

sulfur colloid, sternoclavicular (joint)

SCLCA

small cell lung cancer

without

RDS

respiratory distress syndrome

SD

standard deviation

rem

roentgen equivalent man

SDE

shallow dose equivalent

RES

reticuloendothelial system

SEXA

single-energy x-ray absorptiometry

RFA

right fore arm

S/F

sent for

RIA

radioimmunoassay

SGOT

(AST) serum glutamic-oxaloacetate transaminase

RIND

reversible ischemic neurologic deficit

SGPT

RIS

radioimmunoscintigraphy

(ALT) serum glutamic-oxaloacetate transaminase

526

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 527

Quick Reference J — Abbreviations Commonly Used in Nuclear Medicine

shldr

shoulder

Tb

biological half-life

SI

small intestine

TB

tubercle bacilli (tuberculosis)

SI joint

sacroiliac joint

TB

total body (scan)

SI unit

système internationale

TBG

thyroxine binding globulin

SLN

sentinel lymph node

T bili

total bilirubin

Sm

samarium

Tc

technetium

SNM

Society of Nuclear Medicine

Tc04−

pertechnetate

SOB

short(ness) of breath

TCT

transmission computed tomography

SOD

sphincter of Oddi disease

Te

effective half-life

SOS

sphincter of Oddi Spasm (dysfunction)

TEDE

total effective dose equivalent

S/P

status post

TEE

trans-esophageal echocardiogram

SPA

single photon absorptiometry

TER

tubular excretion rate

SPECT

single photon emission computer tomography

TFT

thyroid function test

THR

total hip replacement

SPEM

single photon emission mammograph

TIA (brain)

trans ischemic attack

SPN

single pulmonary nodule

Sr

strontium

SRF

split renal function

SSKI

saturated solution potassium iodide

SSN

suprasternal notch

STAT

order to be done immediately

STEP

simultaneous transmission emission protocol

sTg

TIA (position) tail in the air tib

tibia

t.i.d.

ter in die, three times a day

TKR

total knee replacement

Tl

thallium

TLD

thermoluminescence dosimetry

Tmax

time to peak activity

serum thyroglobulin

TMBIDA

mebrofenin

sTSH

sensitive thyroid stimulating hormone

TMJ

temporomandibular joint

SUV

standard uptake value (specific uptake value)

TMJD

temporomandibular joint dysfunction

TMT

treadmill test, tarsometatarsal (joint)

Sv

sievert

TN

true negative

SV

stroke volume

TO

telephone order

SVC

superior vena cava

TOC

telephone order confirmed

Sx

surgery

TOD

tail on detector

T1–T12

thoracic spine

TODE

total organ dose equivalent

T1/2

radioactive half-life

Tp

radioactive half-life

T3

total triiodothyronine

TP

true positive

T3U

T3 uptake

TPBS

three (triple) phase bone scan

TAA

tumor-associated antigen

TPER

time to peak ejection rate

TAC

time activity curve

TPFR

time to peak filling rate

TAG

tumor-associated glycoprotein

TPN

total parenteral nutrition 527

10766-71_QuickRef-J.qxd

12/3/07

5:44 PM

Page 528

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

TRH

thyroid releasing hormone

vit.

vitamin

TSH

thyroid stimulating hormone

V/O

verbal order

TTP

time to peak

VPC’s

ventricular premature contractions

TTT

tilt table test

V/P (V/Q)

TURP

trans-urethral resection of the prostate

ventilation/perfusion study (ventilation/quantitation study)

Tx

therapy or treatment

VTE

venous thromboembolism

UBT

urea breath test

VUR

vesicoureteral reflux

uCi

microcuries

W

watts

UEP

upper extremity pain

w/

with

ug

microgram

w/in

within

UGI

upper gastrointestinal

WB

whole-body (scan)

ULI

upper large intestine

WBC

white blood cell

URQ

upper right quadrant weeks

ultrasound

wks

US

United States Pharmacopeia

WNL

within normal limits

USP usu.

usually

wt.

weight

uSv

microsievert

W/U

work up

UTI

urinary tract infection

y or yrs

years

UV

ultraviolet

Y/O

years old

v

neutrino

x

x-rays

V

volt

Xe

Xenon

v-fib.

ventricular fibrillation

XRT

x-ray therapy

Some of the above abbreviations are not approved for formal medical use.

528

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 529

QUICK REFERENCE K

Coding Nuclear Medicine Imaging CPT Codes 2008 Radiopharmaceutical HCPCS (Healthcare Common Procedure Coding System)

CPT copyright 2006 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. 529

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 530

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

NUCLEAR MEDICINE IMAGING CPT CODES 2008* Diagnostic Nuclear Medicine Exam

Adrenal imaging cortex and/or medulla Unlisted endocrine diagnostic procedure Angiography/venography (non-cardiac vascular flow) Bone and/or joint imaging limited area Bone and/or joint imaging multiple areas Bone and/or joint imaging wholebody Bone and/or joint imaging three-phase Bone and/or joint imaging tomographic (SPECT) Bone density single photon absorptiometry Bone density dual photon absorptiometry Unlisted musculoskeletal procedure Bone marrow imaging limited area Bone marrow imaging multiple areas Bone marrow imaging whole body Brain imaging, less than 4 views Brain imaging, less than 4 views with vascular flow Brain imaging, minimum 4 views Brain imaging, minimum 4 views with vascular flow Brain imaging, tomographic (SPECT) Brain imaging PET metabolic Brain imaging PET perfusion Brain vascular flow only Cardiac shunt detection Cerebrospinal fluid flow cisternography (imaging only) Cerebrospinal fluid flow imaging ventriculography Cerebrospinal fluid flow SPECT Cerebrospinal fluid leakage and detection Dacryocystography Unlisted nervous system procedure Determination of central c-v hemodynamics DVT venogram unilateral DVT venogram bilateral Esophageal motility Gastric emptying study (e.g., liquid or solid) Gastric mucosa imaging Gastroesophageal reflux study Gastrointestinal blood loss imaging (acute) Gastrointestinal protein loss Unlisted gastrointestinal imaging Inflammatory process limited area Inflammatory process whole body (e.g., gallium, white blood cells) Inflammatory process SPECT Liver imaging static only Liver imaging with vascular flow Liver SPECT (Hemangioma Study) Liver SPECT with vascular flow (Hemangioma Study)

CPT Code

78075 78099 78445 78300 78305 78306 78315 78320 78350 78351 78399 78102 78103 78104 78600 78601 78605 78606 78607 78608 78609 78610 78428 78630 78635 78647 78650 78660 78699 78414 78457 78358 78258 78264 78261 78262 78278 78282 78299 78805 78806 78807 78201 78202 78205 78206

*Please refer to SNM.org guidelines, Practice Management, Coding Corner for correct usage of these codes. Codes do not guarantee payments, check with your local payers. You may also contact Denise Merlino, president of Merlino Health Care Consulting Corp. for updated information at [email protected]. These codes are subject to changes. If in doubt, please refer to the SNM website or Ms. Merlino for current status. CPT codes are copyright by the American Medical Association. Merlino, Denise A., and Jeff Majchrzak. Nuclear Medicine Coder. St. Paul, MN: Medical Learning, Inc., 2006.

530

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 531

Quick Reference K — Coding Diagnostic Nuclear Medicine Exam

Liver/Spleen imaging static only Liver/Spleen imaging with vascular flow Liver function study serial images Liver HIDA ductal, gallbladder imaging, w/wo cck, w/wo ef Lung perfusion particulate Lung perf particulate with vent single breath Lung perf particulate with vent rebreath and washout Lung vent aerosol single view Lung vent aerosol multiple views Lung perf particulate with aerosol vent single/multiple views Lung vent gas single breath, single view Lung vent gas rebreath and washout single view Lung vent gas rebreath and washout multiple views Lung quantitative differential function both vent and perfusion Unlisted respiratory procedure Lymphoscintigraphy imaging Lymphoscintigraphy without imaging Unlisted lymph, blood or RES procedure Meckel’s imaging, intestinal imaging MUGA single equil study stress or rest MUGA multiple equil study stress and rest MUGA single study with wall motion, ef, and first pass MUGA multiple study with wall motion, ef, and first pass MUGA single equil study rest SPECT with wall motion, ef Add-on MUGA single study rest right ventricular ef and first pass Myocardial imaging planar imaging Myocardial imaging first pass ef planar Myocardial imaging SPECT Myocardial perfusion planar single study Myocardial perfusion planar multiple studies Myocardial perfusion single study SPECT Myocardial perfusion multiple studies SPECT Add-on Myocardial perfusion with wall motion Add-on Myocardial perfusion with ejection fraction Myocardial PET metabolic Myocardial PET perfusion single study rest or stress Myocardial PET perfusion multiple studies rest and stress Unlisted cardiovascular procedure Parathyroid imaging Peritoneal-venous shunt patency (LeVeen, Denver) PET imaging whole body melanoma (Medicare non covered) PET imaging not otherwise specified (Medicare non covered) PET imaging full/partial ring breast cancer (Medicare non covered) PET limited, chest, head/neck PET skull base/mid thigh PET whole body PET w CT AC and AL limited, chest, head and neck PET w CT AC and AL skull base/mid thigh PET w CT AC and AL whole body (CT other than AC and AL, use specific CT code with modifier 59) Plasma volume single sampling Plasma volume multiple samplings Platelet survival kinetics w/wo organ/tissue localization Platelet survival study

CPT Code

78215 78216 78220 78223 78580 78584 78585 78586 78587 78588 78591 78593 78594 78596 78599 78195 38792 78199 78290 78472 78473 78481 78483 78494 78496 78466 78468 78469 78460 78461 78464 78465 78478 78480 78459 78491 78492 78499 78070 78291 G0219 G0235 G0252 78811 78812 78813 78814 78815 78816 78110 78111 78190 78191 531

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 532

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference Diagnostic Nuclear Medicine Exam

Red cell volume single sampling Red cell volume multiple sampling Red cell/plasma whole blood volume Red cell survival study Red cell survival study splenic/hepatic sequestration Red cell labeled splenic/hepatic sequestration Renal (Kidney) imaging morphology only Renal imaging morphology with vascular flow Renal w vascular flow and function w/o pharm (no capto or lasix) Renal w vascular flow and function w pharm (capto and/or lasix) Renal multiple studies w/wo pharm Renal imaging SPECT Renal function study non-imaging radioisotopic study Salivary gland imaging Salivary gland imaging, serial images Salivary gland function study only Spleen imaging only w/wo flow Testicular imaging w vascular flow Thyroid uptake single determination Thyroid uptake multiple determinations Thyroid uptake stimulation, suppression or discharge Thyroid imaging with uptake single determination Thyroid imaging with uptake multiple determinations Thyroid imaging only; 99mTc Scan or 123I Thyroid imaging with vascular flow 99mTc Thyroid carcinoma mets imaging limited area (head and chest) Thyroid carcinoma mets imaging additional studies Thyroid carcinoma mets imaging whole body Add-on Thyroid carcinoma mets uptake with 78018 Tumor localization or RP distribution limited areas Tumor localization or RP distribution multiple areas Tumor localization or RP distribution whole body single day Tumor localization or RP distribution SPECT Tumor loc or RP distribution wb w two or more days imaging Urea breath test, 14C acquisition for analysis Urea breath test, 14C analysis Add-on Urinary bladder residual study with 78740 Ureteral reflux study (voiding cystogram) Unlisted genitourinary procedure Vitamin B-12 absorption (Schilling) w/o intrinsic factor Vitamin B-12 absorption (Schilling) with intrinsic factor Vitamin B-12 absorption w and w/o intrinsic factor Unlisted miscellaneous diagnostic procedure Therapeutic Nuclear Medicine Procedures

Therapy oral administration (131I-Sodium Iodide) Hyperthyroidism Re-treatments Remnant CA ablation (<33 mCi) Therapy by intravenous administration Therapy by intracavitary administration Therapy by interstitial administration Therapy monoclonal antibody intravenous infusion Therapy by intra-articular 532

CPT Code

78120 78121 78122 78130 78135 78140 78700 78701 78707 78708 78709 78710 78735 78230 78231 78232 78185 78761 78000 78001 78003 78006 78007 78010 78011 78015 78016 78018 78020 78800 78801 78802 78803 78804 78267 78268 78730 78740 78799 78270 78271 78272 78999 CPT Code

79005 79005 79005 79005 79101 79200 79300 79403 79440

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 533

Quick Reference K — Coding Therapeutic Nuclear Medicine Procedures

Therapy by intra-arterial particulate administration Unlisted therapy procedure Miscellaneous

Chemotherapy intravenous infusion up to 1 hour Injections for sentinel nodes Injections for evaluation of peritoneal shunts Insertion non-indwelling bladder catheter Insertion temporary indwelling bladder catheter (simple, Foley) Insertion temporary indwelling bladder catheter (complicated)

CPT Code

79445 79999 CPT Code

96413 38792 49427 51701 51702 51703

RADIOPHARMACEUTICAL HCPCS (HEALTHCARE COMMON PROCEDURE CODING SYSTEM) PSD, per study dose; SOL, solution; CAP, capsule Radiopharmaceutical

RP Diagnostic not otherwise classified 57Co-Cyanocobalamin (oral, Shillings) per 1 uCi 57/58Co-Cyanocobalamin per 1 uCi 51Cr-Chromate PSD 18F-fluorodeoxyglucose (FDG, up to 45 mCi) PSD 67Ga-citrate per mCi 123I-Sodium iodide (diagnostic, CAP, per 100 uCi, up to 999 uCi) 123I-Sodium iodide (diagnostic, CAP or SOL per mCi) 125I-Iodine Serum Albumin (diagnostic SOL or CAP per 5 mCi) 125I-Iothalamate (Glofil) PSD 131I-Iodobenguate sulfate (mIBG) per .5 mCi 131I-Serum albumin (per 5 uCi) 131I-Sodium iodide (diagnostic CAP, per mCi) 131I-Sodium iodide (therapeutic CAP, per mCi) 131I-Sodium iodide (diagnostic SOL, per mCi) 131I-Sodium iodide (therapeutic SOL, per mCi) 131I-Sodium iodide (diagnostic CAP, per uCi up to 100) 111In-Oxyquinoline (WBC studies, per .5 mCi) 111In-labeled autologous WBC PSD 111In-labeled platelets PSD 111In-Pentetate (DTPA, per .5 mCi) 111In-Capromab (Prostascint) PSD 111In-Pentetriotide (Octreoscan) PSD up to 6 mCi 13N—ammonia PSD 82Rb-Rubidium (Cardiogen) PSD 99mTc-Glucoscan (Gluceptate) PSD 99mTc-succimer (DMSA) PSD 99mTc-04-pertechnatate per mCi 99mTc-fanolesomab (Neutrospec) PSD

HCPCS Code (2008)*

A4641 A9559 A9546 A9553 A9552 A9556 A9516 A9509 A9532 A9554 A9508 A9524 A9528 A9517 A9529 A9530 A9531 A9547 A9570 A9571 A9548 A9507 A9572 A9526 A9555 A9550 A9551 A9512 A9566

*Please refer to SNM.org guidelines, Practice Management, Coding Corner for correct usage of these codes. Codes do not guarantee payments, check with your local payers. You may also contact Denise Merlino, president of Merlino Health Care Consulting Corp. for updated information at [email protected]. These codes are subject to changes. If in doubt, please refer to the SNM website (www.cms.hhs.gov) or Ms. Merlino for current status. Merlino, Denise A., and Jeff Majchrzak. Nuclear Medicine Coder. St. Paul, MN: Medical Learning, Inc., 2006. CMS web site for HCPCS Level II complete alphanumeric file: http://www.cms.hhs.gov/HCPCSReleaseCodeSets/ANHCPCS/list.asp#TopOfPage

533

10766-72_QuickRef-K.qxd

12/3/07

5:45 PM

Page 534

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference Radiopharmaceutical 99m

Tc-pyrophosphate (Pyrolite, MI imaging only) PSD Tc-oxidronate (HDP) PSD 99m Tc-medronate (MDP) PSD 99m Tc-exametazime (Ceretec, HMPAO) PSD 99m Tc-exametazime (Ceretec, HMPAO, autologous WBC) PSD 99m Tc-bicisate (Neurolite, ECD) PSD 99m Tc-mebrofenin (Choletec) PSD 99m Tc-pentetate (DTPA) PSD 99m Tc-disofenin (Hepatolite) PSD 99m Tc-sestamibi (Cardiolite, Miraluma) PSD 99m Tc-tetrofosmin (Myoview) PSD 99m Tc-mertiatide (MAG3) PSD 99mTc-labeled rbc’s (Pyp or Ultratag, up to 30 mCi) PSD 99m Tc-MAA PSD 99m Tc-aerosol DTPA (lung ventilation, up to 75 mCi) PSD 99m Tc-sulfur colloid PSD 99m Tc-teboroxime PSD 201 TL-thallous chloride per mCi 133 Xe-gas per 10 mCi 131 I-Tositumomab (Bexxar, diagnostic) PSD 131 I-Tositumomab (Bexxar, therapeutic) PSD 111 In-Ibritumomab (Zevalin, diagnostic) PSD 90 Y-Ibritumomab (Zevalin, therapeutic) PSD 32 P-Chromic phosphate (therapeutic, per mCi) 32 P-Sodium phosphate (therapeutic, per mCi) 89 Sr-strontium chloride (Metastron, therapeutic, per mCi) 153 Sm-lexidronamm (Quadramet, therapeutic, per 50 mCi) 99m

Miscellaneous Drugs and Supplies

Non-radioactive contrast not otherwise classified Radiopharmaceutical, therapeutic, not otherwise classified Adenosine (diagnostic, per 30 mg, Adenocard) Acetazolamide sodium up to 500 mg (Diamox) Aminophyllin up to 250 mg Atropine sulfate up to 0.3 mg Digoxin up to 0.5 mg (Lanoxin) Dipyridamole per 10 mg (Persantine) Dobutamine HCL per 250 mg (Dobutrex) Dopamine HCL per 40 mg Enalaprilat (Vasotec) Furosemide up to 20 mg (Lasix) Glucagon HCL per 1 mg Heparin flush IV (per 10 units) (100 units/mL) Injection Methylene Blue (sentinal node) IV/Catheter Starts (usually already included in coding) Morphine sulfate injection up to 10 mg Morphine sulfate injection 100 mg Normal saline infusion 1000 cc Normal saline infusion 500 cc Normal saline infusion 250 cc Propranolol up to 1 mg (Inderol) Rituximab 100 mg Sincalide 5 mcg (Kinevac) Thyrotropin injection (.9 mg in a 1.1 mg vial, Thyrogen) Tositumomab 450 mg administration and supply (non-RP Bexxar) 534

HCPCS Code (2008)*

A9538 A9561 A9503 A9521 A9569 A9557 A9537 A9539 A9510 A9500 A9502 A9562 A9560 A9540 A9567 A9541 A9501 A9505 A9558 A9544 A9545 A9542 A9543 A9564 A9563 A9600 A9605 HCPCS Code

A9698 A9699 J0152 J1120 J0280 J0460 J1160 J1245 J1250 J1265 J3490 / name / amt J1940 J1610 J1642 A9535 36415 J2270 J2271 J7030 J7040 J7050 J1800 J9310 J2805 J3240 G3001

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 535

QUICK REFERENCE L

Anatomical Images Brain (and Brain CSF) Cardiac System Endocrine System and Thyroid Gastrointestinal System (Esophagus, GI Tract, Stomach) Hepatobiliary System Lungs Lymphatic System Miscellaneous Systems Renal System Skeletal System Vascular System

535

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 536

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

BRAIN

Anterior

Sulcus Corpus callosum

Posterior Gyrus Choroid plexus Parietal lobe

Thalamus

Pineal gland

Frontal lobe

Occipital lobe

Hypothalamus Temporal lobe Optic chiasma

Pituitary gland Pons

Cerebellum Medulla oblongata Central canal

Fourth ventricle

L-1. The brain, sagittal section. (From Bear M, Conner B, Paradiso M. Neuroscience, Exploring the Brain, 2nd Ed. Baltimore: Lippincott Williams and Wilkins, 2000.)

536

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 537

Quick Reference L — Anatomical Images

Arachnoid granulations (villi) Superior sagittal sinus

Subarachnoid space containing CSF Choroid plexus of the lateral ventricle

Lateral ventricles Cerebral aqueduct Interventricular foramen 4th ventricle Choroid plexus of the 4th ventricle Median aperture 3rd ventricle Communication via lateral apertures

Central canal of spinal cord

(A)

Cerebral subarachnoid space

Septum pellucidum

Body of corpus callosum

Pineal body

3rd ventricle

Quadrigeminal cistern (cistern of great cerebral vein)

Optic chiasm

Choroid plexus

Cerebral aqueduct

Choroid plexus

Chiasmatic cistern Interpeduncular cistern

Posterior cerebellomedullary cistern

Pontine cistern Spinal subarachnoid space (B)

L-2. Subarachnoid (leptomeningeal) spaces, ventricles, and subarachnoid cisterns. Diagrammatic views of median sections of the head. A. Ventricular system and circulation of cerebrospinal fluid (CSF). The production of CSF is mainly by the choroid plexuses of the lateral, 3rd, and 4th ventricles. The plexuses in the lateral ventricles are the largest and most important. The main site of absorption of CSF into the venous system is through the arachnoid granulations projecting into the dural venous sinuses. B. Observe the subarachnoid cisterns-expanded regions of the subarachnoid space-that contain more substantial amounts of CSF. The posterior cerebellomedullary cistern (L. cisterna magna) is clinically important as a site for cisternal puncture. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.) 537

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 538

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Normal brain — Lateral view

Venous angle

Lateral Thalamostriate ventricle (terminal) vein

Inferior sagittal sinus Choroidal vein Internal cerebral vein

Superior sagittal sinus

Great cerebral vein (of Galen)

Posterior horn Straight sinus

Anterior horn

Interventricular foramen (Monro)

Third ventricle

Basal vein (of Rosenthal) Cavernous sinus

Inferior horn

Inferior petrosal sinus

Transverse sinus Occipital sinus

Superior petrosal sinus

Cerebral aqueduct (Sylvius)

Fourth Sigmoid ventricle sinus

Lateral aperture (Luschka)

Median aperture (Magendie)

L-3. Ventricles of the normal brain, lateral view. (Asset provided by Anatomical Chart Co.)

538

10766-73_QuickRef-L.qxd

12/3/07

6:05 PM

Page 539

Quick Reference L — Anatomical Images

Anterior

Posterior

Central sulcus Premotor cortex (complex movement Sensory cortex Motor cortex sequences) (cutaneous and other senses) (control of voluntary Taste area Motor muscles) speech General interpretive area area (Broca's Parietal lobe area) Visual association cortex (sight)

Frontal lobe

Occipital lobe Visual area

Prefrontal cortex (thought elaboration)

Cerebellum Brainstem Temporal lobe

Vestibular area Lateral Auditory sulcus area Wernicke’s area (speech comprehension) Primary olfactory cortex (analyzes smells)

L-4. The brain, lateral view. (From Bear M, Conner B, Paradiso M. Neuroscience, Exploring the Brain, 2nd Ed. Baltimore: Lippincott Williams and Wilkins, 2000.)

539

10766-73_QuickRef-L.qxd

12/3/07

6:05 PM

Page 540

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

CARDIAC SYSTEM

Right interior view

Left subclavian artery Right brachiocephalic vein

Left common carotid artery Brachiocephalic trunk

Left brachiocephalic vein Superior vena cava

Arch of aorta Ligamentum arteriosum Pulmonary trunk Pulmonary valve Right semilunar cusp Anterior semilunar cusp Left semilunar cusp

Reflection of pericardium Right auricle

Conus arteriosus

Pectinate muscles

Left auricle Fossa ovalis

Supraventricular crest Great cardiac vein Anterior interventricular branch of left coronary artery Left ventricle

Limbus Crista terminalis Right atrium Right coronary artery

Chordae tendineae Moderator band

Tricuspid valve Anterior cusp Septal cusp Posterior cusp

Muscular interventricular septum

Anterior papillary muscle Hepatic veins Inferior vena cava

Pericardial sac Abdominal aorta

L-5. Heart, right interior view. (Asset provided by Anatomical Chart Co.)

540

Apex of heart

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 541

Quick Reference L — Anatomical Images

Aorta AV bundle (bundle of His)

Superior vena cava

Internodal pathway

SA node (pacemaker)

Purkinje fibers

AV node Interventricular septum Inferior vena cava

Purkinje fibers Right bundle branch

Left bundle branch

L-6. The conducting system of the heart. (From McArdle WD, Katch FI, Katch VL. Essentials of Exercise Physiology, 2nd Ed. Baltimore: Lippincott Williams and Wilkins, 2000.)

541

10766-73_QuickRef-L.qxd

12/3/07

6:06 PM

Page 542

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

ENDOCRINE SYSTEM THYROID AND PARATHYROID GLANDS

PITUITARY GLAND AND HYPOTHALAMUS

PINEAL GLAND

Anterior lobe Growth hormone (GH) Prolactin Thyroid-stimulating hormone (TSH) Adrenocorticotropic hormone (ACTH) Follicle-stimulating hormone (FSH) Luteinizing hormone (LH) Melanocyte-stimulating hormone (MSH)

Pineal gland Melatonin

Thyroid cartilage

Superior parathyroids Inferior parathyroids Parathyroid hormone (PTH)

Thyroid gland Triiodothyronine Thyroxine Thyrocalcitonin

Hypothalamicohypophysial tract Thyrotropin-releasing hormone (TRH) Somatotropin hormone (STH) Posterior lobe Corticotropin factor Antidiuretic hormone (ADH) Prolactin-inhibiting factor Oxytocin

Trachea

THYMUS GLAND Right lobe

Hypothalamus

STOMACH, DUODENUM, AND JEJUNUM

Left lobe

HEART

G-cells in pyloric glands Gastrin

Thymus gland Thymosin 1 Thymulin Thymopoietin Thymic-humoral factor IGF-1

S-cell in duodenal and Stomach jejunal glands Gastrin Secretin Secretin Motilin Cholecystokinin Enterocrinin Gastric inhibitory peptide

Cardiac muscle fibers from the right atrium Atrial natriuretic peptide (ANP)

ADRENAL GLANDS Cross section

Microscopic view

PANCREAS Cortex Mineralocorticoids Glucocorticoids Androgens Estrogens Medulla Norepinephrine Epinephrine

Common bile duct Pancreatic duct

Alpha cell Beta cell

KIDNEY

Islet of Langerhans Glucagon Insulin Somatostatin Pancreatic polypeptide

Kidney Prostaglandins Erythropoietin Renin Juxtaglomerular apparatus

Delta cell

Microscopic view TESTES Epididymis

Glomerulus

Efferent ducts of epididymis

Microscopic view OVARY Fimbria

Site of ruptured follicle Maturing follicles

Cross section Ovary Estrogen Progesterone Follicular fluid

Fallopian tube

Corpus luteum Developing follicles

Seminiferous tubule Androgen-binding protein A small amount of estrogen Leydig cells Testosterone Androsterone Placental hormones from uterus during pregnancy Chorionic gonadotropins Progesterone Estrogen Relaxin

L-7. Endocrine system. (Asset provided by Anatomical Chart Co.)

542

Cross section Microscopic view

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 543

Quick Reference L — Anatomical Images

GASTROINTESTINAL SYSTEM Clavicle Apex of right lung Left lung

Cardiac notch of left lung

Horizontal fissure of right lung

Apex of heart Right dome of diaphragm

Spleen Splenic flexure

Liver

Outline of pancreas

Hepatic flexure

Stomach

Fundus of gallbladder

Transverse colon

Pylorus Outline of duodenum Ascending colon Cecum

Anterior superior iliac spine

Jejunum Ileum

Small intestine

Descending colon

Sigmoid colon Urinary bladder

Anterior view

L-8. Overview of thoracic and abdominal viscera. A-B. Observe that some abdominal organs extend superiorly into the thoracic cage (rib cage) and are protected by it. Observe also that a large part of the small intestine is in the pelvis and that the right kidney is lower than the left kidney; this results from the mass of the liver on the right side. Observe that the appendix projects posteriorly and inferomedially toward the pelvic brim; consequently, it is visible only in the posterior view. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.) 543

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 544

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Fundus (or proximal stomach) Esophagus

Cardia

Greater curvature

Lower esophageal sphincter (or cardiac sphincter) Gastric Pacemaker Duodenum

Lesser curvature Body Serosa Muscularis: Longitudinal muscle

Pyloric sphincter Pyloric canal Pylorus

Circular muscle Pyloric Mucosa antrum (or distal Rugae of stomach) mucosa

Oblique muscle

L-9. External and internal structures of the stomach. (From Stedman’s Medical Dictionary, 27th ed. Baltimore: Lippincott Williams & Wilkins, 2000.)

544

10766-73_QuickRef-L.qxd

12/3/07

5:46 PM

Page 545

Quick Reference L — Anatomical Images

HEPATOBILIARY SYSTEM

Falciform ligament Right lobe

Left lobe

Left branches of common hepatic duct, hepatic artery, and portal vein

Liver

Right branches of hepatic duct, hepatic artery, and portal vein Celiac trunk Common hepatic artery

Gallbladder Cystic artery Cystic duct Proper hepatic artery

Portal vein

Head of pancreas

Gastroduodenal artery Pylorus Duodenum

L-10. Gallbladder. (Asset provided by Anatomical Chart Co.)

545

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 546

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Right hepatic duct

Left hepatic duct Common hepatic duct Cystic duct

Corpus

Neck Common bile duct Pyloric sphincter Pancreas

Gallbladder

Fundus Common bile duct Sphincter of Oddi

Pancreatic duct

Duodenal papilla (Ampulla of Vater)

Accessory pancreatic duct

Duodenum Small bowel

L-11. Gallbladder duct system. (Asset provided by Anatomical Chart Co.)

546

10766-73_QuickRef-L.qxd

12/3/07

6:06 PM

Page 547

Quick Reference L — Anatomical Images

LUNGS Anterior view Right main bronchus

Trachea Left main bronchus Left superior lobar bronchus

Right superior lobar (“eparterial”) bronchus Bronchial tree

Right middle lobar bronchus

Left inferior lobar bronchus

Segmental bronchus

Right lung

Right lower lobe bronchus

Left lung Posterior view

(B) Key (right lung)

Key (Left lung)

Superior lobe Apical Posterior Anterior

Superior lobe Apical Posterior Anterior Superior Inferior

Middle lobe Lateral Medial Left lung

Inferior lobe Superior Anterior basal Medial basal Lateral basal Posterior basal

Right lung

(A) Anterior view

Lateral view (C) Right lung

Lateral view (D) Left lung

Medial view

Medial view

Inferior lobe Superior Anterior basal Medial basal Lateral basal Posterior basal

Typically combined into apicoposterior Lingular

Often combined into anteromedial basal

Inferior view

Inferior view

L-12. Trachea, bronchi, and bronchopulmonary segments. A. Anterior and posterior views of the lungs following injection of a different color of latex into each segmental (tertiary) bronchus, thus demonstrating the bronchopulmonary segments. B. Observe that the right main bronchus is more vertical and shorter than the left main bronchus. Although it lies posterior to the anterior margin of the lung and thus is not apparent in this view, the right main bronchus gives off the right superior lobar (lobe) bronchus before entering the hilum of the lung. The lobar bronchi are divided into segmental bronchi (colored), each of which serves a bronchopulmonary segment of the same name. C-D. Bronchopulmonary segments of the right and left lungs in lateral, medial, and inferior views. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.) 547

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 548

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

LYMPHATIC SYSTEM

Key 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Right brachiocephalic vein Left brachiocephalic vein Left common carotid artery Anterior superior mediastinal nodes Superior vena cava Right cardiac lymph branch Internal thoracic node Right tracheobronchial nodes Left tracheobronchial nodes Right and left bronchopulmonary nodes Internal thoracic lymph vessel ending in subclavicular nodes Interpectoral nodes Lymph vessels from deep part of breast Posterior mediastinal nodes Intercostal nodes and lymph vessels Thoracic duct Thoracic aorta Descending right and left intercostal lymph trunks Cisterna chyli Intestinal trunk Right and left lumbar trunks Lumbar nodes Testicular lymph vessels Retroaortic node (lumbar nodes) Preaortic node (lumbar nodes) Common iliac nodes Internal iliac artery and nodes Sacral nodes Lymph vessels to internal iliac nodes Obturator vessels and nerve Presymphysial node Collecting lymph vessels from glans penis Superficial lymph vessels from the penis Lymph vessels from the scrotum Lymph vessels of testis and epididymus

Superior temporal artery and vein Anterior auricular nodes Superficial parotid nodes Deep parotid node Posterior auricular nodes Parotid salivary node Occipital nodes Superior deep cervical nodes Right internal jugular vein Superior deep cervical nodes Inferior deep cervical nodes Right jugular trunk Right subclavian trunk Right bronchomediastinal trunk Deltopectoral nodes 1 Subclavian axillary group 5 4 Right internal 11 7 6 thoracic trunk 12 8 Central axillary group Pectoral axillary 13 group Subscapular 16 axillary group 17 Brachial nodes Anterior axillary group Superficial 19 lymph vessels 21 24 25 Basilic vein Supratrochlear 23 nodes 26 Cephalic vein

Interdigital lymph vessels from palmar cutaneous plexus

27

Superficial inguinal nodes

Supramandibular node Submandibular nodes Submental nodes

Inferior deep cervical nodes Prelaryngeal nodes Left jugular trunk 3 Thoracic duct 2 Left subclavian trunk Left subclavian artery and vein Subclavian axillary group Left bronchomediastinal trunk 10 Pretracheal nodes 9 Central axillary group 14 Left internal thoracic trunk Lateral axillary group 15 Subscapular axillary group Pectoral axillary group 18 Brachial artery and veins and deep lymphatic vessels Brachial node 20 Deep lymphatic vessels 22 Supratrochlear nodes Deep cubital nodes Radial node Radial artery 27 Cephalic vein 29 Ulnar artery 28 Ulnar node 30 Superf. Radial node inguinal 33 31 Lymph vessels nodes 34 accompanying the 32 Deep palmar arches inguinal 35 Lateral lymph nodes vessels of the thumb Deep lymphatic vessels Lymphatic network

Deep subinguinal node Great saphenous vein (cut) Superficial subinguinal nodes Anterior femoral cutaneous vein Superficial lymphatic vessels Lymph vessels from back of thigh

Lymph vessels passing to the network of the hand Lymph vessels of the fingers Femoral artery and vein with deep lymphatic vessels Great saphenous vein

Great saphenous vein Lymph vessels from back of leg

Popliteal nodes (in back of knee) Small saphenous vein with lymph vessels Anterior tibial artery and veins and lymph vessels Posterior tibial artery and veins and lymph vessels Anterior tibial node Posterior tibial node Peroneal artery and veins and lymph vessels Great saphenous vein Small saphenous vein

Interdigital lymph vessels from plantar plexus

L-13. Lymphatic system. (Asset provided by Anatomical Chart Co.) 548

Facial node Buccal node

Peroneal artery and veins and lymph vessels Posterior tibial artery and veins and lymph vessels Dorsalis pedis artery and vein and lymph vessels Dorsal venous arch

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 549

Quick Reference L — Anatomical Images

MISCELLANEOUS SYSTEMS ADRENAL MEDULLA PHEOCHROMOCYTOMA SCAN

Heart

Adrenal glands

Kidneys

L-14. Multiple sites of catecholamine-secreting tissue.

549

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 550

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Lacrimal gland pars palpebralis Lacrimal gland pars palpebralis

Superior lacrimal punctum Canaliculi Nasolacrimal sac Nasal septum

Lacrimal gland duct

Nasal Canthus Inferior lacrimal punctum

Caruncula

Nasolacrimal duct Orifice of nasolacrimal duct (Valve of Hasner) Inferior concha Inferior meatus

L-15. Nasolacrimal ducts. (Courtesy of Neil O. Hardy, Westpoint, CT.)

Opening of parotid duct (near second maxillary molar) Parotid duct Tongue

Parotid gland

Lesser sublingual duct Sublingual gland Submandibular duct

Submandibular gland

L-16. The salivary glands. (From Premkumar K. The Massage Connection Anatomy and Physiology. Baltimore: Lippincott Williams & Wilkins, 2004.)

550

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 551

Quick Reference L — Anatomical Images

IVC

Aorta Chyle cistern Abdominal aorta Left renal artery

Right renal artery

Left testicular artery Preaortic nodes Lymphatic vessels Right testicular artery

L. testicular vein L. testicular artery

R. testicular artery

Lumbar (lateral aortic) nodes

R. testicular vein

External iliac vein Internal spermatic vein (testicular V.)

Right common iliac artery Arterial anatomy

Venous anatomy

External iliac artery Internal iliac artery Inferior epigastric artery Testicular artery External iliac artery Perineal branch of internal pudendal artery

Ilioinguinal nerve Inferior epigastric vein Differential vein (vasal v.) Genital branch of genitofemoral nerve

Superficial inguinal nodes Cremasteric branch of inferior epigastric artery Differential artery Cremasteric artery

Cremasteric vein (external spermatic vein) Pudendal nerve Posterior scrotal (perineal) nerves

Superficial external pudendal artery

Pampiniform plexus

Femoral artery External pudendal branch of femoral artery Deep external pudendal artery

Lymphatic drainage From testis From scrotum

Posterior femoral Anterior scrotal cutaneous nerve nerves

Testis

Scrotum Spermatic cord

Femoral profunda artery Anterior scrotal arteries Internal pudendal artery

L-17. Arterial supply and lymphatic drainage of the testis and scrotum. The pudendal nerve, a branch of the sacral plexus, arises from the ventral primary rami of S2, S3, and S4. This nerve is part of the somatic nervous system and is shown innervating the scrotum. Observe the long, slender testicular artery arising from the abdominal aorta inferior to the renal arteries. The long course of the artery through the abdomen and inguinal canal results from the descent of the fetal testis from the dorsal abdominal wall into the scrotum. Observe that the lymphatic drainage from the testis and scrotum differs, which is clinically significant. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.)

551

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 552

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

RENAL SYSTEM Superior pole Medial margin Renal hilum

Anterior surface

Posterior and anterior lips

Renal sinus

Renal hilum

Renal artery

Lateral margin

Renal vein Renal pelvis

Anterior surface

Ureter

Medial margin Posterior surface

Inferior pole (A) Anterior view

(B) Anteromedial view Fibrous capsule

Renal cortex

Cortex Renal papilla Minor calix

Minor calix Calices Major calix Medulla and renal column Pyramid

Calices Major calix Renal pelvis Ureter

Pelvis Papilla Renal sinus Medullary ray Ureter

Renal columns

Renal pyramids

(C) Anterior view exposing calices

(D) Anterior view, coronal section

L-18. External and internal appearance of the kidneys. A. Right kidney, anterior view. Observe the order of the structures at the renal hilum. B. Renal sinus as seen through the renal hilum. As shown here and in (A), the renal sinus contains the renal pelvis and renal vessels. C. The anterior lip of the renal hilum has been cut away to expose the renal pelvis and calices within the renal sinus. D. Coronal section of the kidney showing its internal structure. The renal pyramids contain the collecting tubules and form the medulla of the kidney. The renal cortex contains the renal corpuscles. Observe that the blunted apices of the pyramids (the renal papillae) project into the minor calices, into which they discharge urine, which passes into the major calices and renal pelvis. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.) Renal cortex Renal medulla (pyramid)

Kidney

Papilla of pyramid

Inferior vena cava

Calyx

Abdominal aorta

Renal artery

Ureter Urinary bladder

Renal vein

Urethra

Ureter

Renal pelvis

Kidney

L-19. The urinary tract includes the kidneys (enlargement at right), ureters, and bladder. (Adapted from Willis, MC. Medical terminology: The language of healthcare. Baltimore: Williams & Wilkins, 1996.) 552

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 553

Quick Reference L — Anatomical Images

SKELETAL SYSTEM

Anterior view

Frontal

Coronal suture Supraorbital notch Sphenoid Temporal Zygomatic Infraorbital foramen Maxilla

Superior transverse scapular l. Coracoclavicular l. Acromioclavicular l Coracoacromial l. Subdeltoid bursa Subscapularis m. Articular capsule Biceps brachii m. (long head) Internal intercostal mm. External intercostal mm. Interchondral ll.

Outline of frontal sinus Nasal Superior orbital fissure Inferior orbital fissure Outline of maxillary sinus Mandible

Mental foramen Interclavicular l. Anterior sternoclavicular l.

Anterior longitudinal l. C7 1st rib Clavicle Manubrium Acromion Coracoid process Greater tubercle Lesser tubercle Scapula Humerus Sternum Xiphoid process Costal cartilages 12th rib Intervertebral disks Anterior longitudinal l. Medial epicondyle Lateral epicondyle

External intercostal membranes Thoracolumbar fascia Transverse abdominal m. Articular capsule Ulnar collateral l. Radial collateral l. Annular l. Iliolumbar l. Anterior sacroiliac l. Inguinal l. Interosseous membrane Center of gravity Sacrospinal l. Sacrotuberal l. Iliofemoral l. Scaphoid Lunate Triquetral Hamate Capitate Trapezoid Trapezium

L1

S1

Trochlea Capitulum Radial tuberosity Outline of female pelvis Anterior superior iliac spine Anterior inferior iliac spine Radius Ulna Head of femur Transverse axis Greater trochanter

Ilium

Sacrum Pubis

Neck of femur Carpals Ischium Arcuate pubic l.

Metacarpals Phalanges

Pubic symphysis

Obturator membrane Superior pubic l. Articularis genus m. Quadriceps femoris t. Tibial collateral l. Lateral patellar retinaculum Medial patellar retinaculum Fibular collateral l. Patellar l.

Lesser trochanter Femur Medial epicondyle Patella Lateral epicondyle Transverse axis Lateral femoral and tibial condyles Intercondylar eminence Medial femoral condyle Head of fibula Tibial tuberosity Medial tibial condyle Tibia Fibula

l. ll. m. mm. t. tt.

Interosseous membrane

Anterior tibiofibular l. Talus Medial cuneiform

Key

Medial malleolus Transverse axis Lateral malleolus

Ligament Ligaments Muscle Muscles Tendon Tendons

Vertebrae C Cervical S Sacral L Lumbar

L-20. The skeletal system, anterior view. (Asset provided by Anatomical Chart Co.) 553

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 554

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Superior angle

Infraspinous fossa

Crest of spine of scapula Spine of scapula Acromioclavicular joint Acromion of scapula Acromial angle Greater tubercle Head Surgical neck Deltoid tuberosity Radial groove (groove for radial nerve) Humerus Lateral supracondylar ridge Lateral epicondyle

Medial epicondyle Olecranon Posterior border of ulna

Ulna Head Styloid process Carpal bones Metacarpal bones

(1st) Proximal Phalanges (2nd) Middle (3rd) Distal

of humerus

Head Posterior oblique line Pronator teres impression Radius

of radius

Dorsal radial tubercle Styloid process of radius Proximal phalanx Distal phalanx

(B) Posterior view

L-21. Posterior view of the superior appendicular and thoracic part of the axial skeleton. Note the relationship of the scapula to the ribs (L. costae) and thoracic vertebrae. The scapula overlaps parts of the 2nd through 7th ribs. The upper limb is supported and stabilized by thoracoappendicular muscles, which extend from the ribs and vertebrae (axial skeleton) to the limb (appendicular skeleton), forming a conceptual “scapulothoracic joint” between the scapula and the thoracic (chest) wall. (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.)

554

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 555

Quick Reference L — Anatomical Images

Sagittal view External acoustic meatus

Mastoid process

Occipital bone

C-1 C-2

Atlas Axis

C-3 C-4 Cervical curvature

C-5 C-6 Vertebra prominens

C-7 T-1 T-2 T-3 Superior articular facet T-4 Facet for tubercle of rib Spinal nerve

T-5 T-6

Intervertebral disk

Thoracic curvature

Demifacets for heads of ribs

T-7 T-8

Body of vertebra

T-9 Spinous process T-10 Inferior vertebral notch T-11 Superior articular process T-12 L-1 L-2 L-3

Lumbar curvature

L-4

L-5

Promontory Sacral curvature

Sacrum (5 fused vertebrae)

Coccyx (4 rudimentary fused vertebrae)

L-22. Vertebral column, sagittal view. (Asset provided by Anatomical Chart Co.) 555

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 556

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Articular cartilage Epiphyseal line Epiphyseal artery Metaphyseal artery Lymphatics Periosteum (peeled back) Vein Periosteal nerve Periosteal artery Compact bone with haversian system Nutrient artery and vein

L-23. Vasculature and innervation of a long bone. The epiphysis is supplied with blood by the epiphyseal artery. The diaphysis, metaphyses, and bone marrow of a long bone are supplied mainly by the large nutrient artery (or arteries). Metaphyseal and epiphyseal arteries pierce the compact bone and supply the spongy bone and marrow of the ends of the bone. Branches of the periosteal arteries supply the periosteum. The periosteum is rich in sensory nerves-the periosteal nerves. The bulk of compact bone is composed of haversian canal systems (osteons). The haversian canal in the system houses one or two small blood vessels for nourishing the osteocytes (bone cells). (From Moore KL & Dalley AF II. Clinical Oriented Anatomy, 4th ed. Baltimore: Lippincott Williams & Wilkins, 1999.)

556

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 557

Quick Reference L — Anatomical Images

VASCULAR SYSTEM

Occipital artery Vertebral artery Internal carotid artery External carotid artery Common carotid arteries Thyrocervical trunk Costocervical trunk Subclavian artery Acromial branch

Superficial temporal artery Maxillary artery Infraorbital artery Transverse facial artery Posterior superior alveolar artery Buccal artery Facial artery Inferior alveolar artery Submental artery Lingual artery Aortic arch Pericardiacophrenic artery Descending aorta

Anterior and posterior circumflex humeral arteries Axillary artery Internal thoracic artery Radial collateral artery Brachial artery Intercostal arteries Superior epigastric artery Inferior epigastric artery

Radial collateral artery Brachial artery Inferior phrenic artery Celiac trunk Superior mesenteric artery Renal artery Inferior mesenteric artery Radial recurrent artery Gonadal artery

Ascending branch of deep circumflex iliac artery

Common iliac artery Internal iliac artery External iliac artery

Superficial circumflex iliac artery Medial femoral circumflex artery

Radial artery Ulnar artery

Lateral femoral circumflex artery

Arteries of the hand

Femoral artery

Deep femoral artery Perforating branch

Descending genicular artery

Medial superior genicular artery

Lateral superior genicular artery Popliteal artery Lateral inferior genicular artery

Medial inferior genicular artery

Anterior tibial artery Peroneal artery Posterior tibial artery

Deep plantar arterial arch Dorsal metatarsal arteries Dorsal digital arteries

Dorsalis pedis artery Lateral plantar artery Lateral tarsal artery Arcuate artery

L-24. Major arteries. (Asset provided by Anatomical Chart Co.) 557

10766-73_QuickRef-L.qxd

12/3/07

5:47 PM

Page 558

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference

Superior sagittal sinus Inferior sagittal sinus Straight sinus Superior petrosal sinus Sigmoid sinus Occipital vein Internal jugular vein External jugular vein Axillary vein Lateral thoracic vein Cephalic vein Basilic vein Superficial branches Thoracoepigastric vein

Median cubital vein

Superficial temporal vein Superior ophthalmic vein Cavernous sinus Angular vein Infraorbital vein Maxillary vein Buccal vein Facial vein Inferior labial vein Inferior alveolar vein Subclavian vein Internal thoracic vein Intercostal vein Brachial vein Inferior vena cava Right, left, and middle hepatic veins Superior epigastric vein Renal vein Abdominal vena cava Thoracoepigastric vein Gonadal vein Common iliac vein Inferior epigastric vein Internal iliac vein External iliac vein

Basilic vein Cephalic vein

Radial vein Ulnar vein

Superficial circumflex iliac vein Superficial epigastric vein

Superficial veins of the hand

Great saphenous vein Popliteal vein

Deep veins of the hand

Femoral vein Deep veins of the knee

Superficial veins of the thigh and knee Popliteal vein Lesser saphenous vein

Great saphenous vein Superficial veins of the anterior foot

L-25. Major veins. (Asset provided by Anatomical Chart Co.)

More images are available on thePoint website. 558

Deep veins of the foot

10766-74_References.qxd

12/3/07

5:49 PM

Page 559

REFERENCES Alazraki, Naomi P., and Fred S. Mishkin, eds. Fundamentals of Nuclear Medicine, 2nd ed. New York: Society of Nuclear Medicine, 1988. American College of Radiology. ACR Practice Guideline for the Performance of Adult and Pediatric Hepatobiliary Scintigraphy. Amended 2006, acr.org. American College of Radiology. ACR Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography. Revised 2005, acr.org. American College of Radiology. ACR Practice Guideline for the Performance of Cardiac Scintigraphy. Revised 2004, acr.org. American College of Radiology. ACR Practice Guideline for the Performance of FDG-PET Scintigraphy in Oncology. Revised 2006, acr.org. American College of Radiology. ACR Practice Guideline for the Performance of Parathyroid Scintigraphy. Revised 2004, acr.org. American College of Radiology. ACR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements. Revised 2006, acr.org. Bernier, Donald R. et al. eds. Nuclear Medicine: Technology and Techniques, 2nd ed. St. Louis: Mosby, 1989. Bernier, Donald R., Paul E. Christian, James K. Langan, and L. David Wells, eds. Nuclear Medicine: Technology and Techniques, 2nd ed. St. Louis: Mosby, 1989. Bernier, Donald R., Paul E. Christian, and James K. Langan, eds. Nuclear Medicine: Technology and Techniques, 3rd ed. St. Louis: Mosby, 1994. Bexxar (tositumomab): Package insert. Seattle, WA: Corixa Corp., June 2003. Brener, Toby, ed. Nursing 2007 Drug Handbook, 27th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Chohan, Naina, ed. Nursing 99 Drug Handbook. Springhouse, PA: Springhouse, 1999. Cytogen Corporation. http://www.cytogen.com/ professional/prostascint/pi.php Datz, Frederick L. Handbook of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1993. Diatide, Inc. AcuTect Image Atlas. Londonderry, NH, 1998. Duffy, Marjorie A., ed. Physicians’ Desk Reference, 46th ed. Montvale, NJ: Medical Economics, 1992. Duncan, Kara. Radiopharmaceuticals in PET imaging. Pamphlet. Journal of Nuclear Medicine Technology 1998;26:228–234. Du Pont Pharma Radiopharmaceuticals. Introduction to Nuclear Cardiology, 3rd ed. Du Pont Pharma, 1993. Early, Paul J., and D. Bruce Sodee. Principles and Practice of Nuclear Medicine, 2nd ed. St. Louis: Mosby, 1995. General Electric. Nuclides and Isotopes, 14th ed. San Jose, CA: General Electric, 1989.

Genzyme Therapeutics. Thyrogen®, thyrotropin alfa for injection. Pamphlet. Cambridge: Genzyme and Knoll, 1999. Gilbert, Susan, ed. Journal of Nuclear Medicine Technology. Reston, VA: The Society of Nuclear Medicine, 1997. Goldsmith, Stanley J., ed. Journal of Nuclear Medicine. Reston, VA: The Society of Nuclear Medicine, 1997. Hacker, Charles. Radiation Decay: Emissions Tables and Spectra. 3.5 inch floppy disk program, Rockville, MD: Grove Engineering, 1995. Harruff, Richard C. Pathology Facts. Philadelphia: Lippincott, 1994. Hladik, W. B. et al., eds. Essentials of Nuclear Medicine Science: Iatrogenic Alterations in the Biodistribution of Radiotracers as a Result of Drug Therapy: Reported Instances. Pamphlet. Du Pont, circa 1985. IDEC Pharmaceuticals Corporation. Package insert. www.zevalin.com/. Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 1992–93. Englewood, CO: Wick, 1993. Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 1997–98. Englewood, CO: Wick, 1998. Klingensmith, William, Dennis Eshima, and John Goddard. Nuclear Medicine Procedure Manual 2006–08. Englewood, CO: Wick, 2006. Kowalsky, Richard J., and Steven W. Falen. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd ed. Washington, DC: American Pharmacists Association, 2004. Labtestonline.org. D-dimer, the test. www. labtestonline.org. 2006. Leven, David. Understanding DrugRadiopharmaceutical Interactions. Bay Pines, FL: Veterans Administration Medical Center, February 1990. Loeb, Stanley, ed. Nursing 94 Drug Handbook. Springhouse, PA: Springhouse, 1994. Lombardi, Max H. Radiation Safety in Nuclear Medicine. Boca Raton, FL: CRC Press LLC, 1999. Lombardi, Max H. Radiation Safety in Nuclear Medicine, 2nd ed. Boca Raton, FL: CRC Press LLC, 2007. Marieb, Elaine N. Human Anatomy and Physiology, 2nd ed. Redwood City, CA: Benjamin/Cummings, 1992. Merlino, Denise A., and Jeff Majchrzak. Nuclear Medicine Coder. St. Paul, MN: Medical Learning, Inc., 2006. Mettler, Fred A. Jr., and Milton J. Guiberteau. Essentials of Nuclear Medicine Imaging, 5th ed. Philadelphia: Saunders, 2006. Murray, I. P. C. et al., eds. Nuclear Medicine in Clinical Diagnosis and Treatment, vols. 1 and 2. New York: Churchill Livingstone, 1994. 559

10766-74_References.qxd

12/3/07

5:49 PM

Page 560

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference NeutroSpec® (Fanolesomab): Package insert. Cranbury, NJ: Palatin Technologies, Inc.; St. Louis, MO: Mallinckrodt, Inc., 2004. O’Connor, Michael K. The Mayo Clinic Manual of Nuclear Medicine. New York: Churchill Livingstone, 1996. PDR. Physicians’ Desk Reference, 57th ed. Montvale, NJ: Thompson PDR, 2003. Sandler, M. P. et al., eds. Diagnostic Nuclear Medicine, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2003. Sartori, Kathi. Prostate Agent Benefits from Technology Advances. Advance for Imaging and Radiation Therapy Professionals, vol. 19, No. 18. August 21, 2006. Schulthess, Gustav K. Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality Imaging, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2007. Shared PET Imaging of Florida, Shared PET Imaging. Canton, OH: Administrative Policy & Procedure Manual. Smeltzer, Suzanne C., and Brenda G. Bare. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 8th ed. Philadelphia: Lippincott, 1996. Smeltzer, Suzanne C., and Brenda G. Bare. Brunner and Suddarth’s Textbook of Medical-Surgical Nursing, 11th ed. Philadelphia: Lippincott, 2007. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy. Version 2.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation. Version 3.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for 111In-Leukocyte Scintigraphy for Suspected Infection/Inflammation. Version 3.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Diagnosis of Renovascular Hypertension. Version 3.0, June 20, 2003. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in Inflammation. Version 3.0, June 2, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gallium Scintigraphy in the Evaluation of Malignant Disease. Version 3.0, June 23, 2001. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gastric Emptying and Motility. Version 2.0, June 6, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Gastrointestinal Bleeding and Meckel’s Diverticulum Scintigraphy. Version 1.0, February 7, 1999. SNM.org. 560

Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for General Imaging. Version 3.0, May 30, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Lung Scintigraphy, Version 3.0, February 7, 2004. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Myocardial Perfusion Imaging. Version 3.0, June 15, 2002. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases. Version 3.0, January 25, 2003. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Somatostatin Receptor Scintigraphy with In-111 Pentetreotide. Version 1.0, February 21, 2001. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide). Version 2.0. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Tumor Imaging using F-18 FDG. Version 2.0, February 7, 1999. SNM.org. Society of Nuclear Medicine. Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement. Version 3.0, September 5, 2006. SNM.org. Sorenson, James A., and Michael E. Phelps. Physics in Nuclear Medicine, 2nd ed. Philadelphia: Saunders, 1987. Soudry, Gabrial. Somatostatin Receptor Imaging. http://www.med.harvard.edu/JPNM/TF94_95/ May30/WriteUpMay30.html. Squibb. Nuclear Medicine Handbook. Princeton: E. R. Squibb & Sons, Inc., 1990. Stedman, TL. Stedman’s Medical Dictionary, 27th ed. Baltimore: Lippincott Williams & Wilkins, 2006. Steves, Ann M. Review of Nuclear Medicine Technology, 2nd ed. Reston, VA: The Society of Nuclear Medicine, 1996. Taylor A. T., D. M. Schuster, and N. Alazraki. A Clinician’s Guide to Nuclear Medicine. Reston, VA: The Society of Nuclear Medicine, 2000. Thomas, Clayton, ed. Taber’s Cyclopedic Medical Dictionary, 17th ed. Philadelphia: F. A. Davis, 1993. Travis, Elizabeth LaTorre. Primer of Medical Radiobiology, 2nd ed. Chicago: Year Book, 1989. UCLA Nuclear Medicine Clinic. Protocols-LeVeen Shunt. Laxmi.nuc.ucla.edu:8000/nm-mediabook/ main_protocols, 2006. Van De Graaff, Kent M., and Stuart Ira Fox. Concepts of Human Anatomy and Physiology. Dubuque, IO: Brown, 1986. Wearne, Michael J., et al. Comparison of dacryocystography and lacrimal scintigraphy in the diagnosis of functional nasolacrimal duct obstruction. British Journal of Ophthalmology, 83:1032–1035, 1999. Weissleder, Ralph, Mark J. Rieumont, and Jack Wittenberg. Primer of Diagnostic Imaging, 2nd ed. St. Louis: Mosby, 1997.

10766-74_References.qxd

12/3/07

5:49 PM

Page 561

References Wikipedia. Suspensory muscle of the duodenum. http://en.wikipedia.org/wiki/Ligament_of_Treitz. Wilson, Michael A. Textbook of Nuclear Medicine. Philadelphia: Lippincott, 1998. Zevalin (ibritumomab tiuxetan): Package insert. San Diego, CA: IDEC Pharmaceuticals, August 2005. http://nuclearpharmacy.uams.edu/nicki.html www.auntminnie.com/index.asp?sec=ref&sub=ncm &pag=pet&itemid=54533 www.halls.md/body-surface-area/refs.htm www.medscape.com/viewarticle/440526 www.radiology.wisc.edu/divisions/nucmed/protocols/ files/therapies/BexxarBMTStudy0401.pdf www.rad.msu.edu/research/gages/PET-CT/cardiac/ ARRS/2004_files www.uphs.upenn.edu/radiology/reso/handbook/ nm.html

Unpublished Resources Information from the Nuclear Medicine curriculum at: Hillsborough Community College, Tampa, FL. Dr. Max Lombardi, Director (retired).

Information from courses at: Plymouth State College (now Plymouth State University) of the University of New Hampshire, Plymouth, NH. St. Petersburg Junior College (now St. Petersburg College), St. Petersburg, FL.

Information from Nuclear Medicine Department Manuals at: Bayfront Medical Center, St. Petersburg, FL. Bloomingdale Radiology Center, Brandon, FL. Columbia Doctor’s Hospital, Sarasota, FL. Columbia South Bay Hospital, Sun City, FL. H. Lee Moffitt Cancer Center, Tampa, FL. James A. Haley Veterans Hospital, Tampa, FL. Morton Plant Hospital, Clearwater, FL. Palms of Pasadena Hospital, St. Petersburg, FL. St. Joseph’s Hospital, Tampa, FL. Shared PET Imaging of Florida/Shared PET Imaging, Canton, OH. Westcoast Radiology, Clearwater, FL.

561

10766-74_References.qxd

12/3/07

5:49 PM

Page 562

10766-75_Trademark.qxd

12/3/07

5:50 PM

Page 563

ACKNOWLEDGMENT OF TRADEMARKS Accupril® is a registered trademark of Parke-Davis, Morris Plains, NJ. Accuretic® is a registered trademark of Parke-Davis, Morris Plains, NJ. Aceon Tablets® is a registered trademark of Solvay Pharmaceuticals, In., Mariett, GA. Aciphex® is a registered trademark of Eisai, Inc., Teaneck, NJ. Actonel® is a registered trademark of Proctor & Gamble, Cincinnati, OH. Adalat® is a registered trademark of Miles, Inc., West Haven, CT. Adenocard® is a registered trademark of Fujisawa Healthcare, Inc., Deerfield, IL. Aggrastat® is a registered trademark of Merck and Company, Inc., West Point, PA. Altace® is a registered trademark of Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ. Angiomax® is a registered trademark of The Medicine Company, Parsippany, NJ. Aredia® is a registered trademark of Novartis Pharmaceutical Corporation, Summit, NJ. Argatroban® is a registered trademark of GlaxoSmithKline, Research Triangle Park, NC. Arixtra® is a registered trademark of Sandofi-Synthelabo, New York, NY. Atacand® is a registered trademark of AstraZeneca LP, Wilmington, DE. Ativan® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Avapro® is a registered trademark of Sandofi-Synthelabo, New York, NY. Avalide® is a registered trademark of Sandofi-Synthelabo, New York, NY. Axid® is a registered trademark of Whitehall-Robins Laboratories, New York, NY. Benadryl® is a registered trademark of Parke-Davis, Morris Plains, NJ. Benicar® is a registered trademark of Forest Pharmaceuticals, Inc., St. Louis, MO. Bexxar® is a registered trademark of Corixa Corporation, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA. Betadine® is a registered trademark of Purdue Fredrick Co., Norwalk, CT. Blocadren® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Boniva® is a registered trademark of Roche Laboratories, Nutley, NJ. Brevibloc® is a registered trademark of Du Pont Pharmaceuticals, Wilmington, DE. Calan® is a registered trademark of G.D. Searle & Co., Chicago, IL.. Calcimar® is a registered trademark of Aventis Pharmaceuticals, Parsippany, NJ. Capoten® is a registered trademark of E.R. Squibb & Sons, Inc., Princeton, NJ. Capozide® is a registered trademark of E.R. Squibb & Sons, Inc., Princeton, NJ. Cardene® is a registered trademark of Syntex Laboratories, Inc., Palo Alto, CA. Cardiogen® is a registered trademark of Bracco Diagnostics, Inc, Princeton, NJ. Cardiolite® is a registered trademark of DuPont Pharmaceuticals, Wilmington, DE. Cardizem® is a registered trademark of Marion Merrell Dow Inc., Kansas City, MO. Cartrol® is a registered trademark of Abbott Laboratories, North Chicago, IL. CEA - Scan® is a registered trademark of Immunomedics, Inc., Morris Plains, NJ. Centrax® is a registered trademark of Parke-Davis, Morris Plains, NJ. Ceretec® is a registered trademark of Amersham International plc - Amersham, UK. Choletec® is a registered trademark of Bracco Diagnostics, Inc., Princeton, NJ. CLOtest® is a registered trademark of Tri-Med Specialties, Inc., Lenexa, KS. Conray® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Corgard® is a registered trademark of Bristol Laboratories, Evansville, IN. Coumadin® is a registered trademark of Bristol-Meyers Squibb, Princeton, NJ. Cozaar® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Cytomel® is a registered trademark of SmithKline Beecham Pharmaceuticals, Philadelphia, PA. Dalmane® is a registered trademark of Roche Laboratories, Nutley, NJ. Demerol® is a registered trademark of Sanofi Winthrop Pharmaceuticals, New York, NY. Diamox® is a registered trademark of Lederle Laboratories, Wayne, NJ. Didronel® is a registered trademark of Proctor & Gamble, Cincinnati, OH. Dilaudid® is a registered trademark of Knoll Pharmaceuticals, Whippany, NJ. Diovan® is a registered trademark of Novartis Consumer Health, Summit, NJ. Dobutrex® is a registered trademark of Eli Lilly and Company, Indianapolis, IN. Doral® is a registered trademark of Wallace Laboratories, Cranbury, NJ. Dulcolax® is a registered trademark of CIBA Consumer Pharmaceuticals, Edison, NJ. DynaCirc® is a registered trademark of Sandoz Pharmaceuticals, East Hanover, NJ. Elixophyllin® is a registered trademark of Forest Pharmaceuticals, Inc., St. Louis, MO. Evista® is a registered trademark of Eli Lilly and Company, Indianapolis, IN. Excel® is a registered trademark of Microsoft Corporation. 563

10766-75_Trademark.qxd

12/3/07

5:50 PM

Page 564

NUCLEAR MEDICINE TECHNOLOGY: Procedures and Quick Reference Fleet Kit® is a registered trademark of C.B. Fleet Co., Inc., Lynchburg, VA. Forteo® is a registered trademark of Eli Lilly and Company, Indianapolis, IN. Fortical® is a registered trademark of Usher-Smith Laboratories, Minneapolis, MN. Fosamax® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Fragmin® is a registered trademark of Pfizer, Inc., New York, NY. Gelusil® is a registered trademark of Warner-Lambert Co., Morris Plains, NJ. Glofil® is a registered trademark of Questcor Pharmaceuticals, Inc., Hayward, CA. Gluceptate® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Halcyon® is a registered trademark of The Upjohn Company, Kalamazoo, MI. Hepatolite® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Hyzaar® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Inderal® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Inderide® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Innohep® is a registered trademark of Pharmion, Boulder, CO. Iprivask® is a registered trademark of Canyon Pharmaceuticals, Inc., Hunt Valley, MD. Isoptin® is a registered trademark of Knoll Pharmaceuticals, Whippany, NJ. Kerlone® is a registered trademark of G.D. Searle & Co., Chicago, IL. Kinevac® is a registered trademark of Bracco Diagnostics, Inc., Princeton, NJ. Klonopin® is a registered trademark of Roche Laboratories, Nutley, NJ. Lanoxin® is a registered trademark of GlaxoSmithKline, Research Triangle Park, NC. Lasix® is a registered trademark of Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ. Levatol® is a registered trademark of Reed & Carnrick, Jersey City, NJ. Lexxel® is a registered trademark of AstraZeneca LP, Wilmington, DE. Librium® is a registered trademark of Roche Laboratories, Nutley, NJ. Lopressor® is a registered trademark of Geigy Pharmaceuticals, Ardsley, NY. Lotensin® is a registered trademark of CIBA Consumer Pharmaceuticals, Edison, NJ. Lotrel® is a registered trademark of Novartis Consumer Health, Summit, NJ. Lovenox® is a registered trademark of Sanofi Aventis, New York, NY. Maalox® is a registered trademark of CIBA Consumer Pharmaceuticals, Edison, NJ. MAG3® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Mavik® is a registered trademark of Abbott Laboratories, Inc., North Chicago, IL. Metamucil® is a registered trademark of Proctor & Gamble, Cincinnati, OH. Metastron® is a registered trademark of Amersham International plc - Amersham, UK. Miacalcin® is a registered trademark of Novartis Pharmaceutical Corporation, Summit, NJ. Microlite® is a registered trademark of DuPont Merck, Wilmington, DE. Micardis® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. MiralumaJ is a trademark of DuPont Merck, Wilmington, DE. Monopril® is a registered trademark of Mead Johnson Pharmaceuticals, Evansville, IN. Mylanta® is a registered trademark of Merck & Co., Inc., Fort Washington, PA. Myoview® is a registered trademark of Amersham International plc - Amersham, UK. NeoTect® is a registered trademark of Diatide, Inc., Londonderry, N.H. Neurolite® is a registered trademark of DuPont Merck, Wilmington, DE. NeutroSpec® is a trademark of Palatin Technologies, Inc. Cranbury, NJ. Nexium® is a registered trademark of AstraZeneca LP, Wilmington, DE. Nimotop® is a registered trademark of Miles, Inc., West Haven, CT. Normiflo® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Normozide® is a registered trademark of Schering Corporation, Kenilworth, NJ. OctreoScan® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Orgaran® is a registered trademark of Organon, Roseland, NJ. Osteolite® is a registered trademark of DuPont Merck, Wilmington, DE. Paxipam® is a registered trademark of Schering Corporation, Kenilworth, NJ. PDR® is a registered trademark of Medical Economics Company, Montvale, NJ. Plavix® is a registered trademark of Sandofi-Synthelabo, New York, NY. Prefest ® is a registered trademark of Ortho-McNeil Pharmaceutical, Raritan, NJ. Premphase® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Prempro® is a trademark of Wyeth Pharmaceuticals, Philadelphia, PA. Pepcid® is a registered trademark of Merck & Co., Inc., Fort Washington, PA. Peptavlon® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Pepto-Bismol® is a registered trademark of Proctor & Gamble, Cincinnati, OH. 564

10766-75_Trademark.qxd

12/3/07

5:50 PM

Page 565

Acknowledgment of Trademarks Persantine® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. Plendil® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Prevacid® is a registered trademark of TAP, Deerfield, Il. Prilosec® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Prinivil® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Prinzide® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Procardia® is a registered trademark of Pfizer Labs Division, New York, NY. ProstaScint® is a registered trademark of Cytogen Corporation, Princeton, NJ. Protonix® is a registered trademark of Wyeth Pharmaceuticals, Philadelphia, PA. Proventil® is a registered trademark of Schering Corporation, Kenilworth, NJ. Pulmocare® is a registered trademark of Ross Laboratories, Columbus, OH. Pulmolite® is a registered trademark of DuPont Merck, Wilmington, DE. Pulmonex® is a registered trademark of Atomic Products, Center Moriches,NY. Pyrolite® is a registered trademark of DuPont Merck, Wilmington, DE. Pytest7 is a registered trademark of Tri-Med Specialties, Inc., Lenexa, KS. Quadramet® is a registered trademark of Cytogen Corporation, Princeton, NJ. Quibron® is a registered trademark of Bristol Laboratories, Evansville, IN. Reglan® is a registered trademark of A. H. Robbins Company, Richmond, VA. Reo-Pro® is a registered trademark of Eli Lilly and Company, Indianapolis, IN. Restoril® is a registered trademark of Sandoz Pharmaceuticals, East Hanover, NJ. Rolaids® is a registered trademark of Warner-Lambert Co., Morris Plains, NJ. Sectral® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Serax® is a registered trademark of Wyeth-Ayerst Laboratories, Philadelphia, PA. Slo-phyllin® is a registered trademark of Rhône-Poulenc Rorer Pharmaceuticals, Inc., Collegeville, PA. Synthroid® is a registered trademark of Boots Laboratories, Lincolnshire, IL. Tagamet® is a registered trademark of SmithKline Beecham Pharmaceuticals, Pittsburgh, PA. Tarka® is a registered trademark of Abbott Laboratories, Inc., North Chicago, IL. Tenoretic Tablets® is a registered trademark of ICI Pharma, Wilmington, DE. Tenormin® is a registered trademark of ICI Pharma, Wilmington, DE. Teveten® is a registered trademark of Solvay Pharmaceuticals, In., Marietta, GA. Theo-Dur® is a registered trademark of Key Pharmaceuticals, Inc., Kenilworth, NJ. Thyrogen® is a registered trademark of Genzyme Therapeutics, Cambridge, MA. Ticlid® is a registered trademark of Roche Pharmaceuticals, Nutley, NJ. Timolide Tablets® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Tums® is a registered trademark of SmithKline Beecham Pharmaceuticals, Pittsburgh, PA. UltraTag® is a registered trademark of Mallinckrodt Medical, Inc., St. Louis, MO. Uniretic® is a registered trademark of Schwartz Pharma, Inc., Mequon, WI. Univasc® is a registered trademark of Schwartz Pharma, Inc., Mequon, WI. Valium® is a registered trademark of Roche Laboratories, Nutley, NJ. Vascor® is a registered trademark of Wallace Laboratories, Cranbury, NJ. Vaseretic® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Vasotec® is a registered trademark of Merck, Sharp, & Dohme, West Point, PA. Viagra® is a registered trademark of Pfizer, Inc., New York, NY. Visken® is a registered trademark of Sandoz Pharmaceuticals, East Hanover, NJ. Xanax® is a registered trademark of The Upjohn Company, Kalamazoo, MI. Zantac® is a registered trademark of Glaxo Wellcome, Inc., Morris Plains, NJ. Zestoretic® is a registered trademark of Stuart Pharmaceuticals, Wilmington, DE. Zestril® is a registered trademark of Stuart Pharmaceuticals, Wilmington, DE. Zevalin® is a registered trademark of Biogen Idec, Cambridge, MA.

565

10766-75_Trademark.qxd

12/3/07

5:50 PM

Page 566

10766-76_Index.qxd

12/3/07

5:51 PM

Page 567

INDEX A Abbreviations, 518–528 ACE inhibitors, for renal scans, 256, 438 Acetazolamide (Diamox) for brain SPECT, 43–44 dosage and administration of, 423 Acipimox, 219 ACTH-augmented adrenocortical scan, 4 Activity, equation for, 373 Adenoma, toxic, radioiodine for, 330–334 dosage for, 369 patient information sheet for, 495 Adenosine in cardiac stress test, 73, 74 with PET, 215, 218 dosage and administration of, 423, 428–429 perfusion tables, 428–429 Adrenal cortex, structure and function of, 5 Adrenal hormones, 5 Adrenal medulla, pheochromocytoma scan, 7–12, 549 Adrenergics, side effects of, 433 Adrenocortical scan, 2–6 with ACTH augmentation, 4 dosage for, 368 patient history sheet for, 497 with suppression, 4 Adrenocortical steroids, side effects of, 433 Agreement states, 494 ALARA, 481 Analgesics, side effects of, 433 Anatomical images, 535–558 brain (and brain CSF), 536–539 cardiac system, 540–541 catecholamine-secreting tissue, 549 endocrine system, 542 gastrointestinal system, 543–544 hepatobiliary system, 545–546 lungs, 547 lymphatic system, 548 nasolacrimal ducts, 550 renal system, 552 salivary glands, 550 skeletal system, 553–556 testis and scrotum, 551 thyroid, 542 vascular system, 557–558 Angiography, 13–16 Angiotensin-converting enzyme (ACE) inhibitors, for renal scans, 256, 438 Angiotensin receptor blockers (ARBs), for renal scans, 256, 438 Annual dose limits, 480 Annual limit on intake (ALI), 480 Antacids, side effects of, 433 Antianginals, side effects of, 433

Antiarrhythmics, side effects of, 433 Anticholinergics, side effects of, 433 Anticoagulants, 437 side effects of, 433 Anticonvulsants, side effects of, 434 Antidepressants, side effects of, 434 Antidiabetics, side effects of, 433 Antiemetics, side effects of, 433 Antihistamines for iodine sensitivity, 5, 8 side effects of, 433 Antihypertensives, side effects of, 433 Anti-infectives/antivirals, side effects of, 433 Antilipemics, side effects of, 433 Antineoplastics, side effects of, 433 Antiparkinsons, side effects of, 433 Antipsychotics, side effects of, 434 ARBs (angiotensin receptor blockers), for renal scans, 256 Arteries, 557 Ascites, shunt patency scan and, 134–137 198Au, for synovectomy, 301

B B-cell non-Hodgkin’s lymphoma BEXXAR for, 287–292 Zevalin for, 313–317 Benzodiazepines, withholding of, for brain SPECT, 44 Beta blockers for cardiac resting test, 69 for cardiac stress test, 77 Bethanechol (urecholine), dosage and administration of, 423 BEXXAR (radioimmunotherapy), for B-cell nonHodgkin’s lymphoma, 287–292 dosage for, 368 patient history sheet for, 498 Bicisate for brain scan, 39 for brain SPECT, 41 Biliary dyskinesia, HIDA scan and, 126 Biologic half-lives, equation for, 373 Bleeding, gastrointestinal. See Gastrointestinal bleed scan Body surface area, 385, 426 nomogram, 379 Body weight, ideal, 426 Bone density assessment, 17–22 Bone marrow scan, 23–27 dosage for, 368 patient history sheet for, 499 Bone pain, palliative treatment for, 293–298 Bone scan, 28–35 dosage for, 368 patient history sheet for, 499 567

10766-76_Index.qxd

12/3/07

5:51 PM

Page 568

Index Bowel preparation, for adrenocortical scan, 3 Brain, anatomical images of, 536–539 Brain scan/death, 36–40 dosage for, 368 Brain scan-PET, 197, 205–211 Brain scan-SPECT, 41–46 with Diamox, 43–44 dosage for, 368 patient history sheet for, 500 Breath test, for H. pylori, 47–50 5-Bromoacetanilido-iminodiacetic acid (BRIDA), for HIDA scan, 125 Bronchodilators, side effects of, 433

C 11

C-acetate, 196, 203 Calcium-channel blockers for cardiac resting test, 69 for cardiac stress test, 77 Cancer PET for, 198, 200–201, 222–230 whole body study for, 222–230, 349–353 Captopril (Capoten) study dosage and administration in, 423 for glomerular filtration study, 249–258 patient history sheet for, 514 for renal tubular function, 249–258 Cardiac function, equations for, 373 Cardiac glycosides, side effects of, 433 Cardiac imaging dosage for, 368 gated first-pass study, 51–55 MUGA/MUGA-X, 56–61 myocardial infarction (MI) scan, 62–65 patient history sheet for, 501 perfusion and viability, 212–221 PET, 197–198, 212–221 resting test (perfusion), 66–70 stress-rest test, 71, 73–78 stress test (perfusion), 71–78 Cardiac output, equation for, 373 Cardiac PET, 197–198, 212–221 Cardiac SPECT, 278 Cardiac system, anatomical images of, 540–541 Cardiolite. See 99mTc-sestamibi Cariporide, 64 Catecholamine-secreting tissue, image of, 549 Catheters, urinary, for children, 87 11 C-choline, 196, 209 CCK. See Cholecystokinin (CCK) CDE (committed dose equivalent), 480 CEDE (committed effective dose equivalent), 480 Centimeters-inches conversion equation for, 373 table for, 364 Ceretec for brain scan, 36, 39 for brain scan-SPECT dosage of, 368 for brain SPECT, 41 568

patient history sheet for, 502 for white blood cell scan, 354 dosage of, 369 11 C-glucose, 203 Children dosages for, 379–385 calculation of, 373, 379–381, 426 urinary catheters for, 87 Chinese, translations for, 452–454 Cholecystokinin (CCK) actions of, 132 dosage and administration of, 423 for HIDA scan, 126, 131, 132 Choletec, for HIDA scan, 125 dosage of, 368 Cholinergics, side effects of, 434 Chromatography, kit preparation for, 375–378 Cimetidine (Tagamet) dosage and administration of, 423 for Meckel’s diverticulum scan, 174 Cisternography, 79–83 dosage for, 368 11 C-methionine, 196 11C-n-butanol, 203 11C-nicotine, 209 11C-N-methylspiperone, 203, 209 57Co, decay table for, 412 57Co cookie sheet in lung transmission scan, 157 in lymphoscintigraphy, 167, 170 57 Co-cyanocobalamin (vitamin B-12), for Schilling test, 263 Coding CPT codes, 530–533 HCPCS codes, 533–534 Committed dose equivalent (CDE), 480 Committed effective dose equivalent (CEDE), 480 Computed tomography (CT) for deep vein thrombosis, 97 with PET, 280–281 in single/dual photon absorptiometry, 20 Concentrations doses from, 373 equations for, 373 Conversion tables inches-centimeters, 364 millicuries-megabecquerels, 366 pounds-kilograms, 363 target heart rates, 365 Coronary blood flow, quantitation of, 217 Cortical imaging, 244–248 Corticosteroids, side effects of, 433 11C-palmitate, 203 CPT codes 2008, 530–533 51Cr (Na CrO )-labeled red blood cells, for red blood 2 4 cell studies, 238 137Cs, decay table for, 411 CT. See Computed tomography (CT) 11C-thymidine, 209 62Cu-pyruvaldehyde-bis(4N-thiosemicarbazone) (PTSM), 219

10766-76_Index.qxd

12/3/07

5:51 PM

Page 569

Index C-14 urea breath test, 47–50 Cystography, 84–88 dosage for, 368

D DAC (derived air concentration), 480 Dacryocystography, 92 Dacryoscintigraphy, 89–93 dosage for, 368 DDE (deep dose equivalent), 480 D-dimer, for deep vein thrombosis, 97–98 Decay. See Radionuclide decay Deep dose equivalent (DDE), 480 Deep venous thrombosis (DVT), venography for, 94–99 Demerol, for HIDA scan, 131 Densitometry, 17–22 Denver shunt patency, 134–137 Derived air concentration (DAC), 480 DEXA (dual energy x-ray absorptiometry), 18, 20 Diamox (acetazolamide) for brain SPECT, 43 dosage and administration of, 423 2,6-Diisopropylacetanilodo-iminodiacetic acid, for HIDA scan, 125 Dilaudid (hydromorphone), for HIDA scan, 131 Dipyridamole (Persantine) in cardiac stress test, 73 with PET, 215, 218 dosage and administration of, 424 infusion table, 431 Disofenin (DISIDA), for HIDA scan, 125 Diuretics, side effects of, 434 Diverticulum, Meckel’s, 173–177 dosage for, 368 patient history sheet for, 504 Dobutamine in cardiac stress test, 73 with PET, 215, 218 dosage and administration of, 424, 430 infusion table, 430 Dosages adult, 368–369 calculation of, 373 pediatric, 379–385 calculation of, 373, 379–381, 426 Dose equivalents, 480 Dose limits, annual, 480 DPA (dual photon absorptiometry), 18, 20 Drip conversions, 426 Drugs. See also Radiopharmaceuticals dosage and administration of, 423–427 infusion tables for, 428–432 side effects of, 433–434 Drug withholding for brain SPECT, 44 for cardiac resting test, 67 for glomerular filtration rate, 250, 256 for 123I, 435–436 for pheochromocytoma scan, 10–11 for renal tubular function scan, 250, 256

Dual energy x-ray absorptiometry (DEXA), 18, 20 Dual photon absorptiometry (DPA), 18, 20 DVT. See Deep venous thrombosis (DVT) 165 Dy-FHMA (ferric hydroxide macroaggregates), for synovectomy, 301

E Ectopic thyroid tissue scan, 325–329 dosage for, 369 Edge sign, in lung perfusion scan, 150 Effective dose equivalent, 480 Effective half-lives, equation for, 373 Effective renal plasma flow (ERPF), calculation of, 255 Ejection fraction, equation for, 373 Electrolytes, side effects of, 433 Enalaprilat (Vasotec) dosage and administration of, 424 for renal scan, 252 Endocrine system, anatomical images of, 542 Enzymes, production sites, substrates, and actions of, 446–450 Epinephrine, in pheochromocytoma, 8 Equations, 373 ERPF (effective renal plasma flow), 255 Erythrocytes, tagged. See Tagged red blood cells Erythromycin, dosage and administration of, 424 Esophageal transit time, 100–103

F 18

F, decay table for, 413 F-16α-fluoro-17β-estradiol, 203 Fatty meal, for HIDA scan, 131, 132 Fentanyl citrate, for HIDA scan, 131 18 F-ethyltyrosine, 209 18 F-FDDNP (fluoro-ethyl methyl amino-2 naphthyl ethylidene malononitrile), 209 18 F-FDG, 196, 203 for brain imaging, 205 for cardiac perfusion and viability scan, 212, 213, 216–217 dosage of, 369 for whole body cancer scan, 222–230 18 F-fluoroethylcholine, 203 FHMA (90Y-calcium oxalate), for synovectomy, 301 First-transit radionuclide angiocardiography, 51–55 Fissure sign, in lung perfusion scan, 150 18 F-methyltyrosine, 209 Foreign language translations, 451–473 French, translations for, 454–457 18 F-sodium fluoride, 203 18 F-spiperone, 203 Furosemide (Lasix) dosage and administration of, 424 for renal scan, 251 18

G 67

Ga, decay table for, 414 Ga-citrate for brain scan, 39

67

569

10766-76_Index.qxd

12/3/07

5:51 PM

Page 570

Index 67

Ga-citrate (contd.) for gallium scan, 104 dosage of, 368 68 Ga-citrate/transferrin, 203 Gallbladder, anatomical image of, 545–546 Gallbladder scan with ejection fraction (HIDA), 125–133 dosage for, 368 patient history sheet for, 505 Gallium scan, 104–109 brain, 39 dosage for, 368 patient history sheet for, 502 Gastric emptying scan, 110–115 dosage for, 368 patient history sheet for, 503 Gastric ulcers, breath test for, 47–50 Gastroesophageal reflux scan, 116–119 Gastrointestinal bleed scan, 120–124 dosage for, 368 patient history sheet for, 504 Gastrointestinal system, anatomical images of, 543–544 Gated first-pass cardiac study, 51–55 Gates method, for glomerular filtration rate, 254 German, translations for, 457–459 Glomerular filtration rate (GFR), 249–258 Glucagon dosage and administration of, 425 for Meckel’s diverticulum scan, 174 Glucose loading, glucose/insulin clamping, 219 Goiter, toxic nodular, radioiodine for, 330–334 dosage for, 369 patient history sheet for, 495 Graves’ disease, radioiodine for, 330–334 dosage for, 369 patient information sheet for, 495

H Half-lives for commonly used radionuclides, 370–372 equation for, 373 HAM. See Human albumin microspheres (HAM) HAMA titer, 288, 314, 315 HDP (hydroxymethylene diphosphonate), for bone scan, 28 Healthcare Common Procedure Coding System (HCPCS), 533–534 Heart, anatomical images of, 540–541 Heart rates conversion table for, 365 equation for, 373 Helicobacter pylori, breath test for, 47–50 Hemangioma, hepatic, SPECT for, 138–141 Hepatobiliary scan with ejection fraction (HIDA). See HIDA (hepatobiliary/gallbladder scan) Hepatobiliary system, anatomical images of, 545–546 Hepatolite, for HIDA scan, 125 Hibernating myocardium, 218 570

HIDA (hepatobiliary/gallbladder scan), 125–133 dosage for, 368 patient history sheet for, 505 H215O, 209, 213 Hormesis, 479 Hormones adrenal, 5 production sites, substrates, and actions of, 446–450 thyroid, 433 Hot pyp, for myocardial infarction scan, 368 Human albumin microspheres (HAM) for LeVeen/Denver shunt patency scan, 134 for lung perfusion scan, 148 Hydromorphone hydrochloride (Dilaudid), for HIDA scan, 131 Hydroxymethylene diphosphonate (HDP), for bone scan, 28 Hyperthyroidism, radioiodine for, 330–334 dosage for, 369 patient information for, 495 Hypnotics, side effects of, 433

I 123

I decay table for, 416 drugs/studies affecting, 435–436 for ectopic thyroid tissue scan, 325, 326, 327 dosage of, 369 for pheochromocytoma scan dosage of, 369 with rTSH augmentation, 351–352 for thyroid scan, 335 for thyroid uptake, 341 for whole body cancer study, 349 131 I decay table for, 417 drugs/studies affecting, 435–436 for ectopic thyroid tissue scan, 325, 326, 327 for hyperthyroidism, 330 dosage of, 369 with rTSH augmentation, 351–352 for thyroid ablation, 318 dosage of, 369 for thyroid scan, 335 dosage of, 369 for thyroid uptake, 341 dosage of, 369 for whole body cancer study, 349–353 dosage of, 369 131 I-6-β-iodomethyl-19-norcholesterol (NP-59), for adrenocortical scan, 2 dosage of, 368 IDA (iminodiacetic acid), for HIDA scan, 125 Ideal body weight, 426 131 I-diphosphonate, for bone pain palliation, 296 125 I-fibrinogen, for deep vein thrombosis, 97 125 I-human serum albumin, for red blood cell studies, 238 123 I-iodoamphetamine, for brain scan, 39

10766-76_Index.qxd

12/3/07

5:51 PM

Page 571

Index 123

I-mIBG (-meta-iodobenzylguanidine), for pheochromocytoma scan, 7–12 dosage for, 369 patient history sheet for, 508 131 I-mIBG (-meta-iodobenzylguanidine), for pheochromocytoma scan, 7–12 dosage for, 369 patient history sheet for, 508 Iminodiacetic acid (IDA), for HIDA scan, 125 111 In, decay table for, 415 111 In-capromab pendetide, for ProstaScint scan, 231 Inches-centimeters conversion equation for, 373 table for, 364 111 In-chloride for B-cell non-Hodgkin’s lymphoma, 313 for bone marrow scan, 25 111 In-CYT-356, for ProstaScint scan, 231 dosage of, 369 Indium scan, patient history sheet for, 502 111 In-DTPA (diethylenetriaminepentaacetic acid) for cisternography, 79 dosage of, 368 for gastric emptying scan, 110 Infection, radioimmunoscintigraphy for, 178–181 Infusion tables, 428–432 111In-ibritumomab, for Zevalin therapy, 313 dosage of, 369 Inotropics, side effects of, 433 111In-oxine (oxyquinoline), for white blood cell scan, 354–360 111In-pentetreotide, for OctreoScan, 182 dosage of, 369 125 In-platelets, for deep vein thrombosis, 97 Inspection, self-assessment for nuclear medicine facilities, 483–490 Intra-articular (joint) synovectomy, 299–303 Intracavitary (serosal) infusion, 304–308 Inverse square law, 373 Iodine sensitivity, antihistamine for, 5, 8 131I-OIH (orthoiodohippurate) for cystography, 84 for glomerular filtration rate, 249 dosage for, 369 123I-sodium iodide, for parathyroid scan, 188 Isotopes, 386–409 PET, 203 Italian, translations for, 459–462 131I-tositumomab, for Bexxar therapy, 287–290 dosage of, 368

J Japanese, phonetic translations for, 470–471 Jones dye test, 91

K Kidney depth calculation, Tonnesen method of, 255 Kidneys, anatomical image, 552 Kilograms-pounds conversion equation for, 373 table for, 363

Kinevac (cholecystokinin), 132 dosage and administration of, 423 Kit preparation, 374–378

L Labels, package, 481 Laboratory tests, normal ranges for, 440–444 Lacrimal ducts, anatomical image of, 550 Lacrimal scan, 89–93 dosage for, 368 Language translations, 451–473 Lasix (furosemide) dosage and administration of, 424 for renal scan, 251 Laxatives, side effects of, 433 Lens dose equivalent (LDE), 480 LeVeen shunt patency, 134–137 Liver SPECT, 138–141 dosage for, 368 Liver/spleen scan, 142–147 dosage for, 368 patient history sheet for, 508 Lung, anatomical images of, 547 Lung perfusion scan, 148–155 dosage for, 368 lung ventilation scan and, 160–165 quantitation in, 152 Lung scan, patient history sheets for, 506–507 Lung transmission scan, 156–159 Lung ventilation scan, 160–165 dosage for, 368 lung perfusion scan and, 148–155 Lymphangiogram, 166–172 Lymphatic system, anatomical images of, 548 Lymphoscintigraphy, 166–172 dosage for, 368

M Macroaggregated albumin (MAA), for lung perfusion scan, 148 Magnesium citrate, for OctreoScan, 184 Magnetic resonance imaging (MRI) for deep vein thrombosis, 97 with PET, 281 with SPECT, 280 MDP (methylene diphosphonate), for bone scan, 28 Mebrofenin, for HIDA scan, 125 dosage of, 368 Meckel’s diverticulum scan, 173–177 dosage for, 368 patient history sheet for, 504 Megabecquerels-millicuries conversion table, 366 Meperidine (Demerol), for HIDA scan, 131 Metastasis, whole-body study for, 349–353 bone scan and, 28–34 6-Methoxyisobutyl isonitrile. See 99mTc-sestamibi Methylene diphosphonate (MDP), for bone scan, 28 Metoclopramide (Reglan) dosage and administration of, 425 for gastric emptying scan, 111, 112, 113 571

10766-76_Index.qxd

12/3/07

5:51 PM

Page 572

Index MET-PET, 209 mIBG scan, for pheochromocytoma, 7–12, 549 dosage for, 369 patient history sheet for, 508 Millicuries-megabecquerels conversion table, 366 Minerals, side effects of, 433 Miraluma. See 99mTc-sestamibi Misadministration, 475–476 Miscellaneous patient history worksheet, 509 99 Mo, decay table for, 418 Morphine sulfate dosage and administration of, 425 for HIDA scan, 126, 131 MRI. See Magnetic resonance imaging (MRI) MUGA/MUGA-X, 56–61 dosage for, 368 patient history sheet for, 501 Muscle relaxants, side effects of, 433 Myocardial blood flow, 217 Myocardial infarction (MI) scan, 62–65 dosage for, 368 Myocardium hibernating, 218 stunned, 218 Myoview. See 99mTc-tetrofosmin

N Na99mTCO4. See 99mTc-pertechnetate Narcotic analgesics, side effects of, 433 Nasolacrimal ducts, anatomical image of, 550 Neurolite for brain scan, 39 for brain SPECT4, 1 NeutroSpec, 178–181 dosage for, 368 patient history sheet for, 510 Nicotinic acid derivatives, 219 13 N-NH3, 196, 203 for cardiac perfusion and viability scan, 212, 213, 215, 217 dosage of, 369 Nonnarcotic analgesics, side effects of, 433 Nonstochastic effects, 479 Norepinephrine, in pheochromocytoma, 7 NP-59 (131I-6-β-iodomethyl-19-norcholesterol), for adrenocortical scan, 2 dosage of, 368 Nuclear medicine imaging CPT codes 2008, 530–533

O 15

O, 196 Occupational dose limits, 480 15 O-CO, 203 15 O-CO2, for cardiac perfusion and viability scan, 212 OctreoScan, 182–187 dosage for, 369 patient history sheet for, 511 Octreotide, for OctreoScan, 182 15 O-H2O, 203 572

for cardiac perfusion and viability scan, 212, 213, 217 dosage of, 369 Oncologic scan-PET, 198 15 O-O2, 203 for cardiac perfusion and viability scan, 212 Osteopenia, densitometry for, 17–21 Osteoporosis, densitometry for, 17–21

P Package labels, 481 Pain, bone, palliative treatment for, 293–298 Palliation for bone pain, 293–298 intracavitary infusion for, 304–308 Parathyroid scan, 188–195 dosage for, 369 dual isotope subtraction technique for, 190–191 single-isotope two-phase, 191 Patient end-of-day report, 489 Patient history sheets, 496–517 Patient information sheet, for thyroid therapies, 495 Patient release methods, for thyroid therapies, 492–494 32 P-chromic phosphate for serosal intracavitary infusion, 304 for synovectomy, 299 Pediatric dosages, 379–385 calculation of, 373, 379–381, 426 Pentagastrin (Peptavlon) dosage and administration of, 425 for Meckel’s diverticulum scan Pentazocine hydrochloride, for HIDA scan, 131 Peptavlon (pentagastrin), dosage and administration of, 425 Peptic ulcers, breath test for, 47–50 Perchlorate, for angiography, 14 Peritoneovenous shunt patency scan, 134–137 Persantine (dipyridamole) in cardiac stress test, 73 with PET, 215, 218 dosage and administration of, 424, 431 infusion table, 431 PET, 196–204 brain, 197, 205–211 cardiac, 197–198, 212–221 isotopes for, 203 oncologic, 198, 200–201, 222–230 patient history sheet for, 512 whole body (tumor), 222–230 PET/CT, 280–281 whole body (tumor), 222–230 PET/CT/SPECT, 281 PET/MRI, 281 PET/SPECT, 279 Phenobarbital dosage and administration of, 425 for HIDA scan, 131 Pheochromocytoma scan (mIBG), 7–12, 549 dosage for, 369 with renal and skeletal imaging, 11

10766-76_Index.qxd

12/3/07

5:51 PM

Page 573

Index Plasma volume measurement, 239–240, 241 Plethysmography, for deep vein thrombosis, 97 Plummer’s disease, radioiodine for, 330–334 dosage for, 369 patient information sheet for, 495 Polish, translations for, 471–473 Polycythemia vera, 32P-sodium phosphate for, 309–312 32 P-orthophosphate, for bone pain palliation, 296 Portuguese, translations for, 462–464 Positron emission tomography. See PET Positrons, 201 Potassium perchlorate, for Meckel’s diverticulum scan, 175 Pounds-kilograms conversion equation for, 373 table for, 363 Pregnancy, annual dose limits and, 480, 481 ProstaScint scan, 231–237 dosage for, 369 patient history sheet for, 513 32 P-sodium phosphate for bone pain palliation, 293 for polycythemia vera, 309–312 PTSM (62Cu-pyruvaldehyde-bis-4Nthiosemicarbazone), 219 Pyrophosphate (pyp; Pyrolite) dosage and administration of, 425 for liver SPECT, 138 for myocardial infarction (MI) scan, 62 dosage of, 368 PYtest C-14 urea breath test, 47–50

R Radiation annual dose limits, 480–481 biologic effects of, 478–479 properties of, 476–478 Radiation safety, 476–482 Radioimmunoscintigraphy (RIS) NeutroSpec scan, 178–181 ProstaScint scan, 231–237 Radioimmunotherapy (RIT), for B-cell nonHodgkin’s lymphoma BEXXAR, 287–292 Zevalin, 313–317 Radioiodine therapy dosage for, 369 for hyperthyroidism, 330–334 for thyroid ablation, 318–324 Radionuclide decay equation for, 373 modes of, 477 tables for, 410–421 Radionuclide(s). See also specific radionuclides activity of, equation for, 373 concentrations of, equation for, 373 misadministration of, 475 properties and medical uses of, 370–372 properties of, 386–409

Radiopharmaceutical HCPCS, 533–534 Radiopharmaceutical rec-disp daily report, 490 Radiopharmaceuticals. See also specific compounds blood-brain penetrating, 39 documentation for inspection, 487–488 dosages for, 368–369 medical applications of, 203 misadministration of, 475 non-blood-brain penetrating, 39 for PET, 196–197, 203 82 Rb-chloride, 196, 203 for cardiac perfusion and viability scan, 212, 213, 217 dosage of, 369 Recordable events, 475 Red blood cells, tagged. See Tagged red blood cells Red blood cell studies, 238–243 Red blood cell survival, 240, 241, 242 Red blood cell volume measurement, 240, 241 186 Re-etidronate (hydroxyethylidene diphosphonate), for bone pain palliation, 296 Reglan (metoclopramide) dosage and administration of, 425 for gastric emptying scan, 111, 112, 113 Renal depth calculation, Tonnesen method for, 255 Renal scan ACE inhibitors and angiotensin receptor blockers for, 438 cortical imaging, 244–248 dosage for, 369 effective renal plasma flow, 249–258 glomerular filtration rate, 249–258 patient history sheet for, 514 tubular function, 249–258 Renal system, anatomical images of, 552 Renin/angiotensin/aldosterone system, 255 Renography, 249–258 dosage for, 369 patient history sheet for, 514 188 Re-phosphonate, for bone pain palliation, 296 Reportable events, 475–476 Resting test, cardiac (perfusion), 66–70 RIS. See Radioimmunoscintigraphy RIT. See Radioimmunotherapy Rule of two’s, for Meckel’s diverticulum, 175 Russian, translations for, 464–467

S Safety measures, 476–482 in PET, 201–202 Salivary gland imaging, 259–262 Salivary glands, anatomical image of, 550 Schegel method for 131I-OIH, 255 Schilling test, 263–267 dosage for, 369 Scintimammography, 268–273 dosage for, 369 patient history sheet for, 515 Scrotal imaging, 283–286 Scrotum, anatomical image of, 551 573

10766-76_Index.qxd

12/3/07

5:51 PM

Page 574

Index Sedatives, side effects of, 433 Segmented attenuation correction (SAC), 207 Serosal intracavitary infusion, 304–308 SEXA (single energy x-ray absorptiometry), 18, 19 Shallow dose equivalent (SDE), 480 Shielding equations for, 373 methods of, 478 Shunt patency, for LeVeen/Denver shunt, 134–137 Sincalide (cholecystokinin; Kinevac), 132 dosage and administration of, 423 Single energy x-ray absorptiometry (SEXA), 18, 19 Single photon absorptiometry (SPA), 18, 19 Single photon emission computed tomography. See SPECT Single strip/single solvent method of thin-layer chromatography, 376 Skeletal imaging, 28–35 Skeletal system, anatomical images of, 553–556 153 Sm-lexidronam, for bone pain palliation, 293 117m SN-chelate, for bone pain palliation, 296 Sodium iodide thyroid ablation, 318–324 Sodium 99mTcO4. See 99mTc-pertechnetate Somatostatin, OctreoScan and, 185 Spanish, translations for, 467–470 SPA (single photon absorptiometry), 18, 19 SPECT in bone scan, 29, 32 brain, 41–46 dosage for, 368 patient history sheet for, 500 cardiac, 278 in cardiac resting test, 67, 68, 69 in cardiac stress test, 73, 74 in gallium scan, 105 liver, 138–141 dosage for, 368 in liver/gallbladder scan, 139–140 in myocardial infarction (MI) scan, 63 in NeutroSpec, 179, 180 in OctreoScan, 183 overview, 274–282 in parathyroid scan, 189, 191 with PET, 279, 281 in ProstaScint scan, 233 in scintimammography, 270 SPECT/CT, 279–280 SPECT/MRI, 280 Sphincter of Oddi spasm, HIDA scan and, 126, 131–132 Spleen scan, 142–147 dosage for, 368 patient history sheet for, 508 Splenic sequestration, 241, 242 89 Sr-chloride, for bone pain palliation, 293 State inspection self-assessment, 483–490 Steroids, side effects of, 433 Stochastic effects, 479 Stomach, anatomical images of, 542-544 Stool softeners, side effects of, 433 574

Stress MUGA (or MUGA-X), 56–61 Stress test, cardiac (perfusion), 71–78 Stroke volume, equation for, 373 Stunned myocardium, 218 Substernal thyroid tissue scan, 325–329 dosage for, 369 Super Scan, in bone scanning, 31 Synovectomy, 299–303

T Tagamet (cimetidine) dosage and administration of, 423 for Meckel’s diverticulum scan, 174 Tagged red blood cells angiography, 13 for brain scan, 39 for deep venous thrombosis, 94, 96 for gastrointestinal bleed scan, 120 dosage of, 368 for liver SPECT, 138 dosage of, 368 for MUGA/MUGA-X scan, 56, 58 dosage of, 368 for ProstaScint scan, 231 for red blood cell studies, 238 Talbot’s nomogram, modified, 379 Target heart rates conversion table for, 365 equation for, 373 99m Tc, decay table for, 419 99m Tc-albumin colloid, for gastric emptying scan, 110 99m Tc-DMSA (dimercaptosuccinic acid), for renal scan, 244 dosage of, 369 99m Tc-DTPA (diethylenetriaminepentaacetic acid) for adrenocortical scan, 4 for angiography, 13 for brain scan, 36, 39 dosage of, 368 for cisternography, 79 for cystography, 84 for gastric emptying scan, 110 for glomerular filtration rate, 249 dosage of, 369 for lung ventilation scan, 160, 161, 162–163 dosage of, 368 for testicular scan, 283 99m Tc-ECD (ethyl cysteinate dimer) for brain scan, 39 for brain SPECT, 41 99m Tc-fanolesomab, for NeutroSpec, 178 dosage of, 368 99m Tc-GH (glucoheptonate) for brain scan, 36, 39 dosage of, 368 for renal scan, 244 99m Tc-HAM (human albumin microspheres) for LeVeen/Denver shunt patency scan, 134 for lung perfusion scan, 148 99m Tc-HDP (hydroxymethylene diphosphonate)

10766-76_Index.qxd

12/3/07

5:51 PM

Page 575

Index for bone scan, 358 dosage of, 368 for brain scan, 39 99m Tc-HMPAO (hexamethylpropyleneamine oxime) for brain scan/death, 36, 39 for brain SPECT, 41 for white blood cell scan, 354–360 99m Tc-HMPAO (hexamethylpropyleneamine oxime) platelets, for deep vein thrombosis, 97 99m Tc-MAA (macroaggregated albumin) for deep venous thrombosis, 94 for LeVeen/Denver shunt patency scan, 134, 136 for lung perfusion scan, 148 dosage of, 368 99m Tc-MAG3 (mercaptoacetyltriglycine) for cystography, 84 for renal scan, 249 dosage of, 369 99m Tc-MDP (methylene diphosphonate) for bone scan, 358 dosage of, 368 for brain scan, 39 99m Tc-pertechnetate for angiography, 13, 14 for brain scan, 36, 39 dosage of, 368 for cystography, 84 dosage of, 368 for dacryoscintigraphy, 89 dosage of, 368 for deep venous thrombosis, 94 for ectopic thyroid tissue scan, 325, 326, 327 for gastrointestinal bleed scan, 120 for gated first-pass cardiac study, 51 kit preparation for, 374 for liver SPECT, 138 for lung transmission scan, 156 for Meckel’s diverticulum scan, 173 dosage of, 368 for MUGA/MUGA-X scan, 56 for parathyroid scan, 188 dosage of, 369 for ProstaScint scan, 231 for salivary gland imaging, 259 for testicular scan, 283 dosage of, 369 for thyroid scan, 335, 337, 338 dosage of, 369 for thyroid uptake, 341, 343, 344 99m Tc-pyp for liver SPECT, 138, 139 dosage of, 368 for myocardial infarction (MI) scan, 62, 63 dosage of, 368 99m Tc-SC (sulfur colloid) for bone marrow study, 23 dosage of, 368 for cystography, 84 dosage of, 368 for esophageal transit time, 100

for gastric emptying scan, 110 dosage of, 368 for gastroesophageal reflux assessment, 116 for gastrointestinal bleed scan, 120, 121, 122–123 for LeVeen/Denver shunt patency scan, 134, 136 for liver/spleen scan, 142–147, 357 dosage of, 368 for lymphoscintigraphy, 166 dosage of, 368 for serosal intracavitary infusion, 304 for synovectomy, 299 99m Tc-sestamibi (hexakis[2-methoxyisobutylisonitril]) for cardiac resting test, 66, 67, 68 dosage of, 368 for cardiac stress test, 71, 74, 75, 76 dosage of, 368 for gated first-pass cardiac study, 51 dosage of, 368 for parathyroid scan, 188 dosage of, 369 for scintimammography, 268 dosage of, 369 99m Tc-stannous pyrophosphate, for myocardial infarction scan, 62 99m Tc-tetrofosmin (1,2-bis[bis(2-ethoxyethyl) phosphino]ethane) for cardiac resting test, 66, 68 for cardiac stress test, 71, 74, 76 for gated-first pass cardiac study, 51 for parathyroid scan, 188 for scintimammography, 268 99m Tc-T2G1 antifibrin, for deep vein thrombosis, 97 TEDE (total effective dose equivalent), 480 Testicular scan, 283–286 dosage for, 369 Testis, anatomical image of, 551 Thin-layer chromatography (TLC), 376–378 Thrombosis, venous. See Deep venous thrombosis (DVT) Thyroid, anatomical image of, 542 Thyroid ablation, 318–324 dosage for, 369 Thyroid antagonists, 346 Thyroid hormones, side effects of, 433 Thyroid hyperactivity, radioiodine for, 330–334 dosage for, 369 patient information sheet for, 495 Thyroid scan dosage for, 369 patient information sheet for, 495 substernal, 325–329 dosage for, 369 whole-body, 335–340, 349–353 with rTSH augmentation, 351–352 Thyroid serum laboratory ranges, 346 Thyroid stimulators, 345 Thyroid therapies measured dose rate, 493 patient release methods and information, 492–495 patient-specific dose calculations, 493–494 575

10766-76_Index.qxd

12/3/07

5:51 PM

Page 576

Index Thyroid uptake, 341–348 dosage for, 369 patient history sheet for, 516–517 Thyrotropin alpha (Thyrogen), for whole-body scan with rTSH augmentation, 351–352 201 Tl for brain scan, 39 for cardiac resting test, 66, 67, 68 for cardiac stress test, 71, 74, 76 dosage of, 368 decay table for, 420 201 Tl-chloride for parathyroid scan, 188 dosage of, 369 TLC (thin-layer chromatography), 376–378 TODE (total organ dose equivalent), 480 Tonnesen method of kidney depth calculation, 255 Tositumomab, for B-cell non-Hodgkin’s lymphoma, 290 Total effective dose equivalent (TEDE), 480 Total organ dose equivalent (TODE), 480 Toxic nodular goiter, radioiodine for, 330–334 dosage for, 369 patient information sheet for, 495 Tranquilizers, side effects of, 434 Translations, language, 451–473 Treadmill test, 73–74 2,4,6-Trimethyl, for HIDA scan, 125 Tubular function, 249–258 Two strip/two solvent method of thin-layer chromatography, 376–377

V Vascular system, anatomical images of, 557–558 Vasodilators, side effects of, 434 Vasotec (enalaprilat) dosage and administration of, 424 for renal scan, 252 Veins, 558 Venography, for deep vein thrombosis, 94–99 Venous thrombosis. See Deep venous thrombosis (DVT) Ventilation scan, 160–165 Vitamin B-12, for Schilling test, 263 dosage of, 369 Vitamins, side effects of, 433 Voiding cystourethrogram, 84–88

W Webster’s rule, for pediatric dosage, 381 Weight/metabolic rule, for pediatric dosage, 381 Wellman’s rule, for pediatric dosage, 381 White blood cell scan, 354–360 dosage for, 369 Whole-body cancer study, 349–353 dosage for, 369 with PET, PET-CT, 222–230 Wright’s formula, modified, 381–382

X 133

Xe (xenon) for brain scan, 39 decay table for, 421 for lung ventilation scan, 160, 161–162 dosage of, 368

U Ulcers, breath test for, 47–50 Ultrasonography, for deep vein thrombosis, 97 UltraTag for angiography, 13–16 for deep venous thrombosis, 94–99 dosage and administration of, 425 for gastrointestinal bleed, 120–124 for liver SPECT, 138–141 for MUGA/MUGA-X scan, 56–61 for ProstaScint scan, 231–237 Urea breath test, 47–50 Urecholine (Bethanechol), dosage and administration of, 423 Urinary catheters, for children, 87 Urinary tract, anatomical image, 552 Urokinase dosage and administration of, 432 infusion table for, 432

576

Y 90

Y-calcium oxalate (FHMA), for synovectomy, 301 Y-chloride, for B-cell non-Hodgkin’s lymphoma, 313 90Y-citrate, for bone pain palliation, 296 90Y-labeled microspheres, for hepatoma and liver metastases, 316 90Y-LymphCide, 316 Young’s rule, for pediatric dosage, 381 90

Z Zevalin scan, for B-cell non-Hodgkin’s lymphoma, 313–317 dosage for, 369 patient history sheet for, 498 Zona fasciculata, 5 Zona glomerulosa, 5 Zona reticularis, 5